

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
21 December 2000 (21.12.2000)

PCT

(10) International Publication Number  
**WO 00/77256 A1**

(51) International Patent Classification<sup>7</sup>: C12Q 1/68, C12P  
21/06, C12N 5/00, 15/00, C07H 21/04

(74) Agents: HOOVER, Kenley, K. et al.: Human Genome  
Sciences, Inc., 9410 Key West Avenue, Rockville, MD  
20850 (US).

(21) International Application Number: PCT/US00/14963

(22) International Filing Date: 1 June 2000 (01.06.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/138,631 11 June 1999 (11.06.1999) US

(71) Applicant (for all designated States except US): HUMAN  
GENOME SCIENCES, INC. [US/US]; 9410 Key West  
Avenue, Rockville, MD 20850 (US).

(81) Designated States (national): AE, AL, AM, AT, AU, AZ,  
BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK,  
DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL,  
IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,  
LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,  
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,  
UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,  
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and

(75) Inventors/Applicants (for US only): ROSEN, Craig, A.  
[US/US]; 22400 Rolling Hill Road, Laytonville, MD 20882  
(US). RUBEN, Steven, M. [US/US]; 18528 Heritage Hills  
Drive, Laytonville, MD 20882 (US). KOMATSOULIS,  
George, A. [US/US]; 9518 Garwood Street, Silver Spring,  
MD 20901 (US).

Published:

— With international search report.

For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.



WO 00/77256 A1

(54) Title: 48 HUMAN SECRETED PROTEINS

(57) Abstract: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to these novel human secreted proteins.

## 48 Human Secreted Proteins

### *Field of the Invention*

This invention relates to newly identified polynucleotides and the polypeptides encoded by these polynucleotides, uses of such polynucleotides and polypeptides, and their production.

### *Background of the Invention*

Unlike bacterium, which exist as a single compartment surrounded by a membrane, human cells and other eucaryotes are subdivided by membranes into many functionally distinct compartments. Each membrane-bounded compartment, or organelle, contains different proteins essential for the function of the organelle. The cell uses "sorting signals," which are amino acid motifs located within the protein, to target proteins to particular cellular organelles.

One type of sorting signal, called a signal sequence, a signal peptide, or a leader sequence, directs a class of proteins to an organelle called the endoplasmic reticulum (ER). The ER separates the membrane-bounded proteins from all other types of proteins. Once localized to the ER, both groups of proteins can be further directed to another organelle called the Golgi apparatus. Here, the Golgi distributes the proteins to vesicles, including secretory vesicles, the cell membrane, lysosomes, and the other organelles.

Proteins targeted to the ER by a signal sequence can be released into the extracellular space as a secreted protein. For example, vesicles containing secreted proteins can fuse with the cell membrane and release their contents into the extracellular space - a process called exocytosis. Exocytosis can occur constitutively or after receipt of a triggering signal. In the latter case, the proteins are stored in secretory vesicles (or secretory granules) until exocytosis is triggered. Similarly,

proteins residing on the cell membrane can also be secreted into the extracellular space by proteolytic cleavage of a “linker” holding the protein to the membrane.

Despite the great progress made in recent years, only a small number of genes encoding human secreted proteins have been identified. These secreted proteins  
5 include the commercially valuable human insulin, interferon, Factor VIII, human growth hormone, tissue plasminogen activator, and erythropoietin. Thus, in light of the pervasive role of secreted proteins in human physiology, a need exists for identifying and characterizing novel human secreted proteins and the genes that encode them. This knowledge will allow one to detect, to treat, and to prevent  
10 medical diseases, disorders, and/or conditions by using secreted proteins or the genes that encode them.

### ***Summary of the Invention***

The present invention relates to novel polynucleotides and the encoded  
15 polypeptides. Moreover, the present invention relates to vectors, host cells, antibodies, and recombinant and synthetic methods for producing the polypeptides and polynucleotides. Also provided are diagnostic methods for detecting diseases, disorders, and/or conditions related to the polypeptides and polynucleotides, and therapeutic methods for treating such diseases, disorders, and/or conditions. The  
20 invention further relates to screening methods for identifying binding partners of the polypeptides.

### ***Detailed Description***

#### **Definitions**

The following definitions are provided to facilitate understanding of certain terms used throughout this specification.

In the present invention, "isolated" refers to material removed from its original environment (e.g., the natural environment if it is naturally occurring), and thus is altered "by the hand of man" from its natural state. For example, an isolated polynucleotide could be part of a vector or a composition of matter, or could be contained within a cell, and still be "isolated" because that vector, composition of matter, or particular cell is not the original environment of the polynucleotide. The term "isolated" does not refer to genomic or cDNA libraries, whole cell total or mRNA preparations, genomic DNA preparations (including those separated by electrophoresis and transferred onto blots), sheared whole cell genomic DNA preparations or other compositions where the art demonstrates no distinguishing features of the polynucleotide/sequences of the present invention.

In the present invention, a "secreted" protein refers to those proteins capable of being directed to the ER, secretory vesicles, or the extracellular space as a result of a signal sequence, as well as those proteins released into the extracellular space without necessarily containing a signal sequence. If the secreted protein is released into the extracellular space, the secreted protein can undergo extracellular processing to produce a "mature" protein. Release into the extracellular space can occur by many mechanisms, including exocytosis and proteolytic cleavage.

In specific embodiments, the polynucleotides of the invention are at least 15, at least 30, at least 50, at least 100, at least 125, at least 500, or at least 1000 continuous nucleotides but are less than or equal to 300 kb, 200 kb, 100 kb, 50 kb, 15 kb, 10 kb, 7.5 kb, 5 kb, 2.5 kb, 2.0 kb, or 1 kb, in length. In a further embodiment, polynucleotides of the invention comprise a portion of the coding sequences, as



disclosed herein, but do not comprise all or a portion of any intron. In another embodiment, the polynucleotides comprising coding sequences do not contain coding sequences of a genomic flanking gene (i.e., 5' or 3' to the gene of interest in the genome). In other embodiments, the polynucleotides of the invention do not contain  
5 the coding sequence of more than 1000, 500, 250, 100, 50, 25, 20, 15, 10, 5, 4, 3, 2, or 1 genomic flanking gene(s).

As used herein, a "polynucleotide" refers to a molecule having a nucleic acid sequence contained in SEQ ID NO:X or the cDNA contained within the clone deposited with the ATCC. For example, the polynucleotide can contain the  
10 nucleotide sequence of the full length cDNA sequence, including the 5' and 3' untranslated sequences, the coding region, with or without the signal sequence, the secreted protein coding region, as well as fragments, epitopes, domains, and variants of the nucleic acid sequence. Moreover, as used herein, a "polypeptide" refers to a molecule having the translated amino acid sequence generated from the  
15 polynucleotide as broadly defined.

In the present invention, the full length sequence identified as SEQ ID NO:X was often generated by overlapping sequences contained in multiple clones (contig analysis). A representative clone containing all or most of the sequence for SEQ ID NO:X was deposited with the American Type Culture Collection ("ATCC"). As  
20 shown in Table 1, each clone is identified by a cDNA Clone ID-(Identifier) and the ATCC Deposit Number. The ATCC is located at 10801 University Boulevard, Manassas, Virginia 20110-2209, USA. The ATCC deposit was made pursuant to the terms of the Budapest Treaty on the international recognition of the deposit of microorganisms for purposes of patent procedure.

25 A "polynucleotide" of the present invention also includes those polynucleotides capable of hybridizing, under stringent hybridization conditions, to

sequences contained in SEQ ID NO:X, the complement thereof, or the cDNA within the clone deposited with the ATCC. "Stringent hybridization conditions" refers to an overnight incubation at 42 degree C in a solution comprising 50% formamide, 5x SSC (750 mM NaCl, 75 mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x  
5 Denhardt's solution, 10% dextran sulfate, and 20  $\mu$ g/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65 degree C.

Also contemplated are nucleic acid molecules that hybridize to the polynucleotides of the present invention at lower stringency hybridization conditions. Changes in the stringency of hybridization and signal detection are primarily  
10 accomplished through the manipulation of formamide concentration (lower percentages of formamide result in lowered stringency); salt conditions, or temperature. For example, lower stringency conditions include an overnight incubation at 37 degree C in a solution comprising 6X SSPE (20X SSPE = 3M NaCl; 0.2M  $\text{NaH}_2\text{PO}_4$ ; 0.02M EDTA, pH 7.4), 0.5% SDS, 30% formamide, 100 ug/ml  
15 salmon sperm blocking DNA; followed by washes at 50 degree C with 1XSSPE, 0.1% SDS. In addition, to achieve even lower stringency, washes performed following stringent hybridization can be done at higher salt concentrations (e.g. 5X SSC).

Note that variations in the above conditions may be accomplished through the  
20 inclusion and/or substitution of alternate blocking reagents used to suppress background in hybridization experiments. Typical blocking reagents include Denhardt's reagent, BLOTTO, heparin, denatured salmon sperm DNA, and commercially available proprietary formulations. The inclusion of specific blocking reagents may require modification of the hybridization conditions described above,  
25 due to problems with compatibility.

Of course, a polynucleotide which hybridizes only to polyA+ sequences (such as any 3' terminal polyA+ tract of a cDNA shown in the sequence listing), or to a complementary stretch of T (or U) residues, would not be included in the definition of "polynucleotide," since such a polynucleotide would hybridize to any nucleic acid molecule containing a poly (A) stretch or the complement thereof (e.g., practically any double-stranded cDNA clone generated using oligo dT as a primer).

The polynucleotide of the present invention can be composed of any polyribonucleotide or polydeoxribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. For example, polynucleotides can be composed of single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions. In addition, the polynucleotide can be composed of triple-stranded regions comprising RNA or DNA or both RNA and DNA. A polynucleotide may also contain one or more modified bases or DNA or RNA backbones modified for stability or for other reasons. "Modified" bases include, for example, tritylated bases and unusual bases such as inosine. A variety of modifications can be made to DNA and RNA; thus, "polynucleotide" embraces chemically, enzymatically, or metabolically modified forms.

The polypeptide of the present invention can be composed of amino acids joined to each other by peptide bonds or modified peptide bonds, i.e., peptide isosteres, and may contain amino acids other than the 20 gene-encoded amino acids. The polypeptides may be modified by either natural processes, such as posttranslational processing, or by chemical modification techniques which are well known in the art. Such modifications are well described in basic texts and in more

detailed monographs, as well as in a voluminous research literature. Modifications can occur anywhere in a polypeptide, including the peptide backbone, the amino acid side-chains and the amino or carboxyl termini. It will be appreciated that the same type of modification may be present in the same or varying degrees at several sites in a given polypeptide. Also, a given polypeptide may contain many types of modifications. Polypeptides may be branched, for example, as a result of ubiquitination, and they may be cyclic, with or without branching. Cyclic, branched, and branched cyclic polypeptides may result from posttranslation natural processes or may be made by synthetic methods. Modifications include acetylation, acylation, ADP-ribosylation, amidation, covalent attachment of flavin, covalent attachment of a heme moiety, covalent attachment of a nucleotide or nucleotide derivative, covalent attachment of a lipid or lipid derivative, covalent attachment of phosphatidylinositol, cross-linking, cyclization, disulfide bond formation, demethylation, formation of covalent cross-links, formation of cysteine, formation of pyroglutamate, formylation, gamma-carboxylation, glycosylation, GPI anchor formation, hydroxylation, iodination, methylation, myristoylation, oxidation, pegylation, proteolytic processing, phosphorylation, prenylation, racemization, selenoylation, sulfation, transfer-RNA mediated addition of amino acids to proteins such as arginylation, and ubiquitination. (See, for instance, PROTEINS - STRUCTURE AND MOLECULAR PROPERTIES, 2nd Ed., T. E. Creighton, W. H. Freeman and Company, New York (1993); POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, B. C. Johnson, Ed., Academic Press, New York, pgs. 1-12 (1983); Seifter et al., Meth Enzymol 182:626-646 (1990); Rattan et al., Ann NY Acad Sci 663:48-62 (1992).)

"SEQ ID NO:X" refers to a polynucleotide sequence while "SEQ ID NO:Y" refers to a polypeptide sequence, both sequences identified by an integer specified in Table 1.

"A polypeptide having biological activity" refers to polypeptides exhibiting activity similar, but not necessarily identical to, an activity of a polypeptide of the present invention, including mature forms, as measured in a particular biological assay, with or without dose dependency. In the case where dose dependency does  
5 exist, it need not be identical to that of the polypeptide, but rather substantially similar to the dose-dependence in a given activity as compared to the polypeptide of the present invention (i.e., the candidate polypeptide will exhibit greater activity or not more than about 25-fold less and, preferably, not more than about tenfold less activity, and most preferably, not more than about three-fold less activity relative to  
10 the polypeptide of the present invention.)

Many proteins (and translated DNA sequences) contain regions where the amino acid composition is highly biased toward a small subset of the available residues. For example, membrane spanning domains and signal peptides (which are also membrane spanning) typically contain long stretches where Leucine (L), Valine  
15 (V), Alanine (A), and Isoleucine (I) predominate. Poly-Adenosine tracts (polyA) at the end of cDNAs appear in forward translations as poly-Lysine (poly-K) and poly-Phenylalanine (poly-F) when the reverse complement is translated. These regions are often referred to as "low complexity" regions.

Such regions can cause database similarity search programs such as BLAST to  
20 find high-scoring sequence matches that do not imply true homology. The problem is exacerbated by the fact that most weight matrices (used to score the alignments generated by BLAST) give a match between any of a group of hydrophobic amino acids (L,V and I) that are commonly found in certain low complexity regions almost as high a score as for exact matches.

25 In order to compensate for this, BLASTX.2 (version 2.0a5MP-WashU) employs two filters ("seg" and "xnu") which "mask" the low complexity regions in a

particular sequence. These filters parse the sequence for such regions, and create a new sequence in which the amino acids in the low complexity region have been replaced with the character "X". This is then used as the input sequence (sometimes referred to herein as "Query" and/or "Q") to the BLASTX program. While this regime helps to ensure that high-scoring matches represent true homology, there is a negative consequence in that the BLASTX program uses the query sequence that has been masked by the filters to draw alignments.

Thus, a stretch of "X"s in an alignment shown in the following application does not necessarily indicate that either the underlying DNA sequence or the translated protein sequence is unknown or uncertain. Nor is the presence of such stretches meant to indicate that the sequence is identical or not identical to the sequence disclosed in the alignment of the present invention. Such stretches may simply indicate that the BLASTX program masked amino acids in that region due to the detection of a low complexity region, as defined above. In all cases, the reference sequence(s) (sometimes referred to herein as "Subject", "Sbjct", and/or "S") indicated in the specification, sequence table (Table 1), and/or the deposited clone is (are) the definitive embodiment(s) of the present invention, and should not be construed as limiting the present invention to the partial sequence shown in an alignment, unless specifically noted otherwise herein.

20

### **Polynucleotides and Polypeptides of the Invention**

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 1**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting

25

example, the sequence accessible through the following database accession no.

gil773414 (all information available through the recited accession number is

incorporated herein by reference) which is described therein as "beta galactosidase

[Cloning vector pBBR1MCS-2]". A partial alignment demonstrating the observed

5 homology is shown immediately below.

10 >gi|773414 beta galactosidase [Cloning vector pBBR1MCS-2] >gi|833819 LacZ alpha  
peptide [Cloning vector pBBR1MCS-3] >gi|833823 LacZ alpha peptide  
[Cloning vector pBBR1MCS-4] >gi|833827 LacZ alpha peptide [Cloning  
vector pBBR1MCS-5] >sp|Q57344|Q57344 LACZ ALPHA PEPTIDE.  
Length = 121

Plus Strand HSPs:

15 Score = 176 (62.0 bits), Expect = 2.9e-19, Sum P(2) = 2.9e-19  
Identities = 32/41 (78%), Positives = 34/41 (82%), Frame = +1

20 Q: 1165 PTILXTSSLLVPNSCSPGDPLVLERPPPRWSSNSPYSESYY 1287  
P+ S L+ NSCSPGDPLVLERPPPRWSSNSPYSESYY  
S: 24 PSRSTVSISLISNSCSPGDPLVLERPPPRWSSNSPYSESYY 64

Score = 84 (29.6 bits), Expect = 2.9e-19, Sum P(2) = 2.9e-19  
Identities = 16/18 (88%), Positives = 16/18 (88%), Frame = +3

25 Q: 3 SAQLTLTKGNKSWVRAPP 56  
SAQLTLTKGNKSWV PP  
S: 7 SAQLTLTKGNKSWVPGPP 24

30 The segments of gil773414 that are shown as "S" above are set out in  
the sequence listing as SEQ ID NO. 107 and SEQ ID NO. 109. Based on the  
structural similarity, these homologous polypeptides are expected to share at least  
some biological activities. Such activities are known in the art, some of which are  
described elsewhere herein. Assays for determining such activities are also known in  
the art, some of which have been described elsewhere herein.

35 Preferred polypeptides of the invention comprise a polypeptide having the  
amino acid sequence set out in the sequence listing as SEQ ID NO. 108 and/or SEQ  
ID NO. 110 which correspond to the "Q" sequences in the alignment shown above  
(gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Fetal Kidney; Stomach cancer (human), re-excision; Human Fetal Brain.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 59 as residues: Asn-26 to Thr-33. Polynucleotides encoding said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:11 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1275 of SEQ ID NO:11, b is an integer of 15 to 1289, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:11, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 2**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Cerebellum and to a lesser extent in Activated T-cells; Apoptotic T-cell, re-excision; Human Umbilical Vein, Reexcision; Ulcerative Colitis; Colon Tumor; Human Fetal Lung III; Human Placenta; Bone marrow; Human Adult Pulmonary, re-excision; Colon Normal III; NCI\_CGAP\_GC4; NCI\_CGAP\_Lu5; Soares\_NbHFB; Human Osteoclastoma; Human Amygdala; Monocyte activated and Soares\_pineal\_gland\_N3HPG.



Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:12 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

5 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2899 of SEQ ID NO:12, b is an integer of 15 to 2913, where both a and b correspond to the positions of

10 nucleotide residues shown in SEQ ID NO:12, and where b is greater than or equal to a + 14.

### **FEATURES OF PROTEIN ENCODED BY GENE NO: 3**

It has been discovered that this gene is expressed primarily in the following

15 tissues/cDNA libraries: Human Neutrophil; Human Brain, Striatum; Primary Dendritic Cells, lib 1.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:13 and may have been publicly available prior to conception of

20 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1680 of SEQ ID NO:13, b

25 is an integer of 15 to 1694, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:13, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 4

- 5           It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Myeloid Progenitor Cell Line and to a lesser extent in TF-1 Cell Line GM-CSF Treated; HUMAN JURKAT MEMBRANE BOUND POLYSOMES; HL-60, PMA 4H, re-excision; Bone Marrow Cell Line (RS4,11); Soares fetal liver spleen 1NFLS; Normal Human Trabecular Bone Cells; Human OB
- 10   MG63 treated (10 nM E2) fraction I; Soares retina N2b4HR; Soares\_NhHMPu\_S1; Human Umbilical Vein, Reexcision; Synovial Fibroblasts (control); Human Microvascular Endothelial Cells, fract. A; Human Bone Marrow, treated; Soares ovary tumor NbHOT; Soares\_total\_fetus\_Nb2HF8\_9w; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Soares\_senescent\_fibroblasts\_NbHSF; H.
- 15   hypothalamus, frac A; H. Frontal Cortex, Epileptic; Human epithelioid sarcoma; Human Pituitary, re-excision; HUMAN TONSILS, FRACTION 2; Soares retina N2b5HR; Human Primary Breast Cancer; Invasive poorly differentiated lung adenocarcinoma, metastatic; Human endometrial stromal cells-treated with estradiol; Healing groin wound, 7.5 hours post incision; Human Colon, re-excision;
- 20   Soares\_total\_fetus\_Nb2HF8\_9w; Healing groin wound, 6.5 hours post incision; Spleen metastatic melanoma; Breast Cancer Cell line, angiogenic; NCI\_CGAP\_GC6; NCI\_CGAP\_Ut2; NCI\_CGAP\_Pan1; Olfactory epithelium,nasalcavity; Human Adipose; Macrophage (GM-CSF treated); NCI\_CGAP\_GC4; NCI\_CGAP\_Co12; NCI\_CGAP\_GCB1; NCI\_CGAP\_Pr25; Smooth muscle, serum induced,re-exc;
- 25   CHME Cell Line,untreated; Smooth muscle, serum treated; Normal colon; Soares melanocyte 2NbHM; Soares\_multiple\_sclerosis\_2NbHMSP; Primary Dendritic

cells,frac 2; Human Fetal Lung III; Activated T-Cell (12hs)/Thiouridine labelledEco;  
Human adult (K.Okubo); NCI\_CGAP\_Brn25; Soares\_multiple\_sclerosis\_2NbHMSP;  
T Cell helper I; Human Endometrial Tumor; Activated T-cell(12h)/Thiouridine-re-  
excision; Human 8 Week Whole Embryo and Primary Dendritic Cells, lib 1.

5 Preferred polypeptides of the present invention comprise immunogenic  
epitopes shown in SEQ ID NO: 62 as residues: Pro-21 to Trp-27, Thr-33 to Pro-39,  
Pro-62 to Trp-78, Pro-86 to Phe-91, Thr-109 to Ser-114. Polynucleotides encoding  
said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly  
10 available and accessible through sequence databases. Some of these sequences are  
related to SEQ ID NO:14 and may have been publicly available prior to conception of  
the present invention. Preferably, such related polynucleotides are specifically  
excluded from the scope of the present invention. To list every related sequence  
would be cumbersome. Accordingly, preferably excluded from the present invention  
15 are one or more polynucleotides comprising a nucleotide sequence described by the  
general formula of a-b, where a is any integer between 1 to 1214 of SEQ ID NO:14, b  
is an integer of 15 to 1228, where both a and b correspond to the positions of  
nucleotide residues shown in SEQ ID NO:14, and where b is greater than or equal to a  
+ 14.

20

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 5**

It has been discovered that this gene is expressed primarily in the following  
tissues/cDNA libraries: Human Old Ovary; H. Epididymus, cauda; Human Adipose  
Tissue, re-excision; Stratagene liver (#937224); Human Gall Bladder; Endothelial  
25 cells-control; Soares\_pregnant\_uterus\_NbHPU; Human Amygdala; Neutrophils IL-1  
and LPS induced; Soares fetal liver spleen 1NFLS.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 63 as residues: Arg-14 to Ile-24. Polynucleotides encoding said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:15 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 874 of SEQ ID NO:15, b is an integer of 15 to 888, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:15, and where b is greater than or equal to a + 14.

15

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 6**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain 1NIB and to a lesser extent in Stratagene ovary (#937217); NCI\_CGAP\_GCB1; Soares ovary tumor NbHOT; Monocyte activated; Human Cerebellum; Soares placenta Nb2HP; Soares fetal liver spleen 1NFLS; Macrophage-oxLDL; Human Hypothalamus, Schizophrenia; Human Adipose Tissue, re-excision; Soares\_senescent\_fibroblasts\_NbHSF; NCI\_CGAP\_Brn25; Human Pancreas Tumor; Soares\_NhHMPu\_S1; Soares adult brain N2b5HB55Y; Stratagene colon (#937204); Human adult testis, large inserts; Stratagene liver (#937224); Pancreas Islet Cell Tumor; Fetal Heart; 12 Week Old Early Stage Human; Endothelial-induced; Soares\_fetal\_heart\_NbHH19W; Stratagene colon (#937204);

25

- Prostate-BPH subtracted II; Larynx Tumour; Human Pituitary; HL-60, RA 4h, Subtracted; Larynx carcinoma III; Human Adult Pulmonary; Human Pancreatic Carcinoma; Human Pituitary, subtracted; H. Epididymus, cauda; Human Whole Brain #2 - Oligo dT > 1.5Kb; Jurkat T-Cell, S phase; Soares\_fetal\_heart\_NbHH19W;
- 5 H. Kidney Medulla, re-excision; CD34 depleted Buffy Coat (Cord Blood); KMH2; Human Thymus; NCI\_CGAP\_Co8; NCI\_CGAP\_Lu5; NCI\_CGAP\_Kid3; NCI\_CGAP\_Kid5; NCI\_CGAP\_Kid6; NCI\_CGAP\_Br1.1; Monocyte activated, re-excision; L428; 12 Week Old Early Stage Human, II; Human Adult Testes, Large Inserts, Reexcision; Merkel Cells; Human Pancreas Tumor, Reexcision; Spinal cord;
- 10 Ulcerative Colitis; Soares breast 2NbHBst; Human Adrenal Gland Tumor; Macrophage-oxLDL, re-excision; Human Gall Bladder; Colon Carcinoma; Colon Normal II; Adipocytes; Dendritic cells, pooled; Human Synovial Sarcoma; Activated T-Cell (12hs)/Thiouridine labelledEco; Soares\_testis\_NHT; H. Frontal cortex,epileptic,re-excision; Hodgkin's Lymphoma II and Osteoblasts.
- 15 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 64 as residues: Cys-2 to Leu-8. Polynucleotides encoding said polypeptides are also encompassed by the invention.
- Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are
- 20 related to SEQ ID NO:16 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the
- 25 general formula of a-b, where a is any integer between 1 to 3225 of SEQ ID NO:16, b is an integer of 15 to 3239, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:16, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 7**

5           It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Adipose; Human Fetal Brain, normalized A5002F.

          Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:17 and may have been publicly available prior to conception of  
10   the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 940 of SEQ ID NO:17, b  
15   is an integer of 15 to 954, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:17, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 8**

20           It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Stratagene NT2 neuronal precursor 937230 and to a lesser extent in Human Amygdala Depression, re-excision; Human Fetal Epithelium (Skin); Stratagene hNT neuron (#937233); Human Umbilical Vein Endothelial Cells, uninduced; Human Fetal Lung III; Spleen, Chronic lymphocytic leukemia and Soares  
25   infant brain 1NIB.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:18 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

5 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 316 of SEQ ID NO:18, b is an integer of 15 to 330, where both a and b correspond to the positions of

10 nucleotide residues shown in SEQ ID NO:18, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 9**

It has been discovered that this gene is expressed primarily in the following

15 tissues/cDNA libraries: Prostate BPH; Human Amygdala.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:19 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

20 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1950 of SEQ ID NO:19, b is an integer of 15 to 1964, where both a and b correspond to the positions of

25 nucleotide residues shown in SEQ ID NO:19, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 10**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Synovial hypoxia-RSF subtracted;

- 5 Soares\_fetal\_heart\_NbHH19W; Spleen, Chronic lymphocytic leukemia and to a lesser extent in Spleen/normal; NCI\_CGAP\_GCB1; Soares\_fetal\_lung\_NbHL19W; Soares\_parathyroid\_tumor\_NbHPA; Soares infant brain 1NIB; Thalamus; Human White Fat; HUMAN TONSILS, FRACTION 2; Frontal lobe,dementia,re-excision; Human Hypothalamus,schizophrenia, re-excision; H. Kidney Cortex, subtracted;
- 10 Human Prostate; human ovarian cancer; Human umbilical vein endothelial cells, IL-4 induced; Human Rhabdomyosarcoma; Ulcerative Colitis; Colon Carcinoma; Soares melanocyte 2NbHM; Human Amygdala; Human Bone Marrow, treated and Soares placenta Nb2HP.

- Preferred polypeptides of the present invention comprise immunogenic
- 15 epitopes shown in SEQ ID NO: 68 as residues: His-23 to Asn-28, Phe-55 to Asp-61. Polynucleotides encoding said polypeptides are also encompassed by the invention.

- Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:20 and may have been publicly available prior to conception of
- 20 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1053 of SEQ ID NO:20, b
- 25 is an integer of 15 to 1067, where both a and b correspond to the positions of



nucleotide residues shown in SEQ ID NO:20, and where b is greater than or equal to a + 14.

## FEATURES OF PROTEIN ENCODED BY GENE NO: 11

- 5           The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gnl|PID|e1291794 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "X-like 1 protein [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

```

>gnl|PID|e1291794 (AJ005821) X-like 1 protein [Homo sapiens]
>sp|E1291794|E1291794 X-LIKE 1 PROTEIN.
15           Length = 3027

Plus Strand HSPs:

Score = 923 (324.9 bits), Expect = 3.1e-90, P = 3.1e-90
20           Identities = 173/294 (58%), Positives = 221/294 (75%), Frame = +3

Q:       9 FIRYIFTKKRKQSEVEADLGYPGGKRAKVIHKESDMIMAFSVNKCNEIVLASTHDVQEL 188
         FI+ IFTKKR +E+EADLGYPGGKA++IHKESD+I AF+VNKAN N I +AS+HDVQEL
25       S: 2608 FIKNIFTKKRCLNEIEADLGYPGGKARIHKESDIITAFVANKANRNCIAIASSHDVQEL 2667

Q:       189 DVTSLACQSYIWIWIGEEYDRESKSSDD--VDYRGSTTTLYQPSATSYASQVHPPSSLPW 362
         DV+ +LA Q Y W+ ++ + E+K S+D V +       T Q   T Y+ S   P ++PW
30       S: 2668 DVSGILATQVYTWVDDDDIEVETKGSDFLVIHARDDLTAVQ-GTTPYTHSNPGTIPINMPW 2726

Q:       363 LGTGQTSTGASVLMKRNHNGKRMTSHPVHQYYLTGAQDGSVRMFEWTRPQQLVCFRQAG 542
         LG+ QT   GASV++K+ ++N +RMTSHP   YYLTGAQDGSVRMFEW   QQ+ CFR   G
35       S: 2727 LGSTQTGRGASVMIKKAINNVRRMTSHPTLPYYLTGAQDGSVRMFEWGHSSQITCFRSGG 2786

Q:       543 NARVTRLYFNSQGNKCGVADGEGFLSIWQVNO-----TASNPKPYMSWQCHSKATSDFAF 707
         N+RVTR+ FN QGNK G+ D +G+LS++Q N       T S PKPY++WQCH+K   +DF F
40       S: 2787 NSRVTRMRFNYQGNKFGIVDADGYLSLYQTNWKCCPVTGSMKPYLTWQCHNKTANDFVF 2846

Q:       708 ITSSSLVATSGHSNDNRNVLWDTLISPGNSLIHGFTCHDHGATVLQYAPKQQLL 872
         ++SSSL+AT+G S D RNVCLWDTL++P +SL+H FTCHD GATVL YAPK QLL
40       S: 2847 VSSSLIATAGLSTDXRNVCLWDTLVAPADSLVHAFTCHDSGATVLAYAPKHQLL 2901

```

The segment of gnlPIDle1291794 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 111. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein.

5 Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 112 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a

10 sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain 1NIB; Monocyte activated and to a lesser extent in Ulcerative Colitis; Human Fetal Brain; Human Amygdala and Human Bone Marrow, treated.

15 Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 69 as residues: Met-1 to Lys-6. Polynucleotides encoding said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

20 related to SEQ ID NO:21 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the

25 general formula of a-b, where a is any integer between 1 to 860 of SEQ ID NO:21, b is an integer of 15 to 874, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:21, and where b is greater than or equal to a + 14.

## FEATURES OF PROTEIN ENCODED BY GENE NO: 12

5           The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gnl|PID|e1360930 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "DET1 protein  
10 [Lycopersicon esculentum]". A partial alignment demonstrating the observed homology is shown immediately below.

```

>gnl|PID|e1360930 (AJ222798) DET1 protein [Lycopersicon esculentum]
>sp|E1360930|E1360930 DET1 PROTEIN.
15           Length = 523

Plus Strand HSPs:

Score = 250 (88.0 bits), Expect = 1.5e-32, Sum P(2) = 1.5e-32
20           Identities = 64/169 (37%), Positives = 96/169 (56%), Frame = +3

Q:     54 FINSCLKHRLLVYL----WRRAEQDGSAMA-KRRFFQYFDQLRQLRMWKMQLLDENHLFIK 218
          F++ +K RLL Y+    W A+Q           K++F+ +F    L +WK+Q LD +HL IK
S:     264 FLSGIKQRLLSYIFRGIWNEADQTMRVQCLKKKFYFHFQDYIDLIIWKVQFLDRHHLLIK 323

25           Q:     219 YTSEDVVTLRVTDPSQASFFVYVMVTTEVIADFENTSDELLELFENFCDLFRNATLHS- 395
                  + S D    R D    SFF VYNM TTE++A ++N++DEL LFE F D F ++ S
S:     324 FGSVDGGVSRNAD-IHPSFFAVYNMETTEIVAFYQNSADELYFLFELFSDHFDVSSKSSL 382

30           Q:     396 EVQFPSCASSNNFARQIQRFRKDTIINAKYGGHTEAVRRLGQLPISAQSYSGTP 560
                  + F S S+N A + R K+    N       ++ V++++ LP S QS S +P
S:     383 HMNFMSSHNNIHALEQLRCTKNKATN-----FSQFVKMMASLPCSCQSQSPSP 432

```

35           The segment of gnl|PID|e1360930 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 113. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein.

Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 114 which  
5 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Adult Heart, re-excision; NCI\_CGAP\_GCB1; Soares\_fetal\_lung\_NbHL19W; Soares\_pineal\_gland\_N3HPG and to a lesser extent in  
10 Human Prostate; Soares placenta Nb2HP.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:22 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
15 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1332 of SEQ ID NO:22, b is an integer of 15 to 1346, where both a and b correspond to the positions of  
20 nucleotide residues shown in SEQ ID NO:22, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 13**

It has been discovered that this gene is expressed primarily in the following  
25 tissues/cDNA libraries: Soares ovary tumor NbHOT; Soares fetal liver spleen 1NFLS and to a lesser extent in Bone Marrow Cell Line (RS4,11); Human endometrial

- stromal cells-treated with progesterone; Macrophage (GM-CSF treated); Early Stage Human Brain; NCI\_CGAP\_GCB1; Soares infant brain 1NIB; Human Pituitary, subtracted; Amniotic Cells - Primary Culture; Macrophage-oxLDL, re-excision; Soares\_pregnant\_uterus\_NbHPU; Soares breast 3NbHBst; Soares melanocyte
- 5 2NbHM; Soares placenta Nb2HP; Soares retina N2b4HR; Human Pituitary, subt IX; H Macrophage (GM-CSF treated), re-excision; CD34 positive cells (Cord Blood); Human Cerebellum; Human Adult Heart, subtracted; Smooth muscle-ILb induced; Human Pineal Gland; Human Normal Breast; Human endometrial stromal cells-treated with estradiol; Human Fetal Kidney; Human Uterine Cancer;
- 10 Hemangiopericytoma; Smooth muscle, serum induced, re-exc; Endothelial-induced; Endothelial cells-control; Human Microvascular Endothelial Cells, fract. A; HM1; NCI\_CGAP\_Kid5; Human 7 Weeks Old Embryo, subtracted; NCI\_CGAP\_Kid3; Human Pituitary, re-excision; Human Aortic Endothelium; Human Fetal Bone; Smooth Muscle- HASTE normalized; Glioblastoma;
- 15 Soares\_parathyroid\_tumor\_NbHPA; 12 Week Old Early Stage Human, II; Soares\_testis\_NHT; Soares\_parathyroid\_tumor\_NbHPA; Human Pancreas Tumor, Reexcision; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Epithelial-TNF $\alpha$  and INF induced; Human Fetal Brain; Human Thymus Stromal Cells; Human Liver, normal; Smooth muscle, serum treated; Adipocytes; Human Testes Tumor; Colon Tumor II;
- 20 Soares\_fetal\_lung\_NbHL19W; Human Fetal Kidney, Reexcision; Soares\_fetal\_heart\_NbHH19W; HUMAN B CELL LYMPHOMA; Human Bone Marrow, treated; Hodgkin's Lymphoma II; Human fetal brain (TFujiwara); NCI\_CGAP\_Co3; NCI\_CGAP\_Ew1; NCI\_CGAP\_Kid6; NCI\_CGAP\_Pr22; Osteoblasts; Soares\_pregnant\_uterus\_NbHPU; Keratinocyte;
- 25 Soares\_fetal\_lung\_NbHL19W; Soares\_parathyroid\_tumor\_NbHPA; Soares\_senescent\_fibroblasts\_NbHSF; HI-60, untreated, subtracted; Human

- Cardiomyopathy, RNA remake; HE7, subtracted by hybridization with E7 cDNA;  
 CAMAIEe Cell Line; Human Adult Lymph Node, subtracted; Gessler Wilms tumor;  
 HM3; Soares\_pineal\_gland\_N3HPG; Soares\_pregnant\_uterus\_NbHPU;  
 Soares\_total\_fetus\_Nb2HF8\_9w; Colon, normal; WI 38 cells; Human Thymus
- 5 Tumor, subtracted; Bone Cancer; LNCAP + 30nM R1881; NCI\_CGAP\_GC4;  
 NCI\_CGAP\_Lu5; NCI\_CGAP\_Kid5; NCI\_CGAP\_Pan1; Normal lung; LNCAP  
 untreated; Soares retina N2b5HR; Human Fetal Brain; Human Cerebellum,  
 subtracted; Human Primary Breast Cancer, re-excision; Human Cardiomyopathy,  
 subtracted; Human Adult Retina; Healing Abdomen wound, 70&90 min post incision;
- 10 Human Thyroid; Amniotic Cells - TNF induced; Human Quadriceps;  
 Soares\_testis\_NHT; Lung Carcinoma A549 TNFalpha activated; Human Skin Tumor;  
 Soares\_pineal\_gland\_N3HPG; Soares\_pregnant\_uterus\_NbHPU; Stratagene corneal  
 stroma (#937222); Raji Cells, cyclohexamide treated; Healing groin wound - zero hr  
 post-incision (control); Human Synovium; NTERA2 + retinoic acid, 14 days;
- 15 Synovial hypoxia-RSF subtracted; H. Kidney Cortex, subtracted; Stratagene  
 endothelial cell 937223; Salivary Gland, Lib 2; LNCAP prostate cell line; Human  
 endometrial stromal cells; Healing groin wound, 6.5 hours post incision; wilm's  
 tumor; Human Manic Depression Tissue; Human fetal heart, Lambda ZAP Express;  
 H. Lymph node breast Cancer; Mo7e Cell Line GM-CSF treated (1ng/ml);
- 20 Soares\_testis\_NHT; Soares\_fetal\_heart\_NbHH19W;  
 Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Soares\_senescent\_fibroblasts\_NbHSF; TF-1  
 Cell Line GM-CSF Treated; Breast Cancer Cell line, angiogenic; Human Brain;  
 Striatum; Human Activated T-Cells; Macrophage-oxLDL; Spinal cord;  
 Soares\_fetal\_heart\_NbHH19W; Human Thymus; Bone Marrow Stromal Cell,
- 25 untreated; Soares breast 2NbHBst; Soares\_pregnant\_uterus\_NbHPU;  
 Soares\_pregnant\_uterus\_NbHPU; Human Gall Bladder; PC3 Prostate cell line;

- Human Ovarian Cancer Reexcision; Resting T-Cell Library,II; 12 Week Old Early Stage Human; Human Substantia Nigra; breast lymph node CDNA library; Colon Normal II; Soares\_parathyroid\_tumor\_NbHPA;
- Soares\_placenta\_8to9weeks\_2NbHP8to9W; Human Synovial Sarcoma; Human Fetal Lung III; 12 Week Early Stage Human II, Reexcision; Bone marrow; Human Primary Breast Cancer Reexcision; CD34 depleted Buffy Coat (Cord Blood), re-excision; Colon Normal III; Human Amygdala; Soares\_fetal\_liver\_spleen\_INFLS\_S1; H. Frontal cortex,epileptic,re-excision; NCI\_CGAP\_AA1; NCI\_CGAP\_Co9; NCI\_CGAP\_Lu6; NCI\_CGAP\_Pr9; NCI\_CGAP\_Co10; NCI\_CGAP\_Kid3;
- 10 NCI\_CGAP\_Br1.1; NCI\_CGAP\_Brn23; NCI\_CGAP\_Brn25;
- Soares\_fetal\_heart\_NbHH19W; Nine Week Old Early Stage Human and Soares\_placenta\_8to9weeks\_2NbHP8to9W.

- Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 71 as residues: Leu-32 to Gly-46. Polynucleotides encoding said polypeptides are also encompassed by the invention.

- Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:23 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 579 of SEQ ID NO:23, b is an integer of 15 to 593, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:23, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 14**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Synovial hypoxia and to a lesser extent in human corpus colosum; Soares\_NhHMPu\_S1; Human Adipose; Ulcerative Colitis; Epithelial-TNFa and INF induced; Human Ovarian Cancer Reexcision; Human Placenta; Normal colon; Human Amygdala; Human 8 Week Whole Embryo and Soares infant brain INIB.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:24 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1168 of SEQ ID NO:24, b is an integer of 15 to 1182, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:24, and where b is greater than or equal to a + 14.

20

**FEATURES OF PROTEIN ENCODED BY GENE NO: 15**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil3002527 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "neuronal thread

25



protein AD7c-NTP [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

```

5      >gi|3002527 (AF010144) neuronal thread protein AD7c-NTP [Homo sapiens]
      >sp|O60448|O60448 NEURONAL THREAD PROTEIN AD7C-NTP.
      Length = 375

      Minus Strand HSPs:

10     Score = 114 (40.1 bits), Expect = 1.5e-10, Sum P(2) = 1.5e-10
      Identities = 25/40 (62%), Positives = 28/40 (70%), Frame = -1

      Q:   711 FAFQ*NQGFTMLARMVPI*-PCDPPASASQSARTTGVNHH 595
           F F   GFTM AR++ I  PCD PASASQSA  TGV+HH
15     S:   253 FVFLVEMGFTMFARLILISGPCDLPASASQSAGITGVSHH 292

```

The segment of gil3002527 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 115. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities.

20 Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 116 which  
 25 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares placenta Nb2HP and to a lesser extent in Human Synovium; Soares fetal liver spleen 1NFLS; Soares\_multiple\_sclerosis\_2NbHMSP;  
 30 Larynx tumor; Human brain cDNA; Human Normal Cartilage, Fraction I; Human Normal Cartilage Fraction II; Synovial hypoxia; Soares\_pregnant\_uterus\_NbHPU; Soares\_senescent\_fibroblasts\_NbHSF; Stratagene pancreas (#937208); Human Bone Marrow, re-excision; Stratagene fetal spleen (#937205); 12 Week Old Early Stage

Human, II; Human Hippocampus; 12 Week Old Early Stage Human; Endothelial cells-control; Monocyte activated and Soares\_fetal\_lung\_NbHL19W.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 73 as residues: Lys-18 to Gly-23, Arg-25 to Ser-31.

- 5 Polynucleotides encoding said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:25 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
10 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 862 of SEQ ID NO:25, b is an integer of 15 to 876, where both a and b correspond to the positions of  
15 nucleotide residues shown in SEQ ID NO:25, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 16

The computer algorithm BLASTX has been used to determine that the  
20 translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil3002527 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "neuronal thread protein AD7c-NTP [Homo sapiens]". A partial alignment demonstrating the observed  
25 homology is shown immediately below.

>gi|3002527 (AF010144) neuronal thread protein AD7c-NTP [Homo sapiens]

>sp|O60448|O60448 NEURONAL THREAD PROTEIN AD7C-NTP.  
Length = 375

Plus Strand HSPs:

5  
Score = 241 (84.8 bits), Expect = 1.5e-19, P = 1.5e-19  
Identities = 47/67 (70%), Positives = 50/67 (74%), Frame = +1

10  
Q: 493 VAQAGVQWRDLGSPQHPPPGFKRFSCLSLSSWEYRHAFLHLANFCIFS\*DGVPFRWSGW 672  
V QAGVQW +LGS Q PPG KRFSCLSL SSW+Y H P H ANFCIF GV P SGW  
S: 309 VTQAGVQWPNLGSLQPLPPGLKRFSCLSLPSSWDYGHLPHPANFCIFIRGGVSPYLSGW 368

Q: 673 SRTPDLR 693  
S+TPDLR

15  
S: 369 SQTPDLR 375

Score = 227 (79.9 bits), Expect = 1.2e-17, Sum P(2) = 1.2e-17  
Identities = 49/81 (60%), Positives = 54/81 (66%), Frame = +2

20  
Q: 485 SLLLPKLECNGAISAHHNIRLLGXXXXXXXXXXXXGNTGM-RHYTWLIFVFLVEMGFFHV 661  
SLLLP+LECNGAISAH N+RL G G TGM H +++ FLVEM F HV  
S: 4 SLLLPRLCNGAISAHRNRLPGSSDSPASASPVAGITGMCTHARLILYFFLVEMEFLHV 63

Q: 662 GQAGLELLTSGDPSTSASQRA 724  
GQAGLEL TS DPS SASQ A

25  
S: 64 GQAGLELPTSDDPSVSASQSA 84

The segments of gil3002527 that are shown as "S" above are set out in the sequence listing as SEQ ID NO. 117 and SEQ ID NO. 119. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 118 and/or SEQ ID NO. 120 which correspond to the "Q" sequences in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Eosinophils; Soares fetal liver spleen 1NFLS and to a

lesser extent in Primary Dendritic cells,frac 2; Human Fetal Heart and Human Adult Pulmonary, re-excision.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:26 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1351 of SEQ ID NO:26, b is an integer of 15 to 1365, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:26, and where b is greater than or equal to a + 14.

## 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 17

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. bbsl129340 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "X-linked retinopathy protein {C-terminal, clone XEH.8c} [human, Peptide Partial, 100 aa] [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

25       >bbsl129340 X-linked retinopathy protein {C-terminal, clone XEH.8c}  
       [human,  
                                   Peptide Partial, 100 aa] [Homo sapiens] >pir|A46010|A46010 X-  
       linked

retinopathy protein (C-terminal, clone XEH.8c) - human  
 (fragment)  
 >sp|Q07826|Q07826 X-LINKED RETINOPATHY PROTEIN (FRAGMENT).  
 Length = 100

5

Minus Strand HSPs:

Score = 118 (41.5 bits), Expect = 1.4e-11, Sum P(2) = 1.4e-11  
 Identities = 26/38 (68%), Positives = 28/38 (73%), Frame = -1

10

Q: 144 PGLSNPASASQVAGITGMHHHTWLTTFASPVAGITGVH 31  
 PG S+SPASAS+VAGITGMHHHT L F V TG H  
 S: 31 PGSSDSPASASRVAGITGMHHHTQLIFVFLVE--TGSH 66

15

The segment of bbs129340 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 121. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

20

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 122 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

25

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain 1NIB and to a lesser extent in Soares ovary tumor NbHOT; Soares\_testis\_NHT; Nine Week Old Early Stage Human; normalized infant brain cDNA; Soares breast 2NbHBst; NCI\_CGAP\_GCB1; Soares breast 3NbHBst; Colon Tumor II; Soares placenta Nb2HP; Human promyelocyte; Jia bone marrow stroma; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Stratagene lung carcinoma 937218; Normal lung; human colon cancer; Cem cells cyclohexamide treated; Human Colon Cancer, re-excision; Hepatocellular Tumor; Human Manic Depression Tissue; Human Infant Brain; H. Kidney Medulla, re-excision; Human

30

Umbilical Vein Endothelial Cells, uninduced; Human Pancreas Tumor; T-Cell PHA  
 24 hrs; Bone Marrow Stromal Cell, untreated; Human Liver, normal; Pancreas Islet  
 Cell Tumor; NCI\_CGAP\_Lu5; NCI\_CGAP\_Co10; Colon Tumor; Resting T-Cell  
 Library,II; Human T-Cell Lymphoma; KG1-a Lambda Zap Express cDNA library;  
 5 Dendritic cells, pooled; Soares melanocyte 2NbHM; Primary Dendritic cells,frac 2;  
 human tonsils; Human Adult Pulmonary,re-excision; Bone Marrow Cell Line  
 (RS4,11); T cell helper II and Soares fetal liver spleen 1NFLS.

Many polynucleotide sequences, such as EST sequences, are publicly  
 available and accessible through sequence databases. Some of these sequences are  
 10 related to SEQ ID NO:27 and may have been publicly available prior to conception of  
 the present invention. Preferably, such related polynucleotides are specifically  
 excluded from the scope of the present invention. To list every related sequence  
 would be cumbersome. Accordingly, preferably excluded from the present invention  
 are one or more polynucleotides comprising a nucleotide sequence described by the  
 15 general formula of a-b, where a is any integer between 1 to 1366 of SEQ ID NO:27, b  
 is an integer of 15 to 1380, where both a and b correspond to the positions of  
 nucleotide residues shown in SEQ ID NO:27, and where b is greater than or equal to a  
 + 14.

## 20 FEATURES OF PROTEIN ENCODED BY GENE NO: 18

It has been discovered that this gene is expressed primarily in the following  
 tissues/cDNA libraries: Soares adult brain N2b4HB55Y and to a lesser extent in  
 Soares ovary tumor NbHOT; Soares\_testis\_NHT; Stratagene fetal spleen (#937205);  
 Human Synovial Sarcoma; T cell helper II; Human Cerebellum; Gessler Wilms  
 25 tumor; Soares\_parathyroid\_tumor\_NbHPA; Normal trachea; Resting T-Cell; H.  
 Epididymus, cauda; NTERA2 + retinoic acid, 14 days; Olfactory

epithelium,nasalcavity; Soares breast 2NbHBst; Human Adrenal Gland Tumor;  
Human adult testis, large inserts; Pancreas Islet Cell Tumor;  
Soares\_multiple\_sclerosis\_2NbHMSP; Resting T-Cell Library,II;  
Soares\_placenta\_8to9weeks\_2NbHP8to9W; Human Neutrophil, Activated; CD34  
5 positive cells (Cord Blood); Human Endometrial Tumor; Human 8 Week Whole  
Embryo; NCI\_CGAP\_GC3; NCI\_CGAP\_Lu5; NCI\_CGAP\_GCB1 and Primary  
Dendritic Cells, lib 1.

Preferred polypeptides of the present invention comprise immunogenic  
epitopes shown in SEQ ID NO: 76 as residues: Lys-11 to Met-16. Polynucleotides  
10 encoding said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly  
available and accessible through sequence databases. Some of these sequences are  
related to SEQ ID NO:28 and may have been publicly available prior to conception of  
the present invention. Preferably, such related polynucleotides are specifically  
15 excluded from the scope of the present invention. To list every related sequence  
would be cumbersome. Accordingly, preferably excluded from the present invention  
are one or more polynucleotides comprising a nucleotide sequence described by the  
general formula of a-b, where a is any integer between 1 to 1185 of SEQ ID NO:28, b  
is an integer of 15 to 1199, where both a and b correspond to the positions of  
20 nucleotide residues shown in SEQ ID NO:28, and where b is greater than or equal to a  
+ 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 19**

It has been discovered that this gene is expressed primarily in Human Adrenal  
25 Gland Tumor.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 77 as residues: Glu-19 to Pro-27. Polynucleotides encoding said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:29 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1094 of SEQ ID NO:29, b is an integer of 15 to 1108, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:29, and where b is greater than or equal to a + 14.

15

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 20**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares\_pregnant\_uterus\_NbHPU and to a lesser extent in Testis, normal; Glioblastoma; Synovial Fibroblasts (Il1/TNF), subt; Hemangiopericytoma and Human Adrenal Gland Tumor.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:30 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

25



are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 916 of SEQ ID NO:30, b is an integer of 15 to 930, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:30, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 21**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Smooth muscle, control and to a lesser extent in Bone Marrow Stromal Cell, untreated; Human Testes; Human Adult Liver, subtracted; Human Gall Bladder, fraction II; B Cell lymphoma; Human Synovium; human corpus colosum; H Female Bladder, Adult; Human Bone Marrow, re-excision; human ovarian cancer; Human Adrenal Gland Tumor; Human Placenta; Normal colon; Human Fetal Lung III; Human Adult Pulmonary, re-excision; Human Bone Marrow, treated; Hodgkin's Lymphoma II and Nine Week Old Early Stage Human.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:31 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2083 of SEQ ID NO:31, b is an integer of 15 to 2097, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:31, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 22**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gn||PID|e206544 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "pval [Plasmodium vivax]". A partial alignment demonstrating the observed homology is shown immediately below.

```

10      >gnl|PID|e206544 pval [Plasmodium vivax] >sp|Q26195|Q26195-PVAL GENE.
        Length = 200

15      Minus Strand HSPs:

        Score = 154 (54.2 bits), Expect = 1.3e-13, Sum P(2) = 1.3e-13
        Identities = 29/55 (52%), Positives = 33/55 (60%), Frame = -3

20      Q: 1291 FVFVLRAGVSLCHPGWSAVVRSWLTATSTFVFKQXXXXXXXXXXWDYRHHVPPCPAN 1127
           F+F R V LCHPGWSAVV+S T STF+ KQ          WDYR +PP AN
        S: 108 FIFFRDRVLLCHPGWSAVVQSLFTVASTFLVKQSSCLGLPSSWDYRRIPPHLAN 162

        Score = 57 (20.1 bits), Expect = 1.3e-13, Sum P(2) = 1.3e-13
        Identities = 15/24 (62%), Positives = 16/24 (66%), Frame = -1

25      Q: 1098 LARLVLS*SQVIRPSRSPKVLGL 1027
           L RL+LNS QVI      PKVLGL
        S: 175 LPRILNSWPQVILLPWPPKVLGL 198

```

30 The segments of gn||PID|e206544 that are shown as "S" above are set out in the sequence listing as SEQ ID NO. 123 and SEQ ID NO. 125. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in

35 the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 124 and/or SEQ ID NO. 126 which correspond to the "Q" sequences in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

5 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Primary Dendritic Cells, lib 1 and to a lesser extent in Tongue carcinoma; H. Whole Brain #2, re-excision; Human Bone Marrow, re-excision; Human Adrenal Gland Tumor and Pancreas Islet Cell Tumor.

Many polynucleotide sequences, such as EST sequences, are publicly  
10 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:32 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention  
15 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1288 of SEQ ID NO:32, b is an integer of 15 to 1302, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:32, and where b is greater than or equal to a + 14.

20

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 23**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Primary Dendritic Cells, lib 1 and to a lesser extent in Osteoblasts; Activated T-cell(12h)/Thiouridine-re-excision; Macrophage-oxLDL, re-  
25 excision; Epithelial-TNF $\alpha$  and INF induced; Smooth muscle, serum treated; Smooth muscle, serum induced, re-exc; Amniotic Cells - Primary Culture; Stratagene lung

- (#937210); Primary Dendritic cells,frac 2; Macrophage (GM-CSF treated); HUMAN JURKAT MEMBRANE BOUND POLYSOMES; Activated T-Cell (12hs)/Thiouridine labelledEco; H Macrophage (GM-CSF treated), re-excision; Macrophage-oxLDL; Human T-Cell Lymphoma; T cell helper II; Monocyte
- 5 activated; Hodgkin's Lymphoma II; HUMAN B CELL LYMPHOMA; Human Microvascular Endothelial Cells, fract. A; Human 8 Week Whole Embryo; Human Fetal Kidney, Reexcision; Nine Week Old Early Stage Human; Human Bone Marrow, treated; Human Pancreas Tumor, Reexcision; Human Fetal Lung III; Human Adult Pulmonary, re-excision; Keratinocyte; human tonsils; Human
- 10 Rhabdomyosarcoma; Spleen, Chronic lymphocytic leukemia; T Cell helper I; Human Umbilical Vein, Reexcision; Bone Marrow Stromal Cell, untreated; Human Thymus Stromal Cells; Messangial cell, frac 2; Human Fetal Kidney; NTERA2, control; Adipocytes; Dendritic cells, pooled; Colon Tumor II; Human Cerebellum; Bone marrow; Colon Normal III; Soares fetal liver spleen 1NFLS; Endothelial-induced;
- 15 Bone Marrow Cell Line (RS4,11); STROMAL -OSTEOCLASTOMA; Jurkat T-Cell, S phase; breast lymph node CDNA library; Amniotic Cells - TNF induced; HSA 172 Cells; Monocyte activated, re-excision; Ulcerative Colitis; Human Eosinophils; Activated T-cells; Human Osteoclastoma Stromal Cells - unamplified; Human Endometrial Tumor; Smooth muscle, IL1b induced; Human umbilical vein
- 20 endothelial cells, IL-4 induced; PC3 Prostate cell line; Human Neutrophil, Activated; Fetal Heart; Aorta endothelial cells + TNF-a; Endothelial cells-control; Human Placenta; Stratagene neuroepithelium (#937231); Human Thymus; Human Testes Tumor; Human Pancreas Tumor; Human Fetal Brain; Human Synovial Sarcoma; Human Fetal Heart; Soares ovary tumor NbHOT; Activated T-Cells, 12 hrs, re-
- 25 excision; H. Lymph node breast Cancer; Human Thymus; T-Cell PHA 24 hrs; Normal colon; Soares placenta Nb2HP; Human Umbilical Vein, Endo. remake;

- Human Fetal Dura Mater; Human Adipose; Hemangiopericytoma; Colon Tumor; Colon Carcinoma; Soares melanocyte 2NbHM; CD34 depleted Buffy Coat (Cord Blood), re-excision; wilm's tumor; Human Activated Monocytes; Colon Normal II; Smooth muscle, control; Jia bone marrow stroma; Human Fetal Brain; Early Stage
- 5 Human Lung, subtracted; Human T-cell lymphoma, re-excision; Human Umbilical Vein Endothelial Cells, uninduced; Stratagene liver (#937224); Activated T-cells, 24 hrs, re-excision; Human Manic Depression Tissue; Human Infant Brain; Human Testes Tumor, re-excision; Human Whole Six Week Old Embryo; Human Amygdala; Human Testes; T-Cell PHA 16 hrs; Human Brain, Striatum; L428; Human Placenta;
- 10 Human Primary Breast Cancer Reexcision; Human Bone Marrow, re-excision; Human Osteoblasts II; Human Fetal Brain; HSC172 cells; Human Prostate Cancer, Stage C fraction; Stratagene placenta (#937225); Healing groin wound, 7.5 hours post incision; Stratagene colon (#937204); Jurkat T-cell G1 phase; Breast Cancer Cell line, angiogenic; Human Osteoclastoma; neutrophils control; Soares infant brain 1NIB;
- 15 Human Lung Cancer, re-excision; Human endometrial stromal cells-treated with estradiol; Human endometrial stromal cells-treated with progesterone; Healing groin wound, 6.5 hours post incision; Prostate BPH; Human Hypothalamus, Schizophrenia; Human Gall Bladder; eosinophil-IL5 induced; B Cell lymphoma; Stratagene pancreas (#937208); Human Adipose Tissue, re-excision; Human Osteosarcoma; Human
- 20 endometrial stromal cells; Human Colon, re-excision; Stratagene HeLa cell s3 937216; Human Neutrophil; KMH2; Stratagene fetal spleen (#937205); Liver, Hepatoma; Human Activated T-Cells, re-excision; Early Stage Human Brain; NCI\_CGAP\_Co12; NCI\_CGAP\_Pr25; Weizmann Olfactory Epithelium; Human OB HOS treated (10 nM E2) fraction I; Human Adult Pulmonary; Smooth Muscle Serum
- 25 Treated, Norm; Smooth muscle-ILb induced; Apoptotic T-cell, re-excision; Human Hypothalamus, schizophrenia, re-excision; H Female Bladder, Adult; TF-1 Cell Line

- GM-CSF Treated; Normal Human Trabecular Bone Cells; Stratagene ovarian cancer (#937219); Stratagene NT2 neuronal precursor 937230; Human Pre-Differentiated Adipocytes; Breast Lymph node cDNA library; Stratagene pancreas (#937208); Human Chronic Synovitis; CD34 depleted Buffy Coat (Cord Blood); Human
- 5 Activated T-Cells; Rejected Kidney, lib 4; Pancreas Islet Cell Tumor; Neutrophils control, re-excision; Stratagene neuroepithelium (#937231); Stratagene colon (#937204); Human OB MG63 treated (10 nM E2) fraction I; H. Atrophic Endometrium; Human Neutrophils, Activated, re-excision; Soares retina N2b4HR; Human Tonsils, Lib 2; Stratagene ovarian cancer (#937219); Stratagene muscle
- 10 937209; NCI\_CGAP\_Kid6; Human Uterine Cancer; Human Chondrosarcoma; Synovial Fibroblasts (control); Human Adrenal Gland Tumor; Gessler Wilms tumor; Human Substantia Nigra; Stratagene fibroblast (#937212); Stratagene ovarian cancer (#937219); Smooth muscle-edited A; Messangial cell, frac 1; Human Adult Spleen; Adipocytes, re-excision; Human Pancreatic Carcinoma; Human Skin Tumor;
- 15 Stratagene ovary (#937217); NTERA2 teratocarcinoma cell line+retinoic acid (14 days); Raji Cells, cyclohexamide treated; Human Normal Breast; HEL cell line; Synovial IL-1/TNF stimulated; pBMC stimulated w/ poly I/C; Breast Cancer cell line, MDA 36; Human Amygdala, re-excision; Stratagene endothelial cell 937223; Stratagene neuroepithelium NT2RAMI 937234; Synovial hypoxia; Stromal cell
- 20 TF274; Human Ovary; Fetal Liver, subtraction II; Ovarian Tumor 10-3-95; 12 Week Old Early Stage Human; Stratagene NT2 neuronal precursor 937230; Human OB HOS control fraction I; Human Aortic Endothelium; Human Primary Breast Cancer; Human Thyroid; Human Colon Cancer, re-excision; LNCAP prostate cell line; Human Osteoclastoma, re-excision; Stratagene colon (#937204); Myeloid Progenitor Cell
- 25 Line; Human Prostate; NCI\_CGAP\_Co12; NCI\_CGAP\_Lu1; NCI\_CGAP\_Pr2; NCI\_CGAP\_Pr23; NCI\_CGAP\_Br1.1; Soares\_parathyroid\_tumor\_NbHPA; Human

- Hippocampus; Stratagene NT2 neuronal precursor 937230; Human OB HOS treated (1 nM E2) fraction I; Saos2 Cells, Untreated; A1-CELL LINE; Human White Adipose; HUMAN STOMACH; Supt Cells, cyclohexamide treated; Human Fetal Bone; LPS activated derived dendritic cells; Human Epididymus; Human Fetal
- 5 Epithelium (Skin); Stratagene neuroepithelium (#937231); Brain Frontal Cortex, re-excision; H. Kidney Medulla, re-excision; NCI\_CGAP\_Co12; Human Adult Testes, Large Inserts, Reexcision; Soares\_senescent\_fibroblasts\_NbHSF; Soares\_fetal\_heart\_NbHH19W; normalized infant brain cDNA; Stratagene NT2 neuronal precursor 937230; NCI\_CGAP\_Pr2; NCI\_CGAP\_Pr3; Human fetal heart,
- 10 Lambda ZAP Express; Soares breast 3NbHBst; Human Testes, Reexcision; Soares\_senescent\_fibroblasts\_NbHSF; Human Hippocampus, prescreened; Human Greater Omentum, fract II remake.; Activated T-Cells, 8 hrs.; Human Umbilical Vein Endothelial cells, frac B, re-excision; HL-60, RA 4h, Subtracted; NCI\_CGAP\_Lu1; Human Primary Breast Cancer, re-excision; Human Colon Carcinoma (HCC) cell line;
- 15 Human Umbilical Vein Endothelial Cells, fract. A; Human Fetal Spleen; Human Placenta; Smooth muscle, control, re-excision; human colon cancer; Human Lung; Cem cells cyclohexamide treated; Human adult small intestine, re-excision; Soares adult brain N2b4HB55Y; Stomach cancer (human), re-excision; Hepatocellular Tumor; human corpus colosum; NTERA2 + retinoic acid, 14 days; H. Kidney Cortex,
- 20 subtracted; Stratagene endothelial cell 937223; Human Adult Small Intestine; Mo7e Cell Line GM-CSF treated (1ng/ml); Soares\_senescent\_fibroblasts\_NbHSF; NCI\_CGAP\_Br1.1; Apoptotic T-cell; Stratagene NT2 neuronal precursor 937230; NCI\_CGAP\_AA1; Pancreatic Islet; Hepatocellular Tumor, re-excision; Human Liver, normal; NCI\_CGAP\_Pr25; Soares\_total\_fetus\_Nb2HF8\_9w; Human Ovarian Cancer
- 25 Reexcision; Resting T-Cell Library, II; NCI\_CGAP\_Pr24; NCI\_CGAP\_Pr1; CD34 positive cells (Cord Blood); H. Frontal cortex, epileptic, re-excision;

- NCI\_CGAP\_Kid6; NCI\_CGAP\_Pr21; Cheek Carcinoma; Pharynx Carcinoma; Colon Tumor; Human Tonsils, lib 1; Human 7 Weeks Old Embryo, subtracted; Human Tonsil, Lib 3; H Umbilical Vein Endothelial Cells, frac A, re-excision; Saos2, Dexamethosome Treated; Human Colon Cancer, subtracted; NCI\_CGAP\_Co11;
- 5 Human Colon, subtraction; Soares retina N2b5HR; Human Colon; Human colon carcinoma (HCC) cell line, remake; Hodgkin's Lymphoma I; Human Adult Heart, re-excision; Resting T-Cell, re-excision; Smooth Muscle- HASTE normalized; Healing groin wound - zero hr post-incision (control); Human Stomach, re-excision; Soares\_pregnant\_uterus\_NbHPU; Stratagene fibroblast (#937212); Stratagene
- 10 neuroepithelium NT2RAMI 937234; NCI\_CGAP\_Alv1; NCI\_CGAP\_Pr24; Spinal cord; CHME Cell Line, treated 5 hrs; Stratagene colon (#937204); Barstead spleen HPLRB2; 22 week old human fetal liver cDNA library; NCI\_CGAP\_GCB0; NCI\_CGAP\_GCB1; NCI\_CGAP\_Kid6; NCI\_CGAP\_Pr2; Anergic T-cell; NCI\_CGAP\_Pr25; NCI\_CGAP\_GC5; NCI\_CGAP\_Lar1; Stratagene fibroblast
- 15 (#937212); Soares\_fetal\_heart\_NbHH19W; Stratagene pancreas (#937208); Stratagene neuroepithelium (#937231); Human Hippocampus; Hemangiopericytoma; Bone Cancer, re-excision; Human Adult Spleen, fraction II; Sinus piniformis Tumour; Aryepiglottis Normal; Thyroid Tumour; Ea.hy.926 cell line; Normal Prostate; CD34+cells, II, FRACTION 2; Normal Ovary, Premenopausal; Human Leukocytes;
- 20 LNCAP + 0.3nM R1881; Human Uterus, normal; Human epithelioid sarcoma; Whole 6 Week Old Embryo; Human OB MG63 control fraction I; NCI\_CGAP\_Co2; Human Fetal Brain, random primed; Morton Fetal Cochlea; Human Gall Bladder, fraction II; L1 Cell line; HUMAN TONSILS, FRACTION 2; Human Cerebellum, subtracted; CD40 activated monocyte dendritic cells; H. cerebellum, Enzyme subtracted; H.
- 25 Epididymus, cauda; Stratagene hNT neuron (#937233); Human Pineal Gland; H. Whole Brain #2, re-excision; Glioblastoma; H. Meningioma, M1; STRATAGENE



- Human skeletal muscle cDNA library, cat. #936215.;
- Soares\_parathyroid\_tumor\_NbHPA; Temporal cortex-Alzheimer, subtracted;
- NCI\_CGAP\_Pr6; NCI\_CGAP\_Pr22; 12 Week Old Early Stage Human, II;
- NCI\_CGAP\_Thy1; Stratagene schizo brain S11; Chromosome 7 Placental cDNA
- 5 Library; NCI\_CGAP\_GC3; NCI\_CGAP\_Co12; Human adult testis, large inserts;
- Human fetal heart, Lambda ZAP Express; CHME Cell Line, untreated; Neutrophils
- IL-1 and LPS induced; NCI\_CGAP\_Pr25; Chromosome 7 Fetal Brain cDNA Library;
- Human fetal heart, Lambda ZAP Express; Human pancreatic islet; HTC DL1; Liver
- HepG2 cell line.; NCI\_CGAP\_Lu5; Stratagene schizo brain S11;
- 10 Soares\_parathyroid\_tumor\_NbHPA; Neutrophils IL-1 and LPS induced;
- NCI\_CGAP\_GC4; Stratagene muscle 937209; NCI\_CGAP\_GC2; NCI\_CGAP\_HN3;
- NCI\_CGAP\_HN4; Soares\_fetal\_lung\_NbHL19W;
- Soares\_parathyroid\_tumor\_NbHPA; Stratagene hNT neuron (#937233); Human
- Myometrium Leiomyoma; Human Fetal Heart, Differential (Adult-Specific);
- 15 C7MCF7 cell line, estrogen treated, Differential; H. Kidney Medulla, subtracted; H.
- Striatum Depression, subt II; Human colon carcinoma (HCC) cell line; KMH2 cell
- line; Jurkat Cells; Thyroid Thyroiditis; Human Old Ovary; Namalwa Cells;
- Soares\_testis\_NHT; Lung Mesothelium; Rectum tumour; Human Kidney Tumor;
- Palate normal; Human Bone Marrow; Colon, tumour; Tongue carcinoma; Pharynx
- 20 carcinoma; Human Placenta, subtracted; Larynx Normal; H. hypothalamus, frac A;
- Human Prostate BPH, re-excision; Tongue Tumour; Human White Fat; Activated T-
- Cells, 8 hrs., ligation 2; H. Frontal Cortex, Epileptic; H. Adipose Tissue; STRIATUM
- DEPRESSION; Human Prostate Cancer, Stage B2 fraction; Activated T-Cells, 12
- hrs.; NCI\_CGAP\_GC2; NCI\_CGAP\_Pr11; Human (Caco-2) cell line,
- 25 adenocarcinoma, colon, remake; LNCAP untreated; stomach cancer (human); Human
- (HCC) cell line liver (mouse) metastasis, remake; H. Epididymus, caput & corpus;

- Salivary Gland; Human Soleus; CD34 positive cells (cord blood),re-ex; Human  
 Synovium; Soares\_total\_fetus\_Nb2HF8\_9w; Alzheimers, spongy change;  
 Soares\_fetal\_lung\_NbHL19W; Human Frontal Cortex, Schizophrenia; Stratagene  
 pancreas (#937208); Stratagene muscle 937209; Stratagene NT2 neuronal precursor  
 5 937230; Stratagene pancreas (#937208); Stratagene lung carcinoma 937218;  
 Stratagene neuroepithelium (#937231); Human Pituitary, subt IX; Stratagene  
 endothelial cell 937223; Spinal Cord, re-excision; Gessler Wilms tumor; Human  
 pancreatic islet; Infant brain, Bento Soares; b4HB3MA Cot8-HAP-Ft; normalized  
 infant brain cDNA; Stratagene NT2 neuronal precursor 937230; NCI\_CGAP\_Co3;  
 10 NCI\_CGAP\_Co4; NCI\_CGAP\_GC4; NCI\_CGAP\_Lu1; NCI\_CGAP\_Pr5;  
 NCI\_CGAP\_Pr8; NCI\_CGAP\_Alv1; NCI\_CGAP\_Pr11; NCI\_CGAP\_Pr21; human  
 ovarian cancer; NCI\_CGAP\_Br3; NCI\_CGAP\_Ew1; NCI\_CGAP\_Pr1;  
 NCI\_CGAP\_Pr3; NCI\_CGAP\_GCB0; NCI\_CGAP\_Lar1; NCI\_CGAP\_Pr22; Human  
 Heart; Merkel Cells; Barstead spleen HPLRB2; HTC DL1; Johnston frontal cortex;  
 15 Soares\_testis\_NHT; Soares adult brain N2b5HB55Y; Stratagene colon (#937204);  
 Stratagene pancreas (#937208); PERM TF274; Human fetal heart, Lambda ZAP  
 Express; NCI\_CGAP\_Br2; NCI\_CGAP\_GC2; NCI\_CGAP\_Brn23; Stratagene HeLa  
 cell s3 937216; Stratagene lung carcinoma 937218; Soares\_NhHMPu\_S1; Clontech  
 human aorta polyA+ mRNA (#6572); Human placenta cDNA (TFujiwara);  
 20 NCI\_CGAP\_Co11; Human pancreatic islet; NCI\_CGAP\_Lu5;  
 Soares\_pregnant\_uterus\_NbHPU; Human heart cDNA (YNakamura); Gessler Wilms  
 tumor; NCI\_CGAP\_GC2; Soares\_NhHMPu\_S1; Soares\_testis\_NHT;  
 Soares\_fetal\_heart\_NbHH19W; Stratagene NT2 neuronal precursor 937230;  
 Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Soares\_fetal\_liver\_spleen\_1NFLS\_S1;  
 25 Soares\_fetal\_lung\_NbHL19W; Soares\_senescent\_fibroblasts\_NbHSF; Stratagene  
 neuroepithelium (#937231); NCI\_CGAP\_Co12; Stratagene fetal retina 937202;

- Human retina cDNA Tsp509I-cleaved sublibrary; NCI\_CGAP\_GCB1; Stratagene colon (#937204); Stratagene colon (#937204); Pancreatic Islet; Stratagene endothelial cell 937223; Stratagene neuroepithelium NT2RAMI 937234; Human fetal heart, Lambda ZAP Express; Stratagene pancreas (#937208); Human Whole 7 Week Old
- 5 Embryo (II); HCBB's Subtractive (- mito genes); Human adult lymph node, subtracted; Human Fetal Brain, subtracted; Jurkat cells, thiouridine activated; H. Umbilical Vein Endothelial Cells, IL4 induced; Human Adult Spleen, subtracted; Human Activated Macrophage (LPS); Human Thymus Tumor; HL-60, PMA 1d, subtracted; Human Leukocytes, normalized control #4; Human (Caco-2) cell line,
- 10 adenocarcinoma, colon; Jurkat Cells, cyclohexamide treated, subtraction; H. Kidney Pyramid, subtracted; H. Leukocytes, control; Poly[I]/Poly[C] Normal Lung Fibroblasts; Human Pituitary, subtracted VII; Basophil; Human Activated Macrophage (LPS), thiour; FGF enriched mixed library; Human Brown Fat; LNCAP, differential expression; Human Platelets; Cem Cells, cyclohexamide treated, subtra;
- 15 Human Brain, striatum, re-excision; Human Greater Omentum, flI remake; Human Fetal Brain, normalized A5002F; Human Fetal Kidney; Human Activated T-Cells (II); Human Astrocyte; Human Adult Lymph Node, subtracted; Adrenal Gland, normal; Smooth muscle control 2; Kidney Cortex; Human Eosinophils; Activated T-Cells, 0hrs, subtracted; Human Umbilical Vein Endothelial Cells, fract.
- 20 B; H. hypothalamus, frac A, re-excision; L428 cell line; Human Macrophage, subtracted; Human Adult Skeletal Muscle; Brain, normal; Human Infant Adrenal Gland, Subtracted; Activated T-Cells, 4 hrs, subtracted; HM3; Larynx carcinoma II; Prostate BPH, Lib 2, subtracted; Human Fetal Thymus; Osteoclastoma-normalized A; Activated T-Cells, 24 hrs.; Larynx Carcinoma; Liver Tumour Met 5 Tu; 7 Week Old
- 25 Early Stage Human, subtracted; Human Adult Heart, subtracted; Human rejected kidney; Supt cells, cyclohexamide treated, subtracted; Larynx Tumour; Thyroid

- Normal (SDCA2 No); Human Tongue, frac 2; Stomach Tumour; Bone marrow stroma,treated; Tongue Normal; Larynx Tumor; Human Adult Heart; Human Fetal Liver, subtracted, neg clone; Human osteoarthritic,fraction II; Testis, normal; Duodenum; brain stem; Human Membrane Bound Polysomes- Enzyme Subtraction;
- 5 Human Microvascular Endothelial Cells, fract. B; Prostate; HPAS (human pancreas, subtracted); Human Whole 6 Week Old Embryo (II), subt; Salivary Gland, Lib 3; CD34+ cell, 1, frac II; Raji cells, cyclohexamide treated, subtracted; Human Thymus Tumor, subtracted; Bone Cancer; Human Prostate, subtracted; H. Meningioma, M6; Soares\_placenta\_8to9weeks\_2NbHP8to9W; Human Kidney; Human Fetal Lung;
- 10 Soares\_senescent\_fibroblasts\_NbHSF; NCI\_CGAP\_AA1; NCI\_CGAP\_Pr21; NCI\_CGAP\_Pr4.1; Dermatofibrosarcoma Protuberance; Human Pituitary, re-excision; Resting T-Cell; Frontal Lobe, Dementia; H. Striatum Depression, subt; A-14 cell line; Human Cardiomyopathy, subtracted; Human Adult Retina; SKIN; Healing Abdomen wound,70&90 min post incision; Frontal lobe,dementia,re-
- 15 excision; Human Liver; Jia bone marrow stroma; Soares\_fetal\_heart\_NbHH19W; Dendritic Cells From CD34 Cells; Pancreas Tumor PCA4 Tu; Hepatocellular Tumor,re-excision; Stratagene neuroepithelium (#937231); Human Whole Brain #2 - Oligo dT > 1.5Kb; Stratagene pancreas (#937208); HL-60, PMA 4H, re-excision; Pancreas normal PCA4 No; Stratagene hNT neuron (#937233);
- 20 Soares\_pregnant\_uterus\_NbHPU; Spleen metastatic melanoma; Stratagene muscle 937209; 1-NIB; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; b4HB3MA-Cot51.5-HAP-Ft; Human Dermal Endothelial Cells,untreated; NCI\_CGAP\_AA1; NCI\_CGAP\_Ew1; NCI\_CGAP\_Lu5; NCI\_CGAP\_Pr3; NCI\_CGAP\_GCB1; NCI\_CGAP\_Kid3; NCI\_CGAP\_Pr10; NCI\_CGAP\_Pr20; HM1; NCI\_CGAP\_Br2; NCI\_CGAP\_Co2;
- 25 NCI\_CGAP\_GC5; NCI\_CGAP\_Pr8; NCI\_CGAP\_SS1; NCI\_CGAP\_Co10; NCI\_CGAP\_Co11; NCI\_CGAP\_Sch1; NCI\_CGAP\_Pr4.1;

- Soares\_total\_fetus\_Nb2HF8\_9w; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Stratagene hNT neuron (#937233); Infant brain, Bento Soares; Stratagene schizo brain S11; Stratagene lung carcinoma 937218; Stratagene endothelial cell 937223; Pancreatic Islet; BATM2; Chromosome 7 Fetal Brain cDNA Library; Human placenta cDNA
- 5 (TFujiwara); Human pancreatic cancer cell line Patu 8988t; KG1-a Lambda Zap Express cDNA library; NCI\_CGAP\_Kid3; Soares breast 2NbHBst; Soares\_NbHFB; Stratagene fetal retina 937202; Stratagene hNT neuron (#937233); Stratagene lung carcinoma 937218; Stratagene ovarian cancer (#937219); Soares\_NhHMPu\_S1; Gessler Wilms tumor; NCI\_CGAP\_GCB1; Soares\_parathyroid\_tumor\_NbHPA;
- 10 Stratagene fetal retina 937202; Chromosome 7 Fetal Brain cDNA Library; KG1-a Lambda Zap Express cDNA library; NCI\_CGAP\_GC4; NCI\_CGAP\_Co10; NCI\_CGAP\_Co12; NCI\_CGAP\_Kid3; NCI\_CGAP\_Lei2; Human retina cDNA randomly primed sublibrary; KG1-a Lambda Zap Express cDNA library; Stratagene hNT neuron (#937233); Brain frontal cortex; Human adult (K.Okubo); Human fetal
- 15 heart, Lambda ZAP Express; NCI\_CGAP\_GC3; NCI\_CGAP\_CNS1; NCI\_CGAP\_Pr16; NCI\_CGAP\_Pr25; Stratagene colon (#937204); Barstead spleen HPLRB2; Soares\_NFL\_T\_GBC\_S1; Soares\_fetal\_heart\_NbHH19W; Soares\_parathyroid\_tumor\_NbHPA; Soares\_senescent\_fibroblasts\_NbHSF; Stratagene HeLa cell s3 937216; Stratagene hNT neuron (#937233); Stratagene colon
- 20 (#937204); 12 Week Early Stage Human II, Reexcision; NCI\_CGAP\_GCB1; Pancreatic Islet; Infant brain, Bento Soares; NCI\_CGAP\_Ov8; NCI\_CGAP\_CNS1; NCI\_CGAP\_GCB1; NCI\_CGAP\_Pr24; NCI\_CGAP\_Pr25; Normalized infant brain, Bento Soares; Soares\_multiple\_sclerosis\_2NbHMSP; Soares\_placenta\_8to9weeks\_2NbHP8to9W; NCI\_CGAP\_Co10; NCI\_CGAP\_Kid5;
- 25 Stratagene endothelial cell 937223; HTC DL1; NCI\_CGAP\_AA1; NCI\_CGAP\_Br7; NCI\_CGAP\_Lu6; NCI\_CGAP\_Ov2; NCI\_CGAP\_Ov8; NCI\_CGAP\_Pr2;

NCI\_CGAP\_Pr3; NCI\_CGAP\_Kid5; NCI\_CGAP\_Lym3; NCI\_CGAP\_Pr12;  
NCI\_CGAP\_Pr22; NCI\_CGAP\_Pr24; Soares\_fetal\_lung\_NbHL19W; Stratagene  
NT2 neuronal precursor.937230; Stratagene pancreas (#937208); Stratagene corneal  
stroma (#937222); Pancreatic Islet and Stratagene colon (#937204).

- 5 Many polynucleotide sequences, such as EST sequences, are publicly  
available and accessible through sequence databases. Some of these sequences are  
related to SEQ ID NO:33 and may have been publicly available prior to conception of  
the present invention. Preferably, such related polynucleotides are specifically  
excluded from the scope of the present invention. To list every related sequence  
10 would be cumbersome. Accordingly, preferably excluded from the present invention  
are one or more polynucleotides comprising a nucleotide sequence described by the  
general formula of a-b, where a is any integer between 1 to 949 of SEQ ID NO:33, b  
is an integer of 15 to 963, where both a and b correspond to the positions of  
nucleotide residues shown in SEQ ID NO:33, and where b is greater than or equal to a  
15 + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 24

- The computer algorithm BLASTX has been used to determine that the  
translation product of this gene shares sequence homology with, as a non-limiting  
20 example, the sequence accessible through the following database accession no.  
gi|3851145 (all information available through the recited accession number is  
incorporated herein by reference) which is described therein as "protein zero related  
protein; PZR [Homo sapiens]". A partial alignment demonstrating the observed  
homology is shown immediately below.

25

```
>gi|3851145 (AF087020) protein zero related protein; PZR [Homo sapiens]
>sp|G3851145|G3851145 PROTEIN ZERO RELATED PROTEIN.
Length = 269
```

## Plus Strand HSPs:

Score = 350 (123.2 bits), Expect = 2.9e-31, P = 2.9e-31  
 Identities = 68/69 (98%), Positives = 68/69 (98%), Frame = +3

5  
 10  
 Q: 285 TCCSTSESLSPVKQAPRKSPSDTEGLVKSLPSGSHQGPVIYAQLDHSGGHHSDKINKSES 464  
       T CSTSESLSPVKQAPRKSPSDTEGLVKSLPSGSHQGPVIYAQLDHSGGHHSDKINKSES  
 S: 201 TGCSTSESLSPVKQAPRKSPSDTEGLVKSLPSGSHQGPVIYAQLDHSGGHHSDKINKSES 260

Q: 465 VVYADIRKN 491  
       VVYADIRKN  
 S: 261 VVYADIRKN 269

15 The segment of gil3851145 that is shown as "S" above is set out in the  
 sequence listing as SEQ ID NO. 127. Based on the structural similarity, these  
 homologous polypeptides are expected to share at least some biological activities.  
 Such activities are known in the art, some of which are described elsewhere herein.  
 Assays for determining such activities are also known in the art, some of which have  
 20 been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the  
 amino acid sequence set out in the sequence listing as SEQ ID NO. 128 which  
 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a  
 sequence by the computer are, of course, removed).

25 It has been discovered that this gene is expressed primarily in the following  
 tissues/cDNA libraries: Human Endometrial Tumor and to a lesser extent in HSA 172  
 Cells; Human Adrenal Gland Tumor; Smooth muscle, control; Stratagene fibroblast  
 (#937212); HUMAN B CELL LYMPHOMA; Soares\_NhHMPu\_S1; Activated T-  
 cell(12h)/Thiouridine-re-excision; Soares\_NhHMPu\_S1; Stratagene HeLa cell s3  
 30 937216 and Keratinocyte.

Many polynucleotide sequences, such as EST sequences, are publicly  
 available and accessible through sequence databases. Some of these sequences are  
 related to SEQ ID NO:34 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the  
5 general formula of a-b, where a is any integer between 1 to 736 of SEQ ID NO:34, b is an integer of 15 to 750, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:34, and where b is greater than or equal to a + 14.

#### 10 FEATURES OF PROTEIN ENCODED BY GENE NO: 25

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: H. cerebellum, Enzyme subtracted; Human Whole Brain #2 - Oligo dT > 1.5Kb; Human Cerebellum.

Preferred polypeptides of the present invention comprise immunogenic  
15 epitopes shown in SEQ ID NO: 83 as residues: Met-1 to Ala-7. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind polypeptides and/or epitopes of the invention are also encompassed by the invention.

When tested against K562 leukemia cell lines, supernatants removed from  
20 cells containing this gene activated the ISRE assay. Thus, it is likely that this gene activates leukemia cells through the Jak-STAT signal transduction pathway. The interferon-sensitive response element is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of  
25 cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and



differentiation of cells. Antibodies that bind to polypeptides of the invention and inhibit said activity are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:35 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2029 of SEQ ID NO:35, b is an integer of 15 to 2043, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:35, and where b is greater than or equal to a + 14.

## 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 26

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil2585991 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "stathmin-like-protein RB3 [Rattus norvegicus]." Members of the Stathmin family are ubiquitous phosphoproteins proposed to be a relay integrating various intracellular signaling pathways. A partial alignment demonstrating the observed homology is shown immediately below.

25

```
>gi|2585991 (AF026528) stathmin-like-protein RB3 [Rattus norvegicus]
>gi|2585991 (AF026528) stathmin-like-protein RB3 [Rattus
```

norvegicus] >gi|4028598 (AF105222) stathmin-like-protein RB3  
[Mus  
musculus] >sp|G4028598|G4028598 STATHMIN-LIKE-PROTEIN RB3.  
Length = 189

5 Plus Strand HSPs:

Score = 681 (239.7 bits), Expect = 9.3e-94, Sum P(2) = 9.3e-94  
Identities = 132/133 (99%), Positives = 133/133 (100%), Frame = +2

10 Q: 125 MTLAAYKEKMKELPLVSLFCSCFLADPLNKSSYKYEADTVDLNWCVISDMEVIELNKCTS 304  
MTLAAYKEKMKELPLVSLFCSCFL+DPLNKSSYKYEADTVDLNWCVISDMEVIELNKCTS  
S: 1 MTLAAYKEKMKELPLVSLFCSCFLSDPLNKSSYKYEADTVDLNWCVISDMEVIELNKCTS 60

15 Q: 305 GQSFEVILKPPSFDGVPEFNASLPRRRDPSLEEIQKKLEAAEERRKYQEAELLKHLAEKR 484  
GQSFEVILKPPSFDGVPEFNASLPRRRDPSLEEIQKKLEAAEERRKYQEAELLKHLAEKR  
S: 61 GQSFEVILKPPSFDGVPEFNASLPRRRDPSLEEIQKKLEAAEERRKYQEAELLKHLAEKR 120

20 Q: 485 EHEREVIQKAIEE 523  
EHEREVIQKAIEE  
S: 121 EHEREVIQKAIEE 133

Score = 278 (97.9 bits), Expect = 9.3e-94, Sum P(2) = 9.3e-94  
Identities = 56/56 (100%), Positives = 56/56 (100%), Frame = +1

25 Q: 523 NNNFIKMAKEKLAQKMESNKENREAHLAAMLERLQEKDKHAEVRKNKELKEEASR 690  
NNNFIKMAKEKLAQKMESNKENREAHLAAMLERLQEKDKHAEVRKNKELKEEASR  
S: 134 NNNFIKMAKEKLAQKMESNKENREAHLAAMLERLQEKDKHAEVRKNKELKEEASR 189

30 The segments of gi|2585991 that are shown as "S" above are set out in the  
sequence listing as SEQ ID NO. 129 and SEQ ID NO. 131. Based on the structural  
similarity, these homologous polypeptides are expected to share at least some  
biological activities. Such activities are known in the art, some of which are described  
elsewhere herein. Assays for determining such activities are also known in the art,  
35 some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the  
amino acid sequence set out in the sequence listing as SEQ ID NO. 130 and/or SEQ  
ID NO. 132 which correspond to the "Q" sequences in the alignment shown above  
(gaps introduced in a sequence by the computer are, of course, removed).

40 It has been discovered that this gene is expressed primarily in the following  
tissues/cDNA libraries: Soares infant brain 1N1B and to a lesser extent in Human

Infant Brain; Stratagene hNT neuron (#937233); Soares\_total\_fetus\_Nb2HF8\_9w;  
Early Stage Human Brain; Human Fetal Brain, normalized c5-11-26; Human Brain,  
striatum, re-excision; Stratagene hNT neuron (#937233); H. hypothalamus, frac A, re-  
excision; Human Brain; STRIATUM DEPRESSION; H. Whole Brain #2, re-  
5 excision; Soares adult brain N2b4HB55Y; human corpus colosum; 4HB3MK; Infant  
brain, Bento Soares; NCI\_CGAP\_GC4; NCI\_CGAP\_Lu5; NCI\_CGAP\_PNS1;  
Normalized infant brain, Bento Soares; Soares\_NbHFB; Brain Frontal Cortex, re-  
excision; Human Fetal Brain; Human Substantia Nigra and Human Cerebellum.

Given the homology to the rat stathmin proteins, and the highly specific tissue  
10 distribution in neural tissues, the protein product of this clone is useful for the  
detection/treatment of neurodegenerative disease states and behavioural disorders  
such as Alzheimers Disease, Parkinsons Disease, Huntingtons Disease, Tourette  
Syndrome, schizophrenia, mania, dementia, paranoia, obsessive compulsive disorder,  
panic disorder, learning disabilities, ALS, psychoses, autism, and altered behaviors,  
15 including disorders in feeding, sleep patterns, balance, and perception. In addition, the  
gene or gene product may also play a role in the treatment and/or detection of  
developmental disorders associated with the developing embryo, or sexually-linked  
disorders. Elevated expression of this gene product within neural tissues suggests that  
it may be involved in neuronal survival; synapse formation; conductance; neural  
20 differentiation, etc. Such involvement may impact many processes, such as learning  
and cognition. It may also be useful in the treatment of such neurodegenerative  
disorders as schizophrenia; ALS; or Alzheimer's. Protein, as well as, antibodies  
directed against the protein may show utility as a tumor marker and/or  
immunotherapy targets for the above listed tissues.

25 Many polynucleotide sequences, such as EST sequences, are publicly  
available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:36 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

5 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1238 of SEQ ID NO:36, b is an integer of 15 to 1252, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:36, and where b is greater than or equal to a + 14.

10

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 27**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares\_fetal\_lung\_NbHL19W; CAMA1Ee Cell Line; Spleen, Chronic lymphocytic leukemia.

15

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:37 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence

20 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1636 of SEQ ID NO:37, b is an integer of 15 to 1650, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:37, and where b is greater than or equal to a

25 + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 28**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Chondrosarcoma; Human Osteoclastoma.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:38 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1032 of SEQ ID NO:38, b is an integer of 15 to 1046, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:38, and where b is greater than or equal to a + 14.

15

**FEATURES OF PROTEIN ENCODED BY GENE NO: 29**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. pirlS72481|S72481 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "probable transposase - human transposable element MER37". A partial alignment demonstrating the observed homology is shown immediately below.

25

```
>pir|S72481|S72481 probable transposase - human transposable element MER37
>pir|S72486|S72486 putative transposase - human transposon
MER37
(fragment) {SUB 177-349}
Length = 454
```

## Plus Strand HSPs:

Score = 634 (223.2 bits), Expect = 3.4e-90, Sum P(3) = 3.4e-90  
 Identities = 129/170 (75%), Positives = 136/170 (80%), Frame = +1

5  
 10  
 15

```

Q: 754 RGEAAAEKLEPGRGWFMRFKERSHPHSIKVQGAANTDVEAAASYPEDLAKIIDEGGYT 933
      RGEAAAEKLE  RGWFMRFKERSH H+IKVQG AA+ DVEAAASYPEDLAKIIDEGGYT
S: 120 RGEAAAEKLEASRGWFMRFKERSHLHNIKVQGEAASADVEAAASYPEDLAKIIDEGGYT 179

Q: 934 KQEIFSVDKRVFFWKKMPSWL*IAGENKEMTDFKGQ----AILLGANAAGDLKSKPMLIY 1101
      KQ+IF+VD+  F+WKKMPS  IA E K M  FK      +LLGANAAGD K KPMLIY
S: 180 KQQIFNVDETAFYWKMPSTTFIAREEKSMPGFKASKDRLTLLLGANAAGDFKLKPMLIY 239

Q: 1102 HSENLRALKNYIKSILPVLYK*NN*AWMPAHLFIA*FTEDFKSTVETYCS 1251
      HSEN RALKNY KS LPVLYK NN AWM AHLF A FTE FK TVETYCS
S: 240 HSENPRALKNYAKSTLPVLYKWNKAWMTAHLFTAFTFYFKPTVETYCS 289
  
```

The segment of pir|S72481|S72481 that is shown as "S" above is set out in the  
 20 sequence listing as SEQ ID NO. 133. Based on the structural similarity, these  
 homologous polypeptides are expected to share at least some biological activities.  
 Such activities are known in the art, some of which are described elsewhere herein.  
 Assays for determining such activities are also known in the art, some of which have  
 been described elsewhere herein.

25 Preferred polypeptides of the invention comprise a polypeptide having the  
 amino acid sequence set out in the sequence listing as SEQ ID NO. 134 which  
 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a  
 sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following  
 30 tissues/cDNA libraries: breast lymph node CDNA library and to a lesser extent in  
 Spleen metastatic melanoma; Merkel Cells; Spleen, Chronic lymphocytic leukemia and  
 Human Cerebellum.

Many polynucleotide sequences, such as EST sequences, are publicly  
 available and accessible through sequence databases. Some of these sequences are  
 35 related to SEQ ID NO:39 and may have been publicly available prior to conception of

the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the  
 5 general formula of a-b, where a is any integer between 1 to 1262 of SEQ ID NO:39, b is an integer of 15 to 1276, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:39, and where b is greater than or equal to a + 14.

## 10 FEATURES OF PROTEIN ENCODED BY GENE NO: 30

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil1777577 (all information available through the recited accession number is  
 15 incorporated herein by reference) which is described therein as "WW-domain binding protein 1 [Mus musculus]". A partial alignment demonstrating the observed homology is shown immediately below.

```

20  >gi|1777577 WW-domain binding protein 1 [Mus musculus] >sp|P97764|P97764
      WW-DOMAIN BINDING PROTEIN 1.
      Length = 305

      Plus Strand HSPs:

25  Score = 599 (210.9 bits), Expect = 2.7e-79, Sum P(3) = 2.7e-79
      Identities = 117/175 (66%), Positives = 125/175 (71%), Frame = +2

      Q: 1574 EINLLAYHGACHGAGPPTGSLDLRFLSTFKPPAYEDVVHXXXXXXXXXXXXXXXXXLTATA 1753
          EINLLAYHGACHGAGP PTGSLDLR LS FKPPAYEDVVH T
30  S: 127 EINLLAYHGACHGAGPVPTGSLDLRLLSAFKPPAYEDVVHHPGTPPPPYTVGPGYPWTT 186

      Q: 1754 XXXXXXXXXXXXXPAHFEQTNVEGVSSHQSAAPHQEGEPGAGVTPASTPPSCRYRRLTGD 1933
          AH EGTNVEGVSS QSA PHQEGEP AG++P PPSCRYRRLTGD
35  S: 187 SSECTRCSSSESSCSAHLEGTNVEGVSSQSAALPHQEGEPAGLSPVHIPPSCRYRRLTGD 246

      Q: 1934 SGIELCPCPASGEGEPVKEVRVSATLPDLEDYSPCALPPESVFPQIFPMGLSSEGE 2098
  
```

SGIELCPCP S EGEF+KE R SA+ PDLED+SPCALPP+SV Q+ PMGL+SS G  
 S: 247 SGIELCPCPDSSERGEPLKEARASASQPDLEDHSPCALPPDSVSQVPPMGLASSCG 301

The segment of gil1777577 that is shown as "S" above is set out in the  
 5 sequence listing as SEQ ID NO. 135. Based on the structural similarity, these  
 homologous polypeptides are expected to share at least some biological activities.  
 Such activities are known in the art, some of which are described elsewhere herein.  
 Assays for determining such activities are also known in the art, some of which have  
 been described elsewhere herein.

10 Preferred polypeptides of the invention comprise a polypeptide having the  
 amino acid sequence set out in the sequence listing as SEQ ID NO. 136 which  
 corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a  
 sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following  
 15 tissues/cDNA libraries: Human Primary Breast Cancer Reexcision and to a lesser  
 extent in Soares adult brain N2b4HB55Y; NCI\_CGAP\_Pr22; Soares\_testis\_NHT;  
 Soares\_fetal\_lung\_NbHL19W; Soares adult brain N2b5HB55Y; Epithelial-TNF $\alpha$  and  
 INF induced; Soares\_total\_fetus\_Nb2HF8\_9w; Soares\_fetal\_lung\_NbHL19W;  
 Activated T-cell(12h)/Thiouridine-re-excision; Soares infant brain 1NIB; Stratagene  
 20 hNT neuron (#937233); Amniotic Cells - TNF induced; Human Quadriceps; Human  
 Uterine Cancer; Human Hypothalamus,Schizophrenia; Soares\_pineal\_gland\_N3HPG;  
 Human Fetal Kidney, Reexcision; Human Testes; Osteoblasts; Human 8 Week Whole  
 Embryo; Human (Caco-2) cell line, adenocarcinoma, colon; Human Macrophage;  
 Human Infant Adrenal Gland, subtracted; Soares\_senescent\_fibroblasts\_NbHSF;  
 25 Prostate,BPH, Lib 2; 7 Week Old Early Stage Human, subtracted;  
 Soares\_total\_fetus\_Nb2HF8\_9w; Human Normal Cartilage Fraction II; Human White  
 Fat; H. Striatum Depression, subt; A1-CELL LINE; Human OB HOS control fraction



- I; Human OB HOS treated (10 nM E2) fraction I; Smooth muscle, control, re-excision; NCI\_CGAP\_Co8; NCI\_CGAP\_CLL1; CD40 activated monocyte dendritic cells; H. Epididymus, caput & corpus; H. cerebellum, Enzyme subtracted; H. Epididymus, cauda; HSA 172 Cells; Resting T-Cell, re-excision; Human Normal
- 5 Breast; Human Epididymus; Human Synovium; Hepatocellular Tumor, re-excision; NTERA2 + retinoic acid, 14 days; Amniotic Cells - Primary Culture; Human Fetal Epithelium (Skin); NCI\_CGAP\_Pr22; Soares\_total\_fetus\_Nb2HF8\_9w; H. Lymph node breast Cancer; Breast Cancer Cell line, angiogenic; Human Thymus; Human Osteoblasts II; Human Adult Testes, Large Inserts, Reexcision; Human Ovary;
- 10 Ulcerative Colitis; Soares\_fetal\_heart\_NbHH19W; Soares\_pregnant\_uterus\_NbHPU; Human Fetal Brain; Human Adrenal Gland Tumor; NCI\_CGAP\_Co8; NCI\_CGAP\_Lu5; NCI\_CGAP\_Kid3; CHME Cell Line, treated 5 hrs; Stratagene hNT neuron (#937233); Smooth muscle, serum induced, re-exc; Pancreas Islet Cell Tumor; Human T-Cell Lymphoma; NCI\_CGAP\_Ew1; NCI\_CGAP\_Co12;
- 15 NCI\_CGAP\_GCB1; NCI\_CGAP\_Pr23; Colon Carcinoma; Colon Normal II; Soares\_NFL\_T\_GBC\_S1; normalized infant brain cDNA; Human Synovial Sarcoma; Human Testes, Reexcision; Endothelial-induced; NCI\_CGAP\_Ut2; NCI\_CGAP\_Gas4; NCI\_CGAP\_Pan1; NCI\_CGAP\_Bm25; Soares\_testis\_NHT; Soares\_fetal\_heart\_NbHH19W; Soares\_pregnant\_uterus\_NbHPU; Human
- 20 Microvascular Endothelial Cells, fract. A; Human Bone Marrow, treated; Bone Marrow Cell Line (RS4,11); Human Endometrial Tumor; Hodgkin's Lymphoma II; Human fetal heart, Lambda ZAP Express; NCI\_CGAP\_GC4; NCI\_CGAP\_Co10; NCI\_CGAP\_Kid5; NCI\_CGAP\_Kid6; Human Cerebellum and Soares fetal liver spleen 1NFLS.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 88 as residues: Leu-30 to Gly-35. Polynucleotides encoding said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:40 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2315 of SEQ ID NO:40, b is an integer of 15 to 2329, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:40, and where b is greater than or equal to a + 14.

15

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 31**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares\_fetal\_heart\_NbHH19W; Soares placenta Nb2HP and to a lesser extent in Human Gastrocnemius; Human Colon; Cem cells cyclohexamide treated; Human Colon, re-excision; BL29 Burkitt's lymphoma, Pascalis Sideras; Human thymus NSTH II; Human adult (K.Okubo); NCI\_CGAP\_Co4; NCI\_CGAP\_Co11; Stratagene hNT neuron (#937233); Stratagene lung carcinoma 937218; KMH2; Soares adult brain N2b5HB55Y; Stratagene pancreas (#937208); Human Fetal Brain; Human Cerebellum and Soares fetal liver spleen 1NFLS.

20

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 89 as residues: Pro-71 to Leu-83, Pro-119 to Ser-129. Polynucleotides encoding said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:41 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1-to 1055 of SEQ ID NO:41, b is an integer of 15 to 1069, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:41, and where b is greater than or equal to a + 14.

15

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 32

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil288145 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "Homo sapiens protein". A partial alignment demonstrating the observed homology is shown immediately below.

25     >gi|288145 put. ORF [Homo sapiens] >pir|I38022|I38022 hypothetical protein  
   human >sp|Q29976|Q29976. MAHLAVU HEPATOCELLULAR CARCINOMA HHC(M)  
 DNA.  
   Length = 196

## Plus Strand HSPs:

Score = 241 (84.8 bits), Expect = 3.3e-19, P = 3.3e-19  
 Identities = 46/68 (67%), Positives = 49/68 (72%), Frame = +2

5           Q: 1187 HLRSGVQDPDQHGETLSLLKIQKLAGHGDACL\*SQXXXXXXQENHLNLGGGGCSEPR LH 1366  
               HLRSGVQD P QHG+ SLLKIQ+LAGHG CL SQ QENHLN GG GCSEP+ H  
 10           S: 3 HLRSGVQDYPGQHGKIPSLKIQELAGHGGRCLQSQLLRRLRQENHLNSGGGRCSEPKSH 62

              Q: 1367 HCTPAWAT 1390  
                   C PAW T  
               S: 63 LCIPAWVT 70

15           The segment of gil288145 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 137. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been

20           described elsewhere herein.

              When tested against fibroblast cell lines, supernatants removed from cells containing this gene activated the EGR1 assay. Thus, it is likely that this gene activates fibroblast cells through a signal transduction pathway. Early growth response 1 (EGR1) is a promoter associated with certain genes that induces various

25           tissues and cell types upon activation, leading the cells to undergo differentiation and proliferation. Antibodies that bind to polypeptides of the invention and inhibit said activity are also encompassed by the invention.

              Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 138 which

30           corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

              It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: 12 Week Old Early Stage Human; Human Cerebellum.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 90 as residues: Ser-15 to Asp-22, Leu-26 to Ala-33. Polynucleotides encoding said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:42 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1411 of SEQ ID NO:42, b is an integer of 15 to 1425, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:42, and where b is greater than or equal to a + 14.

15

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 33**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Cerebellum and to a lesser extent in Soares\_fetal\_heart\_NbHH19W; Soares\_total\_fetus\_Nb2HF8\_9w; Soares fetal liver spleen 1NFLS; H. Atrophic Endometrium; Breast Lymph node cDNA library; Soares\_pineal\_gland\_N3HPG; H. Meningioma, M1; wilm's tumor; Human Infant Brain; Soares\_fetal\_lung\_NbHL19W; T-Cell PHA 24 hrs; Human Hypothalamus, Schizophrenia; Soares breast 2NbHBst; Human Whole Six Week Old Embryo; Human Placenta; Human Adult Pulmonary, re-excision; NCI\_CGAP\_CLL1; NCI\_CGAP\_Kid6; NCI\_CGAP\_Brn25; Soares\_testis\_NHT;

25

Soares\_fetal\_heart\_NbHH19W; Stratagene schizo brain S11; Smooth muscle, control and Soares infant brain 1NIB.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 91 as residues: Gly-31 to Gly-46. Polynucleotides  
5 encoding said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:43 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
10 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1110 of SEQ ID NO:43, b is an integer of 15 to 1124, where both a and b correspond to the positions of  
15 nucleotide residues shown in SEQ ID NO:43, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 34**

20 It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares adult brain N2b4HB55Y and to a lesser extent in Human Cerebellum; H. Frontal cortex, epileptic, re-excision; Synovial hypoxia-RSF subtracted; Soares adult brain N2b5HB55Y; Soares infant brain 1NIB; Clontech human aorta polyA+ mRNA (#6572); Soares\_testis\_NHT; Human Pituitary, subt IX;  
25 Soares\_fetal\_heart\_NbHH19W; Hemangiopericytoma; Human Right Hemisphere of Brain; Human Amygdala Depression, re-excision; Human Pituitary; H. Frontal

Cortex, Epileptic; Soares\_fetal\_lung\_NbHL19W; Frontal Lobe, Dementia; Human Fetal Brain; H. Epididymus, caput & corpus; Gessler Wilms tumor; Human retina cDNA Tsp509I-cleaved sublibrary; NCI\_CGAP\_Br7; NCI\_CGAP\_Lu5; NCI\_CGAP\_Brn23; Soares\_NFL\_T\_GBC\_S1; Soares\_pineal\_gland\_N3HPG;

5 Soares\_fetal\_heart\_NbHH19W; Soares\_parathyroid\_tumor\_NbHPA; Stratagene schizo brain S11; Stratagene hNT neuron (#937233); H. Epididymus, cauda; Stratagene hNT neuron (#937233); Human Whole Brain #2 - Oligo dT > 1.5Kb; Human endometrial stromal cells; Brain Frontal Cortex, re-excision; Human Infant Brain; Soares\_fetal\_lung\_NbHL19W; Breast Cancer Cell line, angiogenic; Human

10 Brain, Striatum; Human Substantia Nigra; Brain frontal cortex; 12 Week Early Stage Human II, Reexcision; Endothelial cells-control; Human Amygdala; NCI\_CGAP\_Brn23 and NCI\_CGAP\_Brn25.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 92 as residues: Gly-42 to Ala-49. Polynucleotides

15 encoding said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:44 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically

20 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1948 of SEQ ID NO:44, b is an integer of 15 to 1962, where both a and b correspond to the positions of

25 nucleotide residues shown in SEQ ID NO:44, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 35**

- It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Primary Dendritic Cells, lib 1 and to a lesser extent in
- 5 Soares\_fetal\_heart\_NbHH19W; Human Fetal Dura Mater; Human Thymus; Human Whole Six Week Old Embryo; Primary Dendritic cells,frac 2; human corpus colosum; Human Synovial Sarcoma; Endothelial cells-control; Soares\_fetal\_heart\_NbHH19W; Keratinocyte; Human Cerebellum; Early Stage Human Brain; Human Fetal Lung III; Soares\_fetal\_heart\_NbHH19W; Human OB HOS control fraction I; Stratagene
  - 10 placenta (#937225); Amniotic Cells - Primary Culture; Human Adipose Tissue, re-excision; HL-60, PMA 4H, re-excision; Stratagene pancreas (#937208); Myeloid Progenitor Cell Line; wilm's tumor; KMH2; Soares\_total\_fetus\_Nb2HF8\_9w; L428; Human Pancreas Tumor; Human Rhabdomyosarcoma; Hemangiopericytoma; 12
  - 15 Week Old Early Stage Human; Human Microvascular Endothelial Cells, fract. A; Smooth muscle,control; Soares\_senescent\_fibroblasts\_NbHSF; Bone Marrow Cell Line (RS4,11); Human Brain, striatum, re-excision; Soares\_pregnant\_uterus\_NbHPU; Messangial cell, frac 1; Human epithelioid sarcoma; HL-60, RA 4h, Subtracted; HUMAN STOMACH; Amniotic Cells - TNF induced; Breast Lymph node cDNA library; Soares adult brain N2b4HB55Y; HEL cell line; Human Synovium; Human
  - 20 endometrial stromal cells-treated with estradiol; Smooth muscle, IL1b induced; Alzheimers, spongy change; Human Umbilical Vein, Endo. remake; H. Kidney Cortex, subtracted; Glioblastoma; Human endometrial stromal cells-treated with progesterone; Prostate BPH; Human Chronic Synovitis; Human Fetal Kidney; Stratagene fetal spleen (#937205); 12 Week Old Early Stage Human, II; Epithelial-
  - 25 TNFa and INF induced; Bone Marrow Stromal Cell, untreated; Human Fetal Brain; Human Thymus Stromal Cells; Ovarian Tumor 10-3-95;



Soares\_fetal\_heart\_NbHH19W; NTERA2, control; Smooth muscle, serum induced, re-exc; PC3 Prostate cell line; Human Substantia Nigra; breast lymph node CDNA library; Brain frontal cortex; Human Fetal Heart; Endothelial-induced; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; Soares\_pregnant\_uterus\_NbHPU; Monocyte  
5 activated; Soares\_fetal\_lung\_NbHL19W; H. Frontal cortex, epileptic, re-excision; Hodgkin's Lymphoma II and Soares\_pregnant\_uterus\_NbHPU.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 93 as residues: Met-1 to Leu-7. Polynucleotides encoding said polypeptides are also encompassed by the invention.

10 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:45 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence  
15 would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 978 of SEQ ID NO:45, b is an integer of 15 to 992, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:45, and where b is greater than or equal to a  
20 + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 36

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting  
25 example, the sequence accessible through the following database accession no. gil2104787 (all information available through the recited accession number is

incorporated herein by reference) which is described therein as "putative purinergic receptor P2Y10 [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

```

5   >gi|2104787 (AF000545) putative purinergic receptor P2Y10 [Homo sapiens]
    >sp|O00398|O00398 PUTATIVE PURINERGIC RECEPTOR P2Y10.
    Length = 339

    Plus Strand HSPs:

10   Score = 1715 (603.7 bits), Expect = 6.6e-176, P = 6.6e-176
    Identities = 328/339 (96%), Positives = 328/339 (96%), Frame = +2

15   Q:  281 MANLDKYTETFKMGSNSTSTAEIYCNVTNVKFAQYSLYATTYILIFIPGLLANSAALWVLC 460
    S:  1  MANLDKYTETFKMGSNSTSTAEIYCNVTNVKFAQYSLYATTYILIFIPGLLANSAALWVLC 60

    Q:  461 RFISKKNKAIIFMINLSVADLAHVLSLPLRIYYYISHHWPQFQALCLLCFYLYLNMYAS 640
    S:  61  RFISKKNKAIIFMINLSVADLAHVLSLPLRIYYYISHHWPQFQALCLLCFYLYLNMYAS 120

20   Q:  641 ICFLTCISLQRCFFLLKPFRRADWKRRYDVGISAAIWIVGTACLPFPILRSTDNLNNKS 820
    S:  121 ICFLTCISLQRCFFLLKPFRRADWKRRYDVGISAAIWIVGTACLPFPILRSTDNLNNKS 180

25   Q:  821 CFADLGYQMNAVALVGMITVAELAGFVIPVIIIAWCTWKTTISLRQPPMAFQGISERQK 1000
    S:  181 CFADLGYQMNAVALVGMITVAELAGFVIPVIIIAWCTWKTTISLRQPPMAFQGISERQK 240

30   Q:  1001 ALRMVFMCAAVFFICFTPYHINFIFYTMVKETIISSCPVVRIALYFHPFXXXXXXXXXXXXX 1180
    S:  241 ALRMVFMCAAVFFICFTPYHINFIFYTMVKETIISSCPVVRIALYFHPFCLCLASLCCLL 300

35   Q:  1181 DPILYYFMASEFRDQLSRHGSSVTRSRRLMSKESGSSMIG 1297
    S:  301 DPILYYFMASEFRDQLSRHGSSVTRSRRLMSKESGSSMIG 339

```

The segment of gi2104787 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 139. Based on the structural similarity, these

40 homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 140 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

- 5           Nonexclusive embodiments of the invention include antibodies that bind to the polypeptides of the invention. Extracellular portions of the polypeptide of SEQ ID NO:140 are also preferred embodiments of the invention.

- It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: NCI\_CGAP\_GCB1 and to a lesser extent in Human Placenta;  
10   Human T-cell lymphoma, re-excision; Cem cells cyclohexamide treated; pBMC stimulated w/ poly I/C; T-Cell PHA 16 hrs; Resting T-Cell Library, II; Human T-Cell Lymphoma; Normal colon; T cell helper II and Primary Dendritic Cells, lib I.

- Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
15   related to SEQ ID NO:46 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the  
20   general formula of a-b, where a is any integer between 1 to 1663 of SEQ ID NO:46, b is an integer of 15 to 1677, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:46, and where b is greater than or equal to a + 14.

**FEATURES OF PROTEIN ENCODED BY GENE NO: 37**

- It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: NCI\_CGAP\_GCB1 and to a lesser extent in Soares\_parathyroid\_tumor\_NbHPA; Soares\_pregnant\_uterus\_NbHPU;
- 5 NCI\_CGAP\_GCB1; Soares\_total\_fetus\_Nb2HF8\_9w; Morton Fetal Cochlea; NCI\_CGAP\_GCB1; Human Osteosarcoma; Soares\_parathyroid\_tumor\_NbHPA; Pancreas Islet Cell Tumor; NCI\_CGAP\_AA1; Stratagene HeLa cell s3 937216; Human Osteoarthritic Cartilage Fraction IV; Human Adult Spleen, fractionII; NCI\_CGAP\_Co3; Placenta; Human Tonsil, Lib 3; Human Colon; Human Umbilical
- 10 Vein Endothelial Cells, fract. A; Human Quadriceps; Human Hypothalamus,schizophrenia, re-excision; Human Colon Cancer,re-excision; H Female Bladder, Adult; Salivary Gland, Lib 2; Synovial Fibroblasts (II1/TNF), subt; T-Cell PHA 16 hrs; Human Bone Marrow, re-excision; Human Hypothalmus,Schizophrenia; Human Rhabdomyosarcoma; Synovial Fibroblasts
- 15 (control); Human promyelocyte; Human pancreatic islet; Soares\_testis\_NHT; Soares\_pregnant\_uterus\_NbHPU; Soares\_senescent\_fibroblasts\_NbHSF; Stratagene lung (#937210); normalized infant brain cDNA; Colon Tumor; 12 Week Old Early Stage Human; Human T-Cell Lymphoma; Dendritic cells, pooled; Primary Dendritic cells,frac 2; Bone marrow; Endothelial cells-control; Gessler Wilms tumor; Human
- 20 fetal heart, Lambda ZAP Express; Human retina cDNA randomly primed sublibrary; NCI\_CGAP\_Br2; NCI\_CGAP\_Br3; NCI\_CGAP\_Ov2; NCI\_CGAP\_Co10; Soares\_testis\_NHT; Stratagene hNT neuron (#937233); Human Osteoclastoma; Human Microvascular Endothelial Cells, fract. A; Soares\_fetal\_heart\_NbHH19W; Stratagene fetal retina 937202; Stratagene endothelial cell 937223; Monocyte
- 25 activated; Spleen, Chronic lymphocytic leukemia; NCI\_CGAP\_Co8; NCI\_CGAP\_CLL1; NCI\_CGAP\_Co14; NCI\_CGAP\_Pan1; NCI\_CGAP\_Brn23; H.

Frontal cortex,epileptic,re-excision; Soares placenta Nb2HP; Soares fetal liver spleen  
1NFLS and Soares infant brain 1NIB.

Many polynucleotide sequences, such as EST sequences, are publicly  
available and accessible through sequence databases. Some of these sequences are  
5 related to SEQ ID NO:47 and may have been publicly available prior to conception of  
the present invention. Preferably, such related polynucleotides are specifically  
excluded from the scope of the present invention. To list every related sequence  
would be cumbersome. Accordingly, preferably excluded from the present invention  
are one or more polynucleotides comprising a nucleotide sequence described by the  
10 general formula of a-b, where a is any integer between 1 to 1329 of SEQ ID NO:47, b  
is an integer of 15 to 1343, where both a and b correspond to the positions of  
nucleotide residues shown in SEQ ID NO:47, and where b is greater than or equal to a  
+ 14.

## 15 FEATURES OF PROTEIN ENCODED BY GENE NO: 38

The computer algorithm BLASTX has been used to determine that the  
translation product of this gene shares sequence homology with, as a non-limiting  
example, the sequence accessible through the following database accession no.  
gnl|PID|e1354980 (all information available through the recited accession number is  
20 incorporated herein by reference) which is described therein as "Ariadne-2 protein  
(ARI2) [Mus musculus]". A partial alignment demonstrating the observed homology  
is shown immediately below.

25 >gnl|PID|e1354980 (AJ130975) Ariadne-2 protein (ARI2) [Mus musculus]  
>sp|E1354980|E1354980 ARIADNE-2 PROTEIN (ARI2).  
Length = 492

Plus Strand HSPs:

30 Score = 327 (115.1 bits); Expect = 1.2e-28, P = 1.2e-28

Identities = 62/62 (100%), Positives = 62/62 (100%), Frame = +1

Q: 10 YMESGPRKKLFYQQAQLEAEIENLSWKVERADSYDRGDLENQMHIAEQRRRTLLKDFH 189  
 YMESGPRKKLFYQQAQLEAEIENLSWKVERADSYDRGDLENQMHIAEQRRRTLLKDFH  
 5 S: 431 YMESGPRKKLFYQQAQLEAEIENLSWKVERADSYDRGDLENQMHIAEQRRRTLLKDFH 490  
 Q: 190 DT 195  
 DT  
 S: 491 DT 492

10

The segment of gnlPIDle1354980 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 141. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein.

15 Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 142 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

20

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain 1NIB and to a lesser extent in Stratagene muscle 937209; Soares fetal liver spleen 1NFLS; NCI\_CGAP\_GCB1; Human Pancreas Tumor; normalized infant brain cDNA;

25 Soares\_multiple\_sclerosis\_2NbHMSP; Stratagene colon (#937204); Stratagene HeLa cell s3 937216; Frontal lobe,dementia,re-excision; HM3; Human pancreatic islet; NCI\_CGAP\_Co3; NCI\_CGAP\_Co9; NCI\_CGAP\_GC4; Soares\_testis\_NHT; Stratagene fetal spleen (#937205); Soares\_testis\_NHT; Soares\_NFL\_T\_GBC\_S1; Soares\_fetal\_heart\_NbHH19W; Human Thymus Stromal Cells; Human Synovial

30 Sarcoma; Soares\_fetal\_heart\_NbHH19W; Soares\_pregnant\_uterus\_NbHPU;

- Activated T-cell(12h)/Thiouridine-re-excision; Human Cerebellum; Aryepiglottis  
 Normal; Tongue Normal; Raji cells, cyclohexamide treated, subtracted; Activated T-  
 Cells, 8 hrs, subtracted; Activated T-Cells, 8 hrs., ligation 2; Human Uterus, normal;  
 Whole 6 Week Old Embryo; Human Cerebellum, subtracted; Human Primary Breast  
 5 Cancer, re-excision; Human Fetal Spleen; Human Placenta; Soares adult brain  
 N2b4HB55Y; STROMAL -OSTEOCLASTOMA; Human Synovium; Glioblastoma;  
 Salivary Gland, Lib 2; Jurkat T-cell G1 phase; Jurkat T-Cell, S phase;  
 Soares\_parathyroid\_tumor\_NbHPA; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; H.  
 Meningioma, M1; Brain Frontal Cortex, re-excision; Human Adult Small Intestine;  
 10 Human Prostate; Human Brain, Striatum; Human heart cDNA (YNakamura);  
 NCI\_CGAP\_AA1; NCI\_CGAP\_Br2; NCI\_CGAP\_HN4; NCI\_CGAP\_Lu5;  
 NCI\_CGAP\_CNS1; NCI\_CGAP\_Co10; NCI\_CGAP\_Pr22;  
 Soares\_senescent\_fibroblasts\_NbHSF; Monocyte activated, re-excision; Apoptotic T-  
 cell; human ovarian cancer; Human Uterine Cancer; Human pancreatic islet;  
 15 Soares\_fetal\_heart\_NbHH19W; Soares\_fetal\_liver\_spleen\_1NFLS\_S1;  
 Soares\_senescent\_fibroblasts\_NbHSF; Human Pancreas Tumor, Reexcision; Human  
 Ovary; Human umbilical vein endothelial cells, IL-4 induced; Human Whole Six  
 Week Old Embryo; Soares\_testis\_NHT; Soares\_fetal\_heart\_NbHH19W; Stratagene  
 lung (#937210); Hepatocellular Tumor, re-excision; Macrophage-oxLDL, re-excision;  
 20 Human Gall Bladder; 12 Week Early Stage Human II, Reexcision; Human Testes,  
 Reexcision; Human Placenta; Human Fetal Heart; Human Primary Breast Cancer  
 Reexcision; Soares\_placenta\_8to9weeks\_2NbHP8to9W; CD34-depleted Buffy Coat  
 (Cord Blood), re-excision; Soares\_pregnant\_uterus\_NbHPU; Stratagene colon  
 (#937204); Smooth muscle, control; Monocyte activated; Human Bone Marrow,  
 25 treated; Stratagene endothelial cell 937223; T Cell helper I; NCI\_CGAP\_Brn25; H.  
 Frontal cortex, epileptic, re-excision; Hodgkin's Lymphoma II; Keratinocyte; Human 8

Week Whole Embryo; Stratagene HeLa cell s3 937216; T cell helper II and Primary Dendritic Cells, lib 1.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 96 as residues: Asp-20 to Ser-29. Polynucleotides  
5 encoding said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:48 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
10 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 538 of SEQ ID NO:48, b is an integer of 15 to 552, where both a and b correspond to the positions of  
15 nucleotide residues shown in SEQ ID NO:48, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 39**

It has been discovered that this gene is expressed primarily in CD34 positive  
20 cells (Cord Blood).

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:49 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically  
25 excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention



are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2281 of SEQ ID NO:49, b is an integer of 15 to 2295, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:49, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 40**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Bone Marrow, treated; Soares fetal liver spleen

10 INFLS and to a lesser extent in Soares ovary tumor NbHOT; Weizmann Olfactory Epithelium; Human Pituitary, subt IX; Soares breast 2NbHBst; Endothelial cells-control; Hodgkin's Lymphoma II; Human OB MG63 control fraction I; Human (Caco-2) cell line, adenocarcinoma, colon, remake; Human Pineal Gland; Human retina cDNA Tsp509I-cleaved sublibrary; Stratagene muscle 937209; Human Adult

15 Testes, Large Inserts, Reexcision; Human Activated Monocytes; Soares\_NFL\_T\_GBC\_S1; Soares\_fetal\_liver\_spleen\_INFLS\_S1; Human Chondrosarcoma; Human Thymus; Human Gall Bladder; Stratagene pancreas (#937208); Soares melanocyte 2NbHM; Human Synovial Sarcoma; Human Fetal Lung III; Bone marrow; Endothelial-induced; Human Primary Breast Cancer

20 Reexcision; Human Microvascular Endothelial Cells, fract. A; Smooth muscle, control; Stratagene HeLa cell s3 937216; Stratagene fibroblast (#937212); Primary Dendritic Cells, lib 1; Soares infant brain 1NIB; HPAS (human pancreas, subtracted); Human Tonsil, Lib 3; Human epithelioid sarcoma; HepG2 Cells, lambda library; L1 Cell line; Human Colon; Human Umbilical Vein Endothelial Cells, fract.

25 A; HUMAN STOMACH; Soares\_pregnant\_uterus\_NbHPU; Stratagene fibroblast (#937212); Smooth Muscle Serum Treated, Norm; Smooth muscle-ILb induced;

- Aorta endothelial cells + TNF- $\alpha$ ; Activated T-cells; Salivary Gland; Human Normal Breast; Pancreas Tumor PCA4 Tu; Human Hypothalamus, schizophrenia, re-excision; Human Colon Cancer, re-excision; NCI\_CGAP\_GC3; NCI\_CGAP\_CLL1; Hepatocellular Tumor, re-excision; Synovial hypoxia-RSF subtracted; Healing groin
- 5 wound, 7.5 hours post incision; Human Whole Brain #2 - Oligo dT > 1.5Kb; LNCAP prostate cell line; Human Adipose Tissue, re-excision; Pancreas normal PCA4 No; Jurkat T-Cell, S phase; H. Meningioma, M1; Prostate BPH; Human Bone Marrow, re-excision; Apoptotic T-cell; human ovarian cancer; 12 Week Old Early Stage Human, II; Human Osteoblasts II; Human Fetal Dura Mater; T-Cell PHA 24 hrs; Merkel
- 10 Cells; NCI\_CGAP\_Co8; NCI\_CGAP\_Br15; NCI\_CGAP\_CLL1; NCI\_CGAP\_Co14; NCI\_CGAP\_Eso2; NCI\_CGAP\_Ov23; NCI\_CGAP\_Lym12; Human Placenta (re-excision); Barstead spleen HPLRB2; Human promyelocyte; Infant brain, Bento Soares; Soares\_testis\_NHT; Soares\_total\_fetus\_Nb2HF8\_9w; Stratagene hNT neuron (#937233); Human Activated T-Cells, re-excision; Bone Marrow Stromal Cell,
- 15 untreated; Human Adrenal Gland Tumor; Rejected Kidney, lib 4; CHME Cell Line, treated 5 hrs; Human adult testis, large inserts; NCI\_CGAP\_Co10; Hepatocellular Tumor, re-excision; Pancreas Islet Cell Tumor; Fetal Heart; Stratagene endothelial cell 937223; Stratagene ovarian cancer (#937219); Resting T-Cell Library, II; 12 Week Old Early Stage Human; Neutrophils IL-1 and LPS induced;
- 20 Human Eosinophils; Smooth muscle, serum treated; breast lymph node CDNA library; Human placenta cDNA (TFujiwara); Colon Tumor II; Dendritic cells, pooled; Primary Dendritic cells, frac 2; 12 Week Early Stage Human II, Reexcision; NCI\_CGAP\_Co3; NCI\_CGAP\_Ew1; NCI\_CGAP\_GCB1; HUMAN B CELL LYMPHOMA; NCI\_CGAP\_Kid6; T Cell helper I; Human Testes; Human
- 25 Endometrial Tumor; Osteoblasts; Keratinocyte; T cell helper II; Human Cerebellum; Stratagene colon (#937204) and Stratagene pancreas (#937208).

When tested against K562 leukemia cell lines, supernatants removed from cells containing this gene activated the ISRE assay. Thus, it is likely that this gene activates leukemia cells through the Jak-STAT signal transduction pathway. The interferon-sensitive response element is a promoter element found upstream of many genes which are involved in the Jak-STAT pathway. The Jak-STAT pathway is a large, signal transduction pathway involved in the differentiation and proliferation of cells. Therefore, activation of the Jak-STAT pathway, reflected by the binding of the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. Antibodies that bind to polypeptides of the invention and inhibit said activity are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:50 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 2078 of SEQ ID NO:50, b is an integer of 15 to 2092, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:50, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 41**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

gil2098575 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "F25451\_2 [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

```

5      >gi|2098575 (AC002115) F25451_2 [Homo sapiens] >sp|O00320|O00320 F25451_2.
      Length = 339

      Plus Strand HSPs:

10      Score = 614 (216.1 bits), Expect = 2.1e-79, Sum P(2) = 2.1e-79
      Identities = 122/147 (82%), Positives = 122/147 (82%), Frame = +1

15      Q: 1054 GLMALEVXXXXXXXXXXXXXXXXXRCIRTAAGSSWEDPSLLEWDADDFRIFCGDLGNEVN 1233
      GLMALEV                                RCIRTAAGSSWEDPSLLEWDADDFRIFCGDLGNEVN
      S: 193 GLMALEVPEPLGEDKKKGKPEKLRCIRTAAGSSWEDPSLLEWDADDFRIFCGDLGNEVN 252

      Q: 1234 DDILARAFSRFPSFLKAKVIRDKRTGKTKGYGFVSFKDPSDYVRAMREMNGKYVGSRPIK 1413
      DDILARAFSRFPSFLKAKVIRDKRTGKTKGYGFVSFKDPSDYVRAMREMNGKYVGSRPIK
20      S: 253 DDILARAFSRFPSFLKAKVIRDKRTGKTKGYGFVSFKDPSDYVRAMREMNGKYVGSRPIK 312

      Q: 1414 LRKSMWKDRNLDVVRXXXXXXXXXLGLR 1494
      LRKSMWKDRNLDVVR                    LGLR
      S: 313 LRKSMWKDRNLDVVRKKQKEKKLGLR 339

25      Score = 209 (73.6 bits), Expect = 2.1e-79, Sum P(2) = 2.1e-79
      Identities = 45/52 (86%), Positives = 45/52 (86%), Frame = +2

      Q: 500 MFLRRAAVAPQRAPILRPAFVPHVLQRA-----AAGPRPMALRPPHQALV 634
      MFLRRAAVAPQRAPILRPAFVPHVLQRA          AAGPRPMALRPPHQALV
30      S: 1 MFLRRAAVAPQRAPILRPAFVPHVLQRADSAALSSAAAGPRPMALRPPHQALV 52

```

The segments of gil2098575 that are shown as "S" above are set out in the sequence listing as SEQ ID NO. 143 and SEQ ID NO. 145. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 144 and/or SEQ

ID NO. 146 which correspond to the "Q" sequences in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares infant brain 1NIB and to a lesser extent in

- 5 NCI\_CGAP\_Brn25; NCI\_CGAP\_Co8; Soares\_testis\_NHT; Synovial hypoxia-RSF subtracted; Human Bone Marrow, re-excision; Hemangiopericytoma; NCI\_CGAP\_Ov23; NCI\_CGAP\_Pr28; Soares melanocyte 2NbHM; Human Fetal Brain, normalized C500H; Gessler Wilms tumor; Human promyelocyte; Infant brain, Bento Soares; NCI\_CGAP\_Br2; NCI\_CGAP\_Br3; NCI\_CGAP\_Co2;
- 10 NCI\_CGAP\_Co3; NCI\_CGAP\_Co9; NCI\_CGAP\_GC2; NCI\_CGAP\_GC4; NCI\_CGAP\_Lu1; NCI\_CGAP\_GCB1; NCI\_CGAP\_Pr25; Soares\_NhHMPu\_S1; Soares ovary tumor NbHOT; H. Meningioma, M6; Human Aortic Endothelium; Human Adult Retina; Glioblastoma; Human Amygdala, re-excision; Breast Cancer Cell line, angiogenic; Liver, Hepatoma; Human adult testis, large inserts;
- 15 NCI\_CGAP\_Ut4; NCI\_CGAP\_CLL1; NCI\_CGAP\_Co14; NCI\_CGAP\_Eso2; NCI\_CGAP\_Kid11; Soares\_fetal\_heart\_NbHH19W; CHME Cell Line, untreated; Soares\_fetal\_lung\_NbHL19W; Primary Dendritic cells, frac 2; 12 Week Early Stage Human II, Reexcision; Bone marrow; Human Amygdala; Bone Marrow Cell Line (RS4,11); Activated T-cell(12h)/Thiouridine-re-excision; Nine Week Old Early Stage
- 20 Human and Soares fetal liver spleen 1NFLS.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 99 as residues: Pro-15 to Cys-32, Pro-48 to Pro-59, Pro-68 to Trp-74. Polynucleotides encoding said polypeptides are also encompassed by the invention.

- 25 Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are

related to SEQ ID NO:51 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

5 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1667 of SEQ ID NO:51, b is an integer of 15 to 1681, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:51, and where b is greater than or equal to a + 14.

10

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 42**

It has been discovered that this gene is expressed primarily in Primary Dendritic Cells, lib 1.

Many polynucleotide sequences, such as EST sequences, are publicly

15 available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:52 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention

20 are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1632 of SEQ ID NO:52, b is an integer of 15 to 1646, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:52, and where b is greater than or equal to a + 14.

25

**FEATURES OF PROTEIN ENCODED BY GENE NO: 43**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no.

- 5   gil2463634 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "monocarboxylate transporter [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

```
10   >gi|2463634 monocarboxylate transporter [Homo sapiens] >sp|O15427|O15427
      MONOCARBOXYLATE TRANSPORTER.
      Length = 465

      Plus Strand HSPs:

15   Score = 514 (180.9 bits), Expect = 1.7e-193, Sum P(5) = 1.7e-193
      Identities = 110/154 (71%), Positives = 110/154 (71%), Frame = +1

20   Q:   394 SFCRSIIQVYLTGTGVTGLGLALNFQPSLIMLNRYFSKRRPMANGLAAAGSPVFLCALSP 573
      SFCRSIIQVYLTGTGVTGLGLALNFQPSLIMLNRYFSKRRPMANGLAAAGSPVFLCALSP
      S:   106 SFCRSIIQVYLTGTGVTGLGLALNFQPSLIMLNRYFSKRRPMANGLAAAGSPVFLCALSP 165

      Q:   574 LGQLQDRYXXXXXXXXXXXXXXXXNCCVCAALMRPLVVTAQXXXXXXXXXXXXXXXXVFRD 753
      LGQLQDRY                                   NCCVCAALMRPLVVTAQ                                   VFRD
25   S:   166 LGQLQDRYGWRGGFLILGGLLNCCVCAALMRPLVVTAQPGSGPPRPSRRLDLSVFRD 225

      Q:   754 RGFVLYAVAASXXXXXXXXXXXXXXXXSYAKDLGVP 855
      RGFVLYAVAAS                                   SYAKDLGVP
30   S:   226 RGFVLYAVAASVMVLGLFVPPVVFVVSYAKDLGVP 259

      Score = 507 (178.5 bits), Expect = 1.7e-193, Sum P(5) = 1.7e-193
      Identities = 101/113 (89%), Positives = 101/113 (89%), Frame = +2

35   Q:   854 PDTKAAFLLTILGFIDIFARPAAGFVAGLGKVRPYSVYLFSFSMFFNGLADLAGSTAGDY 1033
      PDTKAAFLLTILGFIDIFARPAAGFVAGLGKVRPYSVYLFSFSMFFNGLADLAGSTAGDY
      S:   259 PDTKAAFLLTILGFIDIFARPAAGFVAGLGKVRPYSVYLFSFSMFFNGLADLAGSTAGDY 318

      Q:   1034 GGLVVFCIFFGISYGMVGALQFEVLMAIVGTHKFSSAIGXXXXXXXXXXXXXGP 1192
      GGLVVFCIFFGISYGMVGALQFEVLMAIVGTHKFSSAIG                                   GP
40   S:   319 GGLVVFCIFFGISYGMVGALQFEVLMAIVGTHKFSSAIGLVLLMEAVAVLVGP 371

      Score = 392 (138.0 bits), Expect = 1.7e-193, Sum P(5) = 1.7e-193
      Identities = 73/73 (100%), Positives = 73/73 (100%), Frame = +2

45   Q:   77 MGGAVVDEGPTGVKAPDGGGWGAVLFGCFVITGFSYAFPKAVSVFFKELIQEFGIGYSDT 256
      MGGAVVDEGPTGVKAPDGGGWGAVLFGCFVITGFSYAFPKAVSVFFKELIQEFGIGYSDT
      S:   1 MGGAVVDEGPTGVKAPDGGGWGAVLFGCFVITGFSYAFPKAVSVFFKELIQEFGIGYSDT 60
```

Q: 257 AWISSILLAMLYG 295  
     AWISSILLAMLYG  
 S: 61 AWISSILLAMLYG 73  
 5  
 Score = 358 (126.0 bits), Expect = 1.7e-193, Sum P(5) = 1.7e-193  
 Identities = 73/90 (81%), Positives = 73/90 (81%), Frame = +1  
  
 Q: 1204 KLLDATHVYMYVFILAGAEVLTSSLILLLLGNFFCIRXXXXXXXXXXXXXXXXXXXXLHKPPAD 1383  
 10      KLLDATHVYMYVFILAGAEVLTSSLILLLLGNFFCIR                      LHKPPAD  
 S: 376 KLLDATHVYMYVFILAGAEVLTSSLILLLLGNFFCIRKKKPEPQPEVAAEEEEKLHKPPAD 435  
  
 Q: 1384 SGVDLREVEHFLKAEPEKNGEVVHTPETS 1473  
     SGVDLREVEHFLKAEPEKNGEVVHTPETS  
 15 S: 436 SGVDLREVEHFLKAEPEKNGEVVHTPETS 465  
  
 Score = 170 (59.8 bits), Expect = 1.7e-193, Sum P(5) = 1.7e-193  
 Identities = 32/33 (96%), Positives = 32/33 (96%), Frame = +3  
  
 Q: 294 GTSPLCSVCVNRFGCRPVMLVGGLFASLGMVAA 392  
 20      GT PLCSVCVNRFGCRPVMLVGGLFASLGMVAA  
 S: 73 GTGPLCSVCVNRFGCRPVMLVGGLFASLGMVAA 105  
  
 Score = 40 (14.1 bits), Expect = 6.5e-55, Sum P(3) = 6.5e-55  
 25 Identities = 9/24 (37%), Positives = 14/24 (58%), Frame = +2  
  
 Q: 1427 SLRKTGRWFTPRKQVSEWLGGAGS 1498  
     SL R+F+ R+ ++ L AGS  
 30 S: 133 SLIMLNRYFSKRRPMANGLAAAGS 156

The segments of gil2463634 that are shown as "S" above are set out in  
 the sequence listing as SEQ ID NO. 147,SEQ ID NO. 149,SEQ ID NO. 151,SEQ ID  
 NO. 153,SEQ ID NO. 155 and SEQ ID NO. 157 . Based on the structural similarity,  
 these homologous polypeptides are expected to share at least some biological  
 35 activities. Such activities are known in the art, some of which are described elsewhere  
 herein. Assays for determining such activities are also known in the art, some of  
 which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the  
 amino acid sequence set out in the sequence listing as SEQ ID NO. 148,SEQ ID NO.  
 40 150,SEQ ID NO. 152,SEQ ID NO. 154,SEQ ID NO. 156 and/or SEQ ID NO. 158



which correspond to the "Q" sequences in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).

- It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Primary Dendritic Cells, lib 1 and to a lesser extent in Human
- 5 Neutrophil, Activated; HL-60, RA 4h, Subtracted; Epithelial-TNF $\alpha$  and INF induced; Human Thymus Stromal Cells; Dendritic cells, pooled; Soares\_placenta\_8to9weeks\_2NbHP8to9W; Soares\_fetal\_lung\_NbHL19W; Soares\_senescent\_fibroblasts\_NbHSF; Stratagene pancreas (#937208); Soares\_fetal\_heart\_NbHH19W; Bone Marrow Stromal Cell, untreated; Smooth
  - 10 muscle, serum induced, re-exc; Human Placenta; Soares melanocyte 2NbHM; Primary Dendritic cells, frac 2; Poly[I]/Poly[C] Normal Lung Fibroblasts; Bone Marrow Stroma, TNF&LPS ind; Human Tonsil, Lib 3; Activated T-Cells, 12 hrs.; Soares retina N2b5HR; Human OB MG63 treated (10 nM E2) fraction 1; Human Aortic Endothelium; Soares\_placenta\_8to9weeks\_2NbHP8to9W; Human Neutrophils,
  - 15 Activated, re-excision; Smooth muscle-1Lb induced; H. Epididymus, cauda; Activated T-Cells, 12 hrs, re-excision; Stratagene ovary (#937217); Soares\_testis\_NHT; Mesangial cell, frac 2; pBMC stimulated w/ poly I/C; Human Osteosarcoma; HL-60, PMA 4H, re-excision; Human endometrial stromal cells; Stratagene muscle 937209; Synovial hypoxia; Human Neutrophil; Human Uterine
  - 20 Cancer; Human Activated T-Cells; Human Pancreas Tumor; Soares\_pregnant\_uterus\_NbHPU; Ovarian Tumor 10-3-95; Human adult testis, large inserts; PC3 Prostate cell line; H Macrophage (GM-CSF treated), re-excision; Colon Tumor II; Soares\_NhHMPu\_S1; Endothelial-induced; Activated T-Cell (12hs)/Thiouridine labelled Eco; Endothelial cells-control; Human Microvascular
  - 25 Endothelial Cells, fract. A; Smooth muscle, control; Human Bone Marrow, treated; T Cell helper 1; Human Endometrial Tumor; Activated T-cell(12h)/Thiouridine-re-

excision; Soares\_pregnant\_uterus\_NbHPU; Stratagene pancreas (#937208);  
Osteoblasts and Keratinocyte.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 101 as residues: Pro-6 to Pro-11, Ala-43 to Gly-50,  
5 Glu-76 to Cys-92, Ser-101 to Trp-110, Pro-163 to Ser-169. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind polypeptides of the invention are also preferred embodiments of the invention.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are  
10 related to SEQ ID NO:53 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the  
15 general formula of a-b, where a is any integer between 1 to 1976 of SEQ ID NO:53, b is an integer of 15 to 1990, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:53, and where b is greater than or equal to a + 14.

## 20 **FEATURES OF PROTEIN ENCODED BY GENE NO: 44**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil3650492 (all information available through the recited accession number is  
25 incorporated herein by reference) which is described therein as "proliferation inducing ligand APRIL [Homo sapiens]." The APRIL protein is thought to be a

proliferation inducing ligand which promotes the growth of tumor tissues. A partial alignment demonstrating the observed homology is shown immediately below.

5 >gi|3650492 (AF046888) proliferation inducing ligand APRIL [Homo sapiens]  
>sp|O75888|O75888 PROLIFERATION INDUCING LIGAND APRIL.  
Length = 250

Plus Strand HSPs:

10 Score = 206 (72.5 bits), Expect = 5.0e-16, P = 5.0e-16  
Identities = 47/127 (37%), Positives = 75/127 (59%), Frame = +1

Q: 64 EETGSYTFVPWLLSFKRGSAL E EKENKILVKETGYFFIYGQVLYTDKTYAMGH LIQRKKV 243  
++ T V W + +RG L+ + + +++ G + +Y QVL+ D T+ MG ++ R+

15 S: 128 KDDSDVTEVMWQPALRRGRGLQAQGYGVRIQDAGVYLLYSQVLFQDVTFTMGQVVSREGQ 187

Q: 244 HVFGDELSLVTLFRCIQNMPETLPN---NSCYSAGIAKLEEGDELQLAIPRENAQISLDG 414  
G + TLFRCI++MP P+ NSCYSAG+ L +GD L + IPR A+++L

20 S: 188 ---GRQ---ETLFRCIRSMPSH-PDRAYNSCYSAGVFHLHQGDILSVIIPRARA KLNLS P 240

Q: 415 DVTFFGALKL 444  
TF G +KL

S: 241 HGTF LGFVKL 250

25 The segment of gi|3650492 that is shown as "S" above is set out in the  
sequence listing as SEQ ID NO. 159. Based on the structural similarity, these  
homologous polypeptides are expected to share at least some biological activities.  
Such activities are known in the art, some of which are described elsewhere herein.  
Assays for determining such activities are also known in the art, some of which have  
30 been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the  
amino acid sequence set out in the sequence listing as SEQ ID NO. 160 which  
corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a  
sequence by the computer are, of course, removed).

35 It has been discovered that this gene is expressed primarily in the following  
tissues/cDNA libraries: Spleen, Chronic lymphocytic leukemia and to a lesser extent  
in Hodgkin's Lymphoma II; Soares fetal liver spleen 1NFLS; Primary Dendritic Cells,

lib 1; stomach cancer (human); CD40 activated monocyte dendritic cells; Human Neutrophil; Human Bone Marrow, re-excision; T-Cell PHA 24 hrs; Macrophage-oxLDL; Human Pancreas Tumor, Reexcision; Primary Dendritic cells,frac 2; Neutrophils control, re-excision; Soares\_fetal\_liver\_spleen\_1NFLS\_S1; 12 Week  
5 Early Stage Human II, Reexcision; Bone marrow; CD34 depleted Buffy Coat (Cord Blood), re-excision; Smooth muscle,control; HUMAN B CELL LYMPHOMA; Stratagene ovarian cancer (#937219); T Cell helper 1; Bone Marrow Cell Line (RS4,11); Human aorta polyA+ (TFujiwara) and NCI\_CGAP\_Lu5.

Preferred polypeptides of the present invention comprise immunogenic  
10 epitopes shown in SEQ ID NO: 102 as residues: Met-29 to Tyr-39. Polynucleotides encoding said polypeptides are also encompassed by the invention. Antibodies that bind to polypeptides and/or epitopes of the invention are also encompassed by the invention. Antibodies that bind to polypeptides of the invention and inhibit activity are further encompassed by the invention.

15 Based upon the homology of this protein to APRIL, antagonists directed against this protein may be useful in blocking the activity of this protein. Accordingly, preferred are antibodies which specifically bind a portion of the translation product of this gene. Also provided is a kit for detecting tumors. Such a kit comprises in one embodiment an antibody specific for the translation product of this  
20 gene bound to a solid support. Also provided is a method of detecting tumors in an individual which comprises a step of contacting an antibody specific for the translation product of this gene to a bodily fluid from the individual, preferably serum, and ascertaining whether antibody binds to an antigen found in the bodily fluid. Preferably the antibody is bound to a solid support and the bodily fluid is  
25 serum. The above embodiments, as well as other treatments and diagnostic tests (kits and methods), are more particularly described elsewhere herein.

Homology of this protein to APRIL and the tissue distribution in immune cells indicates the polynucleotides and polypeptides corresponding to this gene would be useful for the diagnosis and treatment of a variety of immune system disorders. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections below, in Example 11, 13, 14, 16, 18, 19, 20, and 27, and elsewhere herein. Briefly, the expression indicates a role in regulating the proliferation; survival; differentiation; and/or activation of hematopoietic cell lineages, including blood stem cells. Involvement in the regulation of cytokine production, antigen presentation, or other processes suggests a usefulness for treatment of cancer (e.g. by boosting immune responses). Expression in cells of lymphoid origin, indicates the natural gene product would be involved in immune functions. Therefore it would also be useful as an agent for immunological disorders including arthritis, asthma, immunodeficiency diseases such as AIDS, leukemia, rheumatoid arthritis, granulomatous disease, inflammatory bowel disease, sepsis, acne, neutropenia, neutrophilia, psoriasis, hypersensitivities, such as T-cell mediated cytotoxicity; immune reactions to transplanted organs and tissues, such as host-versus-graft and graft-versus-host diseases, or autoimmunity disorders, such as autoimmune infertility, lense tissue injury, demyelination, systemic lupus erythematosus, drug induced hemolytic anemia, rheumatoid arthritis, Sjogren's disease, and scleroderma. Moreover, the protein may represent a secreted factor that influences the differentiation or behavior of other blood cells, or that recruits hematopoietic cells to sites of injury. Thus, this gene product is thought to be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types. Furthermore, the protein may also be used to determine biological activity, raise antibodies, as tissue markers, to isolate cognate ligands or receptors, to identify agents that modulate their interactions, in addition to its use as a nutritional

supplement. Protein, as well as, antibodies directed against the protein may show utility as a tumor marker and/or immunotherapy targets for the above listed tissues.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:54 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 540 of SEQ ID NO:54, b is an integer of 15 to 554, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:54, and where b is greater than or equal to a + 14.

#### 15 **FEATURES OF PROTEIN ENCODED BY GENE NO: 45**

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Soares placenta Nb2HP and to a lesser extent in Soares\_pregnant\_uterus\_NbHPU; NCI\_CGAP\_GCB1; Primary Dendritic Cells, lib 1; Soares infant brain 1NIB; Soares melanocyte 2NbHM; Soares\_multiple\_sclerosis\_2NbHMSP; Stratagene ovary (#937217); Stratagene HeLa cell s3 937216; Soares\_senescent\_fibroblasts\_NbHSF; Soares\_testis\_NHT; Soares\_NFL\_T\_GBC\_S1; Colon Tumor; Soares\_placenta\_8to9weeks\_2NbHP8to9W; Human Osteoclastoma; NCI\_CGAP\_Br2; NCI\_CGAP\_Lu5; Nine Week Old Early Stage Human; Soares\_pregnant\_uterus\_NbHPU; Human Pancreas Tumor; Soares ovary tumor NbHOT; Cheek Carcinoma; Rectum tumour; Human Fetal Spleen; Activated T-cells; Early Stage Human Lung, subtracted; Cem cells cyclohexamide

treated; normalized infant brain cDNA; NTERA2 teratocarcinoma cell line+retinoic acid (14 days); Human endometrial stromal cells; Synovial Fibroblasts (II1/TNF),  
 subt; Mo7e Cell Line GM-CSF treated (1ng/ml); Stratagene fetal spleen (#937205);  
 Human Heart; Soares\_multiple\_sclerosis\_2NbHMSP; Human umbilical vein  
 5 endothelial cells, IL-4 induced; Ulcerative Colitis; Bone Marrow Stromal Cell,  
 untreated; Human colorectal cancer; Soares\_pregnant\_uterus\_NbHPU;  
 Soares\_total\_fetus\_Nb2HF8\_9w; 12 Week Old Early Stage Human; Human T-Cell  
 Lymphoma; Human Placenta; Endothelial-induced; normalized infant brain cDNA;  
 Anergetic T-cell; NCI\_CGAP\_Co3; NCI\_CGAP\_Co8; NCI\_CGAP\_Kid5;  
 10 Soares\_multiple\_sclerosis\_2NbHMSP; Human Bone Marrow, treated and Stratagene  
 NT2 neuronal precursor 937230.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:55 and may have been publicly available prior to conception of  
 15 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1226 of SEQ ID NO:55, b  
 20 is an integer of 15 to 1240, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:55, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 46**

25 The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting

example, the sequence accessible through the following database accession no.

gnl|PID|d1010096 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "DOCK180 protein [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

```

>gnl|PID|d1010096 DOCK180 protein [Homo sapiens] >sp|Q14185|Q14185 DOCK180
    PROTEIN.
    Length = 1865
10
    Plus Strand HSPs:

    Score = 363 (127.8 bits), Expect = 4.7e-30, P = 4.7e-30
    Identities = 70/88 (79%), Positives = 79/88 (89%), Frame = +3
15
    Q:  927 WRSNSQNIKHNLKKLMEVDGGEIVKFLQDTLDALFNIMMEMSDSETYDFLVFDALVFIIS 1106
        WRSN+  ++ NL++LM+VDGGE+VKFLQDTLDALFNIMME S+SET+D LVFDALVFII
    S:  625 WRSNTSLQQLNRQLMKVDGGEVVKFLQDTLDALFNIMMENSESETFDTLVFDALVFIIG 684

20
    Q:  1107 LIGDIKFQHFNPVLETYIYKHFSATLAY 1190
        LI D KFQHFNPVLETYI KHFSATLAY
    S:  685 LIADRKQHFNPVLETYIKKHFSATLAY 712

```

The segment of gnl|PID|d1010096 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 161. Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein. Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 162 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a sequence by the computer are, of course, removed).



It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Human Lung Cancer, subtracted; Human Osteoblasts II; Primary Dendritic Cells, lib 1.

Preferred polypeptides of the present invention comprise immunogenic epitopes shown in SEQ ID NO: 104 as residues: Ser-25 to Glu-30. Polynucleotides encoding said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:56 and may have been publicly available prior to conception of the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1710 of SEQ ID NO:56, b is an integer of 15 to 1724, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:56, and where b is greater than or equal to a + 14.

#### **FEATURES OF PROTEIN ENCODED BY GENE NO: 47**

The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gnllPIDId1014087 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "KIAA0281 [Homo sapiens]". A partial alignment demonstrating the observed homology is shown immediately below.

>gnl|PID|d1014087 KIAA0281 [Homo sapiens]  
Length = 247

5 Plus Strand HSPs:

Score = 208 (73.2 bits), Expect = 1.7e-15, P = 1.7e-15  
Identities = 36/36 (100%), Positives = 36/36 (100%), Frame = +1

10 Q: 241 DKFWYCRLSPNHNKVLHYGDLEESPOGEVPHDSLQDK 348  
DKFWYCRLSPNHNKVLHYGDLEESPOGEVPHDSLQDK  
S: 92 DKFWYCRLSPNHNKVLHYGDLEESPOGEVPHDSLQDK 127

The segment of gnl|PID|d1014087 that is shown as "S" above is set out in the  
15 sequence listing as SEQ ID NO. 163. Based on the structural similarity, these  
homologous polypeptides are expected to share at least some biological activities.  
Such activities are known in the art, some of which are described elsewhere herein.  
Assays for determining such activities are also known in the art, some of which have  
been described elsewhere herein.

20 Preferred polypeptides of the invention comprise a polypeptide having the  
amino acid sequence set out in the sequence listing as SEQ ID NO. 164 which  
corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a  
sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in  
25 Dermatofibrosarcoma Protuberance.

Preferred polypeptides of the present invention comprise immunogenic  
epitopes shown in SEQ ID NO: 105 as residues: Gly-29 to Lys-49. Polynucleotides  
encoding said polypeptides are also encompassed by the invention.

Many polynucleotide sequences, such as EST sequences, are publicly  
30 available and accessible through sequence databases. Some of these sequences are  
related to SEQ ID NO:57 and may have been publicly available prior to conception of  
the present invention. Preferably, such related polynucleotides are specifically

excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1419 of SEQ ID NO:57, b  
 5 is an integer of 15 to 1433, where both a and b correspond to the positions of nucleotide residues shown in SEQ ID NO:57, and where b is greater than or equal to a + 14.

#### FEATURES OF PROTEIN ENCODED BY GENE NO: 48

10 The computer algorithm BLASTX has been used to determine that the translation product of this gene shares sequence homology with, as a non-limiting example, the sequence accessible through the following database accession no. gil1710216 (all information available through the recited accession number is incorporated herein by reference) which is described therein as "Homo sapiens  
 15 protein". A partial alignment demonstrating the observed homology is shown immediately below.

```

20 >gi|1710216 unknown [Homo sapiens] >sp|Q99770|Q99770 HYPOTHETICAL 15.4 KD
    PROTEIN.
    Length = 139

    Minus Strand HSPs:

25 Score = 236 (83.1 bits), Expect = 8.1e-19, P = 8.1e-19
    Identities = 49/72 (68%), Positives = 56/72 (77%), Frame = -1

    Q: 1180 TVSAHCKLRLPGSHSPASASQVAGTTGACHHARLIFLYFLVETGFHCVSQDGLDL-LVS 1004
        T+SAHC L LPGS +SPASAS+VAGT G C A+LIF+ FL E GFH V +DGLDL LV
    S: 68 TISAHCNLCPLGSSNSPASASRVAGTAGTCRRAQLIFV-FLAEMGFHHVGRDGLDLNLVI 126

30 Q: 1003 RPPQPPKVLGLQA 965
        PP+ PK LGLQA
    S: 127 HPPRSPKALGLQA 139
  
```

The segment of gil1710216 that is shown as "S" above is set out in the sequence listing as SEQ ID NO. 165 . Based on the structural similarity, these homologous polypeptides are expected to share at least some biological activities. Such activities are known in the art, some of which are described elsewhere herein.

5 Assays for determining such activities are also known in the art, some of which have been described elsewhere herein.

Preferred polypeptides of the invention comprise a polypeptide having the amino acid sequence set out in the sequence listing as SEQ ID NO. 166 which corresponds to the "Q" sequence in the alignment shown above (gaps introduced in a

10 sequence by the computer are, of course, removed).

It has been discovered that this gene is expressed primarily in the following tissues/cDNA libraries: Osteoblasts; Soares\_fetal\_heart\_NbHH19W; Soares fetal liver spleen 1NFLS and to a lesser extent in Soares\_fetal\_lung\_NbHL19W; stomach cancer (human); Human Whole Six Week Old Embryo; Soares\_testis\_NHT;

15 NTERA2, control; Hodgkin's Lymphoma II and Soares\_fetal\_liver\_spleen\_1NFLS\_S1.

Many polynucleotide sequences, such as EST sequences, are publicly available and accessible through sequence databases. Some of these sequences are related to SEQ ID NO:58 and may have been publicly available prior to conception of

20 the present invention. Preferably, such related polynucleotides are specifically excluded from the scope of the present invention. To list every related sequence would be cumbersome. Accordingly, preferably excluded from the present invention are one or more polynucleotides comprising a nucleotide sequence described by the general formula of a-b, where a is any integer between 1 to 1253 of SEQ ID NO:58, b

25 is an integer of 15 to 1267, where both a and b correspond to the positions of

nucleotide residues shown in SEQ ID NO:58, and where  $b$  is greater than or equal to  $a + 14$ .

Table 1

Gene No.	cDNA Clone ID	ATCC Deposit No.:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
1	HKBA62	203979 04/29/99	Uni-ZAP XR	11	1289	1	1289	120	120	59	1	24	25	35
2	HILBW03	203979 04/29/99	pBluescript SK-	12	2913	1	2913	331	331	60	1	23	24	35
3	HNEBX72	203979 04/29/99	Uni-ZAP XR	13	1694	21	1694	47	47	61	1	17	18	46
4	H6EEA48	203979 04/29/99	Uni-ZAP XR	14	1228	1	1228	196	196	62	1	22	23	246
5	HACBJ56	203979 04/29/99	Uni-ZAP XR	15	888	1	888		250	63	1	10	11	25
6	HACBS22	203979 04/29/99	Uni-ZAP XR	16	3239	1	3239	217	217	64	1	27	28	41
7	HADDP23	203979 04/29/99	pSport1	17	954	1	954	238	238	65	1	24	25	39

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
8	HADMB15	203979 04/29/99	pBluescript	18	330	1	330		238	66	1	13	14	20
9	HAGAE84	203979 04/29/99	Uni-ZAP XR	19	1964	1	1964		205	67	1			17
10	HAGFD75	203979 04/29/99	Uni-ZAP XR	20	1067	1	1067	13	13	68	1	16	17	61
11	HAGFS57	203979 04/29/99	Uni-ZAP XR	21	874	1	874	241	241	69	1	26	27	54
12	HAHEA15	203979 04/29/99	Uni-ZAP XR	22	1346	1	1346	196	196	70	1			13
13	HAHSD51	203979 04/29/99	pBluescript	23	593	1	593	85	85	71	1	22	23	49
14	HAIDP45	203979 04/29/99	Uni-ZAP XR	24	1182	1	1182	255	255	72	1	15	16	25
15	HANKC93	203979 04/29/99	pSport1	25	876	1	876	198	198	73	1	17	18	39
16	HAPPW83	203979 04/29/99	Uni-ZAP XR	26	1365	35	1365	66	66	74	1			10
17	HAPSH37	203979 04/29/99	Uni-ZAP XR	27	1380	1	1380	251	251	75	1	24	25	56

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	S' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
18	HATAL05	203979 04/29/99	Uni-ZAP XR	28	1199	1	1199	134	134	76	1			45
19	HATCI67	203979 04/29/99	Uni-ZAP XR	29	1108	1	1108	158	158	77	1	18	19	31
20	HATCJ27	203979 04/29/99	Uni-ZAP XR	30	930	1	930		237	78	1			15
21	HATDH55	203979 04/29/99	Uni-ZAP XR	31	2097	1	2097	50	50	79	1			33
22	HATDU01	203979 04/29/99	Uni-ZAP XR	32	1302	1	1302	23	23	80	1	17	18	20
23	HBJCR17	203979 04/29/99	Uni-ZAP XR	33	963	1	935	55	55	81	1	18	19	36
24	HBJEL16	203979 04/29/99	Uni-ZAP XR	34	750	1	750	115	115	82	1	24	25	36
25	HBXBI29	203979 04/29/99	ZAP Express	35	2043	1	2043	87	87	83	1	27	28	28
26	HBXFW01	203979 04/29/99	ZAP Express	36	1252	1	1252		124	84	1			22
27	HCBAB34	203979 04/29/99	Uni-ZAP XR	37	1650	1	1650	93	93	85	1	25	26	39



Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
28	HCDCI42	203979 04/29/99	Uni-ZAP XR	38	1046	1	1046	216	216	86	1			9
29	HCE2H52	203979 04/29/99	Uni-ZAP XR	39	1276	1	1276		29	87	1	16	17	23
30	HCE5H86	203979 04/29/99	Uni-ZAP XR	40	2329	1	2328	288	288	88	1	28	29	64
31	HCEBF54	203979 04/29/99	Uni-ZAP XR	41	1069	1	1069	197	197	89	1	32	33	129
32	HCEDN07	203979 04/29/99	Uni-ZAP XR	42	1425	1	1425	126	126	90	1	20	21	40
33	HCEGH74	203979 04/29/99	Uni-ZAP XR	43	1124	1	1124	203	203	91	1	20	21	56
34	HCELB04	203979 04/29/99	Uni-ZAP XR	44	1962	1	1962		108	92	1	18	19	58
35	HCEOQ67	203979 04/29/99	Uni-ZAP XR	45	992	1	992	18	18	93	1	29	30	32
36	HCFCM81	203979 04/29/99	pSport1	46	1677	1	1677	390	390	94	1	28	29	36
37	HCFCW39	203979 04/29/99	pSport1	47	1343	1	1343	32	32	95	1	14	15	37

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
38	HCUFD17	203979 04/29/99	ZAP Express	48	552	1	552	230	230	96	1	17	18	29
39	HCWCH16	203979 04/29/99	ZAP Express	49	2295	1	2295	166	166	97	1			7
40	HCYBA32	203979 04/29/99	pBluescript SK-	50	2092	1	2092	173	173	98	1	18	19	30
41	HDHEA33	203979 04/29/99	pCMVSPORT 2.0	51	1681	1	1681	414	414	99	1	25	26	85
42	HDPIF65	203979 04/29/99	pCMVSPORT 3.0	52	1646	1	1646	38	38	100	1	36	37	57
43	HDPJH72	203979 04/29/99	pCMVSPORT 3.0	53	1990	12	1348		603	101	1	13	14	186
44	HDPMC52	203979 04/29/99	pCMVSPORT 3.0	54	554	1	554	214	214	102	1	50	51	78
45	HDPSS56	203979 04/29/99	pCMVSPORT 3.0	55	1240	1	1240	186	186	103	1	24	25	31
46	HDPTI49	203979 04/29/99	pCMVSPORT 3.0	56	1724	1	1724	182	182	104	1	17	18	35
47	HDSAO14	203979 04/29/99	Uni-ZAP XR	57	1433	1	1433		208	105	1	26	27	49

Gene No.	cDNA Clone ID	ATCC Deposit No:Z and Date	Vector	NT SEQ ID NO: X	Total NT Seq.	5' NT of Clone Seq.	3' NT of Clone Seq.	5' NT of Start Codon	5' NT of First AA of Signal Pep	AA SEQ ID NO: Y	First AA of Sig Pep	Last AA of Sig Pep	First AA of Secreted Portion	Last AA of ORF
48	HDTAR39	203979 04/29/99	pCMVSPORT 2.0	58	1267	1	1267	199	199	106	1	21	22	52

Table 1 summarizes the information corresponding to each "Gene No." described above. The nucleotide sequence identified as "NT SEQ ID NO:X" was assembled from partially homologous ("overlapping") sequences obtained from the "cDNA clone ID" identified in Table 1 and, in some cases, from additional related DNA clones. The overlapping sequences were assembled into a single contiguous sequence of high redundancy (usually three to five overlapping sequences at each nucleotide position), resulting in a final sequence identified as SEQ ID NO:X.

The cDNA Clone ID was deposited on the date and given the corresponding deposit number listed in "ATCC Deposit No:Z and Date." Some of the deposits contain multiple different clones corresponding to the same gene. "Vector" refers to the type of vector contained in the cDNA Clone ID.

"Total NT Seq." refers to the total number of nucleotides in the contig identified by "Gene No." The deposited clone may contain all or most of these sequences, reflected by the nucleotide position indicated as "5' NT of Clone Seq." and the "3' NT of Clone Seq." of SEQ ID NO:X. The nucleotide position of SEQ ID NO:X of the putative start codon (methionine) is identified as "5' NT of Start Codon." Similarly, the nucleotide position of SEQ ID NO:X of the predicted signal sequence is identified as "5' NT of First AA of Signal Pep."

The translated amino acid sequence, beginning with the methionine, is identified as "AA SEQ ID NO:Y," although other reading frames can also be easily translated using known molecular biology techniques. The polypeptides produced by these alternative open reading frames are specifically contemplated by the present invention.

The first and last amino acid position of SEQ ID NO:Y of the predicted signal peptide is identified as "First AA of Sig Pep" and "Last AA of Sig Pep." The predicted first amino acid position of SEQ ID NO:Y of the secreted portion is

identified as "Predicted First AA of Secreted Portion." Finally, the amino acid position of SEQ ID NO:Y of the last amino acid in the open reading frame is identified as "Last AA of ORF."

SEQ ID NO:X (where X may be any of the polynucleotide sequences disclosed in the sequence listing) and the translated SEQ ID NO:Y (where Y may be any of the polypeptide sequences disclosed in the sequence listing) are sufficiently accurate and otherwise suitable for a variety of uses well known in the art and described further below. For instance, SEQ ID NO:X is useful for designing nucleic acid hybridization probes that will detect nucleic acid sequences contained in SEQ ID NO:X or the cDNA contained in the deposited clone. These probes will also hybridize to nucleic acid molecules in biological samples, thereby enabling a variety of forensic and diagnostic methods of the invention. Similarly, polypeptides identified from SEQ ID NO:Y may be used, for example, to generate antibodies which bind specifically to proteins containing the polypeptides and the secreted proteins encoded by the cDNA clones identified in Table 1.

Nevertheless, DNA sequences generated by sequencing reactions can contain sequencing errors. The errors exist as misidentified nucleotides, or as insertions or deletions of nucleotides in the generated DNA sequence. The erroneously inserted or deleted nucleotides cause frame shifts in the reading frames of the predicted amino acid sequence. In these cases, the predicted amino acid sequence diverges from the actual amino acid sequence, even though the generated DNA sequence may be greater than 99.9% identical to the actual DNA sequence (for example, one base insertion or deletion in an open reading frame of over 1000 bases).

Accordingly, for those applications requiring precision in the nucleotide sequence or the amino acid sequence, the present invention provides not only the generated nucleotide sequence identified as SEQ ID NO:X and the predicted

translated amino acid sequence identified as SEQ ID NO:Y, but also a sample of plasmid DNA containing a human cDNA of the invention deposited with the ATCC, as set forth in Table 1. The nucleotide sequence of each deposited clone can readily be determined by sequencing the deposited clone in accordance with known methods.

- 5 The predicted amino acid sequence can then be verified from such deposits. Moreover, the amino acid sequence of the protein encoded by a particular clone can also be directly determined by peptide sequencing or by expressing the protein in a suitable host cell containing the deposited human cDNA, collecting the protein, and determining its sequence.

- 10 The present invention also relates to the genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or the deposited clone. The corresponding gene can be isolated in accordance with known methods using the sequence information disclosed herein. Such methods include preparing probes or primers from the disclosed sequence and identifying or amplifying the corresponding gene from appropriate  
15 sources of genomic material.

- Also provided in the present invention are allelic variants, orthologs, and/or species homologs. Procedures known in the art can be used to obtain full-length genes, allelic variants, splice variants, full-length coding portions, orthologs, and/or species homologs of genes corresponding to SEQ ID NO:X, SEQ ID NO:Y, or a  
20 deposited clone, using information from the sequences disclosed herein or the clones deposited with the ATCC. For example, allelic variants and/or species homologs may be isolated and identified by making suitable probes or primers from the sequences provided herein and screening a suitable nucleic acid source for allelic variants and/or the desired homologue.

- 25 The polypeptides of the invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly

produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art.

The polypeptides may be in the form of the secreted protein, including the mature form, or may be a part of a larger protein, such as a fusion protein (see below). It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, pro-sequences, sequences which aid in purification, such as multiple histidine residues, or an additional sequence for stability during recombinant production.

The polypeptides of the present invention are preferably provided in an isolated form, and preferably are substantially purified. A recombinantly produced version of a polypeptide, including the secreted polypeptide, can be substantially purified using techniques described herein or otherwise known in the art, such as, for example, by the one-step method described in Smith and Johnson, Gene 67:31-40 (1988). Polypeptides of the invention also can be purified from natural, synthetic or recombinant sources using techniques described herein or otherwise known in the art, such as, for example, antibodies of the invention raised against the secreted protein.

The present invention provides a polynucleotide comprising, or alternatively consisting of, the nucleic acid sequence of SEQ ID NO:X, and/or a cDNA contained in ATCC deposit Z. The present invention also provides a polypeptide comprising, or alternatively, consisting of, the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide encoded by the cDNA contained in ATCC deposit Z. Polynucleotides encoding a polypeptide comprising, or alternatively consisting of the polypeptide sequence of SEQ ID NO:Y and/or a polypeptide sequence encoded by the cDNA contained in ATCC deposit Z are also encompassed by the invention.

#### Signal Sequences

The present invention also encompasses mature forms of the polypeptide having the polypeptide sequence of SEQ ID NO:Y and/or the polypeptide sequence encoded by the cDNA in a deposited clone. Polynucleotides encoding the mature forms (such as, for example, the polynucleotide sequence in SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone) are also encompassed by the invention. According to the signal hypothesis, proteins secreted by mammalian cells have a signal or secretory leader sequence which is cleaved from the mature protein once export of the growing protein chain across the rough endoplasmic reticulum has been initiated. Most mammalian cells and even insect cells cleave secreted proteins with the same specificity. However, in some cases, cleavage of a secreted protein is not entirely uniform, which results in two or more mature species of the protein. Further, it has long been known that cleavage specificity of a secreted protein is ultimately determined by the primary structure of the complete protein, that is, it is inherent in the amino acid sequence of the polypeptide.

Methods for predicting whether a protein has a signal sequence, as well as the cleavage point for that sequence, are available. For instance, the method of McGeoch, *Virus Res.* 3:271-286 (1985), uses the information from a short N-terminal charged region and a subsequent uncharged region of the complete (uncleaved) protein. The method of von Heinje, *Nucleic Acids Res.* 14:4683-4690 (1986) uses the information from the residues surrounding the cleavage site, typically residues -13 to +2, where +1 indicates the amino terminus of the secreted protein. The accuracy of predicting the cleavage points of known mammalian secretory proteins for each of these methods is in the range of 75-80%. (von Heinje, *supra*.) However, the two methods do not always produce the same predicted cleavage point(s) for a given protein.



In the present case, the deduced amino acid sequence of the secreted polypeptide was analyzed by a computer program called SignalP (Henrik Nielsen et al., Protein Engineering 10:1-6 (1997)), which predicts the cellular location of a protein based on the amino acid sequence. As part of this computational prediction of localization, the methods of McGeoch and von Heinje are incorporated. The analysis of the amino acid sequences of the secreted proteins described herein by this program provided the results shown in Table 1.

As one of ordinary skill would appreciate, however, cleavage sites sometimes vary from organism to organism and cannot be predicted with absolute certainty. Accordingly, the present invention provides secreted polypeptides having a sequence shown in SEQ ID NO:Y which have an N-terminus beginning within 5 residues (i.e., + or - 5 residues) of the predicted cleavage point. Similarly, it is also recognized that in some cases, cleavage of the signal sequence from a secreted protein is not entirely uniform, resulting in more than one secreted species. These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

Moreover, the signal sequence identified by the above analysis may not necessarily predict the naturally occurring signal sequence. For example, the naturally occurring signal sequence may be further upstream from the predicted signal sequence. However, it is likely that the predicted signal sequence will be capable of directing the secreted protein to the ER. Nonetheless, the present invention provides the mature protein produced by expression of the polynucleotide sequence of SEQ ID NO:X and/or the polynucleotide sequence contained in the cDNA of a deposited clone, in a mammalian cell (e.g., COS cells, as described below). These polypeptides, and the polynucleotides encoding such polypeptides, are contemplated by the present invention.

**Polynucleotide and Polypeptide Variants**

The present invention is directed to variants of the polynucleotide sequence disclosed in SEQ ID NO:X, the complementary strand thereto, and/or the cDNA  
5 sequence contained in a deposited clone.

The present invention also encompasses variants of the polypeptide sequence disclosed in SEQ ID NO:Y and/or encoded by a deposited clone.

"Variant" refers to a polynucleotide or polypeptide differing from the polynucleotide or polypeptide of the present invention, but retaining essential  
10 properties thereof. Generally, variants are overall closely similar, and, in many regions, identical to the polynucleotide or polypeptide of the present invention.

The present invention is also directed to nucleic acid molecules which comprise, or alternatively consist of, a nucleotide sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for example, the nucleotide  
15 coding sequence in SEQ ID NO:X or the complementary strand thereto, the nucleotide coding sequence contained in a deposited cDNA clone or the complementary strand thereto, a nucleotide sequence encoding the polypeptide of SEQ ID NO:Y, a nucleotide sequence encoding the polypeptide encoded by the cDNA contained in a deposited clone, and/or polynucleotide fragments of any of  
20 these nucleic acid molecules (e.g., those fragments described herein).

Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

The present invention is also directed to polypeptides which comprise, or  
25 alternatively consist of, an amino acid sequence which is at least 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% identical to, for example, the polypeptide sequence

shown in SEQ ID NO:Y, the polypeptide sequence encoded by the cDNA contained in a deposited clone, and/or polypeptide fragments of any of these polypeptides (e.g., those fragments described herein).

By a nucleic acid having a nucleotide sequence at least, for example, 95%  
5 "identical" to a reference nucleotide sequence of the present invention, it is intended that the nucleotide sequence of the nucleic acid is identical to the reference sequence except that the nucleotide sequence may include up to five point mutations per each 100 nucleotides of the reference nucleotide sequence encoding the polypeptide. In other words, to obtain a nucleic acid having a nucleotide sequence at least 95%  
10 identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or substituted with another nucleotide, or a number of nucleotides up to 5% of the total nucleotides in the reference sequence may be inserted into the reference sequence. The query sequence may be an entire sequence shown in Table 1, the ORF (open reading frame), or any fragment specified  
15 as described herein.

As a practical matter, whether any particular nucleic acid molecule or polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the present invention can be determined conventionally using known computer programs. A preferred method for determining the best  
20 overall match between a query sequence (a sequence of the present invention) and a subject sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are both DNA sequences. An RNA sequence can be compared by  
25 converting U's to T's. The result of said global sequence alignment is in percent identity. Preferred parameters used in a FASTDB alignment of DNA sequences to

calculate percent identity are: Matrix=Unitary, k-tuple=4, Mismatch Penalty=1, Joining Penalty=30, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject nucleotide sequence, whichever is shorter.

5           If the subject sequence is shorter than the query sequence because of 5' or 3' deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for 5' and 3' truncations of the subject sequence when calculating percent identity. For subject sequences truncated at the 5' or 3' ends, relative to the query sequence, the percent  
10 identity is corrected by calculating the number of bases of the query sequence that are 5' and 3' of the subject sequence, which are not matched/aligned, as a percent of the total bases of the query sequence. Whether a nucleotide is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from the percent identity, calculated by the above FASTDB program using  
15 the specified parameters, to arrive at a final percent identity score. This corrected score is what is used for the purposes of the present invention. Only bases outside the 5' and 3' bases of the subject sequence, as displayed by the FASTDB alignment, which are not matched/aligned with the query sequence, are calculated for the purposes of manually adjusting the percent identity score.

20           For example, a 90 base subject sequence is aligned to a 100 base query sequence to determine percent identity. The deletions occur at the 5' end of the subject sequence and therefore, the FASTDB alignment does not show a matched/alignment of the first 10 bases at 5' end. The 10 unpaired bases represent 10% of the sequence (number of bases at the 5' and 3' ends not matched/total number  
25 of bases in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 bases were perfectly

matched the final percent identity would be 90%. In another example, a 90 base subject sequence is compared with a 100 base query sequence. This time the deletions are internal deletions so that there are no bases on the 5' or 3' of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only bases 5' and 3' of the subject sequence which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

By a polypeptide having an amino acid sequence at least, for example, 95% "identical" to a query amino acid sequence of the present invention, it is intended that the amino acid sequence of the subject polypeptide is identical to the query sequence except that the subject polypeptide sequence may include up to five amino acid alterations per each 100 amino acids of the query amino acid sequence. In other words, to obtain a polypeptide having an amino acid sequence at least 95% identical to a query amino acid sequence, up to 5% of the amino acid residues in the subject sequence may be inserted, deleted, (indels) or substituted with another amino acid. These alterations of the reference sequence may occur at the amino or carboxy terminal positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among residues in the reference sequence or in one or more contiguous groups within the reference sequence.

As a practical matter, whether any particular polypeptide is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to, for instance, an amino acid sequences shown in Table 1 (SEQ ID NO:Y) or to the amino acid sequence encoded by cDNA contained in a deposited clone can be determined conventionally using known computer programs. A preferred method for determining the best overall match between a query sequence (a sequence of the present invention) and a subject

sequence, also referred to as a global sequence alignment, can be determined using the FASTDB computer program based on the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245(1990)). In a sequence alignment the query and subject sequences are either both nucleotide sequences or both amino acid sequences. The result of said

5 global sequence alignment is in percent identity. Preferred parameters used in a FASTDB amino acid alignment are: Matrix=PAM 0, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Window Size=sequence length, Gap Penalty=5, Gap Size Penalty=0.05, Window Size=500 or the length of the subject amino acid sequence, whichever is shorter.

10 If the subject sequence is shorter than the query sequence due to N- or C-terminal deletions, not because of internal deletions, a manual correction must be made to the results. This is because the FASTDB program does not account for N- and C-terminal truncations of the subject sequence when calculating global percent identity. For subject sequences truncated at the N- and C-termini, relative to the

15 query sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminal of the subject sequence, which are not matched/aligned with a corresponding subject residue, as a percent of the total bases of the query sequence. Whether a residue is matched/aligned is determined by results of the FASTDB sequence alignment. This percentage is then subtracted from

20 the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This final percent identity score is what is used for the purposes of the present invention. Only residues to the N- and C-termini of the subject sequence, which are not matched/aligned with the query sequence, are considered for the purposes of manually adjusting the percent identity

25 score. That is, only query residue positions outside the farthest N- and C-terminal residues of the subject sequence.

For example, a 90 amino acid residue subject sequence is aligned with a 100 residue query sequence to determine percent identity. The deletion occurs at the N-terminus of the subject sequence and therefore, the FASTDB alignment does not show a matching/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the sequence (number of residues at the N- and C-termini not matched/total number of residues in the query sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched the final percent identity would be 90%. In another example, a 90 residue subject sequence is compared with a 100 residue query sequence. This time the deletions are internal deletions so there are no residues at the N- or C-termini of the subject sequence which are not matched/aligned with the query. In this case the percent identity calculated by FASTDB is not manually corrected. Once again, only residue positions outside the N- and C-terminal ends of the subject sequence, as displayed in the FASTDB alignment, which are not matched/aligned with the query sequence are manually corrected for. No other manual corrections are to be made for the purposes of the present invention.

The variants may contain alterations in the coding regions, non-coding regions, or both. Especially preferred are polynucleotide variants containing alterations which produce silent substitutions, additions, or deletions, but do not alter the properties or activities of the encoded polypeptide. Nucleotide variants produced by silent substitutions due to the degeneracy of the genetic code are preferred. Moreover, variants in which 5-10, 1-5, or 1-2 amino acids are substituted, deleted, or added in any combination are also preferred. Polynucleotide variants can be produced for a variety of reasons, e.g., to optimize codon expression for a particular host (change codons in the human mRNA to those preferred by a bacterial host such as *E. coli*).

Naturally occurring variants are called "allelic variants," and refer to one of several alternate forms of a gene occupying a given locus on a chromosome of an organism. (Genes II, Lewin, B., ed., John Wiley & Sons, New York (1985).) These allelic variants can vary at either the polynucleotide and/or polypeptide level and are  
5 included in the present invention. Alternatively, non-naturally occurring variants may be produced by mutagenesis techniques or by direct synthesis.

Using known methods of protein engineering and recombinant DNA technology, variants may be generated to improve or alter the characteristics of the polypeptides of the present invention. For instance, one or more amino acids can be  
10 deleted from the N-terminus or C-terminus of the secreted protein without substantial loss of biological function. The authors of Ron et al., J. Biol. Chem. 268: 2984-2988 (1993), reported variant KGF proteins having heparin binding activity even after deleting 3, 8, or 27 amino-terminal amino acid residues. Similarly, Interferon gamma exhibited up to ten times higher activity after deleting 8-10 amino acid residues from  
15 the carboxy terminus of this protein. (Dobeli et al., J. Biotechnology 7:199-216 (1988).)

Moreover, ample evidence demonstrates that variants often retain a biological activity similar to that of the naturally occurring protein. For example, Gayle and coworkers (J. Biol. Chem 268:22105-22111 (1993)) conducted extensive mutational  
20 analysis of human cytokine IL-1a. They used random mutagenesis to generate over 3,500 individual IL-1a mutants that averaged 2.5 amino acid changes per variant over the entire length of the molecule. Multiple mutations were examined at every possible amino acid position. The investigators found that "[m]ost of the molecule could be altered with little effect on either [binding or biological activity]." (See,  
25 Abstract.) In fact, only 23 unique amino acid sequences, out of more than 3,500



nucleotide sequences examined, produced a protein that significantly differed in activity from wild-type.

Furthermore, even if deleting one or more amino acids from the N-terminus or C-terminus of a polypeptide results in modification or loss of one or more biological functions, other biological activities may still be retained. For example, the ability of a deletion variant to induce and/or to bind antibodies which recognize the secreted form will likely be retained when less than the majority of the residues of the secreted form are removed from the N-terminus or C-terminus. Whether a particular polypeptide lacking N- or C-terminal residues of a protein retains such immunogenic activities can readily be determined by routine methods described herein and otherwise known in the art.

Thus, the invention further includes polypeptide variants which show substantial biological activity. Such variants include deletions, insertions, inversions, repeats, and substitutions selected according to general rules known in the art so as have little effect on activity. For example, guidance concerning how to make phenotypically silent amino acid substitutions is provided in Bowie et al., Science 247:1306-1310 (1990), wherein the authors indicate that there are two main strategies for studying the tolerance of an amino acid sequence to change.

The first strategy exploits the tolerance of amino acid substitutions by natural selection during the process of evolution. By comparing amino acid sequences in different species, conserved amino acids can be identified. These conserved amino acids are likely important for protein function. In contrast, the amino acid positions where substitutions have been tolerated by natural selection indicates that these positions are not critical for protein function. Thus, positions tolerating amino acid substitution could be modified while still maintaining biological activity of the protein.

The second strategy uses genetic engineering to introduce amino acid changes at specific positions of a cloned gene to identify regions critical for protein function. For example, site directed mutagenesis or alanine-scanning mutagenesis (introduction of single alanine mutations at every residue in the molecule) can be used.

- 5 (Cunningham and Wells, Science 244:1081-1085 (1989).) The resulting mutant molecules can then be tested for biological activity.

As the authors state, these two strategies have revealed that proteins are surprisingly tolerant of amino acid substitutions. The authors further indicate which amino acid changes are likely to be permissive at certain amino acid positions in the  
10 protein. For example, most buried (within the tertiary structure of the protein) amino acid residues require nonpolar side chains, whereas few features of surface side chains are generally conserved. Moreover, tolerated conservative amino acid substitutions involve replacement of the aliphatic or hydrophobic amino acids Ala, Val, Leu and Ile; replacement of the hydroxyl residues Ser and Thr; replacement of the acidic  
15 residues Asp and Glu; replacement of the amide residues Asn and Gln, replacement of the basic residues Lys, Arg, and His; replacement of the aromatic residues Phe, Tyr, and Trp, and replacement of the small-sized amino acids Ala, Ser, Thr, Met, and Gly.

Besides conservative amino acid substitution, variants of the present invention include (i) substitutions with one or more of the non-conserved amino acid residues,  
20 where the substituted amino acid residues may or may not be one encoded by the genetic code, or (ii) substitution with one or more of amino acid residues having a substituent group, or (iii) fusion of the mature polypeptide with another compound, such as a compound to increase the stability and/or solubility of the polypeptide (for example, polyethylene glycol), or (iv) fusion of the polypeptide with additional amino  
25 acids, such as, for example, an IgG Fc fusion region peptide, or leader or secretory

sequence, or a sequence facilitating purification. Such variant polypeptides are deemed to be within the scope of those skilled in the art from the teachings herein.

For example, polypeptide variants containing amino acid substitutions of charged amino acids with other charged or neutral amino acids may produce proteins with improved characteristics, such as less aggregation. Aggregation of pharmaceutical formulations both reduces activity and increases clearance due to the aggregate's immunogenic activity. (Pinckard et al., Clin. Exp. Immunol. 2:331-340 (1967); Robbins et al., Diabetes 36: 838-845 (1987); Cleland et al., Crit. Rev. Therapeutic Drug Carrier Systems 10:307-377 (1993).)

A further embodiment of the invention relates to a polypeptide which comprises the amino acid sequence of the present invention having an amino acid sequence which contains at least one amino acid substitution, but not more than 50 amino acid substitutions, even more preferably, not more than 40 amino acid substitutions, still more preferably, not more than 30 amino acid substitutions, and still even more preferably, not more than 20 amino acid substitutions. Of course, in order of ever-increasing preference, it is highly preferable for a peptide or polypeptide to have an amino acid sequence which comprises the amino acid sequence of the present invention, which contains at least one, but not more than 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 amino acid substitutions. In specific embodiments, the number of additions, substitutions, and/or deletions in the amino acid sequence of the present invention or fragments thereof (e.g., the mature form and/or other fragments described herein), is 1-5, 5-10, 5-25, 5-50, 10-50 or 50-150, conservative amino acid substitutions are preferable.

## **Polynucleotide and Polypeptide Fragments**

The present invention is also directed to polynucleotide fragments of the polynucleotides of the invention.

In the present invention, a "polynucleotide fragment" refers to a short polynucleotide having a nucleic acid sequence which: is a portion of that contained in  
5 a deposited clone, or encoding the polypeptide encoded by the cDNA in a deposited clone; is a portion of that shown in SEQ ID NO:X or the complementary strand thereto, or is a portion of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:Y. The nucleotide fragments of the invention are preferably at least about 15 nt, and more preferably at least about 20 nt, still more preferably at least about 30 nt,  
10 and even more preferably, at least about 40 nt, at least about 50 nt, at least about 75 nt, or at least about 150 nt in length. A fragment "at least 20 nt in length," for example, is intended to include 20 or more contiguous bases from the cDNA sequence contained in a deposited clone or the nucleotide sequence shown in SEQ ID NO:X. In this context "about" includes the particularly recited value, a value larger  
15 or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini. These nucleotide fragments have uses that include, but are not limited to, as diagnostic probes and primers as discussed herein. Of course, larger fragments (e.g., 50, 150, 500, 600, 2000 nucleotides) are preferred.

Moreover, representative examples of polynucleotide fragments of the  
20 invention, include, for example, fragments comprising, or alternatively consisting of, a sequence from about nucleotide number 1-50, 51-100, 101-150, 151-200, 201-250, 251-300, 301-350, 351-400, 401-450, 451-500, 501-550, 551-600, 651-700, 701-750, 751-800, 800-850, 851-900, 901-950, 951-1000, 1001-1050, 1051-1100, 1101-1150, 1151-1200, 1201-1250, 1251-1300, 1301-1350, 1351-1400, 1401-1450, 1451-1500,  
25 1501-1550, 1551-1600, 1601-1650, 1651-1700, 1701-1750, 1751-1800, 1801-1850, 1851-1900, 1901-1950, 1951-2000, or 2001 to the end of SEQ ID NO:X, or the

complementary strand thereto, or the cDNA contained in a deposited clone. In this context "about" includes the particularly recited ranges, and ranges larger or smaller by several (5, 4, 3, 2, or 1) nucleotides, at either terminus or at both termini.

Preferably, these fragments encode a polypeptide which has biological activity. More preferably, these polynucleotides can be used as probes or primers as discussed herein. Polynucleotides which hybridize to these nucleic acid molecules under stringent hybridization conditions or lower stringency conditions are also encompassed by the invention, as are polypeptides encoded by these polynucleotides.

In the present invention, a "polypeptide fragment" refers to an amino acid sequence which is a portion of that contained in SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone. Protein (polypeptide) fragments may be "free-standing," or comprised within a larger polypeptide of which the fragment forms a part or region, most preferably as a single continuous region. Representative examples of polypeptide fragments of the invention, include, for example, fragments comprising, or alternatively consisting of, from about amino acid number 1-20, 21-40, 41-60, 61-80, 81-100, 102-120, 121-140, 141-160, or 161 to the end of the coding region. Moreover, polypeptide fragments can be about 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, or 150 amino acids in length. In this context "about" includes the particularly recited ranges or values, and ranges or values larger or smaller by several (5, 4, 3, 2, or 1) amino acids, at either extreme or at both extremes. Polynucleotides encoding these polypeptides are also encompassed by the invention.

Preferred polypeptide fragments include the secreted protein as well as the mature form. Further preferred polypeptide fragments include the secreted protein or the mature form having a continuous series of deleted residues from the amino or the carboxy terminus, or both. For example, any number of amino acids, ranging from 1-60, can be deleted from the amino terminus of either the secreted polypeptide or the

mature form. Similarly, any number of amino acids, ranging from 1-30, can be deleted from the carboxy terminus of the secreted protein or mature form.

Furthermore, any combination of the above amino and carboxy terminus deletions are preferred. Similarly, polynucleotides encoding these polypeptide fragments are also  
5 preferred.

Also preferred are polypeptide and polynucleotide fragments characterized by structural or functional domains, such as fragments that comprise alpha-helix and alpha-helix forming regions, beta-sheet and beta-sheet-forming regions, turn and turn-forming regions, coil and coil-forming regions, hydrophilic regions, hydrophobic  
10 regions, alpha amphipathic regions, beta amphipathic regions, flexible regions, surface-forming regions, substrate binding region, and high antigenic index regions. Polypeptide fragments of SEQ ID NO:Y falling within conserved domains are specifically contemplated by the present invention. Moreover, polynucleotides encoding these domains are also contemplated.

15 Other preferred polypeptide fragments are biologically active fragments. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide of the present invention. The biological activity of the fragments may include an improved desired activity, or a decreased undesirable activity. Polynucleotides encoding these polypeptide fragments are also  
20 encompassed by the invention.

Preferably, the polynucleotide fragments of the invention encode a polypeptide which demonstrates a functional activity. By a polypeptide demonstrating a "functional activity" is meant, a polypeptide capable of displaying one or more known functional activities associated with a full-length (complete)  
25 polypeptide of invention protein. Such functional activities include, but are not limited to, biological activity, antigenicity [ability to bind (or compete with a

polypeptide of the invention for binding) to an antibody to the polypeptide of the invention], immunogenicity (ability to generate antibody which binds to a polypeptide of the invention), ability to form multimers with polypeptides of the invention, and ability to bind to a receptor or ligand for a polypeptide of the invention.

- 5       The functional activity of polypeptides of the invention, and fragments, variants derivatives, and analogs thereof, can be assayed by various methods.

For example, in one embodiment where one is assaying for the ability to bind or compete with full-length polypeptide of the invention for binding to an antibody of the polypeptide of the invention, various immunoassays known in the art can be used, including but not limited to, competitive and non-competitive assay systems using techniques such as radioimmunoassays, ELISA (enzyme linked immunosorbent assay), "sandwich" immunoassays, immunoradiometric assays, gel diffusion precipitation reactions, immunodiffusion assays, in situ immunoassays (using colloidal gold, enzyme or radioisotope labels, for example), western blots, precipitation reactions, agglutination assays (e.g., gel agglutination assays, hemagglutination assays), complement fixation assays, immunofluorescence assays, protein A assays, and immunoelectrophoresis assays, etc. In one embodiment, antibody binding is detected by detecting a label on the primary antibody. In another embodiment, the primary antibody is detected by detecting binding of a secondary antibody or reagent to the primary antibody. In a further embodiment, the secondary antibody is labeled. Many means are known in the art for detecting binding in an immunoassay and are within the scope of the present invention.

10  
15  
20

In another embodiment, where a ligand for a polypeptide of the invention identified, or the ability of a polypeptide fragment, variant or derivative of the invention to multimerize is being evaluated, binding can be assayed, e.g., by means well-known in the art, such as, for example, reducing and non-reducing gel

25

chromatography, protein affinity chromatography, and affinity blotting. See generally, Phizicky, E., et al., 1995, Microbiol. Rev. 59:94-123. In another embodiment, physiological correlates of binding of a polypeptide of the invention to its substrates (signal transduction) can be assayed.

5           In addition, assays described herein (see Examples) and otherwise known in the art may routinely be applied to measure the ability of polypeptides of the invention and fragments, variants derivatives and analogs thereof to elicit related biological activity related to that of the polypeptide of the invention (either in vitro or in vivo). Other methods will be known to the skilled artisan and are within the scope  
10 of the invention.

### **Epitopes and Antibodies**

The present invention encompasses polypeptides comprising, or alternatively consisting of, an epitope of the polypeptide having an amino acid sequence of SEQ ID  
15 NO:Y, or an epitope of the polypeptide sequence encoded by a polynucleotide sequence contained in ATCC deposit No. Z or encoded by a polynucleotide that hybridizes to the complement of the sequence of SEQ ID NO:X or contained in ATCC deposit No. Z under stringent hybridization conditions or lower stringency hybridization conditions as defined supra. The present invention further encompasses  
20 polynucleotide sequences encoding an epitope of a polypeptide sequence of the invention (such as, for example, the sequence disclosed in SEQ ID NO:X), polynucleotide sequences of the complementary strand of a polynucleotide sequence encoding an epitope of the invention, and polynucleotide sequences which hybridize to the complementary strand under stringent hybridization conditions or lower  
25 stringency hybridization conditions defined supra.



The term "epitopes," as used herein, refers to portions of a polypeptide having antigenic or immunogenic activity in an animal, preferably a mammal, and most preferably in a human. In a preferred embodiment, the present invention encompasses a polypeptide comprising an epitope, as well as the polynucleotide encoding this polypeptide. An "immunogenic epitope," as used herein, is defined as a portion of a protein that elicits an antibody response in an animal, as determined by any method known in the art, for example, by the methods for generating antibodies described infra. (See, for example, Geysen et al., Proc. Natl. Acad. Sci. USA 81:3998- 4002 (1983)). The term "antigenic epitope," as used herein, is defined as a portion of a protein to which an antibody can immunospecifically bind its antigen as determined by any method well known in the art, for example, by the immunoassays described herein. Immunospecific binding excludes non-specific binding but does not necessarily exclude cross- reactivity with other antigens. Antigenic epitopes need not necessarily be immunogenic.

Fragments which function as epitopes may be produced by any conventional means. (See, e.g., Houghten, Proc. Natl. Acad. Sci. USA 82:5131-5135 (1985), further described in U.S. Patent No. 4,631,211).

In the present invention, antigenic epitopes preferably contain a sequence of at least 4, at least 5, at least 6, at least 7, more preferably at least 8, at least 9, at least 10, at least 11, at least 12, at least 13, at least 14, at least 15, at least 20, at least 25, at least 30, at least 40, at least 50, and, most preferably, between about 15 to about 30 amino acids. Preferred polypeptides comprising immunogenic or antigenic epitopes are at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100 amino acid residues in length. Additional non-exclusive preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as portions thereof. Antigenic epitopes are useful, for example, to raise antibodies, including monoclonal antibodies,

that specifically bind the epitope. Preferred antigenic epitopes include the antigenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these antigenic epitopes. Antigenic epitopes can be used as the target molecules in immunoassays. (See, for instance, Wilson et al., Cell 37:767-778 (1984); Sutcliffe et al., Science 219:660-666 (1983)).

Similarly, immunogenic epitopes can be used, for example, to induce antibodies according to methods well known in the art. (See, for instance, Sutcliffe et al., supra; Wilson et al., supra; Chow et al., Proc. Natl. Acad. Sci. USA 82:910-914; and Bittle et al., J. Gen. Virol. 66:2347-2354 (1985). Preferred immunogenic epitopes include the immunogenic epitopes disclosed herein, as well as any combination of two, three, four, five or more of these immunogenic epitopes. The polypeptides comprising one or more immunogenic epitopes may be presented for eliciting an antibody response together with a carrier protein, such as an albumin, to an animal system (such as rabbit or mouse), or, if the polypeptide is of sufficient length (at least about 25 amino acids), the polypeptide may be presented without a carrier. However, immunogenic epitopes comprising as few as 8 to 10 amino acids have been shown to be sufficient to raise antibodies capable of binding to, at the very least, linear epitopes in a denatured polypeptide (e.g., in Western blotting).

Epitope-bearing polypeptides of the present invention may be used to induce antibodies according to methods well known in the art including, but not limited to, in vivo immunization, in vitro immunization, and phage display methods. See, e.g., Sutcliffe et al., supra; Wilson et al., supra, and Bittle et al., J. Gen. Virol., 66:2347-2354 (1985). If in vivo immunization is used, animals may be immunized with free peptide; however, anti-peptide antibody titer may be boosted by coupling the peptide to a macromolecular carrier, such as keyhole limpet hemacyanin (KLH) or tetanus toxoid. For instance, peptides containing cysteine residues may be coupled to a

carrier using a linker such as maleimidobenzoyl- N-hydroxysuccinimide ester (MBS), while other peptides may be coupled to carriers using a more general linking agent such as glutaraldehyde. Animals such as rabbits, rats and mice are immunized with either free or carrier- coupled peptides, for instance, by intraperitoneal and/or

5 intradermal injection of emulsions containing about 100  $\mu$ g of peptide or carrier protein and Freund's adjuvant or any other adjuvant known for stimulating an immune response. Several booster injections may be needed, for instance, at intervals of about two weeks, to provide a useful titer of anti-peptide antibody which can be detected, for example, by ELISA assay using free peptide adsorbed to a solid

10 surface. The titer of anti-peptide antibodies in serum from an immunized animal may be increased by selection of anti-peptide antibodies, for instance, by adsorption to the peptide on a solid support and elution of the selected antibodies according to methods well known in the art.

As one of skill in the art will appreciate, and as discussed above, the

15 polypeptides of the present invention comprising an immunogenic or antigenic epitope can be fused to other polypeptide sequences. For example, the polypeptides of the present invention may be fused with the constant domain of immunoglobulins (IgA, IgE, IgG, IgM), or portions thereof (CH1, CH2, CH3, or any combination thereof and portions thereof) resulting in chimeric polypeptides. Such fusion proteins

20 may facilitate purification and may increase half-life in vivo. This has been shown for chimeric proteins consisting of the first two domains of the human CD4- polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. See, e.g., EP 394,827; Traunecker et al., Nature, 331:84-86 (1988). Enhanced delivery of an antigen across the epithelial barrier to the

25 immune system has been demonstrated for antigens (e.g., insulin) conjugated to an FcRn binding partner such as IgG or Fc fragments (see, e.g., PCT Publications WO

96/22024 and WO 99/04813). IgG Fusion proteins that have a disulfide-linked dimeric structure due to the IgG portion disulfide bonds have also been found to be more efficient in binding and neutralizing other molecules than monomeric polypeptides or fragments thereof alone. See, e.g., Fountoulakis et al., J. Biochem., 5 270:3958-3964 (1995). Nucleic acids encoding the above epitopes can also be recombined with a gene of interest as an epitope tag (e.g., the hemagglutinin ("HA") tag or flag tag) to aid in detection and purification of the expressed polypeptide. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht et al., 1991, 10 Proc. Natl. Acad. Sci. USA 88:8972- 897). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the open reading frame of the gene is translationally fused to an amino-terminal tag consisting of six histidine residues. The tag serves as a matrix binding domain for the fusion protein. Extracts from cells infected with the recombinant vaccinia virus are loaded onto Ni<sup>2+</sup> 15 nitriloacetic acid-agarose column and histidine-tagged proteins can be selectively eluted with imidazole-containing buffers.

Additional fusion proteins of the invention may be generated through the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling"). DNA shuffling may be employed to 20 modulate the activities of polypeptides of the invention, such methods can be used to generate polypeptides with altered activity, as well as agonists and antagonists of the polypeptides. See, generally, U.S. Patent Nos. 5,605,793; 5,811,238; 5,830,721; 5,834,252; and 5,837,458, and Patten et al., Curr. Opinion Biotechnol. 8:724-33 (1997); Harayama, Trends Biotechnol. 16(2):76-82 (1998); Hansson, et al., J. Mol. 25 Biol. 287:265-76 (1999); and Lorenzo and Blasco, Biotechniques 24(2):308- 13 (1998) (each of these patents and publications are hereby incorporated by reference in

its entirety). In one embodiment, alteration of polynucleotides corresponding to SEQ ID NO:X and the polypeptides encoded by these polynucleotides may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments by homologous or site-specific recombination to generate variation in the polynucleotide sequence. In another embodiment, polynucleotides of the invention, or the encoded polypeptides, may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of a polynucleotide encoding a polypeptide of the invention may be recombined with one or more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules.

#### Antibodies

Further polypeptides of the invention relate to antibodies and T-cell antigen receptors (TCR) which immunospecifically bind a polypeptide, polypeptide fragment, or variant of SEQ ID NO:Y, and/or an epitope, of the present invention (as determined by immunoassays well known in the art for assaying specific antibody-antigen binding). Antibodies of the invention include, but are not limited to, polyclonal, monoclonal, multispecific, human, humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab') fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies (including, e.g., anti-Id antibodies to antibodies of the invention), and epitope-binding fragments of any of the above. The term "antibody," as used herein, refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen binding site that immunospecifically binds an antigen. The immunoglobulin molecules of the invention can be of any type (e.g., IgG, IgE, IgM,

IgD, IgA and IgY), class (e.g., IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2) or subclass of immunoglobulin molecule.

Most preferably the antibodies are human antigen-binding antibody fragments of the present invention and include, but are not limited to, Fab, Fab' and F(ab')<sub>2</sub>, Fd, 5 single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (sdFv) and fragments comprising either a VL or VH domain. Antigen-binding antibody fragments, including single-chain antibodies, may comprise the variable region(s) alone or in combination with the entirety or a portion of the following: hinge region, CH1, CH2, and CH3 domains. Also included in the invention are antigen-binding 10 fragments also comprising any combination of variable region(s) with a hinge region, CH1, CH2, and CH3 domains. The antibodies of the invention may be from any animal origin including birds and mammals. Preferably, the antibodies are human, murine (e.g., mouse and rat), donkey, ship rabbit, goat, guinea pig, camel, horse, or chicken. As used herein, "human" antibodies include antibodies having the amino 15 acid sequence of a human immunoglobulin and include antibodies isolated from human immunoglobulin libraries or from animals transgenic for one or more human immunoglobulin and that do not express endogenous immunoglobulins, as described infra and, for example in, U.S. Patent No. 5,939,598 by Kucherlapati et al.

The antibodies of the present invention may be monospecific, bispecific, 20 trispecific or of greater multispecificity. Multispecific antibodies may be specific for different epitopes of a polypeptide of the present invention or may be specific for both a polypeptide of the present invention as well as for a heterologous epitope, such as a heterologous polypeptide or solid support material. See, e.g., PCT publications WO 93/17715; WO 92/08802; WO 91/00360; WO 92/05793; Tutt, et al., J. Immunol. 25 147:60-69 (1991); U.S. Patent Nos. 4,474,893; 4,714,681; 4,925,648; 5,573,920; 5,601,819; Kostelny et al., J. Immunol. 148:1547-1553 (1992).

Antibodies of the present invention may be described or specified in terms of the epitope(s) or portion(s) of a polypeptide of the present invention which they recognize or specifically bind. The epitope(s) or polypeptide portion(s) may be specified as described herein, e.g., by N-terminal and C-terminal positions, by size in  
5 contiguous amino acid residues, or listed in the Tables and Figures. Antibodies which specifically bind any epitope or polypeptide of the present invention may also be excluded. Therefore, the present invention includes antibodies that specifically bind polypeptides of the present invention, and allows for the exclusion of the same.

Antibodies of the present invention may also be described or specified in  
10 terms of their cross-reactivity. Antibodies that do not bind any other analog, ortholog, or homolog of a polypeptide of the present invention are included. Antibodies that bind polypeptides with at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 65%, at least 60%, at least 55%, and at least 50% identity (as calculated using methods known in the art and described  
15 herein) to a polypeptide of the present invention are also included in the present invention. In specific embodiments, antibodies of the present invention cross-react with murine, rat and/or rabbit homologs of human proteins and the corresponding epitopes thereof. Antibodies that do not bind polypeptides with less than 95%, less than 90%, less than 85%, less than 80%, less than 75%, less than 70%, less than 65%,  
20 less than 60%, less than 55%, and less than 50% identity (as calculated using methods known in the art and described herein) to a polypeptide of the present invention are also included in the present invention. In a specific embodiment, the above-described cross-reactivity is with respect to any single specific-antigenic or immunogenic polypeptide, or combination(s) of 2, 3, 4, 5, or more of the specific  
25 antigenic and/or immunogenic polypeptides disclosed herein. Further included in the present invention are antibodies which bind polypeptides encoded by polynucleotides

which hybridize to a polynucleotide of the present invention under stringent hybridization conditions (as described herein). Antibodies of the present invention may also be described or specified in terms of their binding affinity to a polypeptide of the invention. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, or  $10^{-15}$  M.

The invention also provides antibodies that competitively inhibit binding of an antibody to an epitope of the invention as determined by any method known in the art for determining competitive binding, for example, the immunoassays described herein. In preferred embodiments, the antibody competitively inhibits binding to the epitope by at least 95%, at least 90%, at least 85 %, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50%.

Antibodies of the present invention may act as agonists or antagonists of the polypeptides of the present invention. For example, the present invention includes antibodies which disrupt the receptor/ligand interactions with the polypeptides of the invention either partially or fully. Preferably, antibodies of the present invention bind an antigenic epitope disclosed herein, or a portion thereof. The invention features both receptor-specific antibodies and ligand-specific antibodies. The invention also features receptor-specific antibodies which do not prevent ligand binding but prevent receptor activation. Receptor activation (i.e., signaling) may be determined by techniques described herein or otherwise known in the art. For example, receptor activation can be determined by detecting the phosphorylation (e.g., tyrosine or serine/threonine) of the receptor or its substrate by immunoprecipitation followed by western blot analysis (for example, as described



supra). In specific embodiments, antibodies are provided that inhibit ligand activity or receptor activity by at least 95%, at least 90%, at least 85%, at least 80%, at least 75%, at least 70%, at least 60%, or at least 50% of the activity in absence of the antibody.

5           The invention also features receptor-specific antibodies which both prevent ligand binding and receptor activation as well as antibodies that recognize the receptor-ligand complex, and, preferably, do not specifically recognize the unbound receptor or the unbound ligand. Likewise, included in the invention are neutralizing antibodies which bind the ligand and prevent binding of the ligand to the receptor, as  
10   well as antibodies which bind the ligand, thereby preventing receptor activation, but do not prevent the ligand from binding the receptor. Further included in the invention are antibodies which activate the receptor. These antibodies may act as receptor agonists, i.e., potentiate or activate either all or a subset of the biological activities of the ligand-mediated receptor activation, for example, by inducing dimerization of the  
15   receptor. The antibodies may be specified as agonists, antagonists or inverse agonists for biological activities comprising the specific biological activities of the peptides of the invention disclosed herein. The above antibody agonists can be made using methods known in the art. See, e.g., PCT publication WO 96/40281; U.S. Patent No. 5,811,097; Deng et al., Blood 92(6):1981-1988 (1998); Chen et al., Cancer Res.  
20   58(16):3668-3678 (1998); Harrop et al., J. Immunol. 161(4):1786-1794 (1998); Zhu et al., Cancer Res. 58(15):3209-3214 (1998); Yoon et al., J. Immunol. 160(7):3170-3179 (1998); Prat et al., J. Cell. Sci. 111(Pt2):237-247 (1998); Pitard et al., J. Immunol. Methods 205(2):177-190 (1997); Liautard et al., Cytokine 9(4):233-241 (1997); Carlson et al., J. Biol. Chem. 272(17):11295-11301 (1997); Taryman et al.,  
25   Neuron 14(4):755-762 (1995); Muller et al., Structure 6(9):1153-1167 (1998);

Bartunek et al., Cytokine 8(1):14-20 (1996) (which are all incorporated by reference herein in their entirety).

Antibodies of the present invention may be used, for example, but not limited to, to purify, detect, and target the polypeptides of the present invention, including both in vitro and in vivo diagnostic and therapeutic methods. For example, the antibodies have use in immunoassays for qualitatively and quantitatively measuring levels of the polypeptides of the present invention in biological samples. See, e.g., Harlow et al., Antibodies: A Laboratory Manual, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988) (incorporated by reference herein in its entirety).

As discussed in more detail below, the antibodies of the present invention may be used either alone or in combination with other compositions. The antibodies may further be recombinantly fused to a heterologous polypeptide at the N- or C-terminus or chemically conjugated (including covalently and non-covalently conjugations) to polypeptides or other compositions. For example, antibodies of the present invention may be recombinantly fused or conjugated to molecules useful as labels in detection assays and effector molecules such as heterologous polypeptides, drugs, radionuclides, or toxins. See, e.g., PCT publications WO 92/08495; WO 91/14438; WO 89/12624; U.S. Patent No. 5,314,995; and EP 396,387.

The antibodies of the invention include derivatives that are modified, i.e., by the covalent attachment of any type of molecule to the antibody such that covalent attachment does not prevent the antibody from generating an anti-idiotypic response. For example, but not by way of limitation, the antibody derivatives include antibodies that have been modified, e.g., by glycosylation, acetylation, pegylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to a cellular ligand or other protein, etc. Any of numerous chemical modifications may be carried out by known techniques,

including, but not limited to specific chemical cleavage, acetylation, formylation, metabolic synthesis of tunicamycin, etc. Additionally, the derivative may contain one or more non-classical amino acids.

The antibodies of the present invention may be generated by any suitable method known in the art. Polyclonal antibodies to an antigen-of-interest can be produced by various procedures well known in the art. For example, a polypeptide of the invention can be administered to various host animals including, but not limited to, rabbits, mice, rats, etc. to induce the production of sera containing polyclonal antibodies specific for the antigen. Various adjuvants may be used to increase the immunological response, depending on the host species, and include but are not limited to, Freund's (complete and incomplete), mineral gels such as aluminum hydroxide, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, keyhole limpet hemocyanins, dinitrophenol, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and corynebacterium parvum. Such adjuvants are also well known in the art.

Monoclonal antibodies can be prepared using a wide variety of techniques known in the art including the use of hybridoma, recombinant, and phage display technologies, or a combination thereof. For example, monoclonal antibodies can be produced using hybridoma techniques including those known in the art and taught, for example, in Harlow et al., *Antibodies: A Laboratory Manual*, (Cold Spring Harbor Laboratory Press, 2nd ed. 1988); Hammerling, et al., in: *Monoclonal Antibodies and T-Cell Hybridomas* 563-681 (Elsevier, N.Y., 1981) (said references incorporated by reference in their entireties). The term "monoclonal antibody" as used herein is not limited to antibodies produced through hybridoma technology. The term "monoclonal antibody" refers to an antibody that is derived from a single clone,

including any eukaryotic, prokaryotic, or phage clone, and not the method by which it is produced.

Methods for producing and screening for specific antibodies using hybridoma technology are routine and well known in the art and are discussed in detail in the

5 Examples (e.g., Example 16). In a non-limiting example, mice can be immunized with a polypeptide of the invention or a cell expressing such peptide. Once an immune response is detected, e.g., antibodies specific for the antigen are detected in the mouse serum, the mouse spleen is harvested and splenocytes isolated. The splenocytes are then fused by well known techniques to any suitable myeloma cells,

10 for example cells from cell line SP20 available from the ATCC. Hybridomas are selected and cloned by limited dilution. The hybridoma clones are then assayed by methods known in the art for cells that secrete antibodies capable of binding a polypeptide of the invention. Ascites fluid, which generally contains high levels of antibodies, can be generated by immunizing mice with positive hybridoma clones.

15 Accordingly, the present invention provides methods of generating monoclonal antibodies as well as antibodies produced by the method comprising culturing a hybridoma cell secreting an antibody of the invention wherein, preferably, the hybridoma is generated by fusing splenocytes isolated from a mouse immunized with an antigen of the invention with myeloma cells and then screening the

20 hybridomas resulting from the fusion for hybridoma clones that secrete an antibody able to bind a polypeptide of the invention.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, Fab and F(ab')<sub>2</sub> fragments of the invention may be produced by proteolytic cleavage of immunoglobulin molecules, using enzymes such

25 as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub> fragments).

F(ab')<sub>2</sub> fragments contain the variable region, the light chain constant region and the CH1 domain of the heavy chain.

For example, the antibodies of the present invention can also be generated using various phage display methods known in the art. In phage display methods, functional antibody domains are displayed on the surface of phage particles which carry the polynucleotide sequences encoding them. In a particular embodiment, such phage can be utilized to display antigen binding domains expressed from a repertoire or combinatorial antibody library (e.g., human or murine). Phage expressing an antigen binding domain that binds the antigen of interest can be selected or identified with antigen, e.g., using labeled antigen or antigen bound or captured to a solid surface or bead. Phage used in these methods are typically filamentous phage including fd and M13 binding domains expressed from phage with Fab, Fv or disulfide stabilized Fv antibody domains recombinantly fused to either the phage gene III or gene VIII protein. Examples of phage display methods that can be used to make the antibodies of the present invention include those disclosed in Brinkman et al., J. Immunol. Methods 182:41-50 (1995); Ames et al., J. Immunol. Methods 184:177-186 (1995); Kettleborough et al., Eur. J. Immunol. 24:952-958 (1994); Persic et al., Gene 187 9-18 (1997); Burton et al., Advances in Immunology 57:191-280 (1994); PCT application No. PCT/GB91/01134; PCT publications WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO 93/11236; WO 95/15982; WO 95/20401; and U.S. Patent Nos. 5,698,426; 5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047; 5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727; 5,733,743 and 5,969,108; each of which is incorporated herein by reference in its entirety.

As described in the above references, after phage selection, the antibody coding regions from the phage can be isolated and used to generate whole antibodies,

including human antibodies, or any other desired antigen binding fragment, and expressed in any desired host, including mammalian cells, insect cells, plant cells, yeast, and bacteria, e.g., as described in detail below. For example, techniques to recombinantly produce Fab, Fab' and F(ab')<sub>2</sub> fragments can also be employed using  
5 methods known in the art such as those disclosed in PCT publication WO 92/22324; Mullinax et al., *BioTechniques* 12(6):864-869 (1992); and Sawai et al., *AJRI* 34:26-34 (1995); and Better et al., *Science* 240:1041-1043 (1988) (said references incorporated by reference in their entireties).

Examples of techniques which can be used to produce single-chain Fvs and  
10 antibodies include those described in U.S. Patents 4,946,778 and 5,258,498; Huston et al., *Methods in Enzymology* 203:46-88 (1991); Shu et al., *PNAS* 90:7995-7999 (1993); and Skerra et al., *Science* 240:1038-1040 (1988). For some uses, including in vivo use of antibodies in humans and in vitro detection assays, it may be preferable to use chimeric, humanized, or human antibodies. A chimeric antibody is a molecule  
15 in which different portions of the antibody are derived from different animal species, such as antibodies having a variable region derived from a murine monoclonal antibody and a human immunoglobulin constant region. Methods for producing chimeric antibodies are known in the art. See e.g., Morrison, *Science* 229:1202 (1985); Oi et al., *BioTechniques* 4:214 (1986); Gillies et al., (1989) *J. Immunol.*  
20 *Methods* 125:191-202; U.S. Patent Nos. 5,807,715; 4,816,567; and 4,816,397, which are incorporated herein by reference in their entirety. Humanized antibodies are antibody molecules from non-human species antibody that binds the desired antigen having one or more complementarity determining regions (CDRs) from the non-human species and a framework regions from a human immunoglobulin molecule.  
25 Often, framework residues in the human framework regions will be substituted with the corresponding residue from the CDR donor antibody to alter, preferably improve,

antigen binding. These framework substitutions are identified by methods well known in the art, e.g., by modeling of the interactions of the CDR and framework residues to identify framework residues important for antigen binding and sequence comparison to identify unusual framework residues at particular positions. (See, e.g.,

5 Queen et al., U.S. Patent No. 5,585,089; Riechmann et al., Nature 332:323 (1988), which are incorporated herein by reference in their entireties.) Antibodies can be humanized using a variety of techniques known in the art including, for example, CDR-grafting (EP 239,400; PCT publication WO 91/09967; U.S. Patent Nos. 5,225,539; 5,530,101; and 5,585,089), veneering or resurfacing (EP 592,106; EP

10 519,596; Padlan, Molecular Immunology 28(4/5):489-498 (1991); Studnicka et al., Protein Engineering 7(6):805-814 (1994); Roguska. et al., PNAS 91:969-973 (1994)), and chain shuffling (U.S. Patent No. 5,565,332).

Completely human antibodies are particularly desirable for therapeutic treatment of human patients. Human antibodies can be made by a variety of methods

15 known in the art including phage display methods described above using antibody libraries derived from human immunoglobulin sequences. See also, U.S. Patent Nos. 4,444,887 and 4,716,111; and PCT publications WO 98/46645, WO 98/50433, WO 98/24893, WO 98/16654, WO 96/34096, WO 96/33735, and WO 91/10741; each of which is incorporated herein by reference in its entirety.

20 Human antibodies can also be produced using transgenic mice which are incapable of expressing functional endogenous immunoglobulins, but which can express human immunoglobulin genes. For example, the human heavy and light chain immunoglobulin gene complexes may be introduced randomly or by homologous recombination into mouse embryonic stem cells. Alternatively, the

25 human variable region, constant region, and diversity region may be introduced into mouse embryonic stem cells in addition to the human heavy and light chain genes.

The mouse heavy and light chain immunoglobulin genes may be rendered non-functional separately or simultaneously with the introduction of human immunoglobulin loci by homologous recombination. In particular, homozygous deletion of the JH region prevents endogenous antibody production. The modified

5 embryonic stem cells are expanded and microinjected into blastocysts to produce chimeric mice. The chimeric mice are then bred to produce homozygous offspring which express human antibodies. The transgenic mice are immunized in the normal fashion with a selected antigen, e.g., all or a portion of a polypeptide of the invention. Monoclonal antibodies directed against the antigen can be obtained from the

10 immunized, transgenic mice using conventional hybridoma technology. The human immunoglobulin transgenes harbored by the transgenic mice rearrange during B cell differentiation, and subsequently undergo class switching and somatic mutation. Thus, using such a technique, it is possible to produce therapeutically useful IgG, IgA, IgM and IgE antibodies. For an overview of this technology for producing human

15 antibodies, see Lonberg and Huszar, Int. Rev. Immunol. 13:65-93 (1995). For a detailed discussion of this technology for producing human antibodies and human monoclonal antibodies and protocols for producing such antibodies, see, e.g., PCT publications WO 98/24893; WO 92/01047; WO 96/34096; WO 96/33735; European Patent No. 0 598 877; U.S. Patent Nos. 5,413,923; 5,625,126; 5,633,425; 5,569,825;

20 5,661,016; 5,545,806; 5,814,318; 5,885,793; 5,916,771; and 5,939,598, which are incorporated by reference herein in their entirety. In addition, companies such as Abgenix, Inc. (Freemont, CA) and Genpharm (San Jose, CA) can be engaged to provide human antibodies directed against a selected antigen using technology similar to that described above.

25 Completely human antibodies which recognize a selected epitope can be generated using a technique referred to as "guided selection." In this approach a



selected non-human monoclonal antibody, e.g., a mouse antibody, is used to guide the selection of a completely human antibody recognizing the same epitope. (Jespers et al., Bio/technology 12:899-903 (1988)).

Further, antibodies to the polypeptides of the invention can, in turn, be utilized to generate anti-idiotypic antibodies that "mimic" polypeptides of the invention using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, FASEB J. 7(5):437-444; (1989) and Nissinoff, J. Immunol. 147(8):2429-2438 (1991)). For example, antibodies which bind to and competitively inhibit polypeptide multimerization and/or binding of a polypeptide of the invention to a ligand can be used to generate anti-idiotypes that "mimic" the polypeptide multimerization and/or binding domain and, as a consequence, bind to and neutralize polypeptide and/or its ligand. Such neutralizing anti-idiotypes or Fab fragments of such anti-idiotypes can be used in therapeutic regimens to neutralize polypeptide ligand. For example, such anti-idiotypic antibodies can be used to bind a polypeptide of the invention and/or to bind its ligands/receptors, and thereby block its biological activity.

#### Polynucleotides Encoding Antibodies

The invention further provides polynucleotides comprising a nucleotide sequence encoding an antibody of the invention and fragments thereof. The invention also encompasses polynucleotides that hybridize under stringent or lower stringency hybridization conditions, e.g., as defined supra, to polynucleotides that encode an antibody, preferably, that specifically binds to a polypeptide of the invention, preferably, an antibody that binds to a polypeptide having the amino acid sequence of SEQ ID NO:Y.

The polynucleotides may be obtained, and the nucleotide sequence of the polynucleotides determined, by any method known in the art. For example, if the

nucleotide sequence of the antibody is known, a polynucleotide encoding the antibody may be assembled from chemically synthesized oligonucleotides (e.g., as described in Kutmeier et al., *BioTechniques* 17:242 (1994)), which, briefly, involves the synthesis of overlapping oligonucleotides containing portions of the sequence  
5 encoding the antibody, annealing and ligating of those oligonucleotides, and then amplification of the ligated oligonucleotides by PCR.

Alternatively, a polynucleotide encoding an antibody may be generated from nucleic acid from a suitable source. If a clone containing a nucleic acid encoding a particular antibody is not available, but the sequence of the antibody molecule is  
10 known, a nucleic acid encoding the immunoglobulin may be chemically synthesized or obtained from a suitable source (e.g., an antibody cDNA library, or a cDNA library generated from, or nucleic acid, preferably poly A+ RNA; isolated from, any tissue or cells expressing the antibody, such as hybridoma cells selected to express an antibody of the invention) by PCR amplification using synthetic primers hybridizable  
15 to the 3' and 5' ends of the sequence or by cloning using an oligonucleotide probe specific for the particular gene sequence to identify, e.g., a cDNA clone from a cDNA library that encodes the antibody. Amplified nucleic acids generated by PCR may then be cloned into replicable cloning vectors using any method well known in the art.

20 Once the nucleotide sequence and corresponding amino acid sequence of the antibody is determined, the nucleotide sequence of the antibody may be manipulated using methods well known in the art for the manipulation of nucleotide sequences, e.g., recombinant DNA techniques, site directed mutagenesis, PCR, etc. (see, for example, the techniques described in Sambrook et al., 1990, *Molecular Cloning, A Laboratory Manual*, 2d Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor,  
25 NY and Ausubel et al., eds., 1998, *Current Protocols in Molecular Biology*, John

Wiley & Sons, NY, which are both incorporated by reference herein in their entireties), to generate antibodies having a different amino acid sequence, for example to create amino acid substitutions, deletions, and/or insertions.

In a specific embodiment, the amino acid sequence of the heavy and/or light chain variable domains may be inspected to identify the sequences of the complementarity determining regions (CDRs) by methods that are well known in the art, e.g., by comparison to known amino acid sequences of other heavy and light chain variable regions to determine the regions of sequence hypervariability. Using routine recombinant DNA techniques, one or more of the CDRs may be inserted within framework regions, e.g., into human framework regions to humanize a non-human antibody, as described supra. The framework regions may be naturally occurring or consensus framework regions, and preferably human framework regions (see, e.g., Chothia et al., J. Mol. Biol. 278: 457-479 (1998) for a listing of human framework regions). Preferably, the polynucleotide generated by the combination of the framework regions and CDRs encodes an antibody that specifically binds a polypeptide of the invention. Preferably, as discussed supra, one or more amino acid substitutions may be made within the framework regions, and, preferably, the amino acid substitutions improve binding of the antibody to its antigen. Additionally, such methods may be used to make amino acid substitutions or deletions of one or more variable region cysteine residues participating in an intrachain disulfide bond to generate antibody molecules lacking one or more intrachain disulfide bonds. Other alterations to the polynucleotide are encompassed by the present invention and within the skill of the art.

In addition, techniques developed for the production of "chimeric antibodies" (Morrison et al., Proc. Natl. Acad. Sci. 81:851-855 (1984); Neuberger et al., Nature 312:604-608 (1984); Takeda et al., Nature 314:452-454 (1985)) by splicing genes

from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. As described supra, a chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived  
5 from a murine mAb and a human immunoglobulin constant region, e.g., humanized antibodies.

Alternatively, techniques described for the production of single chain antibodies (U.S. Patent No. 4,946,778; Bird, Science 242:423- 42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature  
10 334:544-54 (1989)) can be adapted to produce single chain antibodies. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide. Techniques for the assembly of functional Fv fragments in E. coli may also be used (Skerra et al., Science 242:1038- 1041 (1988)).

15

#### Methods of Producing Antibodies

The antibodies of the invention can be produced by any method known in the art for the synthesis of antibodies, in particular, by chemical synthesis or preferably, by recombinant expression techniques.

20

Recombinant expression of an antibody of the invention, or fragment, derivative or analog thereof, (e.g., a heavy or light chain of an antibody of the invention or a single chain antibody of the invention), requires construction of an expression vector containing a polynucleotide that encodes the antibody. Once a polynucleotide encoding an antibody molecule or a heavy or light chain of an  
25 antibody, or portion thereof (preferably containing the heavy or light chain variable domain), of the invention has been obtained, the vector for the production of the

antibody molecule may be produced by recombinant DNA technology using techniques well known in the art. Thus, methods for preparing a protein by expressing a polynucleotide containing an antibody encoding nucleotide sequence are described herein. Methods which are well known to those skilled in the art can be used to construct expression vectors containing antibody coding sequences and appropriate transcriptional and translational control signals. These methods include, for example, in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. The invention, thus, provides replicable vectors comprising a nucleotide sequence encoding an antibody molecule of the invention, or a heavy or light chain thereof, or a heavy or light chain variable domain, operably linked to a promoter. Such vectors may include the nucleotide sequence encoding the constant region of the antibody molecule (see, e.g., PCT Publication WO 86/05807; PCT Publication WO 89/01036; and U.S. Patent No. 5,122,464) and the variable domain of the antibody may be cloned into such a vector for expression of the entire heavy or light chain.

The expression vector is transferred to a host cell by conventional techniques and the transfected cells are then cultured by conventional techniques to produce an antibody of the invention. Thus, the invention includes host cells containing a polynucleotide encoding an antibody of the invention, or a heavy or light chain thereof, or a single chain antibody of the invention, operably linked to a heterologous promoter. In preferred embodiments for the expression of double-chained antibodies, vectors encoding both the heavy and light chains may be co-expressed in the host cell for expression of the entire immunoglobulin molecule, as detailed below.

A variety of host-expression vector systems may be utilized to express the antibody molecules of the invention. Such host-expression systems represent vehicles by which the coding sequences of interest may be produced and subsequently

purified, but also represent cells which may, when transformed or transfected with the appropriate nucleotide coding sequences, express an antibody molecule of the invention in situ. These include but are not limited to microorganisms such as bacteria (e.g., *E. coli*, *B. subtilis*) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing antibody coding sequences; yeast (e.g., *Saccharomyces*, *Pichia*) transformed with recombinant yeast expression vectors containing antibody coding sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing antibody coding sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing antibody coding sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3 cells) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter). Preferably, bacterial cells such as *Escherichia coli*, and more preferably, eukaryotic cells, especially for the expression of whole recombinant antibody molecule, are used for the expression of a recombinant antibody molecule. For example, mammalian cells such as Chinese hamster ovary cells (CHO), in conjunction with a vector such as the major intermediate early gene promoter element from human cytomegalovirus is an effective expression system for antibodies (Foecking et al., *Gene* 45:101 (1986); Cockett et al., *Bio/Technology* 8:2 (1990)).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the antibody molecule being expressed. For example, when a large quantity of such a protein is to be produced, for the

generation of pharmaceutical compositions of an antibody molecule, vectors which direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the *E. coli* expression vector pUR278 (Ruther et al., EMBO J. 2:1791 (1983)), in which the antibody coding sequence may be ligated individually into the vector in frame with the lac Z coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, Nucleic Acids Res. 13:3101-3109 (1985); Van Heeke & Schuster, J. Biol. Chem. 24:5503-5509 (1989)); and the like. pGEX vectors may also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption and binding to matrix glutathione-agarose beads followed by elution in the presence of free glutathione. The pGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

15 In an insect system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in *Spodoptera frugiperda* cells. The antibody coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter).

20 In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the antibody coding sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region

E1 or E3) will result in a recombinant virus that is viable and capable of expressing the antibody molecule in infected hosts. (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA 81:355-359 (1984)). Specific initiation signals may also be required for efficient translation of inserted antibody coding sequences. These signals include the

5 ATG initiation codon and adjacent sequences. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate

10 transcription enhancer elements, transcription terminators, etc. (see Bittner et al., Methods in Enzymol. 153:51-544 (1987)).

In addition, a host cell strain may be chosen which modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g.,

15 cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which

20 possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include but are not limited to CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, breast cancer cell lines such as, for example, BT483, Hs578T, HTB2, BT20 and T47D, and normal mammary gland cell

25 line such as, for example, CRL7030 and Hs578Bst.



For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the antibody molecule may be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by

5 appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection

10 and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the antibody molecule. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that interact directly or indirectly with the antibody molecule.

15 A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler et al., Cell 11:223 (1977)), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA 48:202 (1992)), and adenine phosphoribosyltransferase (Lowy et al., Cell 22:817 (1980)) genes can be employed in tk-, hgp<sup>rt</sup>- or ap<sup>rt</sup>- cells, respectively.

20 Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler et al., Natl. Acad. Sci. USA 77:357 (1980); O'Hare et al., Proc. Natl. Acad. Sci. USA 78:1527 (1981)); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA 78:2072 (1981)); neo, which confers resistance to the aminoglycoside G-

25 418 Clinical Pharmacy 12:488-505; Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science

260:926-932 (1993); and Morgan and Anderson, *Ann. Rev. Biochem.* 62:191-217 (1993); May, 1993, *TIB TECH* 11(5):155-215); and hygromycin, which confers resistance to hygromycin (Santerre et al., *Gene* 30:147 (1984)). Methods commonly known in the art of recombinant DNA technology may be routinely applied to select the desired

5 recombinant clone, and such methods are described, for example, in Ausubel et al. (eds.), *Current Protocols in Molecular Biology*, John Wiley & Sons, NY (1993); Kriegler, *Gene Transfer and Expression, A Laboratory Manual*, Stockton Press, NY (1990); and in Chapters 12 and 13, Dracopoli et al. (eds), *Current Protocols in Human Genetics*, John Wiley & Sons, NY (1994); Colberre-Garapin et al., *J. Mol.*

10 *Biol.* 150:1 (1981), which are incorporated by reference herein in their entireties.

The expression levels of an antibody molecule can be increased by vector amplification (for a review, see Bebbington and Hentschel, *The use of vectors based on gene amplification for the expression of cloned genes in mammalian cells in DNA cloning*, Vol.3. (Academic Press, New York, 1987)). When a marker in the vector

15 system expressing antibody is amplifiable, increase in the level of inhibitor present in culture of host cell will increase the number of copies of the marker gene. Since the amplified region is associated with the antibody gene, production of the antibody will also increase (Crouse et al., *Mol. Cell. Biol.* 3:257 (1983)).

The host cell may be co-transfected with two expression vectors of the

20 invention, the first vector encoding a heavy chain derived polypeptide and the second vector encoding a light chain derived polypeptide. The two vectors may contain identical selectable markers which enable equal expression of heavy and light chain polypeptides. Alternatively, a single vector may be used which encodes, and is capable of expressing, both heavy and light chain polypeptides. In such situations,

25 the light chain should be placed before the heavy chain to avoid an excess of toxic free heavy chain (Proudfoot, *Nature* 322:52 (1986); Kohler, *Proc. Natl. Acad. Sci.*

USA 77:2197 (1980)). The coding sequences for the heavy and light chains may comprise cDNA or genomic DNA.

Once an antibody molecule of the invention has been produced by an animal, chemically synthesized, or recombinantly expressed, it may be purified by any  
5 method known in the art for purification of an immunoglobulin molecule, for example, by chromatography (e.g., ion exchange, affinity, particularly by affinity for the specific antigen after Protein A, and sizing column chromatography), centrifugation, differential solubility, or by any other standard technique for the purification of proteins. In addition, the antibodies of the present invention or  
10 fragments thereof can be fused to heterologous polypeptide sequences described herein or otherwise known in the art, to facilitate purification.

The present invention encompasses antibodies recombinantly fused or chemically conjugated (including both covalently and non-covalently conjugations) to a polypeptide (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80,  
15 90 or 100 amino acids of the polypeptide) of the present invention to generate fusion proteins. The fusion does not necessarily need to be direct, but may occur through linker sequences. The antibodies may be specific for antigens other than polypeptides (or portion thereof, preferably at least 10, 20, 30, 40, 50, 60, 70, 80, 90 or 100 amino acids of the polypeptide) of the present invention. For example, antibodies may be  
20 used to target the polypeptides of the present invention to particular cell types, either in vitro or in vivo, by fusing or conjugating the polypeptides of the present invention to antibodies specific for particular cell surface receptors. Antibodies fused or conjugated to the polypeptides of the present invention may also be used in in vitro immunoassays and purification methods using methods known in the art. See e.g.,  
25 Harbor et al., supra, and PCT publication WO 93/21232; EP 439,095; Naramura et al., Immunol. Lett. 39:91-99 (1994); U.S. Patent 5,474,981; Gillies et al., PNAS

89:1428-1432 (1992); Fell et al., J. Immunol. 146:2446-2452(1991), which are incorporated by reference in their entirety.

The present invention further includes compositions comprising the polypeptides of the present invention fused or conjugated to antibody domains other than the variable regions. For example, the polypeptides of the present invention may be fused or conjugated to an antibody Fc region, or portion thereof. The antibody portion fused to a polypeptide of the present invention may comprise the constant region, hinge region, CH1 domain, CH2 domain, and CH3 domain or any combination of whole domains or portions thereof. The polypeptides may also be fused or conjugated to the above antibody portions to form multimers. For example, Fc portions fused to the polypeptides of the present invention can form dimers through disulfide bonding between the Fc portions. Higher multimeric forms can be made by fusing the polypeptides to portions of IgA and IgM. Methods for fusing or conjugating the polypeptides of the present invention to antibody portions are known in the art. See, e.g., U.S. Patent Nos. 5,336,603; 5,622,929; 5,359,046; 5,349,053; 5,447,851; 5,112,946; EP 307,434; EP 367,166; PCT publications WO 96/04388; WO 91/06570; Ashkenazi et al., Proc. Natl. Acad. Sci. USA 88:10535-10539 (1991); Zheng et al., J. Immunol. 154:5590-5600 (1995); and Vil et al., Proc. Natl. Acad. Sci. USA 89:11337- 11341(1992) (said references incorporated by reference in their entirety).

As discussed, supra, the polypeptides corresponding to a polypeptide, polypeptide fragment, or a variant of SEQ ID NO:Y may be fused or conjugated to the above antibody portions to increase the in vivo half life of the polypeptides or for use in immunoassays using methods known in the art. Further, the polypeptides corresponding to SEQ ID NO:Y may be fused or conjugated to the above antibody portions to facilitate purification. One reported example describes chimeric proteins

consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP 394,827; Traunecker et al., *Nature* 331:84-86 (1988)). The polypeptides of the present invention fused or conjugated to an antibody having

5 disulfide- linked dimeric structures (due to the IgG) may also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., *J. Biochem.* 270:3958-3964 (1995)). In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP A

10 232,262). Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified, would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to

15 identify antagonists of hIL-5. (See, Bennett et al., *J. Molecular Recognition* 8:52-58 (1995); Johanson et al., *J. Biol. Chem.* 270:9459-9471 (1995)).

Moreover, the antibodies or fragments thereof of the present invention can be fused to marker sequences, such as a peptide to facilitate purification. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the

20 tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available. As described in Gentz et al., *Proc. Natl. Acad. Sci. USA* 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Other peptide tags useful for purification include, but are not limited to, the "HA" tag, which

25 corresponds to an epitope derived from the influenza hemagglutinin protein (Wilson et al., *Cell* 37:767 (1984)) and the "flag" tag.

The present invention further encompasses antibodies or fragments thereof conjugated to a diagnostic or therapeutic agent. The antibodies can be used diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection can be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the antibody (or fragment thereof) or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. See, for example, U.S. Patent No. 4,741,900 for metal ions which can be conjugated to antibodies for use as diagnostics according to the present invention. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive material include  $^{125}\text{I}$ ,  $^{131}\text{I}$ ,  $^{111}\text{In}$  or  $^{99}\text{Tc}$ .

Further, an antibody or fragment thereof may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytocidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example,  $^{213}\text{Bi}$ . A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include

paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, carmustine (BSNU) and lomustine (CCNU), cyclophosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-10 dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).

The conjugates of the invention can be used for modifying a given biological response, the therapeutic agent or drug moiety is not to be construed as limited to 15 classical chemical therapeutic agents. For example, the drug moiety may be a protein or polypeptide possessing a desired biological activity. Such proteins may include, for example, a toxin such as abrin, ricin A, pseudomonas exotoxin, or diphtheria toxin; a protein such as tumor necrosis factor,  $\alpha$ -interferon,  $\beta$ -interferon, nerve growth 20 factor, platelet derived growth factor, tissue plasminogen activator, an apoptotic agent, e.g., TNF- $\alpha$ , TNF- $\beta$ , AIM I (See, International Publication No. WO 97/33899), AIM II (See, International Publication No. WO 97/34911), Fas Ligand (Takahashi *et al.*, *Int. Immunol.*, 6:1567-1574 (1994)), VEGI (See, International Publication No. WO 99/23105), a thrombotic agent or an anti-angiogenic agent, e.g., 25 angiostatin or endostatin; or, biological response modifiers such as, for example, lymphokines, interleukin-1 ("IL-1"), interleukin-2 ("IL-2"), interleukin-6 ("IL-6"),

granulocyte macrophage colony stimulating factor ("GM-CSF"), granulocyte colony stimulating factor ("G-CSF"), or other growth factors.

Antibodies may also be attached to solid supports, which are particularly useful for immunoassays or purification of the target antigen. Such solid supports  
5 include, but are not limited to, glass, cellulose, polyacrylamide, nylon, polystyrene, polyvinyl chloride or polypropylene.

Techniques for conjugating such therapeutic moiety to antibodies are well known, see, e.g., Arnon et al., "Monoclonal Antibodies For Immunotargeting Of Drugs In Cancer Therapy", in *Monoclonal Antibodies And Cancer Therapy*, Reisfeld et al. (eds.), pp. 243-56 (Alan R. Liss, Inc. 1985); Hellstrom et al., "Antibodies For  
10 Drug Delivery", in *Controlled Drug Delivery* (2nd Ed.), Robinson et al. (eds.), pp. 623-53 (Marcel Dekker, Inc. 1987); Thorpe, "Antibody Carriers Of Cytotoxic Agents In Cancer Therapy: A Review", in *Monoclonal Antibodies '84: Biological And Clinical Applications*, Pinchera et al. (eds.), pp. 475-506 (1985); "Analysis, Results,  
15 And Future Prospective Of The Therapeutic Use Of Radiolabeled Antibody In Cancer Therapy", in *Monoclonal Antibodies For Cancer Detection And Therapy*, Baldwin et al. (eds.), pp. 303-16 (Academic Press 1985), and Thorpe et al., "The Preparation And Cytotoxic Properties Of Antibody-Toxin Conjugates", *Immunol. Rev.* 62:119-58 (1982).

20 Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate as described by Segal in U.S. Patent No. 4,676,980, which is incorporated herein by reference in its entirety.

An antibody, with or without a therapeutic moiety conjugated to it, administered alone or in combination with cytotoxic factor(s) and/or cytokine(s) can  
25 be used as a therapeutic.



### Immunophenotyping

The antibodies of the invention may be utilized for immunophenotyping of cell lines and biological samples. The translation product of the gene of the present invention may be useful as a cell specific marker, or more specifically as a cellular  
5 marker that is differentially expressed at various stages of differentiation and/or maturation of particular cell types. Monoclonal antibodies directed against a specific epitope, or combination of epitopes, will allow for the screening of cellular populations expressing the marker. Various techniques can be utilized using monoclonal antibodies to screen for cellular populations expressing the marker(s), and  
10 include magnetic separation using antibody-coated magnetic beads, "panning" with antibody attached to a solid matrix (i.e., plate), and flow cytometry (See, e.g., U.S. Patent 5,985,660; and Morrison *et al.*, *Cell*, 96:737-49 (1999)).

These techniques allow for the screening of particular populations of cells, such as might be found with hematological malignancies (i.e. minimal residual  
15 disease (MRD) in acute leukemic patients) and "non-self" cells in transplantations to prevent Graft-versus-Host Disease (GVHD). Alternatively, these techniques allow for the screening of hematopoietic stem and progenitor cells capable of undergoing proliferation and/or differentiation, as might be found in human umbilical cord blood.

### 20 Assays For Antibody Binding

The antibodies of the invention may be assayed for immunospecific binding by any method known in the art. The immunoassays which can be used include but are not limited to competitive and non-competitive assay systems using techniques such as western blots, radioimmunoassays, ELISA (enzyme linked immunosorbent  
25 assay), "sandwich" immunoassays, immunoprecipitation assays, precipitin reactions, gel diffusion precipitin reactions, immunodiffusion assays, agglutination assays,

complement-fixation assays, immunoradiometric assays, fluorescent immunoassays, protein A immunoassays, to name but a few. Such assays are routine and well known in the art (see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York, which is incorporated by  
5 reference herein in its entirety). Exemplary immunoassays are described briefly below (but are not intended by way of limitation).

Immunoprecipitation protocols generally comprise lysing a population of cells in a lysis buffer such as RIPA buffer (1% NP-40 or Triton X- 100, 1% sodium deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate at pH 7.2, 1%  
10 Trasyolol) supplemented with protein phosphatase and/or protease inhibitors (e.g., EDTA, PMSF, aprotinin, sodium vanadate), adding the antibody of interest to the cell lysate, incubating for a period of time (e.g., 1-4 hours) at 4° C, adding protein A and/or protein G sepharose beads to the cell lysate, incubating for about an hour or more at 4° C, washing the beads in lysis buffer and resuspending the beads in  
15 SDS/sample buffer. The ability of the antibody of interest to immunoprecipitate a particular antigen can be assessed by, e.g., western blot analysis. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the binding of the antibody to an antigen and decrease the background (e.g., pre-clearing the cell lysate with sepharose beads). For further discussion regarding  
20 immunoprecipitation protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.16.1.

Western blot analysis generally comprises preparing protein samples, electrophoresis of the protein samples in a polyacrylamide gel (e.g., 8%- 20% SDS-PAGE depending on the molecular weight of the antigen), transferring the protein  
25 sample from the polyacrylamide gel to a membrane such as nitrocellulose, PVDF or nylon, blocking the membrane in blocking solution (e.g., PBS with 3% BSA or non-

fat milk), washing the membrane in washing buffer (e.g., PBS-Tween 20), blocking the membrane with primary antibody (the antibody of interest) diluted in blocking buffer, washing the membrane in washing buffer, blocking the membrane with a secondary antibody (which recognizes the primary antibody, e.g., an anti-human antibody) conjugated to an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) or radioactive molecule (e.g.,  $^{32}\text{P}$  or  $^{125}\text{I}$ ) diluted in blocking buffer, washing the membrane in wash buffer, and detecting the presence of the antigen. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected and to reduce the background noise. For further discussion regarding western blot protocols see, e.g., Ausubel et al, eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 10.8.1.

ELISAs comprise preparing antigen, coating the well of a 96 well microtiter plate with the antigen, adding the antibody of interest conjugated to a detectable compound such as an enzymatic substrate (e.g., horseradish peroxidase or alkaline phosphatase) to the well and incubating for a period of time, and detecting the presence of the antigen. In ELISAs the antibody of interest does not have to be conjugated to a detectable compound; instead, a second antibody (which recognizes the antibody of interest) conjugated to a detectable compound may be added to the well. Further, instead of coating the well with the antigen, the antibody may be coated to the well. In this case, a second antibody conjugated to a detectable compound may be added following the addition of the antigen of interest to the coated well. One of skill in the art would be knowledgeable as to the parameters that can be modified to increase the signal detected as well as other variations of ELISAs known in the art. For further discussion regarding ELISAs see, e.g., Ausubel et al,

eds, 1994, Current Protocols in Molecular Biology, Vol. 1, John Wiley & Sons, Inc., New York at 11.2.1.

The binding affinity of an antibody to an antigen and the off-rate of an antibody-antigen interaction can be determined by competitive binding assays. One example of a competitive binding assay is a radioimmunoassay comprising the incubation of labeled antigen (e.g., 3H or 125I) with the antibody of interest in the presence of increasing amounts of unlabeled antigen, and the detection of the antibody bound to the labeled antigen. The affinity of the antibody of interest for a particular antigen and the binding off-rates can be determined from the data by scatchard plot analysis. Competition with a second antibody can also be determined using radioimmunoassays. In this case, the antigen is incubated with antibody of interest conjugated to a labeled compound (e.g., 3H or 125I) in the presence of increasing amounts of an unlabeled second antibody.

#### 15        Therapeutic Uses

The present invention is further directed to antibody-based therapies which involve administering antibodies of the invention to an animal, preferably a mammal, and most preferably a human, patient for treating one or more of the disclosed diseases, disorders, or conditions. Therapeutic compounds of the invention include, but are not limited to, antibodies of the invention (including fragments, analogs and derivatives thereof as described herein) and nucleic acids encoding antibodies of the invention (including fragments, analogs and derivatives thereof and anti-idiotypic antibodies as described herein). The antibodies of the invention can be used to treat, inhibit or prevent diseases, disorders or conditions associated with aberrant expression and/or activity of a polypeptide of the invention, including, but not limited to, any one or more of the diseases, disorders, or conditions described herein. The treatment

and/or prevention of diseases, disorders, or conditions associated with aberrant expression and/or activity of a polypeptide of the invention includes, but is not limited to, alleviating symptoms associated with those diseases, disorders or conditions. Antibodies of the invention may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC).

Some of these approaches are described in more detail below. Armed with the teachings provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

The antibodies of the invention may be administered alone or in combination with other types of treatments (e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents). Generally, administration of products of a species origin or species reactivity (in the case of antibodies) that is the same species as that of the patient is preferred. Thus, in a preferred embodiment, human antibodies, fragments derivatives, analogs, or nucleic acids, are administered to a human patient for therapy or prophylaxis.

It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and therapy of disorders related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies, fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides of the invention, including fragments thereof. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-2}$  M,  $10^{-2}$  M,  $5 \times 10^{-3}$  M,  $10^{-3}$  M,  $5 \times 10^{-4}$  M,  $10^{-4}$  M,  $5 \times 10^{-5}$  M,  $10^{-5}$  M,  $5 \times 10^{-6}$  M,  $10^{-6}$  M,  $5 \times 10^{-7}$  M,  $10^{-7}$  M,  $5 \times 10^{-8}$  M,  $10^{-8}$  M,  $5 \times 10^{-9}$  M,  $10^{-9}$  M,  $5 \times 10^{-10}$  M,  $10^{-10}$  M,  $5 \times 10^{-11}$  M,  $10^{-11}$  M,  $5 \times 10^{-12}$  M,  $10^{-12}$  M,  $5 \times 10^{-13}$  M,  $10^{-13}$  M,  $5 \times 10^{-14}$  M,  $10^{-14}$  M,  $5 \times 10^{-15}$  M, and  $10^{-15}$  M.

#### Gene Therapy

In a specific embodiment, nucleic acids comprising sequences encoding antibodies or functional derivatives thereof, are administered to treat, inhibit or prevent a disease or disorder associated with aberrant expression and/or activity of a polypeptide of the invention, by way of gene therapy. Gene therapy refers to therapy performed by the administration to a subject of an expressed or expressible nucleic acid. In this embodiment of the invention, the nucleic acids produce their encoded protein that mediates a therapeutic effect.

Any of the methods for gene therapy available in the art can be used according to the present invention. Exemplary methods are described below.

For general reviews of the methods of gene therapy, see Goldspiel et al., Clinical Pharmacy 12:488-505 (1993); Wu and Wu, Biotherapy 3:87-95 (1991); Tolstoshev, Ann. Rev. Pharmacol. Toxicol. 32:573-596 (1993); Mulligan, Science 260:926-932 (1993); and Morgan and Anderson, Ann. Rev. Biochem. 62:191-217

(1993); May, TIBTECH 11(5):155-215 (1993). Methods commonly known in the art of recombinant DNA technology which can be used are described in Ausubel et al. (eds.), Current Protocols in Molecular Biology, John Wiley & Sons, NY (1993); and Kriegler, Gene Transfer and Expression, A Laboratory Manual, Stockton Press, NY  
5 (1990).

In a preferred aspect, the compound comprises nucleic acid sequences encoding an antibody, said nucleic acid sequences being part of expression vectors that express the antibody or fragments or chimeric proteins or heavy or light chains thereof in a suitable host. In particular, such nucleic acid sequences have promoters  
10 operably linked to the antibody coding region, said promoter being inducible or constitutive, and, optionally, tissue- specific. In another particular embodiment, nucleic acid molecules are used in which the antibody coding sequences and any other desired sequences are flanked by regions that promote homologous recombination at a desired site in the genome, thus providing for intrachromosomal expression of the  
15 antibody encoding nucleic acids (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al., Nature 342:435-438 (1989). In specific embodiments, the expressed antibody molecule is a single chain antibody; alternatively, the nucleic acid sequences include sequences encoding both the heavy and light chains, or fragments thereof, of the antibody.

20 Delivery of the nucleic acids into a patient may be either direct, in which case the patient is directly exposed to the nucleic acid or nucleic acid- carrying vectors, or indirect, in which case, cells are first transformed with the nucleic acids in vitro, then transplanted into the patient. These two approaches are known, respectively, as in vivo or ex vivo gene therapy.

25 In a specific embodiment, the nucleic acid sequences are directly administered in vivo, where it is expressed to produce the encoded product. This can be

accomplished by any of numerous methods known in the art, e.g., by constructing them as part of an appropriate nucleic acid expression vector and administering it so that they become intracellular, e.g., by infection using defective or attenuated retrovirals or other viral vectors (see U.S. Patent No. 4,980,286), or by direct

5 injection of naked DNA, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating with lipids or cell-surface receptors or transfecting agents, encapsulation in liposomes, microparticles, or microcapsules, or by administering them in linkage to a peptide which is known to enter the nucleus, by administering it in linkage to a ligand subject to receptor-mediated endocytosis (see,

10 e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)) (which can be used to target cell types specifically expressing the receptors), etc. In another embodiment, nucleic acid-ligand complexes can be formed in which the ligand comprises a fusogenic viral peptide to disrupt endosomes, allowing the nucleic acid to avoid lysosomal degradation. In yet another embodiment, the nucleic acid can be targeted in vivo for

15 cell specific uptake and expression, by targeting a specific receptor (see, e.g., PCT Publications WO 92/06180; WO 92/22635; WO92/20316; WO93/14188, WO 93/20221). Alternatively, the nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination (Koller and Smithies, Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); Zijlstra et al.,

20 Nature 342:435-438 (1989)).

In a specific embodiment, viral vectors that contains nucleic acid sequences encoding an antibody of the invention are used. For example, a retroviral vector can be used (see Miller et al., Meth. Enzymol. 217:581-599 (1993)). These retroviral vectors contain the components necessary for the correct packaging of the viral

25 genome and integration into the host cell DNA. The nucleic acid sequences encoding the antibody to be used in gene therapy are cloned into one or more vectors, which



facilitates delivery of the gene into a patient. More detail about retroviral vectors can be found in Boesen et al., *Biotherapy* 6:291-302 (1994), which describes the use of a retroviral vector to deliver the *mdr1* gene to hematopoietic stem cells in order to make the stem cells more resistant to chemotherapy. Other references illustrating the use of retroviral vectors in gene therapy are: Clowes et al., *J. Clin. Invest.* 93:644-651 (1994); Kiem et al., *Blood* 83:1467-1473 (1994); Salmons and Gunzberg, *Human Gene Therapy* 4:129-141 (1993); and Grossman and Wilson, *Curr. Opin. in Genetics and Devel.* 3:110-114 (1993).

Adenoviruses are other viral vectors that can be used in gene therapy.

Adenoviruses are especially attractive vehicles for delivering genes to respiratory epithelia. Adenoviruses naturally infect respiratory epithelia where they cause a mild disease. Other targets for adenovirus-based delivery systems are liver, the central nervous system, endothelial cells, and muscle. Adenoviruses have the advantage of being capable of infecting non-dividing cells. Kozarsky and Wilson, *Current Opinion in Genetics and Development* 3:499-503 (1993) present a review of adenovirus-based gene therapy. Bout et al., *Human Gene Therapy* 5:3-10 (1994) demonstrated the use of adenovirus vectors to transfer genes to the respiratory epithelia of rhesus monkeys. Other instances of the use of adenoviruses in gene therapy can be found in Rosenfeld et al., *Science* 252:431-434 (1991); Rosenfeld et al., *Cell* 68:143-155 (1992); Mastrangeli et al., *J. Clin. Invest.* 91:225-234 (1993); PCT Publication WO94/12649; and Wang, et al., *Gene Therapy* 2:775-783 (1995). In a preferred embodiment, adenovirus vectors are used.

Adeno-associated virus (AAV) has also been proposed for use in gene therapy (Walsh et al., *Proc. Soc. Exp. Biol. Med.* 204:289-300 (1993); U.S. Patent No. 5,436,146).

Another approach to gene therapy involves transferring a gene to cells in tissue culture by such methods as electroporation, lipofection, calcium phosphate mediated transfection, or viral infection. Usually, the method of transfer includes the transfer of a selectable marker to the cells. The cells are then placed under selection  
5 to isolate those cells that have taken up and are expressing the transferred gene. Those cells are then delivered to a patient.

In this embodiment, the nucleic acid is introduced into a cell prior to administration in vivo of the resulting recombinant cell. Such introduction can be carried out by any method known in the art, including but not limited to transfection,  
10 electroporation, microinjection, infection with a viral or bacteriophage vector containing the nucleic acid sequences, cell fusion, chromosome-mediated gene transfer, microcell-mediated gene transfer, spheroplast fusion, etc. Numerous techniques are known in the art for the introduction of foreign genes into cells (see, e.g., Loeffler and Behr, Meth. Enzymol. 217:599-618 (1993); Cohen et al., Meth.  
15 Enzymol. 217:618-644 (1993); Cline, Pharmac. Ther. 29:69-92m (1985) and may be used in accordance with the present invention, provided that the necessary developmental and physiological functions of the recipient cells are not disrupted. The technique should provide for the stable transfer of the nucleic acid to the cell, so that the nucleic acid is expressible by the cell and preferably heritable and  
20 expressible by its cell progeny.

The resulting recombinant cells can be delivered to a patient by various methods known in the art. Recombinant blood cells (e.g., hematopoietic stem or progenitor cells) are preferably administered intravenously. The amount of cells envisioned for use depends on the desired effect, patient state, etc., and can be  
25 determined by one skilled in the art.

Cells into which a nucleic acid can be introduced for purposes of gene therapy encompass any desired, available cell type, and include but are not limited to epithelial cells, endothelial cells, keratinocytes, fibroblasts, muscle cells, hepatocytes; blood cells such as Tlymphocytes, Blymphocytes, monocytes, macrophages, neutrophils, eosinophils, megakaryocytes, granulocytes; various stem or progenitor cells, in particular hematopoietic stem or progenitor cells, e.g., as obtained from bone marrow, umbilical cord blood, peripheral blood, fetal liver, etc.

In a preferred embodiment, the cell used for gene therapy is autologous to the patient.

10 In an embodiment in which recombinant cells are used in gene therapy, nucleic acid sequences encoding an antibody are introduced into the cells such that they are expressible by the cells or their progeny, and the recombinant cells are then administered in vivo for therapeutic effect. In a specific embodiment, stem or progenitor cells are used. Any stem and/or progenitor cells which can be isolated and  
15 maintained in vitro can potentially be used in accordance with this embodiment of the present invention (see e.g. PCT Publication WO 94/08598; Stemple and Anderson, Cell 71:973-985 (1992); Rheinwald, Meth. Cell Bio. 21A:229 (1980); and Pittelkow and Scott, Mayo Clinic Proc. 61:771 (1986)).

In a specific embodiment, the nucleic acid to be introduced for purposes of  
20 gene therapy comprises an inducible promoter operably linked to the coding region, such that expression of the nucleic acid is controllable by controlling the presence or absence of the appropriate inducer of transcription. Demonstration of Therapeutic or Prophylactic Activity

The compounds or pharmaceutical compositions of the invention are  
25 preferably tested in vitro, and then in vivo for the desired therapeutic or prophylactic activity, prior to use in humans. For example, in vitro assays to demonstrate the

therapeutic or prophylactic utility of a compound or pharmaceutical composition include, the effect of a compound on a cell line or a patient tissue sample. The effect of the compound or composition on the cell line and/or tissue sample can be determined utilizing techniques known to those of skill in the art including, but not limited to, rosette formation assays and cell lysis assays. In accordance with the invention, in vitro assays which can be used to determine whether administration of a specific compound is indicated, include in vitro cell culture assays in which a patient tissue sample is grown in culture, and exposed to or otherwise administered a compound, and the effect of such compound upon the tissue sample is observed.

10.

#### Therapeutic/Prophylactic Administration and Composition

The invention provides methods of treatment, inhibition and prophylaxis by administration to a subject of an effective amount of a compound or pharmaceutical composition of the invention, preferably an antibody of the invention. In a preferred aspect, the compound is substantially purified (e.g., substantially free from substances that limit its effect or produce undesired side-effects). The subject is preferably an animal, including but not limited to animals such as cows, pigs, horses, chickens, cats, dogs, etc., and is preferably a mammal, and most preferably human.

Formulations and methods of administration that can be employed when the compound comprises a nucleic acid or an immunoglobulin are described above; additional appropriate formulations and routes of administration can be selected from among those described herein below.

Various delivery systems are known and can be used to administer a compound of the invention, e.g., encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing the compound, receptor-mediated endocytosis (see, e.g., Wu and Wu, J. Biol. Chem. 262:4429-4432 (1987)),

construction of a nucleic acid as part of a retroviral or other vector, etc. Methods of introduction include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compounds or compositions may be administered by any convenient route, for example by infusion  
5 or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.) and may be administered together with other biologically active agents. Administration can be systemic or local. In addition, it may be desirable to introduce the pharmaceutical compounds or compositions of the invention into the central nervous system by any suitable route,  
10 including intraventricular and intrathecal injection; intraventricular injection may be facilitated by an intraventricular catheter, for example, attached to a reservoir, such as an Ommaya reservoir. Pulmonary administration can also be employed, e.g., by use of an inhaler or nebulizer, and formulation with an aerosolizing agent.

In a specific embodiment, it may be desirable to administer the pharmaceutical  
15 compounds or compositions of the invention locally to the area in need of treatment; this may be achieved by, for example, and not by way of limitation, local infusion during surgery, topical application, e.g., in conjunction with a wound dressing after surgery, by injection, by means of a catheter, by means of a suppository, or by means of an implant, said implant being of a porous, non-porous, or gelatinous material,  
20 including membranes, such as sialastic membranes, or fibers. Preferably, when administering a protein, including an antibody, of the invention, care must be taken to use materials to which the protein does not absorb.

In another embodiment, the compound or composition can be delivered in a vesicle, in particular a liposome (see Langer, Science 249:1527-1533 (1990); Treat et  
25 al., in Liposomes in the Therapy of Infectious Disease and Cancer, Lopez-Berestein

and Fidler (eds.), Liss, New York, pp. 353- 365 (1989); Lopez-Berestein, *ibid.*, pp. 317-327; see generally *ibid.*)

In yet another embodiment, the compound or composition can be delivered in a controlled release system. In one embodiment, a pump may be used (see Langer, 5 *supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.* 14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)). In another embodiment, polymeric materials can be used (see *Medical Applications of Controlled Release*, Langer and Wise (eds.), CRC Pres., Boca Raton, Florida (1974); *Controlled Drug Bioavailability, Drug Product Design and Performance*, Smolen and 10 Ball (eds.), Wiley, New York (1984); Ranger and Peppas, J., *Macromol. Sci. Rev. Macromol. Chem.* 23:61 (1983); see also Levy et al., *Science* 228:190 (1985); During et al., *Ann. Neurol.* 25:351 (1989); Howard et al., *J. Neurosurg.* 71:105 (1989)). In yet another embodiment, a controlled release system can be placed in proximity of the therapeutic target, i.e., the brain, thus requiring only a fraction of the systemic dose 15 (see, e.g., Goodson, in *Medical Applications of Controlled Release*, *supra*, vol. 2, pp. 115-138 (1984)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

In a specific embodiment where the compound of the invention is a nucleic 20 acid encoding a protein, the nucleic acid can be administered *in vivo* to promote expression of its encoded protein, by constructing it as part of an appropriate nucleic acid expression vector and administering it so that it becomes intracellular, e.g., by use of a retroviral vector (see U.S. Patent No. 4,980,286), or by direct injection, or by use of microparticle bombardment (e.g., a gene gun; Biolistic, Dupont), or coating 25 with lipids or cell-surface receptors or transfecting agents, or by administering it in linkage to a homeobox- like peptide which is known to enter the nucleus (see e.g.,

Joliot et al., Proc. Natl. Acad. Sci. USA 88:1864-1868 (1991)), etc. Alternatively, a nucleic acid can be introduced intracellularly and incorporated within host cell DNA for expression, by homologous recombination.

The present invention also provides pharmaceutical compositions. Such compositions comprise a therapeutically effective amount of a compound, and a pharmaceutically acceptable carrier. In a specific embodiment, the term "pharmaceutically acceptable" means approved by a regulatory agency of the Federal or a state government or listed in the U.S. Pharmacopeia or other generally recognized pharmacopeia for use in animals, and more particularly in humans. The term "carrier" refers to a diluent, adjuvant, excipient, or vehicle with which the therapeutic is administered. Such pharmaceutical carriers can be sterile liquids, such as water and oils, including those of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil and the like. Water is a preferred carrier when the pharmaceutical composition is administered intravenously. Saline solutions and aqueous dextrose and glycerol solutions can also be employed as liquid carriers, particularly for injectable solutions. Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, dried skim milk, glycerol, propylene, glycol, water, ethanol and the like. The composition, if desired, can also contain minor amounts of wetting or emulsifying agents, or pH buffering agents. These compositions can take the form of solutions, suspensions, emulsion, tablets, pills, capsules, powders, sustained-release formulations and the like. The composition can be formulated as a suppository, with traditional binders and carriers such as triglycerides. Oral formulation can include standard carriers such as pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate, etc. Examples of suitable

pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences" by E.W. Martin. Such compositions will contain a therapeutically effective amount of the compound, preferably in purified form, together with a suitable amount of carrier so as to provide the form for proper administration to the patient. The formulation  
5 should suit the mode of administration.

In a preferred embodiment, the composition is formulated in accordance with routine procedures as a pharmaceutical composition adapted for intravenous administration to human beings. Typically, compositions for intravenous administration are solutions in sterile isotonic aqueous buffer. Where necessary, the  
10 composition may also include a solubilizing agent and a local anesthetic such as lignocaine to ease pain at the site of the injection. Generally, the ingredients are supplied either separately or mixed together in unit dosage form, for example, as a dry lyophilized powder or water free concentrate in a hermetically sealed container such as an ampoule or sachette indicating the quantity of active agent. Where the  
15 composition is to be administered by infusion, it can be dispensed with an infusion bottle containing sterile pharmaceutical grade water or saline. Where the composition is administered by injection, an ampoule of sterile water for injection or saline can be provided so that the ingredients may be mixed prior to administration.

The compounds of the invention can be formulated as neutral or salt forms.  
20 Pharmaceutically acceptable salts include those formed with anions such as those derived from hydrochloric, phosphoric, acetic, oxalic, tartaric acids, etc., and those formed with cations such as those derived from sodium, potassium, ammonium, calcium, ferric hydroxides, isopropylamine, triethylamine, 2-ethylamino ethanol, histidine, procaine, etc.

25 The amount of the compound of the invention which will be effective in the treatment, inhibition and prevention of a disease or disorder associated with aberrant



expression and/or activity of a polypeptide of the invention can be determined by standard clinical techniques. In addition, in vitro assays may optionally be employed to help identify optimal dosage ranges. The precise dose to be employed in the formulation will also depend on the route of administration, and the seriousness of the disease or disorder, and should be decided according to the judgment of the practitioner and each patient's circumstances. Effective doses may be extrapolated from dose-response curves derived from in vitro or animal model test systems.

For antibodies, the dosage administered to a patient is typically 0.1 mg/kg to 100 mg/kg of the patient's body weight. Preferably, the dosage administered to a patient is between 0.1 mg/kg and 20 mg/kg of the patient's body weight, more preferably 1 mg/kg to 10 mg/kg of the patient's body weight. Generally, human antibodies have a longer half-life within the human body than antibodies from other species due to the immune response to the foreign polypeptides. Thus, lower dosages of human antibodies and less frequent administration is often possible. Further, the dosage and frequency of administration of antibodies of the invention may be reduced by enhancing uptake and tissue penetration (e.g., into the brain) of the antibodies by modifications such as, for example, lipidation.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the pharmaceutical compositions of the invention. Optionally associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. Diagnosis and Imaging

Labeled antibodies, and derivatives and analogs thereof, which specifically bind to a polypeptide of interest can be used for diagnostic purposes to detect,

diagnose, or monitor diseases, disorders, and/or conditions associated with the aberrant expression and/or activity of a polypeptide of the invention. The invention provides for the detection of aberrant expression of a polypeptide of interest, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of aberrant expression.

The invention provides a diagnostic assay for diagnosing a disorder, comprising (a) assaying the expression of the polypeptide of interest in cells or body fluid of an individual using one or more antibodies specific to the polypeptide interest and (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a particular disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

Antibodies of the invention can be used to assay protein levels in a biological sample using classical immunohistological methods known to those of skill in the art (e.g., see Jalkanen, et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, et al., J. Cell Biol. 105:3087-3096 (1987)). Other antibody-based methods useful for detecting protein gene expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody

assay labels are known in the art and include enzyme labels, such as, glucose oxidase; radioisotopes, such as iodine (125I, 121I), carbon (14C), sulfur (35S), tritium (3H), indium (112In), and technetium (99Tc); luminescent labels, such as luminol; and fluorescent labels, such as fluorescein and rhodamine, and biotin.

5           One aspect of the invention is the detection and diagnosis of a disease or disorder associated with aberrant expression of a polypeptide of interest in an animal, preferably a mammal and most preferably a human. In one embodiment, diagnosis comprises: a) administering (for example, parenterally, subcutaneously, or intraperitoneally) to a subject an effective amount of a labeled molecule which  
10           specifically binds to the polypeptide of interest; b) waiting for a time interval following the administering for permitting the labeled molecule to preferentially concentrate at sites in the subject where the polypeptide is expressed (and for unbound labeled molecule to be cleared to background level); c) determining background level; and d) detecting the labeled molecule in the subject, such that  
15           detection of labeled molecule above the background level indicates that the subject has a particular disease or disorder associated with aberrant expression of the polypeptide of interest. Background level can be determined by various methods including, comparing the amount of labeled molecule detected to a standard value previously determined for a particular system.

20           It will be understood in the art that the size of the subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of 99mTc. The labeled antibody or antibody fragment will then preferentially  
25           accumulate at the location of cells which contain the specific protein. In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of

Radiolabeled Antibodies and Their Fragments.” (Chapter 13 in Tumor Imaging: The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds., Masson Publishing Inc. (1982).

Depending on several variables, including the type of label used and the mode  
5 of administration, the time interval following the administration for permitting the labeled molecule to preferentially concentrate at sites in the subject and for unbound labeled molecule to be cleared to background level is 6 to 48 hours or 6 to 24 hours or 6 to 12 hours. In another embodiment the time interval following administration is 5 to 20 days or 5 to 10 days.

10 In an embodiment, monitoring of the disease or disorder is carried out by repeating the method for diagnosing the disease or disease, for example, one month after initial diagnosis, six months after initial diagnosis, one year after initial diagnosis, etc.

Presence of the labeled molecule can be detected in the patient using methods  
15 known in the art for in vivo scanning. These methods depend upon the type of label used. Skilled artisans will be able to determine the appropriate method for detecting a particular label. Methods and devices that may be used in the diagnostic methods of the invention include, but are not limited to, computed tomography (CT), whole body scan such as position emission tomography (PET), magnetic resonance imaging  
20 (MRI), and sonography.

In a specific embodiment, the molecule is labeled with a radioisotope and is detected in the patient using a radiation responsive surgical instrument (Thurston et al., U.S. Patent No. 5,441,050). In another embodiment, the molecule is labeled with a fluorescent compound and is detected in the patient using a fluorescence responsive  
25 scanning instrument. In another embodiment, the molecule is labeled with a positron emitting metal and is detected in the patient using positron emission-tomography. In

yet another embodiment, the molecule is labeled with a paramagnetic label and is detected in a patient using magnetic resonance imaging (MRI).

### Kits

The present invention provides kits that can be used in the above methods. In one embodiment, a kit comprises an antibody of the invention, preferably a purified antibody, in one or more containers. In a specific embodiment, the kits of the present invention contain a substantially isolated polypeptide comprising an epitope which is specifically immunoreactive with an antibody included in the kit. Preferably, the kits of the present invention further comprise a control antibody which does not react with the polypeptide of interest. In another specific embodiment, the kits of the present invention contain a means for detecting the binding of an antibody to a polypeptide of interest (e.g., the antibody may be conjugated to a detectable substrate such as a fluorescent compound, an enzymatic substrate, a radioactive compound or a luminescent compound, or a second antibody which recognizes the first antibody may be conjugated to a detectable substrate).

In another specific embodiment of the present invention, the kit is a diagnostic kit for use in screening serum containing antibodies specific against proliferative and/or cancerous polynucleotides and polypeptides. Such a kit may include a control antibody that does not react with the polypeptide of interest. Such a kit may include a substantially isolated polypeptide antigen comprising an epitope which is specifically immunoreactive with at least one anti-polypeptide antigen antibody. Further, such a kit includes means for detecting the binding of said antibody to the antigen (e.g., the antibody may be conjugated to a fluorescent compound such as fluorescein or rhodamine which can be detected by flow cytometry). In specific embodiments, the kit may include a recombinantly produced or chemically synthesized polypeptide antigen. The polypeptide antigen of the kit may also be attached to a solid support.

In a more specific embodiment the detecting means of the above-described kit includes a solid support to which said polypeptide antigen is attached. Such a kit may also include a non-attached reporter-labeled anti-human antibody. In this embodiment, binding of the antibody to the polypeptide antigen can be detected by  
5 binding of the said reporter-labeled antibody.

In an additional embodiment, the invention includes a diagnostic kit for use in screening serum containing antigens of the polypeptide of the invention. The diagnostic kit includes a substantially isolated antibody specifically immunoreactive with polypeptide or polynucleotide antigens, and means for detecting the binding of  
10 the polynucleotide or polypeptide antigen to the antibody. In one embodiment, the antibody is attached to a solid support. In a specific embodiment, the antibody may be a monoclonal antibody. The detecting means of the kit may include a second, labeled monoclonal antibody. Alternatively, or in addition, the detecting means may include a labeled, competing antigen.

15 In one diagnostic configuration, test serum is reacted with a solid phase reagent having a surface-bound antigen obtained by the methods of the present invention. After binding with specific antigen antibody to the reagent and removing unbound serum components by washing, the reagent is reacted with reporter-labeled anti-human antibody to bind reporter to the reagent in proportion to the amount of  
20 bound anti-antigen antibody on the solid support. The reagent is again washed to remove unbound labeled antibody, and the amount of reporter associated with the reagent is determined. Typically, the reporter is an enzyme which is detected by incubating the solid phase in the presence of a suitable fluorometric, luminescent or colorimetric substrate (Sigma, St. Louis, MO).

25 The solid surface reagent in the above assay is prepared by known techniques for attaching protein material to solid support material, such as polymeric beads, dip

sticks, 96-well plate or filter material. These attachment methods generally include non-specific adsorption of the protein to the support or covalent attachment of the protein, typically through a free amine group, to a chemically reactive group on the solid support, such as an activated carboxyl, hydroxyl, or aldehyde group.

- 5 Alternatively, streptavidin coated plates can be used in conjunction with biotinylated antigen(s).

Thus, the invention provides an assay system or kit for carrying out this diagnostic method. The kit generally includes a support with surface-bound recombinant antigens, and a reporter-labeled anti-human antibody for detecting  
10 surface-bound anti-antigen antibody.

### **Fusion Proteins**

Any polypeptide of the present invention can be used to generate fusion proteins. For example, the polypeptide of the present invention, when fused to a  
15 second protein, can be used as an antigenic tag. Antibodies raised against the polypeptide of the present invention can be used to indirectly detect the second protein by binding to the polypeptide. Moreover, because secreted proteins target cellular locations based on trafficking signals, the polypeptides of the present invention can be used as targeting molecules once fused to other proteins.

20 Examples of domains that can be fused to polypeptides of the present invention include not only heterologous signal sequences, but also other heterologous functional regions. The fusion does not necessarily need to be direct, but may occur through linker sequences.

Moreover, fusion proteins may also be engineered to improve characteristics  
25 of the polypeptide of the present invention. For instance, a region of additional amino acids, particularly charged amino acids, may be added to the N-terminus of the

polypeptide to improve stability and persistence during purification from the host cell or subsequent handling and storage. Also, peptide moieties may be added to the polypeptide to facilitate purification. Such regions may be removed prior to final preparation of the polypeptide. The addition of peptide moieties to facilitate handling  
5 of polypeptides are familiar and routine techniques in the art.

Moreover, polypeptides of the present invention, including fragments, and specifically epitopes, can be combined with parts of the constant domain of immunoglobulins (IgA, IgE, IgG, IgM) or portions thereof (CH1, CH2, CH3, and any combination thereof, including both entire domains and portions thereof), resulting in  
10 chimeric polypeptides. These fusion proteins facilitate purification and show an increased half-life in vivo. One reported example describes chimeric proteins consisting of the first two domains of the human CD4-polypeptide and various domains of the constant regions of the heavy or light chains of mammalian immunoglobulins. (EP A 394,827; Traunecker et al., Nature 331:84-86 (1988).)  
15 Fusion proteins having disulfide-linked dimeric structures (due to the IgG) can also be more efficient in binding and neutralizing other molecules, than the monomeric secreted protein or protein fragment alone. (Fountoulakis et al., J. Biochem. 270:3958-3964 (1995).)

Similarly, EP-A-O 464 533 (Canadian counterpart 2045869) discloses fusion  
20 proteins comprising various portions of constant region of immunoglobulin molecules together with another human protein or part thereof. In many cases, the Fc part in a fusion protein is beneficial in therapy and diagnosis, and thus can result in, for example, improved pharmacokinetic properties. (EP-A 0232 262.) Alternatively, deleting the Fc part after the fusion protein has been expressed, detected, and purified,  
25 would be desired. For example, the Fc portion may hinder therapy and diagnosis if the fusion protein is used as an antigen for immunizations. In drug discovery, for



example, human proteins, such as hIL-5, have been fused with Fc portions for the purpose of high-throughput screening assays to identify antagonists of hIL-5. (See, D. Bennett et al., J. Molecular Recognition 8:52-58 (1995); K. Johanson et al., J. Biol. Chem. 270:9459-9471 (1995).)

- 5           Moreover, the polypeptides of the present invention can be fused to marker sequences, such as a peptide which facilitates purification of the fused polypeptide. In preferred embodiments, the marker amino acid sequence is a hexa-histidine peptide, such as the tag provided in a pQE vector (QIAGEN, Inc., 9259 Eton Avenue, Chatsworth, CA, 91311), among others, many of which are commercially available.
- 10          As described in Gentz et al., Proc. Natl. Acad. Sci. USA 86:821-824 (1989), for instance, hexa-histidine provides for convenient purification of the fusion protein. Another peptide tag useful for purification, the "HA" tag, corresponds to an epitope derived from the influenza hemagglutinin protein. (Wilson et al., Cell 37:767 (1984).)
- 15          Thus, any of these above fusions can be engineered using the polynucleotides or the polypeptides of the present invention.

#### **Vectors, Host Cells, and Protein Production**

- 20          The present invention also relates to vectors containing the polynucleotide of the present invention, host cells, and the production of polypeptides by recombinant techniques. The vector may be, for example, a phage, plasmid, viral, or retroviral vector. Retroviral vectors may be replication competent or replication defective. In the latter case, viral propagation generally will occur only in complementing host cells.
- 25          The polynucleotides may be joined to a vector containing a selectable marker for propagation in a host. Generally, a plasmid vector is introduced in a precipitate,

such as a calcium phosphate precipitate, or in a complex with a charged lipid. If the vector is a virus, it may be packaged in vitro using an appropriate packaging cell line and then transduced into host cells.

The polynucleotide insert should be operatively linked to an appropriate  
5 promoter, such as the phage lambda PL promoter, the E. coli lac, trp, phoA and tac promoters, the SV40 early and late promoters and promoters of retroviral LTRs, to name a few. Other suitable promoters will be known to the skilled artisan. The expression constructs will further contain sites for transcription initiation, termination, and, in the transcribed region, a ribosome binding site for translation. The coding  
10 portion of the transcripts expressed by the constructs will preferably include a translation initiating codon at the beginning and a termination codon (UAA, UGA or UAG) appropriately positioned at the end of the polypeptide to be translated.

As indicated, the expression vectors will preferably include at least one selectable marker. Such markers include dihydrofolate reductase, G418 or neomycin  
15 resistance for eukaryotic cell culture and tetracycline, kanamycin or ampicillin resistance genes for culturing in E. coli and other bacteria. Representative examples of appropriate hosts include, but are not limited to, bacterial cells, such as E. coli, Streptomyces and Salmonella typhimurium cells; fungal cells, such as yeast cells (e.g., Saccharomyces cerevisiae or Pichia pastoris (ATCC Accession No. 201178));  
20 insect cells such as Drosophila S2 and Spodoptera Sf9 cells; animal cells such as CHO, COS, 293, and Bowes melanoma cells; and plant cells. Appropriate culture mediums and conditions for the above-described host cells are known in the art.

Among vectors preferred for use in bacteria include pQE70, pQE60 and pQE-  
9, available from QIAGEN, Inc.; pBluescript vectors, Phagescript vectors, pNH8A,  
25 pNH16a, pNH18A, pNH46A, available from Stratagene Cloning Systems, Inc.; and ptrc99a, pKK223-3, pKK233-3, pDR540, pRIT5 available from Pharmacia Biotech,

Inc. Among preferred eukaryotic vectors are pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; and pSVK3, pBPV, pMSG and pSVL available from Pharmacia. Preferred expression vectors for use in yeast systems include, but are not limited to pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalph, 5 pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, pPIC9K, and PAO815 (all available from Invitrogen, Carlsbad, CA). Other suitable vectors will be readily apparent to the skilled artisan.

Introduction of the construct into the host cell can be effected by calcium phosphate transfection, DEAE-dextran mediated transfection, cationic lipid-mediated 10 transfection, electroporation, transduction, infection, or other methods. Such methods are described in many standard laboratory manuals, such as Davis et al., Basic Methods In Molecular Biology (1986). It is specifically contemplated that the polypeptides of the present invention may in fact be expressed by a host cell lacking a recombinant vector.

15 A polypeptide of this invention can be recovered and purified from recombinant cell cultures by well-known methods including ammonium sulfate or ethanol precipitation, acid extraction, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography, hydroxylapatite chromatography and lectin chromatography. Most 20 preferably, high performance liquid chromatography ("HPLC") is employed for purification.

Polypeptides of the present invention, and preferably the secreted form, can also be recovered from: products purified from natural sources, including bodily fluids, tissues and cells, whether directly isolated or cultured; products of chemical 25 synthetic procedures; and products produced by recombinant techniques from a prokaryotic or eukaryotic host, including, for example, bacterial, yeast, higher plant,

insect, and mammalian cells. Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. In addition, polypeptides of the invention may also include an initial modified methionine residue, in some cases as a result of host-mediated processes. Thus, it is well known in the art that the N-terminal methionine encoded by the translation initiation codon generally is removed with high efficiency from any protein after translation in all eukaryotic cells. While the N-terminal methionine on most proteins also is efficiently removed in most prokaryotes, for some proteins, this prokaryotic removal process is inefficient, depending on the nature of the amino acid to which the N-terminal methionine is covalently linked.

In one embodiment, the yeast *Pichia pastoris* is used to express the polypeptide of the present invention in a eukaryotic system. *Pichia pastoris* is a methylotrophic yeast which can metabolize methanol as its sole carbon source. A main step in the methanol metabolism pathway is the oxidation of methanol to formaldehyde using O<sub>2</sub>. This reaction is catalyzed by the enzyme alcohol oxidase. In order to metabolize methanol as its sole carbon source, *Pichia pastoris* must generate high levels of alcohol oxidase due, in part, to the relatively low affinity of alcohol oxidase for O<sub>2</sub>. Consequently, in a growth medium depending on methanol as a main carbon source, the promoter region of one of the two alcohol oxidase genes (*AOX1*) is highly active. In the presence of methanol, alcohol oxidase produced from the *AOX1* gene comprises up to approximately 30% of the total soluble protein in *Pichia pastoris*. See, Ellis, S.B., *et al.*, *Mol. Cell. Biol.* 5:1111-21 (1985); Koutz, P.J., *et al.*, *Yeast* 5:167-77 (1989); Tschopp, J.F., *et al.*, *Nucl. Acids Res.* 15:3859-76 (1987). Thus, a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, under the transcriptional regulation of all or part of the *AOX1*

regulatory sequence is expressed at exceptionally high levels in *Pichia* yeast grown in the presence of methanol.

In one example, the plasmid vector pPIC9K is used to express DNA encoding a polypeptide of the invention, as set forth herein, in a *Pichea* yeast system essentially  
5 as described in "*Pichia* Protocols: Methods in Molecular Biology," D.R. Higgins and J. Cregg, eds. The Humana Press, Totowa, NJ, 1998. This expression vector allows expression and secretion of a protein of the invention by virtue of the strong *AOXI* promoter linked to the *Pichia pastoris* alkaline phosphatase (PHO) secretory signal peptide (i.e., leader) located upstream of a multiple cloning site.

10 Many other yeast vectors could be used in place of pPIC9K, such as, pYES2, pYD1, pTEF1/Zeo, pYES2/GS, pPICZ, pGAPZ, pGAPZalpha, pPIC9, pPIC3.5, pHIL-D2, pHIL-S1, pPIC3.5K, and PAO815, as one skilled in the art would readily appreciate, as long as the proposed expression construct provides appropriately located signals for transcription, translation, secretion (if desired), and the like,  
15 including an in-frame AUG as required.

In another embodiment, high-level expression of a heterologous coding sequence, such as, for example, a polynucleotide of the present invention, may be achieved by cloning the heterologous polynucleotide of the invention into an expression vector such as, for example, pGAPZ or pGAPZalpha, and growing the  
20 yeast culture in the absence of methanol.

In addition to encompassing host cells containing the vector constructs discussed herein, the invention also encompasses primary, secondary, and immortalized host cells of vertebrate origin, particularly mammalian origin, that have been engineered to delete or replace endogenous genetic material (e.g., coding  
25 sequence), and/or to include genetic material (e.g., heterologous polynucleotide

sequences) that is operably associated with the polynucleotides of the invention, and which activates, alters, and/or amplifies endogenous polynucleotides. For example, techniques known in the art may be used to operably associate heterologous control regions (e.g., promoter and/or enhancer) and endogenous polynucleotide sequences via homologous recombination, resulting in the formation of a new transcription unit (see, e.g., U.S. Patent No. 5,641,670, issued June 24, 1997; U.S. Patent No. 5,733,761, issued March 31, 1998; International Publication No. WO 96/29411, published September 26, 1996; International Publication No. WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA 86:8932-8935 (1989); and Zijlstra et al., Nature 342:435-438 (1989), the disclosures of each of which are incorporated by reference in their entireties).

In addition, polypeptides of the invention can be chemically synthesized using techniques known in the art (e.g., see Creighton, 1983, *Proteins: Structures and Molecular Principles*, W.H. Freeman & Co., N.Y., and Hunkapiller et al., *Nature*, 310:105-111 (1984)). For example, a polypeptide corresponding to a fragment of a polypeptide sequence of the invention can be synthesized by use of a peptide synthesizer. Furthermore, if desired, nonclassical amino acids or chemical amino acid analogs can be introduced as a substitution or addition into the polypeptide sequence. Non-classical amino acids include, but are not limited to, to the D-isomers of the common amino acids, 2,4-diaminobutyric acid,  $\alpha$ -amino isobutyric acid, 4-aminobutyric acid, Abu, 2-amino butyric acid,  $\gamma$ -Abu,  $\epsilon$ -Ahx, 6-amino hexanoic acid, Aib, 2-amino isobutyric acid, 3-amino propionic acid, ornithine, norleucine, norvaline, hydroxyproline, sarcosine, citrulline, homocitrulline, cysteic acid, t-butylglycine, t-butylalanine, phenylglycine, cyclohexylalanine,  $\beta$ -alanine, fluoro-amino acids, designer amino acids such as  $\beta$ -methyl amino acids,  $\gamma$ -methyl amino

acids, Na-methyl amino acids, and amino acid analogs in general. Furthermore, the amino acid can be D (dextrorotary) or L (levorotary).

The invention encompasses polypeptides which are differentially modified during or after translation, *e.g.*, by glycosylation, acetylation, phosphorylation, amidation, derivatization by known protecting/blocking groups, proteolytic cleavage, linkage to an antibody molecule or other cellular ligand, etc. Any of numerous chemical modifications may be carried out by known techniques, including but not limited, to specific chemical cleavage by cyanogen bromide, trypsin, chymotrypsin, papain, V8 protease, NaBH<sub>4</sub>; acetylation, formylation, oxidation, reduction; metabolic synthesis in the presence of tunicamycin; etc.

Additional post-translational modifications encompassed by the invention include, for example, *e.g.*, N-linked or O-linked carbohydrate chains, processing of N-terminal or C-terminal ends), attachment of chemical moieties to the amino acid backbone, chemical modifications of N-linked or O-linked carbohydrate chains, and addition or deletion of an N-terminal methionine residue as a result of procaryotic host cell expression. The polypeptides may also be modified with a detectable label, such as an enzymatic, fluorescent, isotopic or affinity label to allow for detection and isolation of the protein.

Also provided by the invention are chemically modified derivatives of the polypeptides of the invention which may provide additional advantages such as increased solubility, stability and circulating time of the polypeptide, or decreased immunogenicity (see U.S. Patent NO: 4,179,337). The chemical moieties for derivitization may be selected from water soluble polymers such as polyethylene glycol, ethylene glycol/propylene glycol copolymers, carboxymethylcellulose, dextran, polyvinyl alcohol and the like. The polypeptides may be modified at random

positions within the molecule, or at predetermined positions within the molecule and may include one, two, three or more attached chemical moieties.

The polymer may be of any molecular weight, and may be branched or unbranched. For polyethylene glycol, the preferred molecular weight is between  
5 about 1 kDa and about 100 kDa (the term "about" indicating that in preparations of polyethylene glycol, some molecules will weigh more, some less, than the stated molecular weight) for ease in handling and manufacturing. Other sizes may be used, depending on the desired therapeutic profile (e.g., the duration of sustained release desired, the effects, if any on biological activity, the ease in handling, the degree or  
10 lack of antigenicity and other known effects of the polyethylene glycol to a therapeutic protein or analog).

The polyethylene glycol molecules (or other chemical moieties) should be attached to the protein with consideration of effects on functional or antigenic domains of the protein. There are a number of attachment methods available to those  
15 skilled in the art, e.g., EP 0 401 384, herein incorporated by reference (coupling PEG to G-CSF), see also Malik et al., Exp. Hematol. 20:1028-1035 (1992) (reporting pegylation of GM-CSF using tresyl chloride). For example, polyethylene glycol may be covalently bound through amino acid residues via a reactive group, such as, a free amino or carboxyl group. Reactive groups are those to which an activated  
20 polyethylene glycol molecule may be bound. The amino acid residues having a free amino group may include lysine residues and the N-terminal amino acid residues; those having a free carboxyl group may include aspartic acid residues glutamic acid residues and the C-terminal amino acid residue. Sulfhydryl groups may also be used as a reactive group for attaching the polyethylene glycol molecules. Preferred for  
25 therapeutic purposes is attachment at an amino group, such as attachment at the N-terminus or lysine group.



One may specifically desire proteins chemically modified at the N-terminus. Using polyethylene glycol as an illustration of the present composition, one may select from a variety of polyethylene glycol molecules (by molecular weight, branching, etc.), the proportion of polyethylene glycol molecules to protein (polypeptide) molecules in the reaction mix, the type of pegylation reaction to be performed, and the method of obtaining the selected N-terminally pegylated protein. The method of obtaining the N-terminally pegylated preparation (i.e., separating this moiety from other monopegylated moieties if necessary) may be by purification of the N-terminally pegylated material from a population of pegylated protein molecules.

10 Selective proteins chemically modified at the N-terminus modification may be accomplished by reductive alkylation which exploits differential reactivity of different types of primary amino groups (lysine versus the N-terminal) available for derivatization in a particular protein. Under the appropriate reaction conditions, substantially selective derivatization of the protein at the N-terminus with a carbonyl

15 group containing polymer is achieved.

The polypeptides of the invention may be in monomers or multimers (i.e., dimers, trimers, tetramers and higher multimers). Accordingly, the present invention relates to monomers and multimers of the polypeptides of the invention, their preparation, and compositions (preferably, *Therapeutics*) containing them. In specific

20 embodiments, the polypeptides of the invention are monomers, dimers, trimers or tetramers. In additional embodiments, the multimers of the invention are at least dimers, at least trimers, or at least tetramers.

Multimers encompassed by the invention may be homomers or heteromers. As used herein, the term homomer, refers to a multimer containing only polypeptides

25 corresponding to the amino acid sequence of SEQ ID NO:Y or encoded by the cDNA contained in a deposited clone (including fragments, variants, splice variants, and

fusion proteins, corresponding to these polypeptides as described herein). These homomers may contain polypeptides having identical or different amino acid sequences. In a specific embodiment, a homomer of the invention is a multimer containing only polypeptides having an identical amino acid sequence. In another specific embodiment, a homomer of the invention is a multimer containing polypeptides having different amino acid sequences. In specific embodiments, the multimer of the invention is a homodimer (*e.g.*, containing polypeptides having identical or different amino acid sequences) or a homotrimer (*e.g.*, containing polypeptides having identical and/or different amino acid sequences). In additional embodiments, the homomeric multimer of the invention is at least a homodimer, at least a homotrimer, or at least a homotetramer.

As used herein, the term heteromer refers to a multimer containing one or more heterologous polypeptides (*i.e.*, polypeptides of different proteins) in addition to the polypeptides of the invention. In a specific embodiment, the multimer of the invention is a heterodimer, a heterotrimer, or a heterotetramer. In additional embodiments, the heteromeric multimer of the invention is at least a heterodimer, at least a heterotrimer, or at least a heterotetramer.

Multimers of the invention may be the result of hydrophobic, hydrophilic, ionic and/or covalent associations and/or may be indirectly linked, by for example, liposome formation. Thus, in one embodiment, multimers of the invention, such as, for example, homodimers or homotrimers, are formed when polypeptides of the invention contact one another in solution. In another embodiment, heteromultimers of the invention, such as, for example, heterotrimers or heterotetramers, are formed when polypeptides of the invention contact antibodies to the polypeptides of the invention (including antibodies to the heterologous polypeptide sequence in a fusion protein of the invention) in solution. In other embodiments, multimers of the

invention are formed by covalent associations with and/or between the polypeptides of the invention. Such covalent associations may involve one or more amino acid residues contained in the polypeptide sequence ( e.g., that recited in the sequence listing, or contained in the polypeptide encoded by a deposited clone). In one  
5 instance, the covalent associations are cross-linking between cysteine residues located within the polypeptide sequences which interact in the native (i.e., naturally occurring) polypeptide. In another instance, the covalent associations are the consequence of chemical or recombinant manipulation. Alternatively, such covalent associations may involve one or more amino acid residues contained in the  
10 heterologous polypeptide sequence in a fusion protein of the invention.

In one example, covalent associations are between the heterologous sequence contained in a fusion protein of the invention (see, e.g., US Patent Number 5,478,925). In a specific example, the covalent associations are between the heterologous sequence contained in an Fc fusion protein of the invention (as  
15 described herein). In another specific example, covalent associations of fusion proteins of the invention are between heterologous polypeptide sequence from another protein that is capable of forming covalently associated multimers, such as for example, osteoprotegerin (see, e.g., International Publication NO: WO 98/49305, the contents of which are herein incorporated by reference in its entirety). In another  
20 embodiment, two or more polypeptides of the invention are joined through peptide linkers. Examples include those peptide linkers described in U.S. Pat. No. 5,073,627 (hereby incorporated by reference). Proteins comprising multiple polypeptides of the invention separated by peptide linkers may be produced using conventional recombinant DNA technology.

25 Another method for preparing multimer polypeptides of the invention involves use of polypeptides of the invention fused to a leucine zipper or isoleucine zipper

polypeptide sequence. Leucine zipper and isoleucine zipper domains are polypeptides that promote multimerization of the proteins in which they are found. Leucine zippers were originally identified in several DNA-binding proteins (Landschulz et al., Science 240:1759, (1988)), and have since been found in a variety of different

5 proteins. Among the known leucine zippers are naturally occurring peptides and derivatives thereof that dimerize or trimerize. Examples of leucine zipper domains suitable for producing soluble multimeric proteins of the invention are those described in PCT application WO 94/10308, hereby incorporated by reference. Recombinant fusion proteins comprising a polypeptide of the invention fused to a polypeptide

10 sequence that dimerizes or trimerizes in solution are expressed in suitable host cells, and the resulting soluble multimeric fusion protein is recovered from the culture supernatant using techniques known in the art.

Trimeric polypeptides of the invention may offer the advantage of enhanced biological activity. Preferred leucine zipper moieties and isoleucine moieties are

15 those that preferentially form trimers. One example is a leucine zipper derived from lung surfactant protein D (SPD), as described in Hoppe et al. (FEBS Letters 344:191, (1994)) and in U.S. patent application Ser. No. 08/446,922, hereby incorporated by reference. Other peptides derived from naturally occurring trimeric proteins may be employed in preparing trimeric polypeptides of the invention.

20 In another example, proteins of the invention are associated by interactions between Flag® polypeptide sequence contained in fusion proteins of the invention containing Flag® polypeptide sequence. In a further embodiment, associations proteins of the invention are associated by interactions between heterologous polypeptide sequence contained in Flag® fusion proteins of the invention and anti-

25 Flag® antibody.

The multimers of the invention may be generated using chemical techniques known in the art. For example, polypeptides desired to be contained in the multimers of the invention may be chemically cross-linked using linker molecules and linker molecule length optimization techniques known in the art (see, e.g., US Patent  
5 Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally, multimers of the invention may be generated using techniques known in the art to form one or more inter-molecule cross-links between the cysteine residues located within the sequence of the polypeptides desired to be contained in the multimer (see, e.g., US Patent Number 5,478,925, which is herein incorporated by  
10 reference in its entirety). Further, polypeptides of the invention may be routinely modified by the addition of cysteine or biotin to the C terminus or N-terminus of the polypeptide and techniques known in the art may be applied to generate multimers containing one or more of these modified polypeptides (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). Additionally,  
15 techniques known in the art may be applied to generate liposomes containing the polypeptide components desired to be contained in the multimer of the invention (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

Alternatively, multimers of the invention may be generated using genetic  
20 engineering techniques known in the art. In one embodiment, polypeptides contained in multimers of the invention are produced recombinantly using fusion protein technology described herein or otherwise known in the art (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In a specific embodiment, polynucleotides coding for a homodimer of the invention are  
25 generated by ligating a polynucleotide sequence encoding a polypeptide of the invention to a sequence encoding a linker polypeptide and then further to a synthetic

polynucleotide encoding the translated product of the polypeptide in the reverse orientation from the original C-terminus to the N-terminus (lacking the leader sequence) (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety). In another embodiment, recombinant techniques described  
5 herein or otherwise known in the art are applied to generate recombinant polypeptides of the invention which contain a transmembrane domain (or hydrophobic or signal peptide) and which can be incorporated by membrane reconstitution techniques into liposomes (see, e.g., US Patent Number 5,478,925, which is herein incorporated by reference in its entirety).

10

#### **Uses of the Polynucleotides**

Each of the polynucleotides identified herein can be used in numerous ways as reagents. The following description should be considered exemplary and utilizes known techniques.

15

The polynucleotides of the present invention are useful for chromosome identification. There exists an ongoing need to identify new chromosome markers, since few chromosome marking reagents, based on actual sequence data (repeat polymorphisms), are presently available. Each polynucleotide of the present invention can be used as a chromosome marker.

20

Briefly, sequences can be mapped to chromosomes by preparing PCR primers (preferably 15-25 bp) from the sequences shown in SEQ ID NO:X. Primers can be selected using computer analysis so that primers do not span more than one predicted exon in the genomic DNA. These primers are then used for PCR screening of somatic cell hybrids containing individual human chromosomes. Only those hybrids  
25 containing the human gene corresponding to the SEQ ID NO:X will yield an amplified fragment.

Similarly, somatic hybrids provide a rapid method of PCR mapping the polynucleotides to particular chromosomes. Three or more clones can be assigned per day using a single thermal cycler. Moreover, sublocalization of the polynucleotides can be achieved with panels of specific chromosome fragments. Other gene mapping strategies that can be used include in situ hybridization, prescreening with labeled flow-sorted chromosomes, and preselection by hybridization to construct chromosome specific-cDNA libraries.

Precise chromosomal location of the polynucleotides can also be achieved using fluorescence in situ hybridization (FISH) of a metaphase chromosomal spread. This technique uses polynucleotides as short as 500 or 600 bases; however, polynucleotides 2,000-4,000 bp are preferred. For a review of this technique, see Verma et al., "Human Chromosomes: a Manual of Basic Techniques," Pergamon Press, New York (1988).

For chromosome mapping, the polynucleotides can be used individually (to mark a single chromosome or a single site on that chromosome) or in panels (for marking multiple sites and/or multiple chromosomes). Preferred polynucleotides correspond to the noncoding regions of the cDNAs because the coding sequences are more likely conserved within gene families, thus increasing the chance of cross hybridization during chromosomal mapping.

Once a polynucleotide has been mapped to a precise chromosomal location, the physical position of the polynucleotide can be used in linkage analysis. Linkage analysis establishes coinheritance between a chromosomal location and presentation of a particular disease. (Disease mapping data are found, for example, in V. McKusick, Mendelian Inheritance in Man (available on line through Johns Hopkins University Welch Medical Library) .) Assuming 1 megabase mapping resolution and

one gene per 20 kb, a cDNA precisely localized to a chromosomal region associated with the disease could be one of 50-500 potential causative genes.

Thus, once coinheritance is established, differences in the polynucleotide and the corresponding gene between affected and unaffected individuals can be examined.

5 First, visible structural alterations in the chromosomes, such as deletions or translocations, are examined in chromosome spreads or by PCR. If no structural alterations exist, the presence of point mutations are ascertained. Mutations observed in some or all affected individuals, but not in normal individuals, indicates that the mutation may cause the disease. However, complete sequencing of the polypeptide  
10 and the corresponding gene from several normal individuals is required to distinguish the mutation from a polymorphism. If a new polymorphism is identified, this polymorphic polypeptide can be used for further linkage analysis.

Furthermore, increased or decreased expression of the gene in affected individuals as compared to unaffected individuals can be assessed using  
15 polynucleotides of the present invention. Any of these alterations (altered expression, chromosomal rearrangement, or mutation) can be used as a diagnostic or prognostic marker.

Thus, the invention also provides a diagnostic method useful during diagnosis of a disorder, involving measuring the expression level of polynucleotides of the present invention in cells or body fluid from an individual and comparing the  
20 measured gene expression level with a standard level of polynucleotide expression level, whereby an increase or decrease in the gene expression level compared to the standard is indicative of a disorder.

In still another embodiment, the invention includes a kit for analyzing samples  
25 for the presence of proliferative and/or cancerous polynucleotides derived from a test subject. In a general embodiment, the kit includes at least one polynucleotide probe



containing a nucleotide sequence that will specifically hybridize with a polynucleotide of the present invention and a suitable container. In a specific embodiment, the kit includes two polynucleotide probes defining an internal region of the polynucleotide of the present invention, where each probe has one strand  
5 containing a 31' mer-end internal to the region. In a further embodiment, the probes may be useful as primers for polymerase chain reaction amplification.

Where a diagnosis of a disorder, has already been made according to conventional methods, the present invention is useful as a prognostic indicator, whereby patients exhibiting enhanced or depressed polynucleotide of the present  
10 invention expression will experience a worse clinical outcome relative to patients expressing the gene at a level nearer the standard level.

By "measuring the expression level of polynucleotide of the present invention" is intended qualitatively or quantitatively measuring or estimating the level of the polypeptide of the present invention or the level of the mRNA encoding the  
15 polypeptide in a first biological sample either directly (e.g., by determining or estimating absolute protein level or mRNA level) or relatively (e.g., by comparing to the polypeptide level or mRNA level in a second biological sample). Preferably, the polypeptide level or mRNA level in the first biological sample is measured or estimated and compared to a standard polypeptide level or mRNA level, the standard  
20 being taken from a second biological sample obtained from an individual not having the disorder or being determined by averaging levels from a population of individuals not having a disorder. As will be appreciated in the art, once a standard polypeptide level or mRNA level is known, it can be used repeatedly as a standard for comparison.

25 By "biological sample" is intended any biological sample obtained from an individual, body fluid, cell line, tissue culture, or other source which contains the

polypeptide of the present invention or mRNA. As indicated, biological samples include body fluids (such as semen, lymph, sera, plasma, urine, synovial fluid and spinal fluid) which contain the polypeptide of the present invention, and other tissue sources found to express the polypeptide of the present invention. Methods for  
5 obtaining tissue biopsies and body fluids from mammals are well known in the art. Where the biological sample is to include mRNA, a tissue biopsy is the preferred source.

The method(s) provided above may preferably be applied in a diagnostic method and/or kits in which polynucleotides and/or polypeptides are attached to a  
10 solid support. In one exemplary method, the support may be a "gene chip" or a "biological chip" as described in US Patents 5,837,832, 5,874,219, and 5,856,174. Further, such a gene chip with polynucleotides of the present invention attached may be used to identify polymorphisms between the polynucleotide sequences, with polynucleotides isolated from a test subject. The knowledge of such polymorphisms  
15 (i.e. their location, as well as, their existence) would be beneficial in identifying disease loci for many disorders, including cancerous diseases and conditions. Such a method is described in US Patents 5,858,659 and 5,856,104. The US Patents referenced supra are hereby incorporated by reference in their entirety herein.

The present invention encompasses polynucleotides of the present invention  
20 that are chemically synthesized, or reproduced as peptide nucleic acids (PNA), or according to other methods known in the art. The use of PNAs would serve as the preferred form if the polynucleotides are incorporated onto a solid support, or gene chip. For the purposes of the present invention, a peptide nucleic acid (PNA) is a polyamide type of DNA analog and the monomeric units for adenine, guanine,  
25 thymine and cytosine are available commercially (Perceptive Biosystems). Certain components of DNA, such as phosphorus, phosphorus oxides, or deoxyribose

derivatives, are not present in PNAs. As disclosed by P. E. Nielsen, M. Egholm, R. H. Berg and O. Buchardt, *Science* 254, 1497 (1991); and M. Egholm, O. Buchardt, L.Christensen, C. Behrens, S. M. Freier, D. A. Driver, R. H. Berg, S. K. Kim, B. Norden, and P. E. Nielsen, *Nature* 365, 666 (1993), PNAs bind specifically and tightly to complementary DNA strands and are not degraded by nucleases. In fact, PNA binds more strongly to DNA than DNA itself does. This is probably because there is no electrostatic repulsion between the two strands, and also the polyamide backbone is more flexible. Because of this, PNA/DNA duplexes bind under a wider range of stringency conditions than DNA/DNA duplexes, making it easier to perform multiplex hybridization. Smaller probes can be used than with DNA due to the strong binding. In addition, it is more likely that single base mismatches can be determined with PNA/DNA hybridization because a single mismatch in a PNA/DNA 15-mer lowers the melting point ( $T_{sub.m}$ ) by 8°-20° C, vs. 4°-16° C for the DNA/DNA 15-mer duplex. Also, the absence of charge groups in PNA means that hybridization can be done at low ionic strengths and reduce possible interference by salt during the analysis.

The present invention is useful for detecting cancer in mammals. In particular the invention is useful during diagnosis of pathological cell proliferative neoplasias which include, but are not limited to: acute myelogenous leukemias including acute monocytic leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute myelomonocytic leukemia, acute erythroleukemia, acute megakaryocytic leukemia, and acute undifferentiated leukemia, etc.; and chronic myelogenous leukemias including chronic myelomonocytic leukemia, chronic granulocytic leukemia, etc. Preferred mammals include monkeys, apes, cats, dogs, cows, pigs, horses, rabbits and humans. Particularly preferred are humans.

Pathological cell proliferative diseases, disorders, and/or conditions are often associated with inappropriate activation of proto-oncogenes. (Germann, E. P. et al., "The Etiology of Acute Leukemia: Molecular Genetics and Viral Oncology," in Neoplastic Diseases of the Blood, Vol 1., Wiernik, P. H. et al. eds., 161-182 (1985)).

5 Neoplasias are now believed to result from the qualitative alteration of a normal cellular gene product, or from the quantitative modification of gene expression by insertion into the chromosome of a viral sequence, by chromosomal translocation of a gene to a more actively transcribed region, or by some other mechanism. (Germann et al., supra) It is likely that mutated or altered expression of specific genes is  
10 involved in the pathogenesis of some leukemias, among other tissues and cell types. (Germann et al., supra) Indeed, the human counterparts of the oncogenes involved in some animal neoplasias have been amplified or translocated in some cases of human leukemia and carcinoma. (Germann et al., supra)

For example, c-myc expression is highly amplified in the non-lymphocytic leukemia  
15 cell line HL-60. When HL-60 cells are chemically induced to stop proliferation, the level of c-myc is found to be downregulated. (International Publication Number WO 91/15580) However, it has been shown that exposure of HL-60 cells to a DNA construct that is complementary to the 5' end of c-myc or c-myb blocks translation of the corresponding mRNAs which downregulates expression of the c-myc or c-myb  
20 proteins and causes arrest of cell proliferation and differentiation of the treated cells. (International Publication Number WO 91/15580; Wickstrom et al., Proc. Natl. Acad. Sci. 85:1028 (1988); Anfossi et al., Proc. Natl. Acad. Sci. 86:3379 (1989)). However, the skilled artisan would appreciate the present invention's usefulness would not be limited to treatment of proliferative diseases, disorders, and/or conditions of  
25 hematopoietic cells and tissues, in light of the numerous cells and cell types of varying origins which are known to exhibit proliferative phenotypes.

In addition to the foregoing, a polynucleotide can be used to control gene expression through triple helix formation or antisense DNA or RNA. Antisense techniques are discussed, for example, in Okano, J. *Neurochem.* 56: 560 (1991); "Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance Lee et al., *Nucleic Acids Research* 6: 3073 (1979); Cooney et al., *Science* 241: 456 (1988); and Dervan et al., *Science* 251: 1360 (1991). Both methods rely on binding of the polynucleotide to a complementary DNA or RNA. For these techniques, preferred polynucleotides are usually oligonucleotides 20 to 40 bases in length and complementary to either the region of the gene involved in transcription (triple helix - see Lee et al., *Nucl. Acids Res.* 6:3073 (1979); Cooney et al., *Science* 241:456 (1988); and Dervan et al., *Science* 251:1360 (1991) ) or to the mRNA itself (antisense - Okano, J. *Neurochem.* 56:560 (1991); Oligodeoxy-nucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).) Triple helix formation optimally results in a shut-off of RNA transcription from DNA, while antisense RNA hybridization blocks translation of an mRNA molecule into polypeptide. Both techniques are effective in model systems, and the information disclosed herein can be used to design antisense or triple helix polynucleotides in an effort to treat or prevent disease.

Polynucleotides of the present invention are also useful in gene therapy. One goal of gene therapy is to insert a normal gene into an organism having a defective gene, in an effort to correct the genetic defect. The polynucleotides disclosed in the present invention offer a means of targeting such genetic defects in a highly accurate manner. Another goal is to insert a new gene that was not present in the host genome, thereby producing a new trait in the host cell.

The polynucleotides are also useful for identifying individuals from minute biological samples. The United States military, for example, is considering the use of restriction fragment length polymorphism (RFLP) for identification of its personnel. In this technique, an individual's genomic DNA is digested with one or more  
5 restriction enzymes, and probed on a Southern blot to yield unique bands for identifying personnel. This method does not suffer from the current limitations of "Dog Tags" which can be lost, switched, or stolen, making positive identification difficult. The polynucleotides of the present invention can be used as additional DNA markers for RFLP.

10 The polynucleotides of the present invention can also be used as an alternative to RFLP, by determining the actual base-by-base DNA sequence of selected portions of an individual's genome. These sequences can be used to prepare PCR primers for amplifying and isolating such selected DNA, which can then be sequenced. Using this technique, individuals can be identified because each individual will have a  
15 unique set of DNA sequences. Once an unique ID database is established for an individual, positive identification of that individual, living or dead, can be made from extremely small tissue samples.

Forensic biology also benefits from using DNA-based identification techniques as disclosed herein. DNA sequences taken from very small biological  
20 samples such as tissues, e.g., hair or skin, or body fluids, e.g., blood, saliva, semen, synovial fluid, amniotic fluid, breast milk, lymph, pulmonary sputum or surfactant, urine, fecal matter, etc., can be amplified using PCR. In one prior art technique, gene sequences amplified from polymorphic loci, such as DQa class II HLA gene, are used in forensic biology to identify individuals. (Erlich, H., PCR  
25 Technology, Freeman and Co. (1992).) Once these specific polymorphic loci are amplified, they are digested with one or more restriction enzymes, yielding an

identifying set of bands on a Southern blot probed with DNA corresponding to the DQa class II HLA gene. Similarly, polynucleotides of the present invention can be used as polymorphic markers for forensic purposes.

There is also a need for reagents capable of identifying the source of a particular tissue. Such need arises, for example, in forensics when presented with tissue of unknown origin. Appropriate reagents can comprise, for example, DNA probes or primers specific to particular tissue prepared from the sequences of the present invention. Panels of such reagents can identify tissue by species and/or by organ type. In a similar fashion, these reagents can be used to screen tissue cultures for contamination.

In the very least, the polynucleotides of the present invention can be used as molecular weight markers on Southern gels, as diagnostic probes for the presence of a specific mRNA in a particular cell type, as a probe to "subtract-out" known sequences in the process of discovering novel polynucleotides, for selecting and making oligomers for attachment to a "gene chip" or other support, to raise anti-DNA antibodies using DNA immunization techniques, and as an antigen to elicit an immune response.

#### Uses of the Polypeptides

Each of the polypeptides identified herein can be used in numerous ways. The following description should be considered exemplary and utilizes known techniques.

A polypeptide of the present invention can be used to assay protein levels in a biological sample using antibody-based techniques. For example, protein expression in tissues can be studied with classical immunohistological methods. (Jalkanen, M., et al., J. Cell. Biol. 101:976-985 (1985); Jalkanen, M., et al., J. Cell . Biol. 105:3087-3096 (1987).) Other antibody-based methods useful for detecting protein gene

expression include immunoassays, such as the enzyme linked immunosorbent assay (ELISA) and the radioimmunoassay (RIA). Suitable antibody assay labels are known in the art and include enzyme labels, such as, glucose oxidase, and radioisotopes, such as iodine ( $^{125}\text{I}$ ,  $^{121}\text{I}$ ), carbon ( $^{14}\text{C}$ ), sulfur ( $^{35}\text{S}$ ), tritium ( $^3\text{H}$ ), indium ( $^{112}\text{In}$ ), and  
5 technetium ( $^{99\text{m}}\text{Tc}$ ), and fluorescent labels, such as fluorescein and rhodamine, and biotin.

In addition to assaying secreted protein levels in a biological sample, proteins can also be detected in vivo by imaging. Antibody labels or markers for in vivo imaging of protein include those detectable by X-radiography, NMR or ESR. For X-  
10 radiography, suitable labels include radioisotopes such as barium or cesium, which emit detectable radiation but are not overtly harmful to the subject. Suitable markers for NMR and ESR include those with a detectable characteristic spin, such as deuterium, which may be incorporated into the antibody by labeling of nutrients for the relevant hybridoma.

15 A protein-specific antibody or antibody fragment which has been labeled with an appropriate detectable imaging moiety, such as a radioisotope (for example,  $^{131}\text{I}$ ,  $^{112}\text{In}$ ,  $^{99\text{m}}\text{Tc}$ ), a radio-opaque substance, or a material detectable by nuclear magnetic resonance, is introduced (for example, parenterally, subcutaneously, or intraperitoneally) into the mammal. It will be understood in the art that the size of the  
20 subject and the imaging system used will determine the quantity of imaging moiety needed to produce diagnostic images. In the case of a radioisotope moiety, for a human subject, the quantity of radioactivity injected will normally range from about 5 to 20 millicuries of  $^{99\text{m}}\text{Tc}$ . The labeled antibody or antibody fragment will then preferentially accumulate at the location of cells which contain the specific protein.  
25 In vivo tumor imaging is described in S.W. Burchiel et al., "Immunopharmacokinetics of Radiolabeled Antibodies and Their Fragments." (Chapter 13 in Tumor Imaging:



The Radiochemical Detection of Cancer, S.W. Burchiel and B. A. Rhodes, eds.,  
Masson Publishing Inc. (1982).)

Thus, the invention provides a diagnostic method of a disorder, which involves (a) assaying the expression of a polypeptide of the present invention in cells  
5 or body fluid of an individual; (b) comparing the level of gene expression with a standard gene expression level, whereby an increase or decrease in the assayed polypeptide gene expression level compared to the standard expression level is indicative of a disorder. With respect to cancer, the presence of a relatively high amount of transcript in biopsied tissue from an individual may indicate a  
10 predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

15 Moreover, polypeptides of the present invention can be used to treat, prevent, and/or diagnose disease. For example, patients can be administered a polypeptide of the present invention in an effort to replace absent or decreased levels of the polypeptide (e.g., insulin), to supplement absent or decreased levels of a different polypeptide (e.g., hemoglobin S for hemoglobin B, SOD, catalase, DNA repair  
20 proteins), to inhibit the activity of a polypeptide (e.g., an oncogene or tumor suppressor), to activate the activity of a polypeptide (e.g., by binding to a receptor), to reduce the activity of a membrane bound receptor by competing with it for free ligand (e.g., soluble TNF receptors used in reducing inflammation), or to bring about a desired response (e.g., blood vessel growth inhibition, enhancement of the immune  
25 response to proliferative cells or tissues).

Similarly, antibodies directed to a polypeptide of the present invention can also be used to treat, prevent, and/or diagnose disease. For example, administration of an antibody directed to a polypeptide of the present invention can bind and reduce overproduction of the polypeptide. Similarly, administration of an antibody can  
5 activate the polypeptide, such as by binding to a polypeptide bound to a membrane (receptor).

At the very least, the polypeptides of the present invention can be used as molecular weight markers on SDS-PAGE gels or on molecular sieve gel filtration columns using methods well known to those of skill in the art. Polypeptides can also  
10 be used to raise antibodies, which in turn are used to measure protein expression from a recombinant cell, as a way of assessing transformation of the host cell. Moreover, the polypeptides of the present invention can be used to test the following biological activities.

#### 15 Gene Therapy Methods

Another aspect of the present invention is to gene therapy methods for treating or preventing disorders, diseases and conditions. The gene therapy methods relate to the introduction of nucleic acid (DNA, RNA and antisense DNA or RNA) sequences into an animal to achieve expression of a polypeptide of the present  
20 invention. This method requires a polynucleotide which codes for a polypeptide of the invention that operatively linked to a promoter and any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques are known in the art, see, for example, WO90/11092, which is herein incorporated by reference.

25 Thus, for example, cells from a patient may be engineered with a polynucleotide (DNA or RNA) comprising a promoter operably linked to a

polynucleotide of the invention *ex vivo*, with the engineered cells then being provided to a patient to be treated with the polypeptide. Such methods are well-known in the art. For example, see Belldegrün et al., J. Natl. Cancer Inst., 85:207-216 (1993); Ferrantini et al., Cancer Research, 53:107-1112 (1993); Ferrantini et al., J. Immunology 153: 4604-4615 (1994); Kaido, T., et al., Int. J. Cancer 60: 221-229 (1995); Ogura et al., Cancer Research 50: 5102-5106 (1990); Santodonato, et al., Human Gene Therapy 7:1-10 (1996); Santodonato, et al., Gene Therapy 4:1246-1255 (1997); and Zhang, et al., Cancer Gene Therapy 3: 31-38 (1996)), which are herein incorporated by reference. In one embodiment, the cells which are engineered are arterial cells. The arterial cells may be reintroduced into the patient through direct injection to the artery, the tissues surrounding the artery, or through catheter injection.

As discussed in more detail below, the polynucleotide constructs can be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial space of tissues (heart, muscle, skin, lung, liver, and the like). The polynucleotide constructs may be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

In one embodiment, the polynucleotide of the invention is delivered as a naked polynucleotide. The term "naked" polynucleotide, DNA or RNA refers to sequences that are free from any delivery vehicle that acts to assist, promote or facilitate entry into the cell, including viral sequences, viral particles, liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the invention can also be delivered in liposome formulations and lipofectin formulations and the like can be prepared by methods well known to those skilled in the art. Such methods are described, for example, in U.S. Patent Nos. 5,593,972, 5,589,466, and 5,580,859, which are herein incorporated by reference.

The polynucleotide vector constructs of the invention used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Appropriate vectors include pWLNEO, pSV2CAT, pOG44, pXT1 and pSG available from Stratagene; 5 pSVK3, pBPV, pMSG and pSVL available from Pharmacia; and pEF1/V5, pcDNA3.1, and pRc/CMV2 available from Invitrogen. Other suitable vectors will be readily apparent to the skilled artisan.

Any strong promoter known to those skilled in the art can be used for driving the expression of polynucleotide sequence of the invention. Suitable promoters 10 include adenoviral promoters, such as the adenoviral major late promoter; or heterologous promoters, such as the cytomegalovirus (CMV) promoter; the respiratory syncytial virus (RSV) promoter; inducible promoters, such as the MMT promoter, the metallothionein promoter; heat shock promoters; the albumin promoter; the ApoA1 promoter; human globin promoters; viral thymidine kinase promoters, 15 such as the Herpes Simplex thymidine kinase promoter; retroviral LTRs; the b-actin promoter; and human growth hormone promoters. The promoter also may be the native promoter for the polynucleotides of the invention.

Unlike other gene therapy techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the 20 polynucleotide synthesis in the cells. Studies have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct of the invention can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, 25 spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye,

gland, and connective tissue. Interstitial space of the tissues comprises the intercellular, fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked *nucleic acid* sequence injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 mg/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the condition being treated and the route of administration.

The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or mucous membranes of the nose. In addition, naked DNA constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The naked polynucleotides are delivered by any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, and so-called "gene guns". These delivery methods are known in the art.

5       The constructs may also be delivered with delivery vehicles such as viral sequences, viral particles, liposome formulations, lipofectin, precipitating agents, etc. Such methods of delivery are known in the art.

In certain embodiments, the polynucleotide constructs of the invention are complexed in a liposome preparation. Liposomal preparations for use in the instant  
10       invention include cationic (positively charged), anionic (negatively charged) and neutral preparations. However, cationic liposomes are particularly preferred because a tight charge complex can be formed between the cationic liposome and the polyanionic nucleic acid. Cationic liposomes have been shown to mediate intracellular delivery of plasmid DNA (Felgner et al., Proc. Natl. Acad. Sci. USA ,  
15       84:7413-7416 (1987), which is herein incorporated by reference); mRNA (Malone et al., Proc. Natl. Acad. Sci. USA , 86:6077-6081 (1989), which is herein incorporated by reference); and purified transcription factors (Debs et al., J. Biol. Chem., 265:10189-10192 (1990), which is herein incorporated by reference), in functional form.

20       Cationic liposomes are readily available. For example, N[1-2,3-dioleoyloxy)propyl]-N,N,N-triethylammonium (DOTMA) liposomes are particularly useful and are available under the trademark Lipofectin, from GIBCO BRL, Grand Island, N.Y. (See, also, Felgner et al., Proc. Natl Acad. Sci. USA , 84:7413-7416 (1987), which is herein incorporated by reference). Other commercially  
25       available liposomes include transfectace (DDAB/DOPE) and DOTAP/DOPE (Boehringer).

Other cationic liposomes can be prepared from readily available materials using techniques well known in the art. See, e.g. PCT Publication NO: WO 90/11092 (which is herein incorporated by reference) for a description of the synthesis of DOTAP (1,2-bis(oleoyloxy)-3-(trimethylammonio)propane) liposomes. Preparation of DOTMA liposomes is explained in the literature, see, e.g., Felgner et al., Proc. Natl. Acad. Sci. USA, 84:7413-7417, which is herein incorporated by reference. Similar methods can be used to prepare liposomes from other cationic lipid materials.

Similarly, anionic and neutral liposomes are readily available, such as from Avanti Polar Lipids (Birmingham, Ala.), or can be easily prepared using readily available materials. Such materials include phosphatidyl, choline, cholesterol, phosphatidyl ethanolamine, dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), dioleoylphosphatidyl ethanolamine (DOPE), among others. These materials can also be mixed with the DOTMA and DOTAP starting materials in appropriate ratios. Methods for making liposomes using these materials are well known in the art.

For example, commercially dioleoylphosphatidyl choline (DOPC), dioleoylphosphatidyl glycerol (DOPG), and dioleoylphosphatidyl ethanolamine (DOPE) can be used in various combinations to make conventional liposomes, with or without the addition of cholesterol. Thus, for example, DOPG/DOPC vesicles can be prepared by drying 50 mg each of DOPG and DOPC under a stream of nitrogen gas into a sonication vial. The sample is placed under a vacuum pump overnight and is hydrated the following day with deionized water. The sample is then sonicated for 2 hours in a capped vial, using a Heat Systems model 350 sonicator equipped with an inverted cup (bath type) probe at the maximum setting while the bath is circulated at 15EC. Alternatively, negatively charged vesicles can be prepared without sonication to produce multilamellar vesicles or by extrusion through nucleopore membranes to

produce unilamellar vesicles of discrete size. Other methods are known and available to those of skill in the art.

The liposomes can comprise multilamellar vesicles (MLVs), small unilamellar vesicles (SUVs), or large unilamellar vesicles (LUVs), with SUVs being preferred.

- 5 The various liposome-nucleic acid complexes are prepared using methods well known in the art. See, e.g., Straubinger et al., *Methods of Immunology* , 101:512-527 (1983), which is herein incorporated by reference. For example, MLVs containing nucleic acid can be prepared by depositing a thin film of phospholipid on the walls of a glass tube and subsequently hydrating with a solution of the material to be encapsulated.
- 10 SUVs are prepared by extended sonication of MLVs to produce a homogeneous population of unilamellar liposomes. The material to be entrapped is added to a suspension of preformed MLVs and then sonicated. When using liposomes containing cationic lipids, the dried lipid film is resuspended in an appropriate solution such as sterile water or an isotonic buffer solution such as 10 mM Tris/NaCl, sonicated, and
- 15 then the preformed liposomes are mixed directly with the DNA. The liposome and DNA form a very stable complex due to binding of the positively charged liposomes to the cationic DNA. SUVs find use with small nucleic acid fragments. LUVs are prepared by a number of methods, well known in the art. Commonly used methods include  $\text{Ca}^{2+}$ -EDTA chelation (Papahadjopoulos et al., *Biochim. Biophys. Acta*, 394:483 (1975); Wilson et al., *Cell* , 17:77 (1979)); ether injection (Deamer et al., *Biochim. Biophys. Acta*, 443:629 (1976); Ostro et al., *Biochem. Biophys. Res. Commun.*, 76:836 (1977); Fraley et al., *Proc. Natl. Acad. Sci. USA*, 76:3348 (1979)); detergent dialysis (Enoch et al., *Proc. Natl. Acad. Sci. USA* , 76:145 (1979)); and reverse-phase evaporation (REV) (Fraley et al., *J. Biol. Chem.*, 255:10431 (1980);
- 20 Szoka et al., *Proc. Natl. Acad. Sci. USA* , 75:145 (1978); Schaefer-Ridder et al., *Science*, 215:166 (1982)), which are herein incorporated by reference.



Generally, the ratio of DNA to liposomes will be from about 10:1 to about 1:10. Preferably, the ratio will be from about 5:1 to about 1:5. More preferably, the ratio will be about 3:1 to about 1:3. Still more preferably, the ratio will be about 1:1.

U.S. Patent NO: 5,676,954 (which is herein incorporated by reference) reports  
5 on the injection of genetic material, complexed with cationic liposomes carriers, into mice. U.S. Patent Nos. 4,897,355, 4,946,787, 5,049,386, 5,459,127, 5,589,466, 5,693,622, 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide cationic lipids for use in transfecting DNA into cells and mammals. U.S. Patent Nos. 5,589,466, 5,693,622,  
10 5,580,859, 5,703,055, and international publication NO: WO 94/9469 (which are herein incorporated by reference) provide methods for delivering DNA-cationic lipid complexes to mammals.

In certain embodiments, cells are engineered, *ex vivo* or *in vivo*, using a retroviral particle containing RNA which comprises a sequence encoding  
15 polypeptides of the invention. Retroviruses from which the retroviral plasmid vectors may be derived include, but are not limited to, Moloney Murine Leukemia Virus, spleen necrosis virus, Rous sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, gibbon ape leukemia virus, human immunodeficiency virus, Myeloproliferative Sarcoma Virus, and mammary tumor virus.

20 The retroviral plasmid vector is employed to transduce packaging cell lines to form producer cell lines. Examples of packaging cells which may be transfected include, but are not limited to, the PE501, PA317, R-2, R-AM, PA12, T19-14X, VT-19-17-H2, RCRE, RCRIP, GP+E-86, GP+envAm12, and DAN cell lines as described in Miller, Human Gene Therapy, 1:5-14 (1990), which is incorporated herein by  
25 reference in its entirety. The vector may transduce the packaging cells through any means known in the art. Such means include, but are not limited to, electroporation,

the use of liposomes, and  $\text{CaPO}_4$  precipitation. In one alternative, the retroviral plasmid vector may be encapsulated into a liposome, or coupled to a lipid, and then administered to a host.

The producer cell line generates infectious retroviral vector particles which  
5 include polynucleotide encoding polypeptides of the invention. Such retroviral vector particles then may be employed, to transduce eukaryotic cells, either *in vitro* or *in vivo*. The transduced eukaryotic cells will express polypeptides of the invention.

In certain other embodiments, cells are engineered, *ex vivo* or *in vivo*, with polynucleotides of the invention contained in an adenovirus vector. Adenovirus can  
10 be manipulated such that it encodes and expresses polypeptides of the invention, and at the same time is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. Adenovirus expression is achieved without integration of the viral DNA into the host cell chromosome, thereby alleviating concerns about insertional mutagenesis. Furthermore, adenoviruses have been used as live enteric vaccines for  
15 many years with an excellent safety profile (Schwartz et al., Am. Rev. Respir. Dis., 109:233-238 (1974)). Finally, adenovirus mediated gene transfer has been demonstrated in a number of instances including transfer of alpha-1-antitrypsin and CFTR to the lungs of cotton rats (Rosenfeld et al., Science, 252:431-434 (1991); Rosenfeld et al., Cell, 68:143-155 (1992)). Furthermore, extensive studies to attempt  
20 to establish adenovirus as a causative agent in human cancer were uniformly negative (Green et al. Proc. Natl. Acad. Sci. USA, 76:6606 (1979)).

Suitable adenoviral vectors useful in the present invention are described, for example, in Kozarsky and Wilson, Curr. Opin. Genet. Devel., 3:499-503 (1993); Rosenfeld et al., Cell, 68:143-155 (1992); Engelhardt et al., Human Genet. Ther.,  
25 4:759-769 (1993); Yang et al., Nature Genet., 7:362-369 (1994); Wilson et al., Nature, 365:691-692 (1993); and U.S. Patent NO: 5,652,224, which are herein

incorporated by reference. For example, the adenovirus vector Ad2 is useful and can be grown in human 293 cells. These cells contain the E1 region of adenovirus and constitutively express E1a and E1b, which complement the defective adenoviruses by providing the products of the genes deleted from the vector. In addition to Ad2, other varieties of adenovirus (e.g., Ad3, Ad5, and Ad7) are also useful in the present invention.

Preferably, the adenoviruses used in the present invention are replication deficient. Replication deficient adenoviruses require the aid of a helper virus and/or packaging cell line to form infectious particles. The resulting virus is capable of infecting cells and can express a polynucleotide of interest which is operably linked to a promoter, but cannot replicate in most cells. Replication deficient adenoviruses may be deleted in one or more of all or a portion of the following genes: E1a, E1b, E3, E4, E2a, or L1 through L5.

In certain other embodiments, the cells are engineered, *ex vivo* or *in vivo*, using an adeno-associated virus (AAV). AAVs are naturally occurring defective viruses that require helper viruses to produce infectious particles (Muzyczka, Curr. Topics in Microbiol. Immunol., 158:97 (1992)). It is also one of the few viruses that may integrate its DNA into non-dividing cells. Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate, but space for exogenous DNA is limited to about 4.5 kb. Methods for producing and using such AAVs are known in the art. See, for example, U.S. Patent Nos. 5,139,941, 5,173,414, 5,354,678, 5,436,146, 5,474,935, 5,478,745, and 5,589,377.

For example, an appropriate AAV vector for use in the present invention will include all the sequences necessary for DNA replication, encapsidation, and host-cell integration. The polynucleotide construct containing polynucleotides of the invention is inserted into the AAV vector using standard cloning methods, such as those found

in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Press (1989). The recombinant AAV vector is then transfected into packaging cells which are infected with a helper virus, using any standard technique, including lipofection, electroporation, calcium phosphate precipitation, etc. Appropriate helper  
5 viruses include adenoviruses, cytomegaloviruses, vaccinia viruses, or herpes viruses. Once the packaging cells are transfected and infected, they will produce infectious AAV viral particles which contain the polynucleotide construct of the invention. These viral particles are then used to transduce eukaryotic cells, either *ex vivo* or *in vivo*. The transduced cells will contain the polynucleotide construct integrated into its  
10 genome, and will express the desired gene product.

Another method of gene therapy involves operably associating heterologous control regions and endogenous polynucleotide sequences (e.g. encoding the polypeptide sequence of interest) via homologous recombination (see, e.g., U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO  
15 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., Proc. Natl. Acad. Sci. USA, 86:8932-8935 (1989); and Zijlstra et al., Nature, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not normally expressed in the cells, or is expressed at a lower level than desired.

20 Polynucleotide constructs are made, using standard techniques known in the art, which contain the promoter with targeting sequences flanking the promoter. Suitable promoters are described herein. The targeting sequence is sufficiently complementary to an endogenous sequence to permit homologous recombination of the promoter-targeting sequence with the endogenous sequence. The targeting  
25 sequence will be sufficiently near the 5' end of the desired endogenous

polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination.

The promoter and the targeting sequences can be amplified using PCR.

Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter. The amplified promoter and targeting sequences are digested and ligated together.

10 The promoter-targeting sequence construct is delivered to the cells, either as naked polynucleotide, or in conjunction with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, whole viruses, lipofection, precipitating agents, etc., described in more detail above. The P promoter-targeting sequence can be delivered by any method, included direct needle injection, intravenous injection, 15 topical administration, catheter infusion, particle accelerators, etc. The methods are described in more detail below.

The promoter-targeting sequence construct is taken up by cells. Homologous recombination between the construct and the endogenous sequence takes place, such that an endogenous sequence is placed under the control of the promoter. The 20 promoter then drives the expression of the endogenous sequence.

The polynucleotides encoding polypeptides of the present invention may be administered along with other polynucleotides encoding other angiogenic proteins. Angiogenic proteins include, but are not limited to, acidic and basic fibroblast growth factors, VEGF-1, VEGF-2 (VEGF-C), VEGF-3 (VEGF-B), epidermal growth factor 25 alpha and beta, platelet-derived endothelial cell growth factor, platelet-derived growth factor, tumor necrosis factor alpha, hepatocyte growth factor, insulin like growth

factor, colony stimulating factor, macrophage colony stimulating factor, granulocyte/macrophage colony stimulating factor, and nitric oxide synthase.

Preferably, the polynucleotide encoding a polypeptide of the invention contains a secretory signal sequence that facilitates secretion of the protein.

5 Typically, the signal sequence is positioned in the coding region of the polynucleotide to be expressed towards or at the 5' end of the coding region. The signal sequence may be homologous or heterologous to the polynucleotide of interest and may be homologous or heterologous to the cells to be transfected. Additionally, the signal sequence may be chemically synthesized using methods known in the art.

10 Any mode of administration of any of the above-described polynucleotides constructs can be used so long as the mode results in the expression of one or more molecules in an amount sufficient to provide a therapeutic effect. This includes direct needle injection, systemic injection, catheter infusion, biolistic injectors, particle accelerators (i.e., "gene guns"), gelfoam sponge depots, other commercially available  
15 depot materials, osmotic pumps (e.g., Alza minipumps), oral or suppositorial solid (tablet or pill) pharmaceutical formulations, and decanting or topical applications during surgery. For example, direct injection of naked calcium phosphate-precipitated plasmid into rat liver and rat spleen or a protein-coated plasmid into the portal vein has resulted in gene expression of the foreign gene in the  
20 rat livers. (Kaneda et al., Science, 243:375 (1989)).

A preferred method of local administration is by direct injection. Preferably, a recombinant molecule of the present invention complexed with a delivery vehicle is administered by direct injection into or locally within the area of arteries.

Administration of a composition locally within the area of arteries refers to injecting  
25 the composition centimeters and preferably, millimeters within arteries.

Another method of local administration is to contact a polynucleotide construct of the present invention in or around a surgical wound. For example, a patient can undergo surgery and the polynucleotide construct can be coated on the surface of tissue inside the wound or the construct can be injected into areas of tissue  
5 inside the wound.

Therapeutic compositions useful in systemic administration, include recombinant molecules of the present invention complexed to a targeted delivery vehicle of the present invention. Suitable delivery vehicles for use with systemic administration comprise liposomes comprising ligands for targeting the vehicle to a  
10 particular site.

Preferred methods of systemic administration, include intravenous injection, aerosol, oral and percutaneous (topical) delivery. Intravenous injections can be performed using methods standard in the art. Aerosol delivery can also be performed using methods standard in the art (see, for example, Stribling et al., Proc. Natl. Acad.  
15 Sci. USA , 189:11277-11281 (1992), which is incorporated herein by reference). Oral delivery can be performed by complexing a polynucleotide construct of the present invention to a carrier capable of withstanding degradation by digestive enzymes in the gut of an animal. Examples of such carriers, include plastic capsules or tablets, such as those known in the art. Topical delivery can be performed by mixing a  
20 polynucleotide construct of the present invention with a lipophilic reagent (e.g., DMSO) that is capable of passing into the skin.

Determining an effective amount of substance to be delivered can depend upon a number of factors including, for example, the chemical structure and biological activity of the substance, the age and weight of the animal, the precise  
25 condition requiring treatment and its severity, and the route of administration. The frequency of treatments depends upon a number of factors, such as the amount of

polynucleotide constructs administered per dose, as well as the health and history of the subject. The precise amount, number of doses, and timing of doses will be determined by the attending physician or veterinarian. Therapeutic compositions of the present invention can be administered to any animal, preferably to mammals and  
5 birds. Preferred mammals include humans, dogs, cats, mice, rats, rabbits sheep, cattle, horses and pigs, with humans being particularly

### **Biological Activities**

The polynucleotides or polypeptides, or agonists or antagonists of the present  
10 invention can be used in assays to test for one or more biological activities. If these polynucleotides and polypeptides do exhibit activity in a particular assay, it is likely that these molecules may be involved in the diseases associated with the biological activity. Thus, the polynucleotides or polypeptides, or agonists or antagonists could be used to treat the associated disease.

15

### **Immune Activity**

The polynucleotides or polypeptides, or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of the immune system, by activating or inhibiting the proliferation,  
20 differentiation, or mobilization (chemotaxis) of immune cells. Immune cells develop through a process called hematopoiesis, producing myeloid (platelets, red blood cells, neutrophils, and macrophages) and lymphoid (B and T lymphocytes) cells from pluripotent stem cells. The etiology of these immune diseases, disorders, and/or conditions may be genetic, somatic, such as cancer or some autoimmune diseases,  
25 disorders, and/or conditions, acquired (e.g., by chemotherapy or toxins), or infectious. Moreover, a polynucleotides or polypeptides, or agonists or antagonists of the present



invention can be used as a marker or detector of a particular immune system disease or disorder.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may be useful in treating, preventing, and/or diagnosing diseases, disorders, and/or conditions of hematopoietic cells. A polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to increase differentiation and proliferation of hematopoietic cells, including the pluripotent stem cells, in an effort to treat or prevent those diseases, disorders, and/or conditions associated with a decrease in certain (or many) types hematopoietic cells. Examples of immunologic deficiency syndromes include, but are not limited to: blood protein diseases, disorders, and/or conditions (e.g. agammaglobulinemia, dysgammaglobulinemia), ataxia telangiectasia, common variable immunodeficiency, Digeorge Syndrome, HIV infection, HTLV-BLV infection, leukocyte adhesion deficiency syndrome, lymphopenia, phagocyte bactericidal dysfunction, severe combined immunodeficiency (SCIDs), Wiskott-Aldrich Disorder, anemia, thrombocytopenia, or hemoglobinuria.

Moreover, a polynucleotides or polypeptides, or agonists or antagonists of the present invention could also be used to modulate hemostatic (the stopping of bleeding) or thrombolytic activity (clot formation). For example, by increasing hemostatic or thrombolytic activity, a polynucleotides or polypeptides, or agonists or antagonists of the present invention could be used to treat or prevent blood coagulation diseases, disorders, and/or conditions (e.g., afibrinogenemia, factor deficiencies), blood platelet diseases, disorders, and/or conditions (e.g. thrombocytopenia), or wounds resulting from trauma, surgery, or other causes. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention that can decrease hemostatic or thrombolytic activity could be used

to inhibit or dissolve clotting. These molecules could be important in the treatment or prevention of heart attacks (infarction), strokes, or scarring.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be useful in treating, preventing, and/or diagnosing autoimmune  
5 diseases, disorders, and/or conditions. Many autoimmune diseases, disorders, and/or conditions result from inappropriate recognition of self as foreign material by immune cells. This inappropriate recognition results in an immune response leading to the destruction of the host tissue. Therefore, the administration of a polynucleotides or polypeptides, or agonists or antagonists of the present invention that inhibits an  
10 immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing autoimmune diseases, disorders, and/or conditions.

Examples of autoimmune diseases, disorders, and/or conditions that can be treated, prevented, and/or diagnosed or detected by the present invention include, but  
15 are not limited to: Addison's Disease, hemolytic anemia, antiphospholipid syndrome, rheumatoid arthritis, dermatitis, allergic encephalomyelitis, glomerulonephritis, Goodpasture's Syndrome, Graves' Disease, Multiple Sclerosis, Myasthenia Gravis, Neuritis, Ophthalmia, Bullous Pemphigoid, Pemphigus, Polyendocrinopathies, Purpura, Reiter's Disease, Stiff-Man Syndrome, Autoimmune Thyroiditis, Systemic  
20 Lupus Erythematosus, Autoimmune Pulmonary Inflammation, Guillain-Barre Syndrome, insulin dependent diabetes mellitus, and autoimmune inflammatory eye disease.

Similarly, allergic reactions and conditions, such as asthma (particularly allergic asthma) or other respiratory problems, may also be treated, prevented, and/or  
25 diagnosed by polynucleotides or polypeptides, or agonists or antagonists of the

present invention. Moreover, these molecules can be used to treat anaphylaxis, hypersensitivity to an antigenic molecule, or blood group incompatibility.

A polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to treat, prevent, and/or diagnose organ rejection or graft-versus-host disease (GVHD). Organ rejection occurs by host immune cell destruction of the transplanted tissue through an immune response. Similarly, an immune response is also involved in GVHD, but, in this case, the foreign transplanted immune cells destroy the host tissues. The administration of a polynucleotides or polypeptides, or agonists or antagonists of the present invention that inhibits an immune response, particularly the proliferation, differentiation, or chemotaxis of T-cells, may be an effective therapy in preventing organ rejection or GVHD.

Similarly, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may also be used to modulate inflammation. For example, the polypeptide or polynucleotide or agonists or antagonist may inhibit the proliferation and differentiation of cells involved in an inflammatory response. These molecules can be used to treat, prevent, and/or diagnose inflammatory conditions, both chronic and acute conditions, including chronic prostatitis, granulomatous prostatitis and malacoplakia, inflammation associated with infection (e.g., septic shock, sepsis, or systemic inflammatory response syndrome (SIRS)), ischemia-reperfusion injury, endotoxin lethality, arthritis, complement-mediated hyperacute rejection, nephritis, cytokine or chemokine induced lung injury, inflammatory bowel disease, Crohn's disease, or resulting from over production of cytokines (e.g., TNF or IL-1.)

#### **Hyperproliferative Disorders**

A polynucleotides or polypeptides, or agonists or antagonists of the invention can be used to treat, prevent, and/or diagnose hyperproliferative diseases, disorders,

and/or conditions, including neoplasms. A polynucleotides or polypeptides, or agonists or antagonists of the present invention may inhibit the proliferation of the disorder through direct or indirect interactions. Alternatively, a polynucleotides or polypeptides, or agonists or antagonists of the present invention may proliferate other  
5 cells which can inhibit the hyperproliferative disorder.

For example, by increasing an immune response, particularly increasing antigenic qualities of the hyperproliferative disorder or by proliferating, differentiating, or mobilizing T-cells, hyperproliferative diseases, disorders, and/or conditions can be treated, prevented, and/or diagnosed. This immune response may  
10 be increased by either enhancing an existing immune response, or by initiating a new immune response. Alternatively, decreasing an immune response may also be a method of treating, preventing, and/or diagnosing hyperproliferative diseases, disorders, and/or conditions, such as a chemotherapeutic agent.

Examples of hyperproliferative diseases, disorders, and/or conditions that can  
15 be treated, prevented, and/or diagnosed by polynucleotides or polypeptides, or agonists or antagonists of the present invention include, but are not limited to neoplasms located in the: colon, abdomen, bone, breast, digestive system, liver, pancreas, peritoneum, endocrine glands (adrenal, parathyroid, pituitary, testicles, ovary, thymus, thyroid), eye, head and neck, nervous (central and peripheral),  
20 lymphatic system, pelvic, skin, soft tissue, spleen, thoracic, and urogenital.

Similarly, other hyperproliferative diseases, disorders, and/or conditions can also be treated, prevented, and/or diagnosed by a polynucleotides or polypeptides, or agonists or antagonists of the present invention. Examples of such hyperproliferative diseases, disorders, and/or conditions include, but are not limited to:  
25 hypergammaglobulinemia, lymphoproliferative diseases, disorders, and/or conditions, paraproteinemias, purpura, sarcoidosis, Sezary Syndrome, Waldenström's

Macroglobulinemia, Gaucher's Disease, histiocytosis, and any other hyperproliferative disease, besides neoplasia, located in an organ system listed above.

One preferred embodiment utilizes polynucleotides of the present invention to inhibit aberrant cellular division, by gene therapy using the present invention, and/or  
5 protein fusions or fragments thereof.

Thus, the present invention provides a method for treating or preventing cell proliferative diseases, disorders, and/or conditions by inserting into an abnormally proliferating cell a polynucleotide of the present invention, wherein said polynucleotide represses said expression.

10 Another embodiment of the present invention provides a method of treating or preventing cell-proliferative diseases, disorders, and/or conditions in individuals comprising administration of one or more active gene copies of the present invention to an abnormally proliferating cell or cells. In a preferred embodiment, polynucleotides of the present invention is a DNA construct comprising a  
15 recombinant expression vector effective in expressing a DNA sequence encoding said polynucleotides. In another preferred embodiment of the present invention, the DNA construct encoding the polynucleotides of the present invention is inserted into cells to be treated utilizing a retrovirus, or more preferably an adenoviral vector (See G J. Nabel, et. al., PNAS 1999 96: 324-326, which is hereby incorporated by reference).  
20 In a most preferred embodiment, the viral vector is defective and will not transform non-proliferating cells, only proliferating cells. Moreover, in a preferred embodiment, the polynucleotides of the present invention inserted into proliferating cells either alone, or in combination with or fused to other polynucleotides, can then be modulated via an external stimulus (i.e. magnetic, specific small molecule,  
25 chemical, or drug administration, etc.), which acts upon the promoter upstream of said polynucleotides to induce expression of the encoded protein product. As such the

beneficial therapeutic affect of the present invention may be expressly modulated (i.e. to increase, decrease, or inhibit expression of the present invention) based upon said external stimulus.

Polynucleotides of the present invention may be useful in repressing  
5 expression of oncogenic genes or antigens. By "repressing expression of the oncogenic genes " is intended the suppression of the transcription of the gene, the degradation of the gene transcript (pre-message RNA), the inhibition of splicing, the destruction of the messenger RNA, the prevention of the post-translational modifications of the protein, the destruction of the protein, or the inhibition of the  
10 normal function of the protein.

For local administration to abnormally proliferating cells, polynucleotides of the present invention may be administered by any method known to those of skill in the art including, but not limited to transfection, electroporation, microinjection of cells, or in vehicles such as liposomes, lipofectin, or as naked polynucleotides, or any  
15 other method described throughout the specification. The polynucleotide of the present invention may be delivered by known gene delivery systems such as, but not limited to, retroviral vectors (Gilboa, J. Virology 44:845 (1982); Hocke, Nature 320:275 (1986); Wilson, et al., Proc. Natl. Acad. Sci. U.S.A. 85:3014), vaccinia virus system (Chakrabarty et al., Mol. Cell Biol. 5:3403 (1985) or other efficient DNA  
20 delivery systems (Yates et al., Nature 313:812 (1985)) known to those skilled in the art. These references are exemplary only and are hereby incorporated by reference. In order to specifically deliver or transfect cells which are abnormally proliferating and spare non-dividing cells, it is preferable to utilize a retrovirus, or adenoviral (as described in the art and elsewhere herein) delivery system known to those of skill in  
25 the art. Since host DNA replication is required for retroviral DNA to integrate and the retrovirus will be unable to self replicate due to the lack of the retrovirus genes

needed for its life cycle. Utilizing such a retroviral delivery system for polynucleotides of the present invention will target said gene and constructs to abnormally proliferating cells and will spare the non-dividing normal cells.

The polynucleotides of the present invention may be delivered directly to cell  
5 proliferative disorder/disease sites in internal organs, body cavities and the like by use of imaging devices used to guide an injecting needle directly to the disease site. The polynucleotides of the present invention may also be administered to disease sites at the time of surgical intervention.

By "cell proliferative disease" is meant any human or animal disease or  
10 disorder, affecting any one or any combination of organs, cavities, or body parts, which is characterized by single or multiple local abnormal proliferations of cells, groups of cells, or tissues, whether benign or malignant.

Any amount of the polynucleotides of the present invention may be administered as long as it has a biologically inhibiting effect on the proliferation of  
15 the treated cells. Moreover, it is possible to administer more than one of the polynucleotide of the present invention simultaneously to the same site. By "biologically inhibiting" is meant partial or total growth inhibition as well as decreases in the rate of proliferation or growth of the cells. The biologically inhibitory dose may be determined by assessing the effects of the polynucleotides of  
20 the present invention on target malignant or abnormally proliferating cell growth in tissue culture, tumor growth in animals and cell cultures, or any other method known to one of ordinary skill in the art.

The present invention is further directed to antibody-based therapies which involve administering of anti-polypeptides and anti-polynucleotide antibodies to a  
25 mammalian, preferably human, patient for treating, preventing, and/or diagnosing one or more of the described diseases, disorders, and/or conditions. Methods for

producing anti-polypeptides and anti-polynucleotide antibodies polyclonal and monoclonal antibodies are described in detail elsewhere herein. Such antibodies may be provided in pharmaceutically acceptable compositions as known in the art or as described herein.

5           A summary of the ways in which the antibodies of the present invention may be used therapeutically includes binding polynucleotides or polypeptides of the present invention locally or systemically in the body or by direct cytotoxicity of the antibody, e.g. as mediated by complement (CDC) or by effector cells (ADCC). Some of these approaches are described in more detail below. Armed with the teachings  
10       provided herein, one of ordinary skill in the art will know how to use the antibodies of the present invention for diagnostic, monitoring or therapeutic purposes without undue experimentation.

          In particular, the antibodies, fragments and derivatives of the present invention are useful for treating, preventing, and/or diagnosing a subject having or developing  
15       cell proliferative and/or differentiation diseases, disorders, and/or conditions as described herein. Such treatment comprises administering a single or multiple doses of the antibody, or a fragment, derivative, or a conjugate thereof.

          The antibodies of this invention may be advantageously utilized in combination with other monoclonal or chimeric antibodies, or with lymphokines or  
20       hematopoietic growth factors, for example, which serve to increase the number or activity of effector cells which interact with the antibodies.

          It is preferred to use high affinity and/or potent in vivo inhibiting and/or neutralizing antibodies against polypeptides or polynucleotides of the present invention, fragments or regions thereof, for both immunoassays directed to and  
25       therapy of diseases, disorders, and/or conditions related to polynucleotides or polypeptides, including fragments thereof, of the present invention. Such antibodies,



fragments, or regions, will preferably have an affinity for polynucleotides or polypeptides, including fragments thereof. Preferred binding affinities include those with a dissociation constant or  $K_d$  less than  $5 \times 10^{-6}M$ ,  $10^{-6}M$ ,  $5 \times 10^{-7}M$ ,  $10^{-7}M$ ,  $5 \times 10^{-8}M$ ,  $10^{-8}M$ ,  $5 \times 10^{-9}M$ ,  $10^{-9}M$ ,  $5 \times 10^{-10}M$ ,  $10^{-10}M$ ,  $5 \times 10^{-11}M$ ,  $10^{-11}M$ ,  $5 \times 10^{-12}M$ ,  $10^{-12}M$ ,  
5  $5 \times 10^{-13}M$ ,  $10^{-13}M$ ,  $5 \times 10^{-14}M$ ,  $10^{-14}M$ ,  $5 \times 10^{-15}M$ , and  $10^{-15}M$ .

Moreover, polypeptides of the present invention are useful in inhibiting the angiogenesis of proliferative cells or tissues, either alone, as a protein fusion, or in combination with other polypeptides directly or indirectly, as described elsewhere herein. In a most preferred embodiment, said anti-angiogenesis effect may be  
10 achieved indirectly, for example, through the inhibition of hematopoietic, tumor-specific cells, such as tumor-associated macrophages (See Joseph IB, et al. J Natl Cancer Inst, 90(21):1648-53 (1998), which is hereby incorporated by reference). Antibodies directed to polypeptides or polynucleotides of the present invention may also result in inhibition of angiogenesis directly, or indirectly (See Witte L, et al.,  
15 Cancer Metastasis Rev. 17(2):155-61 (1998), which is hereby incorporated by reference)).

Polypeptides, including protein fusions, of the present invention, or fragments thereof may be useful in inhibiting proliferative cells or tissues through the induction of apoptosis. Said polypeptides may act either directly, or indirectly to induce  
20 apoptosis of proliferative cells and tissues, for example in the activation of a death-domain receptor, such as tumor necrosis factor (TNF) receptor-1, CD95 (Fas/APO-1), TNF-receptor-related apoptosis-mediated protein (TRAMP) and TNF-related apoptosis-inducing ligand (TRAIL) receptor-1 and -2 (See Schulze-Osthoff K, et.al., Eur J Biochem 254(3):439-59 (1998), which is hereby incorporated by reference).  
25 Moreover, in another preferred embodiment of the present invention, said polypeptides may induce apoptosis through other mechanisms, such as in the

activation of other proteins which will activate apoptosis, or through stimulating the expression of said proteins, either alone or in combination with small molecule drugs or adjuvants, such as apoptonin, galectins, thioredoxins, antiinflammatory proteins (See for example, Mutat Res 400(1-2):447-55 (1998), Med Hypotheses.50(5):423-33 (1998), Chem Biol Interact. Apr 24;111-112:23-34 (1998), J Mol Med.76(6):402-12 (1998), Int J Tissue React;20(1):3-15 (1998), which are all hereby incorporated by reference).

Polypeptides, including protein fusions to, or fragments thereof, of the present invention are useful in inhibiting the metastasis of proliferative cells or tissues. Inhibition may occur as a direct result of administering polypeptides, or antibodies directed to said polypeptides as described elsewhere herein, or indirectly, such as activating the expression of proteins known to inhibit metastasis, for example alpha 4 integrins, (See, e.g., Curr Top Microbiol Immunol 1998;231:125-41, which is hereby incorporated by reference). Such therapeutic affects of the present invention may be achieved either alone, or in combination with small molecule drugs or adjuvants.

In another embodiment, the invention provides a method of delivering compositions containing the polypeptides of the invention (e.g., compositions containing polypeptides or polypeptide antibodies associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs) to targeted cells expressing the polypeptide of the present invention. Polypeptides or polypeptide antibodies of the invention may be associated with with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions.

Polypeptides, protein fusions to, or fragments thereof, of the present invention are useful in enhancing the immunogenicity and/or antigenicity of proliferating cells or tissues, either directly, such as would occur if the polypeptides of the present

invention 'vaccinated' the immune response to respond to proliferative antigens and immunogens, or indirectly, such as in activating the expression of proteins known to enhance the immune response (e.g. chemokines), to said antigens and immunogens.

5           **Cardiovascular Disorders**

Polynucleotides or polypeptides, or agonists or antagonists of the invention may be used to treat, prevent, and/or diagnose cardiovascular diseases, disorders, and/or conditions, including peripheral artery disease, such as limb ischemia.

Cardiovascular diseases, disorders, and/or conditions include cardiovascular  
10 abnormalities, such as arterio-arterial fistula, arteriovenous fistula, cerebral arteriovenous malformations, congenital heart defects, pulmonary atresia, and Scimitar Syndrome. Congenital heart defects include aortic coarctation, cor triatriatum, coronary vessel anomalies, crisscross heart, dextrocardia, patent ductus arteriosus, Ebstein's anomaly, Eisenmenger complex, hypoplastic left heart syndrome,  
15 levocardia, tetralogy of fallot, transposition of great vessels, double outlet right ventricle, tricuspid atresia, persistent truncus arteriosus, and heart septal defects, such as aortopulmonary septal defect, endocardial cushion defects, Lutembacher's Syndrome, trilogly of Fallot, ventricular heart septal defects.

Cardiovascular diseases, disorders, and/or conditions also include heart  
20 disease, such as arrhythmias, carcinoid heart disease, high cardiac output, low cardiac output, cardiac tamponade, endocarditis (including bacterial), heart aneurysm, cardiac arrest, congestive heart failure, congestive cardiomyopathy, paroxysmal dyspnea, cardiac edema, heart hypertrophy, congestive cardiomyopathy, left ventricular hypertrophy, right ventricular hypertrophy, post-infarction heart rupture, ventricular  
25 septal rupture, heart valve diseases, myocardial diseases, myocardial ischemia, pericardial effusion, pericarditis (including constrictive and tuberculous),

pneumopericardium, postpericardiotomy syndrome, pulmonary heart disease, rheumatic heart disease, ventricular dysfunction, hyperemia, cardiovascular pregnancy complications, Scimitar Syndrome, cardiovascular syphilis, and cardiovascular tuberculosis.

5           Arrhythmias include sinus arrhythmia, atrial fibrillation, atrial flutter, bradycardia, extrasystole, Adams-Stokes Syndrome, bundle-branch block, sinoatrial block, long QT syndrome, parasystole, Lown-Ganong-Levine Syndrome, Mahaim-type pre-excitation syndrome, Wolff-Parkinson-White syndrome, sick sinus syndrome, tachycardias, and ventricular fibrillation. Tachycardias include  
10   paroxysmal tachycardia, supraventricular tachycardia, accelerated idioventricular rhythm, atrioventricular nodal reentry tachycardia, ectopic atrial tachycardia, ectopic junctional tachycardia, sinoatrial nodal reentry tachycardia, sinus tachycardia, Torsades de Pointes, and ventricular tachycardia.

          Heart valve disease include aortic valve insufficiency, aortic valve stenosis,  
15   hear murmurs, aortic valve prolapse, mitral valve prolapse, tricuspid valve prolapse, mitral valve insufficiency, mitral valve stenosis, pulmonary atresia, pulmonary valve insufficiency, pulmonary valve stenosis, tricuspid atresia, tricuspid valve insufficiency, and tricuspid valve stenosis.

          Myocardial diseases include alcoholic cardiomyopathy, congestive  
20   cardiomyopathy, hypertrophic cardiomyopathy, aortic subvalvular stenosis, pulmonary subvalvular stenosis, restrictive cardiomyopathy, Chagas cardiomyopathy, endocardial fibroelastosis, endomyocardial fibrosis, Kearns Syndrome, myocardial reperfusion injury, and myocarditis.

          Myocardial ischemias include coronary disease, such as angina pectoris,  
25   coronary aneurysm, coronary arteriosclerosis, coronary thrombosis, coronary vasospasm, myocardial infarction and myocardial stunning.

Cardiovascular diseases also include vascular diseases such as aneurysms, angiodyplasia, angiomas, bacillary angiomas, Hippel-Lindau Disease, Klippel-Trenaunay-Weber Syndrome, Sturge-Weber Syndrome, angioneurotic edema, aortic diseases, Takayasu's Arteritis, aortitis, Leriche's Syndrome, arterial occlusive diseases, arteritis, enarteritis, polyarteritis nodosa, cerebrovascular diseases, disorders, and/or conditions, diabetic angiopathies, diabetic retinopathy, embolisms, thrombosis, erythromelalgia, hemorrhoids, hepatic veno-occlusive disease, hypertension, hypotension, ischemia, peripheral vascular diseases, phlebitis, pulmonary veno-occlusive disease, Raynaud's disease, CREST syndrome, retinal vein occlusion, Scimitar syndrome, superior vena cava syndrome, telangiectasia, ataxia telangiectasia, hereditary hemorrhagic telangiectasia, varicocele, varicose veins, varicose ulcer, vasculitis, and venous insufficiency.

Aneurysms include dissecting aneurysms, false aneurysms, infected aneurysms, ruptured aneurysms, aortic aneurysms, cerebral aneurysms, coronary aneurysms, heart aneurysms, and iliac aneurysms.

Arterial occlusive diseases include arteriosclerosis, intermittent claudication, carotid stenosis, fibromuscular dysplasias, mesenteric vascular occlusion, Moyamoya disease, renal artery obstruction, retinal artery occlusion, and thromboangiitis obliterans.

Cerebrovascular diseases, disorders, and/or conditions include carotid artery diseases, cerebral amyloid angiopathy, cerebral aneurysm, cerebral anoxia, cerebral arteriosclerosis, cerebral arteriovenous malformation, cerebral artery diseases, cerebral embolism and thrombosis, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, cerebral hemorrhage, epidural hematoma, subdural hematoma, subarachnoid hemorrhage, cerebral infarction, cerebral ischemia

(including transient), subclavian steal syndrome, periventricular leukomalacia, vascular headache, cluster headache, migraine, and vertebrobasilar insufficiency.

Embolisms include air embolisms, amniotic fluid embolisms, cholesterol embolisms, blue toe syndrome, fat embolisms, pulmonary embolisms, and  
5 thromboembolisms. Thrombosis include coronary thrombosis, hepatic vein thrombosis, retinal vein occlusion, carotid artery thrombosis, sinus thrombosis, Wallenberg's syndrome, and thrombophlebitis.

Ischemia includes cerebral ischemia, ischemic colitis, compartment syndromes, anterior compartment syndrome, myocardial ischemia, reperfusion  
10 injuries, and peripheral limb ischemia. Vasculitis includes aortitis, arteritis, Behcet's Syndrome, Churg-Strauss Syndrome, mucocutaneous lymph node syndrome, thromboangiitis obliterans, hypersensitivity vasculitis, Schoenlein-Henoch purpura, allergic cutaneous vasculitis, and Wegener's granulomatosis.

Polynucleotides or polypeptides, or agonists or antagonists of the invention,  
15 are especially effective for the treatment of critical limb ischemia and coronary disease.

Polypeptides may be administered using any method known in the art, including, but not limited to, direct needle injection at the delivery site, intravenous injection, topical administration, catheter infusion, biolistic injectors, particle  
20 accelerators, gelfoam sponge depots, other commercially available depot materials, osmotic pumps, oral or suppository solid pharmaceutical formulations, decanting or topical applications during surgery, aerosol delivery. Such methods are known in the art. Polypeptides of the invention may be administered as part of a *Therapeutic*, described in more detail below. Methods of delivering polynucleotides of the  
25 invention are described in more detail herein.

**Anti-Angiogenesis Activity**

The naturally occurring balance between endogenous stimulators and inhibitors of angiogenesis is one in which inhibitory influences predominate. Rastinejad *et al.*, *Cell* 56:345-355 (1989). In those rare instances in which  
5 neovascularization occurs under normal physiological conditions, such as wound healing, organ regeneration, embryonic development, and female reproductive processes, angiogenesis is stringently regulated and spatially and temporally delimited. Under conditions of pathological angiogenesis such as that characterizing solid tumor growth, these regulatory controls fail. Unregulated angiogenesis becomes  
10 pathologic and sustains progression of many neoplastic and non-neoplastic diseases. A number of serious diseases are dominated by abnormal neovascularization including solid tumor growth and metastases, arthritis, some types of eye diseases, disorders, and/or conditions, and psoriasis. See, e.g., reviews by Moses *et al.*, *Biotech.* 9:630-634 (1991); Folkman *et al.*, *N. Engl. J. Med.*, 333:1757-1763 (1995);  
15 Auerbach *et al.*, *J. Microvasc. Res.* 29:401-411 (1985); Folkman, *Advances in Cancer Research*, eds. Klein and Weinhouse, Academic Press, New York, pp. 175-203 (1985); Patz, *Am. J. Ophthalmol.* 94:715-743 (1982); and Folkman *et al.*, *Science* 221:719-725 (1983). In a number of pathological conditions, the process of angiogenesis contributes to the disease state. For example, significant data have  
20 accumulated which suggest that the growth of solid tumors is dependent on angiogenesis. Folkman and Klagsbrun, *Science* 235:442-447 (1987).

The present invention provides for treatment of diseases, disorders, and/or conditions associated with neovascularization by administration of the polynucleotides and/or polypeptides of the invention, as well as agonists or  
25 antagonists of the present invention. Malignant and metastatic conditions which can be treated with the polynucleotides and polypeptides, or agonists or antagonists of the

invention include, but are not limited to, malignancies, solid tumors, and cancers described herein and otherwise known in the art (for a review of such disorders, see Fishman *et al.*, Medicine, 2d Ed., J. B. Lippincott Co., Philadelphia (1985)). Thus, the present invention provides a method of treating, preventing, and/or diagnosing an

5 angiogenesis-related disease and/or disorder, comprising administering to an individual in need thereof a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist of the invention. For example, polynucleotides, polypeptides, antagonists and/or agonists may be utilized in a variety of additional methods in order to therapeutically treat or prevent a cancer or tumor.

10 Cancers which may be treated, prevented, and/or diagnosed with polynucleotides, polypeptides, antagonists and/or agonists include, but are not limited to solid tumors, including prostate, lung, breast, ovarian, stomach, pancreas, larynx, esophagus, testes, liver, parotid, biliary tract, colon, rectum, cervix, uterus, endometrium, kidney, bladder, thyroid cancer; primary tumors and metastases; melanomas; glioblastoma;

15 Kaposi's sarcoma; leiomyosarcoma; non-small cell lung cancer; colorectal cancer; advanced malignancies; and blood born tumors such as leukemias. For example, polynucleotides, polypeptides, antagonists and/or agonists may be delivered topically, in order to treat or prevent cancers such as skin cancer, head and neck tumors, breast tumors, and Kaposi's sarcoma.

20 Within yet other aspects, polynucleotides, polypeptides, antagonists and/or agonists may be utilized to treat superficial forms of bladder cancer by, for example, intravesical administration. Polynucleotides, polypeptides, antagonists and/or agonists may be delivered directly into the tumor, or near the tumor site, via injection or a catheter. Of course, as the artisan of ordinary skill will appreciate, the appropriate

25 mode of administration will vary according to the cancer to be treated. Other modes of delivery are discussed herein.



Polynucleotides, polypeptides, antagonists and/or agonists may be useful in treating, preventing, and/or diagnosing other diseases, disorders, and/or conditions, besides cancers, which involve angiogenesis. These diseases, disorders, and/or conditions include, but are not limited to: benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis.

For example, within one aspect of the present invention methods are provided for treating, preventing, and/or diagnosing hypertrophic scars and keloids, comprising the step of administering a polynucleotide, polypeptide, antagonist and/or agonist of the invention to a hypertrophic scar or keloid.

Within one embodiment of the present invention polynucleotides, polypeptides, antagonists and/or agonists are directly injected into a hypertrophic scar or keloid, in order to prevent the progression of these lesions. This therapy is of particular value in the prophylactic treatment of conditions which are known to result in the development of hypertrophic scars and keloids (e.g., burns), and is preferably initiated after the proliferative phase has had time to progress (approximately 14 days after the initial injury), but before hypertrophic scar or keloid development. As noted

above, the present invention also provides methods for treating, preventing, and/or diagnosing neovascular diseases of the eye, including for example, corneal neovascularization, neovascular glaucoma, proliferative diabetic retinopathy, retrolental fibroplasia and macular degeneration.

5           Moreover, Ocular diseases, disorders, and/or conditions associated with neovascularization which can be treated, prevented, and/or diagnosed with the polynucleotides and polypeptides of the present invention (including agonists and/or antagonists) include, but are not limited to: neovascular glaucoma, diabetic retinopathy, retinoblastoma, retrolental fibroplasia, uveitis, retinopathy of prematurity  
10   macular degeneration, corneal graft neovascularization, as well as other eye inflammatory diseases, ocular tumors and diseases associated with choroidal or iris neovascularization. See, e.g., reviews by Waltman *et al.*, *Am. J. Ophthalmol.* 85:704-710 (1978) and Gartner *et al.*, *Surv. Ophthalmol.* 22:291-312 (1978).

          Thus, within one aspect of the present invention methods are provided for  
15   treating or preventing neovascular diseases of the eye such as corneal neovascularization (including corneal graft neovascularization), comprising the step of administering to a patient a therapeutically effective amount of a compound (as described above) to the cornea, such that the formation of blood vessels is inhibited. Briefly, the cornea is a tissue which normally lacks blood vessels. In certain  
20   pathological conditions however, capillaries may extend into the cornea from the pericorneal vascular plexus of the limbus. When the cornea becomes vascularized, it also becomes clouded, resulting in a decline in the patient's visual acuity. Visual loss may become complete if the cornea completely opacitates. A wide variety of diseases, disorders, and/or conditions can result in corneal neovascularization,  
25   including for example, corneal infections (e.g., trachoma, herpes simplex keratitis, leishmaniasis and onchocerciasis), immunological processes (e.g., graft rejection and

Stevens-Johnson's syndrome), alkali burns, trauma, inflammation (of any cause), toxic and nutritional deficiency states, and as a complication of wearing contact lenses.

Within particularly preferred embodiments of the invention, may be prepared  
5 for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in eyedrop form. The solution or suspension may be prepared in its pure form and administered several times daily. Alternatively, anti-angiogenic compositions, prepared as described above, may also be administered directly to the cornea. Within  
10 preferred embodiments, the anti-angiogenic composition is prepared with a muco-adhesive polymer which binds to cornea. Within further embodiments, the anti-angiogenic factors or anti-angiogenic compositions may be utilized as an adjunct to conventional steroid therapy. Topical therapy may also be useful prophylactically in corneal lesions which are known to have a high probability of inducing an angiogenic  
15 response (such as chemical burns). In these instances the treatment, likely in combination with steroids, may be instituted immediately to help prevent subsequent complications.

Within other embodiments, the compounds described above may be injected directly into the corneal stroma by an ophthalmologist under microscopic guidance.  
20 The preferred site of injection may vary with the morphology of the individual lesion, but the goal of the administration would be to place the composition at the advancing front of the vasculature (i.e., interspersed between the blood vessels and the normal cornea). In most cases this would involve perilimbic corneal injection to "protect" the cornea from the advancing blood vessels. This method may also be utilized shortly  
25 after a corneal insult in order to prophylactically prevent corneal neovascularization. In this situation the material could be injected in the perilimbic cornea interspersed

between the corneal lesion and its undesired potential limbic blood supply. Such methods may also be utilized in a similar fashion to prevent capillary invasion of transplanted corneas. In a sustained-release form injections might only be required 2-3 times per year. A steroid could also be added to the injection solution to reduce inflammation resulting from the injection itself.

Within another aspect of the present invention, methods are provided for treating or preventing neovascular glaucoma, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. In one embodiment, the compound may be administered topically to the eye in order to treat or prevent early forms of neovascular glaucoma. Within other embodiments, the compound may be implanted by injection into the region of the anterior chamber angle. Within other embodiments, the compound may also be placed in any location such that the compound is continuously released into the aqueous humor. Within another aspect of the present invention, methods are provided for treating or preventing proliferative diabetic retinopathy, comprising the step of administering to a patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eyes, such that the formation of blood vessels is inhibited.

Within particularly preferred embodiments of the invention, proliferative diabetic retinopathy may be treated by injection into the aqueous humor or the vitreous, in order to increase the local concentration of the polynucleotide, polypeptide, antagonist and/or agonist in the retina. Preferably, this treatment should be initiated prior to the acquisition of severe disease requiring photocoagulation.

Within another aspect of the present invention, methods are provided for treating or preventing retrolental fibroplasia, comprising the step of administering to a

patient a therapeutically effective amount of a polynucleotide, polypeptide, antagonist and/or agonist to the eye, such that the formation of blood vessels is inhibited. The compound may be administered topically, via intravitreal injection and/or via intraocular implants.

5           Additionally, diseases, disorders, and/or conditions which can be treated, prevented, and/or diagnosed with the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, hemangioma, arthritis, psoriasis, angiofibroma, atherosclerotic plaques, delayed wound healing, granulations, hemophilic joints, hypertrophic scars, nonunion fractures, Osler-Weber syndrome,  
10           pyogenic granuloma, scleroderma, trachoma, and vascular adhesions.

          Moreover, diseases, disorders, and/or conditions and/or states, which can be treated, prevented, and/or diagnosed with the the polynucleotides, polypeptides, agonists and/or agonists include, but are not limited to, solid tumors, blood born tumors such as leukemias, tumor metastasis, Kaposi's sarcoma, benign tumors, for  
15           example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas, rheumatoid arthritis, psoriasis, ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, and uveitis, delayed wound healing, endometriosis, vasculogenesis, granulations,  
20           hypertrophic scars (keloids), nonunion fractures, scleroderma, trachoma, vascular adhesions, myocardial angiogenesis, coronary collaterals, cerebral collaterals, arteriovenous malformations, ischemic limb angiogenesis, Osler-Webber Syndrome, plaque neovascularization, telangiectasia, hemophilic joints, angiofibroma fibromuscular dysplasia, wound granulation, Crohn's disease, atherosclerosis, birth  
25           control agent by preventing vascularization required for embryo implantation controlling menstruation, diseases that have angiogenesis as a pathologic consequence

such as cat scratch disease (*Rochelle minalia quintosa*), ulcers (*Helicobacter pylori*), Bartonellosis and bacillary angiomatosis.

In one aspect of the birth control method, an amount of the compound sufficient to block embryo implantation is administered before or after intercourse and  
5 fertilization have occurred, thus providing an effective method of birth control, possibly a "morning after" method. Polynucleotides, polypeptides, agonists and/or agonists may also be used in controlling menstruation or administered as either a peritoneal lavage fluid or for peritoneal implantation in the treatment of endometriosis.

10 Polynucleotides, polypeptides, agonists and/or agonists of the present invention may be incorporated into surgical sutures in order to prevent stitch granulomas.

Polynucleotides, polypeptides, agonists and/or agonists may be utilized in a wide variety of surgical procedures. For example, within one aspect of the present  
15 invention a compositions (in the form of, for example, a spray or film) may be utilized to coat or spray an area prior to removal of a tumor, in order to isolate normal surrounding tissues from malignant tissue, and/or to prevent the spread of disease to surrounding tissues. Within other aspects of the present invention, compositions (e.g., in the form of a spray) may be delivered via endoscopic procedures in order to coat  
20 tumors, or inhibit angiogenesis in a desired locale. Within yet other aspects of the present invention, surgical meshes which have been coated with anti- angiogenic compositions of the present invention may be utilized in any procedure wherein a surgical mesh might be utilized. For example, within one embodiment of the invention a surgical mesh laden with an anti-angiogenic composition may be utilized  
25 during abdominal cancer resection surgery (e.g., subsequent to colon resection) in

order to provide support to the structure, and to release an amount of the anti-angiogenic factor.

Within further aspects of the present invention, methods are provided for treating tumor excision sites, comprising administering a polynucleotide, polypeptide, agonist and/or agonist to the resection margins of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at the site is inhibited. Within one embodiment of the invention, the anti-angiogenic compound is administered directly to the tumor excision site (e.g., applied by swabbing, brushing or otherwise coating the resection margins of the tumor with the anti-angiogenic compound). Alternatively, the anti-angiogenic compounds may be incorporated into known surgical pastes prior to administration. Within particularly preferred embodiments of the invention, the anti-angiogenic compounds are applied after hepatic resections for malignancy, and after neurosurgical operations.

Within one aspect of the present invention, polynucleotides, polypeptides, agonists and/or agonists may be administered to the resection margin of a wide variety of tumors, including for example, breast, colon, brain and hepatic tumors. For example, within one embodiment of the invention, anti-angiogenic compounds may be administered to the site of a neurological tumor subsequent to excision, such that the formation of new blood vessels at the site are inhibited.

The polynucleotides, polypeptides, agonists and/or agonists of the present invention may also be administered along with other anti-angiogenic factors. Representative examples of other anti-angiogenic factors include: Anti-Invasive Factor, retinoic acid and derivatives thereof, paclitaxel, Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-1, Plasminogen Activator Inhibitor-2, and various forms of the lighter "d group" transition metals.

Lighter "d group" transition metals include, for example, vanadium, molybdenum, tungsten, titanium, niobium, and tantalum species. Such transition metal species may form transition metal complexes. Suitable complexes of the above-mentioned transition metal species include oxo transition metal complexes.

- 5        Representative examples of vanadium complexes include oxo vanadium complexes such as vanadate and vanadyl complexes. Suitable vanadate complexes include metavanadate and orthovanadate complexes such as, for example, ammonium metavanadate, sodium metavanadate, and sodium orthovanadate. Suitable vanadyl complexes include, for example, vanadyl acetylacetonate and vanadyl sulfate  
10        including vanadyl sulfate hydrates such as vanadyl sulfate mono- and trihydrates.

- Representative examples of tungsten and molybdenum complexes also include oxo complexes. Suitable oxo tungsten complexes include tungstate and tungsten oxide complexes. Suitable tungstate complexes include ammonium tungstate, calcium tungstate, sodium tungstate dihydrate, and tungstic acid. Suitable tungsten  
15        oxides include tungsten (IV) oxide and tungsten (VI) oxide. Suitable oxo molybdenum complexes include molybdate, molybdenum oxide, and molybdenyl complexes. Suitable molybdate complexes include ammonium molybdate and its hydrates, sodium molybdate and its hydrates, and potassium molybdate and its hydrates. Suitable molybdenum oxides include molybdenum (VI) oxide, molybdenum  
20        (VI) oxide, and molybdic acid. Suitable molybdenyl complexes include, for example, molybdenyl acetylacetonate. Other suitable tungsten and molybdenum complexes include hydroxo derivatives derived from, for example, glycerol, tartaric acid, and sugars.

- A wide variety of other anti-angiogenic factors may also be utilized within the  
25        context of the present invention. Representative examples include platelet factor 4; protamine sulphate; sulphated chitin derivatives (prepared from queen crab shells),



(Murata et al., Cancer Res. 51:22-26, 1991); Sulphated Polysaccharide Peptidoglycan Complex (SP- PG) (the function of this compound may be enhanced by the presence of steroids such as estrogen, and tamoxifen citrate); Staurosporine; modulators of matrix metabolism, including for example, proline analogs, cishydroxyproline, d,L-  
5 3,4-dehydropoline, Thiaproline, alpha,alpha-dipyridyl, aminopropionitrile fumarate; 4-propyl-5-(4-pyridinyl)-2(3H)-oxazolone; Methotrexate; Mitoxantrone; Heparin; Interferons; 2 Macroglobulin-serum; ChIMP-3 (Pavloff et al., J. Bio. Chem. 267:17321-17326, 1992); Chymostatin (Tomkinson et al., Biochem J. 286:475-480, 1992); Cyclodextrin Tetradecasulfate; Eponemycin; Camptothecin; Fumagillin  
10 (Ingber et al., Nature 348:555-557, 1990); Gold Sodium Thiomalate ("GST"; Matsubara and Ziff, J. Clin. Invest. 79:1440-1446, 1987); anticollagenase-serum; alpha2-antiplasmin (Holmes et al., J. Biol. Chem. 262(4):1659-1664, 1987); Bisantrene (National Cancer Institute); Lobenzarit disodium (N-(2)-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA"; Takeuchi et al., Agents Actions 36:312-  
15 316, 1992); Thalidomide; Angostatic steroid; AGM-1470; carboxynaminolmidazole; and metalloproteinase inhibitors such as BB94.

#### Diseases at the Cellular Level

Diseases associated with increased cell survival or the inhibition of apoptosis  
20 that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides and/or antagonists or agonists of the invention, include cancers (such as follicular lymphomas, carcinomas with p53 mutations, and hormone-dependent tumors, including, but not limited to colon cancer, cardiac tumors, pancreatic cancer, melanoma, retinoblastoma, glioblastoma, lung cancer, intestinal cancer, testicular  
25 cancer, stomach cancer, neuroblastoma, myxoma, myoma, lymphoma, endothelioma, osteoblastoma, osteoclastoma, osteosarcoma, chondrosarcoma, adenoma, breast

cancer, prostate cancer, Kaposi's sarcoma and ovarian cancer); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and immune-related glomerulonephritis  
5 and rheumatoid arthritis) and viral infections (such as herpes viruses, pox viruses and adenoviruses), inflammation, graft v. host disease, acute graft rejection, and chronic graft rejection. In preferred embodiments, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention are used to inhibit growth, progression, and/or metasis of cancers, in particular those listed above.

10 Additional diseases or conditions associated with increased cell survival that could be treated, prevented or diagnosed by the polynucleotides or polypeptides, or agonists or antagonists of the invention, include, but are not limited to, progression, and/or metastases of malignancies and related disorders such as leukemia (including acute leukemias (e.g., acute lymphocytic leukemia, acute myelocytic leukemia  
15 (including myeloblastic, promyelocytic, myelomonocytic, monocytic, and erythroleukemia)) and chronic leukemias (e.g., chronic myelocytic (granulocytic) leukemia and chronic lymphocytic leukemia)), polycythemia vera, lymphomas (e.g., Hodgkin's disease and non-Hodgkin's disease), multiple myeloma, Waldenstrom's macroglobulinemia, heavy chain disease, and solid tumors including, but not limited  
20 to, sarcomas and carcinomas such as fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal  
25 cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary

carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilm's tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, 5 craniopharyngioma, ependymoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, and retinoblastoma.

Diseases associated with increased apoptosis that could be treated, prevented, and/or diagnosed by the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, include AIDS; neurodegenerative diseases, disorders, 10 and/or conditions (such as Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Retinitis pigmentosa, Cerebellar degeneration and brain tumor or prior associated disease); autoimmune diseases, disorders, and/or conditions (such as, multiple sclerosis, Sjogren's syndrome, Hashimoto's thyroiditis, biliary cirrhosis, Behcet's disease, Crohn's disease, polymyositis, systemic lupus erythematosus and 15 immune-related glomerulonephritis and rheumatoid arthritis) myelodysplastic syndromes (such as aplastic anemia), graft v. host disease, ischemic injury (such as that caused by myocardial infarction, stroke and reperfusion injury), liver injury (e.g., hepatitis related liver injury, ischemia/reperfusion injury, cholestosis (bile duct injury) and liver cancer); toxin-induced liver disease (such as that caused by alcohol), septic 20 shock, cachexia and anorexia.

#### **Wound Healing and Epithelial Cell Proliferation**

In accordance with yet a further aspect of the present invention, there is provided a process for utilizing the polynucleotides or polypeptides, and/or agonists 25 or antagonists of the invention, for therapeutic purposes, for example, to stimulate epithelial cell proliferation and basal keratinocytes for the purpose of wound healing,

and to stimulate hair follicle production and healing of dermal wounds. Polynucleotides or polypeptides, as well as agonists or antagonists of the invention, may be clinically useful in stimulating wound healing including surgical wounds, excisional wounds, deep wounds involving damage of the dermis and epidermis, eye  
5 tissue wounds, dental tissue wounds, oral cavity wounds, diabetic ulcers, dermal ulcers, cubitus ulcers, arterial ulcers, venous stasis ulcers, burns resulting from heat exposure or chemicals, and other abnormal wound healing conditions such as uremia, malnutrition, vitamin deficiencies and complications associated with systemic treatment with steroids, radiation therapy and antineoplastic drugs and  
10 antimetabolites. Polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote dermal reestablishment subsequent to dermal loss

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to increase the adherence of skin grafts to a wound bed and  
15 to stimulate re-epithelialization from the wound bed. The following are a non-exhaustive list of grafts that polynucleotides or polypeptides, agonists or antagonists of the invention, could be used to increase adherence to a wound bed: autografts, artificial skin, allografts, autodermic graft, autoepidermic grafts, avascular grafts, Blair-Brown grafts, bone graft, brephoplastic grafts, cutis graft, delayed graft, dermic graft,  
20 epidermic graft, fascia graft, full thickness graft, heterologous graft, xenograft, homologous graft, hyperplastic graft, lamellar graft, mesh graft, mucosal graft, Ollier-Thiersch graft, omentopial graft, patch graft, pedicle graft, penetrating graft, split skin graft, thick split graft. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, can be used to promote skin strength and to improve the  
25 appearance of aged skin.

It is believed that the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, will also produce changes in hepatocyte proliferation, and epithelial cell proliferation in the lung, breast, pancreas, stomach, small intestine, and large intestine. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could promote proliferation of epithelial cells such as sebocytes, hair follicles, hepatocytes, type II pneumocytes, mucin-producing goblet cells, and other epithelial cells and their progenitors contained within the skin, lung, liver, and gastrointestinal tract. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may promote proliferation of endothelial cells, keratinocytes, and basal keratinocytes.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could also be used to reduce the side effects of gut toxicity that result from radiation, chemotherapy treatments or viral infections. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may have a cytoprotective effect on the small intestine mucosa. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, may also stimulate healing of mucositis (mouth ulcers) that result from chemotherapy and viral infections.

The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could further be used in full regeneration of skin in full and partial thickness skin defects, including burns, (i.e., repopulation of hair follicles, sweat glands, and sebaceous glands), treatment of other skin defects such as psoriasis. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat epidermolysis bullosa, a defect in adherence of the epidermis to the underlying dermis which results in frequent, open and painful blisters by accelerating reepithelialization of these lesions. The polynucleotides or polypeptides, and/or

agonists or antagonists of the invention, could also be used to treat gastric and duodenal ulcers and help heal by scar formation of the mucosal lining and regeneration of glandular mucosa and duodenal mucosal lining more rapidly. Inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, are diseases which result in destruction of the mucosal surface of the small or large intestine, respectively. Thus, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to promote the resurfacing of the mucosal surface to aid more rapid healing and to prevent progression of inflammatory bowel disease. Treatment with the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, is expected to have a significant effect on the production of mucus throughout the gastrointestinal tract and could be used to protect the intestinal mucosa from injurious substances that are ingested or following surgery. The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to treat diseases associated with the under expression of the polynucleotides of the invention.

Moreover, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used to prevent and heal damage to the lungs due to various pathological states. A growth factor such as the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, which could stimulate proliferation and differentiation and promote the repair of alveoli and bronchiolar epithelium to prevent or treat acute or chronic lung damage. For example, emphysema, which results in the progressive loss of alveoli, and inhalation injuries, i.e., resulting from smoke inhalation and burns, that cause necrosis of the bronchiolar epithelium and alveoli could be effectively treated, prevented, and/or diagnosed using the polynucleotides or polypeptides, and/or agonists or antagonists of the invention. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the

invention, could be used to stimulate the proliferation of and differentiation of type II pneumocytes, which may help treat or prevent disease such as hyaline membrane diseases, such as infant respiratory distress syndrome and bronchopulmonary dysplasia, in premature infants.

5           The polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could stimulate the proliferation and differentiation of hepatocytes and, thus, could be used to alleviate or treat liver diseases and pathologies such as fulminant liver failure caused by cirrhosis, liver damage caused by viral hepatitis and toxic substances (i.e., acetaminophen, carbon tetrachloride and other hepatotoxins  
10   known in the art).

          In addition, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used treat or prevent the onset of diabetes mellitus. In patients with newly diagnosed Types I and II diabetes, where some islet cell function remains, the polynucleotides or polypeptides, and/or agonists or antagonists of the  
15   invention, could be used to maintain the islet function so as to alleviate, delay or prevent permanent manifestation of the disease. Also, the polynucleotides or polypeptides, and/or agonists or antagonists of the invention, could be used as an auxiliary in islet cell transplantation to improve or promote islet cell function.

20   —

### **Neurological Diseases**

          Nervous system diseases, disorders, and/or conditions, which can be treated, prevented, and/or diagnosed with the compositions of the invention (e.g., polypeptides, polynucleotides, and/or agonists or antagonists), include, but are not  
25   limited to, nervous system injuries, and diseases, disorders, and/or conditions which

result in either a disconnection of axons, a diminution or degeneration of neurons, or demyelination. Nervous system lesions which may be treated, prevented, and/or diagnosed in a patient (including human and non-human mammalian patients) according to the invention, include but are not limited to, the following lesions of

5 either the central (including spinal cord, brain) or peripheral nervous systems: (1) ischemic lesions, in which a lack of oxygen in a portion of the nervous system results in neuronal injury or death, including cerebral infarction or ischemia, or spinal cord infarction or ischemia; (2) traumatic lesions, including lesions caused by physical injury or associated with surgery, for example, lesions which sever a portion of the

10 nervous system, or compression injuries; (3) malignant lesions, in which a portion of the nervous system is destroyed or injured by malignant tissue which is either a nervous system associated malignancy or a malignancy derived from non-nervous system tissue; (4) infectious lesions, in which a portion of the nervous system is destroyed or injured as a result of infection, for example, by an abscess or associated

15 with infection by human immunodeficiency virus, herpes zoster, or herpes simplex virus or with Lyme disease, tuberculosis, syphilis; (5) degenerative lesions, in which a portion of the nervous system is destroyed or injured as a result of a degenerative process including but not limited to degeneration associated with Parkinson's disease, Alzheimer's disease, Huntington's chorea, or amyotrophic lateral sclerosis (ALS); (6)

20 lesions associated with nutritional diseases, disorders, and/or conditions, in which a portion of the nervous system is destroyed or injured by a nutritional disorder or disorder of metabolism including but not limited to, vitamin B12 deficiency, folic acid deficiency, Wernicke disease, tobacco-alcohol amblyopia, Marchiafava-Bignami disease (primary degeneration of the corpus callosum), and alcoholic cerebellar

25 degeneration; (7) neurological lesions associated with systemic diseases including, but not limited to, diabetes (diabetic neuropathy, Bell's palsy), systemic lupus



erythematosus, carcinoma, or sarcoidosis; (8) lesions caused by toxic substances including alcohol, lead, or particular neurotoxins; and (9) demyelinated lesions in which a portion of the nervous system is destroyed or injured by a demyelinating disease including, but not limited to, multiple sclerosis, human immunodeficiency virus-associated myelopathy, transverse myelopathy or various etiologies, progressive multifocal leukoencephalopathy, and central pontine myelinolysis.

In a preferred embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to protect neural cells from the damaging effects of cerebral hypoxia. According to this embodiment, the compositions of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral hypoxia. In one aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral ischemia. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with cerebral infarction. In another aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose or prevent neural cell injury associated with a stroke. In a further aspect of this embodiment, the polypeptides, polynucleotides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose neural cell injury associated with a heart attack.

The compositions of the invention which are useful for treating or preventing a nervous system disorder may be selected by testing for biological activity in promoting the survival or differentiation of neurons. For example, and not by way of limitation, compositions of the invention which elicit any of the following effects may be useful according to the invention: (1) increased survival time of neurons in culture;

(2) increased sprouting of neurons in culture or *in vivo*; (3) increased production of a neuron-associated molecule in culture or *in vivo*, *e.g.*, choline acetyltransferase or acetylcholinesterase with respect to motor neurons; or (4) decreased symptoms of neuron dysfunction *in vivo*. Such effects may be measured by any method known in the art. In preferred, non-limiting embodiments, increased survival of neurons may routinely be measured using a method set forth herein or otherwise known in the art, such as, for example, the method set forth in Arakawa et al. (J. Neurosci. 10:3507-3515 (1990)); increased sprouting of neurons may be detected by methods known in the art, such as, for example, the methods set forth in Pestronk et al. (Exp. Neurol. 70:65-82 (1980)) or Brown et al. (Ann. Rev. Neurosci. 4:17-42 (1981)); increased production of neuron-associated molecules may be measured by bioassay, enzymatic assay, antibody binding, Northern blot assay, etc., using techniques known in the art and depending on the molecule to be measured; and motor neuron dysfunction may be measured by assessing the physical manifestation of motor neuron disorder, *e.g.*, weakness, motor neuron conduction velocity, or functional disability.

In specific embodiments, motor neuron diseases, disorders, and/or conditions that may be treated, prevented, and/or diagnosed according to the invention include, but are not limited to, diseases, disorders, and/or conditions such as infarction, infection, exposure to toxin, trauma, surgical damage, degenerative disease or malignancy that may affect motor neurons as well as other components of the nervous system, as well as diseases, disorders, and/or conditions that selectively affect neurons such as amyotrophic lateral sclerosis, and including, but not limited to, progressive spinal muscular atrophy, progressive bulbar palsy, primary lateral sclerosis, infantile and juvenile muscular atrophy, progressive bulbar paralysis of childhood (Fazio-

Londe syndrome), poliomyelitis and the post polio syndrome, and Hereditary  
Motorsensory Neuropathy (Charcot-Marie-Tooth Disease).

### Infectious Disease

5           A polypeptide or polynucleotide and/or agonist or antagonist of the present  
invention can be used to treat, prevent, and/or diagnose infectious agents. For  
example, by increasing the immune response, particularly increasing the proliferation  
and differentiation of B and/or T cells, infectious diseases may be treated, prevented,  
and/or diagnosed. The immune response may be increased by either enhancing an  
10   existing immune response, or by initiating a new immune response. Alternatively,  
polypeptide or polynucleotide and/or agonist or antagonist of the present invention  
may also directly inhibit the infectious agent, without necessarily eliciting an immune  
response.

          Viruses are one example of an infectious agent that can cause disease or  
15   symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or  
polypeptide and/or agonist or antagonist of the present invention. Examples of  
viruses, include, but are not limited to Examples of viruses, include, but are not  
limited to the following DNA and RNA viruses and viral families: Arbovirus,  
Adenoviridae, Arenaviridae, Arterivirus, Birnaviridae, Bunyaviridae, Caliciviridae,  
20   Circoviridae, Coronaviridae, Dengue, EBV, HIV, Flaviviridae, Hepadnaviridae  
(Hepatitis), Herpesviridae (such as, Cytomegalovirus, Herpes Simplex, Herpes  
Zoster), Mononegavirus (e.g., Paramyxoviridae, Morbillivirus, Rhabdoviridae),  
Orthomyxoviridae (e.g., Influenza A, Influenza B, and parainfluenza), Papiloma  
virus, Papovaviridae, Parvoviridae, Picornaviridae, Poxviridae (such as Smallpox or  
25   Vaccinia), Reoviridae (e.g., Rotavirus), Retroviridae (HTLV-I, HTLV-II, Lentivirus),  
and Togaviridae (e.g., Rubivirus). Viruses falling within these families can cause a

variety of diseases or symptoms, including, but not limited to: arthritis, bronchiollitis, respiratory syncytial virus, encephalitis, eye infections (e.g., conjunctivitis, keratitis), chronic fatigue syndrome, hepatitis (A, B, C, E, Chronic Active, Delta), Japanese B encephalitis, Junin, Chikungunya, Rift Valley fever, yellow fever, meningitis, opportunistic infections (e.g., AIDS), pneumonia, Burkitt's Lymphoma, chickenpox, hemorrhagic fever, Measles, Mumps, Parainfluenza, Rabies, the common cold, Polio, leukemia, Rubella, sexually transmitted diseases, skin diseases (e.g., Kaposi's, warts), and viremia. polynucleotides or polypeptides, or agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose: meningitis, Dengue, EBV, and/or hepatitis (e.g., hepatitis B). In an additional specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat patients nonresponsive to one or more other commercially available hepatitis vaccines. In a further specific embodiment polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose AIDS.

Similarly, bacterial or fungal agents that can cause disease or symptoms and that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or antagonist of the present invention include, but not limited to, include, but not limited to, the following Gram-Negative and Gram-positive bacteria and bacterial families and fungi: Actinomycetales (e.g., Corynebacterium, Mycobacterium, Nocardia), Cryptococcus neoformans, Aspergillosis, Bacillaceae (e.g., Anthrax, Clostridium), Bacteroidaceae, Blastomycosis, Bordetella, Borrelia (e.g., Borrelia burgdorferi), Brucellosis, Candidiasis, Campylobacter, Coccidioidomycosis, Cryptococcosis, Dermatocycoses, E. coli (e.g., Enterotoxigenic

- E. coli and Enterohemorrhagic E. coli), Enterobacteriaceae (Klebsiella, Salmonella (e.g., Salmonella typhi, and Salmonella paratyphi), Serratia, Yersinia), Erysipelothrix, Helicobacter, Legionellosis, Leptospirosis, Listeria, Mycoplasmatales, Mycobacterium leprae, Vibrio cholerae, Neisseriaceae (e.g., Acinetobacter,
- 5 Gonorrhea, Meningococcal), Meisseria meningitidis, Pasteurellacea Infections (e.g., Actinobacillus, Heamophilus (e.g., Heamophilus influenza type B), Pasteurella), Pseudomonas, Rickettsiaceae, Chlamydiaceae, Syphilis, Shigella spp., Staphylococcal, Meningiococcal, Pneumococcal and Streptococcal (e.g., Streptococcus pneumoniae and Group B Streptococcus). These bacterial or fungal
- 10 families can cause the following diseases or symptoms, including, but not limited to: bacteremia, endocarditis, eye infections (conjunctivitis, tuberculosis, uveitis), gingivitis, opportunistic infections (e.g., AIDS related infections), paronychia, prosthesis-related infections, Reiter's Disease, respiratory tract infections, such as Whooping Cough or Empyema, sepsis, Lyme Disease, Cat-Scratch Disease,
- 15 Dysentery, Paratyphoid Fever, food poisoning, Typhoid, pneumonia, Gonorrhea, meningitis (e.g., meningitis types A and B), Chlamydia, Syphilis, Diphtheria, Leprosy, Paratuberculosis, Tuberculosis, Lupus, Botulism, gangrene, tetanus, impetigo, Rheumatic Fever, Scarlet Fever, sexually transmitted diseases, skin diseases (e.g., cellulitis, dermatocycoses), toxemia, urinary tract infections, wound infections.
- 20 Polynucleotides or polypeptides, agonists or antagonists of the invention, can be used to treat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, agonists or antagonists of the invention are used to treat, prevent, and/or diagnose: tetanus, Diphtheria, botulism, and/or meningitis type B.
- 25 Moreover, parasitic agents causing disease or symptoms that can be treated, prevented, and/or diagnosed by a polynucleotide or polypeptide and/or agonist or

antagonist of the present invention include, but not limited to, the following families or class: Amebiasis, Babesiosis, Coccidiosis, Cryptosporidiosis, Dientamoebiasis, Dourine, Ectoparasitic, Giardiasis, Helminthiasis, Leishmaniasis, Theileriasis, Toxoplasmosis, Trypanosomiasis, and Trichomonas and Sporozoans (e.g.,

5 Plasmodium virax, Plasmodium falciparum, Plasmodium malariae and Plasmodium ovale). These parasites can cause a variety of diseases or symptoms, including, but not limited to: Scabies, Trombiculiasis, eye infections, intestinal disease (e.g., dysentery, giardiasis), liver disease, lung disease, opportunistic infections (e.g., AIDS related), malaria, pregnancy complications, and toxoplasmosis. polynucleotides or

10 polypeptides, or agonists or antagonists of the invention, can be used totreat, prevent, and/or diagnose any of these symptoms or diseases. In specific embodiments, polynucleotides, polypeptides, or agonists or antagonists of the invention are used to treat, prevent, and/or diagnose malaria.

Preferably, treatment or prevention using a polypeptide or polynucleotide

15 and/or agonist or antagonist of the present invention could either be by administering an effective amount of a polypeptide to the patient, or by removing cells from the patient, supplying the cells with a polynucleotide of the present invention, and returning the engineered cells to the patient (ex vivo therapy). Moreover, the polypeptide or polynucleotide of the present invention can be used as an antigen in a

20 vaccine to raise an immune response against infectious disease.

### **Regeneration**

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention can be used to differentiate, proliferate, and attract cells, leading to the

25 regeneration of tissues. (See, Science 276:59-87 (1997).) The regeneration of tissues could be used to repair, replace, or protect tissue damaged by congenital defects,

trauma (wounds, burns, incisions, or ulcers), age, disease (e.g. osteoporosis, osteoarthritis, periodontal disease, liver failure), surgery, including cosmetic plastic surgery, fibrosis, reperfusion injury, or systemic cytokine damage.

Tissues that could be regenerated using the present invention include organs  
5 (e.g., pancreas, liver, intestine, kidney, skin, endothelium), muscle (smooth, skeletal or cardiac), vasculature (including vascular and lymphatics), nervous, hematopoietic, and skeletal (bone, cartilage, tendon, and ligament) tissue. Preferably, regeneration occurs without or decreased scarring. Regeneration also may include angiogenesis.

Moreover, a polynucleotide or polypeptide and/or agonist or antagonist of the  
10 present invention may increase regeneration of tissues difficult to heal. For example, increased tendon/ligament regeneration would quicken recovery time after damage. A polynucleotide or polypeptide and/or agonist or antagonist of the present invention could also be used prophylactically in an effort to avoid damage. Specific diseases that could be treated, prevented, and/or diagnosed include of tendinitis, carpal tunnel  
15 syndrome, and other tendon or ligament defects. A further example of tissue regeneration of non-healing wounds includes pressure ulcers, ulcers associated with vascular insufficiency, surgical, and traumatic wounds.

Similarly, nerve and brain tissue could also be regenerated by using a polynucleotide or polypeptide and/or agonist or antagonist of the present invention to  
20 proliferate and differentiate nerve cells. Diseases that could be treated, prevented, and/or diagnosed using this method include central and peripheral nervous system diseases, neuropathies, or mechanical and traumatic diseases, disorders, and/or conditions (e.g., spinal cord disorders, head trauma, cerebrovascular disease, and stroke). Specifically, diseases associated with peripheral nerve injuries, peripheral  
25 neuropathy (e.g., resulting from chemotherapy or other medical therapies), localized neuropathies, and central nervous system diseases (e.g., Alzheimer's disease,

Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, and Shy-Drager syndrome), could all be treated, prevented, and/or diagnosed using the polynucleotide or polypeptide and/or agonist or antagonist of the present invention.

## 5 **Chemotaxis**

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may have chemotaxis activity. A chemotactic molecule attracts or mobilizes cells (e.g., monocytes, fibroblasts, neutrophils, T-cells, mast cells, eosinophils, epithelial and/or endothelial cells) to a particular site in the body, such as  
10 inflammation, infection, or site of hyperproliferation. The mobilized cells can then fight off and/or heal the particular trauma or abnormality.

A polynucleotide or polypeptide and/or agonist or antagonist of the present invention may increase chemotactic activity of particular cells. These chemotactic molecules can then be used to treat, prevent, and/or diagnose inflammation, infection,  
15 hyperproliferative diseases, disorders, and/or conditions, or any immune system disorder by increasing the number of cells targeted to a particular location in the body. For example, chemotactic molecules can be used to treat, prevent, and/or diagnose wounds and other trauma to tissues by attracting immune cells to the injured location. Chemotactic molecules of the present invention can also attract fibroblasts, which can  
20 be used to treat, prevent, and/or diagnose wounds.

It is also contemplated that a polynucleotide or polypeptide and/or agonist or antagonist of the present invention may inhibit chemotactic activity. These molecules could also be used to treat, prevent, and/or diagnose diseases, disorders, and/or conditions. Thus, a polynucleotide or polypeptide and/or agonist or antagonist of the  
25 present invention could be used as an inhibitor of chemotaxis.



### **Binding Activity**

A polypeptide of the present invention may be used to screen for molecules that bind to the polypeptide or for molecules to which the polypeptide binds. The  
5 binding of the polypeptide and the molecule may activate (agonist), increase, inhibit (antagonist), or decrease activity of the polypeptide or the molecule bound. Examples of such molecules include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

Preferably, the molecule is closely related to the natural ligand of the  
10 polypeptide, e.g., a fragment of the ligand, or a natural substrate, a ligand, a structural or functional mimetic. (See, Coligan et al., Current Protocols in Immunology 1(2):Chapter 5 (1991).) Similarly, the molecule can be closely related to the natural receptor to which the polypeptide binds, or at least, a fragment of the receptor capable of being bound by the polypeptide (e.g., active site). In either case, the molecule can  
15 be rationally designed using known techniques.

Preferably, the screening for these molecules involves producing appropriate cells which express the polypeptide, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, *Drosophila*, or *E. coli*. Cells expressing the polypeptide (or cell membrane containing the expressed  
20 polypeptide) are then preferably contacted with a test compound potentially containing the molecule to observe binding, stimulation, or inhibition of activity of either the polypeptide or the molecule.

The assay may simply test binding of a candidate compound to the polypeptide, wherein binding is detected by a label, or in an assay involving  
25 competition with a labeled competitor. Further, the assay may test whether the candidate compound results in a signal generated by binding to the polypeptide.

Alternatively, the assay can be carried out using cell-free preparations, polypeptide/molecule affixed to a solid support, chemical libraries, or natural product mixtures. The assay may also simply comprise the steps of mixing a candidate compound with a solution containing a polypeptide, measuring polypeptide/molecule activity or binding, and comparing the polypeptide/molecule activity or binding to a standard.

Preferably, an ELISA assay can measure polypeptide level or activity in a sample (e.g., biological sample) using a monoclonal or polyclonal antibody. The antibody can measure polypeptide level or activity by either binding, directly or indirectly, to the polypeptide or by competing with the polypeptide for a substrate.

Additionally, the receptor to which a polypeptide of the invention binds can be identified by numerous methods known to those of skill in the art, for example, ligand panning and FACS sorting (Coligan, et al., Current Protocols in Immun., 1(2), Chapter 5, (1991)). For example, expression cloning is employed wherein polyadenylated RNA is prepared from a cell responsive to the polypeptides, for example, NIH3T3 cells which are known to contain multiple receptors for the FGF family proteins, and SC-3 cells, and a cDNA library created from this RNA is divided into pools and used to transfect COS cells or other cells that are not responsive to the polypeptides. Transfected cells which are grown on glass slides are exposed to the polypeptide of the present invention, after they have been labelled. The polypeptides can be labeled by a variety of means including iodination or inclusion of a recognition site for a site-specific protein kinase.

Following fixation and incubation, the slides are subjected to autoradiographic analysis. Positive pools are identified and sub-pools are prepared and retransfected using an iterative sub-pooling and re-screening process, eventually yielding a single clones that encodes the putative receptor.

As an alternative approach for receptor identification, the labeled polypeptides can be photoaffinity linked with cell membrane or extract preparations that express the receptor molecule. Cross-linked material is resolved by PAGE analysis and exposed to X-ray film. The labeled complex containing the receptors of the polypeptides can be excised, resolved into peptide fragments, and subjected to protein microsequencing. The amino acid sequence obtained from microsequencing would be used to design a set of degenerate oligonucleotide probes to screen a cDNA library to identify the genes encoding the putative receptors.

Moreover, the techniques of gene-shuffling, motif-shuffling, exon-shuffling, and/or codon-shuffling (collectively referred to as "DNA shuffling") may be employed to modulate the activities of polypeptides of the invention thereby effectively generating agonists and antagonists of polypeptides of the invention. See generally, U.S. Patent Nos. 5,605,793, 5,811,238, 5,830,721, 5,834,252, and 5,837,458, and Patten, P. A., et al., *Curr. Opinion Biotechnol.* 8:724-33 (1997); Harayama, S. *Trends Biotechnol.* 16(2):76-82 (1998); Hansson, L. O., et al., *J. Mol. Biol.* 287:265-76 (1999); and Lorenzo, M. M. and Blasco, R. *Biotechniques* 24(2):308-13 (1998) (each of these patents and publications are hereby incorporated by reference). In one embodiment, alteration of polynucleotides and corresponding polypeptides of the invention may be achieved by DNA shuffling. DNA shuffling involves the assembly of two or more DNA segments into a desired polynucleotide sequence of the invention molecule by homologous, or site-specific, recombination. In another embodiment, polynucleotides and corresponding polypeptides of the invention may be altered by being subjected to random mutagenesis by error-prone PCR, random nucleotide insertion or other methods prior to recombination. In another embodiment, one or more components, motifs, sections, parts, domains, fragments, etc., of the polypeptides of the invention may be recombined with one or

more components, motifs, sections, parts, domains, fragments, etc. of one or more heterologous molecules. In preferred embodiments, the heterologous molecules are family members. In further preferred embodiments, the heterologous molecule is a growth factor such as, for example, platelet-derived growth factor (PDGF),  
5 insulin-like growth factor (IGF-I), transforming growth factor (TGF)-alpha, epidermal growth factor (EGF), fibroblast growth factor (FGF), TGF-beta, bone morphogenetic protein (BMP)-2, BMP-4, BMP-5, BMP-6, BMP-7, activins A and B, decapentaplegic(dpp), 60A, OP-2, dorsalin, growth differentiation factors (GDFs), nodal, MIS, inhibin-alpha, TGF-beta1, TGF-beta2, TGF-beta3, TGF-beta5, and glial-  
10 derived neurotrophic factor (GDNF).

Other preferred fragments are biologically active fragments of the polypeptides of the invention. Biologically active fragments are those exhibiting activity similar, but not necessarily identical, to an activity of the polypeptide. The biological activity of the fragments may include an improved desired activity, or a  
15 decreased undesirable activity.

Additionally, this invention provides a method of screening compounds to identify those which modulate the action of the polypeptide of the present invention. An example of such an assay comprises combining a mammalian fibroblast cell, a the polypeptide of the present invention, the compound to be screened and 3[H]  
20 thymidine under cell culture conditions where the fibroblast cell would normally proliferate. A control assay may be performed in the absence of the compound to be screened and compared to the amount of fibroblast proliferation in the presence of the compound to determine if the compound stimulates proliferation by determining the uptake of 3[H] thymidine in each case. The amount of fibroblast cell proliferation is  
25 measured by liquid scintillation chromatography which measures the incorporation of

3[H] thymidine. Both agonist and antagonist compounds may be identified by this procedure.

In another method, a mammalian cell or membrane preparation expressing a receptor for a polypeptide of the present invention is incubated with a labeled polypeptide of the present invention in the presence of the compound. The ability of the compound to enhance or block this interaction could then be measured. Alternatively, the response of a known second messenger system following interaction of a compound to be screened and the receptor is measured and the ability of the compound to bind to the receptor and elicit a second messenger response is measured to determine if the compound is a potential agonist or antagonist. Such second messenger systems include but are not limited to, cAMP guanylate cyclase, ion channels or phosphoinositide hydrolysis.

All of these above assays can be used as diagnostic or prognostic markers. The molecules discovered using these assays can be used to treat, prevent, and/or diagnose disease or to bring about a particular result in a patient (e.g., blood vessel growth) by activating or inhibiting the polypeptide/molecule. Moreover, the assays can discover agents which may inhibit or enhance the production of the polypeptides of the invention from suitably manipulated cells or tissues. Therefore, the invention includes a method of identifying compounds which bind to the polypeptides of the invention comprising the steps of: (a) incubating a candidate binding compound with the polypeptide; and (b) determining if binding has occurred. Moreover, the invention includes a method of identifying agonists/antagonists comprising the steps of: (a) incubating a candidate compound with the polypeptide, (b) assaying a biological activity, and (b) determining if a biological activity of the polypeptide has been altered.

Also, one could identify molecules bind a polypeptide of the invention

experimentally by using the beta-pleated sheet regions contained in the polypeptide sequence of the protein. Accordingly, specific embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of, the amino acid sequence of each beta pleated sheet regions in a disclosed polypeptide sequence. Additional embodiments of the invention are directed to polynucleotides encoding polypeptides which comprise, or alternatively consist of, any combination or all of contained in the polypeptide sequences of the invention. Additional preferred embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, the amino acid sequence of each of the beta pleated sheet regions in one of the polypeptide sequences of the invention. Additional embodiments of the invention are directed to polypeptides which comprise, or alternatively consist of, any combination or all of the beta pleated sheet regions in one of the polypeptide sequences of the invention.

### 15 **Targeted Delivery**

In another embodiment, the invention provides a method of delivering compositions to targeted cells expressing a receptor for a polypeptide of the invention, or cells expressing a cell bound form of a polypeptide of the invention.

As discussed herein, polypeptides or antibodies of the invention may be associated with heterologous polypeptides, heterologous nucleic acids, toxins, or prodrugs via hydrophobic, hydrophilic, ionic and/or covalent interactions. In one embodiment, the invention provides a method for the specific delivery of compositions of the invention to cells by administering polypeptides of the invention (including antibodies) that are associated with heterologous polypeptides or nucleic acids. In one example, the invention provides a method for delivering a therapeutic protein into the targeted cell. In another example, the invention provides a method for

delivering a single stranded nucleic acid (e.g., antisense or ribozymes) or double stranded nucleic acid (e.g., DNA that can integrate into the cell's genome or replicate episomally and that can be transcribed) into the targeted cell.

In another embodiment, the invention provides a method for the specific  
5 destruction of cells (e.g., the destruction of tumor cells) by administering polypeptides of the invention (e.g., polypeptides of the invention or antibodies of the invention) in association with toxins or cytotoxic prodrugs.

By "toxin" is meant compounds that bind and activate endogenous cytotoxic effector systems, radioisotopes, holotoxins, modified toxins, catalytic subunits of  
10 toxins, or any molecules or enzymes not normally present in or on the surface of a cell that under defined conditions cause the cell's death. Toxins that may be used according to the methods of the invention include, but are not limited to, radioisotopes known in the art, compounds such as, for example, antibodies (or complement fixing containing portions thereof) that bind an inherent or induced endogenous cytotoxic  
15 effector system, thymidine kinase, endonuclease, RNase, alpha toxin, ricin, abrin, *Pseudomonas* exotoxin A, diphtheria toxin, saporin, momordin, gelonin, pokeweed antiviral protein, alpha-sarcin and cholera toxin. By "cytotoxic prodrug" is meant a non-toxic compound that is converted by an enzyme, normally present in the cell, into a cytotoxic compound. Cytotoxic prodrugs that may be used according to the  
20 methods of the invention include, but are not limited to, glutamyl derivatives of benzoic acid mustard alkylating agent, phosphate derivatives of etoposide or mitomycin C, cytosine arabinoside, daunorubisin, and phenoxyacetamide derivatives of doxorubicin.

## 25 Drug Screening

Further contemplated is the use of the polypeptides of the present invention, or

the polynucleotides encoding these polypeptides, to screen for molecules which modify the activities of the polypeptides of the present invention. Such a method would include contacting the polypeptide of the present invention with a selected compound(s) suspected of having antagonist or agonist activity, and assaying the  
5 activity of these polypeptides following binding.

This invention is particularly useful for screening therapeutic compounds by using the polypeptides of the present invention, or binding fragments thereof, in any of a variety of drug screening techniques. The polypeptide or fragment employed in such a test may be affixed to a solid support, expressed on a cell surface, free in  
10 solution, or located intracellularly. One method of drug screening utilizes eukaryotic or prokaryotic host cells which are stably transformed with recombinant nucleic acids expressing the polypeptide or fragment. Drugs are screened against such transformed cells in competitive binding assays. One may measure, for example, the formulation of complexes between the agent being tested and a polypeptide of the present  
15 invention.

Thus, the present invention provides methods of screening for drugs or any other agents which affect activities mediated by the polypeptides of the present invention. These methods comprise contacting such an agent with a polypeptide of the present invention or a fragment thereof and assaying for the presence of a complex  
20 between the agent and the polypeptide or a fragment thereof, by methods well known in the art. In such a competitive binding assay, the agents to screen are typically labeled. Following incubation, free agent is separated from that present in bound form, and the amount of free or uncomplexed label is a measure of the ability of a particular agent to bind to the polypeptides of the present invention.

25 Another technique for drug screening provides high throughput screening for compounds having suitable binding affinity to the polypeptides of the present



invention, and is described in great detail in European Patent Application 84/03564, published on September 13, 1984, which is incorporated herein by reference herein.

Briefly stated, large numbers of different small peptide test compounds are synthesized on a solid substrate, such as plastic pins or some other surface. The peptide test compounds are reacted with polypeptides of the present invention and washed. Bound polypeptides are then detected by methods well known in the art. Purified polypeptides are coated directly onto plates for use in the aforementioned drug screening techniques. In addition, non-neutralizing antibodies may be used to capture the peptide and immobilize it on the solid support.

10           This invention also contemplates the use of competitive drug screening assays in which neutralizing antibodies capable of binding polypeptides of the present invention specifically compete with a test compound for binding to the polypeptides or fragments thereof. In this manner, the antibodies are used to detect the presence of any peptide which shares one or more antigenic epitopes with a polypeptide of the invention.

#### **Antisense And Ribozyme (Antagonists)**

In specific embodiments, antagonists according to the present invention are nucleic acids corresponding to the sequences contained in SEQ ID NO:X, or the complementary strand thereof, and/or to nucleotide sequences contained a deposited clone. In one embodiment, antisense sequence is generated internally by the organism, in another embodiment, the antisense sequence is separately administered (see, for example, O'Connor, Neurochem., 56:560 (1991). Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression, CRC Press, Boca Raton, FL (1988).

25   Antisense technology can be used to control gene expression through antisense DNA or RNA, or through triple-helix formation. Antisense techniques are discussed for

example, in Okano, *Neurochem.*, 56:560 (1991); *Oligodeoxynucleotides as Antisense Inhibitors of Gene Expression*, CRC Press, Boca Raton, FL (1988). Triple helix formation is discussed in, for instance, Lee et al., *Nucleic Acids Research*, 6:3073 (1979); Cooney et al., *Science*, 241:456 (1988); and Dervan et al., *Science*, 251:1300  
5 (1991). The methods are based on binding of a polynucleotide to a complementary DNA or RNA.

For example, the use of c-myc and c-myb antisense RNA constructs to inhibit the growth of the non-lymphocytic leukemia cell line HL-60 and other cell lines was previously described. (Wickstrom et al. (1988); Anfossi et al. (1989)). These  
10 experiments were performed in vitro by incubating cells with the oligoribonucleotide. A similar procedure for in vivo use is described in WO 91/15580. Briefly, a pair of oligonucleotides for a given antisense RNA is produced as follows: A sequence complimentary to the first 15 bases of the open reading frame is flanked by an EcoRI site on the 5' end and a HindIII site on the 3' end. Next, the pair of oligonucleotides is  
15 heated at 90°C for one minute and then annealed in 2X ligation buffer (20mM TRIS HCl pH 7.5, 10mM MgCl<sub>2</sub>, 10mM dithiothreitol (DTT) and 0.2 mM ATP) and then ligated to the EcoRI/Hind III site of the retroviral vector PMV7 (WO 91/15580).

For example, the 5' coding portion of a polynucleotide that encodes the mature polypeptide of the present invention may be used to design an antisense RNA  
20 oligonucleotide of from about 10 to 40 base pairs in length. A DNA oligonucleotide is designed to be complementary to a region of the gene involved in transcription thereby preventing transcription and the production of the receptor. The antisense RNA oligonucleotide hybridizes to the mRNA in vivo and blocks translation of the mRNA molecule into receptor polypeptide.

25 In one embodiment, the antisense nucleic acid of the invention is produced intracellularly by transcription from an exogenous sequence. For example, a vector or

a portion thereof, is transcribed, producing an antisense nucleic acid (RNA) of the invention. Such a vector would contain a sequence encoding the antisense nucleic acid of the invention. Such a vector can remain episomal or become chromosomally integrated, as long as it can be transcribed to produce the desired antisense RNA.

- 5 Such vectors can be constructed by recombinant DNA technology methods standard in the art. Vectors can be plasmid, viral, or others known in the art, used for replication and expression in vertebrate cells. Expression of the sequence encoding a polypeptide of the invention, or fragments thereof, can be by any promoter known in the art to act in vertebrate, preferably human cells. Such promoters can be inducible
- 10 or constitutive. Such promoters include, but are not limited to, the SV40 early promoter region (Bernoist and Chambon, *Nature*, 29:304-310 (1981), the promoter contained in the 3' long terminal repeat of Rous sarcoma virus (Yamamoto et al., *Cell*, 22:787-797 (1980), the herpes thymidine promoter (Wagner et al., *Proc. Natl. Acad. Sci. U.S.A.*, 78:1441-1445 (1981), the regulatory sequences of the
- 15 metallothionein gene (Brinster et al., *Nature*, 296:39-42 (1982)), etc.

- The antisense nucleic acids of the invention comprise a sequence complementary to at least a portion of an RNA transcript of a gene of interest. However, absolute complementarity, although preferred, is not required. A sequence "complementary to at least a portion of an RNA," referred to herein, means a
- 20 sequence having sufficient complementarity to be able to hybridize with the RNA, forming a stable duplex; in the case of double stranded antisense nucleic acids of the invention, a single strand of the duplex DNA may thus be tested, or triplex formation may be assayed. The ability to hybridize will depend on both the degree of complementarity and the length of the antisense nucleic acid. Generally, the larger the
- 25 hybridizing nucleic acid, the more base mismatches with a RNA sequence of the invention it may contain and still form a stable duplex (or triplex as the case may be).

One skilled in the art can ascertain a tolerable degree of mismatch by use of standard procedures to determine the melting point of the hybridized complex.

Oligonucleotides that are complementary to the 5' end of the message, *e.g.*, the 5' untranslated sequence up to and including the AUG initiation codon, should  
5 work most efficiently at inhibiting translation. However, sequences complementary to the 3' untranslated sequences of mRNAs have been shown to be effective at inhibiting translation of mRNAs as well. See generally, Wagner, R., *Nature*, 372:333-335 (1994). Thus, oligonucleotides complementary to either the 5' - or 3' - non- translated, non-coding regions of a polynucleotide sequence of the invention  
10 could be used in an antisense approach to inhibit translation of endogenous mRNA. Oligonucleotides complementary to the 5' untranslated region of the mRNA should include the complement of the AUG start codon. Antisense oligonucleotides complementary to mRNA coding regions are less efficient inhibitors of translation but could be used in accordance with the invention. Whether designed to hybridize to the  
15 5' -, 3' - or coding region of mRNA, antisense nucleic acids should be at least six nucleotides in length, and are preferably oligonucleotides ranging from 6 to about 50 nucleotides in length. In specific aspects the oligonucleotide is at least 10 nucleotides, at least 17 nucleotides, at least 25 nucleotides or at least 50 nucleotides.

The polynucleotides of the invention can be DNA or RNA or chimeric  
20 mixtures or derivatives or modified versions thereof, single-stranded or double-stranded. The oligonucleotide can be modified at the base moiety, sugar moiety, or phosphate backbone, for example, to improve stability of the molecule, hybridization, etc. The oligonucleotide may include other appended groups such as peptides (*e.g.*, for targeting host cell receptors *in vivo*), or agents facilitating transport across the cell  
25 membrane (see, *e.g.*, Letsinger et al., *Proc. Natl. Acad. Sci. U.S.A.* 86:6553-6556 (1989); Lemaitre et al., *Proc. Natl. Acad. Sci.*, 84:648-652 (1987); PCT Publication

NO: WO88/09810, published December 15, 1988) or the blood-brain barrier (see, e.g., PCT Publication NO: WO89/10134, published April 25, 1988), hybridization-triggered cleavage agents. (See, e.g., Krol et al., *BioTechniques*, 6:958-976 (1988)) or intercalating agents. (See, e.g., Zon, *Pharm. Res.*, 5:539-549 (1988)). To this end,

5 the oligonucleotide may be conjugated to another molecule, e.g., a peptide, hybridization triggered cross-linking agent, transport agent, hybridization-triggered cleavage agent, etc.

The antisense oligonucleotide may comprise at least one modified base moiety which is selected from the group including, but not limited to, 5-fluorouracil,

10 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine,

15 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxymethylaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil,

20 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide may also comprise at least one modified sugar moiety selected from the group including, but not limited to, arabinose,

25 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide comprises at least one modified phosphate backbone selected from the group including, but not limited to, a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an a-anomeric oligonucleotide. An a-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual b-units, the strands run parallel to each other (Gautier et al., Nucl. Acids Res., 15:6625-6641 (1987)).

10 The oligonucleotide is a 2-O-methylribonucleotide (Inoue et al., Nucl. Acids Res., 15:6131-6148 (1987)), or a chimeric RNA-DNA analogue (Inoue et al., FEBS Lett. 215:327-330 (1987)).

Polynucleotides of the invention may be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples,

15 phosphorothioate oligonucleotides may be synthesized by the method of Stein et al. (Nucl. Acids Res., 16:3209 (1988)), methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., Proc. Natl. Acad. Sci. U.S.A., 85:7448-7451 (1988)), etc.

20 While antisense nucleotides complementary to the coding region sequence of the invention could be used, those complementary to the transcribed untranslated region are most preferred.

Potential antagonists according to the invention also include catalytic RNA, or a ribozyme (See, e.g., PCT International Publication WO 90/11364, published

25 October 4, 1990; Sarver et al, Science, 247:1222-1225 (1990). While ribozymes that cleave mRNA at site specific recognition sequences can be used to destroy mRNAs

corresponding to the polynucleotides of the invention, the use of hammerhead ribozymes is preferred. Hammerhead ribozymes cleave mRNAs at locations dictated by flanking regions that form complementary base pairs with the target mRNA. The sole requirement is that the target mRNA have the following sequence of two bases:

5 5'-UG-3'. The construction and production of hammerhead ribozymes is well known in the art and is described more fully in Haseloff and Gerlach, Nature, 334:585-591 (1988). There are numerous potential hammerhead ribozyme cleavage sites within each nucleotide sequence disclosed in the sequence listing. Preferably, the ribozyme is engineered so that the cleavage recognition site is located near the 5' end of the mRNA corresponding to the polynucleotides of the invention; i.e., to increase efficiency and minimize the intracellular accumulation of non-functional mRNA transcripts.

As in the antisense approach, the ribozymes of the invention can be composed of modified oligonucleotides (e.g. for improved stability, targeting, etc.) and should be delivered to cells which express the polynucleotides of the invention in vivo. DNA constructs encoding the ribozyme may be introduced into the cell in the same manner as described above for the introduction of antisense encoding DNA. A preferred method of delivery involves using a DNA construct "encoding" the ribozyme under the control of a strong constitutive promoter, such as, for example, pol III or pol II promoter, so that transfected cells will produce sufficient quantities of the ribozyme to destroy endogenous messages and inhibit translation. Since ribozymes unlike antisense molecules, are catalytic, a lower intracellular concentration is required for efficiency.

Antagonist/agonist compounds may be employed to inhibit the cell growth and proliferation effects of the polypeptides of the present invention on neoplastic cells and tissues, i.e. stimulation of angiogenesis of tumors, and, therefore, retard or

prevent abnormal cellular growth and proliferation, for example, in tumor formation or growth.

The antagonist/agonist may also be employed to prevent hyper-vascular diseases, and prevent the proliferation of epithelial lens cells after extracapsular  
5 cataract surgery. Prevention of the mitogenic activity of the polypeptides of the present invention may also be desirous in cases such as restenosis after balloon angioplasty.

The antagonist/agonist may also be employed to prevent the growth of scar tissue during wound healing.

10 The antagonist/agonist may also be employed to treat, prevent, and/or diagnose the diseases described herein.

Thus, the invention provides a method of treating or preventing diseases, disorders, and/or conditions, including but not limited to the diseases, disorders, and/or conditions listed throughout this application, associated with overexpression of  
15 a polynucleotide of the present invention by administering to a patient (a) an antisense molecule directed to the polynucleotide of the present invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention.

invention, and/or (b) a ribozyme directed to the polynucleotide of the present invention

## 20 **Other Activities**

The polypeptide of the present invention, as a result of the ability to stimulate vascular endothelial cell growth, may be employed in treatment for stimulating re-vascularization of ischemic tissues due to various disease conditions such as thrombosis, arteriosclerosis, and other cardiovascular conditions. These polypeptide  
25 may also be employed to stimulate angiogenesis and limb regeneration, as discussed above.



The polypeptide may also be employed for treating wounds due to injuries, burns, post-operative tissue repair, and ulcers since they are mitogenic to various cells of different origins, such as fibroblast cells and skeletal muscle cells, and therefore, facilitate the repair or replacement of damaged or diseased tissue.

5       The polypeptide of the present invention may also be employed stimulate neuronal growth and to treat, prevent, and/or diagnose neuronal damage which occurs in certain neuronal disorders or neuro-degenerative conditions such as Alzheimer's disease, Parkinson's disease, and AIDS-related complex. The polypeptide of the invention may have the ability to stimulate chondrocyte growth, therefore, they may  
10 be employed to enhance bone and periodontal regeneration and aid in tissue transplants or bone grafts.

The polypeptide of the present invention may be also be employed to prevent skin aging due to sunburn by stimulating keratinocyte growth.

The polypeptide of the invention may also be employed for preventing hair  
15 loss, since FGF family members activate hair-forming cells and promotes melanocyte growth. Along the same lines, the polypeptides of the present invention may be employed to stimulate growth and differentiation of hematopoietic cells and bone marrow cells when used in combination with other cytokines.

The polypeptide of the invention may also be employed to maintain organs  
20 before transplantation or for supporting cell culture of primary tissues.

The polypeptide of the present invention may also be employed for inducing tissue of mesodermal origin to differentiate in early embryos.

The polypeptide or polynucleotides and/or agonist or antagonists of the  
25 present invention may also increase or decrease the differentiation or proliferation of embryonic stem cells, besides, as discussed above, hematopoietic lineage.

The polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used to modulate mammalian characteristics, such as body height, weight, hair color, eye color, skin, percentage of adipose tissue, pigmentation, size, and shape (e.g., cosmetic surgery). Similarly, polypeptides or polynucleotides and/or agonist or antagonists of the present invention may be used to modulate mammalian metabolism affecting catabolism, anabolism, processing, utilization, and storage of energy.

Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may be used to change a mammal's mental state or physical state by influencing biorhythms, cardiac rhythms, depression (including depressive diseases, disorders, and/or conditions), tendency for violence, tolerance for pain, reproductive capabilities (preferably by Activin or Inhibin-like activity), hormonal or endocrine levels, appetite, libido, memory, stress, or other cognitive qualities.

Polypeptide or polynucleotides and/or agonist or antagonists of the present invention may also be used as a food additive or preservative, such as to increase or decrease storage capabilities, fat content, lipid, protein, carbohydrate, vitamins, minerals, cofactors or other nutritional components.

#### **Other Preferred Embodiments**

Other preferred embodiments of the claimed invention include an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least about 50 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of

positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Clone Sequence and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is a nucleic acid molecule wherein said sequence of contiguous  
5 nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the Start Codon and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Similarly preferred is a nucleic acid molecule wherein said sequence of  
10 contiguous nucleotides is included in the nucleotide sequence of SEQ ID NO:X in the range of positions beginning with the nucleotide at about the position of the 5' Nucleotide of the First Amino Acid of the Signal Peptide and ending with the nucleotide at about the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X in Table 1.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide  
15 sequence which is at least 95% identical to a sequence of at least about 150 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

Further preferred is an isolated nucleic acid molecule comprising a nucleotide  
sequence which is at least 95% identical to a sequence of at least about 500  
20 contiguous nucleotides in the nucleotide sequence of SEQ ID NO:X.

A further preferred embodiment is a nucleic acid molecule comprising a  
nucleotide sequence which is at least 95% identical to the nucleotide sequence of SEQ  
ID NO:X beginning with the nucleotide at about the position of the 5' Nucleotide of  
the First Amino Acid of the Signal Peptide and ending with the nucleotide at about  
25 the position of the 3' Nucleotide of the Clone Sequence as defined for SEQ ID NO:X  
in Table 1.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete nucleotide sequence of SEQ ID NO:X.

Also preferred is an isolated nucleic acid molecule which hybridizes under  
5 stringent hybridization conditions to a nucleic acid molecule, wherein said nucleic acid molecule which hybridizes does not hybridize under stringent hybridization conditions to a nucleic acid molecule having a nucleotide sequence consisting of only A residues or of only T residues.

Also preferred is a composition of matter comprising a DNA molecule which  
10 comprises a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the material deposited with the American Type Culture Collection and given the ATCC Deposit Number shown in Table 1 for said cDNA Clone Identifier.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide  
15 sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in the nucleotide sequence of a human cDNA clone identified by a cDNA Clone Identifier in Table 1, which DNA molecule is contained in the deposit given the ATCC Deposit Number shown in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said sequence of  
20 at least 50 contiguous nucleotides is included in the nucleotide sequence of the complete open reading frame sequence encoded by said human cDNA clone.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at least 150 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

25 A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to sequence of at

least 500 contiguous nucleotides in the nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to the complete  
5 nucleotide sequence encoded by said human cDNA clone.

A further preferred embodiment is a method for detecting in a biological sample a nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X  
10 wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing a nucleotide sequence of at least one nucleic acid molecule in said sample with a sequence selected from said group and  
15 determining whether the sequence of said nucleic acid molecule in said sample is at least 95% identical to said selected sequence.

Also preferred is the above method wherein said step of comparing sequences comprises determining the extent of nucleic acid hybridization between nucleic acid molecules in said sample and a nucleic acid molecule comprising said sequence  
20 selected from said group. Similarly, also preferred is the above method wherein said step of comparing sequences is performed by comparing the nucleotide sequence determined from a nucleic acid molecule in said sample with said sequence selected from said group. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

25 A further preferred embodiment is a method for identifying the species, tissue or cell type of a biological sample which method comprises a step of detecting nucleic

acid molecules in said sample, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for identifying the species, tissue or cell type of a biological sample can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a method for diagnosing in a subject a pathological condition associated with abnormal structure or expression of a gene encoding a secreted protein identified in Table 1, which method comprises a step of detecting in a biological sample obtained from said subject nucleic acid molecules, if any, comprising a nucleotide sequence that is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

The method for diagnosing a pathological condition can comprise a step of detecting nucleic acid molecules comprising a nucleotide sequence in a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least

95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from said group.

Also preferred is a composition of matter comprising isolated nucleic acid molecules wherein the nucleotide sequences of said nucleic acid molecules comprise  
5 a panel of at least two nucleotide sequences, wherein at least one sequence in said panel is at least 95% identical to a sequence of at least 50 contiguous nucleotides in a sequence selected from the group consisting of: a nucleotide sequence of SEQ ID NO:X wherein X is any integer as defined in Table 1; and a nucleotide sequence encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1  
10 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1. The nucleic acid molecules can comprise DNA molecules or RNA molecules.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the  
15 amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1.

Also preferred is a polypeptide, wherein said sequence of contiguous amino acids is included in the amino acid sequence of SEQ ID NO:Y in the range of positions beginning with the residue at about the position of the First Amino Acid of the Secreted Portion and ending with the residue at about the Last Amino Acid of the  
20 Open Reading Frame as set forth for SEQ ID NO:Y in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid  
25 sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the complete amino acid sequence of SEQ ID NO:Y.

Further preferred is an isolated polypeptide comprising an amino acid sequence at least 90% identical to a sequence of at least about 10 contiguous amino acids in the complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is a polypeptide wherein said sequence of contiguous amino acids is included in the amino acid sequence of a secreted portion of the secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 30 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence of at least about 100 contiguous amino acids in the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated polypeptide comprising an amino acid sequence at least 95% identical to the amino acid sequence of the secreted portion of the protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1



and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is an isolated antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a  
5 sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table  
10 1.

Further preferred is a method for detecting in a biological sample a polypeptide comprising an amino acid sequence which is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as  
15 defined in Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1; which method comprises a step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group  
20 and determining whether the sequence of said polypeptide molecule in said sample is at least 90% identical to said sequence of at least 10 contiguous amino acids.

Also preferred is the above method wherein said step of comparing an amino acid sequence of at least one polypeptide molecule in said sample with a sequence selected from said group comprises determining the extent of specific binding of  
25 polypeptides in said sample to an antibody which binds specifically to a polypeptide comprising an amino acid sequence that is at least 90% identical to a sequence of at

least 10 contiguous amino acids in a sequence selected from the group consisting of:  
an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in  
Table 1; and a complete amino acid sequence of a protein encoded by a human cDNA  
clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit  
5 with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is the above method wherein said step of comparing sequences  
is performed by comparing the amino acid sequence determined from a polypeptide  
molecule in said sample with said sequence selected from said group.

Also preferred is a method for identifying the species, tissue or cell type of a  
10 biological sample which method comprises a step of detecting polypeptide molecules  
in said sample, if any, comprising an amino acid sequence that is at least 90%  
identical to a sequence of at least 10 contiguous amino acids in a sequence selected  
from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is  
any integer as defined in Table 1; and a complete amino acid sequence of a secreted  
15 protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in  
Table 1 and contained in the deposit with the ATCC Deposit Number shown for said  
cDNA clone in Table 1.

Also preferred is the above method for identifying the species, tissue or cell  
type of a biological sample, which method comprises a step of detecting polypeptide  
20 molecules comprising an amino acid sequence in a panel of at least two amino acid  
sequences, wherein at least one sequence in said panel is at least 90% identical to a  
sequence of at least 10 contiguous amino acids in a sequence selected from the above  
group.

Also preferred is a method for diagnosing in a subject a pathological condition  
25 associated with abnormal structure or expression of a gene encoding a secreted  
protein identified in Table 1, which method comprises a step of detecting in a

biological sample obtained from said subject polypeptide molecules comprising an amino acid sequence in a panel of at least two amino acid sequences, wherein at least one sequence in said panel is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

In any of these methods, the step of detecting said polypeptide molecules includes using an antibody.

Also preferred is an isolated nucleic acid molecule comprising a nucleotide sequence which is at least 95% identical to a nucleotide sequence encoding a polypeptide wherein said polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence of at least 10 contiguous amino acids in a sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Also preferred is an isolated nucleic acid molecule, wherein said nucleotide sequence encoding a polypeptide has been optimized for expression of said polypeptide in a prokaryotic host.

Also preferred is an isolated nucleic acid molecule, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y wherein Y is any integer as defined in Table 1; and a complete amino acid sequence of a secreted protein encoded by a human cDNA clone

identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA clone in Table 1.

Further preferred is a method of making a recombinant vector comprising inserting any of the above isolated nucleic acid molecule into a vector. Also preferred  
5 is the recombinant vector produced by this method. Also preferred is a method of making a recombinant host cell comprising introducing the vector into a host cell, as well as the recombinant host cell produced by this method.

Also preferred is a method of making an isolated polypeptide comprising culturing this recombinant host cell under conditions such that said polypeptide is  
10 expressed and recovering said polypeptide. Also preferred is this method of making an isolated polypeptide, wherein said recombinant host cell is a eukaryotic cell and said polypeptide is a secreted portion of a human secreted protein comprising an amino acid sequence selected from the group consisting of: an amino acid sequence of SEQ ID NO:Y beginning with the residue at the position of the First Amino Acid of  
15 the Secreted Portion of SEQ ID NO:Y wherein Y is an integer set forth in Table 1 and said position of the First Amino Acid of the Secreted Portion of SEQ ID NO:Y is defined in Table 1; and an amino acid sequence of a secreted portion of a protein encoded by a human cDNA clone identified by a cDNA Clone Identifier in Table 1 and contained in the deposit with the ATCC Deposit Number shown for said cDNA  
20 clone in Table 1. The isolated polypeptide produced by this method is also preferred.

Also preferred is a method of treatment of an individual in need of an increased level of a secreted protein activity, which method comprises administering to such an individual a pharmaceutical composition comprising an amount of an isolated polypeptide, polynucleotide, or antibody of the claimed invention effective to  
25 increase the level of said protein activity in said individual.

The above-recited applications have uses in a wide variety of hosts. Such hosts include, but are not limited to, human, murine, rabbit, goat, guinea pig, camel, horse, mouse, rat, hamster, pig, micro-pig, chicken, goat, cow, sheep, dog, cat, non-human primate, and human. In specific embodiments, the host is a mouse, rabbit, goat, guinea pig, chicken, rat, hamster, pig, sheep, dog or cat. In preferred embodiments, the host is a mammal. In most preferred embodiments, the host is a human.

In specific embodiments of the invention, for each "Contig ID" listed in the fourth column of Table 2, preferably excluded are one or more polynucleotides comprising, or alternatively consisting of, a nucleotide sequence referenced in the fifth column of Table 2 and described by the general formula of a-b, whereas a and b are uniquely determined for the corresponding SEQ ID NO:X referred to in column 3 of Table 2. Further specific embodiments are directed to polynucleotide sequences excluding one, two, three, four, or more of the specific polynucleotide sequences referred to in the fifth column of Table 2. In no way is this listing meant to encompass all of the sequences which may be excluded by the general formula, it is just a representative example. All references available through these accessions are hereby incorporated by reference in their entirety.

TABLE 2

Gene No.	cDNA Clone ID	NT SEQ ID NO: X	Contig ID	Public Accession Numbers
2	HILBW03	12	841377	H93164, AA922769, AA987538, AA775444

Having generally described the invention, the same will be more readily understood by reference to the following examples, which are provided by way of illustration and are not intended as limiting.

5

### Examples

#### Example 1: Isolation of a Selected cDNA Clone From the Deposited Sample

Each cDNA clone in a cited ATCC deposit is contained in a plasmid vector.

- 10 Table 1 identifies the vectors used to construct the cDNA library from which each clone was isolated. In many cases, the vector used to construct the library is a phage vector from which a plasmid has been excised. The table immediately below correlates the related plasmid for each phage vector used in constructing the cDNA library. For example, where a particular clone is identified in Table 1 as being
- 15 isolated in the vector "Lambda Zap," the corresponding deposited clone is in "pBluescript."

	<u>Vector Used to Construct Library</u>	<u>Corresponding Deposited</u>
	<u>Plasmid</u>	
	Lambda Zap	pBluescript (pBS)
20	Uni-Zap XR	pBluescript (pBS)
	Zap Express	pBK
	lafmid BA	plafmid BA
	pSport1	pSport1
	pCMVSPORT 2.0	pCMVSPORT 2.0
25	pCMVSPORT 3.0	pCMVSPORT 3.0
	pCR <sup>®</sup> 2.1	pCR <sup>®</sup> 2.1

Vectors Lambda Zap (U.S. Patent Nos. 5,128,256 and 5,286,636), Uni-Zap XR (U.S. Patent Nos. 5,128, 256 and 5,286,636), Zap Express (U.S. Patent Nos. 5,128,256 and 5,286,636), pBluescript (pBS) (Short, J. M. et al., Nucleic Acids Res. 16:7583-7600 (1988); Alting-Mees, M. A. and Short, J. M., Nucleic Acids Res. 17:9494 (1989)) and pBK (Alting-Mees, M. A. et al., Strategies 5:58-61 (1992)) are commercially available from Stratagene Cloning Systems, Inc., 11011 N. Torrey Pines Road, La Jolla, CA, 92037. pBS contains an ampicillin resistance gene and pBK contains a neomycin resistance gene. Both can be transformed into E. coli strain XL-1 Blue, also available from Stratagene. pBS comes in 4 forms SK+, SK-, KS+ and KS. The S and K refers to the orientation of the polylinker to the T7 and T3 primer sequences which flank the polylinker region ("S" is for SacI and "K" is for KpnI which are the first sites on each respective end of the linker). "+" or "-" refer to the orientation of the f1 origin of replication ("ori"), such that in one orientation, single stranded rescue initiated from the f1 ori generates sense strand DNA and in the other, antisense.

Vectors pSport1, pCMVSPORT 2.0 and pCMVSPORT 3.0, were obtained from Life Technologies, Inc., P. O. Box 6009, Gaithersburg, MD 20897. All Sport vectors contain an ampicillin resistance gene and may be transformed into E. coli strain DH10B, also available from Life Technologies. (See, for instance, Gruber, C. E., et al., Focus 15:59 (1993).) Vector lafmid BA (Bento Soares, Columbia University, NY) contains an ampicillin resistance gene and can be transformed into E. coli strain XL-1 Blue. Vector pCR<sup>®</sup>2.1, which is available from Invitrogen, 1600 Faraday Avenue, Carlsbad, CA 92008, contains an ampicillin resistance gene and may be transformed into E. coli strain DH10B, available from Life Technologies. (See, for instance, Clark, J. M., Nuc. Acids Res. 16:9677-9686 (1988) and Mead, D. et al., Bio/Technology 9: (1991).) Preferably, a polynucleotide of the present invention

does not comprise the phage vector sequences identified for the particular clone in Table 1, as well as the corresponding plasmid vector sequences designated above.

The deposited material in the sample assigned the ATCC Deposit Number cited in Table 1 for any given cDNA clone also may contain one or more additional  
5 plasmids, each comprising a cDNA clone different from that given clone. Thus, deposits sharing the same ATCC Deposit Number contain at least a plasmid for each cDNA clone identified in Table 1. Typically, each ATCC deposit sample cited in Table 1 comprises a mixture of approximately equal amounts (by weight) of about 50 plasmid DNAs, each containing a different cDNA clone; but such a deposit sample  
10 may include plasmids for more or less than 50 cDNA clones, up to about 500 cDNA clones.

Two approaches can be used to isolate a particular clone from the deposited sample of plasmid DNAs cited for that clone in Table 1. First, a plasmid is directly isolated by screening the clones using a polynucleotide probe corresponding to SEQ  
15 ID NO:X.

Particularly, a specific polynucleotide with 30-40 nucleotides is synthesized using an Applied Biosystems DNA synthesizer according to the sequence reported. The oligonucleotide is labeled, for instance, with  $^{32}\text{P}$ - $\gamma$ -ATP using T4 polynucleotide kinase and purified according to routine methods. (E.g., Maniatis et al., Molecular  
20 Cloning: A Laboratory Manual, Cold Spring Harbor Press, Cold Spring, NY (1982).) The plasmid mixture is transformed into a suitable host, as indicated above (such as XL-1 Blue (Stratagene)) using techniques known to those of skill in the art, such as those provided by the vector supplier or in related publications or patents cited above. The transformants are plated on 1.5% agar plates (containing the appropriate selection  
25 agent, e.g., ampicillin) to a density of about 150 transformants (colonies) per plate. These plates are screened using Nylon membranes according to routine methods for



bacterial colony screening (e.g., Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2nd Edit., (1989), Cold Spring Harbor Laboratory Press, pages 1.93 to 1.104), or other techniques known to those of skill in the art.

Alternatively, two primers of 17-20 nucleotides derived from both ends of the  
5 SEQ ID NO:X (i.e., within the region of SEQ ID NO:X bounded by the 5' NT and  
the 3' NT of the clone defined in Table 1) are synthesized and used to amplify the  
desired cDNA using the deposited cDNA plasmid as a template. The polymerase  
chain reaction is carried out under routine conditions, for instance, in 25 ul of reaction  
mixture with 0.5 ug of the above cDNA template. A convenient reaction mixture is  
10 1.5-5 mM MgCl<sub>2</sub>, 0.01% (w/v) gelatin, 20 uM each of dATP, dCTP, dGTP, dTTP, 25  
pmol of each primer and 0.25 Unit of Taq polymerase. Thirty five cycles of PCR  
(denaturation at 94 degree C for 1 min; annealing at 55 degree C for 1 min; elongation  
at 72 degree C for 1 min) are performed with a Perkin-Elmer Cetus automated  
thermal cycler. The amplified product is analyzed by agarose gel electrophoresis and  
15 the DNA band with expected molecular weight is excised and purified. The PCR  
product is verified to be the selected sequence by subcloning and sequencing the  
DNA product.

Several methods are available for the identification of the 5' or 3' non-coding  
portions of a gene which may not be present in the deposited clone. These methods  
20 include but are not limited to, filter probing, clone enrichment using specific probes,  
and protocols similar or identical to 5' and 3' "RACE" protocols which are well  
known in the art. For instance, a method similar to 5' RACE is available for  
generating the missing 5' end of a desired full-length transcript. (Fromont-Racine et  
al., *Nucleic Acids Res.* 21(7):1683-1684 (1993).)

25 Briefly, a specific RNA oligonucleotide is ligated to the 5' ends of a  
population of RNA presumably containing full-length gene RNA transcripts. A

primer set containing a primer specific to the ligated RNA oligonucleotide and a primer specific to a known sequence of the gene of interest is used to PCR amplify the 5' portion of the desired full-length gene. This amplified product may then be sequenced and used to generate the full length gene.

- 5           This above method starts with total RNA isolated from the desired source, although poly-A+ RNA can be used. The RNA preparation can then be treated with phosphatase if necessary to eliminate 5' phosphate groups on degraded or damaged RNA which may interfere with the later RNA ligase step. The phosphatase should then be inactivated and the RNA treated with tobacco acid pyrophosphatase in order
- 10   to remove the cap structure present at the 5' ends of messenger RNAs. This reaction leaves a 5' phosphate group at the 5' end of the cap cleaved RNA which can then be ligated to an RNA oligonucleotide using T4 RNA ligase.

- This modified RNA preparation is used as a template for first strand cDNA synthesis using a gene specific oligonucleotide. The first strand synthesis reaction is
- 15   used as a template for PCR amplification of the desired 5' end using a primer specific to the ligated RNA oligonucleotide and a primer specific to the known sequence of the gene of interest. The resultant product is then sequenced and analyzed to confirm that the 5' end sequence belongs to the desired gene.

20   **Example 2: Isolation of Genomic Clones Corresponding to a Polynucleotide**

          A human genomic P1 library (Genomic Systems, Inc.) is screened by PCR using primers selected for the cDNA sequence corresponding to SEQ ID NO:X., according to the method described in Example 1. (See also, Sambrook.)

25   **Example 3: Tissue Distribution of Polypeptide**

Tissue distribution of mRNA expression of polynucleotides of the present invention is determined using protocols for Northern blot analysis, described by, among others, Sambrook et al. For example, a cDNA probe produced by the method described in Example 1 is labeled with  $P^{32}$  using the rediprime™ DNA labeling system (Amersham Life Science), according to manufacturer's instructions. After labeling, the probe is purified using CHROMA SPIN-100™-column (Clontech Laboratories, Inc.), according to manufacturer's protocol number PT1200-1. The purified labeled probe is then used to examine various human tissues for mRNA expression.

Multiple Tissue Northern (MTN) blots containing various human tissues (H) or human immune system tissues (IM) (Clontech) are examined with the labeled probe using ExpressHyb™ hybridization solution (Clontech) according to manufacturer's protocol number PT1190-1. Following hybridization and washing, the blots are mounted and exposed to film at -70 degree C overnight, and the films developed according to standard procedures.

#### **Example 4: Chromosomal Mapping of the Polynucleotides**

An oligonucleotide primer set is designed according to the sequence at the 5' end of SEQ ID NO:X. This primer preferably spans about 100 nucleotides. This primer set is then used in a polymerase chain reaction under the following set of conditions : 30 seconds, 95 degree C; 1 minute, 56 degree C; 1 minute, 70 degree C. This cycle is repeated 32 times followed by one 5 minute cycle at 70 degree C. Human, mouse, and hamster DNA is used as template in addition to a somatic cell hybrid panel containing individual chromosomes or chromosome fragments (Bios, Inc). The reactions is analyzed on either 8% polyacrylamide gels or 3.5 % agarose

gels. Chromosome mapping is determined by the presence of an approximately 100 bp PCR fragment in the particular somatic cell hybrid.

#### **Example 5: Bacterial Expression of a Polypeptide**

5           A polynucleotide encoding a polypeptide of the present invention is amplified using PCR oligonucleotide primers corresponding to the 5' and 3' ends of the DNA sequence, as outlined in Example 1, to synthesize insertion fragments. The primers used to amplify the cDNA insert should preferably contain restriction sites, such as BamHI and XbaI, at the 5' end of the primers in order to clone the amplified product  
10 into the expression vector. For example, BamHI and XbaI correspond to the restriction enzyme sites on the bacterial expression vector pQE-9. (Qiagen, Inc., Chatsworth, CA). This plasmid vector encodes antibiotic resistance (Amp<sup>r</sup>), a bacterial origin of replication (ori), an IPTG-regulatable promoter/operator (P/O), a ribosome binding site (RBS), a 6-histidine tag (6-His), and restriction enzyme cloning  
15 sites.

The pQE-9 vector is digested with BamHI and XbaI and the amplified fragment is ligated into the pQE-9 vector maintaining the reading frame initiated at the bacterial RBS. The ligation mixture is then used to transform the E. coli strain M15/rep4 (Qiagen, Inc.) which contains multiple copies of the plasmid pREP4, which  
20 expresses the lacI repressor and also confers kanamycin resistance (Kan<sup>r</sup>). Transformants are identified by their ability to grow on LB plates and ampicillin/kanamycin resistant colonies are selected. Plasmid DNA is isolated and confirmed by restriction analysis.

Clones containing the desired constructs are grown overnight (O/N) in liquid  
25 culture in LB media supplemented with both Amp (100 ug/ml) and Kan (25 ug/ml). The O/N culture is used to inoculate a large culture at a ratio of 1:100 to 1:250. The

cells are grown to an optical density 600 (O.D.<sup>600</sup>) of between 0.4 and 0.6. IPTG (Isopropyl-B-D-thiogalacto pyranoside) is then added to a final concentration of 1 mM. IPTG induces by inactivating the lacI repressor, clearing the P/O leading to increased gene expression.

- 5           Cells are grown for an extra 3 to 4 hours. Cells are then harvested by centrifugation (20 mins at 6000Xg). The cell pellet is solubilized in the chaotropic agent 6 Molar Guanidine HCl by stirring for 3-4 hours at 4 degree C. The cell debris is removed by centrifugation, and the supernatant containing the polypeptide is loaded onto a nickel-nitrilo-tri-acetic acid ("Ni-NTA") affinity resin column (available from
- 10   QIAGEN, Inc., *supra*). Proteins with a 6 x His tag bind to the Ni-NTA resin with high affinity and can be purified in a simple one-step procedure (for details see: The QIAexpressionist (1995) QIAGEN, Inc., *supra*).

- Briefly, the supernatant is loaded onto the column in 6 M guanidine-HCl, pH 8, the column is first washed with 10 volumes of 6 M guanidine-HCl, pH 8, then
- 15   washed with 10 volumes of 6 M guanidine-HCl pH 6, and finally the polypeptide is eluted with 6 M guanidine-HCl, pH 5.

- The purified protein is then renatured by dialyzing it against phosphate-buffered saline (PBS) or 50 mM Na-acetate, pH 6 buffer plus 200 mM NaCl. Alternatively, the protein can be successfully refolded while immobilized on the Ni-
- 20   NTA column. The recommended conditions are as follows: renature using a linear 6M-1M urea gradient in 500 mM NaCl, 20% glycerol, 20 mM Tris/HCl pH 7.4, containing protease inhibitors. The renaturation should be performed over a period of 1.5 hours or more. After renaturation the proteins are eluted by the addition of 250 mM imidazole. Imidazole is removed by a final dialyzing step against PBS or 50
- 25   mM sodium acetate pH 6 buffer plus 200 mM NaCl. The purified protein is stored at 4 degree C or frozen at -80 degree C.

In addition to the above expression vector, the present invention further includes an expression vector comprising phage operator and promoter elements operatively linked to a polynucleotide of the present invention, called pHE4a. (ATCC Accession Number 209645, deposited on February 25, 1998.) This vector contains:

- 5 1) a neomycinphosphotransferase gene as a selection marker, 2) an *E. coli* origin of replication, 3) a T5 phage promoter sequence, 4) two lac operator sequences, 5) a Shine-Delgarno sequence, and 6) the lactose operon repressor gene (*lacIq*). The origin of replication (*oriC*) is derived from pUC19 (LTI, Gaithersburg, MD). The promoter sequence and operator sequences are made synthetically.

- 10 DNA can be inserted into the pHEa by restricting the vector with NdeI and XbaI, BamHI, XhoI, or Asp718, running the restricted product on a gel, and isolating the larger fragment (the stuffer fragment should be about 310 base pairs). The DNA insert is generated according to the PCR protocol described in Example 1, using PCR primers having restriction sites for NdeI (5' primer) and XbaI, BamHI, XhoI, or  
15 Asp718 (3' primer). The PCR insert is gel purified and restricted with compatible enzymes. The insert and vector are ligated according to standard protocols.

The engineered vector could easily be substituted in the above protocol to express protein in a bacterial system.

20 **Example 6: Purification of a Polypeptide from an Inclusion Body**

The following alternative method can be used to purify a polypeptide expressed in *E. coli* when it is present in the form of inclusion bodies. Unless otherwise specified, all of the following steps are conducted at 4-10 degree C.

- 25 Upon completion of the production phase of the *E. coli* fermentation, the cell culture is cooled to 4-10 degree C and the cells harvested by continuous centrifugation at 15,000 rpm (Heraeus Sepatech). On the basis of the expected yield

of protein per unit weight of cell paste and the amount of purified protein required, an appropriate amount of cell paste, by weight, is suspended in a buffer solution containing 100 mM Tris, 50 mM EDTA, pH 7.4. The cells are dispersed to a homogeneous suspension using a high shear mixer.

5           The cells are then lysed by passing the solution through a microfluidizer (Microfluidics, Corp. or APV Gaulin, Inc.) twice at 4000-6000 psi. The homogenate is then mixed with NaCl solution to a final concentration of 0.5 M NaCl, followed by centrifugation at 7000 xg for 15 min. The resultant pellet is washed again using 0.5M NaCl, 100 mM Tris, 50 mM EDTA, pH 7.4.

10           The resulting washed inclusion bodies are solubilized with 1.5 M guanidine hydrochloride (GuHCl) for 2-4 hours. After 7000 xg centrifugation for 15 min., the pellet is discarded and the polypeptide containing supernatant is incubated at 4 degree C overnight to allow further GuHCl extraction.

Following high speed centrifugation (30,000 xg) to remove insoluble particles;  
15           the GuHCl solubilized protein is refolded by quickly mixing the GuHCl extract with 20 volumes of buffer containing 50 mM sodium, pH 4.5, 150 mM NaCl, 2 mM EDTA by vigorous stirring. The refolded diluted protein solution is kept at 4 degree C without mixing for 12 hours prior to further purification steps.

To clarify the refolded polypeptide solution, a previously prepared tangential  
20           filtration unit equipped with 0.16 um membrane filter with appropriate surface area (e.g., Filtron), equilibrated with 40 mM sodium acetate, pH 6.0 is employed. The filtered sample is loaded onto a cation exchange resin (e.g., Poros HS-50, Perseptive Biosystems). The column is washed with 40 mM sodium acetate, pH 6.0 and eluted with 250 mM, 500 mM, 1000 mM, and 1500 mM NaCl in the same buffer, in a  
25           stepwise manner. The absorbance at 280 nm of the effluent is continuously monitored. Fractions are collected and further analyzed by SDS-PAGE.

Fractions containing the polypeptide are then pooled and mixed with 4 volumes of water. The diluted sample is then loaded onto a previously prepared set of tandem columns of strong anion (Poros HQ-50, Perseptive Biosystems) and weak anion (Poros CM-20, Perseptive Biosystems) exchange resins. The columns are  
5 equilibrated with 40 mM sodium acetate, pH 6.0. Both columns are washed with 40 mM sodium acetate, pH 6.0, 200 mM NaCl. The CM-20 column is then eluted using a 10 column volume linear gradient ranging from 0.2 M NaCl, 50 mM sodium acetate, pH 6.0 to 1.0 M NaCl, 50 mM sodium acetate, pH 6.5. Fractions are collected under constant  $A_{280}$  monitoring of the effluent. Fractions containing the  
10 polypeptide (determined, for instance, by 16% SDS-PAGE) are then pooled.

The resultant polypeptide should exhibit greater than 95% purity after the above refolding and purification steps. No major contaminant bands should be observed from Commassie blue stained 16% SDS-PAGE gel when 5 ug of purified protein is loaded. The purified protein can also be tested for endotoxin/LPS  
15 contamination, and typically the LPS content is less than 0.1 ng/ml according to LAL assays.

#### **Example 7: Cloning and Expression of a Polypeptide in a Baculovirus Expression System**

20 In this example, the plasmid shuttle vector pA2 is used to insert a polynucleotide into a baculovirus to express a polypeptide. This expression vector contains the strong polyhedrin promoter of the *Autographa californica* nuclear polyhedrosis virus (AcMNPV) followed by convenient restriction sites such as BamHI, Xba I and Asp718. The polyadenylation site of the simian virus 40 ("SV40")  
25 is used for efficient polyadenylation. For easy selection of recombinant virus, the plasmid contains the beta-galactosidase gene from *E. coli* under control of a weak



Drosophila promoter in the same orientation, followed by the polyadenylation signal of the polyhedrin gene. The inserted genes are flanked on both sides by viral sequences for cell-mediated homologous recombination with wild-type viral DNA to generate a viable virus that express the cloned polynucleotide.

5           Many other baculovirus vectors can be used in place of the vector above, such as pAc373, pVL941, and pAcIM1, as one skilled in the art would readily appreciate, as long as the construct provides appropriately located signals for transcription, translation, secretion and the like, including a signal peptide and an in-frame AUG as required. Such vectors are described, for instance, in Luckow et al., Virology 170:31-  
10   39 (1989).

          Specifically, the cDNA sequence contained in the deposited clone, including the AUG initiation codon and the naturally associated leader sequence identified in Table 1, is amplified using the PCR protocol described in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the pA2 vector does  
15   not need a second signal peptide. Alternatively, the vector can be modified. (pA2 GP) to include a baculovirus leader sequence, using the standard methods described in Summers et al., "A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures," Texas Agricultural Experimental Station Bulletin No. 1555 (1987).

20           The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1% agarose gel.

          The plasmid is digested with the corresponding restriction enzymes and  
25   optionally, can be dephosphorylated using calf intestinal phosphatase, using routine

procedures known in the art. The DNA is then isolated from a 1% agarose gel using a commercially available kit ("Geneclean" BIO 101 Inc., La Jolla, Ca.).

The fragment and the dephosphorylated plasmid are ligated together with T4 DNA ligase. *E. coli* HB101 or other suitable *E. coli* hosts such as XL-1 Blue

5 (Stratagene Cloning Systems, La Jolla, CA) cells are transformed with the ligation mixture and spread on culture plates. Bacteria containing the plasmid are identified by digesting DNA from individual colonies and analyzing the digestion product by gel electrophoresis. The sequence of the cloned fragment is confirmed by DNA sequencing.

10 Five ug of a plasmid containing the polynucleotide is co-transfected with 1.0 ug of a commercially available linearized baculovirus DNA ("BaculoGold™ baculovirus DNA", Pharmingen, San Diego, CA), using the lipofection method described by Felgner et al., Proc. Natl. Acad. Sci. USA 84:7413-7417 (1987). One ug of BaculoGold™ virus DNA and 5 ug of the plasmid are mixed in a sterile well of a  
15 microtiter plate containing 50 ul of serum-free Grace's medium (Life Technologies Inc., Gaithersburg, MD). Afterwards, 10 ul Lipofectin plus 90 ul Grace's medium are added, mixed and incubated for 15 minutes at room temperature. Then the transfection mixture is added drop-wise to Sf9 insect cells (ATCC CRL 1711) seeded in a 35 mm tissue culture plate with 1 ml Grace's medium without serum. The plate is  
20 then incubated for 5 hours at 27 degrees C. The transfection solution is then removed from the plate and 1 ml of Grace's insect medium supplemented with 10% fetal calf serum is added. Cultivation is then continued at 27 degrees C for four days.

After four days the supernatant is collected and a plaque assay is performed, as described by Summers and Smith, *supra*. An agarose gel with "Blue Gal" (Life  
25 Technologies Inc., Gaithersburg) is used to allow easy identification and isolation of gal-expressing clones, which produce blue-stained plaques. (A detailed description of

a "plaque assay" of this type can also be found in the user's guide for insect cell culture and baculovirology distributed by Life Technologies Inc., Gaithersburg, page 9-10.) After appropriate incubation, blue stained plaques are picked with the tip of a micropipettor (e.g., Eppendorf). The agar containing the recombinant viruses is then  
5 resuspended in a microcentrifuge tube containing 200 ul of Grace's medium and the suspension containing the recombinant baculovirus is used to infect Sf9 cells seeded in 35 mm dishes. Four days later the supernatants of these culture dishes are harvested and then they are stored at 4 degree C.

To verify the expression of the polypeptide, Sf9 cells are grown in Grace's  
10 medium supplemented with 10% heat-inactivated FBS. The cells are infected with the recombinant baculovirus containing the polynucleotide at a multiplicity of infection ("MOI") of about 2. If radiolabeled proteins are desired, 6 hours later the medium is removed and is replaced with SF900 II medium minus methionine and cysteine (available from Life Technologies Inc., Rockville, MD). After 42 hours, 5  
15 uCi of  $^{35}\text{S}$ -methionine and 5 uCi  $^{35}\text{S}$ -cysteine (available from Amersham) are added. The cells are further incubated for 16 hours and then are harvested by centrifugation. The proteins in the supernatant as well as the intracellular proteins are analyzed by SDS-PAGE followed by autoradiography (if radiolabeled).

Microsequencing of the amino acid sequence of the amino terminus of  
20 purified protein may be used to determine the amino terminal sequence of the produced protein.

#### **Example 8: Expression of a Polypeptide in Mammalian Cells**

The polypeptide of the present invention can be expressed in a mammalian cell. A typical mammalian expression vector contains a promoter element, which  
25 mediates the initiation of transcription of mRNA, a protein coding sequence, and

signals required for the termination of transcription and polyadenylation of the transcript. Additional elements include enhancers, Kozak sequences and intervening sequences flanked by donor and acceptor sites for RNA splicing. Highly efficient transcription is achieved with the early and late promoters from SV40, the long  
5 terminal repeats (LTRs) from Retroviruses, e.g., RSV, HTLVI, HIVI and the early promoter of the cytomegalovirus (CMV). However, cellular elements can also be used (e.g., the human actin promoter).

Suitable expression vectors for use in practicing the present invention include, for example, vectors such as pSVL and pMSG (Pharmacia, Uppsala, Sweden),  
10 pRSVcat (ATCC 37152), pSV2dhfr (ATCC 37146), pBC12MI (ATCC 67109), pCMVSPORT 2.0, and pCMVSPORT 3.0. Mammalian host cells that could be used include, human Hela, 293, H9 and Jurkat cells, mouse NIH3T3 and C127 cells, Cos 1, Cos 7 and CV1, quail QC1-3 cells, mouse L cells and Chinese hamster ovary (CHO) cells.

15 Alternatively, the polypeptide can be expressed in stable cell lines containing the polynucleotide integrated into a chromosome. The co-transfection with a selectable marker such as dhfr, gpt, neomycin, hygromycin allows the identification and isolation of the transfected cells.

The transfected gene can also be amplified to express large amounts of the  
20 encoded protein. The DHFR (dihydrofolate reductase) marker is useful in developing cell lines that carry several hundred or even several thousand copies of the gene of interest. (See, e.g., Alt, F. W., et al., J. Biol. Chem. 253:1357-1370 (1978); Hamlin, J. L. and Ma, C., Biochem. et Biophys. Acta, 1097:107-143 (1990); Page, M. J. and Sydenham, M. A., Biotechnology 9:64-68 (1991).) Another useful selection marker  
25 is the enzyme glutamine synthase (GS) (Murphy et al., Biochem J. 227:277-279 (1991); Bebbington et al., Bio/Technology 10:169-175 (1992). Using these markers,

the mammalian cells are grown in selective medium and the cells with the highest resistance are selected. These cell lines contain the amplified gene(s) integrated into a chromosome. Chinese hamster ovary (CHO) and NSO cells are often used for the production of proteins.

5           Derivatives of the plasmid pSV2-dhfr (ATCC Accession No. 37146), the expression vectors pC4 (ATCC Accession No. 209646) and pC6 (ATCC Accession No. 209647) contain the strong promoter (LTR) of the Rous Sarcoma Virus (Cullen et al., Molecular and Cellular Biology, 438-447 (March, 1985)) plus a fragment of the CMV-enhancer (Boshart et al., Cell 41:521-530 (1985).) Multiple cloning sites, e.g.,  
10   with the restriction enzyme cleavage sites BamHI, XbaI and Asp718, facilitate the cloning of the gene of interest. The vectors also contain the 3' intron, the polyadenylation and termination signal of the rat preproinsulin gene, and the mouse DHFR gene under control of the SV40 early promoter.

          Specifically, the plasmid pC6, for example, is digested with appropriate  
15   restriction enzymes and then dephosphorylated using calf intestinal phosphates by procedures known in the art. The vector is then isolated from a 1% agarose gel.

          A polynucleotide of the present invention is amplified according to the protocol outlined in Example 1. If the naturally occurring signal sequence is used to produce the secreted protein, the vector does not need a second signal peptide.  
20   Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

          The amplified fragment is isolated from a 1% agarose gel using a commercially available kit ("GeneClean," BIO 101 Inc., La Jolla, Ca.). The fragment then is digested with appropriate restriction enzymes and again purified on a 1%  
25   agarose gel.

The amplified fragment is then digested with the same restriction enzyme and purified on a 1% agarose gel. The isolated fragment and the dephosphorylated vector are then ligated with T4 DNA ligase. *E. coli* HB101 or XL-1 Blue cells are then transformed and bacteria are identified that contain the fragment inserted into plasmid pC6 using, for instance, restriction enzyme analysis.

Chinese hamster ovary cells lacking an active DHFR gene is used for transfection. Five  $\mu$ g of the expression plasmid pC6 a pC4 is cotransfected with 0.5  $\mu$ g of the plasmid pSVneo using lipofectin (Felgner et al., *supra*). The plasmid pSV2-neo contains a dominant selectable marker, the *neo* gene from Tn5 encoding an enzyme that confers resistance to a group of antibiotics including G418. The cells are seeded in alpha minus MEM supplemented with 1 mg/ml G418. After 2 days, the cells are trypsinized and seeded in hybridoma cloning plates (Greiner, Germany) in alpha minus MEM supplemented with 10, 25, or 50 ng/ml of methotrexate plus 1 mg/ml G418. After about 10-14 days single clones are trypsinized and then seeded in 6-well petri dishes or 10 ml flasks using different concentrations of methotrexate (50 nM, 100 nM, 200 nM, 400 nM, 800 nM). Clones growing at the highest concentrations of methotrexate are then transferred to new 6-well plates containing even higher concentrations of methotrexate (1  $\mu$ M, 2  $\mu$ M, 5  $\mu$ M, 10 mM, 20 mM). The same procedure is repeated until clones are obtained which grow at a concentration of 100 - 200  $\mu$ M. Expression of the desired gene product is analyzed, for instance, by SDS-PAGE and Western blot or by reversed phase HPLC analysis.

#### **Example 9: Protein Fusions**

The polypeptides of the present invention are preferably fused to other proteins. These fusion proteins can be used for a variety of applications. For example, fusion of the present polypeptides to His-tag, HA-tag, protein A, IgG

domains, and maltose binding protein facilitates purification. (See Example 5; see also EP A 394,827; Traunecker, et al., Nature 331:84-86 (1988).) Similarly, fusion to IgG-1, IgG-3, and albumin increases the half-life time in vivo. Nuclear localization signals fused to the polypeptides of the present invention can target the protein to a specific subcellular localization, while covalent heterodimer or homodimers can increase or decrease the activity of a fusion protein. Fusion proteins can also create chimeric molecules having more than one function. Finally, fusion proteins can increase solubility and/or stability of the fused protein compared to the non-fused protein. All of the types of fusion proteins described above can be made by modifying the following protocol, which outlines the fusion of a polypeptide to an IgG molecule, or the protocol described in Example 5.

Briefly, the human Fc portion of the IgG molecule can be PCR amplified, using primers that span the 5' and 3' ends of the sequence described below. These primers also should have convenient restriction enzyme sites that will facilitate cloning into an expression vector, preferably a mammalian expression vector.

For example, if pC4 (Accession No. 209646) is used, the human Fc portion can be ligated into the BamHI cloning site. Note that the 3' BamHI site should be destroyed. Next, the vector containing the human Fc portion is re-restricted with BamHI, linearizing the vector, and a polynucleotide of the present invention, isolated by the PCR protocol described in Example 1, is ligated into this BamHI site. Note that the polynucleotide is cloned without a stop codon, otherwise a fusion protein will not be produced.

If the naturally occurring signal sequence is used to produce the secreted protein, pC4 does not need a second signal peptide. Alternatively, if the naturally occurring signal sequence is not used, the vector can be modified to include a heterologous signal sequence. (See, e.g., WO 96/34891.)

Human IgG Fc region:

GGGATCCGGAGCCCAAATCTTCTGACAAAACCTCACACATGCCCACCGTGC  
CCAGCACCTGAATTCGAGGGTGCACCGTCAGTCTTCCTCTTCCCCCAAAA  
5 CCCAAGGACACCCTCATGATCTCCCGGACTCCTGAGGTCACATGCGTGGT  
GGTGGACGTAAGCCACGAAGACCCTGAGGTCAAGTTCAACTGGTACGTGG  
ACGGCGTGGAGGTGCATAATGCCAAGACAAAGCCGCGGGAGGAGCAGTA  
CAACAGCACGTACCGTGTGGTCAGCGTCCTCACCGTCCTGCACCAGGACT  
GGCTGAATGGCAAGGAGTACAAGTGCAAGGTCTCCAACAAAGCCCTCCCA  
10 ACCCCCATCGAGAAAACCATCTCCAAAGCCAAAGGGCAGCCCCGAGAAC  
CACAGGTGTACACCCTGCCCCCATCCCGGGATGAGCTGACCAAGAACCAG  
GTCAGCCTGACCTGCCTGGTCAAAGGCTTCTATCCAAGCGACATCGCCGT  
GGAGTGGGAGAGCAATGGGCAGCCGGAGAACAACACTACAAGACCACGCCT  
CCCGTGCTGGACTCCGACGGCTCCTTCTTCCTCTACAGCAAGCTCACCGTG  
15 GACAAGAGCAGGTGGCAGCAGGGGAACGTCTTCTCATGCTCCGTGATGCA  
TGAGGCTCTGCACAACCACTACACGCAGAAGAGCCTCTCCCTGTCTCCGG  
GTAAATGAGTGCGACGGCCGCGACTCTAGAGGAT (SEQ ID NO:1)

**Example 10: Production of an Antibody from a Polypeptide**

20       The antibodies of the present invention can be prepared by a variety of  
methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells  
expressing a polypeptide of the present invention is administered to an animal to  
induce the production of sera containing polyclonal antibodies. In a preferred  
method, a preparation of the secreted protein is prepared and purified to render it  
25       substantially free of natural contaminants. Such a preparation is then introduced into  
an animal in order to produce polyclonal antisera of greater specific activity.



In the most preferred method, the antibodies of the present invention are monoclonal antibodies (or protein binding fragments thereof). Such monoclonal antibodies can be prepared using hybridoma technology. (Köhler et al., *Nature* 256:495 (1975); Köhler et al., *Eur. J. Immunol.* 6:511 (1976); Köhler et al., *Eur. J. Immunol.* 6:292 (1976); Hammerling et al., in: *Monoclonal Antibodies and T-Cell Hybridomas*, Elsevier, N.Y., pp. 563-681 (1981).) In general, such procedures involve immunizing an animal (preferably a mouse) with polypeptide or, more preferably, with a secreted polypeptide-expressing cell. Such cells may be cultured in any suitable tissue culture medium; however, it is preferable to culture cells in Earle's modified Eagle's medium supplemented with 10% fetal bovine serum (inactivated at about 56 degrees C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 ug/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (*Gastroenterology* 80:225-232 (1981).) The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the polypeptide.

Alternatively, additional antibodies capable of binding to the polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells,

and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the protein-specific antibody can be blocked by the polypeptide. Such antibodies comprise anti-idiotypic antibodies to the protein-specific antibody and can be used to immunize an animal to induce formation of  
5 further protein-specific antibodies.

It will be appreciated that Fab and F(ab')<sub>2</sub> and other fragments of the antibodies of the present invention may be used according to the methods disclosed herein. Such fragments are typically produced by proteolytic cleavage, using enzymes such as papain (to produce Fab fragments) or pepsin (to produce F(ab')<sub>2</sub>  
10 fragments). Alternatively, secreted protein-binding fragments can be produced through the application of recombinant DNA technology or through synthetic chemistry.

For in vivo use of antibodies in humans, it may be preferable to use "humanized" chimeric monoclonal antibodies. Such antibodies can be produced  
15 using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric antibodies are known in the art. (See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson  
20 et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

**Example 11: Production Of Secreted Protein For High-Throughput Screening Assays**

The following protocol produces a supernatant containing a polypeptide to be tested. This supernatant can then be used in the Screening Assays described in Examples 13-20.

First, dilute Poly-D-Lysine (644 587 Boehringer-Mannheim) stock solution  
5 (1mg/ml in PBS) 1:20 in PBS (w/o calcium or magnesium 17-516F Biowhittaker) for a working solution of 50ug/ml. Add 200 ul of this solution to each well (24 well plates) and incubate at RT for 20 minutes. Be sure to distribute the solution over each well (note: a 12-channel pipetter may be used with tips on every other channel). Aspirate off the Poly-D-Lysine solution and rinse with 1ml PBS (Phosphate Buffered  
10 Saline). The PBS should remain in the well until just prior to plating the cells and plates may be poly-lysine coated in advance for up to two weeks.

Plate 293T cells (do not carry cells past P+20) at  $2 \times 10^5$  cells/well in .5ml DMEM(Dulbecco's Modified Eagle Medium)(with 4.5 G/L glucose and L-glutamine (12-604F Biowhittaker))/10% heat inactivated FBS(14-503F Biowhittaker)/1x  
15 Penstrep(17-602E Biowhittaker). Let the cells grow overnight.

The next day, mix together in a sterile solution basin: 300 ul Lipofectamine (18324-012 Gibco/BRL) and 5ml Optimem I (31985070 Gibco/BRL)/96-well plate. With a small volume multi-channel pipetter, aliquot approximately 2ug of an expression vector containing a polynucleotide insert, produced by the methods  
20 described in Examples 8 or 9, into an appropriately labeled 96-well round bottom plate. With a multi-channel pipetter, add 50ul of the Lipofectamine/Optimem I mixture to each well. Pipette up and down gently to mix. Incubate at RT 15-45 minutes. After about 20 minutes, use a multi-channel pipetter to add 150ul Optimem I to each well. As a control, one plate of vector DNA lacking an insert should be  
25 transfected with each set of transfections.

Preferably, the transfection should be performed by tag-teaming the following tasks. By tag-teaming, hands on time is cut in half, and the cells do not spend too much time on PBS. First, person A aspirates off the media from four 24-well plates of cells, and then person B rinses each well with .5-1ml PBS. Person A then aspirates  
 5 off PBS rinse, and person B, using a 12-channel pipetter with tips on every other channel, adds the 200ul of DNA/Lipofectamine/Optimem I complex to the odd wells first, then to the even wells, to each row on the 24-well plates. Incubate at 37 degrees C for 6 hours.

While cells are incubating, prepare appropriate media, either 1%BSA in  
 10 DMEM with 1x penstrep, or CHO-5 media (116.6 mg/L of CaCl<sub>2</sub> (anhyd); 0.00130 mg/L CuSO<sub>4</sub>·5H<sub>2</sub>O; 0.050 mg/L of Fe(NO<sub>3</sub>)<sub>3</sub>·9H<sub>2</sub>O; 0.417 mg/L of FeSO<sub>4</sub>·7H<sub>2</sub>O; 311.80 mg/L of KCl; 28.64 mg/L of MgCl<sub>2</sub>; 48.84 mg/L of MgSO<sub>4</sub>; 6995.50 mg/L of NaCl; 2400.0 mg/L of NaHCO<sub>3</sub>; 62.50 mg/L of NaH<sub>2</sub>PO<sub>4</sub>·H<sub>2</sub>O; 71.02 mg/L of Na<sub>2</sub>HPO<sub>4</sub>; .4320 mg/L of ZnSO<sub>4</sub>·7H<sub>2</sub>O; .002 mg/L of Arachidonic Acid ; 1.022 mg/L  
 15 of Cholesterol; .070 mg/L of DL-alpha-Tocopherol-Acetate; 0.0520 mg/L of Linoleic Acid; 0.010 mg/L of Linolenic Acid; 0.010 mg/L of Myristic Acid; 0.010 mg/L of Oleic Acid; 0.010 mg/L of Palmitric Acid; 0.010 mg/L of Palmitic Acid; 100 mg/L of Pluronic F-68; 0.010 mg/L of Stearic Acid; 2.20 mg/L of Tween 80; 4551 mg/L of D-Glucose; 130.85 mg/ml of L- Alanine; 147.50 mg/ml of L-Arginine-HCL; 7.50 mg/ml  
 20 of L-Asparagine-H<sub>2</sub>O; 6.65 mg/ml of L-Aspartic Acid; 29.56 mg/ml of L-Cystine-2HCL-H<sub>2</sub>O; 31.29 mg/ml of L-Cystine-2HCL; 7.35 mg/ml of L-Glutamic Acid; 365.0 mg/ml of L-Glutamine; 18.75 mg/ml of Glycine; 52.48 mg/ml of L-Histidine-HCL-H<sub>2</sub>O; 106.97 mg/ml of L-Isoleucine; 111.45 mg/ml of L-Leucine; 163.75 mg/ml of L-Lysine HCL; 32.34 mg/ml of L-Methionine; 68.48 mg/ml of L-Phenylalanine; 40.0  
 25 mg/ml of L-Proline; 26.25 mg/ml of L-Serine; 101.05 mg/ml of L-Threonine; 19.22 mg/ml of L-Tryptophan; 91.79 mg/ml of L-Tyrosine-2Na-2H<sub>2</sub>O; 99.65 mg/ml of L-

Valine; 0.0035 mg/L of Biotin; 3.24 mg/L of D-Ca Pantothenate; 11.78 mg/L of Choline Chloride; 4.65 mg/L of Folic Acid; 15.60 mg/L of i-Inositol; 3.02 mg/L of Niacinamide; 3.00 mg/L of Pyridoxal HCL; 0.031 mg/L of Pyridoxine HCL; 0.319 mg/L of Riboflavin; 3.17 mg/L of Thiamine HCL; 0.365 mg/L of Thymidine; and  
5 0.680 mg/L of Vitamin B<sub>12</sub>; 25 mM of HEPES Buffer; 2.39 mg/L of Na Hypoxanthine; 0.105 mg/L of Lipoic Acid; 0.081 mg/L of Sodium Putrescine-2HCL; 55.0 mg/L of Sodium Pyruvate; 0.0067 mg/L of Sodium Selenite; 20uM of Ethanolamine; 0.122 mg/L of Ferric Citrate; 41.70 mg/L of Methyl-B-Cyclodextrin complexed with Linoleic Acid; 33.33 mg/L of Methyl-B-Cyclodextrin complexed  
10 with Oleic Acid; and 10 mg/L of Methyl-B-Cyclodextrin complexed with Retinal) with 2mm glutamine and 1x penstrep. (BSA (81-068-3 Bayer) 100gm dissolved in 1L DMEM for a 10% BSA stock solution). Filter the media and collect 50 ul for endotoxin assay in 15ml polystyrene conical.

The transfection reaction is terminated, preferably by tag-teaming, at the end  
15 of the incubation period. Person A aspirates off the transfection media, while person B adds 1.5ml appropriate media to each well. Incubate at 37 degrees C for 45 or 72 hours depending on the media used: 1%BSA for 45 hours or CHO-5 for 72 hours.

On day four, using a 300ul multichannel pipetter, aliquot 600ul in one 1ml deep well plate and the remaining supernatant into a 2ml deep well. The supernatants  
20 from each well can then be used in the assays described in Examples 13-20.

It is specifically understood that when activity is obtained in any of the assays described below using a supernatant, the activity originates from either the polypeptide directly (e.g., as a secreted protein) or by the polypeptide inducing expression of other proteins, which are then secreted into the supernatant. Thus, the  
25 invention further provides a method of identifying the protein in the supernatant characterized by an activity in a particular assay.

**Example 12: Construction of GAS Reporter Construct**

One signal transduction pathway involved in the differentiation and proliferation of cells is called the Jaks-STATs pathway. Activated proteins in the Jaks-STATs pathway bind to gamma activation site "GAS" elements or interferon-sensitive responsive element ("ISRE"), located in the promoter of many genes. The binding of a protein to these elements alter the expression of the associated gene.

GAS and ISRE elements are recognized by a class of transcription factors called Signal Transducers and Activators of Transcription, or "STATs." There are six members of the STATs family. Stat1 and Stat3 are present in many cell types, as is Stat2 (as response to IFN-alpha is widespread). Stat4 is more restricted and is not in many cell types though it has been found in T helper class 1, cells after treatment with IL-12. Stat5 was originally called mammary growth factor, but has been found at higher concentrations in other cells including myeloid cells. It can be activated in tissue culture cells by many cytokines.

The STATs are activated to translocate from the cytoplasm to the nucleus upon tyrosine phosphorylation by a set of kinases known as the Janus Kinase ("Jaks") family. Jaks represent a distinct family of soluble tyrosine kinases and include Tyk2, Jak1, Jak2, and Jak3. These kinases display significant sequence similarity and are generally catalytically inactive in resting cells.

The Jaks are activated by a wide range of receptors summarized in the Table below. (Adapted from review by Schidler and Darnell, Ann. Rev. Biochem. 64:621-51 (1995).) A cytokine receptor family, capable of activating Jaks, is divided into two groups: (a) Class 1 includes receptors for IL-2, IL-3, IL-4, IL-6, IL-7, IL-9, IL-11, IL-12, IL-15, Epo, PRL, GH, G-CSF, GM-CSF, LIF, CNTF, and thrombopoietin; and (b)

Class 2 includes IFN-a, IFN-g, and IL-10. The Class 1 receptors share a conserved cysteine motif (a set of four conserved cysteines and one tryptophan) and a WSXWS motif (a membrane proximal region encoding Trp-Ser-Xxx-Trp-Ser (SEQ ID NO:2)).

Thus, on binding of a ligand to a receptor, Jaks are activated, which in turn  
5 activate STATs, which then translocate and bind to GAS elements. This entire process is encompassed in the Jaks-STATs signal transduction pathway.

Therefore, activation of the Jaks-STATs pathway, reflected by the binding of the GAS or the ISRE element, can be used to indicate proteins involved in the proliferation and differentiation of cells. For example, growth factors and cytokines  
10 are known to activate the Jaks-STATs pathway. (See Table below.) Thus, by using GAS elements linked to reporter molecules, activators of the Jaks-STATs pathway can be identified.

		<u>JAKs</u>			<u>STATS GAS(elements) or ISRE</u>		
	<u>Ligand</u>	<u>tyk2</u>	<u>Jak1</u>	<u>Jak2</u>	<u>Jak3</u>		
	<u>IFN family</u>						
5	IFN-a/B	+	+	-	-	1,2,3	ISRE
	IFN-g		+	+	-	1	GAS (IRF1>Lys6>IFP)
	Il-10	+	?	?	-	1,3	
	<u>gp130 family</u>						
10	IL-6 (Pleiotrophic)	+	+	+	?	1,3	GAS (IRF1>Lys6>IFP)
	Il-11(Pleiotrophic)	?	+	?	?	1,3	
	OnM(Pleiotrophic)	?	+	+	?	1,3	
	LIF(Pleiotrophic)	?	+	+	?	1,3	
	CNTF(Pleiotrophic)	-/+	+	+	?	1,3	
15	G-CSF(Pleiotrophic)	?	+	?	?	1,3	
	IL-12(Pleiotrophic)	+	-	+	+	1,3	
	<u>g-C family</u>						
	IL-2 (lymphocytes)	-	+	-	+	1,3,5	GAS
20	IL-4 (lymph/myeloid)	-	+	-	+	6	GAS (IRF1 = IFP >>Ly6)(IgH)
	IL-7 (lymphocytes)	-	+	-	+	5	GAS
	IL-9 (lymphocytes)	-	+	-	+	5	GAS
	IL-13 (lymphocyte)	-	+	?	?	6	GAS
	IL-15	?	+	?	+	5	GAS
25	<u>gp140 family</u>						
	IL-3 (myeloid)	-	-	+	-	5	GAS (IRF1>IFP>>Ly6)
	IL-5 (myeloid)	-	-	+	-	5	GAS
	GM-CSF (myeloid)	-	-	+	-	5	GAS
30	<u>Growth hormone family</u>						
	GH	?	-	+	-	5	
	PRL	?	+/-	+	-	1,3,5	
	EPO	?	-	+	-	5	GAS(B-CAS>IRF1=IFP>>Ly6)
35	<u>Receptor Tyrosine Kinases</u>						
	EGF	?	+	+	-	1,3	GAS (IRF1)
	PDGF	?	+	+	-	1,3	
	CSF-1	?	+	+	-	1,3	GAS (not IRF1)
40							



To construct a synthetic GAS containing promoter element, which is used in the Biological Assays described in Examples 13-14, a PCR based strategy is employed to generate a GAS-SV40 promoter sequence. The 5' primer contains four tandem copies of the GAS binding site found in the IRF1 promoter and previously demonstrated to bind STATs upon induction with a range of cytokines (Rothman et al., Immunity 1:457-468 (1994).), although other GAS or ISRE elements can be used instead. The 5' primer also contains 18bp of sequence complementary to the SV40 early promoter sequence and is flanked with an XhoI site. The sequence of the 5' primer is:

10 5':GCGCCTCGAGATTTCCTCCGAAATCTAGATTTCCTCCGAAATGATTTCCTCCGAAATGATTTCCTCCGAAATATCTGCCATCTCAATTAG:3' (SEQ ID NO:3)

The downstream primer is complementary to the SV40 promoter and is flanked with a Hind III site: 5':GCGGCAAGCTTTTGGCAAAGCCTAGGC:3' (SEQ ID NO:4)

15 PCR amplification is performed using the SV40 promoter template present in the B-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI/Hind III and subcloned into BLSK2-. (Stratagene.) Sequencing with forward and reverse primers confirms that the insert contains the following sequence:

20 5':CTCGAGATTTCCTCCGAAATCTAGATTTCCTCCGAAATGATTTCCTCCGAAATGATTTCCTCCGAAATATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCCATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGACTAATTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTATTCCAGAAAGTAGTGAGGAGGCTTTTTTGGAGGCCT  
25 AGGCTTTTGGAAAAAGCTT:3' (SEQ ID NO:5)

With this GAS promoter element linked to the SV40 promoter, a GAS:SEAP2 reporter construct is next engineered. Here, the reporter molecule is a secreted alkaline phosphatase, or "SEAP." Clearly, however, any reporter molecule can be instead of SEAP, in this or in any of the other Examples. Well known reporter

5 molecules that can be used instead of SEAP include chloramphenicol acetyltransferase (CAT), luciferase, alkaline phosphatase, B-galactosidase, green fluorescent protein (GFP), or any protein detectable by an antibody.

The above sequence confirmed synthetic GAS-SV40 promoter element is subcloned into the pSEAP-Promoter vector obtained from Clontech using HindIII and

10 XhoI, effectively replacing the SV40 promoter with the amplified GAS:SV40 promoter element, to create the GAS-SEAP vector. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

Thus, in order to generate mammalian stable cell lines expressing the GAS-

15 SEAP reporter, the GAS-SEAP cassette is removed from the GAS-SEAP vector using SalI and NotI, and inserted into a backbone vector containing the neomycin resistance gene, such as pGFP-1 (Clontech), using these restriction sites in the multiple cloning site, to create the GAS-SEAP/Neo vector. Once this vector is transfected into mammalian cells, this vector can then be used as a reporter molecule for GAS binding

20 as described in Examples 13-14.

Other constructs can be made using the above description and replacing GAS with a different promoter sequence. For example, construction of reporter molecules containing NFK-B and EGR promoter sequences are described in Examples 15 and

16. However, many other promoters can be substituted using the protocols described

25 in these Examples. For instance, SRE, IL-2, NFAT, or Osteocalcin promoters can be substituted, alone or in combination (e.g., GAS/NF-KB/EGR, GAS/NF-KB, IL-

2/NFAT, or NF-KB/GAS). Similarly, other cell lines can be used to test reporter construct activity, such as HELA (epithelial), HUVEC (endothelial), Reh (B-cell), Saos-2 (osteoblast), HUVAC (aortic), or Cardiomyocyte.

5 **Example 13: High-Throughput Screening Assay for T-cell Activity.**

The following protocol is used to assess T-cell activity by identifying factors, and determining whether supernate containing a polypeptide of the invention proliferates and/or differentiates T-cells. T-cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP  
10 activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The T-cell used in this assay is Jurkat T-cells (ATCC Accession No. TIB-152), although Molt-3 cells (ATCC Accession No. CRL-1552) and Molt-4 cells (ATCC Accession No. CRL-1582) cells can also be used.

Jurkat T-cells are lymphoblastic CD4+ Th1 helper cells. In order to generate  
15 stable cell lines, approximately 2 million Jurkat cells are transfected with the GAS-SEAP/neo vector using DMR1E-C (Life Technologies)(transfection procedure described below). The transfected cells are seeded to a density of approximately 20,000 cells per well and transfectants resistant to 1 mg/ml gentamicin selected. Resistant colonies are expanded and then tested for their response to increasing  
20 concentrations of interferon gamma. The dose response of a selected clone is demonstrated.

Specifically, the following protocol will yield sufficient cells for 75 wells containing 200 ul of cells. Thus, it is either scaled up, or performed in multiple to generate sufficient cells for multiple 96 well plates. Jurkat cells are maintained in  
25 RPMI + 10% serum with 1% Pen-Strep. Combine 2.5 mls of OPTI-MEM (Life

Technologies) with 10 ug of plasmid DNA in a T25 flask. Add 2.5 ml OPTI-MEM containing 50 ul of DMRIE-C and incubate at room temperature for 15-45 mins.

During the incubation period, count cell concentration, spin down the required number of cells ( $10^7$  per transfection), and resuspend in OPTI-MEM to a final  
5 concentration of  $10^7$  cells/ml. Then add 1ml of  $1 \times 10^7$  cells in OPTI-MEM to T25 flask and incubate at 37 degrees C for 6 hrs. After the incubation, add 10 ml of RPMI + 15% serum.

The Jurkat:GAS-SEAP stable reporter lines are maintained in RPMI + 10% serum, 1 mg/ml Genticin, and 1% Pen-Strep. These cells are treated with  
10 supernatants containing polypeptides of the invention and/or induced polypeptides of the invention as produced by the protocol described in Example 11.

On the day of treatment with the supernatant, the cells should be washed and resuspended in fresh RPMI + 10% serum to a density of 500,000 cells per ml. The exact number of cells required will depend on the number of supernatants being  
15 screened. For one 96 well plate, approximately 10 million cells (for 10 plates, 100 million cells) are required.

Transfer the cells to a triangular reservoir boat, in order to dispense the cells into a 96 well dish, using a 12 channel pipette. Using a 12 channel pipette, transfer 200 ul of cells into each well (therefore adding 100, 000 cells per well).

20 After all the plates have been seeded, 50 ul of the supernatants are transferred directly from the 96 well plate containing the supernatants into each well using a 12 channel pipette. In addition, a dose of exogenous interferon gamma (0.1, 1.0, 10 ng) is added to wells H9, H10, and H11 to serve as additional positive controls for the assay.

25 The 96 well dishes containing Jurkat cells treated with supernatants are placed in an incubator for 48 hrs (note: this time is variable between 48-72 hrs). 35 ul

samples from each well are then transferred to an opaque 96 well plate using a 12 channel pipette. The opaque plates should be covered (using sellophene covers) and stored at -20 degrees C until SEAP assays are performed according to Example 17. The plates containing the remaining treated cells are placed at 4 degrees C and serve  
5 as a source of material for repeating the assay on a specific well if desired.

As a positive control, 100 Unit/ml interferon gamma can be used which is known to activate Jurkat T cells. Over 30 fold induction is typically observed in the positive control wells.

The above protocol may be used in the generation of both transient, as well as,  
10 stable transfected cells, which would be apparent to those of skill in the art.

**Example 14: High-Throughput Screening Assay Identifying Myeloid Activity**

The following protocol is used to assess myeloid activity by determining whether polypeptides of the invention proliferates and/or differentiates myeloid cells.  
15 Myeloid cell activity is assessed using the GAS/SEAP/Neo construct produced in Example 12. Thus, factors that increase SEAP activity indicate the ability to activate the Jaks-STATS signal transduction pathway. The myeloid cell used in this assay is U937, a pre-monocyte cell line, although TF-1, HL60, or KG1 can be used.

To transiently transfect U937 cells with the GAS/SEAP/Neo construct  
20 produced in Example 12, a DEAE-Dextran method (Kharbanda et. al., 1994, Cell Growth & Differentiation, 5:259-265) is used. First, harvest  $2 \times 10^7$  U937 cells and wash with PBS. The U937 cells are usually grown in RPMI 1640 medium containing 10% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 mg/ml streptomycin.

25 Next, suspend the cells in 1 ml of 20 mM Tris-HCl (pH 7.4) buffer containing 0.5 mg/ml DEAE-Dextran, 8 ug GAS-SEAP2 plasmid DNA, 140 mM NaCl, 5 mM

KCl, 375  $\mu$ M  $\text{Na}_2\text{HPO}_4 \cdot 7\text{H}_2\text{O}$ , 1 mM  $\text{MgCl}_2$ , and 675  $\mu$ M  $\text{CaCl}_2$ . Incubate at 37 degrees C for 45 min.

Wash the cells with RPMI 1640 medium containing 10% FBS and then resuspend in 10 ml complete medium and incubate at 37 degrees C for 36 hr.

- 5        The GAS-SEAP/U937 stable cells are obtained by growing the cells in 400  $\mu$ g/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 400  $\mu$ g/ml G418 for couple of passages.

- These cells are tested by harvesting  $1 \times 10^8$  cells (this is enough for ten 96-well plates assay) and wash with PBS. Suspend the cells in 200 ml above described  
10 growth medium, with a final density of  $5 \times 10^5$  cells/ml. Plate 200  $\mu$ l cells per well in the 96-well plate (or  $1 \times 10^5$  cells/well).

- Add 50  $\mu$ l of the supernatant prepared by the protocol described in Example  
11. Incubate at 37 degrees C for 48 to 72 hr. As a positive control, 100 Unit/ml  
interferon gamma can be used which is known to activate U937 cells. Over 30 fold  
15 induction is typically observed in the positive control wells. SEAP assay the supernatant according to the protocol described in Example 17.

**Example 15: High-Throughput Screening Assay Identifying Neuronal Activity.**

- When cells undergo differentiation and proliferation, a group of genes are  
20 activated through many different signal transduction pathways. One of these genes, EGR1 (early growth response gene 1), is induced in various tissues and cell types upon activation. The promoter of EGR1 is responsible for such induction. Using the EGR1 promoter linked to reporter molecules, activation of cells can be assessed.

- Particularly, the following protocol is used to assess neuronal activity in PC12  
25 cell lines. PC12 cells (rat phenochromocytoma cells) are known to proliferate and/or differentiate by activation with a number of mitogens, such as TPA (tetradecanoyl

phorbol acetate), NGF (nerve growth factor), and EGF (epidermal growth factor).

The EGR1 gene expression is activated during this treatment. Thus, by stably transfecting PC12 cells with a construct containing an EGR promoter linked to SEAP reporter, activation of PC12 cells can be assessed.

- 5           The EGR/SEAP reporter construct can be assembled by the following protocol. The EGR-1 promoter sequence (-633 to +1)(Sakamoto K et al., Oncogene 6:867-871 (1991)) can be PCR amplified from human genomic DNA using the following primers:

5' GCGCTCGAGGGATGACAGCGATAGAACCCCGG -3' (SEQ ID NO:6)

- 10           5' GCGAAGCTTCGCGACTCCCCGGATCCGCCTC-3' (SEQ ID NO:7)

- Using the GAS:SEAP/Neo vector produced in Example 12, EGR1 amplified product can then be inserted into this vector. Linearize the GAS:SEAP/Neo vector using restriction enzymes XhoI/HindIII, removing the GAS/SV40 stuffer. Restrict the EGR1 amplified product with these same enzymes. Ligate the vector and the EGR1  
15 promoter.

To prepare 96 well-plates for cell culture, two mls of a coating solution (1:30 dilution of collagen type I (Upstate Biotech Inc. Cat#08-115) in 30% ethanol (filter sterilized)) is added per one 10 cm plate or 50 ml per well of the 96-well plate, and allowed to air dry for 2 hr.

- 20           PC12 cells are routinely grown in RPMI-1640 medium (Bio Whittaker) containing 10% horse serum (JRH BIOSCIENCES, Cat. # 12449-78P), 5% heat-inactivated fetal bovine serum (FBS) supplemented with 100 units/ml penicillin and 100 ug/ml streptomycin on a precoated 10 cm tissue culture dish. One to four split is done every three to four days. Cells are removed from the plates by scraping and  
25 resuspended with pipetting up and down for more than 15 times.

Transfect the EGR/SEAP/Neo construct into PC12 using the Lipofectamine protocol described in Example 11. EGR-SEAP/PC12 stable cells are obtained by growing the cells in 300 ug/ml G418. The G418-free medium is used for routine growth but every one to two months, the cells should be re-grown in 300 ug/ml G418 for couple of passages.

To assay for neuronal activity, a 10 cm plate with cells around 70 to 80% confluent is screened by removing the old medium. Wash the cells once with PBS (Phosphate buffered saline). Then starve the cells in low serum medium (RPMI-1640 containing 1% horse serum and 0.5% FBS with antibiotics) overnight.

The next morning, remove the medium and wash the cells with PBS. Scrape off the cells from the plate, suspend the cells well in 2 ml low serum medium. Count the cell number and add more low serum medium to reach final cell density as  $5 \times 10^5$  cells/ml.

Add 200 ul of the cell suspension to each well of 96-well plate (equivalent to  $1 \times 10^5$  cells/well). Add 50 ul supernatant produced by Example 11, 37°C for 48 to 72 hr. As a positive control, a growth factor known to activate PC12 cells through EGR can be used, such as 50 ng/ul of Neuronal Growth Factor (NGF). Over fifty-fold induction of SEAP is typically seen in the positive control wells. SEAP assay the supernatant according to Example 17.

20

#### **Example 16: High-Throughput Screening Assay for T-cell Activity**

NF-KB (Nuclear Factor KB) is a transcription factor activated by a wide variety of agents including the inflammatory cytokines IL-1 and TNF, CD30 and CD40, lymphotoxin-alpha and lymphotoxin-beta, by exposure to LPS or thrombin, and by expression of certain viral gene products. As a transcription factor, NF-KB regulates the expression of genes involved in immune cell activation, control of

25



apoptosis (NF- KB appears to shield cells from apoptosis), B and T-cell development, anti-viral and antimicrobial responses, and multiple stress responses.

In non-stimulated conditions, NF- KB is retained in the cytoplasm with I-KB (Inhibitor KB). However, upon stimulation, I- KB is phosphorylated and degraded,  
5 causing NF- KB to shuttle to the nucleus, thereby activating transcription of target genes. Target genes activated by NF- KB include IL-2, IL-6, GM-CSF, ICAM-1 and class I MHC.

Due to its central role and ability to respond to a range of stimuli, reporter constructs utilizing the NF-KB promoter element are used to screen the supernatants  
10 produced in Example 11. Activators or inhibitors of NF-KB would be useful in treating diseases. For example, inhibitors of NF-KB could be used to treat those diseases related to the acute or chronic activation of NF-KB, such as rheumatoid arthritis.

To construct a vector containing the NF-KB promoter element, a PCR based  
15 strategy is employed. The upstream primer contains four tandem copies of the NF-KB binding site (GGGGACTTTCCC) (SEQ ID NO:8), 18 bp of sequence complementary to the 5' end of the SV40 early promoter sequence, and is flanked with an XhoI site:

5':GCGGCCTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGAC  
20 TTTCCATCCTGCCATCTCAATTAG:3' (SEQ ID NO:9)

The downstream primer is complementary to the 3' end of the SV40 promoter and is flanked with a Hind III site:

5':GCGGCAAGCTTTTTGCAAAGCCTAGGC:3' (SEQ ID NO:4)

PCR amplification is performed using the SV40 promoter template present in  
25 the pB-gal:promoter plasmid obtained from Clontech. The resulting PCR fragment is digested with XhoI and Hind III and subcloned into BLSK2-. (Stratagene)

Sequencing with the T7 and T3 primers confirms the insert contains the following sequence:

5':CTCGAGGGGACTTTCCCGGGGACTTTCCGGGGACTTTCCGGGACTTTCC  
 5 ATCTGCCATCTCAATTAGTCAGCAACCATAGTCCCGCCCCTAACTCCGCCC  
 ATCCCGCCCCTAACTCCGCCCAGTTCCGCCCATTCTCCGCCCCATGGCTGA  
 CTAATTTTTTTTTATTTATGCAGAGGCCGAGGCCGCCTCGGCCTCTGAGCTA  
 TTCCAGAAGTAGTGAGGAGGCTTTTTTGGAGGCCTAGGCTTTTGCAAAAA  
 GCTT:3' (SEQ ID NO:10)

10

Next, replace the SV40 minimal promoter element present in the pSEAP2-promoter plasmid (Clontech) with this NF-KB/SV40 fragment using XhoI and HindIII. However, this vector does not contain a neomycin resistance gene, and therefore, is not preferred for mammalian expression systems.

15

In order to generate stable mammalian cell lines, the NF-KB/SV40/SEAP cassette is removed from the above NF-KB/SEAP vector using restriction enzymes Sall and NotI, and inserted into a vector containing neomycin resistance. Particularly, the NF-KB/SV40/SEAP cassette was inserted into pGFP-1 (Clontech), replacing the GFP gene, after restricting pGFP-1 with Sall and NotI.

20

Once NF-KB/SV40/SEAP/Neo vector is created, stable Jurkat T-cells are created and maintained according to the protocol described in Example 13. Similarly, the method for assaying supernatants with these stable Jurkat T-cells is also described in Example 13. As a positive control, exogenous TNF alpha (0.1, 1, 10 ng) is added to wells H9, H10, and H11, with a 5-10 fold activation typically observed.

25

#### **Example 17: Assay for SEAP Activity**

As a reporter molecule for the assays described in Examples 13-16, SEAP activity is assayed using the Tropix Phospho-light Kit (Cat. BP-400) according to the following general procedure. The Tropix Phospho-light Kit supplies the Dilution, Assay, and Reaction Buffers used below.

- 5           Prime a dispenser with the 2.5x Dilution Buffer and dispense 15 ul of 2.5x dilution buffer into Optiplates containing 35 ul of a supernatant. Seal the plates with a plastic sealer and incubate at 65 degree C for 30 min. Separate the Optiplates to avoid uneven heating.

- 10           Cool the samples to room temperature for 15 minutes. Empty the dispenser and prime with the Assay Buffer. Add 50 ml Assay Buffer and incubate at room temperature 5 min. Empty the dispenser and prime with the Reaction Buffer (see the table below). Add 50 ul Reaction Buffer and incubate at room temperature for 20 minutes. Since the intensity of the chemiluminescent signal is time dependent, and it takes about 10 minutes to read 5 plates on luminometer, one should treat 5 plates at
- 15           each time and start the second set 10 minutes later.

Read the relative light unit in the luminometer. Set H12 as blank, and print the results. An increase in chemiluminescence indicates reporter activity.

**Reaction Buffer Formulation:**

# of plates	Rxn buffer diluent (ml)	CSPD (ml)
10	60	3
11	65	3.25
12	70	3.5
13	75	3.75
14	80	4
15	85	4.25
16	90	4.5
17	95	4.75
18	100	5
19	105	5.25
20	110	5.5

21	115	5.75
22	120	6
23	125	6.25
24	130	6.5
25	135	6.75
26	140	7
27	145	7.25
28	150	7.5
29	155	7.75
30	160	8
31	165	8.25
32	170	8.5
33	175	8.75
34	180	9
35	185	9.25
36	190	9.5
37	195	9.75
38	200	10
39	205	10.25
40	210	10.5
41	215	10.75
42	220	11
43	225	11.25
44	230	11.5
45	235	11.75
46	240	12
47	245	12.25
48	250	12.5
49	255	12.75
50	260	13

**Example 18: High-Throughput Screening Assay Identifying Changes in Small Molecule Concentration and Membrane Permeability**

Binding of a ligand to a receptor is known to alter intracellular levels of small molecules, such as calcium, potassium, sodium, and pH, as well as alter membrane potential. These alterations can be measured in an assay to identify supernatants which bind to receptors of a particular cell. Although the following protocol describes an assay for calcium, this protocol can easily be modified to detect changes

in potassium, sodium, pH, membrane potential, or any other small molecule which is detectable by a fluorescent probe.

The following assay uses Fluorometric Imaging Plate Reader ("FLIPR") to measure changes in fluorescent molecules (Molecular Probes) that bind small molecules. Clearly, any fluorescent molecule detecting a small molecule can be used instead of the calcium fluorescent molecule, fluo-4 (Molecular Probes, Inc.; catalog no. F-14202), used here.

For adherent cells, seed the cells at 10,000 -20,000 cells/well in a Co-star black 96-well plate with clear bottom. The plate is incubated in a CO<sub>2</sub> incubator for 20 hours. The adherent cells are washed two times in Biotek washer with 200 ul of HBSS (Hank's Balanced Salt Solution) leaving 100 ul of buffer after the final wash.

A stock solution of 1 mg/ml fluo-4 is made in 10% pluronic acid DMSO. To load the cells with fluo-4, 50 ul of 12 ug/ml fluo-4 is added to each well. The plate is incubated at 37 degrees C in a CO<sub>2</sub> incubator for 60 min. The plate is washed four times in the Biotek washer with HBSS leaving 100 ul of buffer.

For non-adherent cells, the cells are spun down from culture media. Cells are re-suspended to  $2.5 \times 10^6$  cells/ml with HBSS in a 50-ml conical tube. 4 ul of 1 mg/ml fluo-4 solution in 10% pluronic acid DMSO is added to each ml of cell suspension. The tube is then placed in a 37 degrees C water bath for 30-60 min. The cells are washed twice with HBSS, resuspended to  $1 \times 10^6$  cells/ml, and dispensed into a microplate, 100 ul/well. The plate is centrifuged at 1000 rpm for 5 min. The plate is then washed once in Denley CellWash with 200 ul, followed by an aspiration step to 100 ul final volume.

For a non-cell based assay, each well contains a fluorescent molecule, such as fluo-4. The supernatant is added to the well, and a change in fluorescence is detected.

To measure the fluorescence of intracellular calcium, the FLIPR is set for the following parameters: (1) System gain is 300-800 mW; (2) Exposure time is 0.4 second; (3) Camera F/stop is F/2; (4) Excitation is 488 nm; (5) Emission is 530 nm; and (6) Sample addition is 50 ul. Increased emission at 530 nm indicates an  
5 extracellular signaling event which has resulted in an increase in the intracellular  $\text{Ca}^{++}$  concentration.

**Example 19: High-Throughput Screening Assay Identifying Tyrosine Kinase Activity**

10 The Protein Tyrosine Kinases (PTK) represent a diverse group of transmembrane and cytoplasmic kinases. Within the Receptor Protein Tyrosine Kinase (RPTK) group are receptors for a range of mitogenic and metabolic growth factors including the PDGF, FGF, EGF, NGF, HGF and Insulin receptor subfamilies. In addition there are a large family of RPTKs for which the corresponding ligand is  
15 unknown. Ligands for RPTKs include mainly secreted small proteins, but also membrane-bound and extracellular matrix proteins.

Activation of RPTK by ligands involves ligand-mediated receptor dimerization, resulting in transphosphorylation of the receptor subunits and activation of the cytoplasmic tyrosine kinases. The cytoplasmic tyrosine kinases include  
20 receptor associated tyrosine kinases of the src-family (e.g., src, yes, lck, lyn, fyn) and non-receptor linked and cytosolic protein tyrosine kinases, such as the Jak family, members of which mediate signal transduction triggered by the cytokine superfamily of receptors (e.g., the Interleukins, Interferons, GM-CSF, and Leptin).

Because of the wide range of known factors capable of stimulating tyrosine  
25 kinase activity, the identification of novel human secreted proteins capable of activating tyrosine kinase signal transduction pathways are of interest. Therefore, the

following protocol is designed to identify those novel human secreted proteins capable of activating the tyrosine kinase signal transduction pathways.

Seed target cells (e.g., primary keratinocytes) at a density of approximately 25,000 cells per well in a 96 well Loprodyne Silent Screen Plates purchased from

5 Nalge Nunc (Naperville, IL). The plates are sterilized with two 30 minute rinses with 100% ethanol, rinsed with water and dried overnight. Some plates are coated for 2 hr with 100 ml of cell culture grade type I collagen (50 mg/ml), gelatin (2%) or polylysine (50 mg/ml), all of which can be purchased from Sigma Chemicals (St. Louis, MO) or 10% Matrigel purchased from Becton Dickinson (Bedford, MA), or

10 calf serum, rinsed with PBS and stored at 4 degree C. Cell growth on these plates is assayed by seeding 5,000 cells/well in growth medium and indirect quantitation of cell number through use of alamarBlue as described by the manufacturer Alamar Biosciences, Inc. (Sacramento, CA) after 48 hr. Falcon plate covers #3071 from Becton Dickinson (Bedford, MA) are used to cover the Loprodyne Silent Screen

15 Plates. Falcon Microtest III cell culture plates can also be used in some proliferation experiments.

To prepare extracts, A431 cells are seeded onto the nylon membranes of Loprodyne plates (20,000/200ml/well) and cultured overnight in complete medium. Cells are quiesced by incubation in serum-free basal medium for 24 hr. After 5-20

20 minutes treatment with EGF (60ng/ml) or 50 ul of the supernatant produced in Example 11, the medium was removed and 100 ml of extraction buffer ((20 mM HEPES pH 7.5, 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 2 mM Na<sub>3</sub>VO<sub>4</sub>, 2 mM Na<sub>4</sub>P<sub>2</sub>O<sub>7</sub> and a cocktail of protease inhibitors (# 1836170) obtained from Boehringer Mannheim (Indianapolis, IN) is added to each well and the plate is

25 shaken on a rotating shaker for 5 minutes at 4 degrees C. The plate is then placed in a vacuum transfer manifold and the extract filtered through the 0.45 mm membrane

bottoms of each well using house vacuum. Extracts are collected in a 96-well catch/assay plate in the bottom of the vacuum manifold and immediately placed on ice. To obtain extracts clarified by centrifugation, the content of each well, after detergent solubilization for 5 minutes, is removed and centrifuged for 15 minutes at 4  
5 degrees C at 16,000 x g.

Test the filtered extracts for levels of tyrosine kinase activity. Although many methods of detecting tyrosine kinase activity are known, one method is described here.

Generally, the tyrosine kinase activity of a supernatant is evaluated by  
10 determining its ability to phosphorylate a tyrosine residue on a specific substrate (a biotinylated peptide). Biotinylated peptides that can be used for this purpose include PSK1 (corresponding to amino acids 6-20 of the cell division kinase cdc2-p34) and PSK2 (corresponding to amino acids 1-17 of gastrin). Both peptides are substrates for a range of tyrosine kinases and are available from Boehringer Mannheim.

15 The tyrosine kinase reaction is set up by adding the following components in order. First, add 10ul of 5uM Biotinylated Peptide, then 10ul ATP/Mg<sub>2</sub><sup>+</sup> (5mM ATP/50mM MgCl<sub>2</sub>), then 10ul of 5x Assay Buffer (40mM imidazole hydrochloride, pH7.3, 40 mM beta-glycerophosphate, 1mM EGTA, 100mM MgCl<sub>2</sub>, 5 mM MnCl<sub>2</sub>, 0.5 mg/ml BSA), then 5ul of Sodium Vanadate(1mM), and then 5ul of water. Mix the  
20 components gently and preincubate the reaction mix at 30 degrees C for 2 min. Initial the reaction by adding 10ul of the control enzyme or the filtered supernatant.

The tyrosine kinase assay reaction is then terminated by adding 10 ul of 120mM EDTA and place the reactions on ice.

Tyrosine kinase activity is determined by transferring 50 ul aliquot of reaction  
25 mixture to a microtiter plate (MTP) module and incubating at 37 degrees C for 20



min. This allows the streptavidin coated 96 well plate to associate with the biotinylated peptide. Wash the MTP module with 300ul/well of PBS four times. Next add 75 ul of anti-phosphotyrosine antibody conjugated to horse radish peroxidase(anti-P-Tyr-POD(0.5u/ml)) to each well and incubate at 37 degrees C for  
5 one hour. Wash the well as above.

Next add 100ul of peroxidase substrate solution (Boehringer Mannheim) and incubate at room temperature for at least 5 mins (up to 30 min). Measure the absorbance of the sample at 405 nm by using ELISA reader. The level of bound peroxidase activity is quantitated using an ELISA reader and reflects the level of  
10 tyrosine kinase activity.

#### **Example 20: High-Throughput Screening Assay Identifying Phosphorylation Activity**

As a potential alternative and/or compliment to the assay of protein tyrosine  
15 kinase activity described in Example 19, an assay which detects activation (phosphorylation) of major intracellular signal transduction intermediates can also be used. For example, as described below one particular assay can detect tyrosine phosphorylation of the Erk-1 and Erk-2 kinases. However, phosphorylation of other molecules, such as Raf, JNK, p38 MAP, Map kinase kinase (MEK), MEK kinase,  
20 Src, Muscle specific kinase (MuSK), IRAK, Tec, and Janus, as well as any other phosphoserine, phosphotyrosine, or phosphothreonine molecule, can be detected by substituting these molecules for Erk-1 or Erk-2 in the following assay.

Specifically, assay plates are made by coating the wells of a 96-well ELISA plate with 0.1ml of protein G (1ug/ml) for 2 hr at room temp, (RT). The plates are  
25 then rinsed with PBS and blocked with 3% BSA/PBS for 1 hr at RT. The protein G plates are then treated with 2 commercial monoclonal antibodies (100ng/well) against

Erk-1 and Erk-2 (1 hr at RT) (Santa Cruz Biotechnology). (To detect other molecules, this step can easily be modified by substituting a monoclonal antibody detecting any of the above described molecules.) After 3-5 rinses with PBS, the plates are stored at 4 degrees C until use.

5           A431 cells are seeded at 20,000/well in a 96-well Loprodyne filterplate and cultured overnight in growth medium. The cells are then starved for 48 hr in basal medium (DMEM) and then treated with EGF (6ng/well) or 50 ul of the supernatants obtained in Example 11 for 5-20 minutes. The cells are then solubilized and extracts filtered directly into the assay plate.

10           After incubation with the extract for 1 hr at RT, the wells are again rinsed. As a positive control, a commercial preparation of MAP kinase (10ng/well) is used in place of A431 extract. Plates are then treated with a commercial polyclonal (rabbit) antibody (1ug/ml) which specifically recognizes the phosphorylated epitope of the Erk-1 and Erk-2 kinases (1 hr at RT). This antibody is biotinylated by standard  
15           procedures. The bound polyclonal antibody is then quantitated by successive incubations with Europium-streptavidin and Europium fluorescence enhancing reagent in the Wallac DELFIA instrument (time-resolved fluorescence). An increased fluorescent signal over background indicates a phosphorylation.

20    **Example 21: Method of Determining Alterations in a Gene Corresponding to a Polynucleotide**

          RNA isolated from entire families or individual patients presenting with a phenotype of interest (such as a disease) is be isolated. cDNA is then generated from these RNA samples using protocols known in the art. (See, Sambrook.) The cDNA  
25           is then used as a template for PCR, employing primers surrounding regions of interest in SEQ ID NO:X. Suggested PCR conditions consist of 35 cycles at 95 degrees C for

30 seconds; 60-120 seconds at 52-58 degrees C; and 60-120 seconds at 70 degrees C, using buffer solutions described in Sidransky et al., Science 252:706 (1991).

PCR products are then sequenced using primers labeled at their 5' end with T4 polynucleotide kinase, employing SequiTherm Polymerase. (Epicentre Technologies). The intron-exon borders of selected exons is also determined and genomic PCR products analyzed to confirm the results. PCR products harboring suspected mutations is then cloned and sequenced to validate the results of the direct sequencing.

PCR products is cloned into T-tailed vectors as described in Holton et al., Nucleic Acids Research, 19:1156 (1991) and sequenced with T7 polymerase (United States Biochemical). Affected individuals are identified by mutations not present in unaffected individuals.

Genomic rearrangements are also observed as a method of determining alterations in a gene corresponding to a polynucleotide. Genomic clones isolated according to Example 2 are nick-translated with digoxigenindeoxy-uridine 5'-triphosphate (Boehringer Mannheim), and FISH performed as described in Johnson et al., Methods Cell Biol. 35:73-99 (1991). Hybridization with the labeled probe is carried out using a vast excess of human cot-1 DNA for specific hybridization to the corresponding genomic locus.

Chromosomes are counterstained with 4,6-diamino-2-phenylidole and propidium iodide, producing a combination of C- and R-bands. Aligned images for precise mapping are obtained using a triple-band filter set (Chroma Technology, Brattleboro, VT) in combination with a cooled charge-coupled device camera (Photometrics, Tucson, AZ) and variable excitation wavelength filters. (Johnson et al., Genet. Anal. Tech. Appl., 8:75 (1991).) Image collection, analysis and chromosomal fractional length measurements are performed using the ISee Graphical

Program System. (Inovision Corporation, Durham, NC.) Chromosome alterations of the genomic region hybridized by the probe are identified as insertions, deletions, and translocations. These alterations are used as a diagnostic marker for an associated disease.

5

**Example 22: Method of Detecting Abnormal Levels of a Polypeptide in a Biological Sample**

A polypeptide of the present invention can be detected in a biological sample, and if an increased or decreased level of the polypeptide is detected, this polypeptide is a marker for a particular phenotype. Methods of detection are numerous, and thus, it is understood that one skilled in the art can modify the following assay to fit their particular needs.

For example, antibody-sandwich ELISAs are used to detect polypeptides in a sample, preferably a biological sample. Wells of a microtiter plate are coated with specific antibodies, at a final concentration of 0.2 to 10 ug/ml. The antibodies are either monoclonal or polyclonal and are produced by the method described in Example 10. The wells are blocked so that non-specific binding of the polypeptide to the well is reduced.

The coated wells are then incubated for > 2 hours at RT with a sample containing the polypeptide. Preferably, serial dilutions of the sample should be used to validate results. The plates are then washed three times with deionized or distilled water to remove unbound polypeptide.

Next, 50 ul of specific antibody-alkaline phosphatase conjugate, at a concentration of 25-400 ng, is added and incubated for 2 hours at room temperature. The plates are again washed three times with deionized or distilled water to remove unbound conjugate.

Add 75 ul of 4-methylumbelliferyl phosphate (MUP) or p-nitrophenyl phosphate (NPP) substrate solution to each well and incubate 1 hour at room temperature. Measure the reaction by a microtiter plate reader. Prepare a standard curve, using serial dilutions of a control sample, and plot polypeptide concentration on the X-axis (log scale) and fluorescence or absorbance of the Y-axis (linear scale).  
5 Interpolate the concentration of the polypeptide in the sample using the standard curve.

#### **Example 23: Formulation**

10 The invention also provides methods of treatment and/or prevention diseases, disorders, and/or conditions (such as, for example, any one or more of the diseases or disorders disclosed herein) by administration to a subject of an effective amount of a Therapeutic. By therapeutic is meant a polynucleotides or polypeptides of the invention (including fragments and variants), agonists or antagonists thereof, and/or  
15 antibodies thereto, in combination with a pharmaceutically acceptable carrier type (e.g., a sterile carrier).

The Therapeutic will be formulated and dosed in a fashion consistent with good medical practice, taking into account the clinical condition of the individual patient (especially the side effects of treatment with the Therapeutic alone), the site of  
20 delivery, the method of administration, the scheduling of administration, and other factors known to practitioners. The "effective amount" for purposes herein is thus determined by such considerations.

As a general proposition, the total pharmaceutically effective amount of the Therapeutic administered parenterally per dose will be in the range of about  
25 1ug/kg/day to 10 mg/kg/day of patient body weight, although, as noted above, this will be subject to therapeutic discretion. More preferably, this dose is at least 0.01

mg/kg/day, and most preferably for humans between about 0.01 and 1 mg/kg/day for the hormone. If given continuously, the Therapeutic is typically administered at a dose rate of about 1 ug/kg/hour to about 50 ug/kg/hour, either by 1-4 injections per day or by continuous subcutaneous infusions, for example, using a mini-pump. An  
5 intravenous bag solution may also be employed. The length of treatment needed to observe changes and the interval following treatment for responses to occur appears to vary depending on the desired effect.

Therapeutics can be are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments,  
10 gels, drops or transdermal patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and  
15 intraarticular injection and infusion.

Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics are administered orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, gels, drops or transdermal  
20 patch), buccally, or as an oral or nasal spray. "Pharmaceutically acceptable carrier" refers to a non-toxic solid, semisolid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. The term "parenteral" as used herein refers to modes of administration which include intravenous, intramuscular, intraperitoneal, intrasternal, subcutaneous and intraarticular injection and infusion.

25 Therapeutics of the invention are also suitably administered by sustained-release systems. Suitable examples of sustained-release Therapeutics include suitable

polymeric materials (such as, for example, semi-permeable polymer matrices in the form of shaped articles, e.g., films, or microcapsules), suitable hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, and sparingly soluble derivatives (such as, for example, a sparingly soluble salt).

- 5           Sustained-release matrices include polylactides (U.S. Pat. No. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma-ethyl-L-glutamate (Sidman et al., *Biopolymers* 22:547-556 (1983)), poly (2- hydroxyethyl methacrylate) (Langer et al., *J. Biomed. Mater. Res.* 15:167-277 (1981), and Langer, *Chem. Tech.* 12:98-105 (1982)), ethylene vinyl acetate (Langer et al., *Id.*) or poly-D- (-)-3-hydroxybutyric  
10   acid (EP 133,988).

- Sustained-release Therapeutics also include liposomally entrapped Therapeutics of the invention (*see generally*, Langer, *Science* 249:1527-1533 (1990); Treat et al., in *Liposomes in the Therapy of Infectious Disease and Cancer*, Lopez-Berestein and Fidler (eds.), Liss, New York, pp. 317 -327 and 353-365 (1989)).
- 15   Liposomes containing the Therapeutic are prepared by methods known per se: DE 3,218,121; Epstein et al., *Proc. Natl. Acad. Sci. (USA)* 82:3688-3692 (1985); Hwang et al., *Proc. Natl. Acad. Sci.(USA)* 77:4030-4034 (1980); EP 52,322; EP 36,676; EP 88,046; EP 143,949; EP 142,641; Japanese Pat. Appl. 83-118008; U.S. Pat. Nos. 4,485,045 and 4,544,545; and EP 102,324. Ordinarily, the liposomes are of the small  
20   (about 200-800 Angstroms) unilamellar type in which the lipid content is greater than about 30 mol. percent cholesterol, the selected proportion being adjusted for the optimal Therapeutic.

- In yet an additional embodiment, the Therapeutics of the invention are delivered by way of a pump (*see Langer, supra*; Sefton, *CRC Crit. Ref. Biomed. Eng.*  
25   14:201 (1987); Buchwald et al., *Surgery* 88:507 (1980); Saudek et al., *N. Engl. J. Med.* 321:574 (1989)).

Other controlled release systems are discussed in the review by Langer (*Science* 249:1527-1533 (1990)).

For parenteral administration, in one embodiment, the Therapeutic is formulated generally by mixing it at the desired degree of purity, in a unit dosage  
5 injectable form (solution, suspension, or emulsion), with a pharmaceutically acceptable carrier, i.e., one that is non-toxic to recipients at the dosages and concentrations employed and is compatible with other ingredients of the formulation. For example, the formulation preferably does not include oxidizing agents and other compounds that are known to be deleterious to the Therapeutic.

10 Generally, the formulations are prepared by contacting the Therapeutic uniformly and intimately with liquid carriers or finely divided solid carriers or both. Then, if necessary, the product is shaped into the desired formulation. Preferably the carrier is a parenteral carrier, more preferably a solution that is isotonic with the blood of the recipient. Examples of such carrier vehicles include water, saline, Ringer's  
15 solution, and dextrose solution. Non-aqueous vehicles such as fixed oils and ethyl oleate are also useful herein, as well as liposomes.

The carrier suitably contains minor amounts of additives such as substances that enhance isotonicity and chemical stability. Such materials are non-toxic to recipients at the dosages and concentrations employed, and include buffers such as  
20 phosphate, citrate, succinate, acetic acid, and other organic acids or their salts; antioxidants such as ascorbic acid; low molecular weight (less than about ten residues) polypeptides, e.g., polyarginine or tripeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids, such as glycine, glutamic acid, aspartic acid, or  
25 arginine; monosaccharides, disaccharides, and other carbohydrates including cellulose or its derivatives, glucose, manose, or dextrans; chelating agents such as EDTA; sugar



alcohols such as mannitol or sorbitol; counterions such as sodium; and/or nonionic surfactants such as polysorbates, poloxamers, or PEG.

The Therapeutic is typically formulated in such vehicles at a concentration of about 0.1 mg/ml to 100 mg/ml, preferably 1-10 mg/ml, at a pH of about 3 to 8. It will  
5 be understood that the use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of polypeptide salts.

Any pharmaceutical used for therapeutic administration can be sterile. Sterility is readily accomplished by filtration through sterile filtration membranes (e.g., 0.2 micron membranes). Therapeutics generally are placed into a container  
10 having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Therapeutics ordinarily will be stored in unit or multi-dose containers, for example, sealed ampoules or vials, as an aqueous solution or as a lyophilized formulation for reconstitution. As an example of a lyophilized formulation, 10-ml  
15 vials are filled with 5 ml of sterile-filtered 1% (w/v) aqueous Therapeutic solution, and the resulting mixture is lyophilized. The infusion solution is prepared by reconstituting the lyophilized Therapeutic using bacteriostatic Water-for-Injection.

The invention also provides a pharmaceutical pack or kit comprising one or more containers filled with one or more of the ingredients of the Therapeutics of the  
20 invention. Associated with such container(s) can be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of pharmaceuticals or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration. In addition, the Therapeutics may be employed in conjunction with other therapeutic compounds.

25 The Therapeutics of the invention may be administered alone or in combination with adjuvants. Adjuvants that may be administered with the

Therapeutics of the invention include, but are not limited to, alum, alum plus deoxycholate (ImmunoAg), MTP-PE (Biocine Corp.), QS21 (Genentech, Inc.), BCG, and MPL. In a specific embodiment, Therapeutics of the invention are administered in combination with alum. In another specific embodiment, Therapeutics of the invention are administered in combination with QS-21. Further adjuvants that may be administered with the Therapeutics of the invention include, but are not limited to, Monophosphoryl lipid immunomodulator, AdjuVax 100a, QS-21, QS-18, CRL1005, Aluminum salts, MF-59, and Virosomal adjuvant technology. Vaccines that may be administered with the Therapeutics of the invention include, but are not limited to, vaccines directed toward protection against MMR (measles, mumps, rubella), polio, varicella, tetanus/diphtheria, hepatitis A, hepatitis B, haemophilus influenzae B, whooping cough, pneumonia, influenza, Lyme's Disease, rotavirus, cholera, yellow fever, Japanese encephalitis, poliomyelitis, rabies, typhoid fever, and pertussis. Combinations may be administered either concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

The Therapeutics of the invention may be administered alone or in combination with other therapeutic agents. Therapeutic agents that may be administered in combination with the Therapeutics of the invention, include but not limited to, other members of the TNF family, chemotherapeutic agents, antibiotics, steroidal and non-steroidal anti-inflammatories, conventional immunotherapeutic agents, cytokines and/or growth factors. Combinations may be administered either

concomitantly, e.g., as an admixture, separately but simultaneously or concurrently; or sequentially. This includes presentations in which the combined agents are administered together as a therapeutic mixture, and also procedures in which the combined agents are administered separately but simultaneously, e.g., as through  
5 separate intravenous lines into the same individual. Administration "in combination" further includes the separate administration of one of the compounds or agents given first, followed by the second.

In one embodiment, the Therapeutics of the invention are administered in combination with members of the TNF family. TNF, TNF-related or TNF-like  
10 molecules that may be administered with the Therapeutics of the invention include, but are not limited to, soluble forms of TNF-alpha, lymphotoxin-alpha (LT-alpha, also known as TNF-beta), LT-beta (found in complex heterotrimer LT-alpha2-beta), OPGL, FasL, CD27L, CD30L, CD40L, 4-1BBL, DcR3, OX40L, TNF-gamma (International Publication No. WO 96/14328), AIM-I (International Publication No.  
15 WO 97/33899), endokine-alpha (International Publication No. WO 98/07880), TR6 (International Publication No. WO 98/30694), OPG, and neutrokine-alpha (International Publication No. WO 98/18921, OX40, and nerve growth factor (NGF), and soluble forms of Fas, CD30, CD27, CD40 and 4-1BB, TR2 (International Publication No. WO 96/34095), DR3 (International Publication No. WO 97/33904),  
20 DR4 (International Publication No. WO 98/32856), TR5 (International Publication No. WO 98/30693), TR6 (International Publication No. WO 98/30694), TR7 (International Publication No. WO 98/41629), TRANK, TR9 (International Publication No. WO 98/56892), TR10 (International Publication No. WO 98/54202), 312C2 (International Publication No. WO 98/06842), and TR12, and soluble forms  
25 CD154, CD70, and CD153.

In certain embodiments, Therapeutics of the invention are administered in combination with antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors. Nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, RETROVIR™ (zidovudine/AZT), VIDEX™ (didanosine/ddI), HIVID™ (zalcitabine/ddC), ZERIT™ (stavudine/d4T), EPIVIR™ (lamivudine/3TC), and COMBIVIR™ (zidovudine/lamivudine). Non-nucleoside reverse transcriptase inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, VIRAMUNE™ (nevirapine), RESCRIPTOR™ (delavirdine), and SUSTIVA™ (efavirenz). Protease inhibitors that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, CRIVAN™ (indinavir), NORVIR™ (ritonavir), INVIRASE™ (saquinavir), and VIRACEPT™ (nelfinavir). In a specific embodiment, antiretroviral agents, nucleoside reverse transcriptase inhibitors, non-nucleoside reverse transcriptase inhibitors, and/or protease inhibitors may be used in any combination with Therapeutics of the invention to treat AIDS and/or to prevent or treat HIV infection.

In other embodiments, Therapeutics of the invention may be administered in combination with anti-opportunistic infection agents. Anti-opportunistic agents that may be administered in combination with the Therapeutics of the invention, include, but are not limited to, TRIMETHOPRIM-SULFAMETHOXAZOLE™, DAPSONE™, PENTAMIDINE™, ATOVAQUONE™, ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, ETHAMBUTOL™, RIFABUTIN™, CLARITHROMYCIN™, AZITHROMYCIN™, GANCICLOVIR™, FOSCARNET™, CIDOFOVIR™, FLUCONAZOLE™, ITRACONAZOLE™,

KETOCONAZOLE™, ACYCLOVIR™, FAMCICOLVIR™, PYRIMETHAMINE™, LEUCOVORIN™, NEUPOGEN™ (filgrastim/G-CSF), and LEUKINE™ (sargramostim/GM-CSF). In a specific embodiment, Therapeutics of the invention are used in any combination with TRIMETHOPRIM-SULFAMETHOXAZOLE™, 5 DAPSONE™, PENTAMIDINE™, and/or ATOVAQUONE™ to prophylactically treat or prevent an opportunistic *Pneumocystis carinii* pneumonia infection. In another specific embodiment, Therapeutics of the invention are used in any combination with ISONIAZID™, RIFAMPIN™, PYRAZINAMIDE™, and/or ETHAMBUTOL™ to prophylactically treat or prevent an opportunistic 10 *Mycobacterium avium* complex infection. In another specific embodiment, Therapeutics of the invention are used in any combination with RIFABUTIN™, CLARITHROMYCIN™, and/or AZITHROMYCIN™ to prophylactically treat or prevent an opportunistic *Mycobacterium tuberculosis* infection. In another specific embodiment, Therapeutics of the invention are used in any combination with 15 GANCICLOVIR™, FOSCARNET™, and/or CIDOFOVIR™ to prophylactically treat or prevent an opportunistic cytomegalovirus infection. In another specific embodiment, Therapeutics of the invention are used in any combination with FLUCONAZOLE™, ITRACONAZOLE™, and/or KETOCONAZOLE™ to prophylactically treat or prevent an opportunistic fungal infection. In another 20 specific embodiment, Therapeutics of the invention are used in any combination with ACYCLOVIR™ and/or FAMCICOLVIR™ to prophylactically treat or prevent an opportunistic herpes simplex virus type I and/or type II infection. In another specific embodiment, Therapeutics of the invention are used in any combination with PYRIMETHAMINE™ and/or LEUCOVORIN™ to prophylactically treat or prevent 25 an opportunistic *Toxoplasma gondii* infection. In another specific embodiment,

Therapeutics of the invention are used in any combination with LEUCOVORIN™ and/or NEUPOGEN™ to prophylactically treat or prevent an opportunistic bacterial infection.

In a further embodiment, the Therapeutics of the invention are administered  
5 in combination with an antiviral agent. Antiviral agents that may be administered with the Therapeutics of the invention include, but are not limited to, acyclovir, ribavirin, amantadine, and remantidine.

In a further embodiment, the Therapeutics of the invention are administered in combination with an antibiotic agent. Antibiotic agents that may be administered  
10 with the Therapeutics of the invention include, but are not limited to, amoxicillin, beta-lactamases, aminoglycosides, beta-lactam (glycopeptide), beta-lactamases, Clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, ciprofloxacin, erythromycin, fluoroquinolones, macrolides, metronidazole, penicillins, quinolones, rifampin, streptomycin, sulfonamide, tetracyclines, trimethoprim, trimethoprim-  
15 sulfamthoxazole, and vancomycin.

Conventional nonspecific immunosuppressive agents, that may be administered in combination with the Therapeutics of the invention include, but are not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide methylprednisone, prednisone, azathioprine, FK-506, 15-deoxyspergualin, and other  
20 immunosuppressive agents that act by suppressing the function of responding T cells.

In specific embodiments, Therapeutics of the invention are administered in combination with immunosuppressants. Immunosuppressants preparations that may be administered with the Therapeutics of the invention include, but are not limited to, ORTHOCLONE™ (OKT3), SANDIMMUNE™/NEORAL™/SANGDYA™  
25 (cyclosporin), PROGRAF™ (tacrolimus), CELLCEPT™ (mycophenolate), Azathioprine, glucocorticosteroids, and RAPAMUNE™ (sirolimus). In a specific

embodiment, immunosuppressants may be used to prevent rejection of organ or bone marrow transplantation.

In an additional embodiment, Therapeutics of the invention are administered alone or in combination with one or more intravenous immune globulin preparations.

5 Intravenous immune globulin preparations that may be administered with the Therapeutics of the invention include, but not limited to, GAMMAR™, IVEEGAM™, SANDOGLOBULIN™, GAMMAGARD S/D™, and GAMIMUNE™.

In a specific embodiment, Therapeutics of the invention are administered in combination with intravenous immune globulin preparations in transplantation  
10 therapy (e.g., bone marrow transplant).

In an additional embodiment, the Therapeutics of the invention are administered alone or in combination with an anti-inflammatory agent. Anti-inflammatory agents that may be administered with the Therapeutics of the invention include, but are not limited to, glucocorticoids and the nonsteroidal anti-  
15 inflammatories, aminoarylcarboxylic acid derivatives, arylacetic acid derivatives, arylbutyric acid derivatives, arylcarboxylic acids, arylpropionic acid derivatives, pyrazoles, pyrazolones, salicylic acid derivatives, thiazinecarboxamides, e-acetamidocaproic acid, S-adenosylmethionine, 3-amino-4-hydroxybutyric acid, amixetrine, bendazac, benzydamine, bucolome, difenpiramide, ditazol, emorfazone,  
20 guaiazulene, nabumetone, nimesulide, orgotein, oxaceprol, paranyline, perisoxal, pifoxime, proquazone, proxazole, and tenidap.

In another embodiment, compositions of the invention are administered in combination with a chemotherapeutic agent. Chemotherapeutic agents that may be administered with the Therapeutics of the invention include, but are not limited to,  
25 antibiotic derivatives (e.g., doxorubicin, bleomycin, daunorubicin, and dactinomycin); antiestrogens (e.g., tamoxifen); antimetabolites (e.g., fluorouracil, 5-

FU, methotrexate, floxuridine, interferon alpha-2b, glutamic acid, plicamycin, mercaptopurine, and 6-thioguanine); cytotoxic agents (e.g., carmustine, BCNU, lomustine, CCNU, cytosine arabinoside, cyclophosphamide, estramustine, hydroxyurea, procarbazine, mitomycin, busulfan, cis-platin, and vincristine sulfate);  
5 hormones (e.g., medroxyprogesterone, estramustine phosphate sodium, ethinyl estradiol, estradiol, megestrol acetate, methyltestosterone, diethylstilbestrol diphosphate, chlorotrianisene, and testolactone); nitrogen mustard derivatives (e.g., mephallen, chorambucil, mechlorethamine (nitrogen mustard) and thiotepa); steroids and combinations (e.g., bethamethasone sodium phosphate); and others (e.g.,  
10 dicarbazine, asparaginase, mitotane, vincristine sulfate, vinblastine sulfate, and etoposide).

In a specific embodiment, Therapeutics of the invention are administered in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or any combination of the components of CHOP. In another  
15 embodiment, Therapeutics of the invention are administered in combination with Rituximab. In a further embodiment, Therapeutics of the invention are administered with Rituxmab and CHOP, or Rituxmab and any combination of the components of CHOP.

In an additional embodiment, the Therapeutics of the invention are  
20 administered in combination with cytokines. Cytokines that may be administered with the Therapeutics of the invention include, but are not limited to, IL2, IL3, IL4, IL5, IL6, IL7, IL10, IL12, IL13, IL15, anti-CD40, CD40L, IFN-gamma and TNF-alpha. In another embodiment, Therapeutics of the invention may be administered with any interleukin, including, but not limited to, IL-1alpha, IL-1beta, IL-2, IL-3,  
25 IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-11, IL-12, IL-13, IL-14, IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, and IL-21.



In an additional embodiment, the Therapeutics of the invention are administered in combination with angiogenic proteins. Angiogenic proteins that may be administered with the Therapeutics of the invention include, but are not limited to, Glioma Derived Growth-Factor (GDGF), as disclosed in European Patent Number  
5 EP-399816; Platelet Derived Growth Factor-A (PDGF-A), as disclosed in European Patent Number EP-682110; Platelet Derived Growth Factor-B (PDGF-B), as disclosed in European Patent Number EP-282317; Placental Growth Factor (PIGF), as disclosed in International Publication Number WO 92/06194; Placental Growth Factor-2 (PIGF-2), as disclosed in Hauser et al., Growth Factors, 4:259-268 (1993);  
10 Vascular Endothelial Growth Factor (VEGF), as disclosed in International Publication Number WO 90/13649; Vascular Endothelial Growth Factor-A (VEGF-A), as disclosed in European Patent Number EP-506477; Vascular Endothelial Growth Factor-2 (VEGF-2), as disclosed in International Publication Number WO 96/39515; Vascular Endothelial Growth Factor B (VEGF-3); Vascular Endothelial Growth  
15 Factor B-186 (VEGF-B186), as disclosed in International Publication Number WO 96/26736; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/02543; Vascular Endothelial Growth Factor-D (VEGF-D), as disclosed in International Publication Number WO 98/07832; and Vascular Endothelial Growth Factor-E (VEGF-E), as disclosed in German Patent  
20 Number DE19639601. The above mentioned references are incorporated herein by reference herein.

In an additional embodiment, the Therapeutics of the invention are administered in combination with hematopoietic growth factors. Hematopoietic growth factors that may be administered with the Therapeutics of the invention  
25 include, but are not limited to, LEUKINE™ (SARGRAMOSTIM™) and NEUPOGEN™ (FILGRASTIM™).

In an additional embodiment, the Therapeutics of the invention are administered in combination with Fibroblast Growth Factors. Fibroblast Growth Factors that may be administered with the Therapeutics of the invention include, but are not limited to, FGF-1, FGF-2, FGF-3, FGF-4, FGF-5, FGF-6, FGF-7, FGF-8, 5 FGF-9, FGF-10, FGF-11, FGF-12, FGF-13, FGF-14, and FGF-15.

In additional embodiments, the Therapeutics of the invention are administered in combination with other therapeutic or prophylactic regimens, such as, for example, radiation therapy.

10 **Example 24: Method of Treating Decreased Levels of the Polypeptide**

The present invention relates to a method for treating an individual in need of an increased level of a polypeptide of the invention in the body comprising administering to such an individual a composition comprising a therapeutically effective amount of an agonist of the invention (including polypeptides of the 15 invention). Moreover, it will be appreciated that conditions caused by a decrease in the standard or normal expression level of a secreted protein in an individual can be treated by administering the polypeptide of the present invention, preferably in the secreted form. Thus, the invention also provides a method of treatment of an individual in need of an increased level of the polypeptide comprising administering 20 to such an individual a Therapeutic comprising an amount of the polypeptide to increase the activity level of the polypeptide in such an individual.

For example, a patient with decreased levels of a polypeptide receives a daily dose 0.1-100 ug/kg of the polypeptide for six consecutive days. Preferably, the polypeptide is in the secreted form. The exact details of the dosing scheme, based on 25 administration and formulation, are provided in Example 23.

**Example 25: Method of Treating Increased Levels of the Polypeptide**

The present invention also relates to a method of treating an individual in need of a decreased level of a polypeptide of the invention in the body comprising  
5 administering to such an individual a composition comprising a therapeutically effective amount of an antagonist of the invention (including polypeptides and antibodies of the invention).

In one example, antisense technology is used to inhibit production of a polypeptide of the present invention. This technology is one example of a method of  
10 decreasing levels of a polypeptide, preferably a secreted form, due to a variety of etiologies, such as cancer. For example, a patient diagnosed with abnormally increased levels of a polypeptide is administered intravenously antisense polynucleotides at 0.5, 1.0, 1.5, 2.0 and 3.0 mg/kg day for 21 days. This treatment is repeated after a 7-day rest period if the treatment was well tolerated. The formulation  
15 of the antisense polynucleotide is provided in Example 23.

**Example 26: Method of Treatment Using Gene Therapy-Ex Vivo**

One method of gene therapy transplants fibroblasts, which are capable of expressing a polypeptide, onto a patient. Generally, fibroblasts are obtained from a  
20 subject by skin biopsy. The resulting tissue is placed in tissue-culture medium and separated into small pieces. Small chunks of the tissue are placed on a wet surface of a tissue culture flask, approximately ten pieces are placed in each flask. The flask is turned upside down, closed tight and left at room temperature over night. After 24 hours at room temperature, the flask is inverted and the chunks of tissue remain fixed  
25 to the bottom of the flask and fresh media (e.g., Ham's F12 media, with 10% FBS,

penicillin and streptomycin) is added. The flasks are then incubated at 37 degree C for approximately one week.

At this time, fresh media is added and subsequently changed every several days. After an additional two weeks in culture, a monolayer of fibroblasts emerge.

- 5 The monolayer is trypsinized and scaled into larger flasks.

pMV-7 (Kirschmeier, P.T. et al., DNA, 7:219-25 (1988)), flanked by the long terminal repeats of the Moloney murine sarcoma virus, is digested with EcoRI and HindIII and subsequently treated with calf intestinal phosphatase. The linear vector is fractionated on agarose gel and purified, using glass beads.

- 10 The cDNA encoding a polypeptide of the present invention can be amplified using PCR primers which correspond to the 5' and 3' end sequences respectively as set forth in Example 1 using primers and having appropriate restriction sites and initiation/stop codons, if necessary. Preferably, the 5' primer contains an EcoRI site and the 3' primer includes a HindIII site. Equal quantities of the Moloney murine  
15 sarcoma virus linear backbone and the amplified EcoRI and HindIII fragment are added together, in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The ligation mixture is then used to transform bacteria HB101, which are then plated onto agar containing kanamycin for the purpose of confirming that the vector has the gene  
20 of interest properly inserted.

- The amphotropic pA317 or GP+am12 packaging cells are grown in tissue culture to confluent density in Dulbecco's Modified Eagles Medium (DMEM) with 10% calf serum (CS), penicillin and streptomycin. The MSV vector containing the gene is then added to the media and the packaging cells transduced with the vector.  
25 The packaging cells now produce infectious viral particles containing the gene (the packaging cells are now referred to as producer cells).

Fresh media is added to the transduced producer cells, and subsequently, the media is harvested from a 10 cm plate of confluent producer cells. The spent media, containing the infectious viral particles, is filtered through a millipore filter to remove detached producer cells and this media is then used to infect fibroblast cells. Media is removed from a sub-confluent plate of fibroblasts and quickly replaced with the media from the producer cells. This media is removed and replaced with fresh media. If the titer of virus is high, then virtually all fibroblasts will be infected and no selection is required. If the titer is very low, then it is necessary to use a retroviral vector that has a selectable marker, such as neo or his. Once the fibroblasts have been efficiently infected, the fibroblasts are analyzed to determine whether protein is produced.

The engineered fibroblasts are then transplanted onto the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads.

**Example 27: Gene Therapy Using Endogenous Genes Corresponding To Polynucleotides of the Invention**

Another method of gene therapy according to the present invention involves operably associating the endogenous polynucleotide sequence of the invention with a promoter via homologous recombination as described, for example, in U.S. Patent NO: 5,641,670, issued June 24, 1997; International Publication NO: WO 96/29411, published September 26, 1996; International Publication NO: WO 94/12650, published August 4, 1994; Koller et al., *Proc. Natl. Acad. Sci. USA*, 86:8932-8935 (1989); and Zijlstra et al., *Nature*, 342:435-438 (1989). This method involves the activation of a gene which is present in the target cells, but which is not expressed in the cells, or is expressed at a lower level than desired.

Polynucleotide constructs are made which contain a promoter and targeting sequences, which are homologous to the 5' non-coding sequence of endogenous polynucleotide sequence, flanking the promoter. The targeting sequence will be sufficiently near the 5' end of the polynucleotide sequence so the promoter will be operably linked to the endogenous sequence upon homologous recombination. The promoter and the targeting sequences can be amplified using PCR. Preferably, the amplified promoter contains distinct restriction enzyme sites on the 5' and 3' ends. Preferably, the 3' end of the first targeting sequence contains the same restriction enzyme site as the 5' end of the amplified promoter and the 5' end of the second targeting sequence contains the same restriction site as the 3' end of the amplified promoter.

The amplified promoter and the amplified targeting sequences are digested with the appropriate restriction enzymes and subsequently treated with calf intestinal phosphatase. The digested promoter and digested targeting sequences are added together in the presence of T4 DNA ligase. The resulting mixture is maintained under conditions appropriate for ligation of the two fragments. The construct is size fractionated on an agarose gel then purified by phenol extraction and ethanol precipitation.

In this Example, the polynucleotide constructs are administered as naked polynucleotides via electroporation. However, the polynucleotide constructs may also be administered with transfection-facilitating agents, such as liposomes, viral sequences, viral particles, precipitating agents, etc. Such methods of delivery are known in the art.

Once the cells are transfected, homologous recombination will take place which results in the promoter being operably linked to the endogenous polynucleotide sequence. This results in the expression of polynucleotide corresponding to the

polynucleotide in the cell. Expression may be detected by immunological staining, or any other method known in the art.

Fibroblasts are obtained from a subject by skin biopsy. The resulting tissue is placed in DMEM + 10% fetal calf serum. Exponentially growing or early stationary  
5 phase fibroblasts are trypsinized and rinsed from the plastic surface with nutrient medium. An aliquot of the cell suspension is removed for counting, and the remaining cells are subjected to centrifugation. The supernatant is aspirated and the pellet is resuspended in 5 ml of electroporation buffer (20 mM HEPES pH 7.3, 137 mM NaCl, 5 mM KCl, 0.7 mM Na<sub>2</sub> HPO<sub>4</sub>, 6 mM dextrose). The cells are recentrifuged, the  
10 supernatant aspirated, and the cells resuspended in electroporation buffer containing 1 mg/ml acetylated bovine serum albumin. The final cell suspension contains approximately  $3 \times 10^6$  cells/ml. Electroporation should be performed immediately following resuspension.

Plasmid DNA is prepared according to standard techniques. For example, to  
15 construct a plasmid for targeting to the locus corresponding to the polynucleotide of the invention, plasmid pUC18 (MBI Fermentas, Amherst, NY) is digested with HindIII. The CMV promoter is amplified by PCR with an XbaI site on the 5' end and a BamHI site on the 3' end. Two non-coding sequences are amplified via PCR: one non-coding sequence (fragment 1) is amplified with a HindIII site at the 5' end and an  
20 Xba site at the 3' end; the other non-coding sequence (fragment 2) is amplified with a BamHI site at the 5' end and a HindIII site at the 3' end. The CMV promoter and the fragments (1 and 2) are digested with the appropriate enzymes (CMV promoter - XbaI and BamHI; fragment 1 - XbaI; fragment 2 - BamHI) and ligated together. The resulting ligation product is digested with HindIII, and ligated with the HindIII-  
25 digested pUC18 plasmid.

Plasmid DNA is added to a sterile cuvette with a 0.4 cm electrode gap (Bio-Rad). The final DNA concentration is generally at least 120  $\mu\text{g/ml}$ . 0.5 ml of the cell suspension (containing approximately  $1.5 \times 10^6$  cells) is then added to the cuvette, and the cell suspension and DNA solutions are gently mixed. Electroporation is performed with a Gene-Pulser apparatus (Bio-Rad). Capacitance and voltage are set at 960  $\mu\text{F}$  and 250-300 V, respectively. As voltage increases, cell survival decreases, but the percentage of surviving cells that stably incorporate the introduced DNA into their genome increases dramatically. Given these parameters, a pulse time of approximately 14-20 mSec should be observed.

Electroporated cells are maintained at room temperature for approximately 5 min, and the contents of the cuvette are then gently removed with a sterile transfer pipette. The cells are added directly to 10 ml of prewarmed nutrient media (DMEM with 15% calf serum) in a 10 cm dish and incubated at 37 degree C. The following day, the media is aspirated and replaced with 10 ml of fresh media and incubated for a further 16-24 hours.

The engineered fibroblasts are then injected into the host, either alone or after having been grown to confluence on cytodex 3 microcarrier beads. The fibroblasts now produce the protein product. The fibroblasts can then be introduced into a patient as described above.

20

#### **Example 28: Method of Treatment Using Gene Therapy - In Vivo**

Another aspect of the present invention is using *in vivo* gene therapy methods to treat disorders, diseases and conditions. The gene therapy method relates to the introduction of naked nucleic acid (DNA, RNA, and antisense DNA or RNA) sequences into an animal to increase or decrease the expression of the polypeptide. The polynucleotide of the present invention may be operatively linked to a promoter



or any other genetic elements necessary for the expression of the polypeptide by the target tissue. Such gene therapy and delivery techniques and methods are known in the art, see, for example, WO90/11092, WO98/11779; U.S. Patent NO. 5693622, 5705151, 5580859; Tabata et al., *Cardiovasc. Res.* 35(3):470-479 (1997); Chao et al.,  
5 *Pharmacol. Res.* 35(6):517-522 (1997); Wolff, *Neuromuscul. Disord.* 7(5):314-318 (1997); Schwartz et al., *Gene Ther.* 3(5):405-411 (1996); Tsurumi et al., *Circulation* 94(12):3281-3290 (1996) (incorporated herein by reference).

The polynucleotide constructs may be delivered by any method that delivers injectable materials to the cells of an animal, such as, injection into the interstitial  
10 space of tissues (heart, muscle, skin, lung, liver, intestine and the like). The polynucleotide constructs can be delivered in a pharmaceutically acceptable liquid or aqueous carrier.

The term "naked" polynucleotide, DNA or RNA, refers to sequences that are free from any delivery vehicle that acts to assist, promote, or facilitate entry into the  
15 cell, including viral sequences, viral particles; liposome formulations, lipofectin or precipitating agents and the like. However, the polynucleotides of the present invention may also be delivered in liposome formulations (such as those taught in Felgner P.L. et al. (1995) *Ann. NY Acad. Sci.* 772:126-139 and Abdallah B. et al. (1995) *Biol. Cell* 85(1):1-7) which can be prepared by methods well known to those  
20 skilled in the art.

The polynucleotide vector constructs used in the gene therapy method are preferably constructs that will not integrate into the host genome nor will they contain sequences that allow for replication. Any strong promoter known to those skilled in the art can be used for driving the expression of DNA. Unlike other gene therapies  
25 techniques, one major advantage of introducing naked nucleic acid sequences into target cells is the transitory nature of the polynucleotide synthesis in the cells. Studies

have shown that non-replicating DNA sequences can be introduced into cells to provide production of the desired polypeptide for periods of up to six months.

The polynucleotide construct can be delivered to the interstitial space of tissues within the an animal, including of muscle, skin, brain, lung, liver, spleen, bone marrow, thymus, heart, lymph, blood, bone, cartilage, pancreas, kidney, gall bladder, stomach, intestine, testis, ovary, uterus, rectum, nervous system, eye, gland, and connective tissue. Interstitial space of the tissues comprises the intercellular fluid, mucopolysaccharide matrix among the reticular fibers of organ tissues, elastic fibers in the walls of vessels or chambers, collagen fibers of fibrous tissues, or that same matrix within connective tissue ensheathing muscle cells or in the lacunae of bone. It is similarly the space occupied by the plasma of the circulation and the lymph fluid of the lymphatic channels. Delivery to the interstitial space of muscle tissue is preferred for the reasons discussed below. They may be conveniently delivered by injection into the tissues comprising these cells. They are preferably delivered to and expressed in persistent, non-dividing cells which are differentiated, although delivery and expression may be achieved in non-differentiated or less completely differentiated cells, such as, for example, stem cells of blood or skin fibroblasts. *In vivo* muscle cells are particularly competent in their ability to take up and express polynucleotides.

For the naked polynucleotide injection, an effective dosage amount of DNA or RNA will be in the range of from about 0.05 g/kg body weight to about 50 mg/kg body weight. Preferably the dosage will be from about 0.005 mg/kg to about 20 mg/kg and more preferably from about 0.05 mg/kg to about 5 mg/kg. Of course, as the artisan of ordinary skill will appreciate, this dosage will vary according to the tissue site of injection. The appropriate and effective dosage of nucleic acid sequence can readily be determined by those of ordinary skill in the art and may depend on the

condition being treated and the route of administration. The preferred route of administration is by the parenteral route of injection into the interstitial space of tissues. However, other parenteral routes may also be used, such as, inhalation of an aerosol formulation particularly for delivery to lungs or bronchial tissues, throat or  
5 mucous membranes of the nose. In addition, naked polynucleotide constructs can be delivered to arteries during angioplasty by the catheter used in the procedure.

The dose response effects of injected polynucleotide in muscle *in vivo* is determined as follows. Suitable template DNA for production of mRNA coding for polypeptide of the present invention is prepared in accordance with a standard  
10 recombinant DNA methodology. The template DNA, which may be either circular or linear, is either used as naked DNA or complexed with liposomes. The quadriceps muscles of mice are then injected with various amounts of the template DNA.

Five to six week old female and male Balb/C mice are anesthetized by intraperitoneal injection with 0.3 ml of 2.5% Avertin. A 1.5 cm incision is made on  
15 the anterior thigh, and the quadriceps muscle is directly visualized. The template DNA is injected in 0.1 ml of carrier in a 1 cc syringe through a 27 gauge needle over one minute, approximately 0.5 cm from the distal insertion site of the muscle into the knee and about 0.2 cm deep. A suture is placed over the injection site for future localization, and the skin is closed with stainless steel clips.

20 After an appropriate incubation time (e.g., 7 days) muscle extracts are prepared by excising the entire quadriceps. Every fifth 15 um cross-section of the individual quadriceps muscles is histochemically stained for protein expression. A time course for protein expression may be done in a similar fashion except that quadriceps from different mice are harvested at different times. Persistence of DNA  
25 in muscle following injection may be determined by Southern blot analysis after preparing total cellular DNA and HIRT supernatants from injected and control mice.

The results of the above experimentation in mice can be use to extrapolate proper dosages and other treatment parameters in humans and other animals using naked DNA.

5 **Example 29: Transgenic Animals.**

The polypeptides of the invention can also be expressed in transgenic animals. Animals of any species, including, but not limited to, mice, rats, rabbits, hamsters, guinea pigs, pigs, micro-pigs, goats, sheep, cows and non-human primates, *e.g.*, baboons, monkeys, and chimpanzees may be used to generate transgenic animals. In a  
10 specific embodiment, techniques described herein or otherwise known in the art, are used to express polypeptides of the invention in humans, as part of a gene therapy protocol.

Any technique known in the art may be used to introduce the transgene (*i.e.*, polynucleotides of the invention) into animals to produce the founder lines of  
15 transgenic animals. Such techniques include, but are not limited to, pronuclear microinjection (Paterson et al., Appl. Microbiol. Biotechnol. 40:691-698 (1994); Carver et al., Biotechnology (NY) 11:1263-1270 (1993); Wright et al., Biotechnology (NY) 9:830-834 (1991); and Hoppe et al., U.S. Pat. No. 4,873,191 (1989)); retrovirus mediated gene transfer into germ lines (Van der Putten et al., Proc. Natl. Acad. Sci.,  
20 USA 82:6148-6152 (1985)), blastocysts or embryos; gene targeting in embryonic stem cells (Thompson et al., Cell 56:313-321 (1989)); electroporation of cells or embryos (Lo, 1983, Mol Cell. Biol. 3:1803-1814 (1983)); introduction of the polynucleotides of the invention using a gene gun (see, *e.g.*, Ulmer et al., Science 259:1745 (1993); introducing nucleic acid constructs into embryonic pluripotent  
25 stem cells and transferring the stem cells back into the blastocyst; and sperm-mediated gene transfer (Lavitrano et al., Cell 57:717-723 (1989); etc. For a review of

such techniques, see Gordon, "Transgenic Animals," Intl. Rev. Cytol. 115:171-229 (1989), which is incorporated by reference herein in its entirety.

Any technique known in the art may be used to produce transgenic clones containing polynucleotides of the invention, for example, nuclear transfer into  
5 enucleated oocytes of nuclei from cultured embryonic, fetal, or adult cells induced to quiescence (Campell et al., Nature 380:64-66 (1996); Wilmut et al., Nature 385:810-813 (1997)).

The present invention provides for transgenic animals that carry the transgene in all their cells, as well as animals which carry the transgene in some, but not all their  
10 cells, *i.e.*, mosaic animals or chimeric. The transgene may be integrated as a single transgene or as multiple copies such as in concatamers, *e.g.*, head-to-head tandems or head-to-tail tandems. The transgene may also be selectively introduced into and activated in a particular cell type by following, for example, the teaching of Lasko et al. (Lasko et al., Proc. Natl. Acad. Sci. USA 89:6232-6236 (1992)). The regulatory  
15 sequences required for such a cell-type specific activation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art. When it is desired that the polynucleotide transgene be integrated into the chromosomal site of the endogenous gene, gene targeting is preferred. Briefly, when such a technique is to be utilized, vectors containing some nucleotide sequences homologous to the  
20 endogenous gene are designed for the purpose of integrating, via homologous recombination with chromosomal sequences, into and disrupting the function of the nucleotide sequence of the endogenous gene. The transgene may also be selectively introduced into a particular cell type, thus inactivating the endogenous gene in only that cell type, by following, for example, the teaching of Gu et al. (Gu et al., Science  
25 265:103-106 (1994)). The regulatory sequences required for such a cell-type specific

inactivation will depend upon the particular cell type of interest, and will be apparent to those of skill in the art.

Once transgenic animals have been generated, the expression of the recombinant gene may be assayed utilizing standard techniques. Initial screening  
5 may be accomplished by Southern blot analysis or PCR techniques to analyze animal tissues to verify that integration of the transgene has taken place. The level of mRNA expression of the transgene in the tissues of the transgenic animals may also be assessed using techniques which include, but are not limited to, Northern blot analysis of tissue samples obtained from the animal, *in situ* hybridization analysis, and reverse  
10 transcriptase-PCR (rt-PCR). Samples of transgenic gene-expressing tissue may also be evaluated immunocytochemically or immunohistochemically using antibodies specific for the transgene product.

Once the founder animals are produced, they may be bred, inbred, outbred, or crossbred to produce colonies of the particular animal. Examples of such breeding  
15 strategies include, but are not limited to: outbreeding of founder animals with more than one integration site in order to establish separate lines; inbreeding of separate lines in order to produce compound transgenics that express the transgene at higher levels because of the effects of additive expression of each transgene; crossing of heterozygous transgenic animals to produce animals homozygous for a given  
20 integration site in order to both augment expression and eliminate the need for screening of animals by DNA analysis; crossing of separate homozygous lines to produce compound heterozygous or homozygous lines; and breeding to place the transgene on a distinct background that is appropriate for an experimental model of interest.

25 Transgenic animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of

polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

5 **Example 30: Knock-Out Animals.**

Endogenous gene expression can also be reduced by inactivating or "knocking out" the gene and/or its promoter using targeted homologous recombination. (*E.g.*, see Smithies et al., *Nature* 317:230-234 (1985); Thomas & Capecchi, *Cell* 51:503-512 (1987); Thompson et al., *Cell* 5:313-321 (1989); each of which is incorporated by  
10- reference herein in its entirety). For example, a mutant, non-functional polynucleotide of the invention (or a completely unrelated DNA sequence) flanked by DNA homologous to the endogenous polynucleotide sequence (either the coding regions or regulatory regions of the gene) can be used, with or without a selectable marker and/or a negative selectable marker, to transfect cells that express  
15 polypeptides of the invention *in vivo*. In another embodiment, techniques known in the art are used to generate knockouts in cells that contain, but do not express the gene of interest. Insertion of the DNA construct, via targeted homologous recombination, results in inactivation of the targeted gene. Such approaches are particularly suited in research and agricultural fields where modifications to embryonic stem cells can be  
20 used to generate animal offspring with an inactive targeted gene (*e.g.*, see Thomas & Capecchi 1987 and Thompson 1989, *supra*). However this approach can be routinely adapted for use in humans provided the recombinant DNA constructs are directly administered or targeted to the required site *in vivo* using appropriate viral vectors that will be apparent to those of skill in the art.

25 In further embodiments of the invention, cells that are genetically engineered to express the polypeptides of the invention, or alternatively, that are genetically

engineered not to express the polypeptides of the invention (e.g., knockouts) are administered to a patient *in vivo*. Such cells may be obtained from the patient (i.e., animal, including human) or an MHC compatible donor and can include, but are not limited to fibroblasts, bone marrow cells, blood cells (e.g., lymphocytes), adipocytes, muscle cells, endothelial cells etc. The cells are genetically engineered *in vitro* using recombinant DNA techniques to introduce the coding sequence of polypeptides of the invention into the cells, or alternatively, to disrupt the coding sequence and/or endogenous regulatory sequence associated with the polypeptides of the invention, e.g., by transduction (using viral vectors, and preferably vectors that integrate the transgene into the cell genome) or transfection procedures, including, but not limited to, the use of plasmids, cosmids, YACs, naked DNA, electroporation, liposomes, etc. The coding sequence of the polypeptides of the invention can be placed under the control of a strong constitutive or inducible promoter or promoter/enhancer to achieve expression, and preferably secretion, of the polypeptides of the invention. The engineered cells which express and preferably secrete the polypeptides of the invention can be introduced into the patient systemically, e.g., in the circulation, or intraperitoneally.

Alternatively, the cells can be incorporated into a matrix and implanted in the body, e.g., genetically engineered fibroblasts can be implanted as part of a skin graft; genetically engineered endothelial cells can be implanted as part of a lymphatic or vascular graft. (See, for example, Anderson et al. U.S. Patent No. 5,399,349; and Mulligan & Wilson, U.S. Patent No. 5,460,959 each of which is incorporated by reference herein in its entirety).

When the cells to be administered are non-autologous or non-MHC compatible cells, they can be administered using well known techniques which prevent the development of a host immune response against the introduced cells. For



example, the cells may be introduced in an encapsulated form which, while allowing for an exchange of components with the immediate extracellular environment, does not allow the introduced cells to be recognized by the host immune system.

Transgenic and "knock-out" animals of the invention have uses which include, but are not limited to, animal model systems useful in elaborating the biological function of polypeptides of the present invention, studying diseases, disorders, and/or conditions associated with aberrant expression, and in screening for compounds effective in ameliorating such diseases, disorders, and/or conditions.

#### 10 **Example 31: Production of an Antibody**

##### a) Hybridoma Technology

The antibodies of the present invention can be prepared by a variety of methods. (See, Current Protocols, Chapter 2.) As one example of such methods, cells expressing XXX are administered to an animal to induce the production of sera containing polyclonal antibodies. In a preferred method, a preparation of XXX protein is prepared and purified to render it substantially free of natural contaminants. Such a preparation is then introduced into an animal in order to produce polyclonal antisera of greater specific activity.

Monoclonal antibodies specific for protein XXX are prepared using hybridoma technology. (Kohler et al., Nature 256:495 (1975); Kohler et al., Eur. J. Immunol. 6:511 (1976); Kohler et al., Eur. J. Immunol. 6:292 (1976); Hammerling et al., in: Monoclonal Antibodies and T-Cell Hybridomas, Elsevier, N.Y., pp. 563-681 (1981)). In general, an animal (preferably a mouse) is immunized with XXX polypeptide or, more preferably, with a secreted XXX polypeptide-expressing cell. Such polypeptide-expressing cells are cultured in any suitable tissue culture medium, preferably in Earle's modified Eagle's medium supplemented with 10% fetal bovine

serum (inactivated at about 56°C), and supplemented with about 10 g/l of nonessential amino acids, about 1,000 U/ml of penicillin, and about 100 µg/ml of streptomycin.

The splenocytes of such mice are extracted and fused with a suitable myeloma cell line. Any suitable myeloma cell line may be employed in accordance with the present invention; however, it is preferable to employ the parent myeloma cell line (SP2O), available from the ATCC. After fusion, the resulting hybridoma cells are selectively maintained in HAT medium, and then cloned by limiting dilution as described by Wands et al. (Gastroenterology 80:225-232 (1981)). The hybridoma cells obtained through such a selection are then assayed to identify clones which secrete antibodies capable of binding the XXX polypeptide.

Alternatively, additional antibodies capable of binding to XXX polypeptide can be produced in a two-step procedure using anti-idiotypic antibodies. Such a method makes use of the fact that antibodies are themselves antigens, and therefore, it is possible to obtain an antibody which binds to a second antibody. In accordance with this method, protein specific antibodies are used to immunize an animal, preferably a mouse. The splenocytes of such an animal are then used to produce hybridoma cells, and the hybridoma cells are screened to identify clones which produce an antibody whose ability to bind to the XXX protein-specific antibody can be blocked by XXX. Such antibodies comprise anti-idiotypic antibodies to the XXX protein-specific antibody and are used to immunize an animal to induce formation of further XXX protein-specific antibodies.

For in vivo use of antibodies in humans, an antibody is "humanized". Such antibodies can be produced using genetic constructs derived from hybridoma cells producing the monoclonal antibodies described above. Methods for producing chimeric and humanized antibodies are known in the art and are discussed herein.

(See, for review, Morrison, Science 229:1202 (1985); Oi et al., BioTechniques 4:214 (1986); Cabilly et al., U.S. Patent No. 4,816,567; Taniguchi et al., EP 171496; Morrison et al., EP 173494; Neuberger et al., WO 8601533; Robinson et al., WO 8702671; Boulianne et al., Nature 312:643 (1984); Neuberger et al., Nature 314:268 (1985).)

b) Isolation Of Antibody Fragments Directed

Against XXX From A Library Of scFvs

Naturally occurring V-genes isolated from human PBLs are constructed into a library of antibody fragments which contain reactivities against XXX to which the donor may or may not have been exposed (see e.g., U.S. Patent 5,885,793 incorporated herein by reference in its entirety).

Rescue of the Library. A library of scFvs is constructed from the RNA of human PBLs as described in PCT publication WO 92/01047. To rescue phage displaying antibody fragments, approximately 10<sup>9</sup> E. coli harboring the phagemid are used to inoculate 50 ml of 2xTY containing 1% glucose and 100 µg/ml of ampicillin (2xTY-AMP-GLU) and grown to an O.D. of 0.8 with shaking. Five ml of this culture is used to inoculate 50 ml of 2xTY-AMP-GLU, 2 x 10<sup>8</sup> TU of delta gene 3 helper (M13 delta gene III, see PCT publication WO 92/01047) are added and the culture incubated at 37°C for 45 minutes without shaking and then at 37°C for 45 minutes with shaking. The culture is centrifuged at 4000 r.p.m. for 10 min. and the pellet resuspended in 2 liters of 2xTY containing 100 µg/ml ampicillin and 50 µg/ml kanamycin and grown overnight. Phage are prepared as described in PCT publication WO 92/01047.

M13 delta gene III is prepared as follows: M13 delta gene III helper phage does not encode gene III protein, hence the phage(mid) displaying antibody

fragments have a greater avidity of binding to antigen. Infectious M13 delta gene III particles are made by growing the helper phage in cells harboring a pUC19 derivative supplying the wild type gene III protein during phage morphogenesis. The culture is incubated for 1 hour at 37° C without shaking and then for a further hour at 37°C with shaking. Cells are spun down (IEC-Centra 8,400 r.p.m. for 10 min), resuspended in 300 ml 2xTY broth containing 100 µg ampicillin/ml and 25 µg kanamycin/ml (2xTY-AMP-KAN) and grown overnight, shaking at 37°C. Phage particles are purified and concentrated from the culture medium by two PEG-precipitations (Sambrook et al., 1990), resuspended in 2 ml PBS and passed through a 0.45 µm filter (Minisart NML; Sartorius) to give a final concentration of approximately 10<sup>13</sup> transducing units/ml (ampicillin-resistant clones).

Panning of the Library. Immunotubes (Nunc) are coated overnight in PBS with 4 ml of either 100 µg/ml or 10 µg/ml of a polypeptide of the present invention. Tubes are blocked with 2% Marvel-PBS for 2 hours at 37°C and then washed 3 times in PBS. Approximately 10<sup>13</sup> TU of phage is applied to the tube and incubated for 30 minutes at room temperature tumbling on an over and under turntable and then left to stand for another 1.5 hours. Tubes are washed 10 times with PBS 0.1% Tween-20 and 10 times with PBS. Phage are eluted by adding 1 ml of 100 mM triethylamine and rotating 15 minutes on an under and over turntable after which the solution is immediately neutralized with 0.5 ml of 1.0M Tris-HCl, pH 7.4. Phage are then used to infect 10 ml of mid-log E. coli TG1 by incubating eluted phage with bacteria for 30 minutes at 37°C. The E. coli are then plated on TYE plates containing 1% glucose and 100 µg/ml ampicillin. The resulting bacterial library is then rescued with delta gene 3 helper phage as described above to prepare phage for a subsequent round of selection. This process is then repeated for a total of 4 rounds of affinity purification

with tube-washing increased to 20 times with PBS, 0.1% Tween-20 and 20 times with PBS for rounds 3 and 4.

Characterization of Binders. Eluted phage from the 3rd and 4th rounds of selection are used to infect E. coli HB 2151 and soluble.scFv is produced (Marks, et al., 1991) from single colonies for assay. ELISAs are performed with microtitre plates coated with either 10 pg/ml of the polypeptide of the present invention in 50 mM bicarbonate pH 9.6. Clones positive in ELISA are further characterized by PCR fingerprinting (see, e.g., PCT publication WO 92/01047) and then by sequencing. These ELISA positive clones may also be further characterized by techniques known in the art, such as, for example, epitope mapping, binding affinity, receptor signal transduction, ability to block or competitively inhibit antibody/antigen binding, and competitive agonistic or antagonistic activity.

**Example 32: Assays Detecting Stimulation or Inhibition of B cell Proliferation and Differentiation**

Generation of functional humoral immune responses requires both soluble and cognate signaling between B-lineage cells and their microenvironment. Signals may impart a positive stimulus that allows a B-lineage cell to continue its programmed development, or a negative stimulus that instructs the cell to arrest its current developmental pathway. To date, numerous stimulatory and inhibitory signals have been found to influence B cell responsiveness including IL-2, IL-4, IL-5, IL-6, IL-7, IL10, IL-13, IL-14 and IL-15. Interestingly, these signals are by themselves weak effectors but can, in combination with various co-stimulatory proteins, induce activation, proliferation, differentiation, homing, tolerance and death among B cell populations.

One of the best studied classes of B-cell co-stimulatory proteins is the TNF-superfamily. Within this family CD40, CD27, and CD30 along with their respective

ligands CD154, CD70, and CD153 have been found to regulate a variety of immune responses. Assays which allow for the detection and/or observation of the proliferation and differentiation of these B-cell populations and their precursors are valuable tools in determining the effects various proteins may have on these B-cell populations in terms of proliferation and differentiation. Listed below are two assays designed to allow for the detection of the differentiation, proliferation, or inhibition of B-cell populations and their precursors.

In Vitro Assay- Purified polypeptides of the invention, or truncated forms thereof, is assessed for its ability to induce activation, proliferation, differentiation or inhibition and/or death in B-cell populations and their precursors. The activity of the polypeptides of the invention on purified human tonsillar B cells, measured qualitatively over the dose range from 0.1 to 10,000 ng/mL, is assessed in a standard B-lymphocyte co-stimulation assay in which purified tonsillar B cells are cultured in the presence of either formalin-fixed *Staphylococcus aureus* Cowan I (SAC) or immobilized anti-human IgM antibody as the priming agent. Second signals such as IL-2 and IL-15 synergize with SAC and IgM crosslinking to elicit B cell proliferation as measured by tritiated-thymidine incorporation. Novel synergizing agents can be readily identified using this assay. The assay involves isolating human tonsillar B cells by magnetic bead (MACS) depletion of CD3-positive cells. The resulting cell population is greater than 95% B cells as assessed by expression of CD45R(B220).

Various dilutions of each sample are placed into individual wells of a 96-well plate to which are added  $10^5$  B-cells suspended in culture medium (RPMI 1640 containing 10% FBS,  $5 \times 10^{-5}$ M 2ME, 100U/ml penicillin, 10ug/ml streptomycin, and  $10^{-5}$  dilution of SAC) in a total volume of 150ul. Proliferation or inhibition is quantitated by a 20h pulse  
5 (1uCi/well) with  $^3$ H-thymidine (6.7 Ci/mM) beginning 72h post factor addition. The positive and negative controls are IL2 and medium respectively.

In Vivo Assay- BALB/c mice are injected (i.p.) twice per day with buffer only, or 2 mg/Kg of a polypeptide of the invention, or truncated forms thereof. Mice receive this treatment for 4 consecutive days, at which time they are sacrificed and  
10 various tissues and serum collected for analyses. Comparison of H&E sections from normal spleens and spleens treated with polypeptides of the invention identify the results of the activity of the polypeptides on spleen cells, such as the diffusion of peri-arterial lymphatic sheaths, and/or significant increases in the nucleated cellularity of the red pulp regions, which may indicate the activation of the differentiation and  
15 proliferation of B-cell populations. Immunohistochemical studies using a B cell marker, anti-CD45R(B220), are used to determine whether any physiological changes to splenic cells, such as splenic disorganization, are due to increased B-cell representation within loosely defined B-cell zones that infiltrate established T-cell regions.

20 Flow cytometric analyses of the spleens from mice treated with polypeptide is used to indicate whether the polypeptide specifically increases the proportion of ThB+, CD45R(B220)dull B cells over that which is observed in control mice.

Likewise, a predicted consequence of increased mature B-cell representation in vivo is a relative increase in serum Ig titers. Accordingly, serum IgM and IgA levels are  
25 compared between buffer and polypeptide-treated mice.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

5

**Example 33: T Cell Proliferation Assay**

A CD3-induced proliferation assay is performed on PBMCs and is measured by the uptake of  $^3\text{H}$ -thymidine. The assay is performed as follows. Ninety-six well plates are coated with 100  $\mu\text{l}$ /well of mAb to CD3 (HIT3a, Pharmingen) or isotype-matched control  
10 mAb (B33.1) overnight at 4 degrees C (1  $\mu\text{g}/\text{ml}$  in .05M bicarbonate buffer, pH 9.5), then washed three times with PBS. PBMC are isolated by F/H gradient centrifugation from human peripheral blood and added to quadruplicate wells ( $5 \times 10^4/\text{well}$ ) of mAb coated plates in RPMI containing 10% FCS and P/S in the presence of varying concentrations of polypeptides of the invention (total volume 200  $\mu\text{l}$ ). Relevant protein buffer and medium  
15 alone are controls. After 48 hr. culture at 37 degrees C, plates are spun for 2 min. at 1000 rpm and 100  $\mu\text{l}$  of supernatant is removed and stored  $-20$  degrees C for measurement of IL-2 (or other cytokines) if effect on proliferation is observed. Wells are supplemented with 100  $\mu\text{l}$  of medium containing 0.5  $\mu\text{Ci}$  of  $^3\text{H}$ -thymidine and cultured at 37 degrees C for 18-24 hr. Wells are harvested and incorporation of  $^3\text{H}$ -thymidine used as a measure of  
20 proliferation. Anti-CD3 alone is the positive control for proliferation. IL-2 (100 U/ml) is also used as a control which enhances proliferation. Control antibody which does not induce proliferation of T cells is used as the negative controls for the effects of polypeptides of the invention.

The studies described in this example tested activity of polypeptides of the  
25 invention. However, one skilled in the art could easily modify the exemplified studies to



test the activity of polynucleotides of the invention (e.g., gene therapy), agonists, and/or antagonists of polynucleotides or polypeptides of the invention.

**Example 34: Effect of Polypeptides of the Invention on the Expression of MHC Class II, Costimulatory and Adhesion Molecules and Cell Differentiation of Monocytes and Monocyte-Derived Human Dendritic Cells**

Dendritic cells are generated by the expansion of proliferating precursors found in the peripheral blood: adherent PBMC or elutriated monocytic fractions are cultured for 7-10 days with GM-CSF (50 ng/ml) and IL-4 (20 ng/ml). These dendritic cells have the characteristic phenotype of immature cells (expression of CD1, CD80, CD86, CD40 and MHC class II antigens). Treatment with activating factors, such as TNF- $\alpha$ , causes a rapid change in surface phenotype (increased expression of MHC class I and II, costimulatory and adhesion molecules, downregulation of FC $\gamma$ RII, upregulation of CD83). These changes correlate with increased antigen-presenting capacity and with functional maturation of the dendritic cells.

FACS analysis of surface antigens is performed as follows. Cells are treated 1-3 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled monoclonal antibodies for 30 minutes at 4 degrees C. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

Effect on the production of cytokines. Cytokines generated by dendritic cells, in particular IL-12, are important in the initiation of T-cell dependent immune responses. IL-12 strongly influences the development of Th1 helper T-cell immune response, and induces cytotoxic T and NK cell function. An ELISA is used to

measure the IL-12 release as follows. Dendritic cells ( $10^6/\text{ml}$ ) are treated with increasing concentrations of polypeptides of the invention for 24 hours. LPS (100 ng/ml) is added to the cell culture as positive control. Supernatants from the cell cultures are then collected and analyzed for IL-12 content using commercial ELISA  
5 kit (e.g., R & D Systems (Minneapolis, MN)). The standard protocols provided with the kits are used.

Effect on the expression of MHC Class II, costimulatory and adhesion molecules. Three major families of cell surface antigens can be identified on  
10 monocytes: adhesion molecules, molecules involved in antigen presentation, and Fc receptor. Modulation of the expression of MHC class II antigens and other costimulatory molecules, such as B7 and ICAM-1, may result in changes in the antigen presenting capacity of monocytes and ability to induce T cell activation. Increase expression of Fc receptors may correlate with improved monocyte cytotoxic  
15 activity, cytokine release and phagocytosis.

FACS analysis is used to examine the surface antigens as follows. Monocytes are treated 1-5 days with increasing concentrations of polypeptides of the invention or LPS (positive control), washed with PBS containing 1% BSA and 0.02 mM sodium azide, and then incubated with 1:20 dilution of appropriate FITC- or PE-labeled  
20 monoclonal antibodies for 30 minutes at 4 degreesC. After an additional wash, the labeled cells are analyzed by flow cytometry on a FACScan (Becton Dickinson).

Monocyte activation and/or increased survival. Assays for molecules that activate (or alternatively, inactivate) monocytes and/or increase monocyte survival (or  
25 alternatively, decrease monocyte survival) are known in the art and may routinely be applied to determine whether a molecule of the invention functions as an inhibitor or

activator of monocytes. Polypeptides, agonists, or antagonists of the invention can be screened using the three assays described below. For each of these assays, Peripheral blood mononuclear cells (PBMC) are purified from single donor leukopacks (American Red Cross, Baltimore, MD) by centrifugation through a Histopaque  
5 gradient (Sigma). Monocytes are isolated from PBMC by counterflow centrifugal elutriation.

Monocyte Survival Assay. Human peripheral blood monocytes progressively lose viability when cultured in absence of serum or other stimuli. Their death results  
10 from internally regulated process (apoptosis). Addition to the culture of activating factors, such as TNF-alpha dramatically improves cell survival and prevents DNA fragmentation. Propidium iodide (PI) staining is used to measure apoptosis as follows. Monocytes are cultured for 48 hours in polypropylene tubes in serum-free medium (positive control), in the presence of 100 ng/ml TNF-alpha (negative  
15 control), and in the presence of varying concentrations of the compound to be tested. Cells are suspended at a concentration of  $2 \times 10^6$ /ml in PBS containing PI at a final concentration of 5  $\mu$ g/ml, and then incubated at room temperature for 5 minutes before FACScan analysis. PI uptake has been demonstrated to correlate with DNA  
fragmentation in this experimental paradigm.

20

Effect on cytokine release. An important function of monocytes/macrophages is their regulatory activity on other cellular populations of the immune system through the release of cytokines after stimulation. An ELISA to measure cytokine release is performed as follows. Human monocytes are incubated at a density of  $5 \times 10^5$  cells/ml  
25 with increasing concentrations of the a polypeptide of the invention and under the same conditions, but in the absence of the polypeptide. For IL-12 production, the

cells are primed overnight with IFN (100 U/ml) in presence of a polypeptide of the invention. LPS (10 ng/ml) is then added. Conditioned media are collected after 24h and kept frozen until use. Measurement of TNF-alpha, IL-10, MCP-1 and IL-8 is then performed using a commercially available ELISA kit (e.g., R & D Systems (Minneapolis, MN)) and applying the standard protocols provided with the kit.

Oxidative burst. Purified monocytes are plated in 96-w plate at  $2 \times 10^5$  cell/well. Increasing concentrations of polypeptides of the invention are added to the wells in a total volume of 0.2 ml culture medium (RPMI 1640 + 10% FCS, glutamine and antibiotics). After 3 days incubation, the plates are centrifuged and the medium is removed from the wells. To the macrophage monolayers, 0.2 ml per well of phenol red solution (140 mM NaCl, 10 mM potassium phosphate buffer pH 7.0, 5.5 mM dextrose, 0.56 mM phenol red and 19 U/ml of HRPO) is added, together with the stimulant (200 nM PMA). The plates are incubated at 37°C for 2 hours and the reaction is stopped by adding 20  $\mu$ l 1N NaOH per well. The absorbance is read at 610 nm. To calculate the amount of  $H_2O_2$  produced by the macrophages, a standard curve of a  $H_2O_2$  solution of known molarity is performed for each experiment.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polypeptides, polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

### Example 35: Biological Effects of Polypeptides of the Invention

#### Astrocyte and Neuronal Assays

Recombinant polypeptides of the invention, expressed in *Escherichia coli* and purified as described above, can be tested for activity in promoting the survival, neurite

outgrowth, or phenotypic differentiation of cortical neuronal cells and for inducing the proliferation of glial fibrillary acidic protein immunopositive cells, astrocytes. The selection of cortical cells for the bioassay is based on the prevalent expression of FGF-1 and FGF-2 in cortical structures and on the previously reported enhancement of cortical neuronal survival resulting from FGF-2 treatment. A thymidine incorporation assay, for example, can be used to elucidate a polypeptide of the invention's activity on these cells.

Moreover, previous reports describing the biological effects of FGF-2 (basic FGF) on cortical or hippocampal neurons *in vitro* have demonstrated increases in both neuron survival and neurite outgrowth (Walicke et al., "Fibroblast growth factor promotes survival of dissociated hippocampal neurons and enhances neurite extension." *Proc. Natl. Acad. Sci. USA* 83:3012-3016. (1986), assay herein incorporated by reference in its entirety). However, reports from experiments done on PC-12 cells suggest that these two responses are not necessarily synonymous and may depend on not only which FGF is being tested but also on which receptor(s) are expressed on the target cells. Using the primary cortical neuronal culture paradigm, the ability of a polypeptide of the invention to induce neurite outgrowth can be compared to the response achieved with FGF-2 using, for example, a thymidine incorporation assay.

#### Fibroblast and endothelial cell assays

Human lung fibroblasts are obtained from Clonetics (San Diego, CA) and maintained in growth media from Clonetics. Dermal microvascular endothelial cells are obtained from Cell Applications (San Diego, CA). For proliferation assays, the human lung fibroblasts and dermal microvascular endothelial cells can be cultured at 5,000 cells/well in a 96-well plate for one day in growth medium. The cells are then incubated for one day in 0.1% BSA basal medium. After replacing the medium with fresh 0.1% BSA

medium, the cells are incubated with the test proteins for 3 days. Alamar Blue (Alamar Biosciences, Sacramento, CA) is added to each well to a final concentration of 10%. The cells are incubated for 4 hr. Cell viability is measured by reading in a CytoFluor fluorescence reader. For the PGE<sub>2</sub> assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or polypeptides of the invention with or without IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for PGE<sub>2</sub> by EIA kit (Cayman, Ann Arbor, MI). For the IL-6 assays, the human lung fibroblasts are cultured at 5,000 cells/well in a 96-well plate for one day. After a medium change to 0.1% BSA basal medium, the cells are incubated with FGF-2 or with or without polypeptides of the invention IL-1 $\alpha$  for 24 hours. The supernatants are collected and assayed for IL-6 by ELISA kit (Endogen, Cambridge, MA).

Human lung fibroblasts are cultured with FGF-2 or polypeptides of the invention for 3 days in basal medium before the addition of Alamar Blue to assess effects on growth of the fibroblasts. FGF-2 should show a stimulation at 10 - 2500 ng/ml which can be used to compare stimulation with polypeptides of the invention.

#### Parkinson Models.

The loss of motor function in Parkinson's disease is attributed to a deficiency of striatal dopamine resulting from the degeneration of the nigrostriatal dopaminergic projection neurons. An animal model for Parkinson's that has been extensively characterized involves the systemic administration of 1-methyl-4 phenyl 1,2,3,6-tetrahydropyridine (MPTP). In the CNS, MPTP is taken-up by astrocytes and catabolized by monoamine oxidase B to 1-methyl-4-phenyl pyridine (MPP<sup>+</sup>) and released. Subsequently, MPP<sup>+</sup> is actively accumulated in dopaminergic neurons by the high-affinity

reuptake transporter for dopamine. MPP<sup>+</sup> is then concentrated in mitochondria by the electrochemical gradient and selectively inhibits nicotinamide adenine disphosphate: ubiquinone oxidoreductionase (complex I), thereby interfering with electron transport and eventually generating oxygen radicals.

5           It has been demonstrated in tissue culture paradigms that FGF-2 (basic FGF) has trophic activity towards nigral dopaminergic neurons (Ferrari et al., Dev. Biol. 1989). Recently, Dr. Unsicker's group has demonstrated that administering FGF-2 in gel foam implants in the striatum results in the near complete protection of nigral dopaminergic neurons from the toxicity associated with MPTP exposure (Otto and Unsicker, J.  
10   Neuroscience, 1990).

          Based on the data with FGF-2, polypeptides of the invention can be evaluated to determine whether it has an action similar to that of FGF-2 in enhancing dopaminergic neuronal survival *in vitro* and it can also be tested *in vivo* for protection of dopaminergic neurons in the striatum from the damage associated with MPTP treatment. The potential  
15   effect of a polypeptide of the invention is first examined *in vitro* in a dopaminergic neuronal cell culture paradigm. The cultures are prepared by dissecting the midbrain floor plate from gestation day 14 Wistar rat embryos. The tissue is dissociated with trypsin and seeded at a density of 200,000 cells/cm<sup>2</sup> on polyorthinine-laminin coated glass coverslips. The cells are maintained in Dulbecco's Modified Eagle's medium and F12 medium  
20   containing hormonal supplements (N1). The cultures are fixed with paraformaldehyde after 8 days *in vitro* and are processed for tyrosine hydroxylase, a specific marker for dopaminergic neurons, immunohistochemical staining. Dissociated cell cultures are prepared from embryonic rats. The culture medium is changed every third day and the factors are also added at that time.

25           Since the dopaminergic neurons are isolated from animals at gestation day 14, a developmental time which is past the stage when the dopaminergic precursor cells are

proliferating, an increase in the number of tyrosine hydroxylase immunopositive neurons would represent an increase in the number of dopaminergic neurons surviving *in vitro*. Therefore, if a polypeptide of the invention acts to prolong the survival of dopaminergic neurons, it would suggest that the polypeptide may be involved in Parkinson's Disease.

5       The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

10       **Example 36: The Effect of Polypeptides of the Invention on the Growth of Vascular Endothelial Cells**

On day 1, human umbilical vein endothelial cells (HUVEC) are seeded at  $2.5 \times 10^4$  cells/35 mm dish density in M199 medium containing 4% fetal bovine serum (FBS), 16  
15       units/ml heparin, and 50 units/ml endothelial cell growth supplements (ECGS, Biotechnology, Inc.). On day 2, the medium is replaced with M199 containing 10% FBS, 8 units/ml heparin. A polypeptide having the amino acid sequence of SEQ ID NO:Y, and positive controls, such as VEGF and basic FGF (bFGF) are added, at varying concentrations. On days 4 and 6, the medium is replaced. On day 8, cell number is  
20       determined with a Coulter Counter.

An increase in the number of HUVEC cells indicates that the polypeptide of the invention may proliferate vascular endothelial cells.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to  
25       test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.



**Example 37: Stimulatory Effect of Polypeptides of the Invention on the Proliferation of Vascular Endothelial Cells**

- 5 For evaluation of mitogenic activity of growth factors, the colorimetric MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium) assay with the electron coupling reagent PMS (phenazine methosulfate) was performed (CellTiter 96 AQ, Promega). Cells are seeded in a 96-well plate (5,000 cells/well) in 0.1 mL serum-supplemented medium and are allowed to attach overnight.
- 10 After serum-starvation for 12 hours in 0.5% FBS, conditions (bFGF, VEGF<sub>165</sub> or a polypeptide of the invention in 0.5% FBS) with or without Heparin (8 U/ml) are added to wells for 48 hours. 20 mg of MTS/PMS mixture (1:0.05) are added per well and allowed to incubate for 1 hour at 37°C before measuring the absorbance at 490 nm in an ELISA plate reader. Background absorbance from control wells (some media, no cells) is
- 15 subtracted, and seven wells are performed in parallel for each condition. See, Leak *et al. In Vitro Cell. Dev. Biol.* 30A:512-518 (1994).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the

20 invention.

**Example 38: Inhibition of PDGF-induced Vascular Smooth Muscle Cell Proliferation Stimulatory Effect**

- 25 HAoSMC proliferation can be measured, for example, by BrdUrd incorporation. Briefly, subconfluent, quiescent cells grown on the 4-chamber slides are transfected with CRP or FITC-labeled AT2-3LP. Then, the cells are pulsed with 10% calf serum and 6

mg/ml BrdUrd. After 24 h, immunocytochemistry is performed by using BrdUrd Staining Kit (Zymed Laboratories). In brief, the cells are incubated with the biotinylated mouse anti-BrdUrd antibody at 4 degrees C for 2 h after being exposed to denaturing solution and then incubated with the streptavidin-peroxidase and diaminobenzidine. After  
5 counterstaining with hematoxylin, the cells are mounted for microscopic examination, and the BrdUrd-positive cells are counted. The BrdUrd index is calculated as a percent of the BrdUrd-positive cells to the total cell number. In addition, the simultaneous detection of the BrdUrd staining (nucleus) and the FITC uptake (cytoplasm) is performed for individual cells by the concomitant use of bright field illumination and dark field-UV  
10 fluorescent illumination. See, Hayashida et al., J. Biol. Chem. 6:271(36):21985-21992 (1996).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the  
15 invention.

#### **Example 39: Stimulation of Endothelial Migration**

This example will be used to explore the possibility that a polypeptide of the  
20 invention may stimulate lymphatic endothelial cell migration.

Endothelial cell migration assays are performed using a 48 well microchemotaxis chamber (Neuroprobe Inc., Cabin John, MD; Falk, W., et al., J. Immunological Methods 1980;33:239-247). Polyvinylpyrrolidone-free polycarbonate filters with a pore size of 8 um (Nucleopore Corp. Cambridge, MA) are coated with 0.1% gelatin for at least 6 hours  
25 at room temperature and dried under sterile air. Test substances are diluted to appropriate concentrations in M199 supplemented with 0.25% bovine serum albumin (BSA), and 25

ul of the final dilution is placed in the lower chamber of the modified Boyden apparatus. Subconfluent, early passage (2-6) HUVEC or BMEC cultures are washed and trypsinized for the minimum time required to achieve cell detachment. After placing the filter between lower and upper chamber,  $2.5 \times 10^5$  cells suspended in 50 ul M199 containing 1% FBS are seeded in the upper compartment. The apparatus is then incubated for 5 hours at 37°C in a humidified chamber with 5% CO<sub>2</sub> to allow cell migration. After the incubation period, the filter is removed and the upper side of the filter with the non-migrated cells is scraped with a rubber policeman. The filters are fixed with methanol and stained with a Giemsa solution (Diff-Quick, Baxter, McGraw Park, IL). Migration is quantified by counting cells of three random high-power fields (40x) in each well, and all groups are performed in quadruplicate.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.


#### **Example 40: Stimulation of Nitric Oxide Production by Endothelial Cells**

Nitric oxide released by the vascular endothelium is believed to be a mediator of vascular endothelium relaxation. Thus, activity of a polypeptide of the invention can be assayed by determining nitric oxide production by endothelial cells in response to the polypeptide.

Nitric oxide is measured in 96-well plates of confluent microvascular endothelial cells after 24 hours starvation and a subsequent 4 hr exposure to various levels of a positive control (such as VEGF-1) and the polypeptide of the invention. Nitric oxide in the medium is determined by use of the Griess reagent to measure total nitrite after

reduction of nitric oxide-derived nitrate by nitrate reductase. The effect of the polypeptide of the invention on nitric oxide release is examined on HUVEC.

Briefly, NO release from cultured HUVEC monolayer is measured with a NO-specific polarographic electrode connected to a NO meter (Iso-NO, World Precision Instruments Inc.) (1049). Calibration of the NO elements is performed according to the following equation:



The standard calibration curve is obtained by adding graded concentrations of  $\text{KNO}_2$  (0, 5, 10, 25, 50, 100, 250, and 500 nmol/L) into the calibration solution containing KI and  $\text{H}_2\text{SO}_4$ . The specificity of the Iso-NO electrode to NO is previously determined by measurement of NO from authentic NO gas (1050). The culture medium is removed and HUVECs are washed twice with Dulbecco's phosphate buffered saline. The cells are then bathed in 5 ml of filtered Krebs-Henseleit solution in 6-well plates, and the cell plates are kept on a slide warmer (Lab Line Instruments Inc.) To maintain the temperature at 37°C.

The NO sensor probe is inserted vertically into the wells, keeping the tip of the electrode 2 mm under the surface of the solution, before addition of the different conditions. S-nitroso acetyl penicillamin (SNAP) is used as a positive control. The amount of released NO is expressed as picomoles per  $1 \times 10^6$  endothelial cells. All values reported are means of four to six measurements in each group (number of cell culture wells). See, Leak *et al. Biochem. and Biophys. Res. Comm.* 217:96-105 (1995).

The studies described in this example tested activity of polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 41: Effect of Polypeptides of the Invention on Cord Formation in Angiogenesis**

Another step in angiogenesis is cord formation, marked by differentiation of  
5 endothelial cells. This bioassay measures the ability of microvascular endothelial cells to form capillary-like structures (hollow structures) when cultured *in vitro*.

CADMEC (microvascular endothelial cells) are purchased from Cell Applications, Inc. as proliferating (passage 2) cells and are cultured in Cell Applications' CADMEC Growth Medium and used at passage 5. For the *in vitro* angiogenesis assay, the wells of a  
10 48-well cell culture plate are coated with Cell Applications' Attachment Factor Medium (200 µl/well) for 30 min. at 37°C. CADMEC are seeded onto the coated wells at 7,500 cells/well and cultured overnight in Growth Medium. The Growth Medium is then replaced with 300 µl Cell Applications' Cord Formation Medium containing control buffer or a polypeptide of the invention (0.1 to 100 ng/ml) and the cells are cultured for an  
15 additional 48 hr. The numbers and lengths of the capillary-like chords are quantitated through use of the Boeckeler VIA-170 video image analyzer. All assays are done in triplicate.

Commercial (R&D) VEGF (50 ng/ml) is used as a positive control.  $\beta$ -estradiol (1 ng/ml) is used as a negative control. The appropriate buffer (without protein) is also  
20 utilized as a control.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the  
invention.

**Example 42: Angiogenic Effect on Chick Chorioallantoic Membrane**

Chick chorioallantoic membrane (CAM) is a well-established system to examine angiogenesis. Blood vessel formation on CAM is easily visible and quantifiable. The ability of polypeptides of the invention to stimulate angiogenesis in CAM can be examined.

Fertilized eggs of the White Leghorn chick (*Gallus gallus*) and the Japanese qual (*Coturnix coturnix*) are incubated at 37.8°C and 80% humidity. Differentiated CAM of 16-day-old chick and 13-day-old qual embryos is studied with the following methods.

On Day 4 of development, a window is made into the egg shell of chick eggs. The embryos are checked for normal development and the eggs sealed with cello tape. They are further incubated until Day 13. Thermanox coverslips (Nunc, Naperville, IL) are cut into disks of about 5 mm in diameter. Sterile and salt-free growth factors are dissolved in distilled water and about 3.3 mg/ 5 ml are pipetted on the disks. After air-drying, the inverted disks are applied on CAM. After 3 days, the specimens are fixed in 3% glutaraldehyde and 2% formaldehyde and rinsed in 0.12 M sodium cacodylate buffer. They are photographed with a stereo microscope [Wild M8] and embedded for semi- and ultrathin sectioning as described above. Controls are performed with carrier disks alone.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 43: Angiogenesis Assay Using a Matrigel Implant in Mouse**

25

*In vivo* angiogenesis assay of a polypeptide of the invention measures the ability of an existing capillary network to form new vessels in an implanted capsule of murine

extracellular matrix material (Matrigel). The protein is mixed with the liquid Matrigel at 4 degree C and the mixture is then injected subcutaneously in mice where it solidifies. After 7 days, the solid "plug" of Matrigel is removed and examined for the presence of new blood vessels. Matrigel is purchased from Becton Dickinson Labware/Collaborative Biomedical Products.

When thawed at 4 degree C the Matrigel material is a liquid. The Matrigel is mixed with a polypeptide of the invention at 150 ng/ml at 4 degrees C and drawn into cold 3 ml syringes. Female C57Bl/6 mice approximately 8 weeks old are injected with the mixture of Matrigel and experimental protein at 2 sites at the midventral aspect of the abdomen (0.5 ml/site). After 7 days, the mice are sacrificed by cervical dislocation, the Matrigel plugs are removed and cleaned (i.e., all clinging membranes and fibrous tissue is removed). Replicate whole plugs are fixed in neutral buffered 10% formaldehyde, embedded in paraffin and used to produce sections for histological examination after staining with Masson's Trichrome. Cross sections from 3 different regions of each plug are processed. Selected sections are stained for the presence of vWF. The positive control for this assay is bovine basic FGF (150 ng/ml). Matrigel alone is used to determine basal levels of angiogenesis.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 44: Rescue of Ischemia in Rabbit Lower Limb Model**

To study the in vivo effects of polynucleotides and polypeptides of the invention on ischemia, a rabbit hindlimb ischemia model is created by surgical removal of one

femoral arteries as described previously (Takeshita *et al.*, *Am J. Pathol* 147:1649-1660 (1995)). The excision of the femoral artery results in retrograde propagation of thrombus and occlusion of the external iliac artery. Consequently, blood flow to the ischemic limb is dependent upon collateral vessels originating from the internal iliac artery (Takeshita *et al.* *Am J. Pathol* 147:1649-1660 (1995)). An interval of 10 days is allowed for post-operative recovery of rabbits and development of endogenous collateral vessels. At 10 day post-operatively (day 0), after performing a baseline angiogram, the internal iliac artery of the ischemic limb is transfected with 500 mg naked expression plasmid containing a polynucleotide of the invention by arterial gene transfer technology using a hydrogel-coated balloon catheter as described (Riessen *et al. Hum Gene Ther.* 4:749-758 (1993); Leclerc *et al. J. Clin. Invest.* 90: 936-944 (1992)). When a polypeptide of the invention is used in the treatment, a single bolus of 500 mg polypeptide of the invention or control is delivered into the internal iliac artery of the ischemic limb over a period of 1 min. through an infusion catheter. On day 30, various parameters are measured in these rabbits: (a) BP ratio - The blood pressure ratio of systolic pressure of the ischemic limb to that of normal limb; (b) Blood Flow and Flow Reserve - Resting FL: the blood flow during undilated condition and Max FL: the blood flow during fully dilated condition (also an indirect measure of the blood vessel amount) and Flow Reserve is reflected by the ratio of max FL: resting FL; (c) Angiographic Score - This is measured by the angiogram of collateral vessels. A score is determined by the percentage of circles in an overlaying grid that with crossing opacified arteries divided by the total number in the rabbit thigh; (d) Capillary density - The number of collateral capillaries determined in light microscopic sections taken from hindlimbs.

The studies described in this example tested activity of polynucleotides and polypeptides of the invention. However, one skilled in the art could easily modify the exemplified studies to test the agonists, and/or antagonists of the invention.



**Example 45: Effect of Polypeptides of the Invention on Vasodilation**

Since dilation of vascular endothelium is important in reducing blood pressure, the  
5 ability of polypeptides of the invention to affect the blood pressure in spontaneously  
hypertensive rats (SHR) is examined. Increasing doses (0, 10, 30, 100, 300, and 900  
mg/kg) of the polypeptides of the invention are administered to 13-14 week old  
spontaneously hypertensive rats (SHR). Data are expressed as the mean +/- SEM.  
Statistical analysis are performed with a paired t-test and statistical significance is defined  
10 as  $p < 0.05$  vs. the response to buffer alone.

The studies described in this example tested activity of a polypeptide of the  
invention. However, one skilled in the art could easily modify the exemplified studies to  
test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the  
invention.

15

**Example 46: Rat Ischemic Skin Flap Model**

The evaluation parameters include skin blood flow, skin temperature, and factor  
VIII immunohistochemistry or endothelial alkaline phosphatase reaction. Expression of  
20 polypeptides of the invention, during the skin ischemia, is studied using in situ  
hybridization.

The study in this model is divided into three parts as follows:

- a) Ischemic skin
- b) Ischemic skin wounds
- 25 c) Normal wounds

The experimental protocol includes:

- a) Raising a 3x4 cm, single pedicle full-thickness random skin flap (myocutaneous flap over the lower back of the animal).
- b) An excisional wounding (4-6 mm in diameter) in the ischemic skin (skin-flap).
- c) Topical treatment with a polypeptide of the invention of the excisional wounds (day 0, 1, 2, 3, 4 post-wounding) at the following various dosage ranges: 1mg to 100 mg.
- d) Harvesting the wound tissues at day 3, 5, 7, 10, 14 and 21 post-wounding for histological, immunohistochemical, and in situ studies.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

#### **Example 47: Peripheral Arterial Disease Model**

Angiogenic therapy using a polypeptide of the invention is a novel therapeutic strategy to obtain restoration of blood flow around the ischemia in case of peripheral arterial diseases. The experimental protocol includes:

- a) One side of the femoral artery is ligated to create ischemic muscle of the hindlimb, the other side of hindlimb serves as a control.
- b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-3 weeks.
- c) The ischemic muscle tissue is collected after ligation of the femoral artery at 1, 2, and 3 weeks for the analysis of expression of a polypeptide of the invention and histology. Biopsy is also performed on the other side of normal muscle of the contralateral hindlimb.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

5

**Example 48: Ischemic Myocardial Disease Model**

A polypeptide of the invention is evaluated as a potent mitogen capable of stimulating the development of collateral vessels, and restructuring new vessels after coronary artery occlusion. Alteration of expression of the polypeptide is investigated in situ. The experimental protocol includes:

a) The heart is exposed through a left-side thoracotomy in the rat. Immediately, the left coronary artery is occluded with a thin suture (6-0) and the thorax is closed.

b) a polypeptide of the invention, in a dosage range of 20 mg - 500 mg, is delivered intravenously and/or intramuscularly 3 times (perhaps more) per week for 2-4 weeks.

c) Thirty days after the surgery, the heart is removed and cross-sectioned for morphometric and in situ analyzes.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

**Example 49: Rat Corneal Wound Healing Model**

25

This animal model shows the effect of a polypeptide of the invention on neovascularization. The experimental protocol includes:

- a) Making a 1-1.5 mm long incision from the center of cornea into the stromal layer.
- 5        b) Inserting a spatula below the lip of the incision facing the outer corner of the eye.
- c) Making a pocket (its base is 1-1.5 mm from the edge of the eye).
- d) Positioning a pellet, containing 50ng- 5ug of a polypeptide of the invention, within the pocket.
- 10       e) Treatment with a polypeptide of the invention can also be applied topically to the corneal wounds in a dosage range of 20mg - 500mg (daily treatment for five days).

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the  
15    invention.

#### **Example 50: Diabetic Mouse and Glucocorticoid-Impaired Wound Healing Models**

##### **20        A.        *Diabetic db+/db+ Mouse Model.***

To demonstrate that a polypeptide of the invention accelerates the healing process, the genetically diabetic mouse model of wound healing is used. The full thickness wound healing model in the db+/db+ mouse is a well characterized, clinically relevant and reproducible model of impaired wound healing. Healing of the diabetic wound is  
25    dependent on formation of granulation tissue and re-epithelialization rather than

contraction (Gartner, M.H. *et al.*, *J. Surg. Res.* 52:389 (1992); Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)).

The diabetic animals have many of the characteristic features observed in Type II diabetes mellitus. Homozygous (db+/db+) mice are obese in comparison to their normal  
5 heterozygous (db+/+m) littermates. Mutant diabetic (db+/db+) mice have a single autosomal recessive mutation on chromosome 4 (db+) (Coleman *et al.* *Proc. Natl. Acad. Sci. USA* 77:283-293 (1982)). Animals show polyphagia, polydipsia and polyuria. Mutant diabetic mice (db+/db+) have elevated blood glucose, increased or normal insulin levels, and suppressed cell-mediated immunity (Mandel *et al.*, *J. Immunol.* 120:1375  
10 (1978); Debray-Sachs, M. *et al.*, *Clin. Exp. Immunol.* 51(1):1-7 (1983); Leiter *et al.*, *Am. J. of Pathol.* 114:46-55 (1985)). Peripheral neuropathy, myocardial complications, and microvascular lesions, basement membrane thickening and glomerular filtration abnormalities have been described in these animals (Norido, F. *et al.*, *Exp. Neurol.* 83(2):221-232 (1984); Robertson *et al.*, *Diabetes* 29(1):60-67 (1980); Giacomelli *et al.*,  
15 *Lab Invest.* 40(4):460-473 (1979); Coleman, D.L., *Diabetes* 31 (Suppl):1-6 (1982)). These homozygous diabetic mice develop hyperglycemia that is resistant to insulin analogous to human type II diabetes (Mandel *et al.*, *J. Immunol.* 120:1375-1377 (1978)).

The characteristics observed in these animals suggests that healing in this model may be similar to the healing observed in human diabetes (Greenhalgh, *et al.*, *Am. J. of*  
20 *Pathol.* 136:1235-1246 (1990)).

Genetically diabetic female C57BL/KsJ (db+/db+) mice and their non-diabetic (db+/+m) heterozygous littermates are used in this study (Jackson Laboratories). The animals are purchased at 6 weeks of age and are 8 weeks old at the beginning of the study. Animals are individually housed and received food and water ad libitum. All  
25 manipulations are performed using aseptic techniques. The experiments are conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional

Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

Wounding protocol is performed according to previously reported methods (Tsuboi, R. and Rifkin, D.B., *J. Exp. Med.* 172:245-251 (1990)). Briefly, on the day of  
5 wounding, animals are anesthetized with an intraperitoneal injection of Avertin (0.01 mg/mL), 2,2,2-tribromoethanol and 2-methyl-2-butanol dissolved in deionized water. The dorsal region of the animal is shaved and the skin washed with 70% ethanol solution and iodine. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is then created using a Keyes tissue punch. Immediately following  
10 wounding, the surrounding skin is gently stretched to eliminate wound expansion. The wounds are left open for the duration of the experiment. Application of the treatment is given topically for 5 consecutive days commencing on the day of wounding. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

Wounds are visually examined and photographed at a fixed distance at the day of  
15 surgery and at two day intervals thereafter. Wound closure is determined by daily measurement on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

A polypeptide of the invention is administered using at a range different doses,  
20 from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology and immunohistochemistry. Tissue specimens are placed in 10% neutral  
25 buffered formalin in tissue cassettes between biopsy sponges for further processing.

Three groups of 10 animals each (5 diabetic and 5 non-diabetic controls) are evaluated: 1) Vehicle placebo control, 2) untreated group, and 3) treated group.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total square area of the wound. Contraction is then estimated by establishing the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

10

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using a Reichert-Jung microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds are used to assess whether the healing process and the morphologic appearance of the repaired skin is altered by treatment with a polypeptide of the invention. This assessment included verification of the presence of cell accumulation, inflammatory cells, capillaries, fibroblasts, re-epithelialization and epidermal maturity (Greenhalgh, D.G. *et al.*, *Am. J. Pathol.* 136:1235 (1990)). A calibrated lens micrometer is used by a blinded observer.

20 Tissue sections are also stained immunohistochemically with a polyclonal rabbit anti-human keratin antibody using ABC Elite detection system. Human skin is used as a positive tissue control while non-immune IgG is used as a negative control. Keratinocyte growth is determined by evaluating the extent of reepithelialization of the wound using a calibrated lens micrometer.

25 Proliferating cell nuclear antigen/cyclin (PCNA) in skin specimens is demonstrated by using anti-PCNA antibody (1:50) with an ABC Elite detection system. Human colon

cancer can serve as a positive tissue control and human brain tissue can be used as a negative tissue control. Each specimen includes a section with omission of the primary antibody and substitution with non-immune mouse IgG. Ranking of these sections is based on the extent of proliferation on a scale of 0-8, the lower side of the scale reflecting slight proliferation to the higher side reflecting intense proliferation.

Experimental data are analyzed using an unpaired t test. A p value of < 0.05 is considered significant.

#### ***B. Steroid Impaired Rat Model***

The inhibition of wound healing by steroids has been well documented in various *in vitro* and *in vivo* systems (Wahl, Glucocorticoids and Wound healing. In: Anti-Inflammatory Steroid Action: Basic and Clinical Aspects. 280-302 (1989); Wahler *et al.*, *J. Immunol.* 115: 476-481 (1975); Werb *et al.*, *J. Exp. Med.* 147:1684-1694 (1978)). Glucocorticoids retard wound healing by inhibiting angiogenesis, decreasing vascular permeability (Ebert *et al.*, *Am. Intern. Med.* 37:701-705 (1952)), fibroblast proliferation, and collagen synthesis (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978)) and producing a transient reduction of circulating monocytes (Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989)). The systemic administration of steroids to impaired wound healing is a well establish phenomenon in rats (Beck *et al.*, *Growth Factors.* 5: 295-304 (1991); Haynes *et al.*, *J. Clin. Invest.* 61: 703-797 (1978); Wahl, "Glucocorticoids and wound healing", In: Antiinflammatory Steroid Action: Basic and Clinical Aspects, Academic Press, New York, pp. 280-302 (1989); Pierce *et al.*, *Proc. Natl. Acad. Sci. USA* 86: 2229-2233 (1989)).



To demonstrate that a polypeptide of the invention can accelerate the healing process, the effects of multiple topical applications of the polypeptide on full thickness excisional skin wounds in rats in which healing has been impaired by the systemic administration of methylprednisolone is assessed.

5           Young adult male Sprague Dawley rats weighing 250-300 g (Charles River Laboratories) are used in this example. The animals are purchased at 8 weeks of age and are 9 weeks old at the beginning of the study. The healing response of rats is impaired by the systemic administration of methylprednisolone (17mg/kg/rat intramuscularly) at the time of wounding. Animals are individually housed and received food and water *ad*  
10 *libitum*. All manipulations are performed using aseptic techniques. This study is conducted according to the rules and guidelines of Human Genome Sciences, Inc. Institutional Animal Care and Use Committee and the Guidelines for the Care and Use of Laboratory Animals.

          The wounding protocol is followed according to section A, above. On the day of  
15 wounding, animals are anesthetized with an intramuscular injection of ketamine (50 mg/kg) and xylazine (5 mg/kg). The dorsal region of the animal is shaved and the skin washed with 70% ethanol and iodine solutions. The surgical area is dried with sterile gauze prior to wounding. An 8 mm full-thickness wound is created using a Keyes tissue punch. The wounds are left open for the duration of the experiment. Applications of the  
20 testing materials are given topically once a day for 7 consecutive days commencing on the day of wounding and subsequent to methylprednisolone administration. Prior to treatment, wounds are gently cleansed with sterile saline and gauze sponges.

          Wounds are visually examined and photographed at a fixed distance at the day of wounding and at the end of treatment. Wound closure is determined by daily measurement  
25 on days 1-5 and on day 8. Wounds are measured horizontally and vertically using a

calibrated Jameson caliper. Wounds are considered healed if granulation tissue is no longer visible and the wound is covered by a continuous epithelium.

The polypeptide of the invention is administered using at a range different doses, from 4mg to 500mg per wound per day for 8 days in vehicle. Vehicle control groups  
5 received 50mL of vehicle solution.

Animals are euthanized on day 8 with an intraperitoneal injection of sodium pentobarbital (300mg/kg). The wounds and surrounding skin are then harvested for histology. Tissue specimens are placed in 10% neutral buffered formalin in tissue cassettes between biopsy sponges for further processing.

10 Four groups of 10 animals each (5 with methylprednisolone and 5 without glucocorticoid) are evaluated: 1) Untreated group 2) Vehicle placebo control 3) treated groups.

Wound closure is analyzed by measuring the area in the vertical and horizontal axis and obtaining the total area of the wound. Closure is then estimated by establishing  
15 the differences between the initial wound area (day 0) and that of post treatment (day 8). The wound area on day 1 is 64mm<sup>2</sup>, the corresponding size of the dermal punch. Calculations are made using the following formula:

$$[\text{Open area on day 8}] - [\text{Open area on day 1}] / [\text{Open area on day 1}]$$

20

Specimens are fixed in 10% buffered formalin and paraffin embedded blocks are sectioned perpendicular to the wound surface (5mm) and cut using an Olympus microtome. Routine hematoxylin-eosin (H&E) staining is performed on cross-sections of bisected wounds. Histologic examination of the wounds allows assessment of whether the  
25 healing process and the morphologic appearance of the repaired skin is improved by

treatment with a polypeptide of the invention. A calibrated lens micrometer is used by a blinded observer to determine the distance of the wound gap.

Experimental data are analyzed using an unpaired t test. -A p value of  $< 0.05$  is considered significant.

- 5        The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

10    **Example 51: Lymphadema Animal Model**

- or       The purpose of this experimental approach is to create an appropriate and consistent lymphedema model for testing the therapeutic effects of a polypeptide of the invention in lymphangiogenesis and re-establishment of the lymphatic circulatory system
- 15    in the rat hind limb. Effectiveness is measured by swelling volume of the affected limb, quantification of the amount of lymphatic vasculature, total blood plasma protein, and histopathology. Acute lymphedema is observed for 7-10 days. Perhaps more importantly, the chronic progress of the edema is followed for up to 3-4 weeks.

- Prior to beginning surgery, blood sample is drawn for protein concentration
- 20    analysis. Male rats weighing approximately ~350g are dosed with Pentobarbital. Subsequently, the right legs are shaved from knee to hip. The shaved area is swabbed with gauze soaked in 70% EtOH. Blood is drawn for serum total protein testing. Circumference and volumetric measurements are made prior to injecting dye into paws after marking 2 measurement levels (0.5 cm above heel, at mid-pt of dorsal paw). The
- 25    intradermal dorsum of both right and left paws are injected with 0.05 ml of 1% Evan's

Blue. Circumference and volumetric measurements are then made following injection of dye into paws.

Using the knee joint as a landmark, a mid-leg inguinal incision is made circumferentially allowing the femoral vessels to be located. Forceps and hemostats are  
5 used to dissect and separate the skin flaps. After locating the femoral vessels, the lymphatic vessel that runs along side and underneath the vessel(s) is located. The main lymphatic vessels in this area are then electrically coagulated suture ligated.

Using a microscope, muscles in back of the leg (near the semitendinosus and adductors) are bluntly dissected. The popliteal lymph node is then located. The 2  
10 proximal and 2 distal lymphatic vessels and distal blood supply of the popliteal node are then and ligated by suturing. The popliteal lymph node, and any accompanying adipose tissue, is then removed by cutting connective tissues.

Care is taken to control any mild bleeding resulting from this procedure. After lymphatics are occluded, the skin flaps are sealed by using liquid skin (Vetbond) (AJ  
15 Buck). The separated skin edges are sealed to the underlying muscle tissue while leaving a gap of ~0.5 cm around the leg. Skin also may be anchored by suturing to underlying muscle when necessary.

To avoid infection, animals are housed individually with mesh (no bedding). Recovering animals are checked daily through the optimal edematous peak, which  
20 typically occurred by day 5-7. The plateau edematous peak are then observed. To evaluate the intensity of the lymphedema, the circumference and volumes of 2 designated places on each paw before operation and daily for 7 days are measured. The effect plasma proteins on lymphedema is determined and whether protein analysis is a useful testing perimeter is also investigated. The weights of both control and edematous limbs are  
25 evaluated at 2 places. Analysis is performed in a blind manner.

Circumference Measurements: Under brief gas anesthetic to prevent limb movement, a cloth tape is used to measure limb circumference. Measurements are done at the ankle bone and dorsal paw by 2 different people then those 2 readings are averaged. Readings are taken from both control and edematous limbs.

5       Volumetric Measurements: On the day of surgery, animals are anesthetized with Pentobarbital and are tested prior to surgery. For daily volumetrics animals are under brief halothane anesthetic (rapid immobilization and quick recovery), both legs are shaved and equally marked using waterproof marker on legs. Legs are first dipped in water, then dipped into instrument to each marked level then measured by Buxco edema  
10 software(Chen/Victor). Data is recorded by one person, while the other is dipping the limb to marked area.

Blood-plasma protein measurements: Blood is drawn, spun, and serum separated prior to surgery and then at conclusion for total protein and Ca<sup>2+</sup> comparison.

Limb Weight Comparison: After drawing blood, the animal is prepared for tissue  
15 collection. The limbs are amputated using a quillitine, then both experimental and control legs are cut at the ligature and weighed. A second weighing is done as the tibio-cacaneal joint is disarticulated and the foot is weighed.

Histological Preparations: The transverse muscle located behind the knee (popliteal) area is dissected and arranged in a metal mold, filled with freezeGel, dipped  
20 into cold methylbutane, placed into labeled sample bags at - 80EC until sectioning. Upon sectioning, the muscle is observed under fluorescent microscopy for lymphatics..

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the  
25 invention.

**Example 52: Suppression of TNF alpha-induced adhesion molecule expression by a Polypeptide of the Invention**

The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in both  
5 normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium  
10 determines the efficiency with which leukocytes may adhere to the local vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Tumor necrosis factor alpha (TNF- $\alpha$ ), a potent proinflammatory cytokine, is a  
15 stimulator of all three CAMs on endothelial cells and may be involved in a wide variety of inflammatory responses, often resulting in a pathological outcome.

The potential of a polypeptide of the invention to mediate a suppression of TNF- $\alpha$  induced CAM expression can be examined. A modified ELISA assay which uses ECs as a solid phase absorbent is employed to measure the amount of CAM expression on TNF- $\alpha$   
20 treated ECs when co-stimulated with a member of the FGF family of proteins.

To perform the experiment, human umbilical vein endothelial cell (HUVEC) cultures are obtained from pooled cord harvests and maintained in growth medium (EGM-2; Clonetics, San Diego, CA) supplemented with 10% FCS and 1% penicillin/streptomycin in a 37 degree C humidified incubator containing 5% CO<sub>2</sub>.  
25 HUVECs are seeded in 96-well plates at concentrations of  $1 \times 10^4$  cells/well in EGM medium at 37 degree C for 18-24 hrs or until confluent. The monolayers are subsequently

washed 3 times with a serum-free solution of RPMI-1640 supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, and treated with a given cytokine and/or growth factor(s) for 24 h at 37 degree C. Following incubation, the cells are then evaluated for CAM expression.

- 5 Human Umbilical Vein Endothelial cells (HUVECs) are grown in a standard 96 well plate to confluence. Growth medium is removed from the cells and replaced with 90 ul of 199 Medium (10% FBS). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10 ul volumes). Plates are incubated at 37 degree C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are  
10 aspirated to remove medium and 100  $\mu$ l of 0.1% paraformaldehyde-PBS(with Ca++ and Mg++) is added to each well. Plates are held at 4°C for 30 min.

- Fixative is then removed from the wells and wells are washed 1X with PBS(+Ca,Mg)+0.5% BSA and drained. Do not allow the wells to dry. Add 10  $\mu$ l of diluted primary antibody to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-  
15 1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10  $\mu$ g/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed X3 with PBS(+Ca,Mg)+0.5% BSA.

- Then add 20  $\mu$ l of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution) to each well and incubated at 37°C for 30 min. Wells are washed X3 with  
20 PBS(+Ca,Mg)+0.5% BSA. 1 tablet of p-Nitrophenol Phosphate pNPP is dissolved in 5 ml of glycine buffer (pH 10.4). 100  $\mu$ l of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer:  $1:5,000 (10^0) > 10^{-0.5} > 10^{-1} > 10^{-1.5}$ . 5  
25  $\mu$ l of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100  $\mu$ l of pNPP reagent must then be added to each of the standard wells. The plate must be incubated at 37°C for 4h. A volume of 50  $\mu$ l of 3M

NaOH is added to all wells. The results are quantified on a plate reader at 405 nm. The background subtraction option is used on blank wells filled with glycine buffer only. The template is set up to indicate the concentration of AP-conjugate in each standard well [ 5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

The studies described in this example tested activity of a polypeptide of the invention. However, one skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), agonists, and/or antagonists of the invention.

10

**Example 53: Assay for the Stimulation of Bone Marrow CD34+ Cell**

**Proliferation**

This assay is based on the ability of human CD34+ to proliferate in the presence of hematopoietic growth factors and evaluates the ability of isolated polypeptides expressed in mammalian cells to stimulate proliferation of CD34+ cells.

It has been previously shown that most mature precursors will respond to only a single signal. More immature precursors require at least two signals to respond. Therefore, to test the effect of polypeptides on hematopoietic activity of a wide range of progenitor cells, the assay contains a given polypeptide in the presence or absence of other hematopoietic growth factors. Isolated cells are cultured for 5 days in the presence of Stem Cell Factor (SCF) in combination with tested sample. SCF alone has a very limited effect on the proliferation of bone marrow (BM) cells, acting in such conditions only as a "survival" factor. However, combined with any factor exhibiting stimulatory effect on these cells (e.g., IL-3), SCF will cause a synergistic effect. Therefore, if the tested polypeptide has a stimulatory effect on a hematopoietic progenitors, such activity can be easily detected. Since normal BM cells have a low



level of cycling cells, it is likely that any inhibitory effect of a given polypeptide, or agonists or antagonists thereof, might not be detected. Accordingly, assays for an inhibitory effect on progenitors is preferably tested in cells that are first subjected to *in vitro* stimulation with SCF+IL+3, and then contacted with the compound that is  
5 being evaluated for inhibition of such induced proliferation.

Briefly, CD34+ cells are isolated using methods known in the art. The cells are thawed and resuspended in medium (QBSF 60 serum-free medium with 1% L-glutamine (500ml) Quality Biological, Inc., Gaithersburg, MD Cat# 160-204-101). After several gentle centrifugation steps at 200 x g, cells are allowed to rest for one  
10 hour. The cell count is adjusted to  $2.5 \times 10^5$  cells/ml. During this time, 100  $\mu$ l of sterile water is added to the peripheral wells of a 96-well plate. The cytokines that can be tested with a given polypeptide in this assay is rhSCF (R&D Systems, Minneapolis, MN, Cat# 255-SC) at 50 ng/ml alone and in combination with rhSCF and rhIL-3 (R&D Systems, Minneapolis, MN, Cat# 203-ML) at 30 ng/ml. After one  
15 hour, 10  $\mu$ l of prepared cytokines, 50  $\mu$ l SID (supernatants at 1:2 dilution = 50  $\mu$ l) and 20  $\mu$ l of diluted cells are added to the media which is already present in the wells to allow for a final total volume of 100  $\mu$ l. The plates are then placed in a 37°C/5% CO<sub>2</sub> incubator for five days.

Eighteen hours before the assay is harvested, 0.5  $\mu$ Ci/well of [3H] Thymidine  
20 is added in a 10  $\mu$ l volume to each well to determine the proliferation rate. The experiment is terminated by harvesting the cells from each 96-well plate to a filtermat using the Tomtec Harvester 96. After harvesting, the filtermats are dried, trimmed and placed into OmniFilter assemblies consisting of one OmniFilter plate and one OmniFilter Tray. 60  $\mu$ l Microscint is added to each well and the plate sealed with  
25 TopSéal-A press-on sealing film. A bar code 15 sticker is affixed to the first plate for counting. The sealed plates is then loaded and the level of radioactivity determined

via the Packard Top Count and the printed data collected for analysis. The level of radioactivity reflects the amount of cell proliferation.

The studies described in this example test the activity of a given polypeptide to stimulate bone marrow CD34+ cell proliferation. One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof. As a nonlimiting example, potential antagonists tested in this assay would be expected to inhibit cell proliferation in the presence of cytokines and/or to increase the inhibition of cell proliferation in the presence of cytokines and a given polypeptide. In contrast, potential agonists tested in this assay would be expected to enhance cell proliferation and/or to decrease the inhibition of cell proliferation in the presence of cytokines and a given polypeptide.

The ability of a gene to stimulate the proliferation of bone marrow CD34+ cells indicates that polynucleotides and polypeptides corresponding to the gene are useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and "Infectious Disease" sections above, and elsewhere herein.

**Example 54: Assay for Extracellular Matrix Enhanced Cell Response (EMECCR)**

The objective of the Extracellular Matrix Enhanced Cell Response (EMECCR) assay is to identify gene products (e.g., isolated polypeptides) that act on the hematopoietic stem cells in the context of the extracellular matrix (ECM) induced signal.

Cells respond to the regulatory factors in the context of signal(s) received from the surrounding microenvironment. For example, fibroblasts, and endothelial and epithelial stem cells fail to replicate in the absence of signals from the ECM.

Hematopoietic stem cells can undergo self-renewal in the bone marrow, but not in *in vitro* suspension culture. The ability of stem cells to undergo self-renewal *in vitro* is dependent upon their interaction with the stromal cells and the ECM protein fibronectin (fn). Adhesion of cells to fn is mediated by the  $\alpha_5\beta_1$  and  $\alpha_4\beta_1$  integrin  
5 receptors, which are expressed by human and mouse hematopoietic stem cells. The factor(s) which integrate with the ECM environment and responsible for stimulating stem cell self-renewal has not yet been identified. Discovery of such factors should be of great interest in gene therapy and bone marrow transplant applications

Briefly, polystyrene, non tissue culture treated, 96-well plates are coated with  
10 fn fragment at a coating concentration of  $0.2 \mu\text{g}/\text{cm}^2$ . Mouse bone marrow cells are plated (1,000 cells/well) in 0.2 ml of serum-free medium. Cells cultured in the presence of IL-3 (5 ng/ml) + SCF (50 ng/ml) would serve as the positive control, conditions under which little self-renewal but pronounced differentiation of the stem cells is to be expected. Gene products are tested with appropriate negative controls in  
15 the presence and absence of SCF(5.0 ng/ml), where test factor supernates represent 10% of the total assay volume. The plated cells are then allowed to grow by incubating in a low oxygen environment (5%  $\text{CO}_2$ , 7%  $\text{O}_2$ , and 88%  $\text{N}_2$ ) tissue culture incubator for 7 days. The number of proliferating cells within the wells is then quantitated by measuring thymidine incorporation into cellular DNA.  
20 Verification of the positive hits in the assay will require phenotypic characterization of the cells, which can be accomplished by scaling up of the culture system and using appropriate antibody reagents against cell surface antigens and FACScan.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or  
25 antagonists and fragments and variants thereof.

If a particular gene product is found to be a stimulator of hematopoietic progenitors, polynucleotides and polypeptides corresponding to the gene may be useful for the diagnosis and treatment of disorders affecting the immune system and hematopoiesis. Representative uses are described in the "Immune Activity" and  
5 "Infectious Disease" sections above, and elsewhere herein. The gene product may also be useful in the expansion of stem cells and committed progenitors of various blood lineages, and in the differentiation and/or proliferation of various cell types.

Additionally, the polynucleotides and/or polypeptides of the gene of interest and/or agonists and/or antagonists thereof, may also be employed to inhibit the  
10 proliferation and differentiation of hematopoietic cells and therefore may be employed to protect bone marrow stem cells from chemotherapeutic agents during chemotherapy. This antiproliferative effect may allow administration of higher doses of chemotherapeutic agents and, therefore, more effective chemotherapeutic treatment.

15 Moreover, polynucleotides and polypeptides corresponding to the gene of interest may also be useful for the treatment and diagnosis of hematopoietic related disorders such as, for example, anemia, pancytopenia, leukopenia, thrombocytopenia or leukemia since stromal cells are important in the production of cells of hematopoietic lineages. The uses include bone marrow cell ex-vivo culture, bone  
20 marrow transplantation, bone marrow reconstitution, radiotherapy or chemotherapy of neoplasia.

**Example 55: Human Dermal Fibroblast and Aortic Smooth Muscle Cell Proliferation**

25 The polypeptide of interest is added to cultures of normal human dermal fibroblasts (NHDF) and human aortic smooth muscle cells (AoSMC) and two co-

assays are performed with each sample. The first assay examines the effect of the polypeptide of interest on the proliferation of normal human dermal fibroblasts (NHDF) or aortic smooth muscle cells (AoSMC). Aberrant growth of fibroblasts or smooth muscle cells is a part of several pathological processes, including fibrosis, and restenosis. The second assay examines IL6 production by both NHDF and SMC. IL6 production is an indication of functional activation. Activated cells will have increased production of a number of cytokines and other factors, which can result in a proinflammatory or immunomodulatory outcome. Assays are run with and without co-TNF $\alpha$  stimulation, in order to check for costimulatory or inhibitory activity.

10 Briefly, on day 1, 96-well black plates are set up with 1000 cells/well (NHDF) or 2000 cells/well (AoSMC) in 100  $\mu$ l culture media. NHDF culture media contains: Clonetics FB basal media, 1mg/ml hFGF, 5mg/ml insulin, 50mg/ml gentamycin, 2%FBS, while AoSMC culture media contains Clonetics SM basal media, 0.5  $\mu$ g/ml hEGF, 5mg/ml insulin, 1 $\mu$ g/ml hFGF, 50mg/ml gentamycin, 50  $\mu$ g/ml Amphotericin B, 5%FBS. After incubation @ 37°C for at least 4-5 hours culture media is aspirated and replaced with growth arrest media. Growth arrest media for NHDF contains fibroblast basal media, 50mg/ml gentamycin, 2% FBS, while growth arrest media for AoSMC contains SM basal media, 50mg/ml gentamycin, 50 $\mu$ g/ml Amphotericin B, 0.4% FBS. Incubate at 37C until day 2.

20 On day 2, serial dilutions and templates of the polypeptide of interest are designed which should always include media controls and known-protein controls. For both stimulation and inhibition experiments, proteins are diluted in growth arrest media. For inhibition experiments, TNF $\alpha$  is added to a final concentration of 2ng/ml (NHDF) or 5ng/ml (AoSMC). Then add 1/3 vol media containing controls or  
25 supernatants and incubate at 37C/5% CO $_2$  until day 5.

Transfer 60  $\mu$ l from each well to another labeled 96-well plate, cover with a plate-sealer, and store at 4C until Day 6 (for IL6 ELISA). To the remaining 100  $\mu$ l in the cell culture plate, aseptically add Alamar Blue in an amount equal to 10% of the culture volume (10  $\mu$ l). Return plates to incubator for 3 to 4 hours. Then measure  
5 fluorescence with excitation at 530nm and emission at 590nm using the CytoFluor. This yields the growth stimulation/inhibition data.

On day 5, the IL6 ELISA is performed by coating a 96 well plate with 50-100  $\mu$ l/well of Anti-Human IL6 Monoclonal antibody diluted in PBS, pH 7.4, incubate ON at room temperature.

10 On day 6, empty the plates into the sink and blot on paper towels. Prepare Assay Buffer containing PBS with 4% BSA. Block the plates with 200  $\mu$ l/well of Pierce Super Block blocking buffer in PBS for 1-2 hr and then wash plates with wash buffer (PBS, 0.05% Tween-20). Blot plates on paper towels. Then add 50  $\mu$ l/well of diluted Anti-Human IL-6 Monoclonal, Biotin-labeled antibody at 0.50 mg/ml. Make  
15 dilutions of IL-6 stock in media (30, 10, 3, 1, 0.3, 0 ng/ml). Add duplicate samples to top row of plate. Cover the plates and incubate for 2 hours at RT on shaker.

Wash plates with wash buffer and blot on paper towels. Dilute EU-labeled Streptavidin 1:1000 in Assay buffer, and add 100  $\mu$ l/well. Cover the plate and incubate 1 h at RT. Wash plates with wash buffer. Blot on paper towels.

20 Add 100  $\mu$ l/well of Enhancement Solution. Shake for 5 minutes. Read the plate on the Wallac DELFIA Fluorometer. Readings from triplicate samples in each assay were tabulated and averaged.

A positive result in this assay suggests AoSMC cell proliferation and that the gene product of interest may be involved in dermal fibroblast proliferation and/or  
25 smooth muscle cell proliferation. A positive result also suggests many potential uses of polypeptides, polynucleotides, agonists and/or antagonists of the gene/gene product

of interest. For example, inflammation and immune responses, wound healing, and angiogenesis, as detailed throughout this specification. Particularly, polypeptides of the gene product and polynucleotides of the gene may be used in wound healing and dermal regeneration, as well as the promotion of vasculogenesis, both of the blood vessels and lymphatics. The growth of vessels can be used in the treatment of, for example, cardiovascular diseases. Additionally, antagonists of polypeptides of the gene product and polynucleotides of the gene may be useful in treating diseases, disorders, and/or conditions which involve angiogenesis by acting as an anti-vascular (e.g., anti-angiogenesis). These diseases, disorders, and/or conditions are known in the art and/or are described herein, such as, for example, malignancies, solid tumors, benign tumors, for example hemangiomas, acoustic neuromas, neurofibromas, trachomas, and pyogenic granulomas; arteriosclerotic plaques; ocular angiogenic diseases, for example, diabetic retinopathy, retinopathy of prematurity, macular degeneration, corneal graft rejection, neovascular glaucoma, retrolental fibroplasia, rubeosis, retinoblastoma, uveitis and Pterygia (abnormal blood vessel growth) of the eye; rheumatoid arthritis; psoriasis; delayed wound healing; endometriosis; vasculogenesis; granulations; hypertrophic scars (keloids); nonunion fractures; scleroderma; trachoma; vascular adhesions; myocardial angiogenesis; coronary collaterals; cerebral collaterals; arteriovenous malformations; ischemic limb angiogenesis; Osler-Webber Syndrome; plaque neovascularization; telangiectasia; hemophilic joints; angiofibroma; fibromuscular dysplasia; wound granulation; Crohn's disease; and atherosclerosis. Moreover, antagonists of polypeptides of the gene product and polynucleotides of the gene may be useful in treating anti-hyperproliferative diseases and/or anti-inflammatory known in the art and/or described herein.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

5 **Example 56: Cellular Adhesion Molecule (CAM) Expression on Endothelial Cells**

The recruitment of lymphocytes to areas of inflammation and angiogenesis involves specific receptor-ligand interactions between cell surface adhesion molecules (CAMs) on lymphocytes and the vascular endothelium. The adhesion process, in  
10 both normal and pathological settings, follows a multi-step cascade that involves intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), and endothelial leukocyte adhesion molecule-1 (E-selectin) expression on endothelial cells (EC). The expression of these molecules and others on the vascular endothelium determines the efficiency with which leukocytes may adhere to the local  
15 vasculature and extravasate into the local tissue during the development of an inflammatory response. The local concentration of cytokines and growth factor participate in the modulation of the expression of these CAMs.

Briefly, endothelial cells (e.g., Human Umbilical Vein Endothelial cells (HUVECs)) are grown in a standard 96 well plate to confluence, growth medium is  
20 removed from the cells and replaced with 100  $\mu$ l of 199 Medium (10% fetal bovine serum (FBS)). Samples for testing and positive or negative controls are added to the plate in triplicate (in 10  $\mu$ l volumes). Plates are then incubated at 37°C for either 5 h (selectin and integrin expression) or 24 h (integrin expression only). Plates are aspirated to remove medium and 100  $\mu$ l of 0.1% paraformaldehyde-PBS(with Ca++  
25 and Mg++) is added to each well. Plates are held at 4°C for 30 min. Fixative is removed from the wells and wells are washed 1X with PBS(+Ca,Mg) + 0.5% BSA



and drained. 10  $\mu$ l of diluted primary antibody is added to the test and control wells. Anti-ICAM-1-Biotin, Anti-VCAM-1-Biotin and Anti-E-selectin-Biotin are used at a concentration of 10  $\mu$ g/ml (1:10 dilution of 0.1 mg/ml stock antibody). Cells are incubated at 37°C for 30 min. in a humidified environment. Wells are washed three times with PBS(+Ca,Mg) + 0.5% BSA. 20  $\mu$ l of diluted ExtrAvidin-Alkaline Phosphatase (1:5,000 dilution, referred to herein as the working dilution) are added to each well and incubated at 37°C for 30 min. Wells are washed three times with PBS(+Ca,Mg)+0.5% BSA. Dissolve 1 tablet of p-Nitrophenol Phosphate pNPP per 5 ml of glycine buffer (pH 10.4). 100  $\mu$ l of pNPP substrate in glycine buffer is added to each test well. Standard wells in triplicate are prepared from the working dilution of the ExtrAvidin-Alkaline Phosphatase in glycine buffer: 1:5,000 ( $10^0$ ) >  $10^{-0.5}$  >  $10^{-1}$  >  $10^{-1.5}$ . 5  $\mu$ l of each dilution is added to triplicate wells and the resulting AP content in each well is 5.50 ng, 1.74 ng, 0.55 ng, 0.18 ng. 100  $\mu$ l of pNPP reagent is then added to each of the standard wells. The plate is incubated at 37°C for 4h. A volume of 50  $\mu$ l of 3M NaOH is added to all wells. The plate is read on a plate reader at 405 nm using the background subtraction option on blank wells filled with glycine buffer only. Additionally, the template is set up to indicate the concentration of AP-conjugate in each standard well [ 5.50 ng; 1.74 ng; 0.55 ng; 0.18 ng]. Results are indicated as amount of bound AP-conjugate in each sample.

20

#### **Example 57: Alamar Blue Endothelial Cells Proliferation Assay**

This assay may be used to quantitatively determine protein mediated inhibition of bFGF-induced proliferation of Bovine Lymphatic Endothelial Cells (LECs), Bovine Aortic Endothelial Cells (BAECs) or Human Microvascular Uterine Myometrial Cells (UTMECs). This assay incorporates a fluorometric growth indicator based on detection of metabolic activity. A standard Alamar Blue

25

Proliferation Assay is prepared in EGM-2MV with 10 ng /ml of bFGF added as a source of endothelial cell stimulation. This assay may be used with a variety of endothelial cells with slight changes in growth medium and cell concentration.

Dilutions of the protein batches to be tested are diluted as appropriate. Serum-free  
5 medium (GIBCO SFM) without bFGF is used as a non-stimulated control and Angiostatin or TSP-1 are included as a known inhibitory controls.

Briefly, LEC, BAECs or UTMECs are seeded in growth media at a density of 5000 to 2000 cells/well in a 96 well plate and placed at 37°C overnight. After the overnight incubation of the cells, the growth media is removed and replaced with  
10 GIBCO EC-SFM. The cells are treated with the appropriate dilutions of the protein of interest or control protein sample(s) (prepared in SFM ) in triplicate wells with additional bFGF to a concentration of 10 ng/ ml. Once the cells have been treated with the samples, the plate(s) is/are placed back in the 37° C incubator for three days. After three days 10 ml of stock alamar blue (Biosource Cat# DAL1100) is added to  
15 each well and the plate(s) is/are placed back in the 37°C incubator for four hours. The plate(s) are then read at 530nm excitation and 590nm emission using the CytoFluor fluorescence reader. Direct output is recorded in relative fluorescence units.

Alamar blue is an oxidation-reduction indicator that both fluoresces and changes color in response to chemical reduction of growth medium resulting from cell  
20 growth. As cells grow in culture, innate metabolic activity results in a chemical reduction of the immediate surrounding environment. Reduction related to growth causes the indicator to change from oxidized (non-fluorescent blue) form to reduced (fluorescent red) form. i.e. stimulated proliferation will produce a stronger signal and inhibited proliferation will produce a weaker signal and the total signal is proportional  
25 to the total number of cells as well as their metabolic activity. The background level of activity is observed with the starvation medium alone. This is compared to the

output observed from the positive control samples (bFGF in growth medium) and protein dilutions.

**Example 58: Detection of Inhibition of a Mixed Lymphocyte Reaction**

- 5           This assay can be used to detect and evaluate inhibition of a Mixed Lymphocyte Reaction (MLR) by gene products (e.g., isolated polypeptides). Inhibition of a MLR may be due to a direct effect on cell proliferation and viability, modulation of costimulatory molecules on interacting cells, modulation of adhesiveness between lymphocytes and accessory cells, or modulation of cytokine
- 10   production by accessory cells. Multiple cells may be targeted by these polypeptides since the peripheral blood mononuclear fraction used in this assay includes T, B and natural killer lymphocytes, as well as monocytes and dendritic cells.

- Polypeptides of interest found to inhibit the MLR may find application in diseases associated with lymphocyte and monocyte activation or proliferation. These
- 15   include, but are not limited to, diseases such as asthma, arthritis, diabetes, inflammatory skin conditions, psoriasis, eczema, systemic lupus erythematosus, multiple sclerosis, glomerulonephritis, inflammatory bowel disease, crohn's disease, ulcerative colitis, arteriosclerosis, cirrhosis, graft vs. host disease, host vs. graft disease, hepatitis, leukemia and lymphoma.

- 20           Briefly, PBMCs from human donors are purified by density gradient centrifugation using Lymphocyte Separation Medium (LSM®, density 1.0770 g/ml, Organon Teknika Corporation, West Chester, PA). PBMCs from two donors are adjusted to  $2 \times 10^6$  cells/ml in RPMI-1640 (Life Technologies, Grand Island, NY) supplemented with 10% FCS and 2 mM glutamine. PBMCs from a third donor is
- 25   adjusted to  $2 \times 10^5$  cells/ml. Fifty microliters of PBMCs from each donor is added to wells of a 96-well round bottom microtiter plate. Dilutions of test materials (50  $\mu$ l) is

added in triplicate to microtiter wells. Test samples (of the protein of interest) are added for final dilution of 1:4; rhIL-2 (R&D Systems, Minneapolis, MN, catalog number 202-IL) is added to a final concentration of 1 µg/ml; anti-CD4 mAb (R&D Systems, clone 34930.11, catalog number MAB379) is added to a final concentration of 10 µg/ml. Cells are cultured for 7-8 days at 37°C in 5% CO<sub>2</sub>, and 1 µC of [<sup>3</sup>H] thymidine is added to wells for the last 16 hrs of culture. Cells are harvested and thymidine incorporation determined using a Packard TopCount. Data is expressed as the mean and standard deviation of triplicate determinations.

Samples of the protein of interest are screened in separate experiments and compared to the negative control treatment, anti-CD4 mAb, which inhibits proliferation of lymphocytes and the positive control treatment, IL-2 (either as recombinant material or supernatant), which enhances proliferation of lymphocytes.

One skilled in the art could easily modify the exemplified studies to test the activity of polynucleotides (e.g., gene therapy), antibodies, agonists, and/or antagonists and fragments and variants thereof.

It will be clear that the invention may be practiced otherwise than as particularly described in the foregoing description and examples. Numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, are within the scope of the appended claims.

The entire disclosure of each document cited (including patents, patent applications, journal articles, abstracts, laboratory manuals, books, or other disclosures) in the Background of the Invention, Detailed Description, and Examples is hereby incorporated herein by reference. Further, the hard copy of the sequence listing submitted herewith and the corresponding computer readable form are both incorporated herein by reference in their entireties. Additionally, U.S. provisional application Serial No. 60/138,631 is hereby incorporated by reference in its entirety.

Applicant's or agent's file reference number	PS553PCT	International application No.	UNASSIGNED
--	----------	-------------------------------	------------

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description on page <u>97</u> , line <u>N/A</u>	
B. IDENTIFICATION OF DEPOSIT Further deposits are identified on an additional sheet <input type="checkbox"/>	
Name of depositary institution American Type Culture Collection	
Address of depositary institution (including postal code and country) 10801 University Boulevard Manassas, Virginia 20110-2209 United States of America	
Date of deposit 29 April 1999	Accession Number 203979
C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet <input type="checkbox"/>	
D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States) Europe In respect to those designations in which a European Patent is sought a sample of the deposited microorganism will be made available until the publication of the mention of the grant of the European patent or until the date on which application has been refused or withdrawn or is deemed to be withdrawn, only by the issue of such a sample to an expert nominated by the person requesting the sample (Rule 28 (4) EPC). Continued on the Attached Pages 2 & 3	
E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable) The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")	
<div>For receiving Office use only</div> <input checked="" type="checkbox"/> This sheet was received with the international application <div>Authorized officer</div> <div>MELVIN S. BROOKS SR INTERNATIONAL DIVISION 703-305-5163 722</div>	<div>For International Bureau use only</div> <input type="checkbox"/> This sheet was received by the International Bureau on: <div>Authorized officer</div>

**ATCC Deposit No. 203979****Page No. 2****CANADA**

The applicant requests that, until either a Canadian patent has been issued on the basis of an application or the application has been refused, or is abandoned and no longer subject to reinstatement, or is withdrawn, the Commissioner of Patents only authorizes the furnishing of a sample of the deposited biological material referred to in the application to an independent expert nominated by the Commissioner, the applicant must, by a written statement, inform the International Bureau accordingly before completion of technical preparations for publication of the international application.

**NORWAY**

The applicant hereby requests that the application has been laid open to public inspection (by the Norwegian Patent Office), or has been finally decided upon by the Norwegian Patent Office without having been laid open inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Norwegian Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Norwegian Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on the list of recognized experts drawn up by the Norwegian Patent Office or any person approved by the applicant in the individual case.

**AUSTRALIA**

The applicant hereby gives notice that the furnishing of a sample of a microorganism shall only be effected prior to the grant of a patent, or prior to the lapsing, refusal or withdrawal of the application, to a person who is a skilled addressee without an interest in the invention (Regulation 3.25(3) of the Australian Patents Regulations).

**FINLAND**

The applicant hereby requests that, until the application has been laid open to public inspection (by the National Board of Patents and Regulations), or has been finally decided upon by the National Board of Patents and Registration without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art.

**UNITED KINGDOM**

The applicant hereby requests that the furnishing of a sample of a microorganism shall only be made available to an expert. The request to this effect must be filed by the applicant with the International Bureau before the completion of the technical preparations for the international publication of the application.

**ATCC Deposit No.: 203979****Page No. 3****DENMARK**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Danish Patent Office), or has been finally decided upon by the Danish Patent office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the Danish Patent Office not later than at the time when the application is made available to the public under Sections 22 and 33(3) of the Danish Patents Act. If such a request has been filed by the applicant, any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Danish Patent Office or any person by the applicant in the individual case.

**SWEDEN**

The applicant hereby requests that, until the application has been laid open to public inspection (by the Swedish Patent Office), or has been finally decided upon by the Swedish Patent Office without having been laid open to public inspection, the furnishing of a sample shall only be effected to an expert in the art. The request to this effect shall be filed by the applicant with the International Bureau before the expiration of 16 months from the priority date (preferably on the Form PCT/RO/134 reproduced in annex Z of Volume I of the PCT Applicant's Guide). If such a request has been filed by the applicant any request made by a third party for the furnishing of a sample shall indicate the expert to be used. That expert may be any person entered on a list of recognized experts drawn up by the Swedish Patent Office or any person approved by a applicant in the individual case.

**NETHERLANDS**

The applicant hereby requests that until the date of a grant of a Netherlands patent or until the date on which the application is refused or withdrawn or lapsed, the microorganism shall be made available as provided in the 31F(1) of the Patent Rules only by the issue of a sample to an expert. The request to this effect must be furnished by the applicant with the Netherlands Industrial Property Office before the date on which the application is made available to the public under Section 22C or Section 25 of the Patents Act of the Kingdom of the Netherlands, whichever of the two dates occurs earlier.

***What Is Claimed Is:***

1. An isolated nucleic acid molecule comprising a polynucleotide having a nucleotide sequence at least 95% identical to a sequence selected from the group
- 5 consisting of:
- (a) a polynucleotide fragment of SEQ ID NO:X or a polynucleotide fragment of the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (b) a polynucleotide encoding a polypeptide fragment of SEQ ID NO:Y or a
  - 10 polypeptide fragment encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (c) a polynucleotide encoding a polypeptide domain of SEQ ID NO:Y or a polypeptide domain encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - 15 (d) a polynucleotide encoding a polypeptide epitope of SEQ ID NO:Y or a polypeptide epitope encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X;
  - (e) a polynucleotide encoding a polypeptide of SEQ ID NO:Y or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X,
  - 20 having biological activity;
  - (f) a polynucleotide which is a variant of SEQ ID NO:X;
  - (g) a polynucleotide which is an allelic variant of SEQ ID NO:X;
  - (h) a polynucleotide which encodes a species homologue of the SEQ ID NO:Y;



(i) a polynucleotide capable of hybridizing under stringent conditions to any one of the polynucleotides specified in (a)-(h), wherein said polynucleotide does not hybridize under stringent conditions to a nucleic acid molecule having a nucleotide sequence of only A residues or of only T residues.

5

2. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding a secreted protein.

10

3. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises a nucleotide sequence encoding the sequence identified as SEQ ID NO:Y or the polypeptide encoded by the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

15

4. The isolated nucleic acid molecule of claim 1, wherein the polynucleotide fragment comprises the entire nucleotide sequence of SEQ ID NO:X or the cDNA sequence included in ATCC Deposit No:Z, which is hybridizable to SEQ ID NO:X.

20

5. The isolated nucleic acid molecule of claim 2, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

25

6. The isolated nucleic acid molecule of claim 3, wherein the nucleotide sequence comprises sequential nucleotide deletions from either the C-terminus or the N-terminus.

7. A recombinant vector comprising the isolated nucleic acid molecule of claim 1.

5 8. A method of making a recombinant host cell comprising the isolated nucleic acid molecule of claim 1.

9. A recombinant host cell produced by the method of claim 8.

10 10. The recombinant host cell of claim 9 comprising vector sequences.

11. An isolated polypeptide comprising an amino acid sequence at least 95% identical to a sequence selected from the group consisting of:

(a) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence  
15 included in ATCC Deposit No:Z;

(b) a polypeptide fragment of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z, having biological activity;

(c) a polypeptide domain of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

20 (d) a polypeptide epitope of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(e) a secreted form of SEQ ID NO:Y or the encoded sequence included in ATCC Deposit No:Z;

(f) a full length protein of SEQ ID NO:Y or the encoded sequence included in  
25 ATCC Deposit No:Z;

(g) a variant of SEQ ID NO:Y;

(h) an allelic variant of SEQ ID NO:Y; or

(i) a species homologue of the SEQ ID NO:Y.

12. The isolated polypeptide of claim 11, wherein the secreted form or the full length protein comprises sequential amino acid deletions from either the C-terminus or the N-terminus.

13. An isolated antibody that binds specifically to the isolated polypeptide of claim 11.

14. A recombinant host cell that expresses the isolated polypeptide of claim 11.

15. A method of making an isolated polypeptide comprising:

(a) culturing the recombinant host cell of claim 14 under conditions such that said polypeptide is expressed; and  
(b) recovering said polypeptide.

16. The polypeptide produced by claim 15.

17. A method for preventing, treating, or ameliorating a medical condition, comprising administering to a mammalian subject a therapeutically effective amount of the polypeptide of claim 11 or the polynucleotide of claim 1.

18. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or absence of a mutation in the polynucleotide of claim 1; and

(b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or absence of said mutation.

5

19. A method of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject comprising:

(a) determining the presence or amount of expression of the polypeptide of claim 11 in a biological sample; and

10 (b) diagnosing a pathological condition or a susceptibility to a pathological condition based on the presence or amount of expression of the polypeptide.

20. A method for identifying a binding partner to the polypeptide of claim 11 comprising:

15 (a) contacting the polypeptide of claim 11 with a binding partner; and

(b) determining whether the binding partner effects an activity of the polypeptide.

21. The gene corresponding to the cDNA sequence of SEQ ID NO:Y.

20

22. A method of identifying an activity in a biological assay, wherein the method comprises:

(a) expressing SEQ ID NO:X in a cell;

(b) isolating the supernatant;

25 (c) detecting an activity in a biological assay; and

(d) identifying the protein in the supernatant having the activity.

23. The product produced by the method of claim 20.

<110> Human Genome Sciences, Inc.

<120> 48 Human Secreted Proteins

<130> PS553PCT

<140> Unassigned

<141> 2000-06-01

<150> 60/138,631

<151> 1999-06-11

<160> 166

<170> PatentIn Ver. 2.0

<210> 1

<211> 733

<212> DNA

<213> Homo sapiens

<400> 1

```

gggatccgga gcccaaatct tctgacaaaa ctcacacatg cccaccgtgc ccagcacctg      60
aattcgaggg tgcaccgtca gtcttcctct tcccccaaa acccaaggac accctcatga      120
tctcccgga ccttgagggt acatgcgtgg tgggtggacgt aagccacgaa gaccctgagg      180
tcaagttcaa ctggtacgtg gacggcgtgg aggtgcataa tgccaagaca aagccgcggg      240
aggagcagta caacagcacg taccgtgtgg tcagcgtcct caccgtcctg caccaggact      300
ggctgaatgg caaggagtac aagtgcagg tctccaacaa agccctcca acccccatcg      360
agaaaacccat ctccaaagcc aaagggcagc cccgagaacc acaggtgtac accctgcccc      420
catcccgga tgagctgacc aagaaccagg tcagcctgac ctgctgtggtc aaaggcttct      480
atccaagcga catgccgtg gagtgggaga gcaatgggca gccggagaac aactacaaga      540
ccacgcctcc cgtgctggac tccgacggct ccttcttct ctacagcaag ctcaccgtgg      600
acaagagcag gtggcagcag gggaacgtct tctcatgctc cgtgatgcat gaggtctctg      660
acaaccacta cagcagaag agcctctccc tgtctccggg taaatgagtg cgacggccgc      720
gactctagag gat                                     733

```

<210> 2

<211> 5

<212> PRT

<213> Homo sapiens

<220>

<221> Site

<222> (3)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 2

Trp Ser Xaa Trp Ser

1 5

<210> 3

<211> 86

<212> DNA

<213> Homo sapiens

<400> 3  
gcgcctcgag atttccccga aatctagatt tccccgaaat gatttccccg aaatgatttc 60  
cccgaatat ctgccatctc aattag 86

<210> 4  
<211> 27  
<212> DNA  
<213> Homo sapiens

<400> 4  
gcggcaagct ttttgcaaag cctaggc 27

<210> 5  
<211> 271  
<212> DNA  
<213> Homo sapiens

<400> 5  
ctcgagattt ccccgaaatc tagatttccc cgaaatgatt tccccgaaat gatttccccg 60  
aaatatctgc catctcaatt agtcagcaac catagtcccc cccctaactc cgcccatccc 120  
gcccctaact ccgcccagtt ccgcccattc tccgcccatt ggctgactaa ttttttttat 180  
ttatgcagag gccgaggccg cctcggcctc tgagctattc cagaagtagt gaggaggctt 240  
ttttggaggc ctaggctttt gcaaaaagct t 271

<210> 6  
<211> 32  
<212> DNA  
<213> Homo sapiens

<400> 6  
gcgctcgagg gatgacagcg atagaacccc gg 32

<210> 7  
<211> 31  
<212> DNA  
<213> Homo sapiens

<400> 7  
gcgaagcttc gcgactcccc ggatccgcct c 31

<210> 8  
<211> 12  
<212> DNA  
<213> Homo sapiens

<400> 8  
ggggactttc cc 12

<210> 9  
<211> 73  
<212> DNA  
<213> Homo sapiens

<400> 9  
 gcggcctcga ggggactttc ccggggactt tccggggact ttccgggact ttccatcctg 60  
 ccatctcaat tag 73

<210> 10  
 <211> 256  
 <212> DNA  
 <213> Homo sapiens

<400> 10  
 ctcgagggga ctttcccggg gactttccgg ggactttccg ggactttcca tctgccatct 60  
 caattagtca gcaaccatag tcccgccctt aactccgcc atcccgcc taactccgcc 120  
 cagttccgcc cattctccgc cccatggctg actaattttt tttatttatg cagaggccga 180  
 ggccgcctcg gcctctgagc tattccagaa gtagtgagga ggcttttttg gaggcctagg 240  
 cttttgcaaa aagctt 256

<210> 11  
 <211> 1289  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (433)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (538)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (598)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (629)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (710)  
 <223> n equals a,t,g, or c

<220>  
 <221> SITE  
 <222> (1177)  
 <223> n equals a,t,g, or c

<400> 11  
 caagcgcgca attaaccttc actaaagga acaaaagctg ggtacgggcc cccctcgag 60  
 tttttttttt ttttttttgt atttatctag ctaaaacttt tgttttgcaa ttaacctaaa 120  
 tgctcttctt caatttattt tgttatctag gctcagtatt aatttcaggt cagattttca 180



ctgttttaag	ccaaaatata	acaaaacgca	gagtaacaac	aacatgatct	ttaaaataag	240
tttaaagagg	gtgtagccag	aatctccctt	actcctgatg	tttcttagta	attttcttag	300
taatttactg	actttctaata	ctgctccttg	gctattaatt	cccacttgcc	catgctgttg	360
aacccaatct	ctctcagaca	ttgcaaaatc	ccattgtagt	ggtcctata	cctagaacga	420
ttgaataaatt	tttctttaac	aaatctcatc	atccagatac	acctgttgat	gtgtaaaata	480
ttacacaaac	aaaaatcaaa	aatttcaagt	aaaaagtaaa	cccaaacatt	aaaggaangg	540
ctaaaataag	aagttcttct	ctctaaactc	agtctaacca	tcctttcccc	aaggtaanca	600
ttgttttctc	gaccttcca	aataaatgng	tatgaaatcc	ggycctggaa	tttgactaa	660
aagamtggta	ctatatacac	cattcagcaa	cttggytttc	cycatttaan	ggawatayct	720
watagacctt	ycwawayctg	cacatacaga	cccacyctct	cgggtttcat	agaagtgaca	780
taattcaact	agtyccycat	tgatgwakgt	cctgcttttt	tycctattgc	aaataatact	840
gcaatatcat	tgtgtgtatg	tattatgcat	gtatgttcat	cttggaacac	tttgaaaata	900
tatccttata	gtaaatata	tgcatttaga	agttttgatg	caagtggaga	attgccattc	960
acaatgttcc	catcaattta	tatatccata	aaaattgtat	gaaagtaccc	ttttgcttat	1020
atcctagaca	acattgggtat	caaaaacgttt	ttattctgaa	agacaaaaaa	ggaagaaaag	1080
atataaaact	gtttttatatt	gtgtttcttt	ttttttttaa	caacagaaac	ataacacttt	1140
cccaggggag	ttgtcgatac	atttcccact	atcctcnaga	ctagttctct	cctcgtgccg	1200
aattcctgca	gccgggggga	tccactagtt	ctagagcggc	cgccaccgcg	gtggagctcc	1260
aattcgccct	atagtgagtc	gtattaccc				1289

&lt;210&gt; 12

&lt;211&gt; 2913

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (2288)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (2753)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 12

acaaaagctg	gagctccacc	gcgggtggcgg	ccgctctaga	actagtggat	cccccgggct	60
gcaggaattc	ggcacgagat	acgattgacg	tatgtaatac	tgttgacata	aaaactgagg	120
atctgtctga	cagcctgcca	cccgtttgtg	acacagtagc	cactgactta	tgttccacag	180
gcattgatat	ctgcagtttc	agtgaagata	taaaacctgg	agactctctg	ttactgagtg	240
ttgaggaagt	actccgcagc	ttagaaaactg	tttcaaatac	agaggtctgt	tgccctaatt	300
tgcagccgaa	cttggaagcc	actgtatcca	atggaccttt	tctgcagctt	tcttcccagt	360
ctcttagcca	taatgttttt	atgtccacca	gtcctgcact	tcattgggta	tcattgtacag	420
cagcaactcc	gaagatagca	aaattgaata	gaaaacgata	cagatcagag	agtgacagtg	480
agaaagttca	gccacttcca	atttctacca	ttatccgagg	cccaacactg	ggggcatctg	540
ctcctgtgac	agtgaacagg	gagagcaaaa	tttctcttca	acctatagca	actgttccca	600
atggaggcac	aacacctaaa	atcagcaaaa	ctgtactttt	atctactaaa	agcatgaaaa	660
agagtcatga	acatggatcc	aagaaatctc	actctaaaac	caagccaggt	attcttaaaa	720
aagacaaaagc	agtaaaggaa	aagattccta	gtcatcattt	tatgccagga	agtcctacca	780
agactgtgta	caaaaaaccc	caggaaaaga	aagggtgtaa	atgtgggcgt	gctactcaaa	840
atccaagtgt	tcttacatgc	cgaggccaac	gctgccttg	ctactctaac	cgcaaacgct	900
gcttagattg	tatatgtcgt	grctggsaaa	acycctatat	ggccaatggg	gagaagaagc	960
tggaggcatt	tgccgtgcca	gaaaaggcct	tggagcagac	caggctcact	ttgggcatta	1020
acgtgactag	cattgtctgtg	cgtaacgcta	gtaccagcac	cagtgtata	aatgtcacag	1080
gggtccccagt	aacgacgttt	ttagctgcca	gtacacatga	tgataaaagt	ttggatgaag	1140
ctatagacat	gagattcgac	tgttaaatca	gtgggtcttt	taaacctact	cctggtaggg	1200
aaatagctac	agttttacgg	cagctatggt	tctgttgggt	taacttgccg	gagctcctgc	1260

atatagatca	cttgatca	gtgtttcat	tgctaagtta	tatgtgttag	tgctggggaa	1320
atagtttgca	gataatggag	gagtaaccct	acaactatat	gtccttagtt	cttacagaac	1380
ctcatagttt	gagaacaaaag	ctgatgcaac	tgattttatac	aaaatgaact	ttggcaagaa	1440
aaataacatt	aacctcattg	tttatggcca	tgctttgtgc	ataatcaaag	tttatgatta	1500
aatgtaagga	agtggatct	agtcagcca	taaagattgt	gctaattttt	ttgtggaaaa	1560
gtagccatta	gttcaggaaa	ctcagtgtg	ccttcagatg	tcattgatgt	ttctcctgtt	1620
ggaaagctga	tgtgtccagc	tcaacctttg	tgctgacatc	ataccatttc	tgatcatgaa	1680
atattggcta	ctggtgtatg	tagcagttct	taaatcagca	gtattatgaa	aaaaaattcc	1740
ccctcattag	aatgtttaag	aaatctttt	aaaaagtaaa	attctgtcag	actacaaatg	1800
tttagctgtt	actcatttct	agggagaaa	ttctaaatcc	ctccttcaact	ttgagcagtg	1860
ttctaattgg	gataaatgaa	ggagagtagt	tttattctga	aggtaattaa	atttagacta	1920
tgtagtatgt	gacagaattt	ttttaaaatt	atwaaaagrt	tttatttagt	aattgggatt	1980
tacttaaaat	aattttggaa	taatgctccc	agacttgccc	agatttgtgt	attgtactta	2040
ttgccaactg	cgcactttt	gacttatttt	ctctaatagt	ttatttgcca	cagtctttat	2100
tttgaatatg	ctcctagttt	ttttttaggg	tgctgttcat	tatgaaggct	tctttataga	2160
ggcctaataa	gaatgccttt	ttataaagcc	tgctgattta	ggtaggttga	agctaggagg	2220
attttcttta	gaatgctctt	ttgcatgtaa	agcaciaaagt	atgtttcagt	ttaaatgcac	2280
ttcttccngg	ttaattttwa	tggggaagac	aagtgaagtca	caaacattct	gttgaaggga	2340
aatctagtca	gttgcttgaa	agagcacagc	ccaaataaaa	caaggactga	ctagggtgtaa	2400
tgaataaacc	tgtgatttaa	aagaagagct	gcagctttga	cagtgtttat	ttaaagaaaa	2460
atactgctgg	aaaatttcca	atttctacta	cggtcaccat	ctctagtaag	atctgacata	2520
tgctgaagtt	atgttttgat	ttggcacaca	gcagtgtcaa	tgatggttac	tcgcctagta	2580
caagacatgg	agaagaaacc	tttgacaca	gagcagatga	cacctccttc	tgttttgtag	2640
tgtatcctgg	tgtcattttc	tgtgaatgtg	gtcaggtaga	gttgtttttg	ttgtgttgt	2700
tgggcttttt	tttctttttt	tttttttgg	ctcttttgg	ggggtggggg	tgngctaaag	2760
ccataggaag	aaaaatgtga	tgtgtccagt	atgtactatt	ttgtttttgt	tttgcaagaa	2820
gagttgaact	atttttgata	acaagagtaa	atggtggaaa	atgcttaaaa	aaaaaaaaaa	2880
aaactcgagg	gggggcccgt	acccaatcgc	cct			2913

&lt;210&gt; 13

&lt;211&gt; 1694

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 13

gggcctcagg	actcatctct	gtcttctcca	acccagctg	gcctccatgt	cccctggggg	60
ctttctgctg	ctgaccagct	tgggccctac	tataggtttt	cttgctgggc	ttaggagcct	120
gagagaggta	gccatttcca	aaagaaaaga	tttctatctc	agattatctg	ggaaagaggc	180
tgagtaggtc	ccttctctga	ggaaacaggc	agcaggacat	aggatggggc	agtgggagga	240
aaaggggtctg	cactatgggg	tccttgggct	gtgcactcct	gaccttatca	cttcacagtt	300
cccaccagat	ctgacttgac	ctccgggcca	tgacccagtc	cctccccac	tctggaaacc	360
tctgtgtccc	ctcctgtctc	tttcaactcc	acctgggagg	ctctgagcag	gccagggtcc	420
ctctctccag	gcctgtcctc	ccctttctcc	tectgtmccc	ccagccatcc	ccccagccag	480
gctctccac	ctctggcccc	acctcacctc	ttggccttct	tctttccctc	gggcgagggg	540
agcctggttt	ggctgcccag	ggaagattgt	atctgaccac	aggagggagg	gctgagggca	600
ctgctgggtg	agctgaggcc	tccttaggtt	cttgctgtag	tctgagttca	agtcatttag	660
aatgagtga	ttgaggaaga	gggagctggg	agcccttttc	accagcaggg	ggactggagg	720
agtcgaatgg	ggtgggggtct	tctcgttttg	attagcttct	ggtggagggtc	ccaggctttg	780
gcgtgctcaa	gcttggagtg	gcagggagca	ggcctggctt	gaccttcttt	ccttctctgt	840
ccctctctc	acccctccct	gcagctcttt	cactccgtct	ctctctctac	agatgggacc	900
cagggtgagcc	cggttgccca	ctactgcagc	cccactggcg	caggtaagag	tcaaaccggg	960
gggagtcctat	ggtaggggagt	ggaagatgag	gggtggaaaag	gctgtaagaa	cgcgagaagc	1020
tgaggggtta	gagaagcagg	gtcgtgtggt	gatctgccag	agagccagga	ggtggcggct	1080
ccagggagggg	scgaggagcc	ggggtaaagag	aggcagctct	ggatgctggc	tgggcacagt	1140
gctaggaaac	acaacaggaa	aaggaaacac	aggatgcccg	tcttgtcctt	gctgggagca	1200
gtgaaacagg	aaggaaagta	agaagcta	atttatactg	agacccctac	cccatgtcag	1260
gcaccaggca	aggtgtgttc	ttgtgtgtgg	actcggctct	cacaccggct	ctgcaagggtg	1320

ggcatggcag	cccttgcagg	actgctctgc	tggaggggaa	gtgttctctc	actgtctgcg	1380
cctcctccct	ctgctggccc	gagcctcctc	tgctgctagg	ctgccctggg	gaaggactgg	1440
acttctctgt	gctgcttttg	tttaggacat	gccccatggg	ccaggtcttg	actagacgcg	1500
gtctgccctt	ccttttagtgt	agccagtatc	aaccaagggc	ctactgagtg	caagatatac	1560
agcctgatgc	ctaataattc	catatagcag	ggagaaatgg	aaccaggtta	tcctccttgc	1620
ttcagtcctg	gctgttgaaa	agctwacagg	caggtttaggg	aggaagcaca	cacaaatata	1680
aaacaaaaaa	aaag					1694

&lt;210&gt; 14

&lt;211&gt; 1228

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 14

ggcacgagga	accctgaggt	gtgcacagcg	ctgggatgcc	aggttcggcc	tcgaagcggg	60
ggatccctgt	gtcccagccg	ggcatggccg	acccccacca	gcttttcgat	gacacaagtt	120
cagcccagag	ccggggctat	ggggcccagc	gggcacctgg	tggcctgagt	tatcctgcag	180
cctctcccac	gccccatgca	gccttcctgg	ctgacccggg	gtccaacatg	gccatggcct	240
atgggagcag	cctggccgcg	cagggcaagg	agctggtgga	taagaacatc	gaccgcttca	300
tccccatcac	caagctcaag	tattactttg	ctgtggacac	catgtatgtg	ggcagaaaagc	360
tgggcctgct	gttcttcccc	tacctacacc	aggactggga	agtgcagtac	caacaggaca	420
ccccggtggc	cccccgcttt	gacgtcaatg	ccccggacct	ctacattcca	gcaatgggct	480
ttcatcacct	acgttttggg	ggctggtctt	gcgctgggga	cccaggatag	gttctcccca	540
gacctcctgg	ggctgcaagc	gagctcagcc	ctggcctggc	tgaccctgga	ggtgctggcc	600
atcctgctca	gcctctatct	ggtcactgtc	aacaccgacc	tcaccacccat	cgacctggtg	660
gccttcttgg	gctacaaata	tgtcgggatg	attggcgggg	tcctcatggg	cctgctcttc	720
gggaagattg	gctactacct	ggtgctgggc	tggtgctgcg	tagccatctt	tgtgttcatg	780
atccggacgc	tgccgctgaa	gatcttggca	gacgcagcag	ctgagggggg	cccgggtcgt	840
ggggcccggg	accagctgcg	catgtacctg	accatggcgg	tggcgggcgg	gcagcctatg	900
ctcatgtact	ggctcacctt	ccacctggtg	cggtgagcgc	gcccgcctgaa	cctcccgcgt	960
ctgctgctgc	tgctgggggc	cactgtggcc	gccgaactca	tctcctgcct	gcaggcccca	1020
agggtccaccc	tgtctggcca	caggcaccgc	ctccatccca	tgtcccgcgc	agccccgcgc	1080
ccaacccaag	tgctgagag	atctccagct	gcacaggcca	ccgccccagg	gcgtggccgc	1140
tgttacagaa	acaataaacc	ctgatgggca	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	1200
aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa				1228

&lt;210&gt; 15

&lt;211&gt; 888

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 15

ggcacgagct	cccgtggcgt	gggagctaaa	gagaggctgg	tgaattaagg	aactttcagg	60
tttacttctc	agtgtgtctt	ctctgttcca	aaccacagtt	gtgaatggga	gagttcacat	120
ccgcgactgg	cgagaggaga	cactgtggaa	gacaaagcaa	ccggaagcga	aacagagact	180
gctctctgaa	gcctgcaaaa	cccgcctctg	ctggttcttc	atgcatcacc	ctgatggctg	240
cgctctgtcc	acggactgct	gcccgtttgc	ccatgggcct	gcggactgcg	gccaccccgg	300
accaccccga	ggaagaagat	ttcatgagct	gcatecttgc	cagccgaggc	ctggttgggg	360
aggccaaacc	aaggagagct	tccccagcag	tcgtcagtgc	tgtggtctct	gctctggctg	420
tgtttcagcc	cacctcctcc	cagctttctc	cacatcctca	cagtgatgaa	ccgtatttca	480
taaacatcac	acgccagaga	agccacagtt	actcggaagc	ccccagctga	ctgcctggct	540
tgtttcagat	gcagccgctt	gaaacgtgcg	cagcatcttc	atatcataaa	gatttgtcac	600
ggatccttac	aatgtctcct	gggggagagc	ggctgaggct	gccttgacaa	ggcccttccc	660
agggcgctgt	ccgacgcctg	ccccaccatg	tccacatctg	tgaagaggat	ggggctcctc	720
gagaagtaag	accgtatctg	ccagcgtttc	tcaccacact	ggagagcagc	tgctctggag	780
cagggatcca	ccagattggt	atttttaaaa	aaggtgtcag	gcttgctatg	ttgaggttgt	840

ttttagagtt acagagaata aaaacactca taatttcctg aaaaaaaa

888

<210> 16

<211> 3239

<212> DNA

<213> Homo sapiens

<400> 16

ggcacgagct	gtcttctgcc	tgcagtgtcc	aggagcttgt	gaagctgtct	aacgagctct	60
ttgcccgtt	tgacaagctg	gcagctaaat	accaccagct	gcggattaag	atcctgggctg	120
actgctacta	ctgcatctgc	ggcttgcccc	actaccggga	ggaccacgcc	gtctgtctcca	180
tcctcatggg	gctggccatg	gtggaggcca	tctcgatgt	gcgggagaag	accaagactg	240
gggtggacat	gcgtgtgggg	gtgcacacgg	gcaccgtgct	ggggggcgctc	ctgggccaga	300
agcgctggca	gtacgacgtg	tggctgactg	atgtcactgt	agccaacaag	atggaggccg	360
gcggcatccc	tgggcgcgtg	cacatctccc	agagcaccat	ggactgcctg	aaagggagtt	420
tgatgtggag	ccaggcgatg	ggggcagccg	ctgtgattac	ctagaagaga	agggattatga	480
aacctacctc	atcattgcct	ccaagccaga	ggtgaagaaa	acagccaccc	agaatggcct	540
caatggctcg	gccctgcccc	atggagcacc	agcttctcca	aagtccagct	cccctgccct	600
cattgagacc	aaggagcccc	acgggagtgc	ccacagcagt	gggtccacgt	cggagaagcc	660
caggagacag	gatgcccagg	ccgacaaccc	ctcatcccc	aaccacgcc	ggaggtgcg	720
ctgcaggac	ctggctgacc	gagtgggtga	tgcctctgaa	gatgagcacg	agctcaacca	780
gctgtctaac	gaggccctgc	ttgagcgaga	gtccgcccc	gtagttaaaga	agagaaacac	840
cttctctctg	tccatgcggt	tcatggaccc	cgagatggaa	acccgctact	cgggtggagaa	900
ggagaagcag	agtggggctg	ccttcagctg	ctcctgcgtc	gtcctgtctt	gcacggccct	960
ggctcgagata	ctcatcgacc	cctggcta	gacaaactat	gtgaccttca	tgggtggggga	1020
gattctgtct	ctcatcctga	ccatctgtct	cctggctgcc	atctttcccc	gggcctttcc	1080
taagaagctt	gtggccttct	caacttggat	tgaccggacc	cgctgggcca	ggaacacctg	1140
ggcatgctc	gccatcttca	tcctggtgat	ggcaaatgtc	gtggacatgc	tcagctgtct	1200
ccagtactac	acgggaccca	gcaatgcaac	ggcagggatg	gaaacggagg	gcagctgcct	1260
ggagaacccc	aagtattaca	actatgtggc	cgtgtgtctc	ctcatcgcca	ccatcatgct	1320
gggtgcaggtc	agccacatgg	tgaagctcac	gctcatgctg	ctcgtcgag	gcgccgtggc	1380
caccatcaac	ctctatgcct	ggcgtcccgt	ctttgatgaa	tacgaccaca	agcgttttcg	1440
ggagcacgac	ttacctatgg	tggccttaga	gcagatgcaa	ggattcaacc	ctgggctcaa	1500
tggcactgac	aggtgcccc	tgggtgcctt	caagtactct	atgacgggtga	tgggtgttct	1560
catgtgctc	agcttctact	acttctccg	ccactgtgaa	aaactggcac	ggacactttt	1620
cttgtggaag	attgaggtcc	acgaccagaa	ggaacgtgtc	tatgagatgc	gacgctggaa	1680
cgaggccttg	gtcaccaaca	tgttgcttga	gcacgtggca	cgccatttcc	tggggctcaa	1740
gaagagagat	gaggagctgt	atagccagac	gtatgatgag	attggagtca	tgtttgcctc	1800
cctgccccaa	tttgtgact	tctacacaga	ggagagcatc	aacaatggtg	gtattgagtg	1860
tctgcgtttc	ctcaatgaaa	tcactctaga	ttttgactct	ctcctggaca	atcccaagtt	1920
ccgggtgatc	accaagatca	aaaccattgg	cagcacgtat	atggcggctt	caggagtcac	1980
ccccgatgtc	aacaccaatg	gctttgccag	ctccaacaag	gaagacaagt	ccgagagaga	2040
gcgctggcag	cacctggctg	acctggccga	cttcgcgtg	gccatgaagg	atacgtcac	2100
caacatcaac	aaccagtctt	tcaataactt	catgtgtcgc	ataggcatga	acaaaggcgg	2160
ggttctggct	ggggctcatc	gagcccggaa	accacactac	gacatctggg	gcaatacagt	2220
caatgtagcc	agcaggatgg	agtccacggg	ggtcatgggc	aacattcagg	tggtagaaga	2280
aacccaagtc	atcctccgag	agtacggctt	ccgctttgtg	aggcgaggcc	ccatctttgt	2340
gaaggggaag	ggggagctgc	tgaccttctt	cttgaagggg	cgggataaag	tagccacctt	2400
ccccaatggc	ccctctgtca	cactgcccc	ccaggtgggtg	gacaactcct	gaatggcctc	2460
gaccttgcaa	cagtccaaac	cggaaaggag	aatttatctt	ttgaaactga	aggaagctcc	2520
gaccttcctg	gattgaagtg	cacactcatg	gactttaggt	ttagaaacct	cctcagcctt	2580
catttggttcg	tggatgtgtg	agctctgagg	gtggccctgc	tattcctgtg	tgtgcctgta	2640
gtgtccccag	cataggggtc	ttaggcatag	ggctgaacag	tccttcacga	gcccctcgtt	2700
caatccctgc	cgctccttgc	cctgaggggc	cctgaccact	gtgagcagga	gggtggcaga	2760
gctgggacaa	agctgccttt	gccgctgggc	tttccgggac	tgtggagggg	gcacaggcgg	2820
ggaagctcca	cttcagacag	ggcttggtgg	ggcaggacat	ggctcccat	ttgaagggag	2880
gtctccatgt	ggctccgagt	aggtgagacg	gccctcgtcc	tgggtgttct	gatcatcttg	2940

aaagggttctt	ctggaactcc	tgtcccctta	gtcatgagaa	cagaaagtgc	aatatttcct	3000
ttcacctggc	aggggagggg	ggatttattt	ctgaaagaaa	aatatataaa	cagatcttct	3060
acattttatat	ttttaatctt	ctgttaaata	cactttccga	tattgccttg	ccttttgagc	3120
tcttgctaca	gtcgcctttg	ctactgcttt	aagagaattt	acagggtattg	ataaagaaca	3180
agactgtttt	attaaaagct	ttattcaact	tgaaaaaaa	aaaaaaaaa	aaaaaaaaa	3239

&lt;210&gt; 17

&lt;211&gt; 954

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 17

ccacgcgtcc	ggttttgatt	catcattttt	atttgactca	ctagcagcca	tctgttagtt	60
acaattttaac	tttcaaggat	ctgcgttaatt	tgttttttgt	taatgaagtg	ctataaacag	120
cattatgaag	gtttttctctt	ttaatcttga	aaggaaaaaa	atccgtctct	aaaaaagcaa	180
tcacaaagaa	gaggaaaact	gtcataaagt	cacctactgt	accagagttt	caggtaaagt	240
tttcaacttt	gtctcgaaat	ttttcaattt	tttgtttcag	tgttcatatc	attcctcgag	300
agtttggctg	aattccaaga	aactgtagca	cacttacttg	taatgaaatg	tttctgacag	360
tgacttttct	ccctgcaagt	gcagatgtaa	ccaagattta	atctgctagt	atttcgtaat	420
ttttacctct	atttttgcct	tttaataata	aaaacccttt	tttatatctt	aatctctact	480
agtacatttc	ctagaagcag	tttaatagaa	atagtatata	tatactatat	agtatatgtg	540
tgtgtgtgtg	tatgtatata	tatataatac	ataaaagcaa	atgtgtgaat	gaaactcttc	600
caagaacaaa	tcataatttg	gagatggtaa	tagtgccctag	atagttcgtt	ttcattttatt	660
tgggcactgt	agaaataaat	ggtagattta	ttaacttggg	aaacaaatct	ttcaactctt	720
agctgtatat	gatcttcaga	gagaatatta	agtaaagggt	aattgaaatg	gtcttttaaac	780
atttctgtgg	aaagaaaaag	taattatctg	tactgccata	tgattaagtg	aagagttttt	840
tatttgtagc	taataactaag	cagagaatct	caccttaatt	aatgctttta	ttttctattt	900
tataaaagat	gtatttttctt	caataaacac	tttctttaaa	aaaaaaaaa	aaaa	954

&lt;210&gt; 18

&lt;211&gt; 330

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 18

ggcacgagcc	agcaccagcg	tcctagatgg	ccccagcacc	agctccacca	tccggaccag	60
aaatgctgcc	agagctggcg	ccagcttctt	ctcctggatc	cagcaccggt	gacgaactgc	120
agcgatctta	ctggccaagc	cagagcgctt	cctctcagat	tccttctcga	cacagcacc	180
taggcggctt	cttcctgtca	gtcggagggtg	gcatgcaaga	tgaagctctc	tttgctcttc	240
ctgctttcat	tttgtgcttt	tccttgtggt	ttcatgtttt	gggtatcagt	gttacattaa	300
agttgcacaaa	ttaaaaaaaa	aaaaaaaaaa				330

&lt;210&gt; 19

&lt;211&gt; 1964

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 19

ggcacgagaa	aagattcatt	tattgatttg	tgcttcaggt	ttaatttgaa	aacaaaaaca	60
ataggagaat	tggaggaaa	gaatgggagg	acagagtaca	tgtgttgga	tacctttgct	120
tagctctaga	ggataatgat	gcagatttag	atcaattatg	tagctgtgct	gaaatttccc	180
tcatttgagc	acctttaatg	tgaattatta	tgtgttcttg	ctggacttac	actgttacat	240
cattgtcaac	ttgcttagtg	tgctcagaaa	taaaattttc	atagctttcc	tctggacctt	300
gttttaaaag	gtaatatatt	gatccacttg	gagacaagag	gctggtaata	gaaatttggt	360
acttggtaac	aaaattgctg	aatgtgtgaa	ataagctttg	aaaaatatat	gttatggtta	420

aaatgttgga	agggcctcag	aattttcaca	gcagttattt	gtgtattttc	tttctaggtg	480
catgctatta	tgatgcta	cagtctatgt	atgtgtttgg	aggctgtacc	cagagcagct	540
gcaatgctgc	tttcaatgac	ctctggagac	ttgacctaaa	cagcaaagag	tgatccgac	600
ctttggcttc	aggttaagaga	tgaatgctg	atctttgcct	ccttaccagg	tgactccctt	660
ggcatggaaa	ctctacctga	tcatttttgg	tggttggtctc	aaggataggt	tactgggact	720
caggctcctta	agtttaatgt	gccatgtaaa	tgataatagt	aatatgcttg	tgtaagtctt	780
tgttttttgt	taaattatac	tttatcatta	gtaatgggtgc	cctgccaaaa	ttgctgtact	840
gctgtgtgaa	ttcatttgca	tggttttctc	aagtatactc	atacagggtgt	gatacatcat	900
ttggtagggag	ggtgaagtaa	gaacagaaac	acagagtcgt	gagaactgta	gttgactgac	960
agaagctatt	gtcctagggc	taaggctctc	gaatatctgt	tggtgttgcc	agctcagata	1020
tttggggag	gtatgggacg	tgctctgct	agttactctt	aacaaccag	gggtgtggga	1080
agattctaca	gtagggtacat	tcctaccag	tcccactatg	ccagaaatct	ggcagaaaga	1140
aactagatta	ttttcttatt	tttgacctaa	cctctcctgg	gggaaaaaat	aaaaacaatg	1200
gtttttgcac	tcagtaggca	gggcaatttg	aggaggcata	gattggaggg	gttgggtgtga	1260
tgagagaaata	gtgtccactg	agtataaagt	attctgctag	gttttttggc	aagcttttcc	1320
caaaacattc	atttggcttt	ttagtattag	gactcagctc	taggactaag	gacatttggg	1380
tttccattgg	gcaagttcct	tatttattta	ggccttgctc	tactactttg	attaccagat	1440
aggaggcatc	attgtatatt	agaaagggca	ctggactaag	agtgagggga	catgagtttc	1500
atctcctggc	atagtcacca	attctccatg	taactataaa	taagtatttg	cacttctctg	1560
ggagaaatgt	ggagtagtac	taaatgacta	tttttaaagt	ggctaaaaag	gctagtttat	1620
gtttcccttt	ctataaccgc	tactgtgaat	gtctaggcca	gggacttaaa	cctgtttatg	1680
agaagaagct	gcattttgct	tccctaaaac	ttaagtctct	gttctttccg	cctacattag	1740
gcaaatatag	ggaggccta	ctgagtggat	accatgggtg	gagctgggct	ttgtgtagat	1800
gaagttcttt	attaaaatta	ttggcatttg	gagggtagga	gggtgggtgt	ccagtctgca	1860
gatggccaca	ccaggaggag	gagctattat	atccccttct	cttcacttc	ctgtcacaac	1920
caataaaggc	cgtttgtg	attcataaaa	aaaaaaaaaa	aaaa		1964

&lt;210&gt; 20

&lt;211&gt; 1067

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 20

ggcacgagct	gaatgagggt	tttgattttg	aatgtttcaa	tgtttttgag	aagccttgct	60
tacattttat	ggtgtagtca	ttggaaatgg	aaaaatggca	ttatatatat	tatatatata	120
aatatatatt	atacatactc	tccttacttt	atttcagtta	ccatcccat	agaatttgac	180
aagaattgct	atgactgaaa	ggttttcgag	tcctaattaa	aactttattt	atggcagtat	240
tcataattag	cctgaaatgc	attctgtagg	taatctctga	gtttctggaa	tattttctta	300
gacttttttg	atgtgcagca	gcttacatgt	ctgaagttac	ttgaaggcat	cacttttaag	360
aaagcttaca	gttgggccct	gtaccatccc	aagtcctttg	tagctcctct	tgaacatgtt	420
tgccatactt	ttaaaagggt	agttgaataa	atagcatcac	cattctttgc	tgtggcacag	480
gttataaaact	taagtggagt	ttaccggcag	catcaaatgt	ttcagcttta	aaaaataaaa	540
gtagggtaca	agtttaatgt	ttagttctag	aaattttgtg	caatatgttc	ataacgatgg	600
ctgtgggtgc	cacaaagtgc	ctcgtttacc	tttaataact	gttaatgtgt	catgcattgca	660
gatggaagg	gtggaactgt	gcactaaagt	gggggcttta	actgtagtat	ttggcagagt	720
tgccctctac	ctgccagttc	aaaagtcca	cctgttttca	tatagaatat	atatactaaa	780
aaatttcagt	ctgttaaaca	gccttactct	gattcagcct	cttcagatac	tcttgtgctg	840
tgacgagtg	gctctgtgtg	taaatgctat	gcactgagga	tacacaaaaa	taccaatatg	900
atgtgtacag	gataatgcct	catcccaatc	agatgtccat	ttgttattgt	gtttgttaac	960
aaccctttat	ctcttagtgt	tataaaactc	acttaaaact	gattaaaagtc	tcattcttgt	1020
caaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaa		1067

&lt;210&gt; 21

&lt;211&gt; 874

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 21

ggcaccgagtt	tattagatat	atthttacta	agaaaagaaa	gcagagtga	gttgaagctg	60
atctgggcta	tccaggtgga	aaggcgaaag	tcatccataa	ggaatctgat	atgatcatgg	120
cattttctgt	taataaggca	aattgtaatg	aaattgtttt	ggcttcaaca	catgatgttc	180
aagaacttga	tggtacttct	ctactggcct	gtcagtcata	catatggatc	ggagaagaat	240
atgacagaga	atccaaaagt	tcagatgatg	ttgattatcg	tggttccact	acaactcttt	300
atcaaccag	tgcaacatcc	tattcagcaa	gtcaggtgca	tccaccttca	tctctgccat	360
ggctgggac	tggacagact	agcactggag	ctagtgtgct	tatgaaaagg	aatctacata	420
atggtaagag	aatgacttca	caccagtc	atcaatacta	tcttacaggt	gtcaggacg	480
gcagtgtacg	tatgtttgaa	tggacgcggc	ctcagcaact	tgtctgcttt	cgtaagctg	540
gcaatgcaag	agtactaga	ttatatttta	attcacaagg	caacaagtgt	ggtgttgagg	600
atggagaggg	ttttctgagt	atctggcaag	ttaaccaaac	tgcatacaat	cctaaacctt	660
atatgagttg	gcagtggcac	agtaaagcca	caagtgactt	tgcatttatt	acctcttcaa	720
gtctagttgc	cacatctgga	cactccaatg	acaatagaaa	tggttgcttc	tgggacacat	780
taatatcacc	cggaaacagc	ctcattcatg	gtttcacgtg	ccacgatcat	ggtgccacgg	840
tactgcagta	tgaccccaaa	cagcaactcc	taat			874

&lt;210&gt; 22

&lt;211&gt; 1346

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 22

ggcaccgagca	gcgggacagt	cagacaggca	tggccaatcc	ctttagggat	cctttcatca	60
attccctcaa	acaccgggtg	ctggtatatt	tgtggcgccg	ggcagaacag	gatggtagtg	120
caatggccaa	gaggcgcttc	ttccagtatt	ttgaccaact	gcggcagctg	cgaatgtgga	180
aatgacagct	tctggatgaa	aaccacctgt	ttatcaagta	cactagttag	gatgtagtaa	240
cactgagagt	cacagatcca	tcacaggcat	ctttctttgt	ggtgtacaat	atgggtgacga	300
cagaggtgat	tgctgtgttt	gagaatacat	cagatgagct	tttggagctc	tttgagaact	360
tctgtgacct	ttttcgtaat	gctaccctgc	acagtgaagt	tcagtttccc	tgctcagctt	420
ctagcaacaa	ttttgcaagg	cagatccagc	gccggttcaa	agacactatt	ataaatgcca	480
agtatggagg	gcacacagag	gcagtacgcc	ggctgctggg	tcagctcccc	atcagtgtc	540
agtcttacag	cgttaccctt	atctggattt	gtctctcttc	agttatgatg	acaagtgggt	600
atctgtcatg	gagcggccca	agacttgtgg	agatcaccca	atcaggttct	atgcccggga	660
ctcgggcctg	ctcaagtttg	agatccaggc	ggggttattg	ggccggccca	tcaaccacac	720
agtgcgacgc	cttgttgctt	tcacctttca	cccttttgag	cctttcgcta	tttctgtgca	780
gaggactaat	gctgagtatg	ttgtcaactt	ccatagcgca	cactgctgca	cgtagggtgcc	840
tcaccagagc	cagattatct	ggctttccaa	gactttgcca	ctcacttatc	tcagtggact	900
ccaaagcaaa	agctcccagc	tactagctct	gttagttcca	gcctgctata	cctcagatgg	960
gagagagcca	gagagaggag	tgagggtggc	tcaacctaat	ggaattttta	aattgtatac	1020
aatactgcta	ctgattgtta	taatactctc	ttgcgttttc	cctgtgggaa	tgcccagcat	1080
taattaagtc	catttcattt	ttgctttact	ttgcatttga	ttgctgtgaa	gatgaaagca	1140
ttagactttt	atcccccttca	tgtcacttct	tcggcattat	ggtttgcatc	tgaaagcagt	1200
taaactcttg	ttactgatga	gaatgacata	catcctttcc	atttagctca	taagcacggc	1260
tatcttttta	agagaaaaat	aaagccatgg	tattttcata	cttaaaaaaa	aaaaaaaaaa	1320
aaaaaaaaaa	aaaaaaaaaa	aaaaaa				1346

&lt;210&gt; 23

&lt;211&gt; 593

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 23

ggcaccgagcg	cgatagccag	ccgcggctgc	ccttgcgctt	cccagagctgg	cgggggtccgt	60
gggtcggggat	cgagattgcg	ggctatggcg	ccgaagtttt	tcgtcagtac	tgggatatcc	120

ccgatggcac	cgattgccac	cgaaaagcct	acagcaccac	cagtattgcc	agcgtcgctg	180
cctgaccgcc	gctgcctaca	gagtcacact	caatcctccg	ggcaccttcc	ttgaaggagt	240
ggctaagggt	ggacaatata	cgttcactgc	agctgctgtc	ggggccgtgt	ttggcctcac	300
cacctgcatc	agcgcccatg	tccgcgagaa	gcccgcagac	cccctgaact	acttcctcgg	360
tggtcgccgc	ggaggcctga	ctctgggagc	acgcacgcac	aactacggga	ttggcgccgc	420
cgctcgctg	tactttggca	tagcggcctc	cctggtcaag	atgggcccgc	tggagggctg	480
ggaggtggtt	gcaaaaccca	aggtgtgagc	cctgtgcctg	ccgggacctc	cagcctgcag	540
aatgcgtcca	gaaataaatt	ctgtgtctgt	gtgtgaaaaa	aaaaaaaaaa	aaa	593

&lt;210&gt; 24

&lt;211&gt; 1182

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 24

ggcacgagct	ttgactcagt	ttcttcatcc	attaaaaatgc	cagcttcatg	atgtggctgt	60
gaagattaaa	tgcaatcatg	tatgtaagga	gctttgcata	ctgcctgata	tgagataggc	120
attcaagaaa	tcattacatt	gaagaaattt	tcaattttcc	ttctcctata	aatccttgta	180
tgaatcgaa	atgagtgttg	agatgaacaa	aagacagcta	gttcaagggt	aaagggttgg	240
aatttgctta	caagatgagt	ctcttcttca	tttggcagct	gactaaattg	ttaaaagctc	300
agcctaattg	tacctttgcc	aggacatttt	aatgacacca	tttgtctctt	cagttcttaa	360
gcactttggg	gaaccagtag	aatacaaaagt	agaatgtctg	tgctttttac	cttactccta	420
catcatcttt	ctaaaattta	aatgtactat	cactaacctt	gttttgattt	agttgagggg	480
agaaaaaaag	cttaaacttt	actttcaggg	tctaattggc	taaagccatt	tttctttttc	540
tgtttccaat	acttttttaa	aaaaattata	agttagtaat	atctttctct	ctgtctacat	600
atgtgaactt	ggattttaaag	ctttctattt	ttttctctta	tatatgtctg	tagtaatcag	660
gttttctcat	tacgaagtgc	taatgaaacc	ttcagcttca	cactggaagc	ttctcaatta	720
ttggcattct	gggtgttttt	ctagacattt	gttggttcga	acgagttggc	cagtgtttgt	780
tgacagaatt	ttaactgcct	gaaaaatctg	tttcagtaac	cagatactca	gtcatctgtt	840
gggaaaatcc	cagtcgtatg	gagtaatcct	tccttctatt	ctatgtttta	taggtcaggc	900
ctaggtgaaa	gggctgggag	ttacaaaagg	ctgcctgttt	actaaggga	tatcagcctg	960
tcttcatttc	actgtttcct	ttcaggattt	caatgatgaa	ttctcagatc	tggatggagt	1020
ggttcaacaa	agaaggcaag	acatggaagg	atatagcagt	tctggttctc	aaactcctga	1080
atctgagaac	tctcgagggt	tgggaaattg	ttgtattttg	actaaaattt	aattcccctc	1140
aaaacatcct	cacccacccc	ccttaaaaaa	aaaaaaaaaa	aa		1182

&lt;210&gt; 25

&lt;211&gt; 876

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 25

ccacgcgtcc	ggaaaaaaag	tatggaaaag	gaatgttgac	cgagctttta	tgcttaagca	60
gcagatgaag	atagaaccaa	gatcactgaa	agcaagtgtt	tagaacagca	aaaagagtat	120
cccaacattt	cagcattgga	actacagaaa	gttttcagac	agaggggaag	ttaccaattt	180
taaatgctaa	gtaaagcatg	agattttgct	gcttgatctt	gcagatactg	accagattag	240
ttctaacaaa	atatggaagg	agtggcatat	gggtggaagaa	agaaggcagt	agctgctgtt	300
gtagttattc	atgttagcct	cagaggatgg	tgagacatcc	agatgaagag	gttgggtacgc	360
aattctagaa	ttgaggagggt	gtctagatag	agatataaat	tgtagtgaca	tcagtaaaga	420
gacaataaca	ggctttggaa	ggtgagtaag	aatgaaaagg	gaaggctctg	cacctaccct	480
gaagacatac	atttaaagga	actatagtag	agagataaga	ggaaaaacaag	aagagtggag	540
tttactgaa	ccaagacaaa	caagtttcaa	aaagggaagg	gaagttggcc	aggtgtgggtg	600
gttcacgcct	gtagtccctg	cactttggga	ggctgaggca	ggcggatcac	aaggtcagat	660
cgggaccatc	ctggccagca	tggtgaagcc	ctggttctac	tggaatgcaa	aaattggccg	720
ggtgtggtg	cgcgtgcctg	tggtcccagc	tgctcggggg	ctgaggcggg	ggagtcgctt	780
gggcccggga	ggcggagggt	gcggtggggg	gggctctcgc	cactgcactc	cagcctgggtg	840



acggagcagg acttcatctc aaaaaaaaaa aaaaaa

876

&lt;210&gt; 26

&lt;211&gt; 1365

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (2)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (7)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 26

cnctgtncgg	aaatctcttt	tgttgatty	acyaagactg	aaaataacca	cttgtaaaca	60
ttcctatgat	tgttactaaa	atgtattttc	atgttttaaaa	tgtttttggg	tatttttggg	120
ttaataaacta	ctacattgaa	ttgcatgtta	aggtgcagaa	ataatacatt	aaaagatttt	180
cacttttaat	taattagtaa	tattgagcgc	tcaccctgtg	cgtggccttg	tgctaaccat	240
tagcactgca	tcatttcaat	tcttttataa	gggcattcaa	tactacaaaa	tcaacatgat	300
ttcataaggt	gcaaataaaa	gttggtgaca	gatttaatat	aattttgatc	acaatttaca	360
aatgatcttt	gcaaataagt	gtcagacggc	attagttttt	cccttagtta	agctaaatta	420
aagggactcc	atcctgttat	gatttatatta	ttattattat	tattattatt	tttgagggtg	480
agtttcactc	ttgttgccca	agctggagt	caatggcgcg	atctcggctc	accacaacat	540
ccgcctcctg	ggttcaagcg	attctcctgc	ctcagcctcc	tgagttagctg	ggaatacagg	600
catgcgccac	tacacctggc	taatttttgt	atttttagtt	gagatgggg	ttttccacgt	660
tggtcaggct	ggtctcgaac	tcctgacctc	aggtgatccg	tccacctcag	cctcccaaag	720
agctgggatt	acaggtgtga	gctaccgcgc	ctggccatga	tgatattatt	aaacaccatt	780
attcacattt	caaataataa	caatactttt	tgtttttcaa	aaataaaatg	caatgttata	840
taaagctata	aactaagttc	tttatgat	ttgagcaaca	actcaggaat	ataacatata	900
agggagatgt	taattttaaaa	atttccacta	cacttattat	ctattaacca	aagcttaaaa	960
ttttgtattc	ttctgttaga	taagaccttt	taccatttta	atttgtcttt	aaggacagtc	1020
atttggcttc	tgaatgtttg	aaacgatttt	aaaaaataag	tagtgctatg	gttgtttcta	1080
taattctaac	ctttgatagt	aatcagaatg	tattacattt	catttctgaa	tagcttttga	1140
atttatgaaa	aattattaac	aatgaaaaat	tggttaatttt	attaagtatt	atgtgtttaa	1200
atatttatatt	agcttatttc	tcttgcat	atagtactgc	tgtttttgtt	ttgcttcttt	1260
atatttatgt	ctagctttta	tatgtaattt	atctagtgtt	tataaaatgt	gatttghtaat	1320
aaatgttggt	aaaatgaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaa		1365

&lt;210&gt; 27

&lt;211&gt; 1380

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 27

ggcacgagaa	acaattagcc	gagcgaggtg	gtgcacgcct	gtaatcccag	ctactggaga	60
tgcaaagggt	agccagggtg	gggtggtgcat	gcctgtaatc	ccagctactt	gggaggctga	120
ggcaggagaa	ttgcttaaac	ctgggaggtg	gagattgtgg	tgagctgaga	tcgtgccact	180
gcactccagc	ctgggagata	gaacgagact	tcctgttctg	ttgtttttcc	gttttgcata	240
aatatctcct	atgttcttgg	cttccttttc	gtcgccagg	tttcagcttt	ccttttagctc	300
ttcttcta	atggcttctg	cccacaaaag	cctgctctgt	caggatctca	tggttctcca	360
cttgccagaa	ccttcttcag	cctcagttcc	tcggcctcaa	cttgtacgtt	taacccattg	420
accaccaccc	cccaaattca	ccttcatttc	tttgacctg	ctcctcactc	cttttctggt	480

gaggaatctg	ttgactaact	ccaggctcac	tcaggctcac	cgctctgctc	tctgcaccag	540
cctttccaga	gcgtgccagt	tctcatggct	tcactgttaa	ctggtgatcg	cttcagtcct	600
gatttttaga	cctaaatggt	tcccttaacg	ccattctaac	tgcctgtgac	tcattttcac	660
ttacagtgtt	tattgtaacg	ccaaaccaac	aatcacagg	tgcttgcttc	tctccataaa	720
tctccccagt	ctaacttttt	gtcattcaac	atgactcgtt	tatccaacct	gaaatcgcat	780
atagcccaa	gtatgggtgtt	ttgtacacag	gtatttaata	agtgacttcc	agttttggct	840
ctgctatgaa	taaaaagaga	tttcagttct	cttcactttg	aaatctaaca	actcagagaa	900
cattgaagaa	attggaattt	agttgggatg	aaatacttgt	ggttttaa	atctctgttc	960
atattttcta	atttggtgcc	ggaggctctg	ggttttctat	ttgagtgtct	gcaaactcaa	1020
tgtgatttct	gtcagcatat	cttaggtttg	tttgttatga	aacttacgca	gtgtgaggtt	1080
ctatctgaaa	atgttattta	gctatcttct	gggactattt	aatgaaaagt	gggtcatgaa	1140
tccttaaaat	tcttggtgag	tttgagaaac	atctctgtta	tttggtgtac	agtttgtaag	1200
tgtggttaa	ccaagatgga	aacgagcact	ttgctttctt	ggttgtgtgt	actggtctaa	1260
cctgcttgaa	ctagtctgct	gtcctgtcaa	atgcatcttt	ttatttacat	gtcccttaaa	1320
ttaaagctga	tcatgaaagt	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	aaaaaaaaa	1380

&lt;210&gt; 28

&lt;211&gt; 1199

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 28

ggcacgagac	ccattggaga	tcttcaacct	ttaccgattc	aaaaggggga	aaagactttt	60
gttttgacac	cagaacttag	tcttgggaaa	cttcaggctc	taccttttga	gaaagcctca	120
gtatgtcatt	atcatggaat	tgaatattgc	ttggatgacc	gaaaagcttt	ggaaagagat	180
ggaggatttt	ctgaacttca	gtctcgtctt	attcgttatg	aaactcaaac	tacctgcacc	240
agagaaagt	ttccagtacc	tactgtgttg	agccctcttc	catctcctgt	agtttcgtca	300
gatcctggaa	gtgtccctga	cggagaagtt	ttacaaaatg	aacttcgaac	tgaagtatcc	360
cgactgaaac	ggagatctaa	agatctgaat	tgcttttatc	ccagaaaaag	acttgtgaaa	420
tctgaaagt	cagagtctct	tctttctcag	acaactggta	atagtaatca	ctatcatcat	480
catgtgacat	ccagaaagcc	acaaacagaa	cggtccttac	cagtgacttg	tccattgggt	540
ccaattccta	gctgtgaaac	tccaaaactt	gctacaaaga	ccagttcagg	tcaaaaaagt	600
atgcatgaat	caaaaacatc	aaggcaaat	aaggaaatcaa	gatcacagaa	acacacacgg	660
atactgaaag	aagtagttac	tgaacccttg	aagaaacaca	gtattaccga	gactcatgaa	720
tgtttcactg	catgcagcca	gcgtctcttt	gaaatctcta	agttctatct	aaaggtactt	780
aaaacttcaa	gggtgtctatt	tgaagaaatg	aagaaaacag	caaacaacaa	tgctgtacag	840
gtgattgact	gggtattaga	aaagacaagc	aagaaatgat	acataatcat	tctctttaag	900
acaattataa	attggatgga	gctattattc	actacttctt	ttcttagttt	gaaaattata	960
aacaaatttt	aagctttatt	caaagaatag	atgttatatt	tctaaagaat	ttcatgaata	1020
tatattctat	atttgatatag	tttgagggat	gctatgttaa	tgtattttta	attagatata	1080
tattttgtaa	agtgttacta	tattttaaag	ttatttttat	atgttttaaa	atgtttactc	1140
ttatttaatt	attacaataa	acagaatttt	ttttttttta	aaaaaaaaa	aaaaaaaaa	1199

&lt;210&gt; 29

&lt;211&gt; 1108

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 29

ggcacgagct	gggtgaaaag	tagaatataa	actcggtaga	cttctggtcc	cttcattgggt	60
catggaatgg	accagtgtct	gcttcattga	gcaacagttc	tggtgttcag	aattcctgga	120
tttcacctca	cttctgtctc	ccctgcaggt	gaatgtgatg	ttcatgtctg	ccattcttct	180
gacattcttc	cacctcttcc	tggtatatcg	ggaatgccgt	acttggaag	aaagtccttc	240
tgcaattgca	tagttcagaa	gccctcactt	ttcagccccg	aggatgggtt	tggtcatctt	300
ccaccacctt	tgaggacctc	gtgtcccaaa	agactttgcc	tatcccagca	aaacacacac	360
acacacacac	acacacacaa	aataaagaca	cacaaggacg	tctgcgcagc	aagaaaagaa	420

tctcagttgc	caagcagatt	gatatcacac	agactcaaag	caaaggcatg	tggaaacttct	480
ttattttcaaa	acagaagtgt	ctccttgac	ttagccttgg	cagacccttg	actccagggg	540
agatgacctg	ggggagggaag	tgtgtcaact	atctcttttag	gcctgttttg	ctccggagcc	600
tatatgtgcc	tggatccttg	cccacgggtt	aaatcttcag	gtgaagagtg	aggttgtcat	660
ggcctcagct	atgcttcctg	gctctccctc	aagagtgcag	ccttggttag	agaactcaca	720
gctctgggaa	aaagaggagc	agacagggtt	ccctgggccc	agtctcagcc	cagccactga	780
tgttgatga	ccttggcctg	accctggctc	ggcttcagaa	tcacttttcc	catctgtaaa	840
attgagatga	atcttgggtg	tgaaaagttc	tcctggagca	gatgtcctag	aagggttttag	900
gaatagtgc	agagtgcagg	cacccaagg	gccatgggag	ccagctgacc	tgcttgaccg	960
aaggatttct	gacagactat	ctttggggat	gttttcaaga	agggatataa	gttatttact	1020
ttgggcattt	aaaagaaaat	ttctctcggg	aataatttta	tagaaaaata	aagcttctgt	1080
gtctaaggca	aaaaaaaaaa	aaaaaaaaaa				1108

&lt;210&gt; 30

&lt;211&gt; 930

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (137)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 30

ggcagcagcc	aatctctggt	ttcagagatt	gttttattat	atgctttaag	tccacataaa	60
tgatctcata	ctgaatgtgt	cactgtagga	ttttttcttc	aaaattgtat	ttttgaactt	120
tctgtatata	tatatancct	taattttaac	cattttatga	attgtaaagt	ttatgtattt	180
ccccatctta	atatattatt	cccagttttt	tgattacaag	caatgtaatc	taaaagtaca	240
tttttgtag	gatttcttct	gtatatgtgc	aatattttgt	ctagggtata	tacctagaag	300
tggaaattgt	gttatagagt	gtgtgctttt	tcagctttac	cagatattgg	taaattgctg	360
tctgaagcaa	atgtagcagt	tcacactgct	gtctagaatt	ttctcatatc	cttattagat	420
tttgaattgt	cagaccctgc	gatttttact	cttatgatgg	ctgtgatatg	ctttttgttt	480
taatttgtag	ttcctttatt	atttatgggg	ataaatatat	ttccatgttt	aataagcatt	540
tggatttggt	cttctgtcaa	caacatatat	aaatctttgt	caccaaatac	gcttttttga	600
ggtatgactt	acatgtaata	aaatgtgcca	atcttgattg	taccattctc	tgagttttga	660
caaatgtatg	aaactatata	tccatcacca	caattgagtt	acaaaacatt	ttcagaatgc	720
caaaaaatgc	tccattgtgg	taactgtctt	ttccccatt	gaattaattg	tcttggtaca	780
atcgttgaaa	attggttgac	cacattatat	gtgaatgtgt	ttctggattc	tattattctc	840
ttgatctata	attatgcaa	taccacactg	tcttgattac	tgtaacttta	gaataaatct	900
tgaaagtaaa	aaaaaaaaaa	aaaaaaaaaa				930

&lt;210&gt; 31

&lt;211&gt; 2097

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 31

ggcagcagga	gagacacagc	aagccatcaa	ctatgggttaa	ttttgaaaaa	tggaaaagtt	60
ggattgggct	tacagtcagc	actcagttat	ttgcaagtgt	atttctttgc	ttttagagat	120
atttttattg	ggtgttaact	ttgacagctg	agagtgggct	tgcaagaaca	caatctaaaa	180
gtgtgtttca	attgagtatc	tctctagtag	aataggagtt	catcctgaaa	agctgtgact	240
cattaaccca	gtaaacatat	acaaagtaag	cttaaaacac	tataaacatg	agataaggga	300
aaatgaatcc	agagtcttca	tattaatagg	tagtgaaaca	ataaggcttt	ttagagcaga	360
ctttgttggc	ataaaataac	ctggcttcta	tccctaacc	tttctacct	ttctctccg	420
tcaacatgtc	ctcactactga	agacaaactt	gtttcaatga	tagtcttcat	tttcaaaaac	480
aaaaaggcag	gcagacagaa	ataatgatgt	tttcttgac	taagaaggta	ctacttgtac	540

acatatatca	aaacctcatt	ctgcaaagtt	tttgaagggt	tcaatgggaa	atttgatttt	600
attacaaaat	aaaacatttt	ttaatgttaa	agtttatata	ttccatgctt	gttttctcat	660
tacttggcat	ggatgatcag	gagctgccta	tatatgaagg	cagaatcaga	ctatcaggaa	720
aggagctggc	cagggccaca	gccagtcaag	atctctgagc	aacttagaga	cattgggtgc	780
attatatgaa	gcttgcattt	aatacattta	tacataatac	atttgtacat	ttaattcata	840
acgtctcttg	gtcacagatg	ccttatatat	aaaataagtt	gccagatctc	taagattgcc	900
tagtacacct	ttgtatctca	tttgatgtga	taccagaag	agatcattgt	ttttgttttt	960
gtttttgttt	tttcaagaag	atccttcgtg	atcaccatgc	tgttctcatg	gtaagaactg	1020
gagttatggt	tttaaatttg	gaaatatgac	attttatgta	gcactttata	aaaagtga	1080
gcgacaaaat	ccaccgctgc	ttaatactgc	tttgcttctt	tttattgaca	tgatagataa	1140
atatgtatct	acacagagta	ataataataa	accacagtaa	acattctatt	tctctatggg	1200
ctacagcatg	ccagtaaata	atatgtaggc	caataataaa	ttatcaatta	cacatttttg	1260
tgtaactaa	ttaaaagcat	agtgtataag	tgagtacact	ctaattaact	tgcttctggt	1320
gcactttagt	ttctacctg	catatggact	gcattttttt	ttttaacaca	gtcagtatgt	1380
agaatgggat	gtattcttct	gctgctgctt	attaaataaa	gaaagcctga	gtgttcttag	1440
atgggggttat	tctgagatga	gggtcttagc	ctacagttct	ttttgaaatg	aaagggtgctt	1500
tgttttttaa	ttatattcat	cttttcaggg	taaatttggt	tttctgagtt	tctcgtaatg	1560
ctcattttta	catgctgcta	ctagcttttt	tttttaaaaa	aagtaaaagt	tgctgctttc	1620
taaaatatta	attgccttat	atttgaaagt	gccattgcaa	tcgtaagtag	actatgtatt	1680
tcctataatg	atgtctgata	tttaaatagg	aaatcagaca	aacaatattc	agaaagttta	1740
agcatataaa	ctttttattt	ttaacttgcc	taaatccctg	tattccaaaa	cctgctgcat	1800
cataataaat	atatctatat	atatttagca	taagacgtga	tatttttaat	ttctttttta	1860
aaaaattata	tttgtctctt	agagttaaaa	ttttctttat	ataatattgt	catatgtcat	1920
agttttaata	caattcacat	gatttctatg	tttcttaatg	atattttgtt	gtgtaaaatt	1980
gatcggaattg	attaaaaaac	aaattctctg	gaatttggtg	gttcatgctt	tttcgtattc	2040
tttatggctt	ttaaataaat	atacaatggg	taatagtaaa	aaaaaaaaaa	aaaaaaa	2097

&lt;210&gt; 32

&lt;211&gt; 1302

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 32

ggcacgagat	atgtacacat	ttatgtgtgg	gtgtacaaca	tttttctgtg	atttatatggg	60
tagttttgaa	agaatatact	tatgagccag	agcaagaaat	tggaaaccaat	atgtgtagag	120
gttattgctt	ttctctgctt	agtgtgtctt	ggaaaaaagt	tctttacagg	taaaataattt	180
taaataccaa	taccttagt	atggatcagc	aaattagggg	ctctgagaag	tcctttcatt	240
acaagagttg	tttagctttg	atttattggt	ttctaaactt	atttgagctg	ggatgctttt	300
tcagagcaga	cacattctag	tatattcttg	ttttatctgc	actatagata	tgtattgtta	360
cataccttca	gcttggcaag	gcagactaat	aatcttaagg	aggttccaag	acttcccttg	420
gtttaatgag	aacattcaaa	agggtcaggc	atagggttaag	gtatgtttga	ggacttgaat	480
atctattaag	aatagacaaa	ggattataat	gtggtagaag	agtttagcat	tcatagtctg	540
tatagatcaa	actgtcaaaa	cttctcaggt	cacatgatgg	cccttaaacc	aggtaatttc	600
tgtgtaacgt	aagccatggt	taaaattgct	ttttcttga	caactattca	gaagtatatg	660
tatgataaac	attttttgag	tgcttagtac	ctactagtct	tacatattct	gtggattact	720
ccacataaaa	tctataataa	aatccacaga	aagctgttaa	aatctttcct	attttttttt	780
gactcaactt	tccatcccc	gaaatcactc	acaagctgag	tttggttaata	ggctctcaat	840
attttatttc	ttatattctg	gccttgtttt	tagtatttct	taagggtgatt	ttaataataa	900
ttaattgtat	atgttttact	gtactagact	tagtaaaaca	taagaaagac	gtataacata	960
gttgaacaac	tttaagttgc	tctaagaagt	ttctattttg	aggctgggtg	ccatgggtca	1020
cgcttataat	cccagcactt	tgggagaccg	agatgggcgt	atcacttgag	atcaggaggt	1080
caagaccagc	ctggccaacc	aaccccatct	ctactaaaat	acaaacatta	gccgggcatg	1140
gtggcacatg	cctgtaatcc	cagctactca	ggaggctgag	gaaggagaat	tgcttgaaca	1200
caaagggtgga	ggttgcagtg	agccaagatc	gcaccactgc	actccagcct	gggtgacaga	1260
gcgagactcc	tgctctcaaa	acaaaaacaa	acaaaaaaaa	aa		1302

<210> 33  
 <211> 963  
 <212> DNA  
 <213> Homo sapiens

<400> 33  
 ggcacgagag aatttcacaa tatgcttaca gttaaatttt cctagcttgt tgaaatgttc 60  
 aattctttgt tggctttctt cttgattctg tgggggtgta taacaagcct gaaggacatt 120  
 gtaatcattt cttacaaggt gaaaattaag aaagattgtg tatgagagcc tatatagttg 180  
 ttttatccat tatcatcttt gattaagact ttaaaaaaat gctatttcca gttaatgcat 240  
 ttggccctat tgaattttca gggaccagaa aacattaaaa agttctgcat cttataatgg 300  
 taaccaatta agcttgagat tgttctgaaa gtatcaattg ctttaaaact gttgtaagta 360  
 cagttggcaa gatctccaag ctgaaactta cacgttaaaa cttttgcctg taagaatttg 420  
 cacatgaatg ttaatggaaa acacaaaact taagatggcc caaaacaaaa gccacaaaca 480  
 gtcatcattt tgggtcttag tctttgtaag ggctctctgt ggtttgactt actccagcta 540  
 ccgttaaatg agggcaaata accttaaaac atgttcattt gattcataac aaggaaaatt 600  
 ggggtctatga ttttttgcca atcttagcct aaaagaaatt gctttagctt ctggtcagca 660  
 ctgattaaaa tgtgaatagt gaagtggcta tcctaaactg gtttatctcc acccacacta 720  
 tcatagattt cttaggtaaa tacaattctt atctagtggg attctacttg tattcagaat 780  
 actgtattaa aattttacta tttcattttt gtattctgtg cttatttttt ttgtcacgca 840  
 tgtatgctta gtataaatgt gtcacttcta aagttttgtc tctgactttt agaaataaat 900  
 ttcagaaaaa ttgtttcaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 960  
 aaa 963

<210> 34  
 <211> 750  
 <212> DNA  
 <213> Homo sapiens

<400> 34  
 ggcacgagtt tcaacatgag actaatccag ggtgggtgaca tgccgggtctt tgtagttctt 60  
 gcttcggggg taatgagggg caggaaagag ttccttagac tcctgcatgg catcatgaat 120  
 gctgctgttc ttcttacctt gggttttttc ctctcctctt accttttcta ccttggtgtg 180  
 ctgggatcag atcctgctta tcttccactt ctttaagaaa gctgacatag aagacacatt 240  
 gggactataa cagggtctgg tctctctctt cactcccact agacacatgc tgcagtacat 300  
 cagagagttt gtcaccagt aagcaggctc ctcggaagtc cccctccgac actgagggtc 360  
 ttgtaaaagag tctgccttct ggatctcacc agggcccagt catatatgca cagttagacc 420  
 actccggcgg acatcacagt gacaagatta acaagtcaga gtctgtgggtg tatgcgata 480  
 tccgaaagaa ttaagagaat acctagaaca tctctcagc aagaaacaaa accaaactgg 540  
 actctcgtgc agaaaatgta gccattacc acatgtagcc ttggagaccc aggcaaggac 600  
 aagtacacgt gtactcacag agggagagaa agatgtgtac aaaggatatg tataaatatt 660  
 ctatttagtc atcctgatat gaggagccag tgttgcatga tgaaaagatg gtatgattct 720  
 acatatgtaa aaaaaaaaaa aaaaaaaaaa 750

<210> 35  
 <211> 2043  
 <212> DNA  
 <213> Homo sapiens

<400> 35  
 ggcacgagta gtacagacgt gttaaattctt ccaccccgac ccgcacacac acccacactg 60  
 ctgccctggc gggggccatg ggggtgatga atgacctcc aacagcccca catgggttgt 120  
 ttctgtttct ttggcttttc tcgctccgca gtggagggtt tactaggatt taagcttttg 180  
 agtgcattga gaaccaagac agggcctggc tccaactctg tgggccaagag gtgggggact 240  
 gctagggtcga gtctgcagct tcgccagttt cttggttggg acactcctct ggcagcccca 300  
 gcaccaccac aaccccttgc agtgtgcccc agtccccctg attcgctgga ctgcaaaaaag 360

gagcaccagg	gaaagctcag	caaaggctca	ggaggcctcc	cgggtcctcg	ggagatgaag	420
catccgtgcc	taggaaaagg	ggacagaggg	caaggagaga	agtgaagct	acaattccag	480
cattggagaa	gcgagggg	gggcgtcaaa	ggcactgctt	caggacgcgc	ttgctgaaac	540
gactccaaca	gctagttcac	agcccagctt	gtacgttggg	taccatagct	actgctgtca	600
ctgtagctgc	ttccgtaggg	tcgttgattc	ctgaacgtat	cacatctcac	ctgccccctt	660
cctcgtaggg	cgtgtcaagt	tgactttaaa	gcctaagggtg	gcttgtgggg	actgcaccag	720
aaagtgtcta	accttgtgtt	ccccgaaatc	ctttctctga	cttaggaacc	agcgcctcct	780
gctggagaag	ttttttcatt	ttgttagccg	acttctggta	gcttagcaaa	gagaccagct	840
gactgtctct	cggcccagcc	caccacgccc	agtagcttgt	gtggatgcag	tcctgtgagg	900
gtgtgcataa	ccgttcccag	gtgtacgcac	gcgcgcgcgc	gcgcacagac	acacacacac	960
acacacacac	acacacacac	agtaaccacg	ggtaggcacc	aggggctttg	tacattcagg	1020
agctgcagag	aggaaaaggtc	tcccatgtac	cagagaagga	aaagtctgat	cccgaaacag	1080
cttgaacgaa	aggtgggttaa	cacgtgacca	atccccatgg	cagacagcgg	gctgggtgaac	1140
aggaagagca	cagaatctct	gtggggcgat	gctgcagcgg	ctgaaaccac	gtcaagtccc	1200
ccagagcccg	gcattctatg	taagcatcca	cctgtgacgc	cgtggagcag	gatcttcatt	1260
catctcacca	gagcaacagc	ccagtccctga	ggatgggagg	gacgtgactt	agccttggga	1320
ttccacgctc	gccgccctcc	cttgccgcgc	ctactcccca	gtttcctggc	gatgagccat	1380
ttattgtgtc	tcacaccagc	ctcatttcca	actccgactt	cctacttaga	atgtggcagt	1440
ggctttgtga	gtgagaatcc	tgatgagttt	tccagtggcc	tctgcagaag	ctggccccct	1500
tctaagggca	tagctaacc	ccttcccact	cctgagtcac	tgaattcgag	gaggggtgggg	1560
cagggaaaagg	gctggccccc	ctgctgaaat	cttgattctg	catttgagga	aggtcagggg	1620
gccgctgggg	gagcagggag	cggggaggga	ggaagagggg	aatgcacatc	ttttgcgcca	1680
ctattaaggc	acctgtcacc	ttacatctca	atctggaatc	aaagtgcctt	gggttgagaa	1740
gcagacctgg	gctctggtca	cactttggtc	actcattagc	tctaggacca	gtcactaatc	1800
tctgagactc	cattttctcc	agggaaacga	ggcttgccca	gatagactaa	caacccttta	1860
gtgctccaag	aagtgagaat	ttccgaaaaa	gatctgccgg	cccagagcac	tccctcttgc	1920
cctaactctg	gcaggggtctg	gatgtattta	ccaactctga	tcttgcgtgc	agggatgctt	1980
gctgatggat	gaaagaccac	aataaaaaca	gattagcagc	aaaacaaaaa	aaaaaaaaaa	2040
aaa						2043

&lt;210&gt; 36

&lt;211&gt; 1252

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 36

tttttttttt	ttttttttca	atgtttcatt	ggcatgatg	atcaaaaaat	gatgggtcac	60
acacacacac	agacctcacc	ccacctgctg	cagggtggaa	gcaacaccac	tggtactcac	120
acccccctcg	gctgggttct	ctgggtgcgc	ctgcagccgc	tgccccaccc	aggactctgt	180
ccttcaccct	gaagttctac	cgccctgggt	ttcatctctc	ctcaacatgg	tgccctggagg	240
ctcaatgtcc	aggtagagat	gtgaaaatca	gatctgcgcc	gggcagggtt	gcaatgtcct	300
tgagttcttc	tccatctccc	tttcccaaac	tctctcctct	cccctctccc	accccgctat	360
tgttccccgg	aaacaaatag	gatggcttca	ctgggtcaatt	cttaacatgt	acaaacacca	420
aaagcagagg	aaacgcccc	tggtccacccc	cctcccccca	aacccagtg	ctgggagcgc	480
accggcgggc	gaggctgcct	ggaacgtgga	gctgctggag	ctgtccggct	gacctggaaa	540
gttctttggc	ctctaggctt	tacctggagg	cctcttcctt	cagctccttg	tttttccgca	600
cctcctcggc	gtgcttgtcc	ttctcttgca	gccgttccaa	catggcgggc	aggtgggcct	660
ccctgttctc	cttggttggat	tccatcttct	gggccagttt	ttccttagcc	atcttgatga	720
agttgttgtt	tccatcaatg	ccttttggat	cacctctctc	tcattgtccc	gtttctctgc	780
taggtgttct	aggagctccg	cttccctgga	cttcccttgc	tcctcagccg	cttctagttt	840
cttctggatc	tcttccagg	atgggtctcg	cgccttggc	agggagcggt	tgaactcggg	900
aaccccatca	aaggagggtg	gcttcaggat	gacttcaaa	gattggcccg	aggtgcattt	960
gttcagctcg	atgacttcca	tgctcgaaat	gacgcaccaa	ttcagggtcca	ccgtgtctgc	1020
ttcatatttg	taggacgact	tattcagggg	atcgccagg	aagcaggagc	agaacaagga	1080
caccagcggg	agctccttca	tcttctcttt	gtaggcagca	aggggtcatgt	ttctgggatc	1140
tggtggctga	atctagctga	aagttacaga	gtgggtctgt	caccagcttg	ggacgctgtc	1200
accaacgtgc	agtcagttta	gaagcgagct	gctctcttcc	tcacctcgtg	cc	1252

<210> 37  
 <211> 1650  
 <212> DNA  
 <213> Homo sapiens

<400> 37  
 ggcacgaggt tcttgcctcg cttgaggaga agcgccaagt gcgcatgggg acgctatagc 60  
 aattcgtttg ctgtccttcc tctccttcga agatgacaag gcctaccatc gtttcttcct 120  
 gcctttgggc cgtcaggcag ttggttggga cccgctccaa ccctcggttc ttcctgcaat 180  
 acagtggata caatttgtca tggctactct gagtgttata gggtcaagtt cacttattgc 240  
 ctatgctgta ttccataata tacagaaatc tccagagata agaccacttt tttatctgag 300  
 cttctgtgac ctgtccttgg gactttgctg gctcacggag acacttctct atggagcttc 360  
 agtagcaaat aaggacatca tctgctataa cctacaagca gttggacagg ggagacgggg 420  
 tttcgccatg tttgccaggc tggctctgaa tgctgacct caagtgattc accgcttggg 480  
 cctcccaaag tgctgggatt acagggtgtga gccactgcac ctggcctcct taaatgtatc 540  
 tttatggcct aattttcacc tttgcaccca gttgatattc tacatttcct catttctcta 600  
 caccgtcaat tacatctggt atttgtacac agagctgagg atgaaacaca cccagagtgg 660  
 acagagcaca tctccactgg tgatagatta tacttgtcga gttgggtcaaa tggcctttgt 720  
 tttctcaagc ctgatacctc tgctattgat gacacctgta ttctgtctgg gaaatactag 780  
 tgaatgtttc caaaacttca gtcagagcca caagtcttac ttatccgagc ccagacattg 840  
 tataagaagt ttgtgaagtc aactggcttt ctggggagtg aacagtgggc agtgattcac 900  
 attgtggacc aacgggtgcg cttctaccca gtggccttct tttgctgctg gggcccagac 960  
 gtgtgtggag gaacctgata cttcagacag tcagggtgta caagaagggt tacactttgt 1020  
 gtattcacag ctgtcattct aatgatcata aagctgacta agccacagga caccaagctt 1080  
 cacatggccc tttatgttct ccaggctcta acggcaacat ctcagggtct actcaactgt 1140  
 ggagtatatg gctggacgca gcacaaattc caccaactaa agcaggaggc tcggcgatgat 1200  
 gcagataccc agacaccatt attatgctca cagaagagat tctatagcag gggcttaaat 1260  
 tcactggaat ccaccctgac tttccttggc agtacttcta ccattttttg aaactacaat 1320  
 actggaacat ccaggaaactg gagttattct acgctaattg attggaaaga atgttgggaa 1380  
 aggacatctt aaatcttttc taactatgcc cttaaactgca gaactcaaag gaaatatagt 1440  
 gccattgtta gtagtcattc tagatgaatt gggagtatct ctccagtat tcccagattc 1500  
 actagtgatc cttaaagtct ctattcaggg agagggaagac actttccatc tcagagatag 1560  
 actcgtgtta ccttgatgga tattggattt gtctaagtct cttctagaaa aaataaattc 1620  
 tagattatta aaaaaaaaaa aaaaaaaaaa 1650

<210> 38  
 <211> 1046  
 <212> DNA  
 <213> Homo sapiens

<400> 38  
 ggcacgagct tatttgttgc tagtggcaat gtcagctact actgacaaca ttatttgaaa 60  
 ggcaatagtg tgtatcagga cctttaaaaat atatggacat atttatcctt taagtctaac 120  
 cttcatcctt tcttcataag ttttacaaat actgtatgca tttctgtggg aggttaagtga 180  
 taaacttact aagcttaaaa tgaacagaat cttagatgag gtttcttttc attttctgtt 240  
 ttttaagagga gttgcttttg tttggcctct aaacaagaag agcacaaatc ttgctgccta 300  
 cacagttgat atttggaact attctagtgg ttctatttaa ttttcaaaac cgggttatga 360  
 aatggagaat taaccacttt ttacagataa ggaacaaga ttagaagtat tttacatgtg 420  
 gttttagaag ggtgtttact gaatgaactg ttttataaga tgtattactg ctggctctat 480  
 gttttattat catactgtac ccttgggtga aatcaacctt agaaactctt ttgtatttaa 540  
 aaatggaaat aattactgtg cctttgaatt gaagtaactc acaaaagaaa tgtggtccag 600  
 actttagact ttgttgggac tgtgatgatc atttctggct tttggcaatc tggatctgaa 660  
 cctttgggtt tatttagctt tccagtcttc agggaaacat agaaaccagt cttcaggata 720  
 tcgacagcag attatctcca ggtggatcac tggcagacgc atgggcacat caagaaggca 780  
 ctcacccgaa agacagaaat gtagaaaaac tacaagtctt gttaaattgc atgacagaga 840

tttactatca	gttcaaaaaa	gacaaagcag	aacgtagtaa	gtaaaatttg	ctatttggtta	900
atttaataaa	tccctccttag	taattagtta	taattcagtt	aaattaattt	ggtatatctg	960
taagggtagc	ttcttaagct	gtttttttca	gagatgtgat	tctgtcagga	aaaagggtga	1020
ttgtgtttta	aaaaaaaaaa	aaaaaa				1046

&lt;210&gt; 39

&lt;211&gt; 1276

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 39

ggcagcagtt	tccgttccag	gatcttgagt	acagacatat	gtgggttttat	tgcactttg	60
tttatcatgc	tttgcagata	ttgtgttttt	tacaaattga	agatttttga	caatcctatg	120
tcaagcaagt	ctattgggtgc	cattgttcca	acagaatgtg	ctcacttttt	gtcacatttt	180
ggtaattctg	aaatatttca	aaagtattta	ttaatctgtt	atgggtgatct	gtgggtctttg	240
atgttaatat	tgtaattggt	tgggagcaca	acaaaccatg	cccatgtagg	ttgcaaactt	300
agttggtaaa	tgttgtgtgt	aatagttgct	acaccaacca	gctgttcccc	aatcactctc	360
cctctcctta	ggcctcccta	ttccttgaga	caaaataata	ctgaaattag	gcaaattcac	420
aaccctataa	tggcttctaa	ctgttcaagt	gtaaggaaga	gtcacacatc	tttactttta	480
aacaaaaacc	tagaaaggat	tgagcttaat	aaagaaggca	tgtcaaaagc	tgagataggc	540
caatagctag	gcctcttggt	ccagttagcc	aagttgtgaa	tgcaaaggaa	aagtccttga	600
agaaaactag	aactacttta	gcgaatacac	aaatgataag	atagtgtgac	attctaattg	660
ctgatatgga	gaaagtttta	gtagtctgga	taggagatca	gccacaacat	tctcttaagc	720
caaagctaac	tctcttcaat	tctatgaaag	cttagagggtg	aggaagctgc	agaagaaaag	780
ttggaacctg	gcagagggtg	gttcatgagg	tttaaggaaa	gaagccatcc	tcatagcata	840
aaagtgcag	gtgggtgcagc	aaatactgat	gtagaagctg	cagcaagtta	tccagaagat	900
ctagctaaga	ttattgatga	aggtggctac	actaaacaag	agattttcag	tgttgacaaa	960
agggttttct	tttgaagaa	gatgccatct	tggctttgaa	tagctggaga	gaataaggaa	1020
atgactgact	tcaagggaca	ggctatcttg	ttaggggcta	atgcagcagg	tgaccttaag	1080
tcgaagccca	tgctcattta	ccattctgaa	aatcttaggg	cccttaagaa	ttatattaaa	1140
tctatcctgc	ctgtgcttta	taaatagaac	aactaagcct	ggatgccagc	acatctgttt	1200
atagcatgat	ttactgaaga	ttttaagtcc	actgttgaga	cttactgctc	aaaaactaaa	1260
aaaaaaaaaa	aaaaaa					1276

&lt;210&gt; 40

&lt;211&gt; 2329

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 40

gtgtgaagtt	cctaaacatg	tctcttccac	tctttgtcta	aactttgtaa	cgtagatgca	60
gctgactttg	cctgtagcct	catagaaccc	atcccatggc	tgcagtggaa	gcttgcggtg	120
gctctccagt	gaccagaggc	atagttaggt	cccaggagg	ctccctctgt	cttgcaacag	180
ttattttgtga	tctttttcta	tgtgcctatt	gtcacacacag	agtccggcag	cgtcttctct	240
tgagggagca	atttgagaa	gagctggaac	ccagactcgc	gccctggatg	ccatccttta	300
tcatccacag	caatcccatc	tggttgggag	cactgctctg	ggtctcacac	tgccctcct	360
ctatcctagg	gagcctgagg	cccaggggtg	gaaagatcca	gttgcggtg	gggggtagt	420
aaccgcgcag	gataatgaaa	gcaacttgct	ttggaaatga	cctaccgcta	cccgttgtct	480
gagactgaga	ttatctcaga	ctgtcttctg	gcttctgcca	aaacactccc	ttaacagaaa	540
gcaccgagg	gatgggggta	gggggggttg	ggagagttag	gcttgagtgt	gaaggaaagc	600
tcatatatgc	agagctgaaa	tctccctctt	tgtatgtcca	cacttttgct	ttgttctcta	660
gactgattct	tgtatttcca	aatcctcttc	cacgttgaca	gcccttcaga	tatttcaaca	720
ctcctctcag	catcctccaa	gctgaacttg	gttcacagg	tgggattgtg	tatgtgcatg	780
caggagggtg	gggtggacag	tgccctgggc	tggaaatccc	cttagttcta	agtgcctcct	840
tgcccgcagc	ttcgagagct	gtgcccagga	gtgaacaacc	agccctacct	ctgtgagagt	900
ggctcactgct	gcggggagac	tggctgctgc	acctactact	atgagctctg	gtgggtctg	960



ctgctctgga	ctgtcctcat	cctcttttagc	tgctgtttgcg	ccttccgccca	ccgacgagct	1020
aaactcaggc	tgcaacaaca	gcagcggcag	cgtgaaatca	acttggtggc	ctatcatggg	1080
gcatgccatg	gggctggtcc	tttcctacc	ggttcactgc	ttgaccttcg	cttcctcagc	1140
accttcaagc	ccccagccta	cgaggatgtg	gttcaccggg	cagtttaccc	cagttacccc	1200
ccttatactg	tggccccagg	ccgccccttg	actgcttcca	gtgaacaacc	ggctggcggt	1260
agaggaggct	gtggctcctca	gggggctgta	ggtggaggta	tggctcgggc	cagcagcggg	1320
aacggcagcg	aggaggcctg	gggggcactt	cgggcgcgcg	aacagcagct	tcgagagctg	1380
tgcccaggag	tgaacaacca	gccctacctc	tgtgagagt	gtcactgctg	cggggagact	1440
ggctgctgca	cctactacta	tgagctctgg	tggttctggc	tgctctggac	tgtcctcatc	1500
ctcttttagct	gctgttgcg	cttccgccac	cgacgaagct	aaactcaggc	tgcaacaaca	1560
gcagcggcag	cgtgaaatca	acttggtggc	ctatcatggg	gcatgccatg	gggctggtcc	1620
tttcctacc	ggttcactgc	ttgaccttcg	cttcctcagc	accttcaagc	ccccagccta	1680
cgaggatgtg	gttcaccgcc	caggcacacc	acccccccct	tatactgtgg	ccccaggccg	1740
ccccttgact	gcttcagtg	aacaaacctg	ctgttctctc	tcattccagct	gccctgcccc	1800
ctttgaagga	acaaatgtgg	aagggtgttc	ctcccaccag	agtgcctccc	ctcatcagga	1860
gggtgagccc	ggggcagggg	tgacccctgc	ctcccacccc	ccctcctgcc	gctatcgccg	1920
tttaactggc	gactccggta	ttgagctctg	cccttgctct	gcctccgggtg	aggggtgagcc	1980
agtcaaggag	gtgaggggta	gtgccaccct	gccagatctg	gaggactact	ccccgtgtgc	2040
actaccccc	gagctctgtac	cgcagatctt	tcccatgggg	ctgtcttcca	gtgaagggga	2100
catcccataa	gtagttttga	gaggggtgat	gggttacttg	cccaccagaa	acagccctag	2160
tcccaactcc	ttgcgttctt	ttggcccctc	cctgcctacc	tagaatctgc	ctgaaagggc	2220
tggagagggg	cagtattggg	ggactgtgct	agctttaccc	ccgcaggaca	tacacaggag	2280
cctttgatct	cattaaagag	atgtgaacca	aaaaaaaaa	aaaaaaaaa		2329

&lt;210&gt; 41

&lt;211&gt; 1069

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 41

gcttttgctt	tctttcaaac	tttctccttc	acagattttt	ctttattaat	cagaatcata	60
ctgaccaaca	tgtgctgagg	actttctgtg	tgctctgtgc	ttcacataca	gtcatgtgca	120
tctttccagt	tcacaagtt	agttatcttc	atttctcggg	gccatagagc	tagtgagtga	180
cagagctagg	ttttgtatgt	caaagcctct	gtcctacatg	acatggcttt	tcctgctgcc	240
ttctccccctg	gtattcgtct	ccctcttttc	tcctctggct	ctgcctggct	ctcctctggc	300
tctgccgagg	gggtggtttt	cagcctgggc	ccttgcatag	gtgtctgtgg	cagcaggcca	360
cacagaccgc	agcgggctgg	gcagcgtcct	gagagaccta	gtgaagccag	gcgacgagaa	420
ccttcgggag	atgaacaaga	agctgcagaa	catgctggag	gagcagctca	ccaagaatat	480
gcacttgcac	aaggatatgg	aagttctgtc	ccaggaaatt	gtgcggctca	gcaaggagtg	540
cgtggggcct	cctgacccag	acctagagcc	aggagaaacc	agctaaagac	ctgcaggctg	600
cacccacctc	ctcccccttc	taccccttag	gatgctattc	ccttgggctg	tgggtggaaaa	660
atgagggctg	gagccaaaat	caaatagctt	gggagactgg	acattaaagg	ggctagaggc	720
ctgatgggta	gtgttaatga	tcctgtctta	gggcagaggc	caccagggag	tggggatcct	780
gaggggaagg	gcagggattt	ctccttcttc	ttggtcctgg	ctcccaagg	cttctgtctt	840
catctctgca	tgagctctcc	ttcccagaga	ccaactcttt	tttattttat	tttattttat	900
tttttaattt	atgtctggag	cctggctact	ctgcatttgg	gattggggat	gctgggtggg	960
tgtgtggtcc	atgttcagcg	ttctagcaac	acgtgtgtgt	gtgtgtgtgt	aaaggctatg	1020
cagccaaaat	accatctggc	cagacgggcc	caaaaaaaaa	aaaaaaaaa		1069

&lt;210&gt; 42

&lt;211&gt; 1425

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 42

ggcacgagaa	tttgaggaga	tataaagtac	aggaatggga	tctcagtaca	atgctgtcca	60
------------	------------	------------	------------	------------	------------	----

cctggtggtg	actttttctaa	gcactgtggt	atattggggac	cttaggggctt	tctttgtgaa	120
tatgtatggt	cattgttaaat	atcttgattc	tttgcttctt	attgacaagt	gatgattata	180
attcaatgga	caacctgaat	cttgagggaa	gggaagaaga	tgctgaactc	tctgttaatt	240
tagcataaaa	cttgactttt	tgtattctag	aaattcaagt	ctatacaggt	ataataaagc	300
aaaaatatgt	aattttatggt	gcttctctca	atacattagg	taatttagtt	tgaaaaaaaa	360
ctacctttta	aaattgacgt	tatttttctc	ttccaaaata	ttccaataaa	acttacatat	420
tgtcttttat	taacattgtg	ttaatgtcca	agtttataaa	tagaattttt	gtataacaag	480
acacattatc	atctaattat	tttttattct	agatgtgaaa	tgccaattta	cagaatattg	540
tttttagattt	ctgtataaat	gttaatccct	cttaaggcct	acttaatgta	gattaataaaa	600
acaattatta	tagtctctta	gagggtcaca	ttacaattcc	aaattgtaag	tgattctatg	660
ctttcatgat	tgtctaagcc	tgatataaca	gtcatgttca	gtttttttta	tattcttgat	720
gtagtttttt	gtttttgcta	taaatacact	gccctggaat	ttaacatatc	tcttcttttt	780
gatgaaactt	aaacagtaat	agacaaaatt	aggctagttt	ttattttttc	atacaacttt	840
taggattaaa	agtgcccttc	tcaaaaacat	gacaatactt	agagatactt	atttcatttt	900
ctgtgtctgc	ctcaaatttt	ccatttaata	taaaaataga	tatatttaat	tgtttataag	960
tataattgat	tggcatatgc	acatgccatc	ttagttttta	cacagggttt	ggaaactaga	1020
taaacaagat	tatttttagct	gtctttttat	acatgcaaat	ggaattttaa	cctggatggt	1080
tcaagtgtag	ttttgaaggg	gaattaaaac	ataataggat	ttctggctgg	gcatggtggc	1140
tcacacctgt	aatcccagca	ctttgggagg	ccgaggtggg	tggtatccact	tgaggctcagg	1200
agttcaagac	cagcctgacc	aacatggaga	aaccctgtct	ctactaaaaa	tacaaaaatt	1260
agctgggcat	ggtgacgcac	gcctgtaatc	tcagctactc	aggaggctga	ggcaggagaa	1320
tcacttgaac	ctggggaggcg	gaggttgcag	tgagccgaga	ttgcaccatt	gcactccagc	1380
ctggggcaaca	agaacgaaac	tccatctcaa	aaaaaaaaaa	aaaaa		1425

&lt;210&gt; 43

&lt;211&gt; 1124

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 43

ggcacgagtc	cagtgccttg	gcctgggggtg	gggggaaggt	gttagaggac	tccaggagct	60
cctgcacccc	tcccaaatg	tccatctttc	tcagacgggg	ctctgtctgg	ggagcaccca	120
caggctgcct	ttgggggtccc	agagcctgct	ctgtgactg	accccagttc	ctccatcctg	180
tggccagcct	agggctcatg	gcatggggccc	ccactggggg	agggaggcat	cttgtttctt	240
gtggttccct	gcaggccagt	cctgtccctc	tttcctgtt	ctgcccactc	tggggaatag	300
ggaggggagg	agaggagagg	agagggagga	tcctggagga	ctgggaagat	ctagcctaaa	360
gaggcttctc	tgaggggccag	ggccctacag	catgccctta	cggccagggg	actgtctgcc	420
agcctccag	gcccattgccc	tcctgggtgcc	cctggcactg	aggcacagat	cgtcaaggca	480
ggtacccctt	caacccttct	tccactggag	cccctgacac	cacagggtgcc	ctggagccct	540
tgtgtgactc	agcctctggt	agctgggtgg	gtgtcatcag	cccctgcctc	ccaggccaga	600
acctgagaac	gggcccaggg	tgctgtggag	atcaacttca	aaagagctaa	ccccttccca	660
cactccaccc	acccacctac	atttctctct	tgaaatctac	ctcagagttg	taccctcaga	720
aggacgggta	agcaggaggc	caggggggtcc	ccagggtcta	ggtggggagc	cttctacggc	780
gaaagcctgc	caccccacaa	tgaatccacc	ctgtccact	gcgcgcctct	cccaggctct	840
agctctgggt	ggggagcagt	ggccgctacc	gacagcgcat	gtcccgtctt	tatccaactc	900
ttccaggccc	cacctccctg	cacccctccc	ctctatagag	caggggagtg	aaggggtatg	960
tcaggcgggg	aaggggccaa	ggacacgtca	ttgtaccctg	agcgtcccca	gggagtggaa	1020
atgggggaagg	gggcctggag	aggggaggca	ggggcccttg	tgctctctga	acaagttgaa	1080
agtccaaata	aaacttacct	gttccaaaaa	aaaaaaaaaa	aaaaa		1124

&lt;210&gt; 44

&lt;211&gt; 1962

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 44

ggcacgagga	cggactgggc	agcagcctgt	cgctggccgt	gccccaggc	cccccaagct	60
ttgaggcgct	gctcggccag	gtgggggcgc	tgggcggcgg	ccagcagctg	cagctcggcc	120
tctgctgcct	gccggtgctc	ttcgtggctc	tgggcatggc	ctcggacccc	atcttcacgc	180
tggcgccccc	gctgcattgc	cactacgggg	ccttcccccc	taatgcctct	ggctgggagc	240
agcctcccaa	tgccagcggc	gtcacgtcgc	cagcgtgcc	ctagcagcca	gcgcgcag	300
ccgtgtcgcc	accagtaccg	acccctcgtg	cagcggcttc	gccccgccc	acttcaacca	360
ttgcctcaag	gattgggact	ataatggcct	tcctgtgctc	accaccaacg	ccatcggcca	420
gtgggatctg	gtgtgtgacc	tgggctggca	gggtatcctg	gagcagatcc	tcttcattct	480
gggctttgcc	tccggtacc	tgctcctggg	ttaccccgca	gacagatttg	gccgtcggcg	540
gattgtgctg	ctgaccttgg	ggctggtggg	cccctgtgga	gtaggagggg	ctgctgcagg	600
ctcctccaca	ggcgtcatgg	ccctccgatt	cctcttgggc	cttctgcttg	ccggtgttga	660
cctgggtgtc	tacctgatgc	gcctggagct	gtgcgaccca	acccagaggc	tccgggtggc	720
cctggcaggg	gagttggtgg	gggtgggagg	gcacttcctg	ttcctggggc	tggcccttgt	780
ctctaaggat	tggggattcc	tacagcgaat	gatcacggct	ccctgcaccc	tcttcttgtt	840
ctatggctgg	cctgggttgt	tcctggagtc	cacacggctg	ctgatagtga	agcggcagat	900
tgaggaggct	cagtctgtgc	tgaggatcct	ggctgagcga	aaccggcccc	atgggcagat	960
gctgggggag	gaggcccagg	aggccctgca	ggcttcattg	cccatgccat	tcgccactgc	1020
taccagccta	tgggaggagg	agggagccca	tcggacttct	acctgtgctc	tctgctggcc	1080
agccggcacc	gcagccctgg	cctgtgtctt	cctgggggtc	accgtggacc	gatttggccg	1140
ccggggcatc	cttcttctct	ccatgacctt	taccggcatt	gcttcccttg	tcctgctggg	1200
cctgtgggat	tatctgaacg	aggctgccat	caccacttct	tctgtccttg	ggctcttctc	1260
ctcccaagct	gccgccatcc	tcagcaccct	ccttgctgct	gaggtcatcc	ccaccactgt	1320
ccggggccgt	ggcctggggc	tgatcatggc	tctaggggcg	cttggaggac	tgagcgcccc	1380
ggcccagcgc	ctccacatgg	gccatggagc	cttctctgag	cacgtggtgc	tgggggcctg	1440
cgccctcctc	tgcattctca	gcattatgct	gctgccggag	accaagcgca	agctcctgcc	1500
cgagggtgctc	cgggacgggg	agctgtgtcg	ccggccttcc	ctgctgcggc	agccaccccc	1560
taccgcgtgt	gaccacgtcc	cgctgcttgc	cacccccaac	cctgccctct	gagcggcctc	1620
tgagtacctt	ggcgggaggc	tggccacac	agaaagggtg	caagaagatc	gggaagactg	1680
agtagggaag	gcagggctgc	ccagaagtct	cagaggcacc	tcacgcccagc	catcgccggg	1740
agctcagagg	gccgtcccca	ccctgcctcc	tcctgtgctc	tttgcatcca	cttccctggc	1800
cagagtcagg	ggacagggag	agagctccac	actgtaacca	ctgggtcttg	gctccatcct	1860
gcgccccaaag	acatccaccc	agacctcatt	atttcttgct	ctatcattct	gtttcaataa	1920
agacatttgg	aataaacgag	cataaaaaaa	aaaaaaaaaa	aa		1962

&lt;210&gt; 45

&lt;211&gt; 992

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 45

ggcacgagca	gcgcacaatg	actggacgcc	agtccctccg	tccaggctgc	gccttactgc	60
tcctccccctc	agtcttctcg	cagctgctat	ccttaggggc	acctgggagt	gaatgaagct	120
gcacgaggtc	cgcgagcctc	tgcccagccc	ctgtccctgc	agcctaggat	gcaaaggag	180
gtcagaacc	caggctcgccc	tgactgtggc	cttggtaaag	tctggaaaca	gtcctcagcc	240
tctgatatgc	cagatatccc	cagggtgctg	ggttccgatg	taggaactgc	ccagggtctg	300
cacgctcggc	ccgggtccatc	ctaccacggc	cgccccctga	ggggcccagg	gcagcatctc	360
ccagccccag	gggcacccca	acctgctgtg	tctggggaag	tggaaagccc	ggatcctcca	420
gtatgggggc	ggaactgccc	ctaccaccaa	tcccctaata	caaaggcaca	tgtcaactaa	480
aagataatgt	gggggtctcct	ggtttgagtg	ttccctgggc	tgcgccttct	caacatccag	540
cgtgccaccg	cagacacccc	caagtcccc	catggtggac	ttacctacaa	gaaccacagc	600
cacttctcac	ccagaactc	ctcctaattg	ctctgggggt	cgcattggcc	acagtcaccc	660
ccctccacgc	gtcccatccc	ccgcttaagg	agggtgtctg	ggcccacgag	ctccggagca	720
ccactggag	ccacggcctc	cctcccaactg	cacactccca	gcactgagct	ggggagccag	780
ggcgcctacc	tgtcccgcca	gccctccac	ccacctcagc	ccccccaccc	acctcagccc	840
caagacacac	acaggccggc	ctggggctgc	agactgagtt	attttatttc	gctatttcca	900
gtttgaagct	actatcatgg	gcgttttagag	ttatacaaat	gacacttaca	aaaaataaaa	960
gaccaagaca	ccccaaaaaa	aaaaaaaaaa	aa			992

<210> 46  
 <211> 1677  
 <212> DNA  
 <213> Homo sapiens

<400> 46  
 tgccgccaga gtaaagcttt ctacccttta ctccctgcaa agaaacaaga gtgcttatcc 60  
 cagctaagct ccagggtaat gttatcatga cagcttcaac ttttagacca caggcaaata 120  
 ctttggtaaa actctatgct ggtcattccc ttcaggattt ggcactcacc aacataccct 180  
 tctttcaagt gaaaaggcat ctcttttaaat ggtcctgacc tttggaatag gaagcatgta 240  
 ccctggacag agcacttcaa actagaggaa ccataaatcc atggctaacc ttgacaaata 300  
 cactgaaaca ttcaagatgg gtagcaacag taccagcact gctgagattt actgtaattg 360  
 cactaatgtg aaatttcaat actccctcta tgcaaccacc tatatcctca tattcattcc 420  
 tgggtcttctg gctaacagtg cagccttggtg ggttctgtgc cgcttcatca gcaagaaaaa 480  
 taaagccatc attttcatga tcaacctctc tgtggctgac cttgctcatg tattatcttt 540  
 acccctccgg atttactatt acatcagcca ccactggcct ttccagagag ccctttgcct 600  
 gctctgcttc tacctgaagt atctcaacat gtatgccagc atttgtttcc tgacgtgcat 660  
 cagtcttcaa aggtgctttt ttctcctcaa gcccttcagg gccagagact ggaagcgtag 720  
 gtacgatgtg ggcatcagtg ctgccatctg gatcgttgtg gggactgcct gtttgccatt 780  
 tcccctcctg agaagcacag acttaaacaa caacaagtc tgccttgctg atcttgata 840  
 caagcaaagt aatgcagttg cgttggtcgg gatgattaca gttgctgagc ttgcaggatt 900  
 tgtgatccca gtgatcatca tcgcatggtg tacctggaaa actactatat ccttgagaca 960  
 gccaccaatg gctttccaag ggatcagtga gaggcagaaa gcactgcgga tgggtgttcat 1020  
 gtgtgctgca gtcttcttca tctgcttcac tccctatcat attaacttta ttttttacac 1080  
 catggtaaag gaaaccatca ttgacagttg tccggttgtc cgaatcgcac tgtatttcca 1140  
 ccctttttgc ctgtgccttg caagtctctg ctgccttttg gatccaattc tttattactt 1200  
 tatggcttca gagtttcgtg accaactatc ccgccatggc agttctgtga cccgctcccg 1260  
 cctcatgagc aaggagagtg gttcatcaat gattggctaa aattaagata tctctttaat 1320  
 tacgcctttg tttacctacg ttcttgtct ttttccaaag gccagaattg tcaaccaatt 1380  
 tctttaattg aacattgtaa aaaacaggaa taagtacttt tgtgtaatat tcacagtcaa 1440  
 caggggtgtg atgggtgaagg cagagtgtga aaaacgtgag agaggaagag aaaatagatt 1500  
 tacctgattc ctctttaaaa ttcaagccac tttcttattt aagaaacctt gatcaagttt 1560  
 ttacagatgt aaataaaaagt tgaatagttt accttaaat tttttcaata agtaagttat 1620  
 tgtaataaat gcacagtaaa tatgtgaatt tttcttagat gtaaaaaaaaa aaaaaaa 1677

<210> 47  
 <211> 1343  
 <212> DNA  
 <213> Homo sapiens

<400> 47  
 ccacgcgtcc gcttatcttc cccaagagaa aatgcttctt ttgagcacac tgtacctacc 60  
 atctgcattg agcagaaaga cttttgtttt actgaagaca aaagatgttt ttattttaga 120  
 cccagaagag aggagtttgc tctgaatttg taaataagtc ttccccattc ctcatactcg 180  
 agcctctcct ctctgggtgc ctctgccac cagcatccat ggctcatttg acaccttttt 240  
 aaatatcagg acaagtctga aacaaagtag taaaaatgtat ataactctta cctgttgtca 300  
 ttctttttct tttaaatttg ttgctaattc ctgataatga agattcttac tctgattctc 360  
 agctgagctg tgagggcttc cagggaaaat ggaacaaaat ggtgttctta ggtaatgggt 420  
 tgtagatact gagtcttctt ttcttttctt gaccttctc gaggaacatt gctttctca 480  
 cacttttgta gtctctcttt acatattact atatggaaat gaattgctct gtgctgaaat 540  
 ttgaagacca gataatgaaa ctgaaaagca aacaatttta ctgaatctgt ctaccttca 600  
 ttcatgagaa ctccagaatg agtgttgacc actgaagcat cttttaagtc tgtgttccat 660  
 tgtgccattc aggtttgctg tcacatatgc atcatctgaa atcatttgaa atttttgtac 720  
 aataaaatat cctggatttg atcctgaagg aaactagtaa gatcagattt ttgggtcatg 780  
 tctgttgtat tttcagtaat gtgatttcag atggctcatc ggattctccc acttctctac 840

tccattat	tttcttact	tttcttact	ccttccagca	aacctgaaac	gtgagggaga	tggattaatg	900
tgagtaacag	gaatgtgtct	ttaaaaagct	agagtggta	catttaataca	ggcgtgaagat		960
aatttggtt	cttgagttgt	tttggagtaa	tatcccacaa	ctggggtagg	aagctcagga		1020
cttttttctt	taaagctagt	catttcaaaa	gcataattgta	tttttttgaa	tgactacagt		1080
atggacaatt	tcaaaaacca	aaaccactt	tggattgggtg	gaaataaaaa	ctggtaactc		1140
actcaagtga	atgaatggtc	ttgcatttta	aaagcttatg	ggaaactcaa	tttgaaatga		1200
ttagaaaatg	tcaagtatta	taagctggta	tttaagatgc	ttgtaaatac	tatttatgtt		1260
tttaattttg	taaaataaag	atttcttttt	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa		1320
aaaaaaaaaa	aaaaaaaaaa	agg					1343

&lt;210&gt; 48

&lt;211&gt; 552

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 48

ggcacgagat	attacatgga	gtccggaccc	aggaagaagc	tgtttgaata	ccagcaggct	60
cagctggagg	ctgagatcga	aaacctctca	tggaaaagtgg	agcgtgcaga	cagctatgac	120
agaggggact	tggagaacca	gatgcatata	gcgagagcagc	ggaggagaac	cctgctgaaa	180
gatttccatg	acacctaagt	tgggatgtgg	atgtgccggg	gtgaggaaga	tgtggctgca	240
aggtctcccg	gctgccatac	tgcatgctgc	aggctctgcc	tttcatgacc	ccaggcaaca	300
gccagggccc	cactcctgag	agacactggc	aacacctctt	agttgatttc	tgttttcttc	360
tcttttctct	ttttgtttct	accagggtag	aggccatgtt	gaactggcct	cttttcagga	420
cttttatttc	cccctggatg	gttgttggga	gggagggaaa	gtgttttctg	aatggctatt	480
aatagtatta	gatcattaca	acttatgtaa	ctttcaaaagg	ttgtacaatt	atacaaaaaa	540
aaaaaaaaaa	aa					552

&lt;210&gt; 49

&lt;211&gt; 2295

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (646)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 49

ggcacgagcc	cctgcctgga	agagtgactg	ctcttctgca	tgctaggggtg	ggagaccttg	60
tggaagtcag	tttatcttta	gagtttcagt	ttccttatct	gtagaagggg	gtaagaatgc	120
ccccagggtt	gacccttcag	gttcatggga	tgataagaaa	ggaaaatggt	ggatgagaaa	180
ggtttctgag	gctctgctgt	gctcctggcc	ctcttgcttg	cttctgccct	acctaaggca	240
cagacaagtt	ctctgtgtag	gaaaaggatt	cttgtttcc	acatgtggca	tcttccagag	300
tatcctggaa	tgtctacatg	cccgattaga	atccagcatt	agaatgaagt	cagactctca	360
gcctcttctt	tgggaaaccc	ctgccatct	ggtcattggt	gctgtgcaac	aggaaagact	420
cggggtgctg	gttgcatgtg	tgacgcagga	gagactcggg	gttctgggtg	cattgctgca	480
gcaggagaga	ctcagggttc	ttgttgcat	gctgcagtag	gagagacttg	gggttctcgt	540
tgcatgtctg	cagcaggaga	gactcggggt	tctcgttgca	ttgctgcagc	aggagagact	600
cagggtactg	cttgcatgtg	tgcatctctc	aaaagcttg	ttttgntgtt	ggtagatttt	660
ggcactgtgt	agtcattggc	atgtggcttc	aggttctcac	aggacacagg	gacatgtgac	720
tgatgaggtt	tcaagagagg	aggatcggat	gagtggggga	ttgcagcttc	cctcctcccg	780
acacctggga	ccctccactc	acagagagaa	tgagcttctc	cagcgtttgg	aggagagagg	840
agaagatggg	ctccccctgca	agtccataga	agcctccgtg	gctttctgga	ttaatgcagc	900
cacacactca	ctccttgcac	agcctctgcc	cagtgtccag	ttttacatat	gctttggaaa	960
taagaacaac	tgtcaataac	accatgacct	aaagaaagaa	acaagtaagc	gctgaaaagc	1020
actggggaaa	gccccctggg	gctcaaagga	gtggaagccc	gtgccttatc	ctctgagccc	1080

cagctatgac	agtgacctcc	tgtaatgcac	aaaaagccct	ggacttcctt	ctcaggcctg	1140
ggcttaaccg	taggacttag	aaactagtga	tcagagggtt	cacaggcagg	cagagggtgga	1200
atcctaccca	cccagggggc	atcccctgct	cggctcctgca	gagactcagc	tcccagcctg	1260
cggcatggca	gggaggaaag	gcagtgggtg	gaggtaagtt	tcacagaaga	ggcacagaga	1320
tggcagaagg	gcctcttagc	tagagtagga	gtaagcaaga	gggccagggg	cgcaccagga	1380
actgtgttct	tccgttcagc	tctcattccc	aaaggagcag	aaaactctgc	agcttagaca	1440
gaagtctgac	ctcccaaaag	ggagcagagc	ccagccctga	ggagccgcct	ccagctggcg	1500
ggaagcctgt	cgggcaccc	gtgaagatga	aggcctgctg	cacatcgccc	ggacctttca	1560
ggccatcccc	gagtgggcag	ggcttcccac	acctgcagga	accagagcga	gactggagac	1620
gagctccccg	ccatgcccc	tggctcattc	tagaccagga	ttgattgacc	tctgccggtt	1680
taaaagggca	tttttttttt	aagcctcaaa	gtcaaaactc	aagtatgagc	ccgtaaaaaa	1740
gtaataataa	taataagcac	tatctatgga	aagcaatcct	gtcctaaaga	ttttagggca	1800
gaggtagctc	tgaaaataga	tctctgcagt	aaacagacaa	tacttttata	gaaagtgtct	1860
gcttggtggg	gtcacagaga	tggactgcat	ggcctgacc	caggagccag	gaacccaagg	1920
tgaggcagga	cctggaacga	aggcagacat	ccaagggttt	tctgaatgaa	atagaagatg	1980
gatacggaga	caccaaagat	gtaaaagtag	agtttagttg	tgtattggga	gctgcaataa	2040
acataaatat	aactgcagaa	aatcaaaaca	gtgataagga	gactaatctt	aaaaccaaga	2100
gataattcac	agaaaaaaaa	aaaaaaaaag	caaggaaatg	gaacaaaaca	gataaagaga	2160
agttggtaga	tctggaggac	agaggatgaa	tatctaactg	aagagtcgtg	gatgctcctg	2220
agggggaacc	tcaatggctc	cagcagaagg	aagaatcaca	ttagagtga	aaccatagtg	2280
ttggaaagaa	agtta					2295

&lt;210&gt; 50

&lt;211&gt; 2092

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 50

ggcacgagtc	tacacaaggc	agaagaggca	cgggttttcc	tgggagcgaa	tatcaagtcg	60
ctgagagcaa	ctacaggact	aactgtgttt	gggttgggtg	tagtataaat	aataataatg	120
gctaataattt	cctgagcadc	tactaaatgc	aaggaattgt	gcttgggtgtg	tcatgtggat	180
tctctcttgc	atcttcatga	taaatgttat	tgtcgtgtgt	ttaccgatga	gggttggatt	240
agaggggtta	aacaacttgt	cttaggctcc	acagctggga	acaagtgggg	ctgggaagct	300
gacttcgtgc	tcttcaccac	cacaaaggat	gtgtgtgcat	cctggggcat	gcctgcctca	360
tgtgggggtg	tcttgggctg	aatttccttg	gcacttctca	gtggaactct	ctagcctcct	420
ggttcggaat	gtcaactatg	agatcccctc	actgaagaag	cagattgcc	agtgccagca	480
gctgcagcaa	gaatacagcc	gcaaggagga	ggagtggcag	gcaggggctg	ccgagatgcg	540
ggagcagttc	taccactcct	gcaagcagta	tggcatcacg	ggcgaaaatg	tccgaggaga	600
actgctggcc	ctgggtgaagg	acctgccgag	tcagctggct	gagattgggg	cagcggctca	660
gcagtccttg	ggggaagcca	ttgacgtgta	ccaggcgtct	gtgggggttg	tgtgtgagag	720
gtagagaggc	ctcagcttct	cctgggtggg	gtgctttgcc	tgtgttcccc	agctcatgac	780
ccttctccag	ttgtcttgtt	cccatataac	atttgaactc	tttacacacc	tgaacctgtg	840
ggggccttgc	ccatttgacc	atgtggccca	ggcctaaagc	cagtgttggc	cttacgcatg	900
gtcggcagga	gagtcagttg	tgtgctctgt	tgaagcccca	cagagcaggt	gttgccaatg	960
ctgcggttcg	tgcagaagcg	gggaaactca	acggtgtacg	agtggaggac	agggacagag	1020
ccctctgtgg	tggaaacgacc	ccacctcgag	gagcttcctg	agcaggtggc	agaagatgcg	1080
attgactggg	gcgactttgg	ggtagaggca	gtgtctgagg	ggactgactc	tggcatctct	1140
gccgaggctg	ctggaatcga	ctggggcatc	ttcccggaat	cagattcaaa	ggatcctgga	1200
ggtgatggga	tagactgggg	agacgatgct	gttgccttgc	agatcacagt	gctggaagca	1260
ggaacccagg	ctccagaagg	tgttgccagg	ggcccagatg	ccctgacact	gcttgaatac	1320
actgagaccc	ggaatcagtt	ccttgatgag	ctcattggagc	ttgagatctt	cttagccag	1380
agagcagtg	agttgagtg	ggaggcagat	gtcctgtctg	tgagccagtt	ccagctggct	1440
ccagccatcc	tgcagggcca	gaccaaagag	aagatggtta	ccatggtgtc	agtgtggag	1500
gatctgattg	gcaagcttac	cagtcttcag	ctgcaacacc	tgtttatgat	cctggcctca	1560
ccaaggtatg	tggaccgagt	gactgaattc	ctccagcaaa	agctgaagca	gtcccagctg	1620
ctggctttga	agaaagagct	gatgggtgcag	aagcagcagg	aggcacttga	ggagcaggcg	1680
gctctggagc	ctaagctgga	cctgctactg	gagaagacca	aggagctgca	gaagctgatt	1740

gaagctgaca	tctccaagag	gtacagcggg	cgcctgtga	acctgatggg	aacctctctg	1800
tgacaccctc	cgtgttcttg	cctgcccata	ttctccgctt	ttgggatgaa	gatgatagcc	1860
agggctgttg	ttttggggcc	cttcaaggca	aaagaccagg	ctgactggaa	gatggaaagc	1920
cacaggaagg	aagcggcacc	tgatggtgat	cttggcactc	tccatgttct	ctacaagaag	1980
ctgtggtgat	tggccctgtg	gtctaccagg	cgaataccac	agattctcct	tctagttagt	2040
atagcggact	taataaaaga	ggaaaaaact	cttgaaaaaa	aaaaaaaaaa	aa	2092

&lt;210&gt; 51

&lt;211&gt; 1681

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 51

ccacgcgtcc	ggacagcaga	accagcggcg	gcggctaagc	agagactgta	gtagcggcga	60
cagcgacgac	ggcagcgatg	gctggggcgg	ggccagcccc	gggactcccc	ggtgcaggag	120
gacccgtggt	cccgggtcct	ggcgtgga	tcccgggcaa	aagcggcgag	gaacgcttga	180
aggaaatgga	ggcggagatg	gccctgtttg	agcaggaagt	tctgggggct	ccagtacctg	240
gaatcccaac	tgctgtgcct	gcggtgcccc	ctgtccccac	ggtccccaca	gtagaagcga	300
tgcaggctcc	agcggctcct	gtgatccgcc	caattatcgc	gaccaacaca	taccagcagg	360
tccagcagac	tctggaggcc	cgagcagctg	ctgcagccac	agtagttcct	cccatggtgg	420
gtggccctcc	ttttgtaggc	cctgttggtg	ttggccctgg	tgatcggagt	cacctggaca	480
gccagaggcc	tcgagagcca	tgttcctgcg	gcgggcagct	gtggccccc	agagggcccc	540
tatcctgcgt	ccagccttcg	tccccacgt	gctacagaga	gcagcagccg	gccccgcgcc	600
tatggcccta	cggccccctc	accaggccct	cgtgggcccc	cctctgcctg	ggccccctgg	660
accacccatg	atgctgccac	caatggctcg	ggctccaggg	cccccgctgg	gctccatggc	720
tgactgagg	ccccctctgg	aagagccagc	agcaccgccg	gagctggggc	taggcctggg	780
gttgggcctg	aaagagaagg	aagaggcagt	ggtggcggcg	gcggctgggc	tggaggaggc	840
tagcgcggct	gtggccgtgg	gggcaggagg	tgccccagct	ggccctgcag	tcattggggc	900
cagcctgcgc	ctggccctgg	ccatgccatt	gcccagacct	gagccccctg	ccctcccggt	960
ggaggtcgtc	cgccgcctcc	tgcccccgct	gcgcattcct	gaactcctgt	ccctgcgtcc	1020
tcggccccgg	cccctcggcc	agagccaccc	ccaggcctca	tggtcttga	ggtcccagag	1080
cccctgggtg	aagacaagaa	gaaggggaag	ccagagaaat	tgaaacggtg	cattcgacac	1140
gcggcagggg	gcagctggga	ggaccccagc	ctgctggagt	gggatgcaga	tgacttccgg	1200
atcttctgtg	gggatctggg	caatgagggt	aacgatgaca	tcttggcacg	cgcttcagc	1260
cgcttcccat	ccttccttaa	ggccaagggt	atccgtgaca	agcgcacagg	caagaccaag	1320
ggctacggct	tcgtcagctt	caaggacccc	agcgactacg	tgcgcccat	gcgtgagatg	1380
aatggggaagt	atgtgggctc	gcgccccatc	aagcttcgca	agagcatgtg	gaaggaccgg	1440
aatctggacg	tggtccgcaa	gaagcagaag	gaaaagaaga	agctgggcct	gagatagggt	1500
ctgtggccag	gcaccgcctc	ccacctggcc	gggcgtggc	tcctccctca	gttctctttg	1560
gaaaaccccc	agctgtccac	ccatccccctg	ccccaaaacc	agtttcaata	aatttacggt	1620
catttccaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaaa	aaaaaaaaag	1680
g						1681

&lt;210&gt; 52

&lt;211&gt; 1646

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 52

ccacgcgtcc	gcacactgat	gccagagggtg	ggctgccatg	gccttggata	gctccaccct	60
tgtggctttg	ctgggtacag	ccccactcct	ggctgctttc	acagctggcg	ttgagtgtct	120
gtggcttttc	caggcactta	gtgcaagctg	tccgtggatc	gaccattctg	gggtctggag	180
gacggtggcc	ctcttctcac	agctccacta	ggtgctgccc	ctgtggggac	tctgtggtaa	240
gtgtgagtcg	attgactctc	tttcctttat	aaattaccca	gtctcggttg	tgtctttgtt	300
agcagtgtga	gaacagactc	atacagtaaa	ttggtactga	gagtggtccc	ggacaaccac	360
tgatcttctt	tcagtcactg	cagattattt	tgaattttta	agagatagaa	atggaataat	420

acagtgtgtc	cttttttcgt	ctgacttttt	tctctcagta	taaatatttt	gagattttatc	480
caagttgtag	gtattcatag	tttatttctt	tttattgaga	gtagtatttg	gttgagatat	540
atagtatagc	tcaactatgt	atcttttgga	ttcattcatc	tggtgataga	catttggggt	600
gtttacaatt	tttggttggt	atacataaat	gtgctataaa	aattcatata	aaagtctttg	660
caaagactta	gtctttcatt	ctcttagaca	catctcttag	ataaatccag	aggtggaatg	720
gctgaaacat	atggtaggca	catgttttat	atatgtatgc	ttgtatgtat	gtatgtatgt	780
ttcagtcacc	aggccggagt	gcagtggcgc	gatcatagct	cactgcagcc	tcaagctcct	840
gtgttcaagc	catcttctcg	cctcagtctc	ccaaagtgtc	gacattacat	tcatgagcca	900
ccgtgcccag	ctccatgtaa	ttaattcctg	ctgtgaactt	gcttagcaca	agcccatcag	960
ttttgtgcta	ttatagtttt	ggaaattcag	tccaatgcta	tgaactcaaa	attattagaa	1020
actatatact	tgtagaggtt	tttttcattc	tttccattct	ttccatgaac	tgccctgaag	1080
acataacact	tgacgattgt	aagtgtctgc	aagtaacttt	cagaaaggca	ttggaataaa	1140
gcaattgcta	tgaacaccaa	ggcttaaaat	ggctatggca	atgcagttga	caaggaaatt	1200
tggttattcg	tgaaccataa	ttatgactga	tagcatttat	atgaagacat	aggtttctag	1260
gaactttata	caatttttga	acatctatta	ataacacatc	catataactg	tcactcgaag	1320
gctaaacatc	attccatgtt	ttgacagtgc	ttcccatata	atttaaaata	ttcgataagc	1380
ccatgttggc	ttaatctctt	tgttttacag	ttccttttag	aagttccagg	gctttctgga	1440
atgtcctaaa	gttaatttcg	gtcaaaagtt	ttttgaaaag	tttgtcaaat	atccaagggt	1500
taaattacat	agctactcag	ggaggctgag	gcaggagaat	tgcttgaacc	caggagttgg	1560
aggttgacgt	gggcccagat	cgcgccactg	cactccagcc	tggcgacgga	gtgagacttc	1620
atctcaaaga	aaaaaaaaaa	aaaagg				1646

&lt;210&gt; 53

&lt;211&gt; 1990

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1747)

&lt;223&gt; n equals a,t,g, or c

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (1752)

&lt;223&gt; n equals a,t,g, or c

&lt;400&gt; 53

aggcgggag	aggcggcgag	aggcgggctg	aggcggccca	gcggcgagcag	gtgaggcgga	60
accaaccctc	ctggccatgg	gagggggcgt	ggtggacgag	ggccccacag	gcgtcaaggc	120
ccctgacggc	ggctgggggt	gggccgtgct	cttcggctgt	ttcgatcatca	ctggcttctc	180
ctacgccttc	cccaaggccg	tcagtgtctt	cttcaaggag	ctcatacagg	agtttgggat	240
cggctacagc	gacacagcct	ggatctcctc	catcctgctg	gccatgctct	acggggacaa	300
gtccgctctg	cagtgtgtgc	gtgaaccgct	ttggctgccc	gcccgtcatg	ctgtgggggg	360
gtctctttgc	gtcgctgggc	atgggtggctg	ccgtcctttt	gccggagcat	catccaggtc	420
tacctcacca	ctgggggtcat	cacgggggtg	ggtttggtcac	tcaacttcca	gccctcgctc	480
atcatgctga	accgctactt	cagcaagcgg	cgccccatgg	ccaacgggct	ggcggcagca	540
ggtagccctg	tcttctgtg	tgccctgagc	ccgtgggg	agctgctgca	ggaccgctac	600
ggctggcggg	gcggcttctt	catcctgggc	ggcctgctgc	tcaactgctg	cgtgtgtgcc	660
gcactcatga	ggccccctggt	ggtcacggcc	cagccgggct	cggggccgccc	gcgaccctcc	720
cggcgccctg	tagacctgag	cgtcttcggg	gaccggcggt	ttgtgcttta	cggcgtggcc	780
gacctgggtca	tggtgctggg	gctcttcgct	ccgcccggtg	tcgtgggtgag	ctacgcgaag	840
gacctggggc	tgcccagaca	ccaaggccgc	cttctgctc	accatcctgg	gcttcattga	900
catcttcgag	cggccggccg	cgggcttcgt	ggcggggctt	gggaagggtgc	ggccctactc	960
cgtctacctc	ttcagcttct	ccatgttctt	caacggcctc	gcggacctgg	cgggctctac	1020
ggcggggcag	tacggcgggc	tcgtgtgtct	ctgcatcttc	tttggcatct	cctacggcat	1080
ggtggggggc	ctgcagttcg	aggtgctcat	ggccatcgctg	ggcaccacaca	agttctccag	1140



tgccattggc	ctggtgctgc	tgatggaggc	ggtaggcgctg	ctcgtcgggc	cccttcggga	1200
ggcaaaactcc	tggatgcgac	ccacgtctac	atgtacgtgt	tcacctcggc	gggggcccag	1260
gtgctcacct	cctccctgat	tttgctgctg	ggcaacttct	tctgcattag	gaagaagccc	1320
aaagagccac	agcctgaggt	ggcggccgcg	gaggaggaga	agctccacaa	gcctcctgca	1380
gactcggggg	tggacttgcg	ggagggtggag	catttcctga	aggctgagcc	tgagaaaaac	1440
ggggagggtg	ttcacacccc	ggaaacaagt	gtctgagtgg	ctgggcgggg	ccggcagcac	1500
agggaggagg	tacagaagcc	ggcaacgctt	gctatttatt	ttacaaactg	gactggctca	1560
ggcagggcca	cggctgggct	ccagctgccg	gcccagcgga	tcgtcgcccg	atcagtgttt	1620
tgagggggaa	ggtggcgggg	tgggaaccgt	gtcattccag	agtggatctg	cgggtgaagcc	1680
aagccgcaag	kttacaaggc	atcctcacca	ggggccccgc	ctgctgctcc	cagggtggcct	1740
gcggcantgc	tnatgctcaa	ggacctggaa	acccatgctt	cgagacaacg	tgactttaat	1800
gggagggtg	gtgggcccga	gacaggctgg	cagggcaggt	gctgcgtggg	gccctctcca	1860
gcccgtccta	ccctgggctc	acatggggcc	tgtgccacc	cctcttgagt	gtcttgggga	1920
cagctctttc	cacccctgga	agatggaaat	aaacctgcgt	gtgggtggag	tgtaggaaa	1980
aaaaaaaa						1990

&lt;210&gt; 54

&lt;211&gt; 554

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 54

acgcgtccgg	gagaaggcaa	ctccagtcag	aacagcagaa	ataagcgtgc	cgttcagggg	60
ccagaagaaa	caggatctta	cacatttggt	ccatggcttc	tcagctttaa	aaggggaagt	120
gccctagaag	aaaaagagaa	taaaatattg	gtcaaagaaa	ctgggtactt	ttttatatat	180
ggtcaggttt	tatatactga	taagacctac	gccatgggac	atctaattca	gaggaagaag	240
gtccatgtct	ttggggatga	attgagtcctg	gtgactttgt	ttcgatgtat	tcaaaatatg	300
cctgaaacac	tacccaataa	ttcctgctat	tcagctggca	ttgcaaaact	ggaagaagga	360
gatgaactcc	aacttgcaat	accaagagaa	aatgcacaaa	tatcactgga	tggagatgct	420
acattttttg	gtgcattgaa	actgctgtga	cctacttaca	ccatgtctgt	agctattttc	480
ctccctttct	ctgtacctct	aagaagaaag	aatctaactg	aaaataccaa	aaaaaaaaaa	540
aaaaaaaaaa	aaaa					554

&lt;210&gt; 55

&lt;211&gt; 1240

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 55

acgcgtccgg	gcatttgtag	gcttggagggt	aaagaactga	agataactgg	tgctggatag	60
aggagcctta	ttttttatta	tggcagcttg	ctatttttat	aacatggtga	ttgagttgaa	120
cacaatcaaa	gtacagtagt	aactgatgtc	cccttcttcc	tggatgaatg	agcagataaa	180
tattgatgtc	agcatccttg	aaccatatca	aagtgagcag	tgtttggtta	ctgcttctat	240
ttgaaatggg	gctgtgtttt	ggtgtgtgtc	tgaagctttg	aagcgctact	tagcatctcc	300
tttcttccat	ggagctctca	cgattcaaac	atgacagatt	tggtaaaatg	ctgggttaggt	360
tgagtcttcc	ttgccccac	tcagtcactc	ttgtatgaat	cccatgattt	gggggttttt	420
ttcttttttt	tttataccag	tttttagctg	gtgtttatga	agaacagtga	gtacctagaa	480
ctgtgccact	aattaaagga	aatcctaaga	agggtcattt	ctttacagag	ctgtgtcatg	540
ccatcctttg	ggccctctgc	tggaaaagta	gaatcaagtc	tcaaataatg	cctttttaat	600
tgtatcctct	agtattatag	atataggaca	gtactgtatc	atacctctgt	gaatgtaaaa	660
tactttgtac	ctgctttatg	atacgttaga	gtgaccgtgc	tttatcagag	ctgtttttta	720
tgatgttatt	ctagaatggt	ttctttccag	atgatgatcc	agaagctaata	tttaaaaaac	780
ggtgccagggt	accacaacag	taacagaact	ttgcaatttt	ctgggggttt	gttttttacc	840
tttttccccc	ctttttttta	aatggagtgt	gctggatgtc	tctataattt	tattcagatg	900
actgcagaac	ctggaaaagc	tgttgctgct	attgatgcat	aacatactgc	tattgggtctt	960
tttatataaa	tatatatata	tatatacata	tatatatata	atttgaattt	ttggaaactt	1020

tagctgtgct	gtcaactttg	gaaaaagtat	cccggtttac	tgtgttgagt	tggcattgta	1080
cagaaattaa	cagccatatt	ggctagaaa	cgtaaactt	aattttttt	ccatttgtac	1140
aggggtaacg	cactgtatta	aatatgtaag	gtcttatcta	catgggtttg	attacagaaa	1200
ctaataaagt	attctctaaa	taaaaaaaaa	aaaaaaaaaa			1240

&lt;210&gt; 56

&lt;211&gt; 1724

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 56

ccacgcgtcc	gacccctcctg	tcttggttcc	ctaaagtgtt	gggattacag	gtgttagcca	60
ctgtgcccag	cccctttgac	atttttaata	gtcaaacatt	tattaaacct	gtaagtggct	120
taaagtttca	aaattctcca	ttgtaagtca	aaaaatgtct	taagattttt	atcccagact	180
tatgctaagg	gttatgaatc	tgttccacct	tttgtttgaa	atagccacct	gtctgatttg	240
cttgtctatt	tcttcaaaga	actctgggga	aaacagtatg	atagagtagc	aaggagttag	300
tttttcaa	cagataaata	tgtataaaaa	ttccatttct	acctctccta	agacatgtaa	360
tttaacttca	caaagcctca	gtttcctcat	ctaaaagatg	aaaaaaataa	aatctgtgca	420
gtcatgatgt	tgaataaaat	taatgcatat	atatatatat	atatatatag	agagagagag	480
agagagagag	agagatacac	acatacctat	gttcctcttt	ccctctgaat	ccaccagac	540
ataggtagt	ataagggaca	atttaaataa	ggcagcaaat	taaaagtagg	aaggttacat	600
tagcatgctt	cttagcttta	cttcttatga	ccatgatgtc	attatttgag	aaatgttagt	660
ttcagtcaga	tattctaagt	tcttatgcat	taatagttaa	tttttttctc	tttgaagaat	720
gaaagaggac	cacaagggtt	tctctgactt	agataggaga	tagtaaatta	aaagaatata	780
taaggcatct	tgaattagcc	actattgaga	gcaattacct	gttctagaga	attcttttagc	840
tatgtcctga	aatgggtctg	gttgttctca	cctgtatcta	atgtttgtgg	ttgttcttcc	900
tagttgacct	gttaggcttg	ttaaattggc	gttccaactc	ccagaacatt	aaacacaacc	960
taaagaagtt	aatggaagt	gatggaggag	agattgttaa	gtttttgcaa	gatacactag	1020
atgcactctt	taacataatg	atggaaatgt	cagacagtga	aacctatgac	ttccttgtgt	1080
ttgacgcact	ggtattttatt	atttcaactga	taggagacat	caagtccag	catttttaatc	1140
ctgtacttga	aacctacatt	tacaagcact	tcagcgccac	tttggcatat	gtgtaagtat	1200
gatctgaagg	aactacatgt	tgttgatctt	ttggatttgt	actcttagga	ctggatttgt	1260
gagaaacgag	acggacctat	tactattcag	taaatacgcc	tgttaaggca	gaactcttat	1320
tctaagcttc	cgggtggaaa	aagggaacca	tctaagtatt	ctaactctgg	aaagggggct	1380
aagatcaggg	ccttcattct	ggatcaggcg	aaatttcctt	aaggatccag	aataggccag	1440
gcgtggttgc	tcatacctgc	aattccagca	ctttgtgggg	aggattgctt	gaggccagga	1500
attcaagacc	agcctaggca	acataacaag	aacctatctt	tacaaaaaat	taaaaagtta	1560
gccaggtgtg	gtgacacaca	cctgtagtcc	tagctactcg	agaggcttag	gtgagaggat	1620
tgtttaagcc	caggaagtc	aaggctgcag	tgagctgtga	tcatgccatt	gcactccagc	1680
ctaagtgaca	gagcaagact	tagtatctaa	aaaaaaaaaa	aaaa		1724

&lt;210&gt; 57

&lt;211&gt; 1433

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 57

ggcacgaggt	tcaatgactt	tactaatggt	taccaaagt	ataccaagca	ggacaggtga	60
taactaaata	ttaaagtcaa	aagggaattt	attgcccagg	gccctagaat	tcattcttcc	120
tcaagactta	aaatcaaag	aactgcttgt	ttcctccagg	caagagtatt	aagaaataac	180
caggctagta	ttttgataaa	ccacaatcac	ttaccttgta	aacttgtgtt	ttttctctca	240
gacaagtgtt	ggtattgtcg	gctttcgcca	aatcacaaag	tcctgcatta	cggagactta	300
gaagagagtc	ctcagggaga	agtgtccac	gattccttgc	aggacaaacg	taagttagctc	360
tccttggcag	aggcctgagt	ggtggtcggt	tggttgtttc	ctagtcacaa	tatatcacgc	420
aacagaacta	tcagcctaag	taagcccttt	gaacacatct	catctagtgt	taagtctgtcg	480
cctgagccat	ctcatcaagt	acaagacctg	gatggacttg	gggtttggaa	ctgaataggg	540

gagaatgtaa	aatggatgca	aaggtatctt	aattgaaaga	cgtaaactgg	gggttcaa	600
gtccactttt	tacattat	atccaggtgc	tgtgtcaagg	agcaaaaaca	atacaaacct	660
gattctgtca	gctgtctttt	tctgaaaacc	caaaataatt	tcttattttc	gtaacttata	720
tgcttgaccc	ctacaacatt	tattccttac	aatttagtgt	atcccatagt	tatgacacag	780
agttaatggc	agagccaaat	atagctagtt	tacctcaaag	acactttgaa	aatgatgatc	840
cgttacctct	actgtttgct	aaatatttct	cttgtatatt	ttttggcttt	ttctatatgt	900
tgtctgtttt	aacatacatg	cttttgaaga	gacagtaatg	tgcaggattc	ttttagcccc	960
acagggaaac	agggtgccagg	ttgacagtgt	taacaataca	aattaaacaa	atltgcccac	1020
agaaccctct	aaatccccct	gtaaatttaa	ctgttagtcc	aaagaggaac	agctcttttg	1080
acactaggaa	aaaaccttgt	agagagagta	aaaaatttaa	cacccatagt	aggcctaaaa	1140
gcagccacca	attaagaaag	cgttcaagct	caacaccac	tacctaaaaa	atcccaaaaa	1200
tataactgaa	ctcctcacac	ccaattggac	caatctatca	ccctatagaa	gaactaatgt	1260
tagtataagt	aacatgaaaa	cattctcctc	cgcataagcc	tgcgtcagat	taaaacactg	1320
aactgacaat	taacagccca	atatctacaa	tcaaccaaca	agtcattatt	accctcactg	1380
tcaacccaac	acaggcatgc	tcataaggaa	aggttaaaaa	aaaaaaaaaa	aaa	1433

&lt;210&gt; 58

&lt;211&gt; 1267

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;400&gt; 58

ccacgcgtcc	gctgtttact	gatatctcat	gcaatagaag	ccctgatttt	ggatccagaa	60
tcagcaagtt	tccaggaata	tggatctact	ggaacagccc	atgctgatag	tgaatatgaa	120
agaagaatga	tgtctgtata	taatcatgtc	ttggaggagg	tagaatcact	caatcgghaa	180
tataccccctg	tttctttatat	gcacacagca	tgcctctgta	atgccatcat	tgctttgtctg	240
aaagttcccc	tttctttcca	gagatatttt	tttccagaaa	ctacagtcta	ccagcatcaa	300
gcttgctctg	tcaccatcgc	cccggaaatcc	tgcagagccc	attgctgtcc	agaataacca	360
gcagctggcg	ctaaaaggtag	agggagtggg	tcagcacgga	tctaaaccag	gactcttccg	420
caaaattcag	tctgtctgtc	tgaatgtttc	ttccacactg	cagagtaaat	ctggacaaga	480
ctacaagata	cccattgaca	acatgacca	tgagatggag	caaaggggtg	aacctcataa	540
tgattacttc	agtactcaat	ttctgttgaa	ctttgctatc	cttggaacac	acaacattac	600
agtggaaatct	tctgtgaaag	atgccaatgg	tatagtatgg	aagactgggtc	ccagaactac	660
catattttgta	aaatccctgg	aagaccctta	ttcccagcaa	attcgcttac	aacagcagca	720
agcccagcag	ccattacagc	agcagcagca	acgcaatgcc	tacacacggg	tttaaccatg	780
gaatgaatgc	actgcagact	ctcaagagat	caatcaaat	gccagaaaca	gtttgggttt	840
tcatatggaa	taagtattaa	agttacagt	tagttcattt	attcattgat	ttttgtaatg	900
taatattctg	gaaaaaattt	tgttttctta	aaaattttgt	ctgacagctg	ggcgtgggtg	960
ctcacgcctg	taatcccagc	actttgggag	gctgaggtgg	gcggctcacg	aggagatcaa	1020
gaccatcctg	gctaacacag	tgaaaccccg	tctccactaa	aaaatacaaa	aaaattagcc	1080
gagcatgggtg	gcaggcgcct	gtagtcccag	ctacttggga	ggctgaggca	ggagaatggg	1140
gtgaacctgg	gaggcggagc	ttgcagtga	ccgagactgt	gctccagcct	gggcgcagaga	1200
gcgagactcc	gtctcaaaaa	aataaataaa	tacattttgt	ctgaaaaaaa	aaaaaaaaaa	1260
aaaaaaa						1267

&lt;210&gt; 59

&lt;211&gt; 36

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (36)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 59

Met Leu Phe Phe Asn Leu Phe Cys Tyr Leu Gly Ser Val Leu Ile Ser  
 1 5 10 15

Gly Gln Ile Phe Thr Val Leu Ser Gln Asn Ile Thr Lys Arg Arg Val  
 20 25 30

Thr Thr Thr Xaa  
 35

<210> 60

<211> 36

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (36)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 60

Met Asp Leu Phe Cys Ser Phe Leu Pro Ser Leu Leu Ala Ile Met Phe  
 1 5 10 15

Leu Cys Pro Pro Val Leu His Phe Met Gly Tyr His Val Gln Gln Gln  
 20 25 30

Leu Arg Arg Xaa  
 35

<210> 61

<211> 47

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (47)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 61

Met Ser Pro Gly Gly Phe Leu Leu Leu Thr Ser Leu Gly Pro Thr Ile  
 1 5 10 15

Gly Phe Leu Ala Gly Leu Arg Ser Leu Arg Glu Val Ala Ile Ser Lys  
 20 25 30

Arg Lys Asp Phe Tyr Leu Arg Leu Ser Gly Lys Glu Ala Glu Xaa  
 35 40 45

<210> 62

<211> 247

<212> PRT

<213> Homo sapiens

<220>

&lt;221&gt; SITE

&lt;222&gt; (247)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 62

Met Gln Pro Ser Trp Leu Thr Arg Cys Pro Thr Trp Pro Trp Pro Met  
 1 5 10 15

Gly Ala Ala Trp Pro Arg Arg Ala Arg Ser Trp Trp Ile Arg Thr Ser  
 20 25 30

Thr Ala Ser Ser Pro Ser Pro Ser Ser Ile Thr Leu Leu Trp Thr  
 35 40 45

Pro Cys Met Trp Ala Glu Ser Trp Ala Cys Cys Ser Ser Pro Thr Tyr  
 50 55 60

Thr Arg Thr Gly Lys Cys Ser Thr Asn Arg Thr Pro Arg Trp Pro Pro  
 65 70 75 80

Ala Leu Thr Ser Met Pro Arg Thr Ser Thr Phe Gln Gln Trp Ala Phe  
 85 90 95

Ile Thr Tyr Val Leu Val Ala Gly Leu Ala Leu Gly Thr Gln Asp Arg  
 100 105 110

Phe Ser Pro Asp Leu Leu Gly Leu Gln Ala Ser Ser Ala Leu Ala Trp  
 115 120 125

Leu Thr Leu Glu Val Leu Ala Ile Leu Leu Ser Leu Tyr Leu Val Thr  
 130 135 140

Val Asn Thr Asp Leu Thr Thr Ile Asp Leu Val Ala Phe Leu Gly Tyr  
 145 150 155 160

Lys Tyr Val Gly Met Ile Gly Gly Val Leu Met Gly Leu Leu Phe Gly  
 165 170 175

Lys Ile Gly Tyr Tyr Leu Val Leu Gly Trp Cys Cys Val Ala Ile Phe  
 180 185 190

Val Phe Met Ile Arg Thr Leu Arg Leu Lys Ile Leu Ala Asp Ala Ala  
 195 200 205

Ala Glu Gly Val Pro Val Arg Gly Ala Arg Asn Gln Leu Arg Met Tyr  
 210 215 220

Leu Thr Met Ala Val Ala Ala Ala Gln Pro Met Leu Met Tyr Trp Leu  
 225 230 235 240

Thr Phe His Leu Val Arg Xaa  
 245

&lt;210&gt; 63

&lt;211&gt; 26

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (26)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 63

His	Gly	Leu	Leu	Pro	Val	Cys	Pro	Trp	Ala	Cys	Gly	Leu	Arg	Pro	Pro
1				5				10					15		

Arg	Thr	Thr	Pro	Arg	Lys	Lys	Ile	Ser	Xaa
			20				25		

&lt;210&gt; 64

&lt;211&gt; 42

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (42)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 64

Met	Cys	Gly	Arg	Arg	Pro	Arg	Leu	Gly	Trp	Thr	Cys	Val	Trp	Gly	Cys
1				5				10					15		

Thr	Arg	Ala	Pro	Cys	Trp	Gly	Ala	Ser	Trp	Ala	Arg	Ser	Ala	Gly	Ser
			20				25					30			

Thr	Thr	Cys	Gly	Arg	Leu	Met	Ser	Leu	Xaa
		35				40			

&lt;210&gt; 65

&lt;211&gt; 40

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (40)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 65

Met	Phe	Gln	Leu	Cys	Leu	Glu	Ile	Phe	Gln	Phe	Phe	Val	Ser	Val	Phe
1				5				10					15		

Ile	Ser	Phe	Leu	Glu	Ser	Leu	Ala	Glu	Phe	Gln	Glu	Thr	Val	Ala	His
			20				25					30			

Leu	Leu	Val	Met	Lys	Cys	Phe	Xaa
		35				40	

&lt;210&gt; 66

&lt;211&gt; 21

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (21)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 66

Phe	Leu	Leu	Ser	Phe	Cys	Ala	Phe	Pro	Cys	Val	Phe	Met	Phe	Trp	Val
1				5				10					15		

Ser	Val	Leu	His	Xaa
			20	

&lt;210&gt; 67

&lt;211&gt; 18

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (18)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 67

Leu	Leu	Cys	Val	Leu	Ala	Gly	Leu	Thr	Leu	Leu	His	His	Cys	Gln	Leu
1				5				10					15		

Ala Xaa

&lt;210&gt; 68

&lt;211&gt; 62

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (62)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 68

Met	Arg	Val	Leu	Ile	Leu	Asn	Val	Ser	Met	Phe	Leu	Arg	Ser	Leu	Ala
1				5				10				15			

Tyr	Ile	Leu	Trp	Cys	Ser	His	Trp	Lys	Trp	Lys	Asn	Gly	Ile	Ile	Tyr
		20						25					30		

Ile	Ile	Tyr	Ile	Asn	Ile	Tyr	Tyr	Thr	Tyr	Ser	Pro	Tyr	Phe	Ile	Ser
		35						40					45		

Val	Thr	Ile	Pro	Ile	Glu	Phe	Asp	Lys	Asn	Cys	Tyr	Asp	Xaa
	50					55					60		

35

<210> 69  
 <211> 55  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (55)  
 <223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 69  
 Met Thr Glu Asn Pro Lys Val Gln Met Met Leu Ile Ile Val Val Pro  
           1                  5                  10                  15  
 Leu Gln Leu Phe Ile Asn Pro Val Gln His Pro Ile Gln Gln Val Arg  
                   20                  25                  30  
 Cys Ile His Leu His Leu Cys His Gly Trp Ala Leu Asp Arg Leu Ala  
                   35                  40                  45  
 Leu Glu Leu Val Cys Leu Xaa  
           50                  55

<210> 70  
 <211> 14  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (14)  
 <223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 70  
 Met Lys Thr Thr Cys Leu Ser Ser Thr Leu Val Arg Met Xaa  
           1                  5                  10

<210> 71  
 <211> 50  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (50)  
 <223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 71  
 Met Ala Pro Lys Phe Phe Val Ser Thr Gly Ile Ser Pro Met Ala Pro  
           1                  5                  10                  15  
 Ile Ala Thr Ala Lys Pro Thr Ala Pro Pro Val Leu Pro Ala Ser Leu  
                   20                  25                  30  
 Pro Asp Arg Arg Cys Leu Gln Ser His Thr Gln Ser Ser Gly His Leu  
           35                  40                  45



Pro Xaa  
50

<210> 72  
<211> 26  
<212> PRT  
<213> Homo sapiens  
  
<220>  
<221> SITE  
<222> (26)  
<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 72  
Met Ser Leu Phe Phe Ile Trp Gln Leu Thr Lys Leu Leu Lys Ala Gln  
1 5 10 15

Pro Asn Cys Thr Phe Ala Arg Thr Phe Xaa  
20 25

<210> 73  
<211> 40  
<212> PRT  
<213> Homo sapiens  
  
<220>  
<221> SITE  
<222> (40)  
<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 73  
Met Arg Phe Cys Cys Leu Ile Leu Gln Ile Leu Thr Arg Leu Val Leu  
1 5 10 15

Thr Lys Tyr Gly Arg Ser Gly Ile Arg Trp Lys Lys Glu Gly Ser Ser  
20 25 30

Cys Cys Cys Ser Tyr Ser Cys Xaa  
35 40

<210> 74  
<211> 11  
<212> PRT  
<213> Homo sapiens  
  
<220>  
<221> SITE  
<222> (11)  
<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 74  
Met Ile Val Thr Lys Met Tyr Phe His Val Xaa  
1 5 10

<210> 75  
 <211> 57  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (57)  
 <223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 75  
 Met Phe Leu Ala Ser Phe Ser Ser Pro Gly Phe Gln Leu Ser Phe Ser  
   1                  5                  10                  15  
 Ser Ser Ser Asn Met Ala Ser Ala His Lys Ser Leu Leu Cys Gln Asp  
                   20                  25                  30  
 Leu Met Val Leu His Leu Pro Glu Pro Ser Ser Ala Ser Val Pro Arg  
           35                  40                  45  
 Pro Gln Leu Val Arg Leu Thr His Xaa  
       50                  55

<210> 76  
 <211> 46  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (46)  
 <223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 76  
 Met Glu Leu Asn Ile Ala Trp Met Thr Glu Lys Leu Trp Lys Glu Met  
   1                  5                  10                  15  
 Glu Asp Phe Leu Asn Phe Ser Leu Val Leu Phe Val Met Lys Leu Lys  
           20                  25                  30  
 Leu Pro Ala Pro Glu Lys Val Phe Gln Tyr Leu Leu Cys Xaa  
       35                  40                  45

<210> 77  
 <211> 32  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (32)  
 <223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 77  
 Met Phe Met Leu Ala Ile Leu Leu Thr Phe Phe His Pro Phe Leu Val

38

1	5	10	15
Tyr	Arg	Glu	Cys
	Arg	Thr	Trp
		Lys	Glu
		Ser	Pro
		Ser	Ala
		Ile	Ala
			Xaa
	20	25	30

<210> 78  
 <211> 16  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (16)  
 <223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 78
Tyr Ile Phe Val Trp Ile Ser Ser Val Tyr Val Gln Tyr Phe Val Xaa
1 5 10 15

<210> 79  
 <211> 34  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (34)  
 <223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 79
Met Glu Lys Leu Asp Trp Ala Tyr Ser Gln His Ser Val Ile Cys Lys
1 5 10 15

Cys Ile Ser Leu Leu Cys Arg Val Phe Leu Leu Gly Val Asn Phe Asp
20 25 30

Ser Xaa

<210> 80  
 <211> 21  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (21)  
 <223> Xaa equals any of the twenty naturally occurring L-amino acids

39

&lt;400&gt; 80

Met Cys Gly Cys Thr Thr Phe Phe Cys Asp Tyr Met Gly Ser Phe Glu  
1 5 10 15

Arg Ile Tyr Leu Xaa  
20

&lt;210&gt; 81

&lt;211&gt; 37

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (37)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 81

Met Phe Asn Ser Leu Leu Ala Phe Phe Leu Ile Leu Trp Gly Cys Ile  
1 5 10 15

Thr Ser Leu Lys Asp Ile Val Ile Ile Ser Tyr Lys Val Lys Ile Lys  
20 25 30

Lys Asp Cys Val Xaa  
35

&lt;210&gt; 82

&lt;211&gt; 37

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (37)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 82

Met Asn Ala Ala Val Leu Leu Thr Leu Val Phe Phe Leu Leu Tyr  
1 5 10 15

Leu Phe Tyr Leu Gly Val Leu Gly Ser Asp Pro Ala Tyr Leu Pro Leu  
20 25 30

Leu Lys Lys Ser Xaa  
35

&lt;210&gt; 83

&lt;211&gt; 29

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (29)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 83

Met Asn Asp Pro Pro Thr Ala Pro His Gly Leu Phe Leu Phe Leu Trp  
 1 5 10 15

Leu Phe Ser Leu Arg Ser Gly Gly Phe Thr Arg Ile Xaa  
 20 25

<210> 84

<211> 23

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (23)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 84

Pro Ser Gly Trp Val Leu Trp Cys Ala Leu Gln Pro Leu Pro His Pro  
 1 5 10 15

Gly Leu Cys Pro Ser Pro Xaa  
 20

<210> 85

<211> 40

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (40)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 85

Met Thr Arg Pro Thr Ile Val Ser Ser Cys Leu Trp Ala Val Arg Gln  
 1 5 10 15

Leu Val Gly Thr Arg Ser Asn Pro Arg Phe Phe Leu Gln Tyr Ser Gly  
 20 25 30

Tyr Asn Leu Ser Trp Leu Leu Xaa  
 35 40

<210> 86

<211> 10

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (10)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 86

Met Arg Phe Leu Phe Ile Phe Cys Phe Xaa  
1 5 10

&lt;210&gt; 87

&lt;211&gt; 24

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (24)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 87

Val Gln Thr Tyr Val Val Leu Leu His Phe Ala Leu Ser Cys Phe Ala  
1 5 10 15Asp Ile Val Phe Phe Thr Asn Xaa  
20

&lt;210&gt; 88

&lt;211&gt; 65

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (65)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 88

Met Pro Ser Phe Ile Ile His Ser Asn Pro Ile Trp Leu Gly Ala Leu  
1 5 10 15Leu Trp Val Ser His Cys Pro Ser Ser Ile Leu Gly Ser Leu Arg Pro  
20 25 30Arg Gly Gly Lys Ile Gln Leu Arg Val Gly Gly Ser Glu Pro Arg Arg  
35 40 45Ile Met Lys Ala Thr Cys Phe Gly Asn Asp Leu Pro Leu Pro Val Val  
50 55 60Xaa  
65

&lt;210&gt; 89

&lt;211&gt; 130

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (130)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 89

Met	Ser	Lys	Pro	Leu	Ser	Tyr	Met	Thr	Trp	Leu	Phe	Leu	Leu	Pro	Ser
1				5					10					15	

Pro	Leu	Val	Phe	Val	Ser	Leu	Phe	Ser	Pro	Leu	Ala	Leu	Pro	Gly	Ser
		20						25					30		

Pro	Leu	Ala	Leu	Pro	Arg	Gly	Trp	Phe	Ser	Ala	Trp	Ala	Leu	Ala	Asp
	35					40						45			

Val	Ser	Val	Ala	Ala	Gly	His	Thr	Asp	Arg	Ser	Gly	Leu	Gly	Ser	Val
	50					55					60				

Leu	Arg	Asp	Leu	Val	Lys	Pro	Gly	Asp	Glu	Asn	Leu	Arg	Glu	Met	Asn
65					70					75				80	

Lys	Lys	Leu	Gln	Asn	Met	Leu	Glu	Glu	Gln	Leu	Thr	Lys	Asn	Met	His
				85					90					95	

Leu	His	Lys	Asp	Met	Glu	Val	Leu	Ser	Gln	Glu	Ile	Val	Arg	Leu	Ser
			100					105					110		

Lys	Glu	Cys	Val	Gly	Pro	Pro	Asp	Pro	Asp	Leu	Glu	Pro	Gly	Glu	Thr
		115					120					125			

Ser	Xaa
	130

&lt;210&gt; 90

&lt;211&gt; 41

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (41)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 90

Met	Val	Ile	Val	Asn	Ile	Leu	Ile	Leu	Cys	Phe	Leu	Leu	Thr	Ser	Asp
1				5					10					15	

Asp	Tyr	Asn	Ser	Met	Asp	Asn	Leu	Asn	Leu	Gly	Gly	Arg	Glu	Glu	Asp
			20					25					30		

Ala	Glu	Leu	Ser	Val	Asn	Leu	Ala	Xaa
		35					40	

&lt;210&gt; 91

&lt;211&gt; 57

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (57)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 91

Met Gly Pro His Trp Gly Arg Glu Ala Ser Cys Phe Leu Trp Phe Pro  
 1 5 10 15

Ala Gly Gln Ser Cys Pro Pro Phe Pro Val Leu Pro Thr Leu Gly Asn  
 20 25 30

Arg Glu Gly Arg Arg Gly Glu Glu Arg Glu Asp Pro Gly Gly Leu Gly  
 35 40 45

Arg Ser Ser Leu Lys Arg Leu Leu Xaa  
 50 55

&lt;210&gt; 92

&lt;211&gt; 59

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (59)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 92

Leu Gln Leu Gly Leu Cys Cys Leu Pro Val Leu Phe Val Ala Leu Gly  
 1 5 10 15

Met Ala Ser Asp Pro Ile Phe Thr Leu Ala Pro Pro Leu His Cys His  
 20 25 30

Tyr Gly Ala Phe Pro Pro Asn Ala Ser Gly Trp Glu Gln Pro Pro Asn  
 35 40 45

Ala Ser Gly Val Thr Ser Pro Ala Leu Pro Xaa  
 50 55

&lt;210&gt; 93

&lt;211&gt; 33

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (33)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 93

Met Thr Gly Arg Gln Ser Leu Arg Pro Gly Cys Ala Leu Leu Leu Leu  
 1 5 10 15

Pro Ser Val Phe Ser Gln Leu Leu Ser Leu Gly Ala Pro Gly Ser Glu



20

25

30

Xaa

&lt;210&gt; 94

&lt;211&gt; 37

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (37)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 94

Met	Gln	Pro	Pro	Ile	Ser	Ser	Tyr	Ser	Phe	Leu	Val	Phe	Trp	Leu	Thr
1				5					10					15	

Val	Gln	Pro	Cys	Gly	Phe	Cys	Ala	Ala	Ser	Ser	Ala	Arg	Lys	Ile	Lys
			20					25					30		

Pro	Ser	Phe	Ser	Xaa
			35	

&lt;210&gt; 95

&lt;211&gt; 38

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (38)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 95

Met	Leu	Leu	Leu	Ser	Thr	Leu	Tyr	Leu	Pro	Ser	Ala	Leu	Ser	Arg	Lys
1				5					10					15	

Thr	Phe	Val	Leu	Leu	Lys	Thr	Lys	Asp	Val	Phe	Ile	Leu	Asp	Pro	Glu
			20					25					30		

Glu	Arg	Ser	Leu	Leu	Xaa
			35		

&lt;210&gt; 96

&lt;211&gt; 30

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (30)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 96

Met Trp Leu Gln Gly Leu Pro Ala Ala Ile Leu His Ala Ala Gly Ser  
 1 5 10 15

Ala Phe His Asp Pro Arg Gln Gln Pro Gly Pro His Ser Xaa  
 20 25 30

&lt;210&gt; 97

&lt;211&gt; 8

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (8)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 97

Met Val Asp Glu Lys Gly Phe Xaa  
 1 5

&lt;210&gt; 98

&lt;211&gt; 31

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (31)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 98

Met Trp Ile Leu Ser Cys Ile Phe Met Ile Asn Val Ile Val Ala Val  
 1 5 10 15

Leu Pro Met Arg Val Gly Leu Glu Gly Leu Asn Asn Leu Ser Xaa  
 20 25 30

&lt;210&gt; 99

&lt;211&gt; 86

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (86)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 99

Met Val Gly Gly Pro Pro Phe Val Gly Pro Val Gly Phe Gly Pro Gly  
 1 5 10 15

Asp Arg Ser His Leu Asp Ser Pro Glu Ala Arg Glu Pro Cys Ser Cys  
 20 25 30

Gly Gly Gln Leu Trp Pro Pro Arg Gly Pro Leu Ser Cys Val Gln Pro  
                   35                                  40                                  45

Ser Ser Pro Thr Cys Tyr Arg Glu Gln Gln Pro Ala Pro Ala Leu Trp  
           50                                  55                                  60

Pro Tyr Gly Pro Leu Thr Arg Pro Ser Trp Ala Pro Leu Cys Leu Gly  
       65                                  70                                  75                                  80

Pro Leu Asp His Pro Xaa  
                                   85

<210> 100  
 <211> 58  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (58)  
 <223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 100  
 Met Ala Leu Asp Ser Ser Thr Leu Val Ala Leu Leu Gly Thr Ala Pro  
       1                                  5                                  10                                  15

Leu Leu Ala Ala Phe Thr Ala Gly Val Glu Cys Leu Trp Leu Phe Gln  
                   20                                  25                                  30

Ala Leu Ser Ala Ser Cys Pro Trp Ile Asp His Ser Gly Val Trp Arg  
           35                                  40                                  45

Thr Val Ala Leu Phe Ser Gln Leu His Xaa  
       50                                  55

<210> 101  
 <211> 187  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (187)  
 <223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 101  
 Leu Ala Gly Arg Leu Pro His Pro Gly Arg Pro Ala Ala Gln Leu Leu  
       1                                  5                                  10                                  15

Arg Val Cys Arg Thr His Glu Ala Pro Gly Gly His Gly Pro Ala Gly  
           20                                  25                                  30

Leu Gly Ala Ala Ala Thr Leu Pro Ala Pro Ala Arg Pro Glu Arg Leu  
       35                                  40                                  45

Pro Gly Pro Arg Leu Cys Ala Leu Arg Arg Gly Arg Leu Gly His Gly

47

50                      55                      60  
 Ala Gly Ala Leu Arg Pro Ala Arg Val Arg Gly Glu Leu Arg Gln Gly  
 65                      70                      75                      80  
 Pro Gly Arg Ala Gln Thr Pro Arg Pro Pro Ser Cys Ser Pro Ser Trp  
 85                      90                      95  
 Ala Ser Leu Thr Ser Ser Arg Gly Arg Pro Arg Ala Ser Trp Arg Gly  
 100                      105                      110  
 Leu Gly Arg Cys Gly Pro Thr Pro Ser Thr Ser Ser Ala Ser Pro Cys  
 115                      120                      125  
 Ser Ser Thr Ala Ser Arg Thr Trp Arg Ala Leu Arg Arg Ala Thr Thr  
 130                      135                      140  
 Ala Ala Ser Trp Ser Ser Ala Ser Ser Leu Ala Ser Pro Thr Ala Trp  
 145                      150                      155                      160  
 Trp Gly Pro Cys Ser Ser Arg Cys Ser Trp Pro Ser Trp Ala Pro Thr  
 165                      170                      175  
 Ser Ser Pro Val Pro Leu Ala Trp Cys Cys Xaa  
 180                      185

&lt;210&gt; 102

&lt;211&gt; 79

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (79)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 102

Met Gly His Leu Ile Gln Arg Lys Lys Val His Val Phe Gly Asp Glu  
 1                      5                      10                      15

Leu Ser Leu Val Thr Leu Phe Arg Cys Ile Gln Asn Met Pro Glu Thr  
 20                      25                      30

Leu Pro Asn Asn Ser Cys Tyr Ser Ala Gly Ile Ala Lys Leu Glu Glu  
 35                      40                      45

Gly Asp Glu Leu Gln Leu Ala Ile Pro Arg Glu Asn Ala Gln Ile Ser  
 50                      55                      60

Leu Asp Gly Asp Val Thr Phe Phe Gly Ala Leu Lys Leu Leu Xaa  
 65                      70                      75

&lt;210&gt; 103

&lt;211&gt; 32

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (32)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 103

Met	Ser	Ala	Ser	Leu	Asn	His	Ile	Lys	Val	Ser	Ser	Val	Trp	Leu	Leu
1				5				10						15	

Leu	Leu	Phe	Glu	Met	Val	Leu	Cys	Phe	Gly	Cys	Gly	Leu	Lys	Leu	Xaa
			20					25					30		

&lt;210&gt; 104

&lt;211&gt; 36

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (36)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 104

Met	Leu	Arg	Val	Met	Asn	Leu	Phe	His	Leu	Leu	Phe	Glu	Ile	Ala	Thr
1				5					10					15	

Cys	Leu	Ile	Cys	Leu	Ser	Ile	Ser	Ser	Lys	Asn	Ser	Gly	Glu	Asn	Ser
			20					25					30		

Met	Ile	Glu	Xaa
		35	

&lt;210&gt; 105

&lt;211&gt; 50

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (50)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 105

His	Leu	Pro	Cys	Lys	Leu	Val	Phe	Phe	Leu	Ser	Asp	Lys	Phe	Trp	Tyr
1				5					10					15	

Cys	Arg	Leu	Ser	Pro	Asn	His	Lys	Val	Leu	His	Tyr	Gly	Asp	Leu	Glu
			20					25					30		

Glu	Ser	Pro	Gln	Gly	Glu	Val	Pro	His	Asp	Ser	Leu	Gln	Asp	Lys	Arg
		35					40					45			

Lys Xaa  
50

<210> 106  
<211> 53  
<212> PRT  
<213> Homo sapiens  
  
<220>  
<221> SITE  
<222> (53)  
<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 106  
Met His Thr Ala Cys Leu Cys Asn Ala Ile Ile Ala Leu Leu Lys Val  
1 5 10 15  
Pro Leu Ser Phe Gln Arg Tyr Phe Phe Pro Glu Thr Thr Val Tyr Gln  
20 25 30  
His Gln Ala Cys Ser Val Thr Ile Ala Pro Glu Ser Cys Arg Ala His  
35 40 45  
Cys Cys Pro Glu Xaa  
50

<210> 107  
<211> 41  
<212> PRT  
<213> Homo sapiens  
  
<400> 107  
Pro Ser Arg Ser Thr Val Ser Ile Ser Leu Ile Ser Asn Ser Cys Ser  
1 5 10 15  
Pro Gly Asp Pro Leu Val Leu Glu Arg Pro Pro Pro Arg Trp Ser Ser  
20 25 30  
Asn Ser Pro Tyr Ser Glu Ser Tyr Tyr  
35 40

<210> 108  
<211> 41  
<212> PRT  
<213> Homo sapiens  
  
<220>  
<221> SITE  
<222> (5)  
<223> Xaa equals any of the naturally occurring L-amino acids  
  
<400> 108  
Pro Thr Ile Leu Xaa Thr Ser Ser Leu Leu Val Pro Asn Ser Cys Ser  
1 5 10 15

50

Pro Gly Asp Pro Leu Val Leu Glu Arg Pro Pro Pro Arg Trp Ser Ser  
                   20                  25                  30

Asn Ser Pro Tyr Ser Glu Ser Tyr Tyr  
           35                  40

&lt;210&gt; 109

&lt;211&gt; 18

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 109

Ser Ala Gln Leu Thr Leu Thr Lys Gly Asn Lys Ser Trp Val Pro Gly  
   1                  5                  10                  15

Pro Pro

&lt;210&gt; 110

&lt;211&gt; 18

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 110

Ser Ala Gln Leu Thr Leu Thr Lys Gly Asn Lys Ser Trp Val Arg Ala  
   1                  5                  10                  15

Pro Pro

&lt;210&gt; 111

&lt;211&gt; 294

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (255)

&lt;223&gt; Xaa equals any of the naturally occurring L-amino acids

&lt;400&gt; 111

Phe Ile Lys Asn Ile Phe Thr Lys Lys Arg Cys Leu Asn Glu Ile Glu  
   1                  5                  10                  15

Ala Asp Leu Gly Tyr Pro Gly Gly Lys Ala Arg Ile Ile His Lys Glu  
                   20                  25                  30

Ser Asp Ile Ile Thr Ala Phe Ala Val Asn Lys Ala Asn Arg Asn Cys  
           35                  40                  45

Ile Ala Ile Ala Ser Ser His Asp Val Gln Glu Leu Asp Val Ser Gly  
   50                  55                  60

Ile Leu Ala Thr Gln Val Tyr Thr Trp Val Asp Asp Asp Ile Glu Val  
   65                  70                  75                  80

```
<210> 112
<211> 288
<212> PRT
<213> Homo sapiens
```

```

<400> 112
Phe Ile Arg Tyr Ile Phe Thr Lys Lys Arg Lys Gln Ser Glu Val Glu
  1             5             10             15
Ala Asp Leu Gly Tyr Pro Gly Gly Lys Ala Lys Val Ile His Lys Glu
      20             25             30
Ser Asp Met Ile Met Ala Phe Ser Val Asn Lys Ala Asn Cys Asn Glu
      35             40             45

```



Ile Val Leu Ala Ser Thr His Asp Val Gln Glu Leu Asp Val Thr Ser  
 50 55 60  
 Leu Leu Ala Cys Gln Ser Tyr Ile Trp Ile Gly Glu Glu Tyr Asp Arg  
 65 70 75 80  
 Glu Ser Lys Ser Ser Asp Asp Val Asp Tyr Arg Gly Ser Thr Thr Thr  
 85 90 95  
 Leu Tyr Gln Pro Ser Ala Thr Ser Tyr Ser Ala Ser Gln Val His Pro  
 100 105 110  
 Pro Ser Ser Leu Pro Trp Leu Gly Thr Gly Gln Thr Ser Thr Gly Ala  
 115 120 125  
 Ser Val Leu Met Lys Arg Asn Leu His Asn Gly Lys Arg Met Thr Ser  
 130 135 140  
 His Pro Val His Gln Tyr Tyr Leu Thr Gly Ala Gln Asp Gly Ser Val  
 145 150 155 160  
 Arg Met Phe Glu Trp Thr Arg Pro Gln Gln Leu Val Cys Phe Arg Gln  
 165 170 175  
 Ala Gly Asn Ala Arg Val Thr Arg Leu Tyr Phe Asn Ser Gln Gly Asn  
 180 185 190  
 Lys Cys Gly Val Ala Asp Gly Glu Gly Phe Leu Ser Ile Trp Gln Val  
 195 200 205  
 Asn Gln Thr Ala Ser Asn Pro Lys Pro Tyr Met Ser Trp Gln Cys His  
 210 215 220  
 Ser Lys Ala Thr Ser Asp Phe Ala Phe Ile Thr Ser Ser Ser Leu Val  
 225 230 235 240  
 Ala Thr Ser Gly His Ser Asn Asp Asn Arg Asn Val Cys Leu Trp Asp  
 245 250 255  
 Thr Leu Ile Ser Pro Gly Asn Ser Leu Ile His Gly Phe Thr Cys His  
 260 265 270  
 Asp His Gly Ala Thr Val Leu Gln Tyr Ala Pro Lys Gln Gln Leu Leu  
 275 280 285

&lt;210&gt; 113

&lt;211&gt; 169

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 113

Phe Leu Ser Gly Ile Lys Gln Arg Leu Leu Ser Tyr Ile Phe Arg Gly  
 1 5 10 15

Ile Trp Asn Glu Ala Asp Gln Thr Met Arg Val Gln Cys Leu Lys Lys  
                   20                  25                  30  
 Lys Phe Tyr Phe His Phe Gln Asp Tyr Ile Asp Leu Ile Ile Trp Lys  
                   35                  40                  45  
 Val Gln Phe Leu Asp Arg His His Leu Leu Ile Lys Phe Gly Ser Val  
                   50                  55                  60  
 Asp Gly Gly Val Ser Arg Asn Ala Asp Ile His Pro Ser Phe Phe Ala  
                   65                  70                  75                  80  
 Val Tyr Asn Met Glu Thr Thr Glu Ile Val Ala Phe Tyr Gln Asn Ser  
                   85                  90                  95  
 Ala Asp Glu Leu Tyr Phe Leu Phe Glu Leu Phe Ser Asp His Phe His  
                   100                  105                  110  
 Val Ser Ser Lys Ser Ser Leu His Met Asn Phe Met Ser Ser His Ser  
                   115                  120                  125  
 Asn Asn Ile His Ala Leu Glu Gln Leu Arg Cys Thr Lys Asn Lys Ala  
                   130                  135                  140  
 Thr Asn Phe Ser Gln Phe Val Lys Lys Met Met Ala Ser Leu Pro Cys  
                   145                  150                  155                  160  
 Ser Cys Gln Ser Gln Ser Pro Ser Pro  
                   165

<210> 114  
 <211> 169  
 <212> PRT  
 <213> Homo sapiens

<400> 114  
 Phe Ile Asn Ser Leu Lys His Arg Leu Leu Val Tyr Leu Trp Arg Arg  
                   1                  5                  10                  15  
 Ala Glu Gln Asp Gly Ser Ala Met Ala Lys Arg Arg Phe Phe Gln Tyr  
                   20                  25                  30  
 Phe Asp Gln Leu Arg Gln Leu Arg Met Trp Lys Met Gln Leu Leu Asp  
                   35                  40                  45  
 Glu Asn His Leu Phe Ile Lys Tyr Thr Ser Glu Asp Val Val Thr Leu  
                   50                  55                  60  
 Arg Val Thr Asp Pro Ser Gln Ala Ser Phe Phe Val Val Tyr Asn Met  
                   65                  70                  75                  80  
 Val Thr Thr Glu Val Ile Ala Val Phe Glu Asn Thr Ser Asp Glu Leu  
                   85                  90                  95  
 Leu Glu Leu Phe Glu Asn Phe Cys Asp Leu Phe Arg Asn Ala Thr Leu  
                   100                  105                  110

His Ser Glu Val Gln Phe Pro Cys Ser Ala Ser Ser Asn Asn Phe Ala  
 115 120 125

Arg Gln Ile Gln Arg Arg Phe Lys Asp Thr Ile Ile Asn Ala Lys Tyr  
 130 135 140

Gly Gly His Thr Glu Ala Val Arg Arg Leu Leu Gly Gln Leu Pro Ile  
 145 150 155 160

Ser Ala Gln Ser Tyr Ser Gly Thr Pro  
 165

<210> 115

<211> 40

<212> PRT

<213> Homo sapiens

<400> 115

Phe Val Phe Leu Val Glu Met Gly Phe Thr Met Phe Ala Arg Leu Ile  
 1 5 10 15

Leu Ile Ser Gly Pro Cys Asp Leu Pro Ala Ser Ala Ser Gln Ser Ala  
 20 25 30

Gly Ile Thr Gly Val Ser His His  
 35 40

<210> 116

<211> 39

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (5)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<220>

<221> SITE

<222> (19)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 116

Phe Ala Phe Gln Xaa Asn Gln Gly Phe Thr Met Leu Ala Arg Met Val  
 1 5 10 15

Pro Ile Xaa Pro Cys Asp Pro Pro Ala Ser Ala Ser Gln Ser Ala Arg  
 20 25 30

Thr Thr Gly Val Asn His His  
 35

<210> 117

<211> 67

55

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 117

Val Thr Gln Ala Gly Val Gln Trp Pro Asn Leu Gly Ser Leu Gln Pro  
 1 5 10 15

Leu Pro Pro Gly Leu Lys Arg Phe Ser Cys Leu Ser Leu Pro Ser Ser  
 20 25 30

Trp Asp Tyr Gly His Leu Pro Pro His Pro Ala Asn Phe Cys Ile Phe  
 35 40 45

Ile Arg Gly Gly Val Ser Pro Tyr Leu Ser Gly Trp Ser Gln Thr Pro  
 50 55 60

Asp Leu Arg  
 65

&lt;210&gt; 118

&lt;211&gt; 67

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; SITE

&lt;222&gt; (50)

&lt;223&gt; Xaa equals any of the twenty naturally occurring L-amino acids

&lt;400&gt; 118

Val Ala Gln Ala Gly Val Gln Trp Arg Asp Leu Gly Ser Pro Gln His  
 1 5 10 15

Pro Pro Pro Gly Phe Lys Arg Phe Ser Cys Leu Ser Leu Leu Ser Ser  
 20 25 30

Trp Glu Tyr Arg His Ala Pro Leu His Leu Ala Asn Phe Cys Ile Phe  
 35 40 45

Ser Xaa Asp Gly Val Phe Pro Arg Trp Ser Gly Trp Ser Arg Thr Pro  
 50 55 60

Asp Leu Arg  
 65

&lt;210&gt; 119

&lt;211&gt; 81

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 119

Ser Leu Leu Leu Pro Arg Leu Glu Cys Asn Gly Ala Ile Ser Ala His  
 1 5 10 15

Arg Asn Leu Arg Leu Pro Gly Ser Ser Asp Ser Pro Ala Ser Ala Ser  
 20 25 30

```
<210> 120
<211> 80
<212> PRT
<213> Homo sapiens

<220>
<221> SITE
<222> (33)
<223> Xaa equals any of the twenty naturally occurring L-amino acids
```

```

<400> 120
Ser Leu Leu Leu Pro Lys Leu Glu Cys Asn Gly Ala Ile Ser Ala His
  1             5             10             15
His Asn Ile Arg Leu Leu Gly Ser Ser Asp Ser Pro Ala Ser Ala Ser
          20             25             30
Xaa Val Ala Gly Asn Thr Gly Met Arg His Tyr Thr Trp Leu Ile Phe
          35             40             45
Val Phe Leu Val Glu Met Gly Phe Phe His Val Gly Gln Ala Gly Leu
          50             55             60
Glu Leu Leu Thr Ser Gly Asp Pro Ser Thr Ser Ala Ser Gln Arg Ala
  65             70             75             80

```

```
<210> 121
<211> 36
<212> PRT
<213> Homo sapiens
```

```

<400> 121
Pro Gly Ser Ser Asp Ser Pro Ala Ser Ala Ser Arg Val Ala Gly Ile
  1             5             10             15
Thr Gly Met His His His Thr Gln Leu Ile Phe Val Phe Leu Val Glu
      20             25             30
Thr Gly Ser His
      35

```

<210> 122  
 <211> 38  
 <212> PRT  
 <213> Homo sapiens

<400> 122  
 Pro Gly Leu Ser Asn Ser Pro Ala Ser Ala Ser Gln Val Ala Gly Ile  
           1                          5                          10                          15  
 Thr Gly Met His His His Thr Trp Leu Thr Phe Ala Ser Pro Val Ala  
                           20                          25                          30  
 Gly Ile Thr Gly Val His  
                           35

<210> 123  
 <211> 55  
 <212> PRT  
 <213> Homo sapiens

<400> 123  
 Phe Ile Phe Phe Phe Arg Asp Arg Val Leu Leu Cys His Pro Gly Trp  
           1                          5                          10                          15  
 Ser Ala Val Val Gln Ser Leu Phe Thr Val Ala Ser Thr Phe Leu Val  
                           20                          25                          30  
 Lys Gln Ser Ser Cys Leu Gly Leu Pro Ser Ser Trp Asp Tyr Arg Arg  
                           35                          40                          45  
 Ile Pro Pro His Leu Ala Asn  
           50                          55

<210> 124  
 <211> 55  
 <212> PRT  
 <213> Homo sapiens

<400> 124  
 Phe Val Phe Val Leu Arg Ala Gly Val Ser Leu Cys His Pro Gly Trp  
           1                          5                          10                          15  
 Ser Ala Val Val Arg Ser Trp Leu Thr Ala Thr Ser Thr Phe Val Phe  
                           20                          25                          30  
 Lys Gln Phe Ser Phe Leu Ser Leu Leu Ser Ser Trp Asp Tyr Arg His  
                           35                          40                          45  
 Val Pro Pro Cys Pro Ala Asn  
           50                          55

<210> 125  
 <211> 24

<212> PRT

<213> Homo sapiens

<400> 125

Leu Pro Arg Leu Ile Leu Asn Ser Trp Pro Gln Val Ile Leu Leu Pro  
1 5 10 15

Trp Pro Pro Lys Val Leu Gly Leu  
20

<210> 126

<211> 24

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (9)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 126

Leu Ala Arg Leu Val Leu Asn Ser Xaa Ser Gln Val Ile Arg Pro Ser  
1 5 10 15

Arg Ser Pro Lys Val Leu Gly Leu  
20

<210> 127

<211> 69

<212> PRT

<213> Homo sapiens

<400> 127

Thr Gly Cys Ser Thr Ser Glu Ser Leu Ser Pro Val Lys Gln Ala Pro  
1 5 10 15

Arg Lys Ser Pro Ser Asp Thr Glu Gly Leu Val Lys Ser Leu Pro Ser  
20 25 30

Gly Ser His Gln Gly Pro Val Ile Tyr Ala Gln Leu Asp His Ser Gly  
35 40 45

Gly His His Ser Asp Lys Ile Asn Lys Ser Glu Ser Val Val Tyr Ala  
50 55 60

Asp Ile Arg Lys Asn  
65

<210> 128

<211> 69

<212> PRT

<213> Homo sapiens

<400> 128

Thr Cys Cys Ser Thr Ser Glu Ser Leu Ser Pro Val Lys Gln Ala Pro

59

1                      5                      10                      15  
 Arg Lys Ser Pro Ser Asp Thr Glu Gly Leu Val Lys Ser Leu Pro Ser  
                          20                      25                      30  
 Gly Ser His Gln Gly Pro Val Ile Tyr Ala Gln Leu Asp His Ser Gly  
                          35                      40                      45  
 Gly His His Ser Asp Lys Ile Asn Lys Ser Glu Ser Val Val Tyr Ala  
                          50                      55                      60  
 Asp Ile Arg Lys Asn  
                          65

<210> 129  
 <211> 133  
 <212> PRT  
 <213> Homo sapiens

<400> 129  
 Met Thr Leu Ala Ala Tyr Lys Glu Lys Met Lys Glu Leu Pro Leu Val  
   1                      5                      10                      15  
 Ser Leu Phe Cys Ser Cys Phe Leu Ser Asp Pro Leu Asn Lys Ser Ser  
                          20                      25                      30  
 Tyr Lys Tyr Glu Ala Asp Thr Val Asp Leu Asn Trp Cys Val Ile Ser  
                          35                      40                      45  
 Asp Met Glu Val Ile Glu Leu Asn Lys Cys Thr Ser Gly Gln Ser Phe  
                          50                      55                      60  
 Glu Val Ile Leu Lys Pro Pro Ser Phe Asp Gly Val Pro Glu Phe Asn  
                          65                      70                      75                      80  
 Ala Ser Leu Pro Arg Arg Arg Asp Pro Ser Leu Glu Glu Ile Gln Lys  
                          85                      90                      95  
 Lys Leu Glu Ala Ala Glu Glu Arg Arg Lys Tyr Gln Glu Ala Glu Leu  
                          100                      105                      110  
 Leu Lys His Leu Ala Glu Lys Arg Glu His Glu Arg Glu Val Ile Gln  
                          115                      120                      125  
 Lys Ala Ile Glu Glu  
                          130

<210> 130  
 <211> 133  
 <212> PRT  
 <213> Homo sapiens

<400> 130  
 Met Thr Leu Ala Ala Tyr Lys Glu Lys Met Lys Glu Leu Pro Leu Val  
   1                      5                      10                      15



60

Ser Leu Phe Cys Ser Cys Phe Leu Ala Asp Pro Leu Asn Lys Ser Ser  
                   20                  25                  30  
 Tyr Lys Tyr Glu Ala Asp Thr Val Asp Leu Asn Trp Cys Val Ile Ser  
                   35                  40                  45  
 Asp Met Glu Val Ile Glu Leu Asn Lys Cys Thr Ser Gly Gln Ser Phe  
                   50                  55                  60  
 Glu Val Ile Leu Lys Pro Pro Ser Phe Asp Gly Val Pro Glu Phe Asn  
                   65                  70                  75                  80  
 Ala Ser Leu Pro Arg Arg Arg Asp Pro Ser Leu Glu Glu Ile Gln Lys  
                   85                  90                  95  
 Lys Leu Glu Ala Ala Glu Glu Arg Arg Lys Tyr Gln Glu Ala Glu Leu  
                   100                  105                  110  
 Leu Lys His Leu Ala Glu Lys Arg Glu His Glu Arg Glu Val Ile Gln  
                   115                  120                  125  
 Lys Ala Ile Glu Glu  
                   130

<210> 131  
 <211> 56  
 <212> PRT  
 <213> Homo sapiens

<400> 131  
 Asn Asn Asn Phe Ile Lys Met Ala Lys Glu Lys Leu Ala Gln Lys Met  
   1                  5                  10                  15  
 Glu Ser Asn Lys Glu Asn Arg Glu Ala His Leu Ala Ala Met Leu Glu  
                   20                  25                  30  
 Arg Leu Gln Glu Lys Asp Lys His Ala Glu Glu Val Arg Lys Asn Lys  
                   35                  40                  45  
 Glu Leu Lys Glu Glu Ala Ser Arg  
                   50                  55

<210> 132  
 <211> 56  
 <212> PRT  
 <213> Homo sapiens

<400> 132  
 Asn Asn Asn Phe Ile Lys Met Ala Lys Glu Lys Leu Ala Gln Lys Met  
   1                  5                  10                  15  
 Glu Ser Asn Lys Glu Asn Arg Glu Ala His Leu Ala Ala Met Leu Glu  
                   20                  25                  30  
 Arg Leu Gln Glu Lys Asp Lys His Ala Glu Glu Val Arg Lys Asn Lys  
                   35                  40                  45

Glu Leu Lys Glu Glu Ala Ser Arg  
 50 55

<210> 133  
 <211> 170  
 <212> PRT  
 <213> Homo sapiens

<400> 133  
 Arg Gly Glu Glu Ala Ala Glu Glu Lys Leu Glu Ala Ser Arg Gly Trp  
 1 5 10 15  
 Phe Met Arg Phe Lys Glu Arg Ser His Leu His Asn Ile Lys Val Gln  
 20 25 30  
 Gly Glu Ala Ala Ser Ala Asp Val Glu Ala Ala Ala Ser Tyr Pro Glu  
 35 40 45  
 Asp Leu Ala Lys Ile Ile Asp Glu Gly Gly Tyr Thr Lys Gln Gln Ile  
 50 55 60  
 Phe Asn Val Asp Glu Thr Ala Phe Tyr Trp Lys Lys Met Pro Ser Arg  
 65 70 75 80  
 Thr Phe Ile Ala Arg Glu Glu Lys Ser Met Pro Gly Phe Lys Ala Ser  
 85 90 95  
 Lys Asp Arg Leu Thr Leu Leu Leu Gly Ala Asn Ala Ala Gly Asp Phe  
 100 105 110  
 Lys Leu Lys Pro Met Leu Ile Tyr His Ser Glu Asn Pro Arg Ala Leu  
 115 120 125  
 Lys Asn Tyr Ala Lys Ser Thr Leu Pro Val Leu Tyr Lys Trp Asn Asn  
 130 135 140  
 Lys Ala Trp Met Thr Ala His Leu Phe Thr Ala Trp Phe Thr Glu Tyr  
 145 150 155 160  
 Phe Lys Pro Thr Val Glu Thr Tyr Cys Ser  
 165 170

<210> 134  
 <211> 166  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> SITE  
 <222> (82)  
 <223> Xaa equals any of the twenty naturally occurring L-amino acids  
 <220>  
 <221> SITE  
 <222> (138)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<220>

<221> SITE

<222> (141)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<220>

<221> SITE

<222> (152)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 134

Arg Gly Glu Glu Ala Ala Glu Glu Lys Leu Glu Pro Gly Arg Gly Trp  
1 5 10 15

Phe Met Arg Phe Lys Glu Arg Ser His Pro His Ser Ile Lys Val Gln  
20 25 30

Gly Gly Ala Ala Asn Thr Asp Val Glu Ala Ala Ala Ser Tyr Pro Glu  
35 40 45

Asp Leu Ala Lys Ile Ile Asp Glu Gly Gly Tyr Thr Lys Gln Glu Ile  
50 55 60

Phe Ser Val Asp Lys Arg Val Phe Phe Trp Lys Lys Met Pro Ser Trp  
65 70 75 80

Leu Xaa Ile Ala Gly Glu Asn Lys Glu Met Thr Asp Phe Lys Gly Gln  
85 90 95

Ala Ile Leu Leu Gly Ala Asn Ala Ala Gly Asp Leu Lys Ser Lys Pro  
100 105 110

Met Leu Ile Tyr His Ser Glu Asn Leu Arg Ala Leu Lys Asn Tyr Ile  
115 120 125

Lys Ser Ile Leu Pro Val Leu Tyr Lys Xaa Asn Asn Xaa Ala Trp Met  
130 135 140

Pro Ala His Leu Phe Ile Ala Xaa Phe Thr Glu Asp Phe Lys Ser Thr  
145 150 155 160

Val Glu Thr Tyr Cys Ser  
165

<210> 135

<211> 175

<212> PRT

<213> Homo sapiens

<400> 135

Glu Ile Asn Leu Leu Ala Tyr His Gly Ala Cys His Gly Ala Gly Pro  
1 5 10 15

Val Pro Thr Gly Ser Leu Leu Asp Leu Arg Leu Leu Ser Ala Phe Lys  
20 25 30

Pro	Pro	Ala	Tyr	Glu	Asp	Val	Val	His	Pro	Gly	Thr	Pro	Pro	Pro	
		35					40				45				
Pro	Tyr	Thr	Val	Gly	Pro	Gly	Tyr	Pro	Trp	Thr	Thr	Ser	Ser	Glu	Cys
	50					55					60				
Thr	Arg	Cys	Ser	Ser	Glu	Ser	Ser	Cys	Ser	Ala	His	Leu	Glu	Gly	Thr
65					70					75					80
Asn	Val	Glu	Gly	Val	Ser	Ser	Gln	Gln	Ser	Ala	Leu	Pro	His	Gln	Glu
				85					90					95	
Gly	Glu	Pro	Arg	Ala	Gly	Leu	Ser	Pro	Val	His	Ile	Pro	Pro	Ser	Cys
			100					105					110		
Arg	Tyr	Arg	Arg	Leu	Thr	Gly	Asp	Ser	Gly	Ile	Glu	Leu	Cys	Pro	Cys
	115						120					125			
Pro	Asp	Ser	Ser	Glu	Gly	Glu	Pro	Leu	Lys	Glu	Ala	Arg	Ala	Ser	Ala
	130					135					140				
Ser	Gln	Pro	Asp	Leu	Glu	Asp	His	Ser	Pro	Cys	Ala	Leu	Pro	Pro	Asp
145					150					155					160
Ser	Val	Ser	Gln	Val	Pro	Pro	Met	Gly	Leu	Ala	Ser	Ser	Cys	Gly	
				165					170					175	

```
<210> 136
<211> 175
<212> PRT
<213> Homo sapiens
```

```

<400> 136
Glu Ile Asn Leu Leu Ala Tyr His Gly Ala Cys His Gly Ala Gly Pro
  1             5             10             15
Phe Pro Thr Gly Ser Leu Leu Asp Leu Arg Phe Leu Ser Thr Phe Lys
      20             25             30
Pro Pro Ala Tyr Glu Asp Val Val His Arg Pro Gly Thr Pro Pro Pro
      35             40             45
Pro Tyr Thr Val Ala Pro Gly Arg Pro Leu Thr Ala Ser Ser Glu Gln
      50             55             60
Thr Cys Cys Ser Ser Ser Ser Ser Cys Pro Ala His Phe Glu Gly Thr
  65             70             75             80
Asn Val Glu Gly Val Ser Ser His Gln Ser Ala Pro Pro His Gln Glu
      85             90             95
Gly Glu Pro Gly Ala Gly Val Thr Pro Ala Ser Thr Pro Pro Ser Cys
      100             105             110
Arg Tyr Arg Arg Leu Thr Gly Asp Ser Gly Ile Glu Leu Cys Pro Cys
      115             120             125

```

64

Pro Ala Ser Gly Glu Gly Glu Pro Val Lys Glu Val Arg Val Ser Ala  
 130 135 140

Thr Leu Pro Asp Leu Glu Asp Tyr Ser Pro Cys Ala Leu Pro Pro Glu  
 145 150 155 160

Ser Val Pro Gln Ile Phe Pro Met Gly Leu Ser Ser Ser Glu Gly  
 165 170 175

<210> 137

<211> 68

<212> PRT

<213> Homo sapiens

<400> 137

His Leu Arg Ser Gly Val Gln Asp Tyr Pro Gly Gln His Gly Lys Ile  
 1 5 10 15

Pro Ser Leu Leu Lys Ile Gln Glu Leu Ala Gly His Gly Gly Arg Cys  
 20 25 30

Leu Gln Ser Gln Leu Leu Arg Arg Leu Arg Gln Glu Asn His Leu Asn  
 35 40 45

Ser Gly Gly Arg Gly Cys Ser Glu Pro Lys Ser His Leu Cys Ile Pro  
 50 55 60

Ala Trp Val Thr  
 65

<210> 138

<211> 68

<212> PRT

<213> Homo sapiens

<220>

<221> SITE

<222> (34)

<223> Xaa equals any of the twenty naturally occurring L-amino acids

<400> 138

His Leu Arg Ser Gly Val Gln Asp Gln Pro Asp Gln His Gly Glu Thr  
 1 5 10 15

Leu Ser Leu Leu Lys Ile Gln Lys Leu Ala Gly His Gly Asp Ala Cys  
 20 25 30

Leu Xaa Ser Gln Leu Leu Arg Arg Leu Arg Gln Glu Asn His Leu Asn  
 35 40 45

Leu Gly Gly Gly Gly Cys Ser Glu Pro Arg Leu His His Cys Thr Pro  
 50 55 60

Ala Trp Ala Thr  
 65

&lt;210&gt; 139

&lt;211&gt; 339

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 139

Met Ala Asn Leu Asp Lys Tyr Thr Glu Thr Phe Lys Met Gly Ser Asn  
 1 5 10 15

Ser Thr Ser Thr Ala Glu Ile Tyr Cys Asn Val Thr Asn Val Lys Phe  
 20 25 30

Gln Tyr Ser Leu Tyr Ala Thr Thr Tyr Ile Leu Ile Phe Ile Pro Gly  
 35 40 45

Leu Leu Ala Asn Ser Ala Ala Leu Trp Val Leu Cys Arg Phe Ile Ser  
 50 55 60

Lys Lys Asn Lys Ala Ile Ile Phe Met Ile Asn Leu Ser Val Ala Asp  
 65 70 75 80

Leu Ala His Val Leu Ser Leu Pro Leu Arg Ile Tyr Tyr Tyr Ile Ser  
 85 90 95

His His Trp Pro Phe Gln Arg Ala Leu Cys Leu Leu Cys Phe Tyr Leu  
 100 105 110

Lys Tyr Leu Asn Met Tyr Ala Ser Ile Cys Phe Leu Thr Cys Ile Ser  
 115 120 125

Leu Gln Arg Cys Phe Phe Leu Leu Lys Pro Phe Arg Ala Arg Asp Trp  
 130 135 140

Lys Arg Arg Tyr Asp Val Gly Ile Ser Ala Ala Ile Trp Ile Val Val  
 145 150 155 160

Gly Thr Ala Cys Leu Pro Phe Pro Ile Leu Arg Ser Thr Asp Leu Asn  
 165 170 175

Asn Asn Lys Ser Cys Phe Ala Asp Leu Gly Tyr Lys Gln Met Asn Ala  
 180 185 190

Val Ala Leu Val Gly Met Ile Thr Val Ala Glu Leu Ala Gly Phe Val  
 195 200 205

Ile Pro Val Ile Ile Ile Ala Trp Cys Thr Trp Lys Thr Thr Ile Ser  
 210 215 220

Leu Arg Gln Pro Pro Met Ala Phe Gln Gly Ile Ser Glu Arg Gln Lys  
 225 230 235 240

Ala Leu Arg Met Val Phe Met Cys Ala Ala Val Phe Phe Ile Cys Phe  
 245 250 255

Thr Pro Tyr His Ile Asn Phe Ile Phe Tyr Thr Met Val Lys Glu Thr  
 260 265 270

Ile Ile Ser Ser Cys Pro Val Val Arg Ile Ala Leu Tyr Phe His Pro  
275 280 285

Phe Cys Leu Cys Leu Ala Ser Leu Cys Cys Leu Leu Asp Pro Ile Leu  
290 295 300

Tyr Tyr Phe Met Ala Ser Glu Phe Arg Asp Gln Leu Ser Arg His Gly  
305 310 315 320

Ser Ser Val Thr Arg Ser Arg Leu Met Ser Lys Glu Ser Gly Ser Ser  
325 330 335

Met Ile Gly

<210> 140

<211> 339

<212> PRT

<213> Homo sapiens

<400> 140

Met Ala Asn Leu Asp Lys Tyr Thr Glu Thr Phe Lys Met Gly Ser Asn  
1 5 10 15

Ser Thr Ser Thr Ala Glu Ile Tyr Cys Asn Val Thr Asn Val Lys Phe  
20 25 30

Gln Tyr Ser Leu Tyr Ala Thr Thr Tyr Ile Leu Ile Phe Ile Pro Gly  
35 40 45

Leu Leu Ala Asn Ser Ala Ala Leu Trp Val Leu Cys Arg Phe Ile Ser  
50 55 60

Lys Lys Asn Lys Ala Ile Ile Phe Met Ile Asn Leu Ser Val Ala Asp  
65 70 75 80

Leu Ala His Val Leu Ser Leu Pro Leu Arg Ile Tyr Tyr Tyr Ile Ser  
85 90 95

His His Trp Pro Phe Gln Arg Ala Leu Cys Leu Leu Cys Phe Tyr Leu  
100 105 110

Lys Tyr Leu Asn Met Tyr Ala Ser Ile Cys Phe Leu Thr Cys Ile Ser  
115 120 125

Leu Gln Arg Cys Phe Phe Leu Leu Lys Pro Phe Arg Ala Arg Asp Trp  
130 135 140

Lys Arg Arg Tyr Asp Val Gly Ile Ser Ala Ala Ile Trp Ile Val Val  
145 150 155 160

Gly Thr Ala Cys Leu Pro Phe Pro Ile Leu Arg Ser Thr Asp Leu Asn  
165 170 175

Asn Asn Lys Ser Cys Phe Ala Asp Leu Gly Tyr Lys Gln Met Asn Ala  
180 185 190

Val Ala Leu Val Gly Met Ile Thr Val Ala Glu Leu Ala Gly Phe Val  
 195 200 205  
 Ile Pro Val Ile Ile Ile Ala Trp Cys Thr Trp Lys Thr Thr Ile Ser  
 210 215 220  
 Leu Arg Gln Pro Pro Met Ala Phe Gln Gly Ile Ser Glu Arg Gln Lys  
 225 230 235 240  
 Ala Leu Arg Met Val Phe Met Cys Ala Ala Val Phe Phe Ile Cys Phe  
 245 250 255  
 Thr Pro Tyr His Ile Asn Phe Ile Phe Tyr Thr Met Val Lys Glu Thr  
 260 265 270  
 Ile Ile Ser Ser Cys Pro Val Val Arg Ile Ala Leu Tyr Phe His Pro  
 275 280 285  
 Phe Cys Leu Cys Leu Ala Ser Leu Cys Cys Leu Leu Asp Pro Ile Leu  
 290 295 300  
 Tyr Tyr Phe Met Ala Ser Glu Phe Arg Asp Gln Leu Ser Arg His Gly  
 305 310 315 320  
 Ser Ser Val Thr Arg Ser Arg Leu Met Ser Lys Glu Ser Gly Ser Ser  
 325 330 335  
 Met Ile Gly

<210> 141  
 <211> 62  
 <212> PRT  
 <213> Homo sapiens

<400> 141  
 Tyr Tyr Met Glu Ser Gly Pro Arg Lys Lys Leu Phe Glu Tyr Gln Gln  
 1 5 10 15  
 Ala Gln Leu Glu Ala Glu Ile Glu Asn Leu Ser Trp Lys Val Glu Arg  
 20 25 30  
 Ala Asp Ser Tyr Asp Arg Gly Asp Leu Glu Asn Gln Met His Ile Ala  
 35 40 45  
 Glu Gln Arg Arg Arg Thr Leu Lys Asp Phe His Asp Thr  
 50 55 60

<210> 142  
 <211> 62  
 <212> PRT  
 <213> Homo sapiens

<400> 142  
 Tyr Tyr Met Glu Ser Gly Pro Arg Lys Lys Leu Phe Glu Tyr Gln Gln



68

1	5	10	15
Ala Gln Leu Glu Ala Glu Ile Glu Asn Leu Ser Trp Lys Val Glu Arg	20	25	30
Ala Asp Ser Tyr Asp Arg Gly Asp Leu Glu Asn Gln Met His Ile Ala	35	40	45
Glu Gln Arg Arg Arg Thr Leu Leu Lys Asp Phe His Asp Thr	50	55	60

<210> 143  
 <211> 147  
 <212> PRT  
 <213> Homo sapiens

<400> 143  
 Gly Leu Met Ala Leu Glu Val Pro Glu Pro Leu Gly Glu Asp Lys Lys  
 1 5 10 15

Lys Gly Lys Pro Glu Lys Leu Lys Arg Cys Ile Arg Thr Ala Ala Gly  
 20 25 30

Ser Ser Trp Glu Asp Pro Ser Leu Leu Glu Trp Asp Ala Asp Asp Phe  
 35 40 45

Arg Ile Phe Cys Gly Asp Leu Gly Asn Glu Val Asn Asp Asp Ile Leu  
 50 55 60

Ala Arg Ala Phe Ser Arg Phe Pro Ser Phe Leu Lys Ala Lys Val Ile  
 65 70 75 80

Arg Asp Lys Arg Thr Gly Lys Thr Lys Gly Tyr Gly Phe Val Ser Phe  
 85 90 95

Lys Asp Pro Ser Asp Tyr Val Arg Ala Met Arg Glu Met Asn Gly Lys  
 100 105 110

Tyr Val Gly Ser Arg Pro Ile Lys Leu Arg Lys Ser Met Trp Lys Asp  
 115 120 125

Arg Asn Leu Asp Val Val Arg Lys Lys Gln Lys Glu Lys Lys Lys Leu  
 130 135 140

Gly Leu Arg  
 145

<210> 144  
 <211> 147  
 <212> PRT  
 <213> Homo sapiens

<400> 144  
 Gly Leu Met Ala Leu Glu Val Pro Glu Pro Leu Gly Glu Asp Lys Lys  
 1 5 10 15

69

Lys Gly Lys Pro Glu Lys Leu Lys Arg Cys Ile Arg Thr Ala Ala Gly  
                     20                    25                    30  
 Ser Ser Trp Glu Asp Pro Ser Leu Leu Glu Trp Asp Ala Asp Asp Phe  
                     35                    40                    45  
 Arg Ile Phe Cys Gly Asp Leu Gly Asn Glu Val Asn Asp Asp Ile Leu  
                     50                    55                    60  
 Ala Arg Ala Phe Ser Arg Phe Pro Ser Phe Leu Lys Ala Lys Val Ile  
                     65                    70                    75                    80  
 Arg Asp Lys Arg Thr Gly Lys Thr Lys Gly Tyr Gly Phe Val Ser Phe  
                     85                    90                    95  
 Lys Asp Pro Ser Asp Tyr Val Arg Ala Met Arg Glu Met Asn Gly Lys  
                     100                    105                    110  
 Tyr Val Gly Ser Arg Pro Ile Lys Leu Arg Lys Ser Met Trp Lys Asp  
                     115                    120                    125  
 Arg Asn Leu Asp Val Val Arg Lys Lys Gln Lys Glu Lys Lys Lys Leu  
                     130                    135                    140  
 Gly Leu Arg  
 145

<210> 145  
 <211> 52  
 <212> PRT  
 <213> Homo sapiens

<400> 145  
 Met Phe Leu Arg Arg Ala Ala Val Ala Pro Gln Arg Ala Pro Ile Leu  
   1                    5                    10                    15  
 Arg Pro Ala Phe Val Pro His Val Leu Gln Arg Ala Asp Ser Ala Leu  
                     20                    25                    30  
 Ser Ser Ala Ala Ala Gly Pro Arg Pro Met Ala Leu Arg Pro Pro His  
                     35                    40                    45  
 Gln Ala Leu Val  
                     50

<210> 146  
 <211> 45  
 <212> PRT  
 <213> Homo sapiens

<400> 146  
 Met Phe Leu Arg Arg Ala Ala Val Ala Pro Gln Arg Ala Pro Ile Leu  
   1                    5                    10                    15  
 Arg Pro Ala Phe Val Pro His Val Leu Gln Arg Ala Ala Ala Gly Pro  
                     20                    25                    30

Arg Pro Met Ala Leu Arg Pro Pro His Gln Ala Leu Val  
                   35                                  40                                  45

<210> 147

<211> 154

<212> PRT

<213> Homo sapiens

<400> 147

Ser Phe Cys Arg Ser Ile Ile Gln Val Tyr Leu Thr Thr Gly Val Ile  
   1                                  5                                  10                                  15

Thr Gly Leu Gly Leu Ala Leu Asn Phe Gln Pro Ser Leu Ile Met Leu  
                                   20                                  25                                  30

Asn Arg Tyr Phe Ser Lys Arg Arg Pro Met Ala Asn Gly Leu Ala Ala  
                   35                                  40                                  45

Ala Gly Ser Pro Val Phe Leu Cys Ala Leu Ser Pro Leu Gly Gln Leu  
   50                                  55                                  60

Leu Gln Asp Arg Tyr Gly Trp Arg Gly Gly Phe Leu Ile Leu Gly Gly  
   65                                  70                                  75                                  80

Leu Leu Leu Asn Cys Cys Val Cys Ala Ala Leu Met Arg Pro Leu Val  
                                   85                                  90                                  95

Val Thr Ala Gln Pro Gly Ser Gly Pro Pro Arg Pro Ser Arg Arg Leu  
                   100                                  105                                  110

Leu Asp Leu Ser Val Phe Arg Asp Arg Gly Phe Val Leu Tyr Ala Val  
   115                                  120                                  125

Ala Ala Ser Val Met Val Leu Gly Leu Phe Val Pro Pro Val Phe Val  
   130                                  135                                  140

Val Ser Tyr Ala Lys Asp Leu Gly Val Pro  
   145                                  150

<210> 148

<211> 154

<212> PRT

<213> Homo sapiens

<400> 148

Ser Phe Cys Arg Ser Ile Ile Gln Val Tyr Leu Thr Thr Gly Val Ile  
   1                                  5                                  10                                  15

Thr Gly Leu Gly Leu Ala Leu Asn Phe Gln Pro Ser Leu Ile Met Leu  
                                   20                                  25                                  30

Asn Arg Tyr Phe Ser Lys Arg Arg Pro Met Ala Asn Gly Leu Ala Ala  
                   35                                  40                                  45

Ala Gly Ser Pro Val Phe Leu Cys Ala Leu Ser Pro Leu Gly Gln Leu

71

50                      55                      60  
 Leu Gln Asp Arg Tyr Gly Trp Arg Gly Gly Phe Leu Ile Leu Gly Gly  
 65                      70                      75                      80  
 Leu Leu Leu Asn Cys Cys Val Cys Ala Ala Leu Met Arg Pro Leu Val  
                     85                      90                      95  
 Val Thr Ala Gln Pro Gly Ser Gly Pro Pro Arg Pro Ser Arg Arg Leu  
                     100                      105                      110  
 Leu Asp Leu Ser Val Phe Arg Asp Arg Gly Phe Val Leu Tyr Ala Val  
                     115                      120                      125  
 Ala Ala Ser Val Met Val Leu Gly Leu Phe Val Pro Pro Val Phe Val  
                     130                      135                      140  
 Val Ser Tyr Ala Lys Asp Leu Gly Val Pro  
 145                      150

<210> 149  
 <211> 113  
 <212> PRT  
 <213> Homo sapiens

<400> 149  
 Pro Asp Thr Lys Ala Ala Phe Leu Leu Thr Ile Leu Gly Phe Ile Asp  
 1                      5                      10                      15  
 Ile Phe Ala Arg Pro Ala Ala Gly Phe Val Ala Gly Leu Gly Lys Val  
                     20                      25                      30  
 Arg Pro Tyr Ser Val Tyr Leu Phe Ser Phe Ser Met Phe Phe Asn Gly  
                     35                      40                      45  
 Leu Ala Asp Leu Ala Gly Ser Thr Ala Gly Asp Tyr Gly Gly Leu Val  
                     50                      55                      60  
 Val Phe Cys Ile Phe Phe Gly Ile Ser Tyr Gly Met Val Gly Ala Leu  
                     65                      70                      75                      80  
 Gln Phe Glu Val Leu Met Ala Ile Val Gly Thr His Lys Phe Ser Ser  
                     85                      90                      95  
 Ala Ile Gly Leu Val Leu Leu Met Glu Ala Val Ala Val Leu Val Gly  
                     100                      105                      110  
 Pro

<210> 150  
 <211> 113  
 <212> PRT  
 <213> Homo sapiens

<400> 150

72

Pro Asp Thr Lys Ala Ala Phe Leu Leu Thr Ile Leu Gly Phe Ile Asp  
 1 5 10 15  
 Ile Phe Ala Arg Pro Ala Ala Gly Phe Val Ala Gly Leu Gly Lys Val  
 20 25 30  
 Arg Pro Tyr Ser Val Tyr Leu Phe Ser Phe Ser Met Phe Phe Asn Gly  
 35 40 45  
 Leu Ala Asp Leu Ala Gly Ser Thr Ala Gly Asp Tyr Gly Gly Leu Val  
 50 55 60  
 Val Phe Cys Ile Phe Phe Gly Ile Ser Tyr Gly Met Val Gly Ala Leu  
 65 70 75 80  
 Gln Phe Glu Val Leu Met Ala Ile Val Gly Thr His Lys Phe Ser Ser  
 85 90 95  
 Ala Ile Gly Leu Val Leu Leu Met Glu Ala Val Ala Val Leu Val Gly  
 100 105 110

Pro

<210> 151  
 <211> 73  
 <212> PRT  
 <213> Homo sapiens

<400> 151  
 Met Gly Gly Ala Val Val Asp Glu Gly Pro Thr Gly Val Lys Ala Pro  
 1 5 10 15  
 Asp Gly Gly Trp Gly Trp Ala Val Leu Phe Gly Cys Phe Val Ile Thr  
 20 25 30  
 Gly Phe Ser Tyr Ala Phe Pro Lys Ala Val Ser Val Phe Phe Lys Glu  
 35 40 45  
 Leu Ile Gln Glu Phe Gly Ile Gly Tyr Ser Asp Thr Ala Trp Ile Ser  
 50 55 60  
 Ser Ile Leu Leu Ala Met Leu Tyr Gly  
 65 70

<210> 152  
 <211> 73  
 <212> PRT  
 <213> Homo sapiens

<400> 152  
 Met Gly Gly Ala Val Val Asp Glu Gly Pro Thr Gly Val Lys Ala Pro  
 1 5 10 15  
 Asp Gly Gly Trp Gly Trp Ala Val Leu Phe Gly Cys Phe Val Ile Thr  
 20 25 30

Gly Phe Ser Tyr Ala Phe Pro Lys Ala Val Ser Val Phe Phe Lys Glu  
                   35                                  40                                  45

Leu Ile Gln Glu Phe Gly Ile Gly Tyr Ser Asp Thr Ala Trp Ile Ser  
           50                                  55                                  60

Ser Ile Leu Leu Ala Met Leu Tyr Gly  
   65                                  70

<210> 153

<211> 90

<212> PRT

<213> Homo sapiens

<400> 153

Lys Leu Leu Asp Ala Thr His Val Tyr Met Tyr Val Phe Ile Leu Ala  
   1                                  5                                  10                                  15

Gly Ala Glu Val Leu Thr Ser Ser Leu Ile Leu Leu Leu Gly Asn Phe  
                   20                                  25                                  30

Phe Cys Ile Arg Lys Lys Pro Lys Glu Pro Gln Pro Glu Val Ala Ala  
           35                                  40                                  45

Ala Glu Glu Glu Lys Leu His Lys Pro Pro Ala Asp Ser Gly Val Asp  
   50                                  55                                  60

Leu Arg Glu Val Glu His Phe Leu Lys Ala Glu Pro Glu Lys Asn Gly  
   65                                  70                                  75                                  80

Glu Val Val His Thr Pro Glu Thr Ser Val  
                   85                                  90

<210> 154

<211> 90

<212> PRT

<213> Homo sapiens

<400> 154

Lys Leu Leu Asp Ala Thr His Val Tyr Met Tyr Val Phe Ile Leu Ala  
   1                                  5                                  10                                  15

Gly Ala Glu Val Leu Thr Ser Ser Leu Ile Leu Leu Leu Gly Asn Phe  
                   20                                  25                                  30

Phe Cys Ile Arg Lys Lys Pro Lys Glu Pro Gln Pro Glu Val Ala Ala  
           35                                  40                                  45

Ala Glu Glu Glu Lys Leu His Lys Pro Pro Ala Asp Ser Gly Val Asp  
   50                                  55                                  60

Leu Arg Glu Val Glu His Phe Leu Lys Ala Glu Pro Glu Lys Asn Gly  
   65                                  70                                  75                                  80

Glu Val Val His Thr Pro Glu Thr Ser Val

74

85

90

&lt;210&gt; 155

&lt;211&gt; 33

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 155

Gly Thr Gly Pro Leu Cys Ser Val Cys Val Asn Arg Phe Gly Cys Arg  
 1 5 10 15

Pro Val Met Leu Val Gly Gly Leu Phe Ala Ser Leu Gly Met Val Ala  
 20 25 30

Ala

&lt;210&gt; 156

&lt;211&gt; 33

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 156

Gly Thr Ser Pro Leu Cys Ser Val Cys Val Asn Arg Phe Gly Cys Arg  
 1 5 10 15

Pro Val Met Leu Val Gly Gly Leu Phe Ala Ser Leu Gly Met Val Ala  
 20 25 30

Ala

&lt;210&gt; 157

&lt;211&gt; 24

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 157

Ser Leu Ile Met Leu Asn Arg Tyr Phe Ser Lys Arg Arg Pro Met Ala  
 1 5 10 15

Asn Gly Leu Ala Ala Ala Gly Ser  
 20

&lt;210&gt; 158

&lt;211&gt; 24

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 158

Ser Leu Arg Lys Thr Gly Arg Trp Phe Thr Pro Arg Lys Gln Val Ser  
 1 5 10 15

Glu Trp Leu Gly Gly Ala Gly Ser

75

20

&lt;210&gt; 159

&lt;211&gt; 123

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 159

Lys Asp Asp Ser Asp Val Thr Glu Val Met Trp Gln Pro Ala Leu Arg  
 1 5 10 15

Arg Gly Arg Gly Leu Gln Ala Gln Gly Tyr Gly Val Arg Ile Gln Asp  
 20 25 30

Ala Gly Val Tyr Leu Leu Tyr Ser Gln Val Leu Phe Gln Asp Val Thr  
 35 40 45

Phe Thr Met Gly Gln Val Val Ser Arg Glu Gly Gln Gly Arg Gln Glu  
 50 55 60

Thr Leu Phe Arg Cys Ile Arg Ser Met Pro Ser His Pro Asp Arg Ala  
 65 70 75 80

Tyr Asn Ser Cys Tyr Ser Ala Gly Val Phe His Leu His Gln Gly Asp  
 85 90 95

Ile Leu Ser Val Ile Ile Pro Arg Ala Arg Ala Lys Leu Asn Leu Ser  
 100 105 110

Pro His Gly Thr Phe Leu Gly Phe Val Lys Leu  
 115 120

&lt;210&gt; 160

&lt;211&gt; 127

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;400&gt; 160

Glu Glu Thr Gly Ser Tyr Thr Phe Val Pro Trp Leu Leu Ser Phe Lys  
 1 5 10 15

Arg Gly Ser Ala Leu Glu Glu Lys Glu Asn Lys Ile Leu Val Lys Glu  
 20 25 30

Thr Gly Tyr Phe Phe Ile Tyr Gly Gln Val Leu Tyr Thr Asp Lys Thr  
 35 40 45

Tyr Ala Met Gly His Leu Ile Gln Arg Lys Lys Val His Val Phe Gly  
 50 55 60

Asp Glu Leu Ser Leu Val Thr Leu Phe Arg Cys Ile Gln Asn Met Pro  
 65 70 75 80

Glu Thr Leu Pro Asn Asn Ser Cys Tyr Ser Ala Gly Ile Ala Lys Leu  
 85 90 95



Glu Glu Gly Asp Glu Leu Gln Leu Ala Ile Pro Arg Glu Asn Ala Gln  
                   100                  105                  110

Ile Ser Leu Asp Gly Asp Val Thr Phe Phe Gly Ala Leu Lys Leu  
           115                  120                  125

<210> 161

<211> 88

<212> PRT

<213> Homo sapiens

<400> 161

Trp Arg Ser Asn Thr Ser Leu Leu Gln Gln Asn Leu Arg Gln Leu Met  
   1                  5                  10                  15

Lys Val Asp Gly Gly Glu Val Val Lys Phe Leu Gln Asp Thr Leu Asp  
                   20                  25                  30

Ala Leu Phe Asn Ile Met Met Glu Asn Ser Glu Ser Glu Thr Phe Asp  
           35                  40                  45

Thr Leu Val Phe Asp Ala Leu Val Phe Ile Ile Gly Leu Ile Ala Asp  
   50                  55                  60

Arg Lys Phe Gln His Phe Asn Pro Val Leu Glu Thr Tyr Ile Lys Lys  
   65                  70                  75                  80

His Phe Ser Ala Thr Leu Ala Tyr  
                   85

<210> 162

<211> 88

<212> PRT

<213> Homo sapiens

<400> 162

Trp Arg Ser Asn Ser Gln Asn Ile Lys His Asn Leu Lys Lys Leu Met  
   1                  5                  10                  15

Glu Val Asp Gly Gly Glu Ile Val Lys Phe Leu Gln Asp Thr Leu Asp  
                   20                  25                  30

Ala Leu Phe Asn Ile Met Met Glu Met Ser Asp Ser Glu Thr Tyr Asp  
           35                  40                  45

Phe Leu Val Phe Asp Ala Leu Val Phe Ile Ile Ser Leu Ile Gly Asp  
   50                  55                  60

Ile Lys Phe Gln His Phe Asn Pro Val Leu Glu Thr Tyr Ile Tyr Lys  
   65                  70                  75                  80

His Phe Ser Ala Thr Leu Ala Tyr  
                   85

<210> 163

<211> 36  
 <212> PRT  
 <213> Homo sapiens

<400> 163  
 Asp Lys Phe Trp Tyr Cys Arg Leu Ser Pro Asn His Lys Val Leu His  
 1 5 10 15  
 Tyr Gly Asp Leu Glu Glu Ser Pro Gln Gly Glu Val Pro His Asp Ser  
 20 25 30  
 Leu Gln Asp Lys  
 35

<210> 164  
 <211> 36  
 <212> PRT  
 <213> Homo sapiens

<400> 164  
 Asp Lys Phe Trp Tyr Cys Arg Leu Ser Pro Asn His Lys Val Leu His  
 1 5 10 15  
 Tyr Gly Asp Leu Glu Glu Ser Pro Gln Gly Glu Val Pro His Asp Ser  
 20 25 30  
 Leu Gln Asp Lys  
 35

<210> 165  
 <211> 72  
 <212> PRT  
 <213> Homo sapiens

<400> 165  
 Thr Ile Ser Ala His Cys Asn Leu Cys Leu Pro Gly Ser Ser Asn Ser  
 1 5 10 15  
 Pro Ala Ser Ala Ser Arg Val Ala Gly Thr Ala Gly Thr Cys Arg Arg  
 20 25 30  
 Ala Gln Leu Ile Phe Val Phe Leu Ala Glu Met Gly Phe His His Val  
 35 40 45  
 Gly Arg Asp Gly Leu Asp Leu Asn Leu Val Ile His Pro Pro Arg Ser  
 50 55 60  
 Pro Lys Ala Leu Gly Leu Gln Ala  
 65 70

<210> 166  
 <211> 72  
 <212> PRT  
 <213> Homo sapiens

&lt;400&gt; 166

Thr Val Ser Ala His Cys Lys Leu Arg Leu Pro Gly Ser His His Ser  
1 5 10 15

Pro Ala Ser Ala Ser Gln Val Ala Gly Thr Thr Gly Ala Cys His His  
20 25 30

Ala Arg Leu Ile Phe Leu Tyr Phe Leu Val Glu Thr Gly Phe His Cys  
35 40 45

Val Ser Gln Asp Gly Leu Asp Leu Leu Val Ser Arg Pro Pro Gln Pro  
50 55 60

Pro Lys Val Leu Gly Leu Gln Ala  
65 70

## INTERNATIONAL SEARCH REPORT

 International application No.  
 PCT/US00/14963
**A. CLASSIFICATION OF SUBJECT MATTER**

IPC(7) : C12Q 1/68; C12P 21/06; C12N 5/00, 15/00; C07H 21/04

US CL : 536/23.1, 23.5; 435/6, 69.1, 320.1, 325

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/23.1, 23.5; 435/6, 69.1, 320.1, 325

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Genbank Accession Number AA340580, 21 April 1997 (21-4-97), comprises a contiguous fragment of SEQ ID NO: 11 of greater than 350 nucleotides.	1, 7-10
X	US 5,776,746 A (DENNEY, JR.) 07 July 1998, col. 36, lines 45-60, and SEQ ID NO: 24 which comprises a contiguous fragment of SEQ ID NO: 11 of at least 88 nucleotides.	1, 7-10
X ----- A	Genbank Accession Number AL022395, 22 March 1999 (22-3-99), comprises a fragment having greater than 1000 nucleotides matching SEQ ID NO: 11 including the open reading frame encoding SEQ ID NO: 59.	1-3, 5-10 ----- 4, 14-15, 21

☐ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	*T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
*A* document defining the general state of the art which is not considered to be of particular relevance	*X* document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
*E* earlier document published on or after the international filing date	*Y* document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
*L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	*G* document member of the same patent family
*O* document referring to an oral disclosure, use, exhibition or other means	
*P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

29 AUGUST 2000

Date of mailing of the international search report

22 SEP 2000

 Name and mailing address of the ISA/US  
 Commissioner of Patents and Trademarks  
 Box PCT  
 Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

MARIANNE P. ALLEN

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/14963

**Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)**

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

Please See Extra Sheet.

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
1-10, 14-15, and 21 for SEQ ID NOS: 11 and 59

Remark on Protest

☐  
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

**BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING**

This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claims 1-10, 14-15, and 21, drawn to nucleic acid molecules, vectors, host cells, and methods of production.

Group II, claims 11-12 and 16, drawn to polypeptides.

Group III, claim 13, drawn to antibodies.

Group IV, claim 17, drawn to a method of treatment.

Group V, claim 18, drawn to a method of diagnosis by determining mutations.

Group VI, claim 19, drawn to a method of diagnosis by determining expression level.

Group VII, claim 20, drawn to a method of identifying a binding partner.

Group VIII, claim 22, drawn to a method of assay to identify activity.

Group IX, claim 23, drawn to a binding partner product.

Note that the claims reference SEQ ID NOS: X and Y and ATCC deposit number Z. Applicant must elect particular SEQ ID NOS. as well as the corresponding deposit.

The inventions listed as Groups I-IX do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Group I forms a single inventive concept and contains claims directed to a first appearing nucleic acid molecule product. This first appearing product possesses no special technical feature as prior art can be applied against the claims of Group I and a special technical feature must define a contribution over the prior art. (See prior art cited herein.) Groups II, III, and IX are drawn to structurally different products which do not share the same or a corresponding special technical feature. Groups IV-VIII are drawn to methods having different goals, method steps, and starting materials which do not share the same or a corresponding special technical feature. Note that PCT Rule 13 does not provide for multiple products or methods within a single application.